

# PROGRAM

PROGRAM

AMERICAN PSYCHIATRIC ASSOCIATION

## 2003 ANNUAL MEETING

American Psychiatric Association



156th Annual Meeting + May 17-22, 2003

San Francisco, CA ■ May 17-22, 2003

# 2003 SCIENTIFIC PROGRAM COMMITTEE



**Seated (left to right):** Drs. McDowell, Muskin, Ordorica. **1<sup>st</sup> Row Standing (left to right):** Drs. Judge, Blake, Worley, Pandurangi, LeMelle, Shafiq, Anderson, Jayaram, Casey, Dawkins, Foulks. **2<sup>nd</sup> Row Standing (left to right):** Drs. Blinder, Cheong, Taylor, Crone, Baker, Hilty, Kanefield, Groves, Goldfinger, Yeung, MacKenzie, Pandya, Alessi, D'Alli. **Not pictured:** Drs. Sukhrani, Stabinsky

May 17, 2003

Dear Colleagues and Guests:

Welcome to the 156th Annual Meeting of the American Psychiatric Association. The coming week will highlight the best in our profession in the largest psychiatric meeting in the world. Our meeting has become an outstanding international forum to discuss the latest scientific advances and traditional humane values in psychiatry and how we will continue to integrate these bodies of knowledge to provide excellent patient care.

This year's Annual Meeting theme is "The Promise of Science, The Power of Healing." Many sessions throughout the week will highlight important aspects of the theme. In addition, please make a special effort to attend the Monday and Tuesday afternoon Presidential Symposia, Monday from 2:00 p.m.-5:00 p.m., entitled, "Moral and Philosophical Issues in Psychiatry" and Tuesday from 2:00 p.m.-5:00 p.m., entitled, "The Foundation of Medical Ethics/Informed Consent."

I join our colleagues from North America in greeting the thousands of colleagues from other parts of the world who have joined us in San Francisco. At the Opening Session, from 5:00 p.m.-6:30 p.m., on Sunday, we will officially welcome the leaders from psychiatric societies in the U.S. and around the world. I will present my Presidential Address, and I look forward to seeing you there.

Please also make sure to attend the Convocation of Distinguished Fellows on Monday night at 6:00 p.m., where we will honor all those being inducted as fellows and distinguished fellows and many receiving awards from APA. The William C. Menninger Memorial lecture will be presented by the distinguished social and political commentator, Charles Krauthammer, M.D.

Organizing a meeting like ours represents the best in collaboration between our members and our staff. Special congratulations go to Dr. Geetha Jayaram and the members of the Scientific Program Committee and to the APA staff who work on the Annual Meeting.

Welcome to San Francisco 2003.



Sincerely,

Paul S. Appelbaum, M.D.  
APA President



## American Psychiatric Association

1000 Wilson Boulevard  
Suite 1825  
Arlington, VA 22209-3901  
Telephone 703.908.7822  
Fax 703.907.1090  
E-mail [apa@psych.org](mailto:apa@psych.org)

May 17, 2003

Dear APA Members and Guests:

Welcome to San Francisco, CA, and the 156th Annual Meeting of the American Psychiatric Association. This historic city, with its vibrancy, cultural diversity, and excitement, provides a perfect setting for the scientific presentations we have planned. As you read through the *Program Book*, you will notice a number of sessions related to the theme "The Promise of Science - The Power of Healing," chosen by our President, Dr. Paul S. Appelbaum. Let me draw your attention to just a few of the many exciting sessions presented this week. The Presidential Symposia will be presented on Monday and Tuesday from 2:00 p.m.-5:00 p.m., entitled, "Moral and Philosophical Issues in Psychiatry" and "The Foundation of Medical Ethics/Informed Consent." Robin Munro, M.D., will present the APA's Patient Advocacy Award Lecture on Monday, at 9:00 a.m.

The Business Meeting will be held on Sunday, from 12:30 p.m. to 1:30 p.m.; all voting members are encouraged to attend. The Opening Session will be held on Sunday, from 5:00 p.m. to 6:30 p.m. Exhibits will be open 11:00 a.m. to 4:30 p.m. on Sunday, 10:00 a.m. to 6:00 p.m. on Monday and Tuesday, and 10:00 a.m. to 3:00 p.m. on Wednesday. Please note that the Convocation of Distinguished Fellows will begin at 6:00 p.m., on Monday, May 20. Charles Krauthammer, M.D., will present the William C. Menninger Memorial Lecture during the Convocation.

The Advances in Research session will be held on Monday at 10:30 a.m. This session highlights the latest research findings in psychiatry and summarizes their relevance to clinical practice. This session has become an excellent way to start off the Annual Meeting's research programs, in conjunction with the Young Investigators' Poster and Oral/Slide Sessions also on Monday. You will find an expanded number of small group sessions, including Discussion Groups; Research Consultations with selected experts in the field; and Master Educator Clinical Consultations, a series of clinically-based seminars with outstanding clinician educators, offered to APA members only.

You will note in the *Program Book* that we are continuing with an expanded series of noon Forums. This format allows us to schedule sessions that may not fit in the usual formats or that focus on late-breaking topics of importance to the field.

It is extremely important that you fill out and return the evaluation forms for this meeting. The members of the Scientific Program Committee are interested in your opinion regarding the quality of the content of the Annual Meeting. The information we obtain will be used to plan next year's Annual Meeting.

Once again, welcome to San Francisco. I look forward to sharing a week of exciting and professionally rewarding activities with you.

Sincerely,

Geetha Jayaram, M.D., M.B.A  
Chairperson  
Scientific Program Committee

**156th Annual Meeting  
San Francisco, CA  
May 17-22, 2003**

**President**  
Paul S. Appelbaum, M.D.

**Scientific Program Committee  
2002-2003**  
Geetha Jayaram, M.D., *Chairperson*  
David M. McDowell, M.D.  
*Vice-Chairperson*

Patricia I. Ordorica, M.D.  
*Vice-Chairperson*

Robert W. Baker, M.D.  
David A. Baron, D.O.  
David A. Casey, M.D.  
Joseph Cheong, M.D.  
Catherine C. Crone, M.D.  
Sheila Judge, M.D.  
Stephanie LeMelle, M.D.

Philip R. Muskin, M.D.  
Anand Pandya, M.D.  
Anthony Rothschild, M.D.  
Duru Sakhrani, M.D.  
*AstraZeneca Fellow*  
Mohammad Shafii, M.D.  
Harvey Stabinsky, M.D.  
David H. Taylor, M.D.  
Linda Worley, M.D.  
Paul Yeung, M.D.

**Consultants**  
Norman Alessi, M.D.  
Tanya Anderson, M.D.  
Barton J. Blinder, M.D.  
James Chou, M.D.  
Richard D'Alli, M.D.  
Edward Foulks, M.D.  
Marion Goldstein, M.D.  
Paul Goodnick, M.D.  
K. Roy MacKenzie, M.D.  
Ananda Pandurangi, M.D.

**Committee on Commercial  
Support**  
Stephen M. Goldfinger, M.D.  
*Chairperson*

**Annual Meetings Department**  
Cathy L. Nash, *Director*  
(703) 907-7822  
Hope Ball-Mann  
*Registrar*  
(703) 907-7810  
Frank Berry  
*Administrator, Commercially-  
Supported Activities*  
(703) 907-7812  
Carrie Smith-Dent  
*Administrator, CME Courses*  
(703) 907-7811  
Douglas M. Brooks, Jr.  
*Scientific Program Coordinator*  
(703) 907-7807  
Celeste M. Mele  
*Operations Manager*  
(703) 907-7813  
Carietta M. Todd  
*Program Assistant*  
(703) 907-7805



# APA 156th ANNUAL MEETING

San Francisco, CA ■ May 17-22, 2003

## KEY LOCATIONS - MOSCONE CENTER

<i>American Journal of Psychiatry</i> Annual Meetings Office	APA Resource Center Rooms 200/202/206/212, Mezzanine Level
APA Communications Center	Rooms 250-262, Mezzanine Level
APA Resource Center	Hall D, Exhibit Level
A/V Preview Room	Room 232, Mezzanine Level
CME Course Enrollment	Hall D, Exhibit Level
Computerized Evaluation	APA Resource Center
<i>Daily Bulletin</i>	Rooms 250-262, Mezzanine Level
Education Office	Room 226, Mezzanine Level
Exhibit Office	Exhibit Level
Exhibits/Publishers' Bookfair	Halls A-C, Exhibit Level
IMG Hospitality Suite	Room 224, Mezzanine Level
Information/Locator Center	Upper Lobby South
Lost & Found	Rooms 200/202/206/212, Mezzanine Level
Message Center	Upper Lobby South
On-Site Job Bank and Placement Center	APA Resource Center
<i>Psychiatric Services</i>	APPI Bookstore, Halls A-C, Exhibit Level
Registration	Hall D, Exhibit Level
Women's Hospitality Center	Room 224, Mezzanine Level

## FIRST AID

Located across from Room 106 and 124, Exhibit Level, Moscone Center and also in the Esplanade Lobby. Hours of operation: Tuesday, May 13, through Thursday, May 22, opens one hour prior to show opening and closes one hour after the last event of the evening. This station will be operated by Registered Nurses. Information on emergency services may be found on page VII.

## COURTESY SHUTTLE BUS SERVICE

Service will begin on Saturday, May 17, at approximately 7:30 a.m., and will operate daily throughout the meeting commensurate with the scientific program schedule, including nighttime activities, and will conclude on Thursday, May 22, at 6:00 p.m. The Moscone Center will serve as the "hub" for all shuttle bus routes. A detailed Shuttle Bus Services Schedule will be included in each registration packet and posted in the lobbies of participating hotels. Refer to the city map on page VI for the location of hotels in relation to Moscone Center.

## EXHIBITS

Commercial and educational exhibits are located in Halls A-C, Exhibit Level, Moscone Center, along with the Publishers' Bookfair. As a convenience to registrants, the Publishers' Bookfair will open on Saturday, May 17, 11:00 a.m.-5:00 p.m. Hours for commercial and educational exhibits: Sunday, May 18, 11:00 a.m.-4:30 p.m.; Monday and Tuesday, May 19-20, 10:00 a.m.-6:00 p.m., and Wednesday, May 21, 10:00 a.m.-3:00 p.m. **All exhibits will close on Wednesday, May 21 at 3:00 p.m.** Please refer to the *APA Exhibits Guide* for additional information on participating companies. APA periodicals will be located in the APPI Bookstore.

## INFORMATION/LOCATOR CENTER

Located on the Upper Lobby South, Moscone Center and staffed during registration hours (with the exception of Thursday, May 21, when the center will be open until 5:00 p.m.). Up-to-date general information about the program, component meetings, the local area, and the locations of various activities and events can be obtained there. Meeting participants also can find out where colleagues who are registered for the meeting are staying.

## MESSAGE CENTER

Located on the Upper Lobby South, Moscone Center and staffed during registration hours. Messages can be left and picked up at the Message Center. Message monitors will be strategically located in the Exhibit Hall and elsewhere in Moscone Center. Registrants whose names appear on these monitors should pick up their messages at the Message Center.

## APA RESOURCE CENTER

Located in Hall D, Exhibit Level, Moscone Center. Hours of operation will be: Saturday, May 17, 10:00 a.m.-5:00 p.m.; Sunday, May 18, 8:00 a.m.-4:30 p.m.; Monday and Tuesday, May 19-20, 10:00 a.m.-6:00 p.m.; and Wednesday, May 21, 10:00 a.m.-3:00 p.m. A few of the many APA activities exhibited include: membership, APA's internet-based programs, continuing medical education, quality improvement, psychiatric services, managed care services, and APA Job Bank.

## APA JOB BANK

Located in the APA Resource Center and open during the Center's hours of operation. The on-line APA Job Bank will power the popular on-site Job Bank providing tools for both employers and candidates at the APA's Annual Meeting. Candidates and employers are encouraged to activate their resume and job postings in advance of the meeting for best results. For more information on the Job Bank go to the APA web site, [www.psych.org](http://www.psych.org), and click on the Job Bank icon.

## APA COMMUNICATIONS OFFICE/PRESS OFFICE

Located in Rooms 250-262, Mezzanine Level, Moscone Center. Hours of operation: Saturday, May 17, 12 noon-5:00 p.m.; Sunday-Wednesday, May 18-21, 8:00 a.m.-6:00 p.m.; and Thursday, May 22, 8:00 a.m.-12 noon. **The Press Office is for the use of registered press only.**

## DAILY BULLETIN

The *Daily Bulletin* accepts written requests from APA members for publicity of component, committee, and allied group events as space allows. Four issues are published. The issue for Saturday/Sunday is printed in advance. Copy for the Monday, Tuesday, and Wednesday/Thursday issues can be dropped off in Rooms 250-262, Mezzanine Level, by 12 noon prior to the date of publication.

## WOMEN'S RESOURCE CENTER

Located in Room 224, Mezzanine Level, Moscone Center. Hours of operation: Sunday, May 18, through Monday, May 19, 7:00 a.m.-5:00 p.m. Meet and network with other women psychiatrists and peruse materials on women's programs offered by APA and other organizations. The Center is funded by an unrestricted educational grant from Wyeth Pharmaceuticals.

## IMG HOSPITALITY CENTER

Located in Room 224, Mezzanine Level, Moscone Center. Hours of operation: Tuesday, May 20, through Wednesday, May 21, 8:00 a.m.-6:00 p.m. Stop by the Center to meet and network with your colleagues.

## RESIDENTS' RESOURCE CENTER

Located in the Pacific Conference Suite I, Fourth Floor, Marriott. The Residents' Resource Center will be open from 7:00 a.m. to 6:00 p.m., Sunday, May 18, through Wednesday, May 21. Daily activities are scheduled for residents (such as the Residents Only Discussion Groups) and for medical students as well. Meet and network with leaders in psychiatry and your colleagues. Resources specifically for residents and medical students available are available here.

## CENTER FOR INTERNATIONAL GUESTS

Due to a lack of funding, we regret we are unable to provide an International Visitor Center this year.

## BUSINESS CENTERS

### Moscone Center

Location: Southwest Lower Lobby, Adjacent to Room 105  
Times of operation: Monday-Sunday, 8:00 a.m.-5:00 p.m.

### Marriott

Location: Golden Gate Hall, B2 Level  
Times of operation: Monday-Friday, 5:30 a.m.-8:00 p.m.  
Saturday-Sunday, 8:00 a.m.-4:00 p.m.

### Hilton

Location: Bldg. 2, Lobby  
Times of operation: Monday-Friday, 8:00 a.m.-5 p.m.  
Saturday – Sunday, To be posted.

## REGISTRATION

### ADMISSION TO ALL SESSIONS BY REGISTRATION BADGE

Located in Hall D, Exhibit Level, Moscone Center. Hours of operation: Saturday, May 17, 10:00 a.m.-5:00 p.m.; Sunday, May 18, 7:30 a.m.-5:00 p.m.; Monday-Tuesday, May 19-20, 7:30 a.m.-6:00 p.m.; Wednesday, May 21, 7:30 a.m.-5:00 p.m.; and Thursday, May 22, 7:30 a.m.-2:00 p.m.

### On-Site Registration Fee Schedule:

#### APA MEMBERS

Full-Time Registration ( <i>North American Members</i> ).....	\$275.00
Full-Time Registration ( <i>International Members</i> ).....	\$425.00
Members-in-Training ( <i>Member Class MT</i> ).....	\$ 75.00
Daily Registration ( <i>North American Members</i> ).....	\$140.00
Daily Registration ( <i>International Members</i> ).....	\$215.00
Medical Students.....	no charge

#### NONMEMBERS

Full-Time Registration.....	\$790.00
Nonmember Residents, Students, Advocacy Group Members, or Mental Health Chaplains.....	95.00
Daily Registration ( <i>all "Nonmember" categories</i> ).....	400.00
Medical Students.....	no charge

#### GUEST REGISTRATION

One only per full-time registrant.....	100.00
Only one guest is allowed to register with each full-time meeting registrant. <i>The guest must reside in the same household and be able to receive mail at the same address. APA members cannot register as a "guest"; they must register as an APA member.</i>	
One-Day Exhibit Hall Only Pass (18 and older).....	10.00
<b>(Only paid registrant can purchase an exhibit hall pass)</b>	
On-site fees can be paid by cash, check, money order, American Express, VISA or MasterCard. Registration fees are waived <b>only</b> for <i>CME Course Faculty, APA Honorary Fellows (does not include APA Distinguished Fellows/Fellows/Life Fellows/Distinguished Life Fellows), medical students (with proper identification), District Branch Executive Staff (who are not APA members), active members of the Association of Mental Health Clergy (with proper identification), and nonmember program participants (only for the day(s) they present).</i>	

#### NONMEMBER PSYCHIATRIC RESIDENTS AND OTHER

**FULL-TIME STUDENTS** must present documentation to register in their respective category and qualify for the reduced fee. (Examples include: a valid full-time [12 + hours per semester] student ID; a letter from your instructor or director of training verifying your status as a psychiatric resident; or similar documentation.)

**Note: There are no exemptions or reduced fees available for CME courses.** The registration fee covers admission to all sessions (except courses), shuttle buses, and includes a badge and copy of the *Program Book*,

*APA Exhibits Guide*, and *New Research Program and Abstracts Books*, and for most categories, a copy of the *Syllabus*.

## NAME BADGES

Badges are required for all sessions including the Opening Session and exhibit area. Only an APA member badge will admit you to the Business Meeting.

**Badge Color Codes:** Blue-Members, Yellow-Nonmembers, Silver-Press, Red-Exhibitors, Green-APA Staff, and Black-Temporary Moscone Personnel.

Registered exhibitors will receive red badges, which allow access only to his/her own booth in the exhibit hall and to ride the shuttle bus. If an exhibitor wants to attend sessions, he/she must register for the meeting and pay the appropriate fee.

## CME COURSE ENROLLMENT TICKET PURCHASE REQUIRED FOR CME COURSES

Located in Hall D, Exhibit Level, Moscone Center. Hours of operation: Saturday, May 17, 10:00 a.m.-5:00 p.m.; Sunday, May 18, 7:30 a.m.-5:00 p.m.; Monday through Tuesday, May 19-20, 7:30 a.m.-6:00 p.m.; Wednesday, May 21, 7:30 a.m.-5:00 p.m.; and Thursday, May 22, 7:30 a.m.-2:00 p.m. Tickets for CME Courses not sold by April 13 will be on sale to all registrants beginning at 10:00 a.m. on Saturday, May 17. You must show your registration badge before you can enroll in courses.

## APA ART ASSOCIATION

Located in the APA Resource Center and staffed during the Resource Center's hours. The exhibit includes paintings, photography, ceramics, and crafts done by APA members and/or their significant others. Please stop by the exhibit for information on joining the APA Art Association.

## APA AUXILIARY BOOTH

Located on the Upper Lobby South, Moscone Center. Hours of operation: Saturday, May 17, through Wednesday, May 21, 9:00 a.m.-5:00 p.m. Stop by the booth to obtain information on the Auxiliary's program schedule and information on membership.

## APA PERIODICALS

Complimentary copies of the latest issues of *The American Journal of Psychiatry*, *Psychiatric Services*, *Academic Psychiatry*, *The American Journal of Geriatric Psychiatry*, *The Journal of Neuropsychiatry and Clinical Neurosciences*, *Psychosomatics*, and APA's new CME journal, *Focus*, may be obtained at the APA/APPI Periodicals Exhibit in the APPI Bookstore. Complimentary copies of *Psychiatric News* will be available at stands located throughout Moscone Center. Staff will sell discounted subscriptions to all APA/APPI journals and demonstrate online access for subscribers. They will also show authors and reviewers how to use Manuscript Central, the new Web-based manuscript submission and review system. Staff of the *American Journal of Psychiatry* and *Psychiatric Services* will be available to answer authors' questions. Persons who wish to contact editors or reporters of *Psychiatric News* are asked to leave a message on the message board in the Annual Meetings Office, Rooms 200/202/206/212, Mezzanine Level, Moscone Center. Written announcements, suggestions for articles, letters to the editor, or other material for the newspaper's consideration may be left with staff at the Periodicals Exhibit.

## AUDIOTAPES

Audiotapes of most sessions are available shortly after each session concludes and may be purchased at the Mobiltape Booth located on the Upper Lobby South, in Moscone Center.

## CONTINUING MEDICAL EDUCATION

**Educational Objectives:** At the conclusion of this meeting, participants will be able to:

- Better understand new research findings in the fields of psychiatry and neuroscience;
- acquire new knowledge and skills in clinical psychiatry, which can be utilized to improve patient care;
- identify and remove barriers to the transfer of new knowledge for their practice, including provision of culturally competent care for diverse populations;
- assess a variety of treatment choices, including psychotherapeutic and pharmacological options; and
- better understand mental health service delivery issues, including barriers to care.

The APA is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The APA designates this educational activity for a maximum of 66 Category 1 credits toward the AMA Physician's Recognition Award and for the CME requirement of the APA. Each physician should claim only those credits that he/she actually spent in the activity.

**Please note: Most portions of the scientific program, as outlined below, have been approved for CME credit.** The scientific sessions on the official Annual Meeting program, with some exceptions, meet the criteria for Category 1 CME credit. Sessions in the following program formats are designated as Category 1: Advances in Psychotherapy, Advances in Research, Clinical Case and Continuous Clinical Case Conferences, CME Courses, Forums, Industry-Supported Symposia, Lectures, Medical Updates, New Research Oral/Slide Sessions, Research Advances in Medicine, Presidential Symposia, Review of Psychiatry, Scientific and Clinical Reports, Symposia, and Workshops. Other program activities may be considered Category 2: Debate, Discussion Groups, Master Educator Clinical Consultations, New Research Poster Sessions, and Research Consultations. Scientific sessions are open to all Annual Meeting registrants, except for the Clinical Case and Continuous Clinical Case Conferences and the Master Educator Clinical Consultations, which are open to APA members only.

**PLEASE NOTE: APA MEMBERS ARE REQUIRED TO MAINTAIN THEIR OWN RECORDS OF CME HOURS. REPORTING OF CME CREDIT IS ON AN HONOR BASIS.**

To document CME credit earned at the Annual Meeting, participants should record the sessions they attended on the *Certificate of Attendance* log sheet found in the front of the *2003 Annual Meeting CME Syllabus & Proceedings Summary Book*. Credit is earned on an hour-for-hour basis. A parchment *Certificate of Attendance* is also available.

The *Certificate of Attendance* (or copy) may be forwarded to other organizations requiring verification of participation in the APA Annual Meeting.

The APA requires members to participate in a total of 150 hours of CME activities within a three-year reporting period. At least 60 hours must be in Category 1 activities.

CME report forms may be obtained from the Department of CME at the APA. Staff will be available in the APA Resource Center to answer any of your questions about CME.

## ANNUAL MEETING EVALUATION

The Annual Meeting Scientific Program Committee needs your recommendations and evaluations to plan next year's Annual Meeting. A participant evaluation form is enclosed with your registration packet and includes instructions for completing the form. **BEFORE YOU LEAVE THE MEETING, PLEASE COMPLETE YOUR FORM AND DROP IT IN ONE OF THE EVALUATION BOXES LOCATED THROUGHOUT THE MEETING SITES.** You can receive a parchment *Certificate of Attendance* at the Annual Meeting by returning your completed form (to the Annual Meetings Office, Information/Locator Center, or APA Resource Center, all located in Moscone Center) or by completing the computerized general evaluation in the APA Resource Center.

## SESSION CAPACITY

So that all in attendance may benefit, we ask your assistance when overcrowding occurs:

- Please find seating as far forward as possible.
- Move to the center of the row and fill all seats so that chairs are available on aisles for additional attendees.
- Overcrowding of meeting rooms may subject the session to shutdown by the Fire Marshal; therefore, we urge all attendees to locate seating rather than stand in aisles or against walls.
- If space does not permit you to attend a session, an audiotape of that session may be available. Please check the order form included in your registration packet.

## TAPE RECORDING AND VISUAL REPRODUCTION POLICIES

Audiotape recording is only permitted for personal use and by members of the media. Registrants are welcome to use their own small, portable audiotape recorders to record any session **except the Master Educator Clinical Consultations, Clinical Case Conferences, and the Continuous Clinical Case Conference, or unless prohibited by the presenters.** Larger professional tape recorders, however, are not permitted other than those utilized by members of the media and personnel representing the professional taping firm authorized by APA to audiotape sessions. The badges of personnel representing this firm and members of the media will clearly identify them. **Non-media registrants are not permitted to videotape any session** because the intrusive nature of the recording may disrupt the session. More detailed guidelines for media representatives may be obtained in the Press Office.

## SMOKING POLICY

There will be **NO SMOKING** in scientific sessions or in the exhibit hall. Smoking will only be permitted in **designated areas.**



## CHILD CARE SERVICE

ACCENT on Children's Arrangements, Inc., the official youth program provider for APA, has planned an exciting on-site children's activity program called Camp APA. Camp APA offers both parents and their children a safe, nurturing, and positive experience. ACCENT's professional, specially trained supervisors are certified in both CPR and pediatric first aid. The ACCENT staff are teachers, professional childcare providers, or mothers who simply love working with children and have completed ACCENT's specialized training program. Camp APA is headquartered at the San Francisco Marriott for the exclusive use of APA registrants and their families. Children aged 6 months to 17 years are welcome and will be provided with developmentally appropriate programs designed specifically for their age group. Activities will take place on site for all children younger than 6 years old. The older children will enjoy arts and crafts projects, active games, and much more. Field Trips will depart and return to the on-site Camp APA activity Center each day. ACCENT provides an exceptional caregiver to child ratio: 1:2 for children 6-12 months; 1:3 for children 13-36 months; 1:5 for children 3-12 years and 1:8 for children 12 years and older.

## GUIDE TO THE PROGRAM BOOK

On page V, you will find the table of contents for ease in locating information about this meeting. A topic index is included to assist you with finding sessions of interest. The individual program for each day's sessions is listed by start time with the formats listed alphabetically under those times. **NOTE: To make it easier for you to plan your day, we have prepared a separate "Days-at-a-Glance," which is included in your registration packet.**

If you have any questions about this book or the scientific sessions, please feel free to stop by the Annual Meetings Office in Moscone Center, and we will be glad to help you. Also, all central office APA staff members will be wearing green badges. Please feel free to direct your questions to them.

**FUTURE APA MEETINGS  
APA ANNUAL MEETINGS**

2004 May 1-6                      New York, NY  
2005 May 21-26                  Atlanta, GA

**APA CLINICAL MEETINGS  
THE INSTITUTE ON PSYCHIATRIC SERVICES**

2003 October 29-Nov. 2        Boston, MA  
2004 October 6-10                Atlanta, GA  
2005 October 5-9                 San Diego, CA

Tentative program schedules and hotel information for the 2003 Institute on Psychiatric Services are available at the Information/Locator Center, located on the Upper Lobby South, Moscone Center.

## TABLE OF CONTENTS

Floor Plans for Moscone Center, Argent, Hilton, Marriott, and Westin St. Francis .....	VI-XV
City Map .....	XVI
Local Information .....	XVII
Special Acknowledgments .....	XVIII-XIX
Format Descriptions .....	XX-XXI
Disclosure Information .....	XXII-XXX
Saturday Sessions .....	1-3
Audiotape Sales Information .....	4
Sunday Sessions .....	5-12
Monday Sessions .....	13-34
Tuesday Sessions .....	35-59
2003 Institute on Psychiatric Services .....	60
Wednesday Sessions .....	61-82
Thursday Sessions .....	83-97
Call for 2004 Annual Meeting Papers .....	98
Topic Index .....	99-112
Participant Index .....	113-123
American Psychiatric Publishing Inc. ....	124-125
Industry-Supported Symposia .....	126-151
APA Resource Center .....	Back Cover

Refer to the *APA Exhibits Guide* for information on: Exhibits, Publishers' Bookfair, Hospitality Lounge, and Dining Facilities in Moscone Center.


The information provided and views expressed by presenters on this program are not necessarily those of the American Psychiatric Association, nor does the American Psychiatric Association warrant the accuracy of any information reported.

©American Psychiatric Association.

# Moscone Center



747 Howard Street, San Francisco, CA 94103-3118  
415-974-4000

## Esplanade & Lobbies Level






# Moscone Center Mezzanine Level




# Moscone Center Exhibit Level




The Argent Hotel  
San Francisco  
50 Third Street, San Francisco CA 94103  
415-974-6400

**SECOND LEVEL**




**THIRD LEVEL**





Hilton  
 San Francisco & Towers  
 333 O'Farrell Street, San Francisco, CA 94102  
 (415) 771-1400

Ballroom Level/Bldgs. 1, 2, 3




# Hilton San Francisco & Towers 4<sup>th</sup> Floor/Bldg. 3



San Francisco Marriott  
55 Fourth Street, San Francisco, CA 94103-3199  
415-896-1600


Golden Gate Hall  
(B2 Level)



# San Francisco Marriott

## Yerba Buena Ballroom (Lower B2 Level)


Yerba Buena Gardens



Fourth Street

# San Francisco Marriott

## Pacific, Sierra Conference Suites and Club Room (Fourth, Fifth & Atrium Levels)






The Westin St. Francis  
 Union Square, 3335 Powell Street, San Francisco, CA 94102  
 (415) 397-7000

# Convention Facilities

THE IMPERIAL FLOOR 32ND FLOOR

1/8" = 4'



ALEXANDRA'S

1/8" = 4'

MAIN FLOOR  
 OAK ROOM

1/8" = 2'




12TH FLOOR  
 ST. FRANCIS SUITE

1/8" = 9'




SECOND FLOOR

1/16" = 5'



MEZZANINE FLOOR

1/8" = 4'



# San Francisco Hotel Key & Map



- |   |  |  |
|---|--|--|
| <b>AH</b> Argent Hotel                  | <b>HJ</b> Hotel Juliana                  | <b>PA</b> Palace Hotel                         |
| <b>BA</b> Beresford Arms                | <b>MP</b> Hotel Metropolis               | <b>PP</b> Pan Pacific Hotel                    |
| <b>HB</b> Beresford Hotel               | <b>HM</b> Hotel Monaco                   | <b>PR</b> Prescott Hotel                       |
| <b>BW</b> Best Western Americana        | <b>NK</b> Hotel Nikko SF                 | <b>RU</b> Ramada Union Sq.                     |
| <b>CI</b> Best Western Carriage Inn     | <b>HP</b> Hotel Palomar                  | <b>P5</b> Renaissance Parc 55 Hotel            |
| <b>BR</b> Briton Hotel                  | <b>HR</b> Hotel Rex                      | <b>RS</b> Renaissance Stanford Court Hotel     |
| <b>CH</b> Canterbury Hotel              | <b>HV</b> Hotel Vintage Court            | <b>SH</b> Serrano Hotel                        |
| <b>CN</b> Chancellor Hotel on Union Sq. | <b>HT</b> Hilton SF                      | <b>CY</b> SF Downtown Courtyard                |
| <b>CL</b> Clift                         | <b>Hilton SF</b> Fisherman's Wharf       | <b>MT</b> San Francisco Marriott               |
| <b>CO</b> Commodore Hotel               | <b>HP</b> Hotel Palomar                  | <b>SW</b> Sheraton at Fisherman's Wharf        |
| <b>CP</b> Crowne Plaza Union Sq.        | <b>HU</b> Hotel Union Sq.                | <b>SF</b> Sir Francis Drake                    |
| <b>DH</b> Donatello Hotel               | <b>HE</b> Hyatt Regency SF               | <b>PW</b> The Pickwick, A Grand Heritage Hotel |
| <b>GP</b> Galleria Park Hotel           | <b>KP</b> Kensington Park                | <b>WS</b> W San Francisco                      |
| <b>GG</b> Holiday Inn Golden Gateway    | <b>KG</b> King George Hotel              | <b>WR</b> Warwick Regis Hotel                  |
| <b>CS</b> Hotel Cosmo                   | <b>MH</b> Mark Hopkins Inter-Continental | <b>WE</b> Westin St. Francis                   |
| <b>HD</b> Hotel Diva                    | <b>MX</b> Maxwell Hotel                  | <b>VF</b> Villa Florence                       |
|   | <b>MI</b> Monticello Inn                 | <b>YH</b> York Hotel                           |
|   | <b>OH</b> Omni SF                        |  |

# LOCAL INFORMATION

Surrounded on three sides by the Pacific Ocean and San Francisco Bay, San Francisco's compact 47 square miles (125 sq. km.) crowd the tip of the San Francisco Peninsula. The City is built on 43 hills. Cosmopolitan flair, spectacular scenery, and cultural diversity make San Francisco one of the top destinations in the world. Perennial favorites include Fisherman's Wharf, Chinatown, the cable cars, the Golden Gate Bridge, and Golden Gate Park. Its shopping hub, Union Square, anchors a who's who of world-famous stores. The City is acclaimed as home of the "World's Best Restaurants," and visitors quickly discover the charm of "the neighborhoods." Headquarters of a vast vacationland, San Francisco is within easy driving distance of the High Sierra resorts of Lake Tahoe and Yosemite; the scenic Monterey-Carmel peninsula; California's wine country; Sausalito and Tiburon just over the Golden Gate Bridge; the East Bay cities of Oakland and Berkeley; family attractions in Vallejo; the spectacular Mendocino Coast; and the bronzed hills of the Livermore Valley.

## WEATHER/WHAT TO WEAR

San Francisco is blessed with a temperate marine climate and enjoys mild weather year-round. Temperatures seldom rise above 70° F (21° C) or fall below 40° F (5° C). Morning and evening fogs roll in during the summer months, but rarely persist. Visitors are most comfortable with a light jacket or coat handy for cool evening wear. Lightweight summer clothes are seldom practical in San Francisco.

## TOBACCO RESTRICTIONS

In California, it is illegal to smoke tobacco products in any public gathering space including restaurants and bars, stores, and office buildings. Please observe signs for designated smoking areas.

## ACCESSIBILITY

When using public transportation, request a copy of the Muni Access Guide, Muni Accessible Services Programs, 949 Presidio Avenue, San Francisco, CA 94115; for assistance call 415.923.6142 or 415.673.MUNI (6864). The MUNI operates more than 41 accessible bus lines in addition to accessible Metro service. The San Francisco Convention & Visitors Bureau maintains a TDD information line at 415.392.0328. For additional information, visit the web site at [www.accessnca.com](http://www.accessnca.com).

## AIRPORT

With the completion of its new International Terminal in December 2000, San Francisco International Airport set several records. The addition of the new terminal doubles the size of SFO. International passengers enjoy faster processing; an estimated 5,000 individuals each hour pass through U.S. Customs and Immigration. San Francisco is a mere 14 miles away and a Bay Area Rapid Transit (BART) station (slated to open in late 2002) will link the airport to San Francisco's city center. For more information on San Francisco International Airport, visit the Web site at [www.flsfo.com](http://www.flsfo.com).

## AIRPORT TRANSPORTATION

American Airporter Shuttle provides 24-hour, door-to-door airport/ground transportation. Major credit cards are accepted. At SFO depart from the red sign, request American Airporter Shuttle on the upper level center island at Continental, British Air, and

United. Each way \$14 adult, \$12 ages 2-12, under 2 free. Fares are subject to change.

## GETTING AROUND

Getting around San Francisco is easy – there are several options when it comes to public transportation. Cable cars operate on three routes: Powell-Mason, Powell-Hyde, and California Street. The fare is \$2. For street-cars and buses, the fare is \$1 (35 cents for seniors, children, and disabled persons). Purchase a MUNI Passport, good on all three, at the kiosk at Market and Powell streets. One-day (\$6), three-day (\$10), and seven-day (\$15) passes are available; call 415.673.MUNI. BART (Bay Area Rapid Transit) trains operate daily from San Francisco and the East Bay; call 650.992.2278. Fares begin at \$1.10. For sightseeing cruises and ferry service Blue & Gold Fleet departs from Pier 39/41; call 415.705.5444.

## TAXI COMPANIES

Luxor Cab 415.282.4141  
Veterans Taxicab Company 415.552.1300  
Yellow Cab Cooperative, Inc. 415.626.2345

## FOREIGN CURRENCY EXCHANGE

Bank of America Downtown 650.615.4700  
Thomas Cook Currency Services, Inc. 415.362.3452  
Western Union 800.325.4176

## MEDICAL EMERGENCIES

**Downtown Medical/Travel Medicine** – Dr. Lawrence Bryson, Physician, 450 Sutter Street, Suite 1723, 415.362.7177. Immediate, same-day appointments specifically for the traveler or visitor. Familiar with travel-related medical conditions and infections, along with gynecology. Full laboratory and pharmacy on-site.

**Saint Francis Memorial Hospital** – 900 Hyde Street. Open 24 hours, 415.353.6000

**UCSF Stanford Medical Center** – 505 Parnassus Avenue. Mon.-Fri. 8:00 a.m.-5:00 p.m., Sat. 8:00 a.m.-4:00 p.m. walk-in clinic open.

General Information: 415.476.1000  
Emergency Services: 415.476.1037

**San Francisco Dental Office** – Dr. Michael H. Sander, DDS, owner, 131 Steuart Street, Suite 323, 415.777.5115.

Near convention sites and public transit, office includes in-house dental appliance laboratory. Emergency treatment available. Open daily early mornings and evenings.

**Traveler Medical Group, A Medical Corporation** – Dr. Jim Y. Savage, President, 490 Post Street, Suite 225, 415.981.1102. One of the best medical services for travelers, available daily 24 hours. Immediate office and hotel visits with physician trained in internal medicine with hospital privileges in the city. Accept most major insurance with prior-authorization and credit cards.

**24 Hours/7 Days Synapse Medical Group** – Dr. Jordan Shlain, Managing Director, 490 Post Street, Suite 710, 415.732.7039. Providing prompt, daily, 24-hour medical services to the traveler with a network of doctors and hospitals for all medical needs.

## TOURS/VISITOR INFORMATION

Attendees are encouraged to use their hotel's concierge services to assist them with local tours and leisure-time activities. There are several web sites available with information on the city: [sfchamber.com](http://sfchamber.com); [sfvisitor.org](http://sfvisitor.org); [sfstation.com](http://sfstation.com).

## APA GOLF TOURNAMENT

The Golfers of the APA (GAPA) invite you to participate in their 2003 golf tournament to benefit the American Psychiatric Foundation. The tournament is scheduled for Monday, May 19, 2003 at the Presidio Golf Course, San Francisco, home to a unique golfing legacy forged by the giants of history and golf's greatest legends. Tee it up here and find yourself in the company of Teddy Roosevelt, Dwight Eisenhower, Joe DiMaggio, Byron Nelson, Ben Hogan, and Arnold Palmer. This majestic, tree-lined course is the perfect setting for our golf outing. Cost per person will be \$200, including round-trip transportation, greens fees, cart, lunch, gifts, and prizes. To enter please contact Stan Jennings, M.D. by e-mail at [walterjennings@hotmail.com](mailto:walterjennings@hotmail.com), by fax at 804.320.2050, by phone at 804.320.7881 or by mail, W.S. Jennings, Jr., M.D., 7149 Jahnke Road, Richmond, VA 23225.

# SPECIAL ACKNOWLEDGMENTS

The American Psychiatric Association expresses its deep appreciation for the following:

**Abbott Laboratories:** support of the Industry-Supported Symposia, "Diagnosis and Treatment: Mood Stabilizers Across the Psychiatric Spectrum," Sunday, May 18, 8:00 a.m.; "Bipolar Disorder Across the Life Cycle," Tuesday, May 20, 7:00 p.m.; and the Industry-Supported Breakfast Symposium, "Impairment of Structural Plasticity in Severe Mood Disorders: Causal or Collateral?" Monday, May 19, and Tuesday, May 20, 7:00 a.m., and support of the internet village.

**American Academy of Psychiatry and the Law:** co-support of the Manfred S. Guttmacher Award Lecture, Sunday, May 18, 2:30 p.m.

**American Psychiatric Foundation:** co-support of the APA Award for Research in Psychiatry; support of the Disaster Psychiatry Fellowship; and support of the APIRE Practice Research Network (PRN).

**Association of Women Psychiatrists:** support of the joint AWP/APA Women's Career reception and meeting.

**AstraZeneca Pharmaceuticals:** support of the Industry-Supported Symposia, "Genetics and Psychiatry: Real Genes, Real Progress," Saturday, May 17, 6:00 p.m.; "Issues in Treating Mania: Acute and Continuation Phase," Sunday, May 18, 1:30 p.m.; "A Rational Algorithm for Selecting Atypicals in Schizophrenia and Bipolar Disorders," Sunday, May 18, 7:00 p.m.; the George Tarjan Award Lecture, Wednesday, May 21, 9:00 a.m.; the APA/AstraZeneca Fellowship and reception, Tuesday, May 21, 7:00 p.m.; support of the American Psychiatric Foundation "Conversations" event, Tuesday, May 21, 5:30 p.m.; and support of the APIRE/AstraZeneca Young Minds in Psychiatry Award.

**Aventis:** support of the Travel Fellowship for Women Resident Leaders in Psychiatry and Leadership Luncheon, Sunday, May 18, 12:00 p.m.

**Bristol-Myers Squibb:** support of the Industry-Supported Symposia, "Biological and Psychological Advances in the Treatment of Schizophrenia: Revisiting and Updating Meyer's Psychobiology for the 21st Century," Tuesday, May 20, 7:00 p.m.; "Novel Therapeutic Options for Psychotic Disorders," Wednesday, May 21, 7:00 p.m.; the Industry-Supported Breakfast Symposium, "Managing the Spectrum of Psychotic Disorders," Monday, May 19, and Tuesday, May 20, 7:00 a.m.; the APA's Solomon Carter Fuller Award Lecture, Thursday, May 22, 11:00 a.m.

**Bristol-Myers Squibb Sweden:** support of the Luncheon for US and International Residents: "Patients Who Want to Die: Are they Suicidal and Where do they Fit Into the DSM?" Sunday, May 18, 12 noon.

**Center for Mental Health Services:** support of the APIRE Practice Research Network, and support of APA's HIV-related education programs and materials.(PRN).

**Center for Substance Abuse Treatment:** support of the APIRE Practice Research Network (PRN).

**Cephalon Inc.:** support of the Industry-Supported Symposia, "Depression, Apathy, and Fatigue in Neuropsychiatric Disorders," Sunday, May 18, 1:30 p.m.; and the Industry-Supported Breakfast Symposium, "Managing Anxiety and Sleep: A New Era for Gamma-Aminobutyric Acid," Monday, May 19, and Tuesday, May 20, 7:00 a.m.

**Eisai Inc., Pfizer Inc.:** support of the Industry-Supported Symposium, "Challenges in Dementia: Evidence-Based Considerations From Early Diagnosis to Long-Term Management," Wednesday, May 21, 7:00 p.m.

**Eli Lilly and Company:** support of the Industry-Supported Symposia, "Enhancing Outcomes by Addressing Critical Challenges in the Treatment of Schizophrenia," Saturday, May 17, 6:00 p.m.; "An Integrated Approach to the Management of Bipolar Disorder: An Alliance of Science and

Medicine," Sunday, May 18, 8:00 a.m.; "Pharmacological Treatment of Chronic Pain: Comorbidity With Depression and Other Psychotic Disorders," Sunday, May 18, 1:30 p.m.; "Medical Considerations in the Management of Special Patient Populations," Sunday, May 18, 7:00 p.m.; the Industry-Supported Breakfast Symposium, "Treating Depression: What Matters?" Monday, May 19, and Tuesday, May 20, 7:00 a.m.; partial support of the Simon Bolivar Award Lecture, Monday, May 19, 2:00 p.m.; the APA/Lilly Resident Research Awards; partial support of the *New Research Abstracts and New Research Program Books*; and support of the Daniel Freedman Congressional Fellowship.

**Estate of Kun-Po Soo, M.D., Ph.D.:** support of the Kun-Po Soo Award Lecture, Thursday, May 22, 9:00 a.m.

**Estate of Agnes Purcell McGavin:** support of the Agnes Purcell McGavin Awards in child and adolescent psychiatry.

**Forest Laboratories, Inc.:** support of the Industry-Supported Symposia, "Anxiety Disorders: Sources, Signs, and Solutions," Saturday, May 17, 12:30 p.m.; "Optimizing Efficacy and Tolerability of Antidepressant Therapy: Does Selectivity of Action Matter?" Saturday, May 17, 6:00 p.m.; and "New Challenges in the Management of Depression," Sunday, May 18, 1:30 p.m.

**Foundations' Fund for Research in Psychiatry:** co-support of the APA Award for Research in Psychiatry.

**GlaxoSmithKline:** support of the Industry-Supported Symposia, "Bipolar Disorder: Strategies for Stabilizing Patients Over the Long Term," Saturday, May 17, 12:30 p.m.; "Moods, Cycles, and Motherhood," Sunday, May 18, 8:00 a.m.; "Barriers to Optimal Outcome in Anxiety and Depression," Sunday, May 18, 1:30 p.m.; "Real-World Challenges in Depression and Anxiety," Tuesday, May 20, 7:00 p.m.; "Combined Pharmacotherapy for Bipolar Disorders," Wednesday, May 21, 7:00 p.m.; the Industry-Supported Breakfast Symposium, "Bipolar Disorder in Women: Special Considerations and Evolving Treatment," Monday, May 19, and Tuesday, May 20, 7:00 a.m.; the APA/GlaxoSmithKline Fellowship Program; the annual contribution to the APA Presidential Fund; the APA/GlaxoSmithKline Young Faculty Award for Research Development in Biological Psychiatry; support of the APIRE/GlaxoSmithKline Health Services Research Awards; support of the APIRE/GlaxoSmithKline Severe Mental Illness Fellowship; and the registration portfolios.

**Gralnick Foundation:** support of the Alexander Gralnick, M.D., Award for Research in Schizophrenia.

**Ittleson Foundation, Inc.:** support of the Blanche F. Ittleson Award for Research in Child Psychiatry.

**Janssen Pharmaceutica and Research Foundation:** support of the Industry-Supported Symposia, "Schizophrenia Treatment in the Community: The Role of Long-Acting Antipsychotics," Saturday, May 17, 12:30 p.m.; "New Strategies for Managing Bipolar Disorder," Saturday, May 17, 6:00 p.m.; "Treatment of Comorbidity in Neuropsychiatric Disorders in Children and Adolescents," Sunday, May 18, 7:00 p.m.; "Facing Unmet Needs: Atypical Antipsychotics for Mood and Anxiety," Tuesday, May 20, 7:00 p.m.; "Compassionate and Safe Emergent Care: Best Practices in Antipsychotic Use," Wednesday, May 21, 7:00 p.m.; the Industry-Supported Breakfast Symposium, "Neuropsychiatry in the Age of Polypharmacy," Wednesday, May 21, and Thursday, May 22, 7:00 a.m.; and the American Psychiatric Institute for Research and Education/Janssen Research Scholars on Severe Mental Illness Program.

**Lilly Research Laboratories, a division of Eli Lilly & Company:** support of the APA/Lilly Psychiatric Research Fellowship.

# SPECIAL ACKNOWLEDGMENTS

May 18, 7:00 p.m.; support of the William C. Menninger Memorial Convocation Lecture, Monday, May 19, 6:00 p.m.; and an unrestricted educational grant in support of various scientific sessions.

**National Institute of Mental Health:** support of American Psychiatric Institute for Research and Education (APIRE) Annual Meeting activities for research trainees, the Program for Minority Research Training in Psychiatry (PMRTP); and the Research Colloquium for Junior Investigators.

**National Institute on Drug Abuse:** support of the American Psychiatric Institute for Research and Education/Research Training activities and the Drug Abuse Research Scholars in Psychiatry Program (DARSPP).

**Novartis Pharmaceuticals Corporation:** support of the Industry-Supported Symposium, "Reducing Suicidality in Schizophrenia and Bipolar Disorder," Sunday, May 18, 7:00 p.m.; "Slowing Disease Progression and the Long-Term Management of Dementia," Tuesday, May 20, 7:00 p.m.; "Juvenile Bipolar Disorder: Contemporary Issues in Research," Wednesday, May 21, 7:00 p.m.; and the Industry-Supported Breakfast Symposium, "Treating ADHD Across the Life Cycle," Wednesday, May 21, and Thursday, May 22, 7:00 a.m.

**Organon Inc.:** support of the Industry-Supported Symposia, "Enhancing Skill Treating Comorbid Depression and Neurological Illness," Sunday, May 18, 8:00 a.m.; and "Tricks of the Trade in the Long-Term Treatment of Depression," Sunday, May 18, 1:30 p.m.

**Ortho-McNeil Pharmaceuticals:** support of the Industry-Supported Symposium, "A Comprehensive Approach to Managing Bipolar Disorder: Bench to Bedside and Beyond," Sunday, May 18, 7:00 p.m.; "Bipolar Disorder: Clinical and Public Health Implications of Medical and Psychiatric Comorbidity," Wednesday, May 21, 7:00 p.m.; and the Industry-Supported Breakfast Symposium, "Obesity in Psychiatric Practice: Recognition and Treatment," Wednesday, May 21, and Thursday, May 22, 7:00 a.m.

**Otsuka Pharmaceuticals:** support of the International Medical Graduate (IMG) Hospitality Suite.

**Professional Risk Management Services, Inc.:** co-support of the Manfred S. Guttmacher Award Lecture, Sunday, May 18, 2:30 p.m.

**Pfizer Inc.:** support of the Industry-Supported Symposia, "Beyond Benzodiazepines: New Molecules for the Treatment of Anxiety," Saturday, May 17, 6:00 p.m.; "Psychiatry and Medicine: Common Patients, Different Perspectives," Sunday, May 18, 7:00 p.m.; and "Optimizing Treatment for Patients With Schizophrenia: Targeting Positive Patient Outcomes," Tuesday, May 20, 7:00 p.m.; the Residents' Session, "Meet the Experts: Sunny-Side Up," Monday, May 20, 7:00 a.m.; the "Abstracts-On-Disk" Program; and the APA *Daily Bulletin* newspaper; partial support of the Simon Bolivar Award Lecture, Monday, May 19, 2:00 p.m.

**The Psychiatrist's Program, The APA-Endorsed Professional Liability Insurance Program:** support of the ECP luncheon, Tuesday, May 20, 12 noon

**Sanofi-Synthelabo, Inc.:** support of the Industry-Supported Breakfast Symposium, "Insomnia in Today's Society: Consequences and Treatments," Wednesday, May 21, and Thursday, May 22, 7:00 a.m.; support of the Residents, Medical Student, and Training Directors Luncheon, Tuesday, May 20, 12 noon.

**Shire U.S., Inc.:** support of the four APA/Shire Child and Adolescent Psychiatry Fellowships

**Solvay Pharmaceuticals, Inc.:** support of the Industry-Supported Breakfast Symposium, "Impulsivity, Aggression, and Suicide: Versatility of Lithium and Mood Stabilizers," Monday, May 19, and Tuesday, May 20, 7:00 a.m.; and the beverage service in the exhibit hall.

**Substance Abuse and Mental Health Services Administration:** sponsorship of the APA/SAMIISA Minority Fellowship Program

**University of California – Davis, Department of Psychiatry:** support of the Residents, Fellows and Medical Student's Reception, Monday, May 19, 5:00 p.m.

**Wyeth Pharmaceuticals:** support of the Industry-Supported Symposia, "Remission in Psychiatric Disorders: Definitions, Issues, and Treatments," Sunday, May 18, 8:00 a.m.; "Stress, Psychopathology, and the Brain: Novel Intervention Strategies," Sunday, May 18, 1:30 p.m.; "Women and Psychiatric Disorders: Does Gender Matter for Treatment?" Tuesday, May 20, 7:00 p.m.; "Striving to Heal the Mind: The Challenge of PTSD," Wednesday, May 21, 7:00 p.m.; the Industry-Supported Breakfast Symposium, "Evidence-Based Treatment of Psychiatric Disorders," Monday, May 19, and Tuesday, May 20, 7:00 a.m.; the APA/Wyeth Pharmaceuticals M.D./Ph.D. Psychiatric Research Fellowship, the Women's Resource Center and Display; the Alexandra Symonds Award Lecture, Wednesday, May 21, 2:00 p.m.; the Jeanne Spurlock, M.D. Congressional Fellowship; and the daily in-house TV program, "APA Event News Network."

# FORMAT DESCRIPTIONS

## ADVANCES IN PSYCHOTHERAPY

This three-and-one-half hour session will summarize important new clinical and research findings in the treatments of selected psychiatric disorders, with an emphasis on psychotherapeutic interventions. The symposium will be based in part, on material contained in the American Psychiatric Publishing textbook edited by Glen Gabbard, M.D., and entitled, *The Treatments of Psychiatric Disorders, Third Edition*. Authors of selected chapters from the textbook will present material from their chapters. The topics were selected by the editor to represent disorders of particular current interest to psychiatrists and to focus on aspects of psychotherapy that may be of greatest importance to APA members.

## ADVANCES IN RESEARCH

This two-hour session is traditionally chaired by the Chairperson of the Council on Research and co-chaired by the Chairperson of the Scientific Program Committee. After a brief overview of major advances in research in psychiatry and a preview of selected research presentations scheduled at the Annual Meeting, leading clinical researchers present the latest developments in four different, clinically-relevant areas of research.

## CLINICAL CASE CONFERENCES

During these 90-minute sessions, clinical material is presented by videotape or the treating therapist. One or more experts then discuss the case. **THESE SESSIONS ARE OPEN TO APA MEMBERS ONLY. BLUE REGISTRATION BADGE OR APA MEMBERSHIP CARD REQUIRED FOR ADMITTANCE.**

## CONTINUOUS CLINICAL CASE CONFERENCES

The presenters will review the progress of psychotherapy in two successive three-hour sessions on consecutive days (Monday-Tuesday and Wednesday-Thursday, beginning at 9:00 a.m.). Audience participation will be encouraged throughout. Participants are requested to attend both sessions in their entirety. **THESE SESSIONS ARE OPEN TO APA MEMBERS ONLY. BLUE REGISTRATION BADGE OR APA MEMBERSHIP CARD REQUIRED FOR ADMITTANCE.**

## COURSES

Courses are designed to emphasize learning experiences that actively involve participants and include the opportunity for informal exchange with the faculty. Offered in four-hour (half-day) and six-hour (full-day), and eight-hour (full-day) sessions, courses either review basic concepts in a special subject area or present advanced material on a circumscribed topic. Enrollment is limited, and participants must purchase tickets to attend.

## DEBATES

Experts in the field, including psychiatrists and nonpsychiatrists, will debate a controversial topic in psychiatry. The debate format allows for members to hear both pro and con views about important, interesting and timely concerns for our members. Someone who has expertise in the topic area moderates the debate. A portion of the time is allocated for questions from the audience to the presenters with active participation by participants.

## DISCUSSION GROUPS

This 90-minute format allows small groups to meet informally with selected experts in psychiatry to discuss topics chosen by the experts. Some of these are reserved for residents only. These sessions are limited to 25 participants on a first-come, first-served basis.

## FORUMS

These are flexible presentations that afford an opportunity to highlight and select topics that are of timely interest to psychiatrists. Speakers

and panel members are chosen for their expertise and leadership in the field.

## LECTURES

Lectures feature a small number of distinguished speakers discussing scientific and cultural topics, many of which will extend our understanding beyond the usual limits of clinical psychiatry. The Scientific Program Committee invites the lecturers.

## MASTER EDUCATOR CLINICAL CONSULTATIONS

These 90-minute, clinically-based seminars are presented by outstanding educators. Formats and subject matter will vary, but all will utilize clinical material offered by participants. These sessions are limited to 25 participants on a first-come, first-served basis. **THESE SESSIONS ARE OPEN TO APA MEMBERS ONLY. BLUE REGISTRATION BADGE OR APA MEMBERSHIP CARD REQUIRED FOR ADMITTANCE.**

## MEDICAL UPDATES

These 90-minute sessions are designed to provide psychiatrists with the latest clinical developments in other areas of medicine. Topics may range from subspecialty areas of adult or pediatric medicine (infectious disease, cardiology, gastroenterology, etc.) to new techniques or procedures in surgery or radiology. The interface between psychiatry and these areas is not necessarily emphasized. The intent is to give participants an update from a physician in a particular specialty.

## NEW RESEARCH

This format allows for presentation of the very recent findings. The three types of presentations include: Posters, which are visual, self-explanatory presentations; and Young Investigators' Posters, with presentations from young investigators, residents, medical students, and research or clinical fellows; and Young Investigators' Oral/Slide which are fifteen-minute presentations with three minutes for discussion.

## RESEARCH ADVANCES IN MEDICINE

This two-hour format presents an overview of cutting-edge research in various aspects of medicine. In contrast to the Medical Update series, which is more clinically focused, this session will help participants keep pace with the rapidly expanding knowledge base and technology in various branches of medicine. Several speakers, authorities in their fields, will present on their topics.

## RESEARCH CONSULTATIONS WITH

This 90-minute format provides an opportunity, in a small group setting, for participants to obtain consultations around problems in research from outstanding senior researchers. Participants should come prepared to present a specific problem in research, whether it's one of research design, methodology, subject selection or data analysis, etc., which could be presented briefly to the consultant. These sessions are limited to 25 participants on a first-come, first-served basis.

## REVIEW OF PSYCHIATRY

There will be four, three-and-one-half hour sessions presented, based on the annual American Psychiatric Press Review of Psychiatry Series. Each session includes an abridged presentation by the senior author from each of the chapters in each volume. The topics were selected by the overall editors of the series to represent current areas of new research, new developments in clinical care, and special issues of importance to APA members.

## SCIENTIFIC AND CLINICAL REPORT SESSIONS

Scientific and Clinical Reports are oral presentations of papers prepared for submission before publication. In this 90-minute format, reports are grouped by topic, with floor discussion from the audience following the presentation of each paper. There is no formal discussant.

# FORMAT DESCRIPTIONS

---

## **SYMPOSIA**

Symposia are three-hour sessions consisting of four to six presentations that are thematically linked and focus on a specific topic relevant to clinical psychiatry. They are designed to provide comprehensive treatment of a topic or discussion of the topic from several points of view by the participants and stimulate discussion with the audience. Some symposia are supported by industry and are designated as "Industry-Supported Symposium" in this *Program Book*.

## **WORKSHOPS**

Workshops are 90-minute sessions, which typically involve brief presentations from individual panel members, followed by the opportunity for lively and informative discussion. This format provides for substantial audience participation and should be highly interactive.

# AMERICAN PSYCHIATRIC ASSOCIATION

## CONTINUING MEDICAL EDUCATION POLICY ON FULL DISCLOSURE

The American Psychiatric Association requires disclosure by presenters at CME activities of any significant financial or other affiliation with commercial goods/organization(s) that may have a direct or indirect interest in the subject matter of the scientific program. A "financial interest" may include, but is not limited to, being a shareholder in the organization; being on retainer with the organization; or having research or honoraria paid by the organization. An "affiliation" may include holding a position on an advisory committee or some other role or benefit to a supporting organization. The existence of such relationships does not necessarily constitute a conflict of interest, but the prospective audience must be informed of the presenter's affiliation with every commercial supporter by an acknowledgement in the printed program and oral or visual disclosure to participants at the session (disclosure by slide or overhead is required if audiovisual equipment is used for the presentation). This policy is intended to openly identify any potential conflict(s) so that members of the audience in an educational activity are able to form their own judgments about the presentation. The APA also requires oral disclosure of discussion of unapproved uses of a commercial product or investigational use of a product not yet approved for this purpose.

**The following presenters have indicated a significant financial interest or other affiliation with a commercial supporter of the session and/or with the manufacturer(s) of a commercial product(s) and/or provider of commercial service(s). The presenter's name, the manufacturer's name, and the page number(s) the presenter appears on in this *Program Book* are listed below:**

Presenter	Manufacturer(s)	Program Page #
Hagop S. Akiskal, M.D.	Abbott Laboratories; Janssen Pharmaceutica and Research Foundation; Lilly Research Laboratories, a division of Eli Lilly and Company; U.S. Pharmaceuticals, Pfizer Inc.	56, 77, 96
Michael H. Allen, M.D.	AstraZeneca Pharmaceuticals; Janssen Pharmaceutica and Research Foundation	9, 80
David B. Allison, Ph.D.	Ortho-McNeil Pharmaceuticals	61
Lori L. Altshuler, M.D.	Forest Laboratories, Inc.; Cephalon	35, 81
Michael G. Aman, Ph.D.	Janssen Pharmaceutica and Research Foundation; Celgene Corporation	32
Paul J. Ambrosini, M.D.	Shire Pharmaceutical	68
Peter D. Anderson, Pharm.D.	Abbott Laboratories; U.S. Pharmaceuticals, Pfizer Inc.	19
Stuart A. Anfang, M.D.	Unumprovident Corporation	65
David B. Arciniegas, M.D.	Organon Inc.	6
Scott C. Armstrong, M.D.	U.S. Pharmaceuticals, Pfizer Inc.	37
John W. Ashford, Jr., M.D.	Janssen Pharmaceutica, Bowles-Langley Technology (BLT)	54
Ron Aubert, Ph.D.	Medco Health Solutions, Inc.	90
Peter M. Aupperle, M.D.	Janssen Pharmaceutica and Research Foundation; Novartis Pharmaceuticals Corporation; Abbott Laboratories	62
Rahn K. Bailey, M.D.	AstraZeneca Pharmaceuticals; Eli Lilly and Company; Janssen Pharmaceutica and Research Foundation	41
Robert W. Baker, M.D.	Eli Lilly and Company	16, 22, 25
Claudia F. Baldassano, M.D.	AstraZeneca Pharmaceuticals	11
Ross J. Baldessarini, M.D.	Novartis Pharmaceuticals Corporation	12
John Barry, M.D.	GlaxoSmithKline; Cyberonics	5
Elizabeth A. Baxter, M.D.	Novartis Pharmaceuticals Corporation; Eli Lilly and Company	32
Anne E. Becker, M.D.	Wyeth-Ayerst Laboratories	70
Jeffrey L. Berlant, M.D.	Ortho-McNeil Pharmaceutical	31
John L. Beyer, M.D.	Eli Lilly and Company; GlaxoSmithKline; SmithKline Beecham Pharmaceuticals; Organon Inc.	81
Rebecca S. Bierman, D.O.	Eli Lilly and Company; GlaxoSmithKline; Wyeth-Ayerst Laboratories; Organon Inc.	40
Pierre Blier, M.D.	Organon Inc.; Eli Lilly and Company; Janssen Pharmaceutica and Research Foundation; U.S. Pharmaceuticals, Pfizer Inc.; Forest Laboratories, Inc.; Asahi	58
Mina S. Bobdey, M.R.C.	Central North West London NMS Trust ( <i>employer</i> )	47
Howard E. Book, M.D.	American Psychiatric Press Inc.	7, 55
Jacques Bradwejn, M.D.	GlaxoSmithKline; Wyeth-Ayerst Laboratories; Servier; Novartis Pharmaceuticals Corporation	90
Kathleen T. Brady, M.D.	Lilly Research Laboratories, a division of Eli Lilly and Company; Abbott Laboratories; U.S. Pharmaceuticals, Pfizer Inc.	96
Stephen K. Brannan, M.D.	Eli Lilly and Company	44
Olga Brawman-Mintzer, M.D.	Janssen Pharmaceutica and Research Foundation	58
William Breitbart, M.D.	Janssen Pharmaceutica and Research Foundation; Purdue Pharma; Ortho-Biotech; Cephalon; Bristol-Myers Squibb	10, 78, 94
Alan S. Brown, M.D.	Bristol-Myers Squibb	45
Thomas E. Brown, Ph.D.	American Psychiatric Press Inc.; Cephalon; Eli Lilly and Company; GlaxoSmithKlineBeecham Healthcare; McNeil Consumer Healthcare; Novartis Pharmaceuticals Corporation; U.S. Pharmaceuticals, Pfizer Inc.; Shire Ridgewood Pharmaceuticals; The Psychological Corporation; Yale University	1, 5, 14



Presenter	Manufacturer(s)	Program Page #
Peter Burnett, B.M.	Bristol-Myers Squibb; U.S. Pharmaceuticals, Pfizer Inc.	79
Charles A. Buscema, M.D.	Eli Lilly and Company; U.S. Pharmaceuticals, Pfizer Inc.; AstraZeneca Pharmaceuticals	32
John B. Buse, M.D.	Eli Lilly and Company	3
Marian I. Butterfield, M.D.	Lilly Research Laboratories, a division of Eli Lilly and Company; U.S. Pharmaceuticals, Pfizer Inc.; GlaxoSmithKline; Organon Inc.	55
Joseph R. Calabrese, M.D.	National Institute of Mental Health; Abbott Laboratories; Ciba-Geigy; Merck & Co., Inc.; GlaxoSmithKline; Janssen Pharmaceutica and Research Foundation; Lilly Research Laboratories, a division of Eli Lilly and Company; MacArthur Foundation; National Alliance for Schizophrenia and Affective Disorders; Parke-Davis, Division of Warner-Lambert Company; Robert Wood Johnson Pharmaceutical Research Institute; Sandoz Pharmaceuticals Corporation; SmithKline Beecham Pharmaceuticals; Stanley Foundation; TAP Holdings; UCB Pharma; Wyeth-Ayerst Laboratories	2, 58, 77
Lori Calabrese, M.D.	GlaxoSmithKline	8
Charles F. Caley, Pharm.D.	AstraZeneca Pharmaceuticals; Bristol-Myers Squibb; Eli Lilly and Company; Janssen Pharmaceutica and Research Foundation; U.S. Pharmaceuticals, Pfizer Inc.	69
Jose M. Canive, M.D.	Janssen Pharmaceutica and Research Foundation; Bristol-Myers Squibb; Wyeth-Ayerst Laboratories; AstraZeneca Pharmaceuticals; Lilly Research Laboratories, a division of Eli Lilly and Company	76
Linda L. Carpenter, M.D.	Wyeth-Ayerst Laboratories	82
Diana Carter, M.B.	GlaxoSmithKline	48
David A. Casey, M.D.	U.S. Pharmaceuticals, Pfizer Inc.; Novartis Pharmaceuticals Corporation; Janssen Pharmaceutica and Research Foundation	22, 44
Carlyle H. Chan, M.D.	Forest Laboratories, Inc.; U.S. Pharmaceuticals, Pfizer Inc.	24, 48
Mark C. Chandler, M.D.	NC Neuropsychiatry	68
Kiki D. Chang, M.D.	Abbott Laboratories; Eli Lilly and Company; GlaxoSmithKline; Janssen Pharmaceutica and Research Foundation; Ortho-McNeil Pharmaceuticals	6, 44, 50
Dennis S. Charney, M.D.	AstraZeneca Pharmaceuticals; Abbott Laboratories; Bristol-Myers Squibb; Cypress Bioscience; Eli Lilly and Company; Janssen Pharmaceutica and Research Foundation; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; Organon Inc.; U.S. Pharmaceuticals, Pfizer Inc.; R.W. Johnson Pharmaceutical Research Institute; SmithKline Beecham Pharmaceuticals; Somerset Pharmaceuticals, Inc.; Vela Pharmaceuticals	77
Henry Chung, M.D.	U.S. Pharmaceuticals, Pfizer Inc.	91
Leslie L. Citrome, M.D.	Abbott Laboratories; AstraZeneca Pharmaceuticals; Eli Lilly and Company; Janssen Pharmaceutica and Research Foundation; U.S. Pharmaceuticals, Pfizer Inc.; Bristol-Myers Squibb; Novartis Pharmaceuticals Corporation	3, 75
Lee S. Cohen, M.D.	Forest Laboratories, Inc.; Janssen Pharmaceutica and Research Foundation; Eli Lilly and Company; Wyeth-Ayerst Laboratories; GlaxoSmithKline; Solvay Pharmaceuticals, Inc.; U.S. Pharmaceuticals, Pfizer Inc.; Berlex Laboratories	12, 13, 35, 59
Robert R. Conley, M.D.	Janssen Pharmaceutica and Research Foundation	80
Larry Culpepper, M.D.	U.S. Pharmaceuticals, Pfizer Inc.; Forest Laboratories, Inc.	8, 11
Jeffrey L. Cummings, M.D.	U.S. Pharmaceuticals, Pfizer Inc.; Eisai Inc.; Janssen Pharmaceutica and Research Foundation; Novartis Pharmaceuticals Corporation; Lilly Research Laboratories, a division of Eli Lilly and Company; Onon-Syn-X	6, 10, 15, 51
Jonathan R.T. Davidson, M.D.	Wyeth-Ayerst Laboratories; Forest Laboratories, Inc.	2, 82
Jose de Leon, M.D.	Eli Lilly Research Foundation; Bristol-Myers Squibb; U.S. Pharmaceuticals, Pfizer Inc.	86
Charles DeBattista, M.D.	Forcept Therapeutic; U.S. Pharmaceuticals, Pfizer Inc.; Organon Inc.; Cephalon; Lilly Research Laboratories, a division of Eli Lilly and Company; Bristol-Myers Squibb; GlaxoSmithKline	11
Melissa P. DelBello, M.D.	AstraZeneca Pharmaceuticals; Abbott Laboratories; Eli Lilly and Company; Ortho-McNeil Pharmaceuticals; GlaxoWellcome; Janssen Pharmaceutica and Research Foundation; U.S. Pharmaceuticals, Pfizer Inc.	9, 43
J. Raymond DePaulo, Jr., M.D.	National Institute of Mental Health; Stanley Foundation Bipolar Disorder Research Center; GlaxoSmithKline; Eli Lilly and Company; Abbott Laboratories; Wyeth-Ayerst Laboratories; Pharmacia & Upjohn Company, Inc.; U.S. Pharmaceuticals, Pfizer Inc.; Janssen Pharmaceutica and Research Foundation; Forest Laboratories, Inc.; Solvay Pharmaceuticals, Inc.; Depression and Related Affective Disorders Association; National Association for Research on Schizophrenia and Depression; National Depressive and Manic-Depressive Association; American Foundation for the Prevention of Suicide	19
Mantosh J. Dewan, M.D.	Lilly Research Laboratories, a division of Eli Lilly and Company; U.S. Pharmaceuticals, Pfizer Inc.	29, 36, 92
Eric W. Dieperink, M.D.	Schering-Plough	92
Joel E. Dimsdale, M.D.	Endo Pharmaceuticals; Eli Lilly and Company	52
P. Murali Doraiswamy, M.D.	Novartis Pharmaceuticals Corporation	58, 83

## DISCLOSURE INDEX

Presenter	Manufacturer(s)	Program Page #
Steven L. Dubovsky, M.D.	U.S. Pharmaceuticals, Pfizer Inc.; Janssen Pharmaceutica and Research Foundation; Bristol-Myers Squibb; Merck & Co., Inc.; Forest Laboratories, Inc.; Wyeth-Ayerst Laboratories; Organon Inc.	6
Mina K. Dulcan, M.D.	Eli Lilly and Company; Celltech Pharmaceuticals	28
Eduardo Dunayevich, M.D.	Eli Lilly and Company	15
David L. Dunner, M.D.	GlaxoSmithKline	59
Richard L. Elliott, M.D.	U.S. Pharmaceuticals, Pfizer Inc.	5
Pete M. Ellis, B.M.	GlaxoSmithKline; Eli Lilly and Company; U.S. Pharmaceuticals, Pfizer Inc.; Bayer Corporation, Pharmaceutical Division; Bristol-Myers Squibb; Boots Pharmaceuticals; Roche Laboratories, a member of the Roche Group; Shire Ridgewood Pharmaceuticals	79
C. Neill Epperson, M.D.	GlaxoSmithKline	6
Javier I. Escobar, M.D.	U.S. Pharmaceuticals, Pfizer Inc.; Wyeth-Ayerst Laboratories; Bristol-Myers Squibb; Johnson and Johnson	15, 51
Dwight L. Evans, M.D.	GlaxoSmithKline; Abbott Laboratories; AstraZeneca Pharmaceuticals; Bristol-Myers Squibb; Eli Lilly and Company; Forest Laboratories, Inc.; Janssen Pharmaceutica and Research Foundation; Novartis Pharmaceuticals Corporation; Organon Inc.; U.S. Pharmaceuticals, Pfizer Inc.; Somerset Pharmaceuticals, Inc.; Wyeth-Ayerst Laboratories	3
Stephen V. Faraone, Ph.D.	McNeil Consumer & Specialty Pharmaceutical	61, 81, 87
Maurizio Fava, M.D.	Eli Lilly and Company; SmithKline Beecham Pharmaceuticals; U.S. Pharmaceuticals, Pfizer Inc.; Wyeth-Ayerst Laboratories; Organon Inc.; Bristol-Myers Squibb; Pharmacia & Upjohn Company, Inc.; GlaxoWellcome; Solvay Pharmaceuticals, Inc.; Forest Laboratories, Inc.; Sanofi/Synthelabo Pharmaceuticals; Janssen Pharmaceutica and Research Foundation; Lundbeck; Knoll Pharmaceuticals; Parke-Davis, Division of Warner-Lambert Company; Somerset Pharmaceuticals, Inc.; Pharmavite; Abbott Laboratories; Roche Laboratories, a member of the Roche Group; Novartis Pharmaceuticals Corporation; Lorex Pharmaceuticals; Litchwer Pharma GmbH	9, 89
Jacqueline M. Feldman, M.D.	Janssen Pharmaceutica and Research Foundation	1
David Fishbain, M.D.	Eli Lilly and Company	9
Robert S. Fisher, M.D.	Novartis Pharmaceuticals Corporation; Ivax Medtronic, Nicolet; Cognetix; GlaxoSmithKline; Ortho-McNeil Pharmaceuticals; UCB Pharma; U.S. Pharmaceuticals, Pfizer Inc.	5
George A. Fouras, M.D.	Janssen Pharmaceutica and Research Foundation	46
Richard J. Frances, M.D.	Forest Laboratories, Inc.; Lilly Research Laboratories, a division of Eli Lilly and Company; U.S. Pharmaceuticals, Pfizer Inc.; Wyeth-Ayerst Laboratories	86
Ellen Frank, Ph.D.	Eli Lilly and Company; Ortho-McNeil Pharmaceuticals	6, 11
Mark A. Frye, M.D.	Abbott Laboratories; American Foundation for Suicide Prevention; GlaxoSmithKline; National Institute of Mental Health; U.S. Pharmaceuticals, Pfizer Inc.; Solvay Pharmaceuticals, Inc.; Stanley Foundation; Cephalon; Elan Pharmaceuticals, Eli Lilly and Company; Janssen-Cilag; Novartis Pharmaceuticals Corporation; Ortho-McNeil Pharmaceuticals; UCB Pharma; Bristol-Myers Squibb	2, 11, 81
Glen O. Gabbard, M.D.	Merck & Co., Inc.	50, 78
Rollin Gallagher, M.D.	Eli Lilly and Company	9
David R. Gastfriend, M.D.	Earley Corporation; Bristol-Myers Squibb; Eli Lilly and Company; Purdue; Tele-Sage, Inc.	31
Albert C. Gaw, M.D.	Eli Lilly and Company	66
Mark S. George, M.D.	Janssen Pharmaceutica and Research Foundation; Lilly Research Laboratories, a division of Eli Lilly and Company; GlaxoSmithKline; Solvay Pharmaceuticals, Inc./Dupha; Parke-Davis, Division of Warner-Lambert Company; Picker International; Dantec; Neotonus, Inc., Cyberonics, Inc. Dupont Pharma; Medipysics/Amersham	8, 15
S. Nassir Ghaemi, M.D.	Janssen Pharmaceutica and Research Foundation; AstraZeneca Pharmaceuticals; Novartis Pharmaceuticals Corporation; Abbott Laboratories; GlaxoSmithKline; Forest Laboratories Inc.; Eli Lilly and Company	2, 3, 16, 65, 81, 96
David L. Ginsberg, M.D.	GlaxoSmithKline; Forest Laboratories, Inc.; Organon Inc.; Forest Laboratories, Inc.; U.S. Pharmaceuticals, Pfizer Inc.; Eli Lilly and Company	9
Leslie H. Gise, M.D.	Merck Medco Managed Care	55
William M. Glazer, M.D.	AstraZeneca Pharmaceuticals; Lilly Research Laboratories, a division of Eli Lilly and Company; Bristol-Myers Squibb; Novartis Pharmaceuticals Corporation	32
Ira D. Glick, M.D.	Lilly Research Laboratories, a division of Eli Lilly and Company; Janssen Pharmaceutica and Research Foundation; AstraZeneca Pharmaceuticals; Bristol-Myers Squibb; Otsuka Pharmaceuticals; U.S. Pharmaceuticals, Pfizer Inc.	13, 41, 79, 80
Joseph F. Goldberg, M.D.	AstraZeneca Pharmaceuticals; Abbott Laboratories; Bristol-Myers Squibb; Eli Lilly and Company; Forest Laboratories, Inc.; GlaxoSmithKline; Janssen Pharmaceutica and Research Foundation; Novartis Pharmaceuticals Corporation; U.S. Pharmaceuticals, Pfizer Inc.; RW Johnson; Shire Pharmaceuticals; UCB Pharma, Inc.	6, 78, 81, 89, 96

Presenter	Manufacturer(s)	Program Page #
Stephen M. Goldfinger, M.D.	U.S. Pharmaceuticals, Pfizer Inc.; Lilly Research Laboratories, a division of Eli Lilly and Company; Janssen Pharmaceutica and Research Foundation; AstraZeneca Pharmaceuticals; Bristol-Myers Squibb; IVAX Pharmaceuticals; Mallinckrudt	19, 40, 65, 72
Joseph Gonzalez-Heydrich, M.D.	Novartis Pharmaceuticals Corporation	81
Frederick K. Goodwin, M.D.	Abbott Laboratories; GlaxoSmithKline; Solvay Pharmaceuticals, Inc.; Lilly Research Laboratories, a division of Eli Lilly and Company; Janssen Pharmaceutica and Research Foundation; U.S. Pharmaceuticals, Pfizer Inc.; Forest Laboratories, Inc.; AstraZeneca Pharmaceuticals; Bristol-Myers Squibb; Novartis Pharmaceuticals Corporation; Elan	35, 81
Jack M. Gorman, M.D.	U.S. Pharmaceuticals, Pfizer Inc.; Wyeth-Ayerst Laboratories	3, 36
Kevin F. Gray, M.D.	U.S. Pharmaceuticals, Pfizer Inc.; Lilly Research Laboratories, a division of Eli Lilly and Company; Novartis Pharmaceuticals Corporation	72
Grad Green, M.S.N.	Janssen Pharmaceutica and Research Foundation	80
Laurence L. Greenhill, M.D.	Novartis Pharmaceuticals Corporation; McNeil Pharmaceuticals; Shire Ridgewood Pharmaceuticals; Janssen Pharmaceutica and Research Foundation	44, 56
John H. Greist, M.D.	Eisai Inc.; U.S. Pharmaceuticals, Pfizer Inc.	81
Robert E. Hales, M.D.	Bristol-Myers Squibb; GlaxoSmithKline; Forest Laboratories, Inc.	13, 35
Ellen Haller, M.D.	U.S. Pharmaceuticals, Pfizer Inc.; Forest Laboratories, Inc.; Bristol-Myers Squibb	8, 80
Scott D. Haltzman, M.D.	Dista-Lilly; Janssen Pharmaceutica and Research Foundation	66
Richard Hargreaves, Ph.D.	Merck & Co., Inc.	11
Patrice A. Harris, M.D.	Eli Lilly and Company	32
Peter Hauser, M.D.	Schering Plough; Forest Laboratories, Inc.	92
David C. Henderson, M.D.	Eli Lilly and Company; Janssen Pharmaceutica and Research Foundation; AstraZeneca Pharmaceuticals; U.S. Pharmaceuticals, Pfizer Inc.; Bristol-Myers Squibb	1, 28
Richard G. Hersh, M.D.	Wyeth-Ayerst Laboratories	5
Keisuke Hirai, Ph.D.	Takeda Chemical Industries Ltd.	68
Robert M.A. Hirschfeld, M.D.	Forest Laboratories, Inc.; Eli Lilly and Company	6, 8
Max Hirshkowitz, Ph.D.	Neurocome; Cephalon; Takeda Pharmaceuticals; Sepracore; Sanofi Pharmaceuticals, Inc.; Wyeth-Ayerst Laboratories; Savoti	73
Eric Hollander, M.D.	Solvay Pharmaceuticals, Inc.; Abbott Laboratories; Wyeth-Ayerst Laboratories; U.S. Pharmaceuticals, Pfizer Inc.; Lilly Research Laboratories, a division of Eli Lilly and Company; GlaxoSmithKline	5, 13, 35, 56
William G. Honer, M.D.	AstraZeneca Pharmaceuticals; Janssen Pharmaceutica and Research Foundation; Novartis Pharmaceuticals Corporation; Eli Lilly and Company	40
Michael Y. Hwang, M.D.	Janssen Pharmaceutica and Research Foundation; Eli Lilly and Company; U.S. Pharmaceuticals, Pfizer Inc.	75, 85, 94
Philip G. Janicak, M.D.	Janssen Pharmaceutica and Research Foundation; Bristol-Myers Squibb; Genentech; National Institutes of Health; U.S. Pharmaceuticals, Pfizer Inc.; Bristol-Myers Squibb; Sepracor; AstraZeneca Pharmaceuticals; Forest Laboratories, Inc.; Abbott Laboratories	14
David C. Jimerson, M.D.	Abbott Laboratories	6, 95
Lewis L. Judd, M.D.	Janssen Pharmaceutica and Research Foundation	42
Ned H. Kalin, M.D.	Wyeth-Ayerst Laboratories; Merck & Co., Inc.	9, 10, 11
John M. Kane, M.D.	Abbott Laboratories; Bristol-Myers Squibb; Novartis Pharmaceuticals Corporation; Lundbeck; Janssen Pharmaceutica and Research Foundation; AstraZeneca Pharmaceuticals; U.S. Pharmaceuticals, Pfizer Inc.; Protarga; Aventis	1, 19, 59
Flavio Kapczinski, Ph.D.	GlaxoSmithKline	8
Siegfried Kasper, M.D.	GlaxoSmithKline; Servier; Lundbeck	96
Walter H. Kaye, M.D.	Eli Lilly and Company	30, 95
Paul E. Keck, Jr., M.D.	Eli Lilly and Company; Ortho-McNeil Pharmaceuticals	6, 81
Richard S. Keefe, Ph.D.	Eli Lilly and Company; Wyeth-Ayerst Laboratories	3, 14
Martin B. Keller, M.D.	Wyeth-Ayerst Laboratories	82
Charles H. Kellner, M.D.	Somatics, Inc.	14
Justine M. Kent, M.D.	Forest Laboratories, Inc.	3
Ronald C. Kessler, Ph.D.	Wyeth-Ayerst Laboratories	82
Steven A. King, M.D.	Eli Lilly and Company	9
David G. Kingdon, M.D.	U.S. Pharmaceuticals, Pfizer Inc.; Janssen Pharmaceutica and Research Foundation; Lilly Research Laboratories, a division of Eli Lilly and Company	41
Reidar Kjaer, M.D.	U.S. Pharmaceuticals, Pfizer Inc.; AstraZeneca Pharmaceuticals	50
Herbert D. Kleber, M.D.	Schering Plough Pharma	57, 62
James H. Kocsis, M.D.	Wyeth-Ayerst Laboratories; Forest Laboratories, Inc.; U.S. Pharmaceuticals, Pfizer Inc.	55
Lorin M. Koran, M.D.	Forest Laboratories, Inc.	27, 70, 96
Christopher J. Kratochvil, M.D.	Novartis Pharmaceuticals Corporation; Eli Lilly and Company; Shire Ridgewood Pharmaceuticals; Alza Pharmaceuticals; McNeil Pharmaceuticals	44
John E. Kraus, Jr., M.D.	Eli Lilly and Company; U.S. Pharmaceuticals, Pfizer Inc.; Wyeth-Ayerst Laboratories	69

## DISCLOSURE INDEX

Presenter	Manufacturer(s)	Program Page #
K. Ranga R. Krishnan, M.D.	Eisai Inc.; Novartis Pharmaceuticals Corporation; U.S. Pharmaceuticals, Pfizer Inc.; Forest Laboratories, Inc.; Abbott Laboratories; GlaxoSmithKline; Merck & Co., Inc.; Organon Inc.; AHP; Vela; Synaptic	14, 35, 39
Ziad A. Kronfol, M.D.	GlaxoSmithKline; Merck & Co., Inc.	31
Robert Kushner, M.D.	Ortho-McNeil Pharmaceuticals	61
Beny Lafer, M.D.	Eli Lilly and Company	13
Raymond W. Lam, M.D.	Cyberonics; Eli Lilly and Company; GlaxoSmithKline; Litebook, Inc.; Lundbeck; Organon Inc.; U.S. Pharmaceuticals, Pfizer Inc.; Wyeth-Ayerst Laboratories; AstraZeneca Pharmaceuticals; Janssen Pharmaceutica and Research Foundation; Servier; Merck-Frosst	8
William B. Lawson, M.D.	Janssen Pharmaceutica and Research Foundation; U.S. Pharmaceuticals, Pfizer Inc.; AstraZeneca Pharmaceuticals; Lilly Research Laboratories, a division of Eli Lilly and Company	51, 65
Arthur L. Lazarus, M.D.	U.S. Pharmaceuticals, Pfizer Inc.	71
Leslie L. Lenert, M.D.	University of California, San Diego; Janssen Pharmaceutica and Research Foundation	33
Andrew F. Leuchter, M.D.	Bristol-Myers Squibb; Eli Lilly and Company; Wyeth-Ayerst Laboratories; Pharmacia & Upjohn Company, Inc.; Aspect Medical Systems, Inc.	24, 89
Alan I. Levenson, M.D.	APA Endorsed Psychiatrists' Professional Liability Insurance Program	18
Jeffrey A. Lieberman, M.D.	Eli Lilly and Company	33
Thomas F. Liffick, M.D.	Eli Lilly and Company	3
Mack Lipkin, M.D.	Forest Laboratories, Inc.	2
Sarah H. Lisanby, M.D.	MagStim Company; Neuronetics	2, 36
R. Bruce Lydiard, M.D.	Organon Inc.	9
Constantine Lyketsos, M.D.	Dupont Pharma; Lilly Research Laboratories, a division of Eli Lilly and Company; Janssen Pharmaceutica and Research Foundation; U.S. Pharmaceuticals, Pfizer Inc.; NeuroLogic; AstraZeneca Pharmaceuticals; Parke-Davis, Division of Warner-Lambert Company; Abbott Laboratories; Bayer Corporation, Pharmaceutical Division; Eisai Inc.; Bristol-Myers Squibb; Novartis Pharmaceuticals Corporation; Forest Laboratories, Inc.	19, 51, 62
Subramoniam Madhusoodanan, M.D.	Janssen Pharmaceutica and Research Foundation; Eli Lilly and Company; AstraZeneca Pharmaceuticals; U.S. Pharmaceuticals, Pfizer Inc.	21
Catherine L. Mancini, M.D.	AstraZeneca Pharmaceuticals; Bristol-Myers Squibb; GlaxoSmithKline; Eli Lilly and Company; Janssen-Ortho, Inc.; Lundbeck; U.S. Pharmaceuticals, Pfizer Inc.; Wyeth-Ayerst Laboratories	22
Husseini K. Manji, M.D.	Janssen Pharmaceutica and Research Foundation; Eli Lilly and Company; AstraZeneca Pharmaceuticals; U.S. Pharmaceuticals, Pfizer Inc.	11, 13, 35
Lauren B. Marangell, M.D.	Eli Lilly and Company; Martek Biosciences; Cyberonics; Forest Laboratories, Inc.; Bristol-Myers Squibb; GlaxoWellcomeSmithKline; Janssen Pharmaceutica and Research Foundation; Wyeth-Ayerst Laboratories; Novartis Pharmaceuticals Corporation; AstraZeneca Pharmaceuticals; Pharmacia & Upjohn Company, Inc.	12
Stephen R. Marder, M.D.	Janssen Pharmaceutica and Research Foundation; Lilly Research Laboratories, a division of Eli Lilly and Company; U.S. Pharmaceuticals, Pfizer Inc.; AstraZeneca Pharmaceuticals; Bristol-Myers Squibb	14, 35, 79
John C. Markowitz, M.D.	American Psychiatric Press Inc.; Basic Books; Franco Angeli; Wyeth-Ayerst Laboratories	5, 55
Laura Marsh, M.D.	AstraZeneca Pharmaceuticals; Eisai Inc.; Eli Lilly and Company	51
Randall D. Marshall, M.D.	GlaxoSmithKline	92
Prakash S. Masand, M.D.	AstraZeneca Pharmaceuticals; Janssen Pharmaceutica and Research Foundation; GlaxoSmithKline; Forest Laboratories, Inc.; Wyeth-Ayerst Laboratories; Health Care Technology; U.S. Pharmaceuticals, Pfizer Inc.; Bristol-Myers Squibb; Eli Lilly and Company; Novartis Pharmaceuticals Corporation; Abbott Laboratories	22, 59, 61, 83
Matig R. Mavissakalian, M.D.	U.S. Pharmaceuticals, Pfizer Inc.; Forest Laboratories, Inc.	70
Christopher J. McDougle, M.D.	Janssen Pharmaceutica and Research Foundation	12
Susan L. McElroy, M.D.	Lilly Research Laboratories, a division of Eli Lilly and Company; Janssen Pharmaceutica and Research Foundation; Wyeth-Ayerst Laboratories; U.S. Pharmaceuticals, Pfizer Inc.; AstraZeneca Pharmaceuticals; Abbott Laboratories; Bristol-Myers Squibb; GlaxoSmithKline; Solvay Pharmaceuticals, Inc.; Stanley	11, 56, 77, 83
Bentson H. McFarland, M.D.	Abbott Laboratories; Wyeth-Ayerst Laboratories; Eli Lilly and Company	88
Patrick D. McGorry, M.D.	Janssen Pharmaceutica and Research Foundation; Eli Lilly and Company; Novartis Pharmaceuticals Corporation; Bristol-Myers Squibb; Sanofi Pharmaceuticals, Inc.; U.S. Pharmaceuticals, Pfizer Inc.	52
Hunter L. McQuiston, M.D.	Bristol-Myers Squibb; Janssen Pharmaceutica and Research Foundation	79
Herbert Y. Meltzer, M.D.	Eli Lilly and Company; Janssen Pharmaceutica and Research Foundation; Sanofi Pharmaceuticals, Inc.; U.S. Pharmaceuticals, Pfizer Inc.; AstraZeneca Pharmaceuticals; GlaxoSmithKline; Pharmacia	12, 59, 72
Alejandro Y. Mendoza, M.D.	Lilly Research Laboratories, a division of Eli Lilly and Company; Janssen Pharmaceutica and Research Foundation	19

Presenter	Manufacturer(s)	Program Page #
Ricardo P. Mendoza, M.D.	Janssen Pharmaceutica and Research Foundation; U.S. Pharmaceuticals, Pfizer Inc.	41, 65
Matthew A. Menza, M.D.	National Institutes of Health; U.S. Pharmaceuticals, Pfizer Inc.; Merck & Co., Inc.; Wyeth-Ayerst Laboratories; Cephalon; Lilly Research Laboratories, a division of Eli Lilly and Company; GlaxoSmithKline; Bristol-Myers Squibb; Forest Laboratories, Inc.; Pharmacia & Upjohn Company, Inc.; Novartis Pharmaceuticals Corporation; Hoechst Marion Roussel; Bayer Corporation, Pharmaceutical Division	50, 51
Alexander L. Miller, M.D.	AstraZeneca Pharmaceuticals; Bristol-Myers Squibb; Eli Lilly and Company	40
Ivan W. Miller, Ph.D.	Wyeth Pharmaceuticals	6
Kenneth Minkoff, M.D.	Zialogic, Inc.	14
Shaila Misri, M.D.	GlaxoSmithKline	6, 48
James E. Mitchell, M.D.	Abbott Laboratories; Lilly Research Laboratories, a division of Eli Lilly and Company	6, 30, 95
Stuart A. Montgomery, M.D.	Eli Lilly and Company	3
Robin M. Murray, M.B.	Lilly Research Laboratories, a division of Eli Lilly and Company; Janssen Pharmaceutica and Research Foundation; U.S. Pharmaceuticals, Pfizer Inc.; Synthélabo; AstraZeneca Pharmaceuticals	25
Joseph C. Napoli, M.D.	AstraZeneca Pharmaceuticals; Bristol-Myers Squib; Eli Lilly and Company; GlaxoSmithKline; Forest Laboratories, Inc.; Janssen Pharmaceutica and Research Foundation; Organon Inc.; Solvay Pharmaceuticals, Inc.; U.S. Pharmaceuticals, Pfizer Inc.; Wyeth-Ayerst Laboratories	36
Henry A. Nasrallah, M.D.	AstraZeneca Pharmaceuticals; Janssen Pharmaceutica and Research Foundation; U.S. Pharmaceuticals, Pfizer Inc.; Abbott Laboratories; Bristol-Myers Squibb	11, 59
Charles B. Nemeroff, M.D.	Abbott Laboratories; Acadia Pharmaceuticals; AstraZeneca Pharmaceuticals; Bristol-Myers Squibb; Cephalon Pharmaceuticals; Corcept; Cypress Biosciences; Eli Lilly and Company; Forest Laboratories, Inc.; GlaxoSmithKline; Janssen Pharmaceutica and Research Foundation; Merck & Co., Inc.; NARSAD; National Institute of Mental Health; Neurocrine Biosciences; Novartis Pharmaceuticals Corporation; Organon Inc.; Otsuka Pharmaceuticals; Pharmacia & Upjohn Company, Inc.; Sanofi Pharmaceuticals, Inc.; Somerset; Vela Pharmaceuticals; Pharmacia-Upjohn; Scherring-Plough Corporation; Stanley Foundation/NAMI; U.S. Pharmaceuticals, Pfizer Inc.; Wyeth-Ayerst Laboratories	11, 16, 58
Ruta M. Nonacs, M.D.	Eli Lilly and Company; Janssen Pharmaceutica and Research Foundation	13
Carol S. North, M.D.	Bristol-Myers Squibb; GlaxoSmithKline; U.S. Pharmaceuticals, Pfizer Inc.	61
Andrei Novac, M.D.	U.S. Pharmaceuticals, Pfizer Inc.; GlaxoSmithKline	66
Mary B. O'Malley, M.D.	Cephalon	10, 90
Mark Olfson, M.D.	Bristol-Myers Squibb, Lilly Research Laboratories, a division of Eli Lilly and Company; Wyeth-Ayerst Laboratories	33
Lewis A. Opler, M.D.	Multi-Health Systems, Inc.	18, 25, 75, 94
Michael W. Otto, Ph.D.	Janssen Pharmaceutica and Research Foundation	58
Michelle T. Pato, M.D.	Forest Laboratories, Inc.; Solvay Pharmaceuticals, Inc.	29, 36, 55
Diana O. Perkins, M.D.	AstraZeneca Pharmaceuticals; Eli Lilly and Company	3, 11
Roy H. Perlis, M.D.	Eli Lilly and Company; GlaxoSmithKline	9, 44
Frederick Petty, M.D.	Bristol-Myers Squibb; Janssen Pharmaceutica and Research Foundation; Lilly Research Laboratories, a division of Eli Lilly and Company; Ortho-McNeil Pharmaceuticals; U.S. Pharmaceuticals, Pfizer Inc.	31
Edmond H.T. Pi, M.D.	Eli Lilly and Company	65, 94
Mark H. Pollack, M.D.	Janssen Pharmaceutica and Research Foundation	58
Robert M. Post, M.D.	Abbott Laboratories; AstraZeneca Pharmaceuticals; Bristol-Myers Squibb; GlaxoSmithKline; Johnson and Johnson; Novartis Pharmaceuticals Corporation; Ortho-McNeil Pharmaceuticals; Shire Ridgewood Pharmaceuticals; UCB Pharma	2
Steven G. Potkin, M.D.	Novartis Pharmaceuticals Corporation	58
David W. Preven, M.D.	Forest Laboratories, Inc.; U.S. Pharmaceuticals, Pfizer Inc.	18, 66
Jefferson B. Prince, M.D.	Alza Pharmaceuticals; Celltech; Forest Laboratories, Inc.; GlaxoSmithKline; Lilly Research Laboratories, a division of Eli Lilly and Company; Shire Ridgewood Pharmaceuticals	1, 5, 14
Luis F. Ramirez, M.D.	Bristol-Myers Squibb; Novartis Pharmaceuticals Corporation; U.S. Pharmaceuticals, Pfizer Inc.	32, 76
Paul M. Ramirez, Ph.D.	Multi-Health Systems	25
Penny K. Randall, M.D.	United Behavioral Health	47
Natalie L. Rasgon, M.D.	Abbott Laboratories; Eli Lilly and Company; GlaxoSmithKline; Forest Laboratories, Inc.; U.S. Pharmaceuticals, Pfizer Inc.; Wyeth-Ayerst Laboratories	2, 43, 58
Steven A. Rasmussen, M.D.	Medtronic	75
William E. Reichman, M.D.	Abbott Laboratories; AstraZeneca Pharmaceuticals; Eisai; Janssen Pharmaceutica and Research Foundation; Organon Inc.; U.S. Pharmaceuticals, Pfizer Inc.	62
Roy O. Resnikoff, M.D.	AstraZeneca Pharmaceuticals; Bristol-Myers Squibb; Eli Lilly and Company; Forest Laboratories, Inc.; U.S. Pharmaceuticals, Pfizer Inc.	25, 86

## DISCLOSURE INDEX

Presenter	Manufacturer(s)	Program Page #
Steven P. Roose, M.D.	Forest Laboratories, Inc.	8
Jerrold F. Rosenbaum, M.D.	Eli Lilly and Company; Forest Laboratories, Inc.; Novartis Pharmaceuticals Corporation; Organon Inc.; Wyeth-Ayerst Laboratories; Cyberonics	9, 59, 77
Murray Rosenthal, D.O.	Cephalon; Forest Laboratories, Inc.; Organon Inc.	88
Richard N. Rosenthal, M.D.	Forest Laboratories, Inc.	31, 57, 97
Bryan L. Roth, M.D.	Bristol-Myers Squibb	59
Barbara O. Rothbaum, Ph.D.	Bristol-Myers Squibb; U.S. Pharmaceuticals, Pfizer Inc.; Virtually Better; Wyeth-Ayerst Laboratories	82
A. John Rush, M.D.	Bristol-Myers Squibb; Cyberonics, Inc.; Eli Lilly and Company; Forest Laboratories, Inc.; GlaxoSmithKline; Janssen Pharmaceutica and Research Foundation; Merck & Co., Inc.; National Institute of Mental Health; Robert Wood Johnson Foundation; Stanley Foundation; Wyeth-Ayerst Laboratories	6, 11
J. Michael Ryan, M.D.	Abbott Laboratories; Bristol-Myers Squibb	5, 13
Jerónimo Saiz-Ruiz, M.D.	Lilly Research Laboratories, a division of Eli Lilly and Company; U.S. Pharmaceuticals, Pfizer Inc.	86
Floyd R. Sallee, M.D.	Lilly Research Laboratories, a division of Eli Lilly and Company; Shire Ridgewood Pharmaceuticals	27, 68, 96
Betty Jo Salmeron, M.D.	Novartis Pharmaceuticals Corporation	61, 83
Randy A. Sansone, M.D.	U.S. Pharmaceuticals, Pfizer Inc.	76
Alan F. Schatzberg, M.D.	Abbott Laboratories; Aventis; Bristol-Myers Squibb; Corcept; Eli Lilly and Company; Forest Laboratories, Inc.; GlaxoSmithKline; Innapharma; Janssen Pharmaceutica and Research Foundation; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; Organon Inc.; Pharmacia & Upjohn Company, Inc.; Solvay Pharmaceuticals, Inc.; Somerset Pharmaceuticals, Inc.; Wyeth-Ayerst Laboratories; U.S. Pharmaceuticals, Pfizer Inc.; Elan	6, 10, 73
Darryle Schoepp, Ph.D.	Eli Lilly and Company	77
S. Charles Schulz, M.D.	Janssen Pharmaceutica and Research Foundation; Eli Lilly and Company; AstraZeneca Pharmaceuticals	27
Michael J. Semyak, M.D.	Janssen Pharmaceutica and Research Foundation	92
Shawn C. Shea, M.D.	GlaxoSmithKline; Eli Lilly and Company; Wyeth-Ayerst Laboratories	8, 15
David V. Sheehan, M.D.	Abbott Laboratories; American Medical Association; Anclote Foundation; AstraZeneca Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals; Boots Pharmaceuticals; Bristol-Myers Squibb; Burroughs Wellcome; Charter Hospitals; Ciba Geigy; Dista Products Company; Eisai America, Inc.; Eli Lilly and Company; Excerpta Medica Asia; Forest Laboratories; GlaxoSmithKline; Glaxo Pharmaceuticals; Glaxo-Wellcome; Hospital Corporation of America; Humana; ICI; International Clinical Research; Janssen Pharmaceutical Products, L.P.; Kali-Duphar; Marion Merrill Dow; McNeil Pharmaceuticals; Mead Johnson; Merck Sharp & Dohme; National Institute of Drug Abuse; National Institute of Health; Organon; Novo Nordisk; Parke-Davis; Pfizer, Inc.; Pharmacia & Upjohn; Rhone-Novartis; Rhone-Poulenc Rorer Pharmaceuticals; Roche Laboratories; Roerig; Sandoz Pharmaceuticals; Schering Corporation; SmithKline Beecham; Solvay Pharmaceuticals; TAP Pharmaceuticals; TGH-University Psychiatry Center; The Upjohn Company; Warner Chilcott; Wyeth-Ayerst Company; Layton Bioscience; Medical Outcomes System; U.S. Pharmaceuticals, Pfizer Inc.; Quintiles; Tampa General Hospital-University Psychiatry Center; Warner Chilcott Pharmaceutical Company; Worldwide Clinical Trials	3, 8
Bruce Singh, M.D.	Eli Lilly and Company; Janssen Pharmaceutica and Research Foundation	86
Samuel G. Siris, M.D.	Eli Lilly and Company; Merck & Co., Inc.; U.S. Pharmaceuticals, Pfizer Inc.	56, 75, 85
Gary W. Small, M.D.	U.S. Pharmaceuticals, Pfizer Inc.; Eisai Inc.	81
Shamsah B. Sonawalla, M.D.	Forest Laboratories, Inc.	28, 59
Thomas J. Spencer, M.D.	Abbott Laboratories; Alza Pharmaceuticals; Boston Life Sciences, Inc.; Bristol-Myers Squibb; Cephalon; Eisai Inc.; Eli Lilly and Company; GlaxoSmithKline; Gliatech Inc.; Medeva Pharmaceuticals, Inc.; Novartis Pharmaceuticals Corporation; U.S. Pharmaceuticals, Pfizer Inc.; Shire Ridgewood Pharmaceuticals; Solvay Pharmaceuticals, Inc.; Wyeth-Ayerst Laboratories	44, 56, 61, 83
Deborah Spitz, M.D.	Janssen-Cilag	26, 54, 73
Stephen M. Stahl, M.D.	Abbott Laboratories; AstraZeneca Pharmaceuticals; Bayer Corporation, Pharmaceutical Division; Boehringer-Ingelheim; Bristol-Myers Squibb; Eli Lilly and Company; Fabre Kramer; Forest Laboratories, Inc.; Glaxo-Wellcome; Janssen Pharmaceutica and Research Foundation; Lorex; Lundbeck; Neurocrine; Novartis Pharmaceuticals Corporation; Organon Inc.; Parke-Davis, Division of Warner-Lambert Company; U.S. Pharmaceuticals, Pfizer Inc.; Pharmacia & Upjohn Company, Inc.; Pierre Fabre; Roche Laboratories, a member of the Roche Group; Sanao; Sanofi Pharmaceuticals, Inc.; Searle; SmithKline Beecham Pharmaceuticals; Solvay Pharmaceuticals, Inc.; Sumitomo; Takeda Pharmaceuticals; Watson Laboratories, Inc.; Watson Laboratories, Inc.; Wyeth-Ayerst Laboratories; Yamanouchi	2, 36

Presenter	Manufacturer(s)	Program Page #
Mark A. Stein, Ph.D.	McNeil Pharmaceuticals	87
Murray B. Stein, M.D.	Janssen Pharmaceutica and Research Foundation; Forest Laboratories, Inc.	2, 58
Hans Steiner, M.D.	Abbott Laboratories; AstraZeneca Pharmaceuticals; Janssen Pharmaceutica and Research Foundation	13, 50
Donna E. Stewart, M.D.	Eli Lilly and Company; U.S. Pharmaceuticals, Pfizer Inc.; Wyeth-Ayerst Laboratories	47, 73
Nada L. Stotland, M.D.	GlaxoSmithKline; U.S. Pharmaceuticals, Pfizer Inc.	29, 30, 56, 86
Stephen M. Strakowski, M.D.	Janssen Pharmaceutica and Research Foundation; Abbott Laboratories; U.S. Pharmaceuticals, Pfizer Inc.; AstraZeneca Pharmaceuticals; Bristol-Myers Squibb; Eli Lilly and Company	59
T. Scott Stroup, M.D.	Bristol-Myers Squibb	81
Charlene M. Stubbs, Ph.D.	Takeda Pharmaceuticals	68
Patricia Suppes, M.D.	Ortho-McNeil Pharmaceuticals	81, 89
Norman Sussman, M.D.	Organon Inc.	6
Alan C. Swann, M.D.	Abbott Laboratories	5
Marijo B. Tamburrino, M.D.	Eli Lilly and Company; Wyeth-Ayerst Laboratories	86
Rajiv Tandon, M.D.	AstraZeneca Pharmaceuticals; Bristol-Myers Squibb; Abbott Laboratories; Eli Lilly and Company; Janssen Pharmaceutica and Research Foundation; Novartis Pharmaceuticals Corporation; U.S. Pharmaceuticals, Pfizer Inc.	11, 14, 81
Pierre N. Tariot, M.D.	Abbott Laboratories; Janssen Pharmaceutica and Research Foundation; Lilly Research Laboratories, a division of Eli Lilly and Company; U.S. Pharmaceuticals, Pfizer Inc.	13, 35, 62
Michael E. Thase, M.D.	Bristol-Myers Squibb; Cephalon, Inc.; Cyberonics, Inc.; Eli Lilly and Company; Forest Laboratories, Inc.; GlaxoSmithKline; Novartis Pharmaceuticals Corporation; Organon Inc.; U.S. Pharmaceuticals, Pfizer Inc.; Pharmacia & Upjohn Company, Inc.; Solvay Pharmaceuticals, Inc.; Wyeth-Ayerst Laboratories	3, 14, 37, 55
Mauricio F. Tohen, M.D.	Eli Lilly and Company	22
Daniel Toledo, M.D.	Janssen Pharmaceutica and Research Foundation; Lilly Research Laboratories, a division of Eli Lilly and Company; Novartis Pharmaceuticals Corporation; Wyeth-Ayerst Laboratories	76
Jane B. Tornatore, Ph.D.	Screen Inc.	54
Vilma Torres, M.S.W.	Safe Horizon; Families of Homicide Victims Program	54
Martin G. Tracy, J.D.	Professional Risk Management Services, Inc.	18, 41, 46
Werner Tschan, M.D.	GlaxoSmithKline; Lilly Research Laboratories, a division of Eli Lilly and Company; U.S. Pharmaceuticals, Pfizer Inc.	94
Michael A. Van Ameringen, M.D.	AstraZeneca Pharmaceuticals; Bristol-Myers Squibb; GlaxoSmithKline; Eli Lilly and Company; Janssen Pharmaceutica and Research Foundation; Lundbeck; Novartis Pharmaceuticals Corporation; U.S. Pharmaceuticals, Pfizer Inc.; Solvay Pharmaceuticals, Inc.; Wyeth-Ayerst Laboratories	22
Garry M. Vickar, M.D.	Eli Lilly and Company; GlaxoSmithKline; Janssen Pharmaceutica and Research Foundation; Merck & Co., Inc.; U.S. Pharmaceuticals, Pfizer Inc.; Wyeth-Ayerst Laboratories	28
Eduard Vieta, M.D.	AstraZeneca Pharmaceuticals; Bristol-Myers Squibb; Eli Lilly and Company; GlaxoSmithKline; Janssen-Cilag; U.S. Pharmaceuticals, Novartis Pharmaceuticals Corporation; Pfizer Inc.	78, 89
Adele C. Viguera, M.D.	GlaxoSmithKline	35
Karen D. Wagner, M.D.	GlaxoSmithKline; Forest Laboratories, Inc.	8, 59
B. Timothy Walsh, M.D.	Eli Lilly and Company; Forest Laboratories, Inc.; Ortho-McNeil Pharmaceuticals	61, 83, 95
Peter J. Weiden, M.D.	AstraZeneca Pharmaceuticals; Bristol-Myers Squibb	11, 59
Daniel R. Weinberger, M.D.	Merck & Co., Inc.	3
Richard D. Weiner, M.D.	Mecta Corporation	14
Richard H. Weisler, M.D.	Abbott Laboratories; AstraZeneca Pharmaceuticals; Biovali; Bristol-Myers Squibb; Eisai Inc.; Cephalon; GlaxoSmithKline; Janssen Pharmaceutica and Research Foundation; Lilly Research Laboratories, a division of Eli Lilly and Company; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; Organon Inc.; Sanofi Pharmaceuticals, Inc.; Schwabe; Shire Ridgewood Pharmaceuticals; Solvay Pharmaceuticals, Inc.; Synaptic Pharmaceutical Inc; TAP Pharmaceuticals; UCB Pharma, Inc.; U.S. Pharmaceuticals, Pfizer Inc.; Wyeth-Ayerst Laboratories	44
Michael M. Welner, M.D.	MHS	54
Timothy E. Wilens, M.D.	Abbott Laboratories; Lilly Research Laboratories, a division of Eli Lilly and Company; McNeil Pharmaceuticals; National Institute on Drug Abuse; National Institute of Mental Health; Novartis Pharmaceuticals Corporation; U.S. Pharmaceuticals, Pfizer Inc.; Shire Ridgewood Pharmaceuticals; SmithKline Beecham Pharmaceuticals; GlaxoSmithKline; Celltech Medieva	45, 56, 80, 96
Denise E. Wilfley, Ph.D.	Ortho-McNeil Pharmaceuticals	6, 83
Mark L. Willenbring, M.D.	Drug Abuse Sciences; Schering-Plough; SmithKline Beecham Pharmaceuticals	92
Kristi S. Williams, M.D.	GlaxoSmithKline; Wyeth-Ayerst Laboratories	86

## DISCLOSURE INDEX

Presenter	Manufacturer(s)	Program Page #
Richard Williams, M.D.	AstraZeneca Pharmaceuticals; Bristol-Myers Squibb; Eli Lilly and Company; Janssen Pharmaceutica and Research Foundation; Novartis Pharmaceuticals Corporation; U.S. Pharmaceuticals, Pfizer Inc.	1
Daniel R. Wilson, M.D.	Abbott Laboratories; Eli Lilly and Company; Elan; GlaxoSmithKline; Janssen Pharmaceutica and Research Foundation; SAMHSA; State of Nebraska; U.S. Pharmaceuticals, Pfizer Inc.; Wyeth-Ayerst Laboratories	56, 63
Katherine Wilson, Ph.D.	Gender Identity Center of Colorado, Inc.	32
John W. Winkelman, M.D.	Cephalon; Elan; Eli Lilly and Company; GlaxoSmithKline; U.S. Pharmaceuticals, Pfizer Inc.; Wyeth-Ayerst Laboratories	10, 48, 93
Daniel K. Winstead, M.D.	Abbott Laboratories; AstraZeneca Pharmaceuticals; Bristol-Myers Squibb; CoCensys; Dista Products, division of Eli Lilly Company; Eli Lilly and Company; Forest Laboratories, Inc.; Janssen Pharmaceutica and Research Foundation; U.S. Pharmaceuticals, Pfizer Inc.; Roerig Division, Pfizer, Inc.; SmithKline Beecham Pharmaceuticals; Pharmacia & Upjohn Company, Inc.; The Upjohn Company (with Solvay); Wyeth-Ayerst Laboratories	28, 72
Katherine L. Wisner, M.D.	Lilly Research Laboratories, a division of Eli Lilly and Company; U.S. Pharmaceuticals, Pfizer Inc.	89
Janet Wozniak, M.D.	Janssen Pharmaceutica and Research Foundation; Eli Lilly and Company	12, 80
Jesse H. Wright, M.D.	GlaxoSmithKline; Lilly Research Laboratories, a division of Eli Lilly and Company; Mindstreet; U.S. Pharmaceuticals, Pfizer Inc.; Wyeth-Ayerst Laboratories	8, 17, 37, 65, 91
Pamela J. Wright-Etter, M.D.	Forest Laboratories, Inc.; GlaxoSmithKline; SmithKline Beecham Pharmaceuticals; Wyeth-Ayerst Laboratories	71
Joel Yager, M.D.	Eli Lilly and Company; Otho-McNeil	6, 18, 30, 58
Lakshmi N. Yatham, M.B.	Astra/Merck Group, Division of Merck & Co.; Eli Lilly and Company; GlaxoSmithKline; Janssen Pharmaceutica and Research Foundation	3
Kimberly A. Yonkers, M.D.	GlaxoSmithKline	6
L. Trevor Young, M.D.	Eli Lilly and Company; GlaxoSmithKline	81
Christoffel J. Yzermans, Ph.D.	Netherlands Institute for Health Services Research; Nivel	89
Mary C. Zaranini, Ed.D.	Eli Lilly and Company	21, 27, 78
Douglas M. Ziedonis, M.D.	Janssen Pharmaceutica and Research Foundation; Lilly Research Laboratories, a division of Eli Lilly and Company	31, 52

## DISCLOSURE INDEX

*The following presenters on this year's scientific program failed to return the APA disclosure form. The presenter's name and the page number(s) the presenter appears on in this Program Book are listed below:*

William Arroyo, M.D.....	89	Norma Hatot.....	77	Eric C. Strain, M.D.....	62
Gregory L. Barker.....	41	Ruben J. Hernandez-Serrano, M.D.....	84	David L. Sultzer, M.D.....	62
Guido Belsasso, M.D.....	89	Dilip V. Jeste, M.D.....	49, 70	James M. Swanson, M.D.....	45
Joseph Biederman, M.D.....	44, 56, 61, 78, 80, 83	Samuel J. Keith, M.D.....	33	Farris Tuma, Sc.D.....	71
Eric G. Bing, M.D.....	94	Michael J. Kittay, M.D.....	90	John W. Tsuang, M.D.....	5, 41
Herve Bokobza, M.D.....	59	Louis J. Kraus, M.D.....	89	Douglas Turkington, M.B.....	41, 59
Charles L. Bowden, M.D.....	2, 58, 74	Earl C. Lawrence, M.A.....	41	Paul Volberding, M.D.....	77
Gary Cobb.....	80	Anton J.M. Loonen, M.D.....	84	Mike Ward.....	41
Rachelle S. Doody, M.D.....	41, 81	Alexandra MacLean, M.D.....	59	Elizabeth B. Weller, M.D.....	43, 72
James M. Ellison, M.D.....	93	Cesare Maffei, M.D.....	31	Wendy Williams.....	80
Marvis Frazier.....	80	Jacobo E. Mintzer, M.D.....	41, 62	Lishan Workeneh, M.D.....	42
Amarsingh M. Ghorpade, M.D.....	48	Dominique L. Musselman, M.D1.....	11	Lawson R. Wulsin, M.D.....	45
Jodi Goldstein, J.D.....	76	David Shannahoff-Khalsa, B.S.....	75		
		Michael W. Smith, M.D.....	15, 91		



# SATURDAY, MAY 17, 2003

## 156TH ANNUAL MEETING

### 8:00 a.m. Sessions



#### COURSES 1-4

Course descriptions are available in the *CME Course Brochure* included in your registration packet. Admission by ticket only.

**COURSE 1** 8:00 a.m.-12 noon  
Room 112, Exhibit Level, Moscone Center

#### ADD IN CHILDREN AND ADOLESCENTS

Director: Thomas E. Brown, Ph.D.  
Faculty: Jefferson B. Prince, M.D.

**COURSE 2** 8:00 a.m.-12 noon  
Room 114, Exhibit Level, Moscone Center

#### EXTENDED COMMUNITY TREATMENT OF PATIENTS WITH BORDERLINE PERSONALITY DISORDER

Director: Lawrence L. Kennedy, M.D.

**COURSE 3** 8:00 a.m.-12 noon  
Room 123, Exhibit Level, Moscone Center

Director: Leonardo Cortese, M.D.  
Faculty: Michael Caligiuri, Ph.D., Richard Williams, M.D.

**COURSE 4** 8:00 a.m.-12 noon  
Room 124, Exhibit Level, Moscone Center

#### DETERMINING MEDICAL FITNESS TO DRIVE: RELEVANT ISSUES FOR PSYCHIATRISTS

Director: Ian A. Gillespie, M.D.

### 9:00 a.m. Sessions



#### COURSES 5-8

Course descriptions are available in the *CME Course Brochure* included in your registration packet. Admission by ticket only.

**COURSE 5** 9:00 a.m.-4:00 p.m.  
Room 110, Exhibit Level, Moscone Center

#### INTEGRATED TREATMENT OF EATING DISORDERS

Co-Directors: Mae S. Sokol, M.D., Kathryn J. Zerbe, M.D.  
Faculty: Kristina Hoffman-Rieken, R.D.

**COURSE 6** 9:00 a.m.-4:00 p.m.  
Room 111, Exhibit Level, Moscone Center

#### DISORDERS OF THE SELF: DIFFERENTIAL DIAGNOSIS AND TREATMENT

Director: James F. Masterson, M.D.

**COURSE 7** 9:00 a.m.-4:00 p.m.  
Room 120, Exhibit Level, Moscone Center

#### INTERPERSONAL PSYCHOTHERAPY

Director: Scott P. Stuart, M.D.  
Faculty: Michael W. O'Hara, Ph.D., Michael Robertson, M.D.

**COURSE 8** 9:00 a.m.-4:00 p.m.  
Room 122, Exhibit Level, Moscone Center

#### BASIC CONCEPTS IN ADMINISTRATIVE PSYCHIATRY I: THEORY, HUMAN RESOURCES, AND FISCAL MANAGEMENT

*American Association of Psychiatric Administrators*

Co-Directors: Christopher G. Fichtner, M.D., Thomas A. Simpatico, M.D.

Faculty: Shivkumar Hatti, M.D., L. Mark Russakoff, M.D., S. Ateaz Saeed, M.D., Stuart B. Silver, M.D.

### 12:30 p.m. Sessions

#### INDUSTRY-SUPPORTED SYMPOSIA 1-3

##### INDUSTRY-SUPPORTED SYMPOSIUM 1

12:30 p.m.-3:30 p.m.

Gateway Ballroom, Exhibit Level, Moscone Center

##### SCHIZOPHRENIA TREATMENT IN THE COMMUNITY: THE ROLE OF LONG-ACTING ANTIPSYCHOTICS

*Supported by Janssen Pharmaceutica*

Chp.: John M. Kane, M.D.

**A Key Issues in Long-Term Pharmacotherapy of Schizophrenia**  
William T. Carpenter, Jr., M.D.

**B The Latest Advance in Long-Acting Antipsychotic Therapy**  
John M. Kane, M.D.

**C Translating From Clinical Trials to Community Care for Patients With Schizophrenia**  
Jacqueline M. Feldman, M.D.

**D Overcoming Obstacles to Patient Acceptance of Long-Acting Antipsychotics**  
David C. Henderson, M.D.

**SATURDAY**

**INDUSTRY-SUPPORTED SYMPOSIUM 2**

12:30 p.m.-3:30 p.m.

Salons 7 & 8, Lower B-2 Level, Marriott

**BIPOLAR DISORDER: STRATEGIES FOR STABILIZING PATIENTS OVER THE LONG TERM**

*Supported by GlaxoSmithKline*

Chp.: Joseph R. Calabrese, M.D.

**A New Results From the Stanley Bipolar Treatment Network**

Robert M. Post, M.D.

**B Update on Anticonvulsants for Bipolar Disorders**

Charles L. Bowden, M.D.

**C Practical Strategies to Avoid Medication-Induced Mood Destabilization in Bipolar Patients**

Carlos M. Zarate, Jr., M.D.

**D Psychosocial Strategies to Promote Stabilization and Enhance Coping in Patients With Bipolar Disorder**

David J. Miklowitz, Ph.D., Holly A. Swartz, M.D., David J. Kupfer, M.D.

**INDUSTRY-SUPPORTED SYMPOSIUM 3**

12:30 p.m.-3:30 p.m.

Salon 9, Lower B-2 Level, Marriott

**ANXIETY DISORDERS: SOURCES, SIGNS, AND SOLUTIONS**

*Supported by Forest Laboratories, Inc.*

Chp.: Jonathan R.T. Davidson, M.D.

**A Examining Anxiety's Underpinnings**

Christine Heim, Ph.D.

**B Anxious Body, Anxious Self, Anxious Psychiatrists**

Mack Lipkin, M.D.

**C Facing Up to Social Anxiety Disorder**

Murray B. Stein, M.D.

**D Generalized Anxiety Disorder: Beneath the Surface**

Jonathan R.T. Davidson, M.D.

**E The Neurobiology of Panic Disorder and OCD**

Stephen M. Stahl, M.D.

**1:00 p.m. Sessions**



**COURSES 9-12**

Course descriptions are available in the *CME Course Brochure* included in your registration packet. Admission by ticket only.

**COURSE 9**

1:00 p.m.-5:00 p.m.

Room 112, Exhibit Level, Moscone Center

**INTRODUCTION TO TRANSCRANIAL MAGNETIC STIMULATION**

Co-Directors: Ziad H. Nahas, M.D., Leon J. Grunhaus, M.D.

Faculty: Ehud M. Klein, M.D., Sarah H. Lisanby, M.D.

**COURSE 10**

1:00 p.m.-5:00 p.m.

Room 114, Exhibit Level, Moscone Center

**GROUP THERAPY FOR PEOPLE WITH CHRONIC MENTAL ILLNESS**

Director: Walter N. Stone, M.D.

**COURSE 11**

1:00 p.m.-5:00 p.m.

Room 121, Exhibit Level, Moscone Center

**NEUROENDOCRINOLOGY IN MOOD DISORDERS: DYSREGULATION AND TREATMENT**

Co-Directors: Mark A. Frye, M.D., Natalie L. Rasgon, M.D.

Faculty: D. Jeffrey Newport, M.D.

**COURSE 12**

1:00 p.m.-5:00 p.m.

Room 124, Exhibit Level, Moscone Center

**DREAM TRANSLATION: ONE EMPIRICALLY-BASED APPROACH**

Director: Milton Kramer, M.D.

**6:00 p.m. Sessions**

**INDUSTRY-SUPPORTED SYMPOSIA 4-8**

**INDUSTRY-SUPPORTED SYMPOSIUM 4**

6:00 p.m.-9:00 p.m.

Gateway Ballroom, Exhibit Level, Moscone Center

**NEW STRATEGIES FOR MANAGING BIPOLAR DISORDER**

*Supported by Janssen Pharmaceutica*

Chp.: S. Nassir Ghaemi, M.D.

**A Clinical Management of Bipolar Patients: A Difficult Task**

Dwight L. Evans, M.D.

**B Rational Polypharmacy in the Treatment of Patients With Bipolar Disorder**

S. Nassir Ghaemi, M.D.

**C Emerging Treatment for Bipolar Disorder: A New Role for Atypical Antipsychotics**

Lakshmi N. Yatham, M.B.

**D Complexities in the Treatment of Juvenile Bipolar Disorder**

Robert L. Findling, M.D.

**INDUSTRY-SUPPORTED SYMPOSIUM 5**

6:00 p.m.-9:00 p.m.

Grand Ballroom Salon B, Grand Ballroom Level, Hilton

**GENETICS AND PSYCHIATRY: REAL GENES, REAL PROGRESS***Supported by AstraZeneca Pharmaceuticals*

Chp.: Daniel R. Weinberger, M.D.

**A Genetic Engineering in Animals: New Insights About Anxiety and Antidepressants**

Rene Hen, Ph.D.

**B Recent Advances in Statistical and Gene-Finding Methods in Psychiatric Genetics**

Richard Straub, Ph.D.

**C Gene and Protein Expression in Brain: It Depends on Inheritance**

Joel E. Kleinman, M.D.

**D Rethinking the Concept of Phenotype in Psychiatry**

Robert Freedman, M.D.

**E In Vivo Approaches to Identifying Genetic Mechanisms of Susceptibility**

Daniel R. Weinberger, M.D.

**INDUSTRY-SUPPORTED SYMPOSIUM 6**

6:00 p.m.-9:00 p.m.

Continental Ballroom, Ballroom Level, Hilton

**BEYOND BENZODIAZEPINES: NEW MOLECULES FOR THE TREATMENT OF ANXIETY***Supported by Pfizer Inc.*

Chp.: Jack M. Gorman, M.D.

**A Childhood Anxiety Disorders: Does Treatment Affect Long-Term Outcome?**

Moira A. Rynn, M.D., Sarosh Khalid-Khan, M.D.

**B The Burden of Anxiety Disorders**

David V. Sheehan, M.D.

**C Treatment for Generalized Anxiety Disorder: Current and Near Term**

Stuart A. Montgomery, M.D.

**D Future Directions: New Molecular Targets for the Treatment of Anxiety**

Jack M. Gorman, M.D.

**INDUSTRY-SUPPORTED SYMPOSIUM 7**

6:00 p.m.-9:00 p.m.

Salons 7 &amp; 8, Lower B-2 Level, Marriott

**ENHANCING OUTCOMES BY ADDRESSING CRITICAL CHALLENGES IN THE TREATMENT OF SCHIZOPHRENIA***Supported by Eli Lilly and Company*

Chp.: Diana O. Perkins, M.D.

**A Schizophrenia: New Understandings of the Early Stage of Illness**

Diana O. Perkins, M.D.

**B Improving Cognition for Quality Outcomes**

Richard S. Keefe, Ph.D.

**C Treatment Challenges for the Patient With Acute Agitation**

Leslie L. Citrome, M.D.

**D Metabolic Issues With Antipsychotic Therapy**

John B. Buse, M.D.

**E Maintenance Strategies: Balancing Efficacy and Safety to Prevent Relapse**

Thomas F. Liffick, M.D.

**INDUSTRY-SUPPORTED SYMPOSIUM 8**

6:00 p.m.-9:00 p.m.

Salon 9, Lower B-2 Level, Marriott

**OPTIMIZING EFFICACY AND TOLERABILITY OF ANTIDEPRESSANT THERAPY: DOES SELECTIVITY OF ACTION MATTER?***Supported by Forest Laboratories, Inc.*

Chp.: Michael E. Thase, M.D.

**A The Alphabet Soup of Antidepressant Pharmacology: From TCA's and MAOI's to SSRI's, SNRI's, and Beyond**

Pedro L. Delgado, M.D.

**B Efficacy of Newer Antidepressants**

Michael E. Thase, M.D.

**C SSRI's and Beyond: Spectrum of Efficacy of Newer Antidepressants**

Justine M. Kent, M.D.

**D Generally Well Tolerated: Comparative Adverse-Event Profiles of Newer Antidepressants**

Andrew A. Nierenberg, M.D.

# American Psychiatric Association

**Audiotapes  
Recorded Live!**



***High Quality Continues for  
the 2003 Annual Meeting ...***

Live recordings will be available  
for most of the following:

- Lectures • Advances in Psychotherapy • Advances in Research
- Presidential Symposia • Medical Updates
- Scientific and Clinical Reports • Symposia
- Debate • Research Advances in Medicine

Tapes may be purchased on site at Mobiltape's booth at the Moscone Center

**Mobiltape Company, Incorporated**

24730 Avenue Tibbitts, Suite 170

Valencia, CA 91355

Phone: (661) 295-0504 ◆ (800) 369-5718

Fax: (661) 295-8474

Website: [www.mobiltape.com](http://www.mobiltape.com)

# SUNDAY, MAY 18, 2003

156TH ANNUAL MEETING

## 8:00 a.m. Sessions



### COURSES 13-20

Course descriptions are available in the *CME Course Brochure* included in your registration packet. Admission by ticket only.

#### COURSE 13 8:00 a.m.-12 noon

Franciscan Room B, Ballroom Level, Hilton

### PSYCHIATRIC CONSULTATIONS IN MEDICAL SETTINGS: THE BASICS

Director: Richard L. Elliott, M.D.

#### COURSE 14 8:00 a.m.-12 noon

Franciscan Room D, Ballroom Level, Hilton

### INTERPERSONAL PSYCHOTHERAPY

Director: John C. Markowitz, M.D.

#### COURSE 15 8:00 a.m.-12 noon

Imperial Ballroom A, Ballroom Level, Hilton

### RISK ASSESSMENT FOR VIOLENCE

Director: Phillip J. Resnick, M.D.

#### COURSE 16 8:00 a.m.-12 noon

Imperial Ballroom B, Ballroom Level, Hilton

### ADD IN ADULTS

Director: Thomas E. Brown, Ph.D.

Faculty: Jefferson B. Prince, M.D.

#### COURSE 17 8:00 a.m.-12 noon

Yosemite Room B, Ballroom Level, Hilton

### PSYCHIATRIC DISORDERS RELATED TO EPILEPSY

Director: Dietrich P. Blumer, M.D.

Faculty: John Barry, M.D., Robert S. Fisher, M.D.

#### COURSE 18 8:00 a.m.-12 noon

Union Square 14, Fourth Floor, Hilton

### BEHAVIORAL NEUROANATOMY: AN INTRODUCTION

Director: Nashaat N. Boutros, M.D.

Faculty: David L. Clark, Ph.D., Edward C. Lauterbach, M.D.

#### COURSE 19 8:00 a.m.-12 noon

Union Square 15 & 16, Fourth Floor, Hilton

### CONTEMPORARY MALPRACTICE LIABILITY: A PRACTICAL GUIDE

Co-Directors: Eugene L. Lowenkopf, M.D., Abe M. Rychik, J.D.

Faculty: Richard G. Hersh, M.D., Jacqueline M. Melonas, J.D.

#### COURSE 20 8:00 a.m.-12 noon

Union Square 23 & 24, Fourth Floor, Hilton

### ACHIEVING EFFECTIVE DUAL DIAGNOSIS TREATMENT

Director: John W. Tsuang, M.D.

Faculty: Andrew P. Ho, M.D., Thomas Newton, M.D.

### INDUSTRY-SUPPORTED SYMPOSIA 9-13

#### INDUSTRY-SUPPORTED SYMPOSIUM 9

8:00 a.m.-11:00 a.m.

Gateway Ballroom, Exhibit Level, Moscone Center

### DIAGNOSIS AND TREATMENT: MOOD STABILIZERS ACROSS THE PSYCHIATRIC SPECTRUM

Supported by *Abbott Laboratories*

Chp.: Carol A. Tamminga, M.D.

**A A Systematic Approach to the Treatment of Impulsivity**  
Alan C. Swann, M.D.

**B The Role of Mood Stabilizers in the Management of Agitation in Dementia**  
J. Michael Ryan, M.D.

**C Efficacy of Treatment With Mood Stabilizers in Acute Schizophrenia**  
Carol A. Tamminga, M.D.

**D Comorbidities and Treatment Issues in Substance Use Disorders**  
Hugh Myrick, M.D.

**E Affective Instability and Impulsive Aggression in Cluster B and Developmental Disorders**  
Eric Hollander, M.D.

**INDUSTRY-SUPPORTED SYMPOSIUM 10**

8:00 a.m.-11:00 a.m.

Grand Ballroom Salon B, Grand Ballroom Level, Hilton

**MOODS, CYCLES, AND MOTHERHOOD**

*Supported by GlaxoSmithKline*

Chp.: Shaila Misri, M.D.

**A Depression in Pregnancy and Lactation: Making Informed Decisions to Protect the Mother and Infant**  
Zachary N. Stowe, M.D., D. Jeffrey Newport, M.D.

**B Mothers, Babies, and Children: Mental Health in the Postpartum and Beyond**  
Shaila Misri, M.D.

**C Pharmacological Treatment of Premenstrual Dysphoria: What Is Sufficient?**  
Kimberly A. Yonkers, M.D.

**D Is It Just Me or Is It Hot in Here? What Every Psychiatrist Should Know About Menopause**  
C. Neill Epperson, M.D.

**INDUSTRY-SUPPORTED SYMPOSIUM 11**

8:00 a.m.-11:00 a.m.

Continental Ballroom, Ballroom Level, Hilton

**ENHANCING SKILL TREATING COMORBID DEPRESSION AND NEUROLOGICAL ILLNESS**

*Supported by Organon Inc.*

Chp.: Steven L. Dubovsky, M.D.

**A Depression in Neurological Disorders**  
Gary J. Tucker, M.D.

**B Depression in Dementing Disorders**  
Jeffrey L. Cummings, M.D.

**C Depression Following Traumatic Brain Injury**  
David B. Arciniegas, M.D.

**D Treatment of Depression in Patients With Life-Threatening and Terminal Illness**  
Norman Sussman, M.D.

**E Targeting Antidepressant Therapy to Medical Comorbidity**  
Steven L. Dubovsky, M.D.

**INDUSTRY-SUPPORTED SYMPOSIUM 12**

8:00 a.m.-11:00 a.m.

Salons 7 & 8, Lower B-2 Level, Marriott

**AN INTEGRATED APPROACH TO THE MANAGEMENT OF BIPOLAR DISORDER: AN ALLIANCE OF SCIENCE AND MEDICINE**

*Supported by Eli Lilly and Company*

Chp.: Robert M.A. Hirschfeld, M.D.

**A The Role of Genetics in Bipolar Disease**  
Wade H. Berrettini, M.D.

**B The Importance of Mood Stabilization in the Treatment of Mania**

John Cookson, M.B.

**C Bipolar Depression and Substance Abuse: Which Is the Driving Force?**

Joseph F. Goldberg, M.D.

**D A Disease Management Strategy for Bipolar Disorder**

Ellen Frank, Ph.D., David J. Kupfer, M.D., Holly A. Swartz, M.D., Andrea Fagiolini, M.D.

**E Optimizing Treatment to Prevent Relapse**

Paul E. Keck, Jr., M.D.

Discussant: Robert M.A. Hirschfeld, M.D.

**INDUSTRY-SUPPORTED SYMPOSIUM 13**

8:00 a.m.-11:00 a.m.

Salon 9, Lower B-2 Level, Marriott

**REMISSION IN PSYCHIATRIC DISORDERS: DEFINITIONS, ISSUES, AND TREATMENTS**

*Supported by Wyeth Pharmaceuticals*

Chp.: Alan J. Gelenberg, M.D.

**A Psychosocial Functioning in Depression**

Ivan W. Miller, Ph.D.

**B Remission in Major Depression: A Frequently Illusive Goal**

Alan F. Schatzberg, M.D.

**C Response and Remission in GAD**

Alan J. Gelenberg, M.D.

**D Remission in Bipolar Disorder Across the Life Span**

Kiki D. Chang, M.D.

**E Response and Remission in Depression: The ACNP Consensus Report**

A. John Rush, M.D.

---

**9:00 a.m. Sessions**

---



**COURSES 21-27**

Course descriptions are available in the *CME Course Brochure* included in your registration packet. Admission by ticket only.

---

**COURSE 21**

9:00 a.m.-4:00 p.m.

Yosemite Room A, Ballroom Level, Hilton

**THERAPEUTIC INTERVENTIONS IN EATING DISORDERS: BASIC PRINCIPLES**

**Director:** David C. Jimerson, M.D.

**Faculty:** Katherine A. Halmi, M.D., James E. Mitchell, M.D., Denise E. Wilfley, Ph.D., Joel Yager, M.D.

**COURSE 22** 9:00 a.m.-4:00 p.m.  
Yosemite Room C, Ballroom Level, Hilton

**BASIC CONCEPTS IN ADMINISTRATIVE  
PSYCHIATRY II: CARE MANAGEMENT, LAW, AND  
ETHICS**

*American Association of Psychiatric Administrators*

**Co-Directors:** Christopher G. Fichtner, M.D., Wesley  
Sowers, M.D.

**Faculty:** Stephen H. Dinwiddie, M.D., H. Steven Moffic, M.D.,  
John A. Talbott, M.D., William G. Wood, M.D.

**COURSE 23** 9:00 a.m.-4:00 p.m.  
Union Square 1 & 2, Fourth Floor, Hilton

**MEDICAL ETHICS 101**

**Director:** Edmund G. Howe, M.D.

**COURSE 24** 9:00 a.m.-4:00 p.m.  
Union Square 5 & 6, Fourth Floor, Hilton

**BUILD YOUR OWN RELATIONAL DATABASE  
ELECTRONIC MEDICAL RECORD**

**Director:** Daniel A. Deutschman, M.D.

**Faculty:** Joshua E. Freedman, M.D., John S. Lloyd, Ph.D.,  
Seth M. Powsner, M.D., Terence L. Witham, M.D.

**COURSE 25** 9:00 a.m.-4:00 p.m.  
Union Square 17 & 18, Fourth Floor, Hilton

**CLINICAL APPLICATIONS AND RESEARCH IN  
TRANSPERSONAL PSYCHIATRY**

**Co-Directors:** Bruce W. Scotton, M.D., Allan B. Chinen, M.D.

**Faculty:** John R. Battista, M.D., William W. Foote, M.D.,  
John F. Hiatt, M.D., Francis G. Lu, M.D., Lewis Mehl-  
Madrona, M.D., Bruce S. Victor, M.D., Roger N. Walsh, M.D.,  
Seymore Borstein, M.D.

**COURSE 26** 9:00 a.m.-4:00 p.m.  
Union Square 19 & 20, Fourth Floor, Hilton

**DAVANLOO'S INTENSIVE SHORT-TERM DYNAMIC  
PSYCHOTHERAPY IN CLINICAL PRACTICE**

**Director:** James Q. Schubmehl, M.D.

**Faculty:** Alan R. Beeber, M.D., Tewfik Said, M.D.

**COURSE 27** 9:00 a.m.-4:00 p.m.  
Union Square 25, Fourth Floor, Hilton

**BRIEF PSYCHODYNAMIC PSYCHOTHERAPY: THE  
CORE CONFLICTUAL RELATIONSHIP THEME  
METHOD**

**Director:** Howard E. Book, M.D.

**12:30 p.m. Session**

**BUSINESS MEETING**

(Voting Members Only\*)

12:30 p.m.-1:30 p.m.

Room 301, Esplanade Level, Moscone Center

**CALL TO ORDER**

Paul S. Appelbaum, M.D., *President*

**MEMORIAL TO DECEASED MEMBERS**

**ANNOUNCEMENT OF ELECTION RESULTS**

Glenn H. Miller, M.D., *Chairperson,*  
*Committee of Tellers*

**REPORTS TO THE MEMBERSHIP**

*Secretary:* Pedro Ruiz, M.D.

*Treasurer:* Carol A. Bernstein, M.D.

*Speaker, Assembly:* Albert C. Gaw, M.D.

*Speaker-Elect, Assembly:* Prakash N. Desai, M.D.

*Chairperson, By-Laws Committee:*

Jo-Ellyn M. Ryall, M.D.

*Chairperson, Elections Committee:*

Yvonne B. Ferguson, M.D.

*Chairperson, Membership Committee:*

Bernard A. Katz, M.D.

*Medical Director:* James H. Scully, Jr., M.D.

**ANNUAL FORUM**

**ADJOURNMENT**

\*Members-in-Training, General Members, Distinguished  
Fellows, Fellows, Life Fellows, Distinguished Life Fellows,  
and Life Members. Badge or APA membership card  
necessary for admission. No cameras or tape recorders will  
be permitted.

**1:00 p.m. Sessions**



**COURSES 28-34**

Course descriptions are available in the *CME  
Course Brochure* included in your registration  
packet. Admission by ticket only.

**COURSE 28** 1:00 p.m.-5:00 p.m.  
Imperial Ballroom B, Ballroom Level, Hilton

**ORGANIZATIONAL AND GROUP INTERVENTIONS  
FOLLOWING DISASTERS**

**Director:** John S. Kennedy, M.D.

**SUNDAY**

**COURSE 29** **1:00 p.m.-5:00 p.m.**  
**Yosemite Room B, Ballroom Level, Hilton**

**COGNITIVE THERAPY FOR SCHIZOPHRENIA**

**Director:** Jesse H. Wright, M.D.  
**Faculty:** Aaron T. Beck, M.D., Jan L. Scott, M.D.

**COURSE 30** **1:00 p.m.-5:00 p.m.**  
**Union Square 13, Fourth Floor, Hilton**

**TREATMENT ISSUES FOR WOMEN IN MINORITY GROUPS**

**Director:** Susan R. Downs, M.D.  
**Faculty:** Ellen Haller, M.D., Sylvia W. Olarte, M.D., Gloria Pitts, D.O., Alice C. Tso, M.D.

**COURSE 31** **1:00 p.m.-5:00 p.m.**  
**Union Square 14, Fourth Floor, Hilton**

**IRRESISTIBLE SLEEP: NARCOLEPSY UPDATE**

**Director:** Lois E. Krahn, M.D.  
**Faculty:** Steven I. Altchuler, M.D., Mark R. Hansen, M.D., Jarrett W. Richardson, M.D.

**COURSE 32** **1:00 p.m.-5:00 p.m.**  
**Union Square 15 & 16, Fourth Floor, Hilton**

**COMPUTER-ASSISTED DIAGNOSTIC INTERVIEW (CADI)**

**Co-Directors:** Paul R. Miller, M.D., Charles Chiu, M.D.  
**Faculty:** Margaret Nazarey, M.S.N.

**COURSE 33** **1:00 p.m.-5:00 p.m.**  
**Union Square 21, Fourth Floor, Hilton**

**INTEGRATIVE PSYCHOTHERAPY SUPERVISION: BASIC TOOLS**

**Director:** Paul Rodenhauer, M.D.  
**Faculty:** Ramona Dvorak, M.D., Albert F. Painter, Psy.D., John R. Rudisill, Ph.D.

**COURSE 34** **1:00 p.m.-5:00 p.m.**  
**Union Square 23 & 24, Fourth Floor, Hilton**

**EVIDENCE-BASED MANAGEMENT OF SAD: FOCUS ON LIGHT THERAPY**

**Co-Directors:** Raymond W. Lam, M.D., Anthony J. Levitt, M.D.

---

**1:30 p.m. Sessions**

---

**INDUSTRY-SUPPORTED SYMPOSIA 14-20**

**INDUSTRY-SUPPORTED SYMPOSIUM 14**

**1:30 p.m.-4:30 p.m.**  
**Gateway Ballroom, Exhibit Level, Moscone Center**

**BARRIERS TO OPTIMAL OUTCOME IN ANXIETY AND DEPRESSION**

*Supported by GlaxoSmithKline*

**Chp.:** David V. Sheehan, M.D.

**A From Medication Noncompliance to Medication Interest: The Art of Discussing Medications With Patients**  
Shawn C. Shea, M.D.

**B Controlled-Release Antidepressant Formulations: Advantages and Limitations**  
David V. Sheehan, M.D.

**C An Evidence-Based Approach to Clinical Trials in Anxiety and Depression**  
Flavio Kapczinski, Ph.D.

**D Case-Based Approach to Optimal Outcome in Depression and Anxiety**  
Lori Calabrese, M.D.

**INDUSTRY-SUPPORTED SYMPOSIUM 15**

**1:30 p.m.-4:30 p.m.**  
**Metropolitan, Second Level, Argent**

**NEW CHALLENGES IN THE MANAGEMENT OF DEPRESSION**

*Supported by Forest Laboratories, Inc.*

**Chp.:** Karen D. Wagner, M.D.

**A Solving the Conundrum of Childhood Depression**  
Karen D. Wagner, M.D.

**B Achieving Rapid-Onset of Action and Remission in Depressed Adults**  
Robert M.A. Hirschfeld, M.D.

**C Tickling the Brain: Advances in Antidepressant Brain Stimulation Techniques**  
Mark S. George, M.D.

**D Enhancing Collaboration Between the Primary Care Physician and the Psychiatrist**  
Larry Culpepper, M.D.

**E Maintaining Quality of Life in the Elderly**  
Steven P. Roose, M.D.



**INDUSTRY-SUPPORTED SYMPOSIUM 16**

1:30 p.m.-4:30 p.m.

Grand Ballroom Salon B, Grand Ballroom Level, Hilton

**ISSUES IN TREATING MANIA: ACUTE AND CONTINUATION PHASE***Supported by AstraZeneca Pharmaceuticals***Chp.:** Michael H. Allen, M.D.**Co-Chp.:** Gary S. Sachs, M.D.**A Managing Acute Mania in the Emergency Room**

Michael H. Allen, M.D.

**B Pharmacological Options for the Treatment of Pediatric Mania**

Melissa P. DelBello, M.D.

**C Approaches to the Treatment of Mania**

Roy H. Perlis, M.D.

**D Family Intervention and Pharmacotherapy in the Post-Episode Phase of Bipolar Disorder**

David J. Miklowitz, Ph.D., Jeffery Richards, Elizabeth George

**E Identifying Suicidal Behavioral and At-Risk Patients**

Gary S. Sachs, M.D.

**INDUSTRY-SUPPORTED SYMPOSIUM 17**

1:30 p.m.-4:30 p.m.

Continental Ballroom, Ballroom Level, Hilton

**TRICKS OF THE TRADE IN THE LONG-TERM TREATMENT OF DEPRESSION***Supported by Organon Inc.***Chp.:** Anita L.H. Clayton, M.D.**Co-Chp.:** Maurizio Fava, M.D.**A Clinical Management of Psychiatric Comorbidities**

R. Bruce Lydiard, M.D.

**B Sexual Dysfunction in Depression**

Anita L.H. Clayton, M.D.

**C Sleep Changes During Long-Term Treatment With Antidepressants**

Maurizio Fava, M.D.

**D Antidepressant-Induced Cognitive Changes and Apathy: Are There any Antidotes?**

Jerrold F. Rosenbaum, M.D.

**E Practical Approaches to Antidepressant-Induced Weight Gain**

David L. Ginsberg, M.D.

**INDUSTRY-SUPPORTED SYMPOSIUM 18**

1:30 p.m.-4:30 p.m.

Salons 7 &amp; 8, Lower B-2 Level, Marriott

**PHARMACOLOGICAL TREATMENT OF CHRONIC PAIN: COMORBIDITY WITH DEPRESSION AND OTHER PSYCHOTIC DISORDERS***Supported by Eli Lilly and Company***Chp.:** David Fishbain, M.D.**A Psychiatric and Other Comorbidities Associated With Chronic Pain**

David Fishbain, M.D.

**B The Neurobiology of Pain**

Edward C. Covington, Jr., M.D.

**C Adjuvants as Analgesics: Mechanism-Based Pharmacotherapy in Pain Medicine**

Rollin Gallagher, M.D.

**D Depression With Painful Physical Symptoms: Treatment With 5HT/Norepinephrine Antidepressants**

Michael J. Detke, M.D.

**E The Use of Opioid Analgesics for Chronic Pain: Controversies and Challenges**

Steven A. King, M.D.

**F Adjuvant Analgesics: Efficacy Evidence for the Treatment of Neuropathic Pain**

David Fishbain, M.D.

**INDUSTRY-SUPPORTED SYMPOSIUM 19**

1:30 p.m.-4:30 p.m.

Salon 9, Lower B-2 Level, Marriott

**STRESS, PSYCHOPATHOLOGY, AND THE BRAIN: NOVEL INTERVENTION STRATEGIES***Supported by Wyeth Pharmaceuticals***Chp.:** Ned H. Kalin, M.D.**A Overview of the Relationship Between Stress, Depression, and Anxiety**

Christine Heim, Ph.D.

**B The Potential for Gene Therapy in the Treatment of Stress and Related Disorders**

Robert Sapolsky, Ph.D.

**C The Biology of Stress and Vulnerability**

Michael Meaney, Ph.D.

**D Novel Pharmacological Strategies to Treat Stress-Related Psychopathology and Medical Illnesses**

Ned H. Kalin, M.D.

## SUNDAY

### INDUSTRY-SUPPORTED SYMPOSIUM 20

1:30 p.m.-4:30 p.m.

Grand Ballroom, Mezzanine Level, Westin St. Francis

#### DEPRESSION, APATHY, AND FATIGUE IN NEUROPSYCHIATRIC DISORDERS

Supported by Cephalon Inc.

Chp.: John W. Winkelman, M.D.

#### A Disorders of Motivation: The Third Domain of Psychopathology

Robert S. Marin, M.D.

#### B Fatigue and Depression in Cancer and AIDS

William Breitbart, M.D.

#### C Apathy in Neuropsychiatric Disorders

Jeffrey L. Cummings, M.D.

#### D Depression, Fatigue, and Excessive Daytime Sleepiness in Sleep Disorders

Mary B. O'Malley, M.D.

#### E Apathy in Schizophrenia

Donald C. Goff, M.D.

## 2:30 p.m. Session

### LECTURE 1

2:30 p.m.-4:00 p.m.

Rooms 130/131, Exhibit Level, Moscone Center

#### AAPL/APA'S MANFRED S. GUTTMACHER AWARD LECTURE

Diane H. Schetky, M.D. and  
Elissa P. Benedek, M.D.

Expert Testimony in the Age of Daubert

Chp.: Deborah Spitz, M.D.

Clinical and legal issues in the psychiatric treatment of children and adolescents will be discussed by Diane H. Schetky, M.D., coeditor with Elissa P. Benedek, M.D., of *Principles and Practice of Child and Adolescent Forensic Psychiatry*, for which they have received the 2003 Manfred S. Guttmacher Award for outstanding contribution to the literature of forensic psychiatry. Dr. Schetky is Clinical Associate Professor of Psychiatry at the University of Vermont College of Medicine at Maine Medical Center in Portland, Maine, and is in the private practice of psychiatry in Rockport, Maine. She has written numerous scientific papers and book chapters in the areas of child psychiatry and forensic psychiatry, is the author or editor of six books, and writes a bimonthly ethics column for *American*

*Academy of Child and Adolescent Psychiatry News*. A Distinguished Life Fellow of the American Psychiatric Association, Dr. Schetky is a member of the APA Council on Psychiatry and Law and has been a member of APA task forces on clinical assessment in child custody and confidentiality of records in child custody disputes. Dr. Schetky received her medical degree from Case Western Reserve University School of Medicine in Cincinnati and completed her residency in psychiatry and a fellowship in child psychiatry at the University Hospitals in Cleveland.

THIS SESSION WILL BE AUDIOTAPED.

## 5:00 p.m. Session

### OFFICIAL OPENING SESSION

5:00 p.m.-6:30 p.m.

Hall E, Exhibit Level, Moscone Center

#### CALL TO ORDER

Paul S. Appelbaum, M.D.

President

#### INTRODUCTION OF STAGE GUESTS

#### INTRODUCTION OF CHAIRPERSON OF THE SCIENTIFIC PROGRAM COMMITTEE

Geetha Jayaram, M.D.

Chairperson, Annual Meeting Scientific Program Committee

#### INTRODUCTION OF VISITING DIGNITARIES

#### PRESIDENTIAL ADDRESS

Paul S. Appelbaum, M.D.

To be introduced by Loren H. Roth, M.D.

#### RESPONSE OF THE PRESIDENT-ELECT

Marcia K. Goin, M.D.

To be introduced by Sherwyn M. Woods, M.D.

#### ADJOURNMENT

## 7:00 p.m. Sessions

### INDUSTRY-SUPPORTED SYMPOSIA 21-27

#### INDUSTRY-SUPPORTED SYMPOSIUM 21

7:00 p.m.-10:00 p.m.

Gateway Ballroom, Exhibit Level, Moscone Center

#### PEPTIDES AND HORMONES AS TARGETS IN ANTIDEPRESSANT TREATMENT

Supported by Merck & Co., Inc.

Chp.: Alan F. Schatzberg, M.D.

Co-Chp.: Ned H. Kalin, M.D.

**A Development of a PET Tracer for Clinical Trials of Substance P Antagonists**

Richard Hargreaves, Ph.D.

**B Recent Studies on Substance P Antagonists**

A. John Rush, M.D.

**C The Therapeutic Potential of Corticotrophin-Releasing Factor Antagonists**

Ned H. Kalin, M.D.

**D Estrogen and Mood**

Elizabeth A. Young, M.D.

**E The Role of Antigluco-corticoid Agents in the Treatment of Major Depression**

Charles DeBattista, M.D.

**Discussant:** Ned H. Kalin, M.D.

**INDUSTRY-SUPPORTED SYMPOSIUM 22**

7:00 p.m.-10:00 p.m.

Metropolitan, Second Level, Argent

**A COMPREHENSIVE APPROACH TO MANAGING BIPOLAR DISORDER: BENCH TO BEDSIDE AND BEYOND**

*Supported by Ortho-McNeil Pharmaceuticals*

**Chp.:** Gary S. Sachs, M.D.

**A Neuroplasticity and Cellular Resilience in Bipolar Disorder**

Husseini K. Manji, M.D., Gregory J. Moore, Ph.D., Grazyna Rajkowska, Ph.D., Guang Chen, Ph.D.

**B The Treatment of Acute Mania**

Mark A. Frye, M.D.

**C Treatment of Bipolar Disorder With Comorbid Psychiatric or Medical Disorders**

Susan L. McElroy, M.D.

**D Management of Suicide Prevention in Bipolar Disorder Patients**

Maria A. Oquendo, M.D., Michael F. Grunebaum, M.D., David J. Printz, M.D., Leo Sher, M.D., J. John Mann, M.D.

**E Psychotherapy for Bipolar Disorder?**

Ellen Frank, Ph.D., Holly A. Swartz, M.D., David J. Kupfer, M.D.

**INDUSTRY-SUPPORTED SYMPOSIUM 23**

7:00 p.m.-10:00 p.m.

Grand Ballroom Salon B, Grand Ballroom Level, Hilton

**A RATIONAL ALGORITHM FOR SELECTING ATYPICALS IN SCHIZOPHRENIA AND BIPOLAR DISORDERS**

*Supported by AstraZeneca Pharmaceuticals*

**Chp.:** Henry A. Nasrallah, M.D.

**A Efficacy of Atypical Antipsychotics: How Do They Compare?**

Rajiv Tandon, M.D.

**B Minimizing Specific Medical Problems by Customizing Antipsychotic Selection**

Henry A. Nasrallah, M.D.

**C Serious Medical Morbidity and Atypicals: Defining and Avoiding Thresholds of Risk**

Diana O. Perkins, M.D.

**D Bipolar Disorders and Schizophrenia: Similarities and Differences in Susceptibilities to Side Effects**

Claudia F. Baldassano, M.D.

**E Efficacy to Effectiveness When Treating Schizophrenia**

Peter J. Weiden, M.D.

**INDUSTRY-SUPPORTED SYMPOSIUM 24**

7:00 p.m.-10:00 p.m.

Continental Ballroom, Ballroom Level, Hilton

**PSYCHIATRY AND MEDICINE: COMMON PATIENTS, DIFFERENT PERSPECTIVES**

*Supported by Pfizer Inc.*

**Chp.:** Charles B. Nemeroff, M.D.

**A The Pathophysiology and Psychopharmacology of Comorbid Cardiovascular Disease and Depression**

Charles B. Nemeroff, M.D.

**B Medical Illness and Depression: A Delicate Interplay Between Biology and Brain**

Dominique L. Musselman, M.D.

**C Management of Anxiety Disorders in Primary Care: Implications for Psychiatrists**

Risa B. Weisberg, Ph.D.

**D Long-Term Treatment of Anxiety and Depression: Why, When, How?**

Philip T. Ninan, M.D.

**E The Successful Intervention: Management of the Patient With Medical Comorbidities**

Larry Culpepper, M.D.

**INDUSTRY-SUPPORTED SYMPOSIUM 25**

7:00 p.m.-10:00 p.m.

Salons 7 & 8, Lower B-2 Level, Marriott

**MEDICAL CONSIDERATIONS IN THE  
MANAGEMENT OF SPECIAL PATIENT  
POPULATIONS**

*Supported by Eli Lilly and Company*

Chp.: Pedro Ruiz, M.D.

**A Medical Vulnerability in Schizophrenia**

Donald C. Goff, M.D.

**B Medical Considerations in Bipolar Disorder**

Lauren B. Marangell, M.D.

**C Medical Concerns in Pharmacotherapy for Complicated  
Pediatric Bipolar Patients**

Charles S. Schultz, M.D.

**D Course and Treatment of Bipolar Illness During  
Pregnancy, Postpartum, and Lactation**

Lee S. Cohen, M.D.

**E Medical Comorbidity and Bipolar Disorders in Old Age:  
Impact on Diagnosis, Treatment, and Outcome**

Kenneth I. Shulman, M.D.

**INDUSTRY-SUPPORTED SYMPOSIUM 26**

7:00 p.m.-10:00 p.m.

Salon 9, Lower B-2 Level, Marriott

**TREATMENT OF COMORBIDITY IN  
NEUROPSYCHIATRIC DISORDERS IN CHILDREN  
AND ADOLESCENTS**

*Supported by Janssen Pharmaceutica*

Chp.: Robert L. Findling, M.D.

**A Child and Adolescent Psychiatric Disorders: Pediatric  
Bipolar Disorders as a Model**

Janet Wozniak, M.D.

**B Rational Management of Disruptive Behavior Disorders  
and Comorbidity**

Jeffrey Newcom, M.D.

**C Combined Pharmacotherapy in the Management of  
Bipolar Disorder**

Robert L. Findling, M.D.

**D Recent Advances in the Pharmacotherapy of Pervasive  
Developmental Disorders**

Christopher J. McDougle, M.D., David J. Posey, M.D.

**E Clinically Relevant Drug-Drug Interactions in Pediatric  
Psychiatry**

Michael D. Reed, Pharm.D.

**INDUSTRY-SUPPORTED SYMPOSIUM 27**

7:00 p.m.-10:00 p.m.

Grand Ballroom, Mezzanine Level, Westin St. Francis

**REDUCING SUICIDALITY IN SCHIZOPHRENIA  
AND BIPOLAR DISORDER**

*Supported by Novartis Pharmaceuticals Corporation*

Chp.: Herbert Y. Meltzer, M.D.

**A Suicidality and Its Management in Schizophrenia and  
Bipolar Disorder**

Kay R. Jamison, Ph.D.

**B A Model for Suicide Assessment**

Douglas G. Jacobs, M.D.

**C Reducing Suicidality in Schizophrenia and  
Schizoaffective Disorder**

Herbert Y. Meltzer, M.D.

**D Treatment and Suicide Risks**

Ross J. Baldessarini, M.D., John Hennen, Ph.D., Leonardo  
Tondo, M.D.

Discussant: Jan A. Fawcett, M.D.

# MONDAY, MAY 19, 2003

156TH ANNUAL MEETING

## 7:00 a.m. Sessions

### PART 1 OF INDUSTRY-SUPPORTED BREAKFAST SYMPOSIA 28-34

#### INDUSTRY-SUPPORTED BREAKFAST SYMPOSIUM 28, PART 1

7:00 a.m.-8:30 a.m.

Gateway Ballroom, Exhibit Level, Moscone Center

#### IMPAIRMENT OF STRUCTURAL PLASTICITY IN SEVERE MOOD DISORDERS: CAUSAL OR COLLATERAL?

*Supported by Abbott Laboratories*

Chp.: Pierre N. Tariot, M.D.

Co-Chp.: Hussein K. Manji, M.D.

#### A Stress, Glucocorticoids, and Neuron Damage: Current Status

Robert Sapolsky, Ph.D.

#### B Regulation of Functional Neurogenesis in the Adult Brain

Fred Gage, M.D.

#### C Neuromorphometric and Neuropathological Abnormalities in Mood Disorders

Wayne C. Drevets, M.D.

#### INDUSTRY-SUPPORTED BREAKFAST SYMPOSIUM 29, PART 1

7:00 a.m.-8:30 a.m.

Metropolitan, Second Level, Argent

#### IMPULSIVITY, AGGRESSION, AND SUICIDE: VERSATILITY OF LITHIUM AND MOOD STABILIZERS

*Supported by Solvay Pharmaceuticals, Inc.*

Chp.: Eric Hollander, M.D.

#### A Treating Impulsivity in Impulse Control and Personality Disorders

Eric Hollander, M.D., Stefano Pallanti, M.D., Erica Sood, B.A.,  
Daphne Simeon, M.D.

#### B Primary and Secondary Disorders of Aggression in Youth: Mood Stabilizers, Atypicals, and Stimulants

Hans Steiner, M.D.

#### C Strategies for Augmentation of Psychopharmacological Interventions in Youth With Disorders of Aggression

Kirti Saxena, M.D.

#### INDUSTRY-SUPPORTED BREAKFAST SYMPOSIUM 30, PART 1

7:00 a.m.-8:30 a.m.

Grand Ballroom Salon B, Grand Ballroom Level, Hilton

#### BIPOLAR DISORDER IN WOMEN: SPECIAL CONSIDERATIONS AND EVOLVING TREATMENT

*Supported by GlaxoSmithKline*

Chp.: Lee S. Cohen, M.D.

Co-Chp.: Martha J. Morrell, M.D.

#### A Bipolar Disorder in Women: Phenomenology and Response to Treatment

Ruta M. Nonacs, M.D.

#### B Course and Treatment of Bipolar Disorder During Pregnancy

Lee S. Cohen, M.D.

#### INDUSTRY-SUPPORTED BREAKFAST SYMPOSIUM 31, PART 1

7:00 a.m.-8:30 a.m.

Continental Ballroom, Ballroom Level, Hilton

#### MANAGING THE SPECTRUM OF PSYCHOTIC DISORDERS

*Supported by Bristol-Myers Squibb Company*

Chp.: Robert E. Hales, M.D.

Co-Chp.: Stuart C. Yudofsky, M.D.

#### A Clinical Considerations in the Management of First- Episode and Acute Exacerbation of Schizophrenia

Ira D. Glick, M.D.

#### B Challenges in the Management of Psychosis in Special Populations

J. Michael Ryan, M.D.

#### INDUSTRY-SUPPORTED BREAKFAST SYMPOSIUM 32, PART 1

7:00 a.m.-8:30 a.m.

Salons 7 & 8, Lower B-2 Level, Marriott

#### TREATING DEPRESSION: WHAT MATTERS?

*Supported by Eli Lilly and Company*

Chp.: Andrew A. Nierenberg, M.D.

Co-Chp.: Susan G. Kornstein, M.D.

#### A Brain Matters

Helen S. Mayberg, M.D.

#### B Gender Matters

Susan G. Kornstein, M.D.

#### C Time Matters

Beny Lafer, M.D.

## MONDAY

### INDUSTRY-SUPPORTED BREAKFAST SYMPOSIUM 33, PART 1

7:00 a.m.-8:30 a.m.

Salon 9, Lower B-2 Level, Marriott

### EVIDENCE-BASED TREATMENT OF PSYCHIATRIC DISORDERS

*Supported by Wyeth Pharmaceuticals*

Chp.: K. Ranga R. Krishnan, M.D.

#### A Evidence-Based Medicine: What Is It?

K. Ranga R. Krishnan, M.D.

#### B Evidence-Based Medicine and Depression Treatments

Michael E. Thase, M.D.

#### C Evidence-Based Medicine: Schizophrenia

Richard S. Keefe, Ph.D.

### INDUSTRY-SUPPORTED BREAKFAST SYMPOSIUM 34, PART 1

7:00 a.m.-8:30 a.m.

Grand Ballroom, Mezzanine Level, Westin St. Francis

### MANAGING ANXIETY AND SLEEP: A NEW ERA FOR GAMMA-AMINO BUTYRIC ACID

*Supported by Cephalon Inc.*

Chp.: Philip T. Ninan, M.D.

#### A Nuances of Inhibition: Gamma-aminobutyric acid in the Human Brain

Philip T. Ninan, M.D.

#### B Gamma-aminobutyric acid Mechanisms in Sleep Disorders

Jed E. Black, M.D.

### RESIDENT'S SESSION

7:00 a.m.-8:30 a.m.

Golden Gate Hall C, B-2 Level, Marriott

### MEET THE EXPERTS: SUNNY-SIDE UP

Chp.: Paul S. Appelbaum, M.D.

At this breakfast, nationally recognized "experts" will sit at tables with small groups of residents and discuss a variety of career issues and opportunities in psychiatry. Topic areas include: Addiction/Substance Abuse, AIDS/HIV, Child and Adolescent Psychiatry, Consultation-Liaison, Cultural Competence, Forensic, Law and Ethics in Psychiatry, Geriatric, Medical Student Issues, Public and Community Mental Health, Professional and Leadership Development, Psychodynamic Psychotherapy, and Research in Psychiatry.

## 8:00 a.m. Sessions



### COURSES 35-42

Course descriptions are available in the *CME Course Brochure* included in your registration packet. Admission by ticket only.

#### COURSE 35

8:00 a.m.-12 noon

Imperial Ballroom A, Ballroom Level, Hilton

### THE PSYCHIATRIST AS EXPERT WITNESS

Director: Phillip J. Resnick, M.D.

#### COURSE 36

8:00 a.m.-12 noon

Imperial Ballroom B, Ballroom Level, Hilton

### DRUG TREATMENT OF SCHIZOPHRENIA

Director: Philip G. Janicak, M.D.

Faculty: Morris B. Goldman, M.D., Stephen R. Marder, M.D., Rajiv Tandon, M.D.

#### COURSE 37

8:00 a.m.-12 noon

Yosemite Room A, Ballroom Level, Hilton

### ADVANCED ASSESSMENT AND TREATMENT OF ADD

Director: Thomas E. Brown, Ph.D.

Faculty: Jefferson B. Prince, M.D.

#### COURSE 38

8:00 a.m.-12 noon

Yosemite Room B, Ballroom Level, Hilton

### ECT PRACTICE UPDATE

Director: Charles H. Kellner, M.D.

Faculty: Richard L. Jaffe, M.D., W. Vaughn McCall, M.D., Richard D. Weiner, M.D.

#### COURSE 39

8:00 a.m.-12 noon

Yosemite Room C, Ballroom Level, Hilton

### INTEGRATED MODEL FOR TREATMENT OF CO- OCCURRING PSYCHIATRIC AND SUBSTANCE DISORDERS

Director: Kenneth Minkoff, M.D.

#### COURSE 40

8:00 a.m.-12 noon

Union Square 13, Fourth Floor, Hilton

### TEACHING PSYCHIATRY? LET HOLLYWOOD HELP!

Director: Steven E. Hyler, M.D.

Faculty: Carol A. Bernstein, M.D., Michael B. First, M.D.

**COURSE 41** 8:00 a.m.-12 noon  
 Union Square 21, Fourth Floor, Hilton

**FAMILIES COPING WITH MEDICAL ILLNESS: AN INTEGRATIVE TREATMENT MODEL**

**Director:** John S. Rolland, M.D.

**COURSE 42** 8:00 a.m.-12 noon  
 Union Square 23 & 24, Fourth Floor, Hilton

**USING NEUROFEEDBACK IN YOUR PRACTICE: LATEST TRENDS AND HANDS-ON EXPERIENCE**

**Director:** Thomas M. Brod, M.D.

**Faculty:** Roger deBeus, Ph.D., Pedro Delgado, M.D., Julian Isaacs, Ph.D.

---

**9:00 a.m. Sessions**

---

**CLINICAL CASE CONFERENCE 1**

9:00 a.m.-10:30 a.m.

Room 121, Exhibit Level, Moscone Center

**DIAGNOSTIC AND TREATMENT ISSUES IN THE CARE OF AN ADOLESCENT WITH COMORBID BIPOLAR DISORDER AND ADHD**

**Moderator:** Earlene E. Strayhorn, M.D.

**Discussant:** Bente Clausen, M.S.

**THIS SESSION IS OPEN TO APA MEMBERS ONLY. BLUE REGISTRATION BADGE OR APA MEMBERSHIP CARD REQUIRED FOR ADMITTANCE.**

**CONTINUOUS CLINICAL CASE CONFERENCE 1: PART 1**

9:00 a.m.-12 noon

Room 120, Exhibit Level, Moscone Center

**TREATMENT OF THE VIP PATIENT: TWO PATIENTS, TWO THERAPISTS**

**Moderator:** Richard L. Munich, M.D.

**Presenter:** Efram Bleiberg, M.D.

**THIS SESSION IS OPEN TO APA MEMBERS ONLY. BLUE REGISTRATION BADGE OR APA MEMBERSHIP CARD REQUIRED FOR ADMITTANCE.**



**COURSES 43-50**

Course descriptions are available in the *CME Course Brochure* included in your registration packet. Admission by ticket only.

**COURSE 43** 9:00 a.m.-4:00 p.m.  
 Franciscan Room D, Ballroom Level, Hilton

**UPDATE IN NEUROPSYCHIATRY: DELIRIUM, TRAUMATIC BRAIN INJURY, AND POST-STROKE DEPRESSION**

**Director:** Jose R. Maldonado, M.D.

**COURSE 44** 9:00 a.m.-4:00 p.m.  
 Grand Ballroom Salon A, Grand Ballroom Level, Hilton

**ADVANCES IN NEUROPSYCHIATRY**

**Director:** C. Edward Coffey, M.D.

**Faculty:** Jeffrey L. Cummings, M.D., Mark S. George, M.D., Michael R. Trimble, M.D.

**COURSE 45** 9:00 a.m.-4:00 p.m.  
 Union Square 1 & 2, Fourth Floor, Hilton

**PSYCHIATRY UPDATE: IN SPANISH**

*American Society of Hispanic Psychiatry*

**Co-Directors:** Gabriel Kaplan, M.D., Javier I. Escobar, M.D.

**Faculty:** Pedro L. Delgado, M.D., Eduardo Dunayevich, M.D., Ana Kaplan, M.D., Jorge R. Petit, M.D., Jacobo E. Mintzer, M.D.

**COURSE 46** 9:00 a.m.-4:00 p.m.  
 Union Square 3 & 4, Fourth Floor, Hilton

**DSM-IV-TR CULTURAL FORMULATIONS: DIAGNOSIS AND THERAPY**

**Director:** Russell F. Lim, M.D.

**Faculty:** Candace M. Fleming, Ph.D., Roberto Lewis-Fernandez, M.D., Francis G. Lu, M.D., J. Charles Ndlela, M.D., Michael W. Smith, M.D.

**COURSE 47** 9:00 a.m.-4:00 p.m.  
 Union Square 5 & 6, Fourth Floor, Hilton

**TRANSPERSONAL PSYCHIATRY: CLINICAL APPLICATIONS**

**Director:** John F. Hiatt, M.D.

**Faculty:** William W. Foote, M.D.

**COURSE 48** 9:00 a.m.-4:00 p.m.  
 Union Square 14, Fourth Floor, Hilton

**EVIDENCE-BASED MEDICINE: AN INTRODUCTION FOR PSYCHIATRISTS**

**Director:** Gregory E. Gray, M.D.

**Faculty:** Gabrielle F. Beaubrun, M.D., Letitia A. Pinson, M.D.

**COURSE 49** 9:00 a.m.-4:00 p.m.  
 Union Square 15 & 16, Fourth Floor, Hilton

**ADVANCED INTERVIEWING TECHNIQUES**

**Director:** Shawn C. Shea, M.D.

MONDAY

**COURSE 50** 9:00 a.m.-4:00 p.m.  
**Union Square 25, Fourth Floor, Hilton**

**THE CONCEPTUAL BASIS OF PSYCHIATRY**

**Co-Directors:** S. Nassir Ghaemi, M.D., David H. Brendel, M.D.

**DEBATE**

9:00 a.m.-10:30 a.m.  
**Room 307, Esplanade Level, Moscone Center**

**RESOLVED: PERSONALITY DISORDERS SHOULD BE LISTED IN AXIS I IN DSM-V**

**Moderator:** John S. McIntyre, M.D.  
**Affirmative:** Roger Peele, M.D.  
**Negative:** John Oldham, M.D.  
**THIS SESSION WILL BE AUDIOTAPED.**

**DISCUSSION GROUPS 1-4**

9:00 a.m.-10:30 a.m.  
**These sessions are limited to 25 participants on a first-come, first-served basis.**

- 1 Margaret G. Spinelli, M.D.,** on *Infanticide: Psychosocial and Legal Perspectives of Mothers Who Kill (Meet the Authors)*  
**Pacific Conference Suite B, 4th Floor, Marriott**
- 2 Donna E. Stewart, M.D.,** on *Depression in Perimenopausal Women*  
**Pacific Conference Suite C, 4th Floor, Marriott**
- 3 Pedro Ruiz, M.D.,** on *Cross-Cultural Psychiatry: The Acculturation Process*  
**Pacific Conference Suite E, 4th Floor, Marriott**
- 4 Alan F. Schatzberg, M.D.,** on *Some Recent Advancements in Psychopharmacology*  
**Pacific Conference Suite F, 4th Floor, Marriott**

**LECTURES 2-3**

**LECTURE 2**  
9:00 a.m.-10:30 a.m.  
Rooms 130/131, Exhibit Level, Moscone Center

**APA'S PATIENT ADVOCACY AWARD LECTURE**

**Robin J. Munro**

**Labeling the Dissenter as Mad: Forensic Psychiatry in China and Its Political Abuses**

**Chp.:** Paul S. Appelbaum, M.D.  
**Co-Chp.:** David M. McDowell, M.D.

Robin J. Munro is a member of the Centre of East Asian Law and of the Law and Public Health in Developing Countries Research Group in the School of Oriental and African Studies at the University of London, where he is currently completing his doctoral thesis on judicial psychiatry and human rights in China. From 1989 to 1998 he was the Principal China Researcher for the human rights organization, Human Rights Watch. He founded the Hong Kong office of Human Rights Watch in 1990 and served as director of the office from 1992 to 1998. During the 1990s he was a frequent lobbying visitor to Capitol Hill and presented written and oral testimony to U.S. Senate and Congressional hearings on China. He is the author of the Human Rights Watch publications, *Dangerous Minds: Political Psychiatry in China Today and Its Origins in the Mao Era* and *Death by Default: A Policy of Fatal Neglect in China's State Orphanages*. His article "China's Judicial Psychiatry," published in the *Asian Wall Street Journal* in February 2000, received the Human Rights Press Award from the Hong Kong Journalists Association.

**THIS SESSION WILL BE AUDIOTAPED.**

**LECTURE 3**  
9:00 a.m.-10:30 a.m.  
Rooms 303/305, Esplanade Level, Moscone Center

**Charles B. Nemeroff, M.D.**

**The Neurobiological Consequences of Child Abuse**

**Chp.:** Robert W. Baker, M.D.  
**Co-Chp.:** Paul P. Yeung, M.D.

Preclinical and clinical studies have revealed that adverse experience such as maternal deprivation early in life is associated with alterations in central nervous system neurotransmitter circuits previously shown to be altered in many patients with depression. Charles B. Nemeroff, M.D., discusses the diagnostic and treatment implications of these findings. Dr. Nemeroff is Reunette W. Harris Professor and Chairman of the Department of Psychiatry and Behavioral Sciences at Emory University School of Medicine in Atlanta. The author of more than 700 research reports and reviews, Dr. Nemeroff is the Editor-in-Chief of *Neuropsychopharmacology* and the co-editor with Alan F. Schatzberg, M.D., of the *American Psychiatric Press Textbook of Psychopharmacology*. Dr. Nemeroff has received numerous honors for his contributions to research on the biological basis of neuropsychiatric disorders, including most recently the Menninger Prize from the American College of Physicians, the Research Award from the American Foundation for Suicide Prevention, and the Burlingame Prize from the Institute of Living.



In 2002 he was elected to the Institute of Medicine. Dr. Nemeroff received his medical degree and doctorate in neurobiology from the University of North Carolina in Chapel Hill and his residency training in psychiatry at North Carolina Memorial Hospital in Chapel Hill and Duke University Medical Center in Durham, North Carolina.  
Distinguished Psychiatrist Lecture Series  
**THIS SESSION WILL BE AUDIOTAPED.**

## MASTER EDUCATOR CLINICAL CONSULTATIONS 1-2

9:00 a.m.-10:30 a.m.

These sessions are limited to 25 participants on a first-come, first-served

- 1 **Godfrey D. Pearlson, M.D.**, on Schizophrenia: What Is It? What Are Its Boundaries? Why Does It Persist in the Gene Pool?  
Room 218, Mezzanine Level, Moscone Center
- 2 **Glen O. Gabbard, M.D.**, on Psychotherapy of Personality Disorders  
Room 220, Mezzanine Level, Moscone Center

THESE SESSIONS ARE OPEN TO APA MEMBERS ONLY. BLUE REGISTRATION BADGE OR APA MEMBERSHIP CARD REQUIRED FOR ADMITTANCE.

## NEW RESEARCH YOUNG INVESTIGATORS' POSTER SESSION 1

9:00 a.m.-10:30 a.m.

Hall D, Exhibit Level, Moscone Center

For further information on New Research Sessions, please refer to the *New Research Program Book* included in your registration packet.

## WORKSHOPS

### COMPONENTS 1-3

**COMPONENT WORKSHOP 1** 9:00 a.m.-10:30 a.m.

Golden Gate Hall A, B-2 Level, Marriott

### RESTRAINTS: STRATEGIES TO REDUCE AND OPTIMIZE PATIENT SAFETY

*APA Committee on Standards and Survey Procedures*

**Chp.:** Charles E. Riordan, M.D.

**Participants:** Kathleen McCann, D.N.S.c, Steven I. Altchuler, M.D., Dennis J. Milke, M.D., Marlin R.A. Mattson, M.D.

**COMPONENT WORKSHOP 2** 9:00 a.m.-10:30 a.m.

Pacific Conference Suite H, 4th Floor, Marriott

### EARLY INTERVENTION FOLLOWING MASS VIOLENCE: DESIGNING AN EFFECTIVE APPROACH

*APA Committee on Psychiatric Dimensions of Disaster*

**Chp.:** John S. Kennedy, M.D.

**Participants:** Joseph C. Napoli, M.D., Matthew J. Friedman, M.D., Beverley Raphael, M.D.

**COMPONENT WORKSHOP 3** 9:00 a.m.-10:30 a.m.

Pacific Conference Suite J, 4th Floor, Marriott

### PATIENT SAFETY IN PSYCHIATRY: MINIMIZING THE USE OF RESTRAINT AND SECLUSION

*APA Council on Quality*

**Co-Chps.:** Alfred Herzog, M.D., Miles F. Shore, M.D.

**Participant:** Steven J. Karp, D.O.

## ISSUES 1-24

**ISSUE WORKSHOP 1**

9:00 a.m.-10:30 a.m.

Room 110, Exhibit Level, Moscone Center

### TEACHING COGNITIVE-BEHAVIOR THERAPY: EFFECTIVE TRAINING IN UNEXPECTED SETTINGS

**Chp.:** Donna M. Sudak, M.D.

**Participants:** Judith S. Beck, Ph.D., Jesse H. Wright, M.D., Robert M. Goisman, M.D.

**ISSUE WORKSHOP 2**

9:00 a.m.-10:30 a.m.

Room 111, Exhibit Level, Moscone Center

### UNDERSTANDING TRANSGENDERED YOUTH: TREATMENT AND SERVICE STRATEGIES

**Co-Chps.:** Richard R. Pleak, M.D., Sarah E. Herbert, M.D.

**ISSUE WORKSHOP 3**

9:00 a.m.-10:30 a.m.

Room 112, Exhibit Level, Moscone Center

### MORAL ASPECTS OF CLINICAL PRACTICE: A FUNCTIONAL APPROACH

**Chp.:** John R. Peteet, M.D.

**MONDAY**

**ISSUE WORKSHOP 4** 9:00 a.m.-10:30 a.m.  
**Room 113, Exhibit Level, Moscone Center**

**MULTICULTURALITY SQUARED: TRAINING  
MULTICULTURAL RESIDENTS TO TREAT  
MULTICULTURAL PATIENTS**

**Co-Chps.:** Susan Stabinsky, M.D., Harvey Stabinsky, M.D.  
**Participants:** Henry L. McCurtis, M.D., David W. Preven, M.D.

**ISSUE WORKSHOP 5** 9:00 a.m.-10:30 a.m.  
**Room 114, Exhibit Level, Moscone Center**

**SANTERIA AS A RELIGION IN MENTAL HEALTH  
PATIENTS**

**Chp.:** Jose M. Soto, M.D.  
**Participants:** Liliam Perez, M.D., Virginia Contreras, M.D.

**ISSUE WORKSHOP 6** 9:00 a.m.-10:30 a.m.  
**Room 122, Exhibit Level, Moscone Center**

**RISK-MANAGEMENT ISSUES IN PSYCHIATRIC  
PRACTICE**

**Chp.:** Alan I. Levenson, M.D.  
**Participants:** Ellen R. Fischbein, M.D., Martin G. Tracy, J.D.,  
Jacqueline M. Melonas, J.D.

**ISSUE WORKSHOP 7** 9:00 a.m.-10:30 a.m.  
**Room 123, Exhibit Level, Moscone Center**

**MEDITATION: THEORY, THERAPY, RESEARCH,  
AND PRACTICE**

**Chp.:** Roger N. Walsh, M.D.  
**Participants:** Charles Tart, Ph.D., Shauna Shapiro, Ph.D.

**ISSUE WORKSHOP 8** 9:00 a.m.-10:30 a.m.  
**Room 124, Exhibit Level, Moscone Center**

**INSTITUTE OF MEDICINE STUDY:  
INCORPORATING RESEARCH INTO RESIDENCY  
TRAINING**

**Chp.:** Joel Yager, M.D.  
**Participants:** Michael T. Abrams, M.P.H., James J. Hudziak, M.D.,  
Michelle B. Riba, M.D.

**ISSUE WORKSHOP 9** 9:00 a.m.-10:30 a.m.  
**Room 125, Exhibit Level, Moscone Center**

**EXPANDING TELEPSYCHIATRY BEYOND  
PATIENT CARE: OPPORTUNITIES AND  
CHALLENGES**

**Co-Chps.:** R. Andrew Harper III, M.D., Anu A. Matorin, M.D.  
**Participants:** Jacqueline C. McGregor, M.D., Christopher R.  
Thomas, M.D.

**ISSUE WORKSHOP 10** 9:00 a.m.-10:30 a.m.  
**Rooms 272/274/276, Mezzanine Level, Moscone Center**

**NONSEXUAL BOUNDARY VIOLATIONS**

**Chp.:** Malkah T. Notman, M.D.  
**Participants:** Elissa P. Benedek, M.D., Carl P. Malmquist, M.D.,  
Linda M. Jorgenson, J.D.

**ISSUE WORKSHOP 11** 9:00 a.m.-10:30 a.m.  
**Room 300, Esplanade Level, Moscone Center**

**PSYCHOLOGICAL MANAGEMENT OF PSYCHOSIS**

**Chp.:** Eric R. Marcus, M.D.  
**Participants:** Lewis A. Opler, M.D., Ian E. Alger, M.D., Clarice J.  
Kestenbaum, M.D.

**ISSUE WORKSHOP 12** 9:00 a.m.-10:30 a.m.  
**Room 301, Esplanade Level, Moscone Center**

**WORKING THROUGH IN PSYCHOTHERAPY**

**Chp.:** Steven H. Lipsius, M.D.

**ISSUE WORKSHOP 13** 9:00 a.m.-10:30 a.m.  
**Room 302, Esplanade Level, Moscone Center**

**DEPRESSION AND THE PHYSICIAN: WHEN BEING  
A "GOOD" DOCTOR IS NOT ENOUGH**

**Chp.:** Michael F. Myers, M.D.  
**Participants:** Daniel P. Chapman, Ph.D., Donna M. Norris, M.D.

**ISSUE WORKSHOP 14** 9:00 a.m.-10:30 a.m.  
**Room 304, Esplanade Level, Moscone Center**

**INNOVATIVE TREATMENT IN BULIMIA NERVOSA**

**Co-Chps.:** Waguih W. Ishak, M.D., McLeod F. Gwynette, M.D.  
**Participants:** Edi Cooke, Psy.D., Michelle McParland, R.D.,  
Marlene Clark, R.D., Antonia N. Ludwig, M.F.T.

**ISSUE WORKSHOP 15** 9:00 a.m.-10:30 a.m.  
**Room 306, Esplanade Level, Moscone Center**

**MANAGEMENT OF DISINHABITION IN  
DEMENTIA**

**Co-Chps.:** Theron C. Bowers, Jr., M.D., Sheila M.  
Loboprabhu, M.D.  
**Participants:** Claudia Orengo, M.D., John H. Coverdale, M.D.

**ISSUE WORKSHOP 16** 9:00 a.m.-10:30 a.m.  
Room 308, Esplanade Level, Moscone Center

**PREPARING PSYCHIATRISTS FOR MASS-CASUALTY EVENTS**

**Chp.:** Kenneth S. Thompson, M.D.  
**Participants:** Anthony T. Ng, M.D., David A. Pollack, M.D., Stephen M. Goldfinger, M.D., Audrey R. Newell, M.D., Gina Perez, M.D.

**ISSUE WORKSHOP 17** 9:00 a.m.-10:30 a.m.  
Room 309, Esplanade Level, Moscone Center

**IMPLEMENTING WEB-BASED PSYCHOPHARMACOLOGY ALGORITHMS: PROBLEMS AND SOLUTIONS**

**Co-Chps.:** David N. Osser, M.D., Peter D. Anderson, Pharm.D.  
**Participants:** Alejandro Y. Mendoza, M.D., William L. Grapentine, M.D.

**ISSUE WORKSHOP 18** 9:00 a.m.-10:30 a.m.  
Room 310, Esplanade Level, Moscone Center

**TELEPSYCHIATRY WITH DEVELOPMENTALLY DISABLED: TEACHING, TRAINING, AND TREATING**

**Chp.:** Roxanne F. Szeftel, M.D.  
**Participants:** Syed S. A. Naqvi, M.D., Arom J. Evans, M.D., Henrik Zakari, M.D., Marina Bussel, M.D.

**ISSUE WORKSHOP 19** 9:00 a.m.-10:30 a.m.  
Salons 1 & 2, Lower B-2 Level, Marriott

**ETHNIC BIODIVERSITY IN SUBSTANCE ABUSE AND MENTAL HEALTH DISORDERS**

**Chp.:** Jeffrey N. Wilkins, M.D.  
**Participants:** Katherine G. Mellott, M.D., Jack Kuo, M.D.

**ISSUE WORKSHOP 20** 9:00 a.m.-10:30 a.m.  
Salons 3 & 4, Lower B-2 Level, Marriott

**DISTINGUISHING MENTAL ILLNESS FROM BAD BEHAVIOR IN PRISONERS**

**Chp.:** Lee H. Rome, M.D.

**ISSUE WORKSHOP 21** 9:00 a.m.-10:30 a.m.  
Salons 5 & 6, Lower B-2 Level, Marriott

**LESSONS LEARNED FROM SEPTEMBER 11**

**Chp.:** David C. Lindy, M.D.  
**Participants:** Neil Pessin, Ph.D., Anand Pandya, M.D., Craig L. Katz, M.D., Sander Koyfman, M.D.

**ISSUE WORKSHOP 22** 9:00 a.m.-10:30 a.m.  
Salons 10 & 11, Lower B-2 Level, Marriott

**A PSYCHIATRIST'S VIEW ON ARTISTS AND THE ARTS**

**Chp.:** Frans de Jonghe, Ph.D.  
**Participants:** Wilco Tuinebreyer, M.D., Cecile M.T. Gijssbers van Wijk, M.D., Hetty M. Visser, M.D.

**ISSUE WORKSHOP 23** 9:00 a.m.-10:30 a.m.  
Salons 12 & 13, Lower B-2 Level, Marriott

**RESTORATIVE JUSTICE AND THERAPEUTIC JURISPRUDENCE: AN ENJOYABLE EXCHANGE OF IDEAS**

**Co-Chps.:** Lawrence K. Richards, M.D., Abraham L. Halpern, M.D.  
**Participants:** Patrick H. Gardner, J.D., Philip F. Kader, B.A., Honorable Peggy Hora, J.D., Pauline H. Tesler, J.D.

**ISSUE WORKSHOP 24** 9:00 a.m.-10:30 a.m.  
Salons 14 & 15, Lower B-2 Level, Marriott

**YOUTH VIOLENCE: PRINCIPLES OF PREVENTION**

**Co-Chps.:** Paul J. Fink, M.D., Carl C. Bell, M.D.

**10:30 a.m. Session**

**ADVANCES IN RESEARCH**  
10:30 a.m.-12:30 p.m.  
Room 104, Exhibit Level, Moscone Center

**LATEST DEVELOPMENTS IN THE GENETICS OF MOOD DISORDERS**  
*APA Scientific Program Committee and APA Council on Research*

**Chp.:** Herbert Pardes, M.D.  
**Co-Chp.:** Geetha Jayaram, M.D.

**Participants:** John M. Kane, M.D., on **Pharmacological Treatment of Schizophrenia: What Now? What Next?**  
Constantine Lyketos, M.D., on **Advances in the Treatment of Alzheimer's Disease**  
J. Raymond DePaulo, Jr., M.D., on **the Latest Developments in the Genetics of Mood Disorder**  
**THIS SESSION WILL BE AUDIOTAPED.**

**11:00 a.m. Sessions**

**DISCUSSION GROUPS 5-9**

11:00 a.m.-12:30 p.m.

**These sessions are limited to 25 participants on a first-come, first-served basis.**

*(Continued on next page)*

## MONDAY

- 5 **Patricia Judd**, on a Developmental Model of BPD: Understanding Variations in Course and Outcome (*Meet the Authors*)  
**Pacific Conference Suite B, 4th Floor, Marriott**
- 6 **Leah J. Dickstein, M.D.**, on Gender and Cultural Issues in Diagnosis and Treatment  
**Pacific Conference Suite C, 4th Floor, Marriott**
- 7 **John M. Oldham, M.D.**, on Understanding the Severe Personality Disorders  
**Pacific Conference Suite E, 4th Floor, Marriott**
- 8 **Marc A. Schuckit, M.D.**, on New Developments in Substance Dependence: Genetics, Criteria, and Treatment  
**Pacific Conference Suite F, 4th Floor, Marriott**
- 9 **Marcia K. Goin, M.D.**, on Borderline Personality Disorder (*For Residents Only*)  
**Pacific Conference Suite I, 4th Floor, Marriott**

### LECTURES 4-5

#### LECTURE 4

11:00 a.m.-12:30 p.m.

Rooms 130/131, Exhibit Level, Moscone Center

Lucian L. Leape, M.D.

Making Health Care Safe

**Chp.:** Paul S. Appelbaum, M.D.

**Co-Chp.:** Jeffrey S. Janofsky, M.D.

Spurred by a 1999 Institute of Medicine report noting the role of faulty systems in bringing about medical errors, a national patient safety movement has emerged. Much of the initial work in improving patient safety has concentrated on safe medication practices, a concern of special relevance to psychiatry. Lucian L. Leape, M.D., a member of the Institute of Medicine Committee that issued the 1999 report, examines the theoretical underpinnings and practical implications of the patient safety movement. Dr. Leape is Adjunct Professor in the Department of Health Policy and Management at the Harvard School of Public Health in Boston, MA. An advocate of the nonpunitive systems approach to the prevention of medical errors, he has conducted research demonstrating the application of systems theory to the prevention of adverse drug events. Dr. Leape was one of the founders of the National Patient Safety Foundation, the Massachusetts Coalition for the Prevention of Medical Error, and the Harvard Kennedy School Executive Session on Medical Error. He is a recipient of the Distinguished Service Award of the American Pediatric Surgical Association, the Donabedian Award from the American Public Health Association, and a Robert Wood Johnson Foundation

Investigator's Award in Health Policy Research. Dr. Leape received his medical degree from Harvard Medical School.

**THIS SESSION WILL BE AUDIOTAPED.**

#### LECTURE 5

11:00 a.m.-12:30 p.m.

Rooms 132/133, Exhibit Level, Moscone Center

Carl C. Bell, M.D.

Community Psychiatry: 1963-2003

**Chp.:** Stephanie LeMelle, M.D.

**Co-Chp.:** Patricia I. Ordonca, M.D.

Carl C. Bell, M.D., is President and Chief Executive Officer of Community Mental Health Council and Foundation, Inc., and Director of Public and Community Psychiatry and Clinical Professor of Psychiatry and Public Health at the University of Illinois in Chicago. He is involved as a collaborator or a principal investigator in studies of methods for promoting adolescent mental health and preventing youth HIV risk in Chicago, South Africa, and New York City. A Fellow of the American Psychiatric Association and the American College of Psychiatrists, Dr. Bell has received a Special Presidential Commendation from APA for his work on prevention of violence. He is currently a member of the APA Council on Advocacy and Public Policy. An Associate Editor on the Editorial Board of American Psychiatric Publishing, Inc., Dr. Bell is the author of more than 200 articles and book chapters on mental health issues and the author or editor of several books, including *Psychiatric Aspects of Violence, Suicide, and Homicide Among Adolescents*, and *Getting Rid of Rats: Perspectives of a Black Community Psychiatrist*. A graduate of Meharry Medical College in Nashville, TN, Dr. Bell completed his residency in psychiatry at Illinois State Psychiatric Institute in Chicago.

**Distinguished Psychiatrist Lecture Series**

**THIS SESSION WILL BE AUDIOTAPED.**

### MASTER EDUCATOR CLINICAL CONSULTATIONS 3-4

11:00 a.m.-12:30 p.m.

**These sessions are limited to 25 participants on a first-come, first-served**

- 3 **Lori I. Altshuler, M.D.**, on Treating Bipolar Depression  
**Room 218, Mezzanine Level, Moscone Center**

**4 Albert C. Gaw, M.D., on Cross-Cultural Issues in Psychiatric Care**  
Room 220, Mezzanine Level, Moscone Center

**THESE SESSIONS ARE OPEN TO APA MEMBERS ONLY. BLUE REGISTRATION BADGE OR APA MEMBERSHIP CARD REQUIRED FOR ADMITTANCE.**

**MEDICAL UPDATE 1**

11:00 a.m.-12:30 p.m.  
Room 300, Esplanade Level, Moscone Center

**ETHNICITY AND PHARMACOGENETICS**

Chp.: Nyapati R. Rao, M.D.  
Presenter: Keh-Ming Lin, M.D.  
**THIS SESSION WILL BE AUDIOTAPED.**

**SCIENTIFIC AND CLINICAL REPORT SESSIONS 1-7**

**SCIENTIFIC AND CLINICAL REPORT SESSION 1**  
11:00 a.m.-12:30 p.m.  
Room 110, Exhibit Level, Moscone Center

**ADDICTION PSYCHIATRY**

Chp.: R. Dale Walker, M.D.  
Co-Chp.: Romulo A. Aromin, Jr., M.D.

11:00 a.m.

**2 Differences in Peripheral Noradrenergic Function Among Actively Drinking and Recently Abstinent Alcohol-Dependent Individuals**  
Anup M. Desai, M.D., Ashwin A. Patkar, M.D., Raman N. Gopalakrishnan, M.D., Stephen P. Weinstein, Ph.D., Michael J. Vergare, M.D.

11:30 a.m.

**3 Changes in Peripheral Noradrenaline and 5HT Levels and Craving During Alcohol Withdrawal**  
Ashwin A. Patkar, M.D., Raman N. Gopalakrishnan, M.D., Heather W. Murray, B.A., Anup M. Desai, M.D., Michael J. Vergare, M.D., Stephen P. Weinstein, Ph.D.

12 noon

**4 Effect of Modafinil on Cocaine Abstinence and Treatment Retention in Cocaine Dependence: Preliminary Results From an Open-Label Study**  
Charles A. Dackis, M.D., Kyle M. Kampman, M.D., Helen Pettinati, Ph.D., Charles P. O'Brien, M.D.  
**THIS SESSION WILL BE AUDIOTAPED.**

**SCIENTIFIC AND CLINICAL REPORT SESSION 2**  
11:00 a.m.-12:30 p.m.  
Room 111, Exhibit Level, Moscone Center

**CONSULTATION-LIAISON AND EMERGENCY PSYCHIATRY**

Chp.: Catherine C. Crone, M.D.  
Co-Chp.: Jayne M. Stevenson, M.D.

11:00 a.m.

**5 Quetiapine Treatment of Hallucinations and Agitation of Lewy Body Disease**  
Andrius Baskys, M.D.

11:30 a.m.

**6 Survey of Practice Preferences in the Pharmacotherapy of Delirium**  
Michael W. Kiang, M.D., Mark R. Katz, M.D., Susan E. Abbey, M.D.

12 noon

**7 Hyponatremia Associated With the Use of Antidepressants in Geriatric Patients**  
Subramoniam Madhusoodanan, M.D., Olivera J. Bogunovic, M.D.  
**THIS SESSION WILL BE AUDIOTAPED.**

**SCIENTIFIC AND CLINICAL REPORT SESSION 3**  
11:00 a.m.-12:30 p.m.  
Rooms 272/274/276, Mezzanine Level, Moscone Center

**PERSONALITY DISORDERS**

Chp.: Lisa A. Mellman, M.D.  
Co-Chp.: Joanna E. Steinglass, M.D.

11:00 a.m.

**8 Sexual Aversion Among Borderline Patients and Axis II Comparison Subjects**  
Mary C. Zanarini, Ed.D., Elizabeth A. Parachini, B.A., Frances R. Frankenburg, M.D., John Hennen, Ph.D.

11:30 a.m.

**9 Effects of Personality Disorders on Functioning and Well-Being in MDD**  
Andrew E. Skodol II, M.D., Carlos M. Grilo, Ph.D., Maria E. Pagano, Ph.D., Donna S. Bender, Ph.D., John G. Gunderson, M.D., M. Tracie Shea, Ph.D., Thomas H. McGlashan, M.D.

12 noon

**10 Supportive Therapy for BPD Patients With Self-Injurious Behavior**  
David J. Hellerstein, M.D., Ron B. Aviram, Ph.D., Jessica Gerson, Ph.D., Barbara H. Stanley, Ph.D.

## MONDAY

### SCIENTIFIC AND CLINICAL REPORT SESSION 4

11:00 a.m.-12:30 p.m.

Room 302, Esplanade Level, Moscone Center

#### ANXIETY DISORDERS

**Chp.:** Teodor T. Postolache, M.D.

**Co-Chp.:** Shannon T. Suo-Chan, M.D.

11:00 a.m.

#### 11 The Prevalence of PTSD in Canada

Michael A. Van Ameringen, M.D., Catherine L. Mancini, M.D.,  
Beth Pipe, B.S.N., Sandra Balseiro, Michael Boyle, Ph.D.

11:30 a.m.

#### 12 A New Self-Report Screening Tool for DSM-IV Axis I Diagnosis

Catherine L. Mancini, M.D., Michael A. Van Ameringen, M.D.,  
Beth Pipe, B.S.N., Jonathan Oakman, Ph.D.

12 noon

#### 13 Sexual Aversion Disorders in Primary Anxiety Disorders

Chris Watson, B.K.I.N., Michael A. Van Ameringen, M.D.,  
Catherine L. Mancini, M.D.

**THIS SESSION WILL BE AUDIOTAPED.**

### SCIENTIFIC AND CLINICAL REPORT SESSION 5

11:00 a.m.-12:30 p.m.

Room 308, Esplanade Level, Moscone Center

#### EVOLVING ISSUES IN ATYPICAL ANTIPSYCHOTICS

**Chp.:** Paul P. Yeung, M.D.

**Co-Chp.:** Yujuan Choy, M.D.

11:00 a.m.

#### 14 Effects on Weight Change of Switching From Olanzapine to Quetiapine

Prakash S. Masand, M.D., Sanjay Gupta, M.D., Subhdeep  
Virk, M.D., Thomas L. Schwartz, M.D., Ahmad Hameed, M.D.,  
Bradford L. Frank, M.D., Kari Lockwood, R.N.

11:30 a.m.

#### 15 A Three-Week Comparison of Olanzapine Versus Risperidone in the Treatment of Bipolar Mania: Improvement in Manic and Depressive Symptoms and Treatment Adherence

Robert W. Baker, M.D., Carlos M. Zarate, Jr., M.D., Eileen  
Brown, Ph.D., Leslie Schuh, Ph.D., Mauricio F. Tohen, M.D.

12 noon

#### 16 Olanzapine/Fluoxetine Combination and Olanzapine in the Treatment of Bipolar Depression

Mauricio F. Tohen, M.D., Eduard Vieta, M.D., Joseph R.  
Calabrese, M.D., Richard C. Risser, M.S., Robert W. Baker, M.D.,  
Angela R. Evans, Ph.D., Sanjay Dube, M.D.

**THIS SESSION WILL BE AUDIOTAPED.**

### SCIENTIFIC AND CLINICAL REPORT SESSION 6

11:00 a.m.-12:30 p.m.

Pacific Conference Suite H, 4th Floor, Marriott

#### MEASURING MOOD DISORDERS

**Chp.:** David A. Casey, M.D.

**Co-Chp.:** Stephen C. Aron, M.D.

11:00 a.m.

#### 17 Tridimensional Personality Questionnaire and Anxiety Disorder Comorbidity in MDD

Dost Ongur, M.D., Amy H. Farabaugh, Ph.D., Maurizio  
Fava, M.D.

11:30 a.m.

#### 18 Difference in Subjective/Objective Sadness Predicts Drug Response

Anand Pandya, M.D., Eric D. Peselow, M.D., Ronald R.  
Fieve, M.D.

12 noon

#### 19 Identifying Depression in Older Inpatients With the Geriatric Depression Scale and Structured Clinical Interview

George Fulop, M.D., James J. Strain, M.D., Glen Stettin, M.D.

**THIS SESSION WILL BE AUDIOTAPED.**

### SCIENTIFIC AND CLINICAL REPORT SESSION 7

11:00 a.m.-12:30 p.m.

Pacific Conference Suite J, 4th Floor, Marriott

#### PSYCHIATRIC EDUCATION AND TELEPSYCHIATRY

**Chp.:** Gordon D. Strauss, M.D.

**Co-Chp.:** Jodi E. Star, M.D.

11:00 a.m.

#### 20 Psychiatry Training in Primary Care: Current Status and Satisfaction

Hoyle Leigh, M.D., Deborah C. Stewart, M.D., Ronna  
Mallios, M.P.H.

11:30 a.m.

#### 21 Retrospective Evaluation of Telemental Health Care Services for Remote Military Populations

Brian J. Grady, M.D., Ted Meller, Ph.D.

12 noon

#### 22 What Increases the Frequency at Which Medical Students Ask Addiction Questions?

Kathleen M. Stack, M.D., Lisa Fore-Arcand, Ed.D.

**THIS SESSION WILL BE AUDIOTAPED.**

**WORKSHOPS****COMPONENTS 4-9**

**COMPONENT WORKSHOP 4** 11:00 a.m.-12:30 p.m.  
Room 310, Esplanade Level, Moscone Center

**AMBULATORY DETOXIFICATION FROM OPIOIDS:  
DOING IT WELL AND GETTING PAID TOO**  
*APA Committee on Treatment Services for Patients with Addictive Disorders*

**Co-Chps.:** George F. Kolodner, M.D., Samuel M. Silverman, M.D.  
**Participants:** Thomas R. Kosten, M.D., Jonathan D. Book, M.D.,  
Brealyn M. Sellers, M.D.

**COMPONENT WORKSHOP 5** 11:00 a.m.-12:30 p.m.  
Salons 1 & 2, Lower B-2 Level, Marriott

**PRACTICE SETTINGS FOR EARLY CAREER  
PSYCHIATRISTS: A PRIMER**  
*APA Assembly Committee of Early Career Psychiatrists*

**Chp.:** Jeffrey A. Naser, M.D.  
**Participants:** Angelique D. Goodhue, M.D., John R.  
Chamberlain, M.D., Adam R. Chester, D.O.

**COMPONENT WORKSHOP 6** 11:00 a.m.-12:30 p.m.  
Salons 5 & 6, Lower B-2 Level, Marriott

**THE RESEARCH BASE FOR NEW DIAGNOSTIC  
CRITERIA FOR DEPRESSION**  
*APA Committee on Psychiatric Diagnosis and Assessment*

**Co-Chps.:** Darrel A. Regier, M.D., Norman Sartorius, M.D.  
**Participants:** J. John Mann, M.D., David Shaffer, M.D.,  
Dennis S. Charney, M.D., Wayne C. Drevets, M.D., T. Bedirhan  
Ustun, M.D., David J. Kupfer, M.D.

**COMPONENT WORKSHOP 7** 11:00 a.m.-12:30 p.m.  
Salons 10 & 11, Lower B-2 Level, Marriott

**MOOD DISORDERS IN PHYSICIANS, AN UPDATE:  
HOW TO IDENTIFY, DIAGNOSE, AND PROVIDE  
TREATMENT**  
*APA Corresponding Committee on Physician Health, Illness, and  
Impairment*

**Chp.:** John A. Fromson, M.D.  
**Participants:** Penelope P. Ziegler, M.D., Patti Tighe, M.D.,  
Michael F. Myers, M.D.

**COMPONENT WORKSHOP 8** 11:00 a.m.-12:30 p.m.  
Salons 12 & 13, Lower B-2 Level, Marriott

**MEDICARE UPDATE 2003**  
*APA Medicare Advisory Corresponding Committee*

**Chp.:** Edward Gordon, M.D.  
**Participants:** Irvin L. Muszynski, J.D., Ellen Jaffe, Seth P.  
Stein, J.D., Gerald Rogan, M.D.

**COMPONENT WORKSHOP 9** 11:00 a.m.-12:30 p.m.  
Salons 14 & 15, Lower B-2 Level, Marriott

**USING RADIO TO COMBAT STIGMA AND IMPROVE  
THE IMAGE OF PSYCHIATRY**  
*APA Alliance*

**Co-Chps.:** Harvey L. Ruben, M.D., Jo Ellen Fasanello  
**Participants:** Michael Blumenfeld, M.D., Frederick K.  
Goodwin, M.D., Linda S. Austin, M.D., Harry A. Croft, M.D.

**ISSUES 25-34**

**ISSUE WORKSHOP 25** 11:00 a.m.-12:30 p.m.  
Room 112, Exhibit Level, Moscone Center

**LONG-TERM STRUCTURED CARE: A FAMILY  
PERSPECTIVE**

**Co-Chps.:** H. Richard Lamb, M.D., Carla Jacobs  
**Participants:** Curtis Flory, M.B.A., E. Fuller Torrey, M.D.

**ISSUE WORKSHOP 26** 11:00 a.m.-12:30 p.m.  
Room 113, Exhibit Level, Moscone Center

**IMMINENT RISK OF SUICIDE IN CORRECTIONAL  
FACILITIES**

**Chp.:** Karl E. Weaver, M.D.

**ISSUE WORKSHOP 27** 11:00 a.m.-12:30 p.m.  
Room 114, Exhibit Level, Moscone Center

**THE IMPACT OF SUICIDE ON CLINICIANS**

**Chp.:** Eric M. Plakun, M.D.  
**Participants:** Jane G. Tillman, Ph.D., Edward R. Shapiro, M.D.,  
Edward K. Rynearson, M.D.

**ISSUE WORKSHOP 28** 11:00 a.m.-12:30 p.m.  
Room 121, Exhibit Level, Moscone Center

**EVIDENCE-BASED MEDICINE: AN APPLICATION  
IN CHILD AND ADOLESCENT  
PSYCHOPHARMACOLOGY**

**Co-Chps.:** Norman E. Alessi, M.D., Robert A. Kowatch, M.D.

**ISSUE WORKSHOP 29** 11:00 a.m.-12:30 p.m.  
Room 122, Exhibit Level, Moscone Center

**PSYCHOTHERAPY WITH AFRICAN-AMERICAN  
PATIENTS: TRAINING PERSPECTIVES**

**Co-Chps.:** Anu A. Matorin, M.D., Irma J. Bland, M.D.  
**Participants:** Henry L. McCurtis, M.D., Pedro Ruiz, M.D.,  
Sujit R. Varma, M.D.

## MONDAY

---

**ISSUE WORKSHOP 30** 11:00 a.m.-12:30 p.m.  
Room 123, Exhibit Level, Moscone Center

### MIND-BODY CONNECTION IN TRADITIONAL CHINESE MEDICINE

Co-Chps.: Jing-Duan Yang, M.D., Daniel A. Monti, M.D.

**ISSUE WORKSHOP 31** 11:00 a.m.-12:30 p.m.  
Room 124, Exhibit Level, Moscone Center

### COGNITIVE THERAPY FOR PERSONALITY DISORDERS

Chp.: Judith S. Beck, Ph.D.

**ISSUE WORKSHOP 32** 11:00 a.m.-12:30 p.m.  
Room 125, Exhibit Level, Moscone Center

### DISCUSSING THE CONCEPT OF MENTAL HEALTH COURTS

Chp.: Lawrence K. Richards, M.D.

Participants: Honorable Harold E. Shabo, J.D., Honorable Peggy Hora, J.D., Pauline H. Tesler, J.D., Meghan Lang, J.D.

**ISSUE WORKSHOP 33** 11:00 a.m.-12:30 p.m.  
Room 304, Esplanade Level, Moscone Center

### LEARNING PSYCHOTHERAPY IN PRIVATE PRACTICE

Co-Chps.: Bernard D. Beitman, M.D., Rodrigo A. Munoz, M.D.  
Participants: Harold I. Eist, M.D., Roger Peele, M.D.

**ISSUE WORKSHOP 34** 11:00 a.m.-12:30 p.m.  
Room 309, Esplanade Level, Moscone Center

### PATIENT RESPONSIBILITY FOR ADDICTION TO PRESCRIBED SUBSTANCES

Chp.: Harold J. Bursztajn, M.D.

Participants: Paul K. Robindra, D.P.H., Brian Johnson, M.D.

---

## 12 noon Sessions

---

### FORUMS 1-3

**FORUM 1** 12 noon-1:30 p.m.  
Room 301, Esplanade Level, Moscone Center

### WORKING WITH ORGANIZED MEDICINE: THE AMA AND STATE MEDICAL SOCIETIES

Chp.: Kenneth M. Certa, M.D.

Participants: Carolyn B. Robinowitz, M.D., John S. McIntyre, M.D., Gwen Lehman, M.D., Rodrigo A. Munoz, M.D.

**FORUM 2** 12 noon-1:30 p.m.  
Room 306, Esplanade Level, Moscone Center

### THE PLACEBO EFFECT: SCIENCE, BELIEF, AND CLINICAL PRACTICE

Chp.: Philip R. Muskin, M.D.

Co-Chp.: Andrew F. Leuchter, M.D.

Participants: Howard Fields, M.D., David Spiegel, M.D.

**FORUM 3** 12 noon-1:30 p.m.  
Golden Gate Hall B, B-2 Level, Marriott

### MUSIC AND THE MIND: GEORGE GERSHWIN

Chp.: Richard Kogan, M.D.

---

## 1:00 p.m. Sessions

---



### COURSES 51-59

Course descriptions are available in the *CME Course Brochure* included in your registration packet. Admission by ticket only.

**COURSE 51** 1:00 p.m.-5:00 p.m.  
Imperial Ballroom A, Ballroom Level, Hilton

### COGNITIVE THERAPY: THE BASICS

Director: Dean Schuyler, M.D.

**COURSE 52** 1:00 p.m.-5:00 p.m.  
Imperial Ballroom B, Ballroom Level, Hilton

### HOW TO USE YOUR PALM OS PDA IN PSYCHIATRIC PRACTICE: BASIC

Director: John S. Luo, M.D.

Faculty: Carlyle H. Chan, M.D., Raymond J. Kloss, M.D., Richard A. Montgomery, M.D., Charles J. Rainey, M.D., Hendry Ton, M.D.

**COURSE 53** 1:00 p.m.-5:00 p.m.  
Yosemite Room B, Ballroom Level, Hilton

### MELATONIN AND LIGHT TREATMENT OF SAD, SLEEP, AND OTHER BODY CLOCK DISORDERS

Director: Alfred J. Lewy, M.D.

Faculty: Kathryn A. Lee, Ph.D.

**COURSE 54** 1:00 p.m.-5:00 p.m.  
Yosemite Room C, Ballroom Level, Hilton

### CHILD MURDER BY PARENTS

Director: Phillip J. Resnick, M.D.



**COURSE 55** 1:00 p.m.-5:00 p.m.  
 Union Square 13, Fourth Floor, Hilton

**PERSONALITY DISORDERS: COMBINING  
 RELATIONAL THERAPY AND  
 PSYCHOPHARMACOLOGY**

Director: Roy O. Resnikoff, M.D.

**COURSE 56** 1:00 p.m.-5:00 p.m.  
 Union Square 17 & 18, Fourth Floor, Hilton

**ENGAGING RESISTANT AND HOSTILE PATIENTS  
 INTO PARTICIPATORY TREATMENT**

Director: David Mee-Lee, M.D.

**COURSE 57** 1:00 p.m.-5:00 p.m.  
 Union Square 19 & 20, Fourth Floor, Hilton

**THE ADVANCED PRACTICE OF PSYCHOTHERAPY**

Director: T. Byram Karasu, M.D.

**COURSE 58** 1:00 p.m.-5:00 p.m.  
 Union Square 21, Fourth Floor, Hilton

**ASSESSING POSITIVE AND NEGATIVE SYMPTOMS  
 IN PSYCHOSIS WITH THE PANSS**

Co-Directors: Lewis A. Opler, M.D., Paul M. Ramirez, Ph.D.

**COURSE 59** 1:00 p.m.-5:00 p.m.  
 Union Square 23 & 24, Fourth Floor, Hilton

**CURRENT CODING AND DOCUMENTATION  
 REQUIREMENTS**

Director: Chester W. Schmidt, Jr., M.D.

**NEW RESEARCH YOUNG INVESTIGATORS'  
 ORAL/SLIDE SESSIONS 2-4**

1:00 p.m.-2:30 p.m.

**2 SYSTEMS ISSUES AND PHENOMENOLOGY**  
 Room 110, Exhibit Level, Moscone Center

**3 MEDICATIONS AND SIDE EFFECTS**  
 Room 111, Exhibit Level, Moscone Center

**4 MOOD DISORDERS**  
 Room 112, Exhibit Level, Moscone Center

For further information on New Research Sessions, please refer to the *New Research Program Book* included in your registration packet.

**2:00 p.m. Sessions**

**ADVANCES IN PSYCHOTHERAPY**  
 2:00 p.m.-5:30 p.m.  
 Room 104, Exhibit Level, Moscone Center

**AN UPDATE ON PSYCHIATRIC TREATMENT FOR  
 PSYCHIATRIC DISORDERS**

Chp.: Glenn O. Gabbard, M.D.

**1 Mind and Brain in Psychiatric Treatment**  
 Glenn O. Gabbard, M.D.

**2 Treatment of PTSD**  
 Barbara O. Rothbaum, Ph.D.

**3 Psychoeducational Psychotherapies for Depression**  
 Michael E. Thase, M.D.

**4 Gender Issues in Psychotherapy**  
 Carol C. Nadelson, M.D.

**5 Treatment of Personality Disorders**  
 John G. Gunderson, M.D.

**LECTURES 6-7**

**LECTURE 6**  
 2:00 p.m.-3:30 p.m.

Rooms 130/131, Exhibit Level, Moscone Center

Robin M. Murray, M.B.

**Schizophrenia Is More Than a  
 Neurodevelopmental Disease**

Chp.: Anand Pandurangi, M.D.  
 Co-Chp.: Robert W. Baker, M.D.

Robin M. Murray, M.B., will discuss how schizophrenia results from the cumulative effect of a number of physical and social risk factors. The individual inherits an unfortunate combination of genes, each of which is not uncommon in the general population. The resultant deviant traits may be compounded by pre- and perinatal complications, and consequently many preschizophrenic children show minor developmental delays and cognitive difficulties. These propel the child on a trajectory of increasing oddness and alienation from his peers, and he may begin to have quasi-psychotic ideas about them. However, additional factors in early adult life such as drug abuse (psychostimulants and cannabis) and/or social adversity (e.g. life events, isolation, migration) are generally required to push the

*(Continued on next page)*

individual over a threshold into the expression of frank psychosis. Robin M. Murray, M.B., received his medical degree from the University of Glasgow, Scotland, and trained in Internal Medicine there. He studied psychiatry at the Maudsley Hospital, London, and has remained there ever since, apart from one year at NIH in Washington, DC. He is now Professor of Psychiatry at the Institute of Psychiatry, and is a recent President of the Association of European Psychiatrists. His department contains some 120 schizophrenia researchers. In the decade, 1991-2000, he was the most widely cited schizophrenia researcher. He also runs a clinical unit at the Bethlem Hospital (Bedlam), which takes referrals from all over England for people with resistant psychotic illnesses.

International Psychiatrist Lecture Series  
THIS SESSION WILL BE AUDIOTAPED.

LECTURE 7

2:00 p.m.-3:30 p.m.

Rooms 132/133, Exhibit Level, Moscone Center

APA'S SIMON BOLIVAR AWARD LECTURE

Juan J. Lopez-Ibor, Jr., M.D.

The Commitment of Psychiatrists:  
Lesson From Al-Andalus

Chp.: Ana E. Campo, M.D.

Juan J. Lopez-Ibor, Jr., M.D., is Professor of Psychiatry and Head of the Psychiatric Unit of San Carlos Hospital of the Complutense University in Madrid; coordinator for Mental Health for Madrid Area 7; and Director, World Health Organization Research and Training Center for Spain. He has twice held the offices of Secretary General and President of the World Psychiatric Association and has been President of the International College of Psychosomatic Medicine, the Spanish Society of Psychiatry, and the Spanish Society for Biological Psychiatry. He is the author of more than 200 scientific papers and 100 book chapters and the author or editor of several books, including the *New Oxford Textbook of Psychiatry*. A Fellow of the Royal National Academy of Medicine in Spain, Dr. Lopez-Ibor was awarded the commendation of the Civil Order of Health in 1998, the highest award in Spain's health care sector. Dr. Lopez-Ibor received his medical and doctoral degrees from the Complutense University of Madrid and completed psychiatry training at the University of Frankfurt in Germany, the Maudsley and St. Bartholomew's Hospitals in London, and the Cantonal Hospital of Vaud in Switzerland.

THIS SESSION WILL BE AUDIOTAPED.

PRESIDENTIAL SYMPOSIUM 1

2:00 p.m.-5:00 p.m.

Room 300, Esplanade Level, Moscone Center

MORAL AND PHILOSOPHICAL ISSUES IN PSYCHIATRY

Chp.: Deborah Spitz, M.D.

**A Values-Based Medicine (VBM): A First for Psychiatry**  
Kenneth Fulford, D.Phil.

**B What Is Good Diagnostic Practice?**  
John Z. Sadler, M.D.

**C Ethical Issues in Behavioral Genetics**  
Kenneth F. Schaffner, M.D.

**D Personal Identity and Mental Disorder**  
Jennifer Radden, Ph.D.

**E The Self in a Scientifically Driven Psychiatry**  
James E. Phillips, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIA 1-28

SYMPOSIUM 1

2:00 p.m.-5:00 p.m.

Room 100, Exhibit Level, Moscone Center

BORDERLINE PATIENTS AT THE BORDER OF TREATABILITY

Chp.: Michael H. Stone, M.D.

**A Managing the Real Risk of Suicide in Borderline Patients**  
John G. Gunderson, M.D.

**B Treatment Utilization by Patients With Severe BPD**  
Donna S. Bender, Ph.D., Andrew E. Skodol II, M.D.

**C Eroticized Transferences in Therapy With Borderline Patients**  
Frank E. Yeomans, M.D.

**D The Almost-Untreatable Narcissistic Patient**  
Otto F. Kernberg, M.D.

**E An Empirical Approach to the Border of Treatability in BPD Patients**  
John F. Clarkin, Ph.D.

**F Borderline Patients With Antisocial Features: Special Treatment Issues**  
Michael H. Stone, M.D.

Discussant: Michael H. Stone, M.D.

THIS SESSION WILL BE AUDIOTAPED.

**SYMPOSIUM 2** 2:00 p.m.-5:00 p.m.  
**Room 101, Exhibit Level, Moscone Center**

**MINERAL/VITAMIN MODIFICATION OF MENTAL DISORDERS AND BRAIN FUNCTION**

**Chp.:** Charles W. Popper, M.D.  
**Co-Chp.:** Bonnie J. Kaplan, Ph.D.

**A Nutrients Alter IQ and Mood in Healthy Volunteers: A Plausible Hypothesis?**  
 David Benton, Ph.D.

**B Influence of Micronutrients on Antisocial Behavior of Young-Adult Prisoners**  
 C. Bernard Gesch, C.Q.S.W., Sean M. Hammond, Ph.D., Sarah E. Hampson, Ph.D., Anita Eves, Ph.D., Martin J. Crowder, Ph.D.

**C Nutrient Treatment of Adult Bipolar Disorder and Childhood Mood Lability**  
 Bonnie J. Kaplan, Ph.D.

**D Clinical Questions and Concerns Raised by Micronutrient Treatments**  
 Charles W. Popper, M.D.

**Discussant:** Floyd R. Sallee, M.D.

**THIS SESSION WILL BE AUDIOTAPED.**

**SYMPOSIUM 3** 2:00 p.m.-5:00 p.m.  
**Room 105, Exhibit Level, Moscone Center**

**BPD: NEUROSCIENCE TO TREATMENT AND BACK**

**Chp.:** S. Charles Schulz, M.D.  
**Co-Chp.:** Mary C. Zanarini, Ed.D.

**A The McLean Screening Instrument for BPD**  
 Mary C. Zanarini, Ed.D., Anna A. Vujanovic, A.B., Elizabeth A. Parachini, B.A., Frances R. Frankenburg, M.D., John Hennen, Ph.D.

**B Biology of BPD: Towards a Rational Pharmaco/Psychotherapy**  
 Larry J. Siever, M.D., Antonia S. New, M.D., Harold W. Koenigsberg, M.D., Marianne Goodman, M.D., Monte S. Buchsbaum, M.D., Anissa Abi-Dargham, M.D., Marc Laruelle, M.D.

**C Neural Substrates of Emotional Dysregulation in BPD**  
 Nelson H. Donegan, Ph.D., Charles A. Sanislow, Ph.D., Robert K. Fulbright, M.D., John C. Gore, Ph.D., Pawel Skudlarski, Ph.D., Thomas H. McGlashan, M.D., Bruce E. Wexler, M.D.

**D Pharmacotherapy for BPD: New Opportunities**  
 S. Charles Schulz, M.D., K. Adityanjee

**E Dialectical Behavior Therapy for Patients Meeting Criteria for BPD**  
 Marsha M. Linehan, Ph.D.  
**THIS SESSION WILL BE AUDIOTAPED.**

**SYMPOSIUM 4** 2:00 p.m.-5:00 p.m.  
**Room 106, Exhibit Level, Moscone Center**

**PATHOLOGICAL BODY SCULPTING IN THE ATHLETE**

*International Society for Sport Psychiatry*

**Chp.:** Antonia L. Baum, M.D.

**A Little Girls in Pretty Boxes: The Making and Breaking of Elite Gymnasts and Figure-Skaters**  
 Joan Ryan

**B Eating Disorders in the Male Athlete**  
 Antonia L. Baum, M.D.

**C Risk Factors for Anabolic-Androgenic Steroid Abuse: A Case-Control Study**  
 Harrison G. Pope, Jr., M.D., Gen Kanayama, M.D., Geoffrey Cohane, B.A., James I. Hudson, M.D.

**THIS SESSION WILL BE AUDIOTAPED.**

**SYMPOSIUM 5** 2:00 p.m.-5:00 p.m.  
**Room 113, Exhibit Level, Moscone Center**

**COMPULSIVE BUYERS: TREATING THE CASUALTIES OF CONSUMERISM**

**Chp.:** Lorrin M. Koran, M.D.

**A Phenomenology and Epidemiology of Compulsive Buying**  
 Donald W. Black, M.D.

**B Examination and Explanation of the Triggers for Compulsive Buying Disorders**  
 Ronald J. Faber, Ph.D.

**C Pharmacotherapy for Compulsive Buying**  
 Kim D. Bullock, M.D., Helen W. Chuong, M.S., Lorrin M. Koran, M.D.

**D Group Psychotherapy for Compulsive Shopping: Pilot Data**  
 Heidi Hartston, Ph.D., Lorrin M. Koran, M.D.

**E A One-Year Naturalistic Follow-Up of Patients With Compulsive Buying Disorder**  
 Elias Aboujaoude, M.D., Lorrin M. Koran, M.D., Kim D. Bullock, M.D., Helen W. Chuong, M.S.

**THIS SESSION WILL BE AUDIOTAPED.**

**MONDAY**

**SYMPOSIUM 6** 2:00 p.m.-5:00 p.m.  
**Room 114, Exhibit Level, Moscone Center**

**QUALITY OF CARE FOR CHILDREN AND ADOLESCENTS**

**Chp.:** Joseph R. MaWhinney, M.D.  
**Co-Chp.:** Farifteh F. Duffy, Ph.D.

- A Estimating Quality of ADHD Treatment In Primary Care and Mental Health Settings**  
Regina Bussing, M.D., Cynthia W. Garraw, Ph.D., Bonnie T. Zima, M.D.
- B Quality of Care for Children in Routine Psychiatric Practice**  
Farifteh F. Duffy, Ph.D., Joyce C. West, Ph.D., William E. Narrow, M.D., Donald S. Rae, M.A., Maritza Rubio-Stipec, Sc.D.
- C Quality of Care for Children and Adolescents With MDD**  
William E. Narrow, M.D., Farifteh F. Duffy, Ph.D., Joyce C. West, Ph.D., Donald S. Rae, M.A., Maritza Rubio-Stipec, Sc.D.
- D The Use of Multiple Informants in Quality of Care: Are They Interchangeable?**  
Maritza Rubio-Stipec, Sc.D., Garrett Fitzmaurice, Sc.D., Glorisa Canino, Ph.D.

**Discussant:** Mina K. Dulcan, M.D.  
**THIS SESSION WILL BE AUDIOTAPED.**

**SYMPOSIUM 7** 2:00 p.m.-5:00 p.m.  
**Room 120, Exhibit Level, Moscone Center**

**PRACTICING PSYCHIATRY IN 2003**

**Chp.:** Rodrigo A. Munoz, M.D.  
**Co-Chp.:** Harold I. Eist, M.D.

- A The Future of Psychiatry**  
Brian Crowley, M.D., John C. Urbaitis, M.D.
- B The ABC's of Private Practice**  
Garry M. Vickar, M.D.
- C Private and Public Psychiatric Patient Advocacy**  
Lee H. Beecher, M.D., Roger Peele, M.D.
- D The Practice of Complete Psychiatry**  
Ronald D. Abramson, M.D., Robert L. Pyles, M.D.

**Discussants:** Edward Gordon, M.D., Janis G. Chester, M.D.  
**THIS SESSION WILL BE AUDIOTAPED.**

**SYMPOSIUM 8** 2:00 p.m.-5:00 p.m.  
**Room 121, Exhibit Level, Moscone Center**

**CHALLENGES IN CROSS-CULTURAL PSYCHIATRY: FOCUS ON DEPRESSION AND ETHNOPSYCHOPHARMACOLOGY**

**Chp.:** Rajesh M. Parikh, M.D.  
**Co-Chp.:** Shamsah B. Sonawalla, M.D.

- A Impact of Cultural Beliefs on the Treatment of Depressed Chinese-Americans**  
Albert Yeung, M.D.
- B Diagnosis and Treatment of Depressive Disorders in the Asian-Indian Population**  
Shamsah B. Sonawalla, M.D.
- C Management of Depression in the Hispanic Population**  
David Mischoulon, M.D.
- D Principles of Ethnopsychopharmacology**  
David C. Henderson, M.D.

**Discussant:** Claudio N. Soares, M.D.  
**THIS SESSION WILL BE AUDIOTAPED.**

**SYMPOSIUM 9** 2:00 p.m.-5:00 p.m.  
**Room 122, Exhibit Level, Moscone Center**

**CORE COMPETENCIES: HOW THEY FIT INTO CERTIFICATION AND RECERTIFICATION**

**Chp.:** Stephen C. Scheiber, M.D.

- A History of the Core Competency Movement**  
Thomas A.M. Kramer, M.D.
- B ABPN Works on Core Competencies**  
Daniel K. Winstead, M.D.
- C The Relationship Between Core Competencies and Maintenance of Certification**  
James H. Scully, Jr., M.D.

**Discussants:** Linda B. Andrews, M.D., Carol A. Bernstein, M.D.  
**THIS SESSION WILL BE AUDIOTAPED.**

**SYMPOSIUM 10** 2:00 p.m.-5:00 p.m.  
**Room 123, Exhibit Level, Moscone Center**

**PSYCHIATRY AND THE PHARMACEUTICAL INDUSTRY: WHERE IS THE BOUNDARY?**

**Chp.:** Amy C. Brodkey, M.D.

- A Pharmaceutical Promotion: Effects on the Practice of Psychiatry**  
Amy C. Brodkey, M.D.

**B Academia, Medical Education, and the Pharmaceutical Industry**

Frederick S. Sierles, M.D.

**C The Pharmaceutical Industry and Public Psychiatry Practice**

Robert M. Factor, M.D.

**D Industry-Sponsored Medical Education: When Educators Serve Two Masters**

Diana M. Koziupa, M.D.

**THIS SESSION WILL BE AUDIOTAPED.**

**SYMPOSIUM 11** 2:00 p.m.-5:00 p.m.

Room 124, Exhibit Level, Moscone Center

**EVALUATING CLINICAL COMPETENCE: CURRENT OPTIONS, FUTURE DIRECTIONS**

Chp.: Mantosh J. Dewan, M.D.

**A Encompassing Assessment of Competency**

Siegfried Streufert, Ph.D., Usha G. Satish, Ph.D.

**B Evaluating Competence in Psychotherapy**

John Manning, M.D., Bernard D. Beitman, M.D., Mantosh J. Dewan, M.D.

**C Toward Improved Evaluations: Training Competency**

Usha G. Satish, Ph.D., Siegfried Streufert, Ph.D., Mantosh J. Dewan, M.D., John Manning, M.D., Sarah Vander Voort, B.S.

Discussant: Bernard D. Beitman, M.D.

**THIS SESSION WILL BE AUDIOTAPED.**

**SYMPOSIUM 12** 2:00 p.m.-5:00 p.m.

Room 125, Exhibit Level, Moscone Center

**OCD SPECTRUM ILLNESSES: WHAT DOES IT MEAN? DOES IT HELP OUR TREATMENT?**

Chp.: Michelle T. Pato, M.D.

**A BDD and Hypochondriasis: Are They Part of the OCD Spectrum?**

Fugen Neziroglu, Ph.D., Dean McKay, Ph.D., Jose A. Yaryura-Tobias, M.D.

**B ADHD and OCD: Cognitive Characteristics**

Paul D. Arnold, M.D., Russell Schachar, M.D., Shirley Chen, M.D., Abel Ickowicz, M.D.

**C Complex Psychopathology and Descriptive Symptomatology in Children**

Jose A. Yaryura-Tobias, M.D., Dena Rabinowitz, Ph.D., Fugen Neziroglu, Ph.D.

**D A Preliminary Investigation of the Genetic Basis of Grooming Disorders**

Margaret A. Richter, M.D., Paul D. Arnold, M.D., Emanuela Mundo, M.D., Sam Fariba, B.S.C., James L. Kennedy, M.D.

Discussant: Michelle T. Pato, M.D.

**THIS SESSION WILL BE AUDIOTAPED.**

**SYMPOSIUM 13** 2:00 p.m.-5:00 p.m.

Rooms 272/274/276, Mezzanine Level, Moscone Center

**EVOLUTION OF THE SOCIAL BRAIN: IMPLICATIONS FOR MEDICAL EDUCATION AND TREATMENT**

*The World Psychiatric Association's Psychotherapy Section*

Chp.: Russell Gardner, M.D.

Co-Chp.: David Spiegel, M.D.

**A Stressed Students Benefit From Focused Social Boosting Signals**

Russell Gardner, M.D.

**B Feeling and Healing: Emotional and Social Expression Among Cancer Patients**

David Spiegel, M.D., Janine Giese-Davis, Ph.D., Cheryl Koopman, Ph.D., Lisa D. Butler, Ph.D., Catherine Classen, Ph.D., Matthew J. Cordova, Ph.D.

**C The Sociodynamics of Personal Identity and Therapeutic Change**

John O. Beahrs, M.D.

**D Nature Disrupted: Darwin and the Borderline Personality**

Mark T. Erickson, M.D.

**E The Evolved Social Brain and Child Development**

John R. Ewaldson, M.D.

**THIS SESSION WILL BE AUDIOTAPED.**

**SYMPOSIUM 14** 2:00 p.m.-5:00 p.m.

Room 301, Esplanade Level, Moscone Center

**ABORTION: SCIENTIFIC DATA TO INFORM CLINICAL CARE**

Chp.: Nada L. Stotland, M.D.

**A An Overview of Abortion in the U.S.**

Stanley Henshaw, Ph.D., Annie Keating

**B Surgical and Medical Abortion in the 21st Century: Update for Psychiatrists**

Karen Meckstroth, M.D.

**C Female Feticide: A Cross-Cultural Perspective**

Geetha Jayaram, M.D.

*(Continued on next page)*

**MONDAY**

**D Abortion and the Law**  
Jennifer Dalven, J.D.

**E Abortion and Psychiatry: Caring for Women and Families**  
Nada L. Stotland, M.D.

**THIS SESSION WILL BE AUDIOTAPED.**

**SYMPOSIUM 15** 2:00 p.m.-5:00 p.m.  
**Room 302, Esplanade Level, Moscone Center**

**SPIRITUALITY AND WORLD VIEW IN CLINICAL PRACTICE**

**Chp.:** Allan M. Josephson, M.D.  
**Co-Chp.:** John R. Peteet, M.D.

**A The Weltanschauung of Sigmund Freud: Clinical Implications**  
Armand M. Nicholi, Jr., M.D.

**B The Clinical Assessment of the Patient's World View**  
Irving S. Wiesner, M.D.

**C Diagnosis and Formulation: Integrating Spiritual and Religious Perspectives**  
Mark E. Servis, M.D., Allan M. Josephson, M.D.

**D Therapeutic Implications of World View**  
John R. Peteet, M.D.

**E Clinical Perspectives on Specific World Views**  
John R. Peteet, M.D., Allan M. Josephson, M.D., Abba E. Borowich, M.D., S. Ateaz Saeed, M.D., Mark E. Servis, M.D., Samuel B. Thielman, M.D.

**THIS SESSION WILL BE AUDIOTAPED.**

**SYMPOSIUM 16** 2:00 p.m.-5:00 p.m.  
**Room 304, Esplanade Level, Moscone Center**

**COGNITIVE THERAPY IN NOVEL CLINICAL SITUATIONS: RATIONALE, ISSUES, AND CONTROVERSIES**

**Chp.:** Anton C. Trinidad, M.D.

**A Developing Cognitive Therapy for Adults With ADHD: Why Bother?**  
Stephen P. McDermott, M.D.

**B Cognitive-Behavior Therapy for Individuals With Schizophrenia**  
Jan L. Scott, M.D.

**C Psychiatric Aspects in Oncology: End-of-Life Decisions**  
Anton C. Trinidad, M.D.

**THIS SESSION WILL BE AUDIOTAPED.**

**SYMPOSIUM 17** 2:00 p.m.-5:00 p.m.  
**Room 306, Esplanade Level, Moscone Center**

**EATING DISORDERS 2003: FROM LABORATORY TO PRACTICE**

**Chp.:** Joel Yager, M.D.  
**Co-Chp.:** David B. Herzog, M.D.

**A Update: Genetics of Anorexia and Bulimia Nervosa**  
Walter H. Kaye, M.D., Wade H. Berrettini, M.D., Bernie Devlin, Ph.D., Andrew Bergen, Ph.D., Cynthia M. Bulik, Ph.D., Dorothy E. Grice, M.D., The Price Foundation Group

**B Realities and Consternations of Outpatient Treatment for Anorexia Nervosa**  
Katherine A. Halmi, M.D., W. Stewart Agras, M.D., Scott J. Crow, M.D., James E. Mitchell, M.D., G. Terrence Wilson, Ph.D.

**C Feeding Laboratory Studies in Patients With Eating Disorders**  
James E. Mitchell, M.D., Blake A. Gosnell, Ph.D., James L. Roerig, Ph.D., Martina deZwaan, M.D., Stephen A. Wonderlich, Ph.D., Melissa A. Burgard, Beth N. Wambach

**D Are Eating Disorders and Substance Use Disorders Related?**  
David B. Herzog, M.D., David J. Dorer, Ph.D., Debra L. Franko, Ph.D., Pamela K. Keel, Ph.D., Valerie Charat, B.A., Erica C. Hutchins, B.A., Rebecca Renn, B.A.

**E Common and Uncommon Mistakes in Managing Eating Disorders**  
Joel Yager, M.D., Arnold E. Andersen, M.D., E.L. Danies, J.D.  
**THIS SESSION WILL BE AUDIOTAPED.**

**SYMPOSIUM 18** 2:00 p.m.-5:00 p.m.  
**Room 307, Esplanade Level, Moscone Center**

**ADVANCES IN THE TREATMENT OF CHILDHOOD TRAUMATIC GRIEF**

**Chp.:** Robert S. Pynoos, M.D.

**A Assessing and Treating Preschool Traumatic Grief After Domestic Violence**  
Alicia F. Lieberman, Ph.D.

**B Assessment and Group-Based Treatment of Traumatically Bereaved Adolescents**  
Christopher M. Layne, Ph.D., William S. Saltzman, Ph.D., Berina Arslanagic, M.D., Rob Davies, B.A., Robert S. Pynoos, M.D., Gary Burlingame, Ph.D.

**C Intervention for Child Survivors of Suicide**  
Cynthia R. Pfeffer, M.D.

**D Terrorism and the Treatment of Childhood Traumatic Grief: Lessons Learned From 9/11**  
Robin F. Goodman, Ph.D.

Discussant: Judith A. Cohen, M.D.

**THIS SESSION WILL BE AUDIOTAPED.**

**SYMPOSIUM 19** 2:00 p.m.-5:00 p.m.  
Room 308, Esplanade Level, Moscone Center

**NOVEL CLINICAL PERSPECTIVES ON THE PATHOPHYSIOLOGY AND TREATMENT OF PTSD**

Chp.: Lori L. Davis, M.D.

**A Animal Models of PTSD: Can Basic Science Inform the Clinic?**

Frederick Petty, M.D.

**B Gamma-Aminobutyric Acid Neurohormonal Modulation in PTSD and Treatment With Anticonvulsants**

Lori L. Davis, M.D.

**C Topiramate Therapy for PTSD**

Jeffrey L. Berlant, M.D.

Discussant: Charles R. Marmar, M.D.

**THIS SESSION WILL BE AUDIOTAPED.**

**SYMPOSIUM 20** 2:00 p.m.-5:00 p.m.  
Room 309, Esplanade Level, Moscone Center

**INTEGRATING INTERPERSONAL NEUROBIOLOGY IN PSYCHIATRIC TRAINING AND PRACTICE**

Chp.: Daniel J. Siegel, M.D.

Co-Chp.: Marilyn B. Benoit, M.D.

**A Integrating Neuroscience Into Clinical Practice**

Marilyn B. Benoit, M.D.

**B Integrating Brain, Mind, and Environment in Psychiatric Education**

Eugene V. Beresin, M.D.

**C The Neuroscience of Psychotherapy**

Louis Cozolino, Ph.D.

**D Interpersonal Neurobiology in the Palm of Your Hand**

Daniel J. Siegel, M.D.

**E Living Without Empathy: The Mirror Neurons**

Nancy S. Wolf, M.D.

Discussant: Marcia K. Goin, M.D.

**THIS SESSION WILL BE AUDIOTAPED.**

**SYMPOSIUM 21** 2:00 p.m.-5:00 p.m.  
Room 310, Esplanade Level, Moscone Center

**UPDATE ON TREATMENT OF STIMULANT ABUSE**

Chp.: David A. Gorelick, M.D.

**A Recovery-Oriented Psychosocial Treatments**

Douglas M. Ziedonis, M.D., Jeffrey A. Berman, M.D., Jon Krejci, M.D., David A. Smelson, Psy.D., Trish Dooley, M.A., Jill Williams, M.D.

**B Therapy and Placement Approaches for Cocaine-Abuse Treatment**

David R. Gastfriend, M.D., G. Shimi Kang, M.D., Estee Sharon, Psy.D., Sandrine Picard, M.D.

**C Pharmacological Treatment of Substance Abuse**

David A. Gorelick, M.D.

**D Psychiatric Comorbidity in Stimulant Abusers**

Richard N. Rosenthal, M.D.

**E Methamphetamine Abuse: Update 2003**

Steven L. Batki, M.D.

**THIS SESSION WILL BE AUDIOTAPED.**

**SYMPOSIUM 22** 2:00 p.m.-5:00 p.m.  
Salons 1 & 2, Lower B-2 Level, Marriott

**INTERFERON-INDUCED NEUROPSYCHIATRIC SIDE EFFECTS: NEW DATA AND TREATMENTS**

Chp.: Gregory M. Asnis, M.D.

Co-Chp.: Richard De La Garza II, Ph.D.

**A Interferon-Induced Depression: A Critical Analysis**

Gregory M. Asnis, M.D., Richard De La Garza II, Ph.D., Shari Kohn, Ph.D.

**B Prediction and Prevention of Interferon Alpha-Induced Depressive Symptoms**

Charles Raison, M.D., Lucile Capuron, Ph.D., Dominique L. Musselman, M.D., David Lawson, M.D., Charles B. Nemeroff, M.D., Andrew H. Miller, M.D.

**C Interferon Alpha-Induced Fronto-Striatal Dysfunction: From Symptoms to Neural Correlates**

Lucile Capuron, Ph.D., Giuseppe Pagnoni, Ph.D., Clinton D. Kilts, Ph.D., Charles B. Nemeroff, M.D., Gregory S. Berns, M.D., Andrew H. Miller, M.D.

**D Animal Models of Interferon-Induced Depression: A Role for Nonsteroidal Anti-Inflammatory Drugs**

Richard De La Garza II, Ph.D., Avi Wittlin, Alicia Mc Caskie, Gregory M. Asnis, M.D.

Discussant: Ziad A. Kronfol, M.D.

**THIS SESSION WILL BE AUDIOTAPED.**

**MONDAY**

**SYMPOSIUM 23** 2:00 p.m.-5:00 p.m.  
Salons 3 & 4, Lower B-2 Level, Marriott

**ROADS TO HEALING IN MENTAL HEALTH IN THE AMERICAS**

*Inter-American Council of Psychiatric Organizations*

**Chp.:** Roberto E. Chaskel, M.D.  
**Co-Chp.:** Amelia E. Musacchio, M.D.

- A Folkloric Roots of Latin-American Psychiatry: The Concept of Illness and Healing**  
Carlos Leon-Andrade, M.D., Roberto E. Chaskel, M.D.
- B Diagnostic Issues in Latin-American Patients: Are We on the Right Road?**  
Miguel R. Jorge, M.D., Monchablow Alberto
- C The Promise of Psychoeducation and Psychopharmacology in the Lives of Latin-American Patients**  
Ruben J. Hernandez-Serrano, M.D., Antonio Pacheco, M.D.
- D Psychotherapy: The Application of a Transcultural Healing Technique**  
Amelia E. Musacchio, M.D., Rodolfo D. Fahrner, M.D.
- E The Promise of Science and Its Delivery in the Americas**  
Andres Meerlein, M.D., Nestor F. Marchant, M.D.

**Discussants:** Renato D. Alarcon, M.D., Luis F. Ramirez, M.D.  
**THIS SESSION WILL BE AUDIOTAPED.**

**SYMPOSIUM 24** 2:00 p.m.-5:00 p.m.  
Salons 5 & 6, Lower B-2 Level, Marriott

**SEXUAL AND GENDER IDENTITY DISORDERS: QUESTIONS FOR DSM-V**

**Chp.:** Dan H. Karasic, M.D.  
**Co-Chp.:** Jack Drescher, M.D.

- A Gender Identity Disorder in Children and Adolescents: A Critical Review**  
Darryl B. Hill, Ph.D., Chris Rozanski, M.S.W., Jessica Carfaginni, B.A., Brian Willoughby
- B Disordering Gender Identity: Issues of Diagnostic Reform**  
Katherine Wilson, Ph.D., Arlene I. Lev, C.S.W.
- C DSM-IV-TR and the Paraphilias: An Argument for Removal**  
Charles A. Moser, M.D., Peggy J. Kleinplatz, Ph.D.

**Discussants:** Robert L. Spitzer, M.D., Paul J. Fink, M.D.  
**THIS SESSION WILL BE AUDIOTAPED.**

**SYMPOSIUM 25** 2:00 p.m.-5:00 p.m.  
Salons 10 & 11, Lower B-2 Level, Marriott

**CONFRONTING CRISES IN EDUCATION, MENTAL HEALTH, AND JUVENILE JUSTICE**

**Chp.:** Lawrence K. Richards, M.D.  
**Co-Chp.:** Karen T. Carey, Ph.D.

- A Noticing National Problems Through Study of California Juvenile Incarceration Data**  
Lawrence K. Richards, M.D., Allison Ganter, M.S.
- B The Fresno-Controlled Prevention Study for Children**  
Philip F. Kader, B.A., Merle Canfield, Ph.D., Lawrence K. Richards, M.D.
- C The Fresno-Controlled Study: Data Analysis, Conclusions, and Predictions**  
Merle Canfield, Ph.D., Adrianna Shoji, M.A., Kader Philip, Lawrence K. Richards, M.D.
- D Preventing Incarceration: Early Prevention for Preschoolers**  
Karen T. Carey, Ph.D., David Barnett, Ph.D.
- E Short- and Long-Term Effects of Risperidone on Conduct Problems in Children**  
Michael G. Aman, Ph.D., Robert L. Findling, M.D.
- F Courts as Case Managers: An End to Transinstitutionalization?**  
Patrick H. Gardner, J.D.

**THIS SESSION WILL BE AUDIOTAPED.**

**SYMPOSIUM 26** 2:00 p.m.-5:00 p.m.  
Salons 12 & 13, Lower B-2 Level, Marriott

**PSYCHIATRY AND THE POWER OF ADVOCACY**

**Chp.:** William M. Glazer, M.D.  
**Co-Chp.:** Patrice A. Harris, M.D.

- A Inspiring Psychiatrists to Empower Their Patients**  
Elizabeth A. Baxter, M.D.
  - B Understanding the Process of Advocating to Policy Makers**  
Patrice A. Harris, M.D.
  - C A Model Presentation: Access to Medications**  
Andrew J. McLean, M.D.
  - D Is Advocacy Required in Correctional Systems?**  
Charles A. Buscema, M.D.
  - E Forging Alliances Outside of the Point of Care**  
David Nelson, M.P.P.
- THIS SESSION WILL BE AUDIOTAPED.**



**SYMPOSIUM 27** 2:00 p.m.-5:00 p.m.  
Salons 14 & 15, Lower B-2 Level, Marriott

**APPLYING DECISION SCIENCE AND GAME THEORY TO CLINICAL PSYCHIATRY**

**Chp.:** Laurence V. Amsel, M.D.  
**Co-Chp.:** Serge M. Sevy, M.D.

**A Toward a Mathematical Psychiatry: The Use and Limitations of Formal Decision Models**  
Laurence V. Amsel, M.D.

**B Decision Modes and Psychiatry Therapy: The Importance of Knowing How Patients Decide**  
Elke V. Weber, Ph.D.

**C The Neurocognitive Mechanisms of Decision Making**  
Antoine Bechara, M.D.

**D The Neuromodulation of Emotional Cues in Human Choice**  
Robert D. Rogers, M.D.

**E Ethnic Differences in Estimating Utilities of Symptom Reduction in Psychosis**  
Leslie L. Lenert, M.D.

**THIS SESSION WILL BE AUDIOTAPED.**

**SYMPOSIUM 28** 2:00 p.m.-5:00 p.m.  
Golden Gate Hall A, B-2 Level, Marriott

**SCHIZOPHRENIA: CURRENT GUIDELINES, PRACTICES, AND EFFECTIVENESS RESEARCH**

**Chp.:** John S. McIntyre, M.D.  
**Co-Chp.:** Darrel A. Regier, M.D.

**A Overview of Best Practices: Current Treatment Guidelines and Protocols for Schizophrenia**  
Anthony F. Lehman, M.D.

**B Research Gaps and Current Research Initiatives to Improve the Treatment of Schizophrenia**  
Jeffrey A. Lieberman, M.D.

**C Factors Affecting the Effectiveness of Clinical Decisions in Treating Schizophrenia**  
Mark Olfson, M.D., Joyce C. West, Ph.D., Joshua E. Wilk, Ph.D., Steve Marcus, Ph.D.

**D The Treatment of Schizophrenia in Routine Psychiatric Practice**  
Joyce C. West, Ph.D., Joshua E. Wilk, Ph.D., Mark Olfson, M.D., Steve Marcus, Ph.D., Donald S. Rae, M.A., William E. Narrow, M.D., Darrel A. Regier, M.D.

**Discussant:** Samuel J. Keith, M.D.

**THIS SESSION WILL BE AUDIOTAPED.**

**3:00 p.m. Session**

**NEW RESEARCH POSTER SESSION 5**

3:00 p.m.-5:00 p.m.

Hall D, Exhibit Level, Moscone Center

**PSYCHOPHARMACOLOGY**

For further information on New Research Sessions, please refer to the *New Research Program and Abstracts Book* included in your registration packet.

**6:00 p.m. Session**

**CONVOCATION OF DISTINGUISHED FELLOWS**

6:00 p.m. – 7:30 p.m.

Hall E, Exhibit Level, Moscone Center

All Distinguished Fellows, Fellows, members, and registered guests are invited.

**Presiding:** Paul S. Appelbaum, M.D., *President*

**Grand Marshals:** Donald J. Scherl, M.D., Lenore C. Terr, M.D.

**Marshals:** Renee L. Binder, MD., Bruce S. Victor, M.D.

**INTRODUCTION OF DISTINGUISHED LIFE FELLOWS**

Marcia K. Goin, M.D., *President-Elect*

**INDUCTION OF DISTINGUISHED FELLOWS**

Marcia K. Goin, M.D.

**INTRODUCTION OF FIFTY-YEAR DISTINGUISHED LIFE FELLOWS, FIFTY-YEAR LIFE MEMBERS, AND INTERNATIONAL FELLOWS**

Paul S. Appelbaum, M.D.

**INTRODUCTION OF FELLOWS**

Paul S. Appelbaum, M.D.

**PRESENTATION OF SPECIAL PRESIDENTIAL COMMENDATIONS**

Paul S. Appelbaum, M.D.

**PRESENTATION OF DISTINGUISHED SERVICE AWARDS**

Paul S. Appelbaum, M.D.

*(Continued on next page)*

**INTRODUCTION OF THE MEMBERSHIP  
COMMITTEE CHAIRPERSON AND AWARD  
BOARD CHAIRPERSONS**

Paul S. Appelbaum, M.D.

**PRESENTATION OF AWARDS**

Paul S. Appelbaum, M.D.

APA/Lilly Resident Research Awards  
APIRE/Kempf Fund Awards for Research  
Development in Psychobiological Psychiatry  
Human Rights Awards  
Blanche F. Ittleson Award for Research  
in Child Psychiatry  
Agnes Purcell McGavin Awards  
Isaac Ray Award  
Jack Weinberg Memorial Award for  
Geriatric Psychiatry

**WILLIAM C. MENNINGER MEMORIAL  
CONVOCATION LECTURE**

Charles Krauthammer, M.D.

**LECTURE 8**

6:00 p.m.-7:00 p.m.

Hall E, Exhibit Level, Moscone Center

**WILLIAM C. MENNINGER MEMORIAL  
LECTURE**

Charles Krauthammer, M.D.

**Horsemen of the Apocalypse: Terror, Nihilism,  
and Science**

Charles Krauthammer, M.D., is a syndicated columnist for the *Washington Post*, an essayist for *Time Magazine*, a political analyst for "Fox News," and a contributing editor to *The Weekly Standard* and *The New Republic*. A psychiatrist by training, Dr. Krauthammer received his medical degree in 1975 from Harvard Medical School and completed his residency in psychiatry at Massachusetts General Hospital. His scientific papers, including his codiscovery of a form of bipolar disease, are still frequently cited in the psychiatric literature. In 1978 he left the practice of psychiatry and came to Washington to serve as a science advisor to the Carter administration. He joined the staff of *The New Republic* as an essayist and editor in 1981. In 1987, his first full year as a syndicated columnist, he won the Pulitzer Prize for Distinguished Commentary. Among the numerous other awards he has received for his writing are the National Magazine Award for Essays and Criticism, the Champion/Tuck Award for Economic Understanding, and the People for the American Way First Amendment Award. Dr. Krauthammer was appointed to the President's Council on Bioethics in 2001.

**THIS SESSION WILL BE AUDIOTAPED.**

# TUESDAY, MAY 20, 2003

## 156TH ANNUAL MEETING

### 7:00 a.m. Sessions

#### PART 2 OF INDUSTRY-SUPPORTED BREAKFAST SYMPOSIA 28-34

#### INDUSTRY-SUPPORTED BREAKFAST SYMPOSIUM 28, PART 2

7:00 a.m. - 8:30 a.m.

Gateway Ballroom, Exhibit Level, Moscone Center

#### IMPAIRMENT OF STRUCTURAL PLASTICITY IN SEVERE MOOD DISORDERS: CASUAL OR COLLATERAL?

*Supported by Abbott Laboratories*

**Chp.:** Pierre N. Tariot, M.D.

**Co-Chp.:** Husseini K. Manji, M.D.

#### **A** Reduced Hippocampal Volume in Adult Major Depression: The Role of Childhood Trauma

Meena Vythilingham, M.D.

#### **B** Targeting Structural Plasticity for Optimal Treatment of Severe Mood Disorders

Husseini K. Manji, M.D.

#### INDUSTRY-SUPPORTED BREAKFAST SYMPOSIUM 29, PART 2

7:00 a.m. - 8:30 a.m.

Metropolitan, Second Level, Argent

#### IMPULSIVITY, AGGRESSION, AND SUICIDE: VERSATILITY OF LITHIUM AND MOOD STABILIZERS

*Supported by Solvay Pharmaceuticals, Inc.*

**Chp.:** Eric Hollander, M.D.

#### **A** Lithium Treatment of Patients With Suicidal Affective Disorder: Risk Factors and Mediators

Jan A. Fawcett, M.D.

#### **B** Effects of Lithium on Impulsivity, Aggression, and Suicide

Frederick K. Goodwin, M.D.

#### INDUSTRY-SUPPORTED BREAKFAST SYMPOSIUM 30, PART 2

7:00 a.m. - 8:30 a.m.

Grand Ballroom Salon B, Grand Ballroom Level, Hilton

#### BIPOLAR DISORDER IN WOMEN: SPECIAL CONSIDERATIONS AND EVOLVING TREATMENT

*Supported by GlaxoSmithKline*

**Chp.:** Lee S. Cohen, M.D.

**Co-Chp.:** Martha J. Morrell, M.D.

#### **A** Bipolar Illness and the Postpartum Period: Clinical Issues and Controversies

Adele C. Viguera, M.D.

#### **B** Use of Antiepileptics Medications in Women

Martha J. Morrell, M.D.

#### INDUSTRY-SUPPORTED BREAKFAST SYMPOSIUM 31, PART 2

7:00 a.m. - 8:30 a.m.

Continental Ballroom, Ballroom Level, Hilton

#### MANAGING THE SPECTRUM OF PSYCHOTIC DISORDERS

*Supported by Bristol-Myers Squibb Company*

**Chp.:** Robert E. Hales, M.D.

**Co-Chp.:** Stuart C. Yudofsky, M.D.

#### **A** Long-Term Effectiveness of Antipsychotic Therapies: Real-World Considerations

Stephen R. Marder, M.D.

#### **B** Evolving Role of Novel Antipsychotics for the Management of Acute Mania

Terence A. Ketter, M.D.

#### INDUSTRY-SUPPORTED BREAKFAST SYMPOSIUM 32, PART 2

7:00 a.m. - 8:30 a.m.

Salons 7 & 8, Lower B-2 Level, Marriott

#### TREATING DEPRESSION: WHAT MATTERS? PART 2

*Supported by Eli Lilly and Company*

**Chp.:** Andrew A. Nierenberg, M.D.

**Co-Chp.:** Susan G. Kornstein, M.D.

#### **A** Bipolar Matters

Lori L. Altshuler, M.D., Mark A. Frye, M.D.

#### **B** Treatment Matters

Andrew A. Nierenberg, M.D.

#### INDUSTRY-SUPPORTED BREAKFAST SYMPOSIUM 33, PART 2

7:00 a.m. - 8:30 a.m.

Salon 9, Lower B-2 Level, Marriott

#### EVIDENCE-BASED TREATMENT OF PSYCHIATRIC DISORDERS

*Supported by Wyeth Pharmaceuticals*

**Chp.:** K. Ranga R. Krishnan, M.D.

*(Continued on next page)*

## TUESDAY

### A Evidence-Supportive Therapies for GAD and Social Anxiety Disorder

Jack M. Gorman, M.D.

### B Evidence-Based ECT and Transcranial Magnetic Stimulation

Sarah H. Lisanby, M.D.

## INDUSTRY-SUPPORTED BREAKFAST

### SYMPOSIUM 34, PART 2

7:00 a.m. - 8:30 a.m.

Grand Ballroom, Mezzanine Level, Westin St. Francis

### MANAGING ANXIETY AND SLEEP: A NEW ERA FOR GAMMA-AMINOBTYRIC ACID

*Supported by Cephalon Inc.*

Chp.: Philip T. Ninan, M.D.

### A Novel Gamma-aminobutyric acid Treatments in Neuropsychiatric Disorders

Stephen M. Stahl, M.D.

### B In Vivo Measurements of Gamma-aminobutyric acid in Neuropsychiatric Disorders

Linda Chang, M.D.

## 8:00 a.m. Sessions



### COURSES 60-68

Course descriptions are available in the *CME Course Brochure* included in your registration packet. Admission by ticket only.

### COURSE 60 8:00 a.m. - 12 noon

Franciscan Room B, Ballroom Level, Hilton

### DISASTER PSYCHIATRY: TERRORISM, TRAUMA, AND THINGS TO DO

*APA Committee on Psychiatric Dimensions of Disaster*

Director: Joseph C. Napoli, M.D.

Faculty: Michael Blumenfeld, M.D., V. Alex Kehayan, Ed.D.

### COURSE 61 8:00 a.m. - 12 noon

Franciscan Room D, Ballroom Level, Hilton

### SELF-REGULATION: THE BRAIN AND THE POWER OF HEALING RELATIONSHIPS

Director: Daniel J. Siegel, M.D.

Faculty: Allan N. Schore, Ph.D.

### COURSE 62 8:00 a.m. - 12 noon

Imperial Ballroom A, Ballroom Level, Hilton

### THE DETECTION OF MALINGERED MENTAL ILLNESS

Director: Phillip J. Resnick, M.D.

### COURSE 63 8:00 a.m. - 12 noon

Yosemite Room C, Ballroom Level, Hilton

### INTEGRATING PSYCHOTHERAPY AND PHARMACOTHERAPY

*APA Committee on Psychotherapy by Psychiatrists*

Director: Barton J. Blinder, M.D.

Faculty: Bernard D. Beitman, M.D., Michelle B. Riba, M.D.

### COURSE 64 8:00 a.m. - 12 noon

Union Square 5 & 6, Fourth Floor, Hilton

### SEXUAL HARASSMENT: PSYCHOLOGICAL AND LEGAL ASPECTS

Director: Gail E. Robinson, M.D.

Faculty: Renee L. Binder, M.D., Sharyn A. Lenhart, M.D., Michael F. Myers, M.D.

### COURSE 65 8:00 a.m. - 12 noon

Union Square 13, Fourth Floor, Hilton

### EXPANDING HEALTH CARE DELIVERY? LET TELEPSYCHIATRY HELP!

Director: Steven E. Hyler, M.D.

Faculty: Gerald Segal, M.S., William M. Tucker, M.D.

### COURSE 66 8:00 a.m. - 12 noon

Union Square 14, Fourth Floor, Hilton

### DOING RESEARCH ON A SHOESTRING BUDGET

Director: Mantosh J. Dewan, M.D.

Faculty: Michelle T. Pato, M.D., Edward K. Silberman, M.D.

### COURSE 67 8:00 a.m. - 12 noon

Union Square 15 & 16, Fourth Floor, Hilton

### THE CLINICAL APPLICATION OF CULTURAL PSYCHIATRY

Director: Wen-Shing Tseng, M.D.

Faculty: J. David Kinzie, M.D., Keh-Ming Lin, M.D., Jon M. Streltzer, M.D., Joseph J. Westermeyer, M.D.

**COURSE 68** 8:00 a.m. - 12 noon  
 Union Square 19 & 20, Fourth Floor, Hilton

**COGNITIVE THERAPY FOR SEVERE MENTAL DISORDERS**

**Director:** Jesse H. Wright, M.D.  
**Faculty:** Monica A. Basco, Ph.D., Michael E. Thase, M.D.

**9:00 a.m. Sessions**

**CLINICAL CASE CONFERENCE 2**  
 9:00 a.m. - 10:30 a.m.  
 Room 121, Exhibit Level, Moscone Center

**DYSKINESIAS IN A SOMATICALLY PREOCCUPIED PATIENT AFTER TREATMENT WITH ATYPICAL ANTIPSYCHOTICS**

**Moderator:** Curley L. Bonds, M.D.  
**Discussant:** Joseph M. Pierre, M.D.

**THIS SESSION IS OPEN TO APA MEMBERS ONLY. BLUE REGISTRATION BADGE OR APA MEMBERSHIP CARD REQUIRED FOR ADMITTANCE.**

**CONTINUOUS CLINICAL CASE CONFERENCE 1: PART 2**  
 9:00 a.m. - 12 noon  
 Room 120, Exhibit Level, Moscone Center

**TREATMENT OF THE VIP PATIENT: TWO PATIENTS, TWO THERAPISTS**

**Moderator:** Richard L. Munich, M.D.  
**Presenter:** Efram Bleiberg, M.D.

**THIS SESSION IS OPEN TO APA MEMBERS ONLY. BLUE REGISTRATION BADGE OR APA MEMBERSHIP CARD REQUIRED FOR ADMITTANCE.**



**COURSES 69-74**  
 Course descriptions are available in the *CME Course Brochure* included in your registration packet. Admission by ticket only.

**COURSE 69** 9:00 a.m. - 4:00 p.m.  
 Imperial Ballroom B, Ballroom Level, Hilton

**MED-PSYCH DRUG-DRUG INTERACTIONS: AN UPDATE**

**Co-Directors:** Scott C. Armstrong, M.D., Kelly L. Cozza, M.D.  
**Faculty:** David M. Benedek, M.D., Jessica R. Oesterheld, M.D., Neil B. Sandson, M.D., Gary H. Wynn, M.D.

**COURSE 70** 9:00 a.m. - 4:00 p.m.  
 Yosemite Room B, Ballroom Level, Hilton

**PSYCHOTHERAPY OF BORDERLINE PERSONALITY**

**Co-Directors:** Otto F. Kernberg, M.D., Frank E. Yeomans, M.D.  
**Faculty:** Eve Caligor, M.D., John F. Clarkin, Ph.D.

**COURSE 71** 9:00 a.m. - 4:00 p.m.  
 Union Square 1 & 2, Fourth Floor, Hilton

**PERSONALITY AND POLITICAL BEHAVIOR**

**Director:** Jerrold M. Post, M.D.

**COURSE 72** 9:00 a.m. - 4:00 p.m.  
 Union Square 21, Fourth Floor, Hilton

**MONEY MATTERS: USING THEORY IN CLINICAL PRACTICE**

**Director:** Cecilia M. Mikalac, M.D.

**COURSE 73** 9:00 a.m. - 4:00 p.m.  
 Union Square 23 & 24, Fourth Floor, Hilton

**INTRODUCTION TO COGNITIVE-BEHAVIORAL THERAPY**

**Co-Directors:** Robert M. Goisman, M.D., Philip G. Levensky, Ph.D.

**COURSE 74** 9:00 a.m. - 4:00 p.m.  
 Union Square 25, Fourth Floor, Hilton

**BASIC HYPNOSIS: PRINCIPLES AND APPLICATIONS**

**Director:** Jose R. Maldonado, M.D.  
**Faculty:** David Spiegel, M.D.

**DISCUSSION GROUPS 10-13**

9:00 a.m. - 10:30 a.m.

These sessions are limited to 25 participants on a first-come, first-served basis.

- 10 **Lauren B. Marangell, M.D.**, on Practical Psychopharmacology for the Busy Clinician (*Meet the Authors*)  
Pacific Conference Suite B, 4th Floor, Marriott
- 11 **Rodrigo A. Munoz, M.D.**, on Protecting Clinical Autonomy  
Pacific Conference Suite C, 4th Floor, Marriott
- 12 **Dilip V. Jeste, M.D.**, on Schizophrenia and Aging  
Pacific Conference Suite E, 4th Floor, Marriott
- 13 **Chowallur D. Chacko, M.D.**, on an Introduction to Starting a Forensic Psychiatric Practice  
Pacific Conference Suite F, 4th Floor, Marriott

**FOCUS LIVE SESSION 1**

9:00 a.m. - 10:30 a.m.

Room 106, Exhibit Level, Moscone Center

**Moderators:** Deborah J. Hales, M.D., Mark H. Rapaport, M.D.

**Presenter:** James W. Jefferson, M.D., on **Bipolar Disorder**

Expert clinicians, who served as the guest editors of the first two issues of *Focus* will lead lively multiple-choice, question-based discussions. This session covers bipolar disorder and the second session at 11:00 a.m. covers substance abuse. Presented with multiple-choice questions, participants will test their knowledge with an interactive audience response system, which instantly presents the audience responses as a histogram on the screen. Each participant is able to take a self-assessment exam with answers and discussion led by the expert faculty.

**LECTURES 9-10**

**LECTURE 9**

9:00 a.m. - 10:30 a.m.

Room 101, Exhibit Level, Moscone Center

**Andrea Grubb Barthwell, M.D.**

**Current Perspectives on  
Our National Drug Control Strategy**

**Chp.:** Patricia I. Ordorica, M.D.

**Co-Chp.:** Teresita Sanjurjo, M.D.

Andrea Grubb Barthwell, M.D., was nominated to serve as Deputy Director of Demand Reduction for the Office of National Drug Control Policy by President George W. Bush in December 2001 and confirmed by

the United States Senate on January 28, 2002. Dr. Barthwell serves as a principal advisor to ONDCP Director John P. Walters on priorities, objectives and goals pertaining to demand reduction policies within the National Drug Control Strategy. As incumbent, Dr. Barthwell provides executive leadership of the Office of Demand Reduction and is responsible for oversight of demand reduction aspects of the Strategy. Dr. Barthwell received a Bachelor of Arts in Psychology from Wesleyan University in Connecticut and a Doctor of Medicine from the University of Michigan Medical School. Following post-graduate training at the University of Chicago and Northwestern University Medical Center, she began her practice in the Chicago area. In 1997, Dr. Barthwell was selected by her peers as one of the "Best Doctors in America" in Addiction Medicine.

**THIS SESSION WILL BE AUDIOTAPED.**

**LECTURE 10**

9:00 a.m. - 10:30 a.m.

Rooms 130/131, Exhibit Level, Moscone Center

**APA'S ADOLF MEYER AWARD LECTURE**

**David Reiss, M.D.**

**Genes, Family Relationships, and DSM-V**

**Chp:** Paul S. Appelbaum, M.D.

**Co-Chp.:** David A. Baron, M.D.

New data from twin and adoption studies suggest that parental, sibling, and marital relationships are important behavioral phenotypes that are influenced by specific genetic factors that also influence anxiety, depression, and conduct problems. David Reiss, M.D., discusses the potential use of features of the patient's intimate social relationships to help define the pathogenesis and distinctive features of psychiatric disorders. Dr. Reiss is the Vivian Gill Distinguished Research Professor and Director of the Division of Research at the Center for Family Research in the Department of Psychiatry and Behavioral Sciences at the George Washington University School of Medicine and Health Sciences in Washington, D.C. He is also a Teaching Analyst at the Washington Psychoanalytic Institute. Dr. Reiss is co-author of *The Relationship Code: Deciphering Genetic and Social Influences on Adolescent Development*. He is Co-Chairperson of the APA Council on Research's Task Force on Prevention of Mental Disorders and Promotion of Mental Health and a member of the Section of Psychology of the American Association for the Advancement of Science. A graduate of Harvard Medical School, Dr. Reiss completed his psychiatric residency at Massachusetts Mental Health Center in Boston, MA, and received his psychoanalytic training at the Washington Psychoanalytic Institute.

**THIS SESSION WILL BE AUDIOTAPED.**

## MASTER EDUCATOR CLINICAL CONSULTATION 5

9:00 a.m. - 10:30 a.m.

This session is limited to 25 participants on a first-come, first-served basis.

**T. Byram Karasu, M.D.**, on Psychotherapeutic Diagnoses and Treatment Planning  
Room 218, Mezzanine Level, Moscone Center

**THIS SESSION IS OPEN TO APA MEMBERS ONLY. BLUE REGISTRATION BADGE OR APA MEMBERSHIP CARD REQUIRED FOR ADMITTANCE.**

## RESEARCH ADVANCES IN MEDICINE

9:00 a.m. - 11:00 am

Room 300, Esplanade Level, Moscone Center

**UNDERSTANDING THE LATEST DEVELOPMENTS IN DEPRESSION: ITS RELATIONSHIP TO THE BRAIN, HEART, AND IMMUNE RESPONSE**

**Chp.:** David M. McDowell, M.D.

**Participants:** Robert G. Robinson, M.D., on Strokes  
Margaret E. Kemeny, Ph.D., on Depression and the Immune Response  
David B. Buchholz, M.D., on New and Improved Understanding of Headaches  
K. Ranga R. Krishnan, M.D., on Vascular Depression

## REVIEW OF PSYCHIATRY: SECTION 1

9:00 a.m. - 12:30 p.m.

Room 104, Exhibit Level, Moscone Center

## 2003 PSYCHIATRY UPDATE: TRAUMA AND DISASTER RESPONSES AND MANAGEMENT

**Co-Chps.:** Robert J. Ursano, M.D., Ann E. Norwood, M.D.

- 1 **Terrorism With Weapons of Mass Disruption: Chemical, Biological, Nuclear, Radiological, and Explosive**  
Robert J. Ursano, M.D.
- 2 **Early Intervention for Trauma-Related Problems**  
Patricia J. Watson, Ph.D.
- 3 **Neurobiological Mechanisms of Psychological Trauma**  
Omer Bonne, M.D.
- 4 **Children, Disasters, and the September 11th World Trade Center Attack**  
Roy H. Lubit, M.D.
- 5 **The Psychiatric Epidemiology of Disaster Responses**  
Carol S. North, M.D.

## WORKSHOPS

### COMPONENTS 10-17

**COMPONENT WORKSHOP 10** 9:00 a.m. - 10:30 a.m.  
Room 105, Exhibit Level, Moscone Center

### PRACTICAL TIPS ON HOW TO BE A SUCCESSFUL AUTHOR

*American Psychiatric Publishing Inc. Editorial Board*

**Chp.:** Robert E. Hales, M.D.

**Participants:** Glen O. Gabbard, M.D., John M. Oldham, M.D., Alan F. Schatzberg, M.D., Donna E. Stewart, M.D.

**COMPONENT WORKSHOP 11** 9:00 a.m. - 10:30 a.m.

Salons 3 & 4, Lower B-2 Level, Marriott

### HOW TO PROVIDE GERIATRIC PSYCHIATRY DURING RESIDENCY

*APA Committee on Access and Effectiveness of Psychiatric Services for the Elderly*

**Chp.:** Colleen J. Northcott, M.D.

**Participants:** Barbara J. Justice, M.D., Iqbal Ahmed, M.D., Josepha A. Cheong, M.D.

**COMPONENT WORKSHOP 12** 9:00 a.m. - 10:30 a.m.

Salons 5 & 6, Lower B-2 Level, Marriott

### PSYCHIATRIC MANAGEMENT OF HIV, HEPATITIS C, AND SUBSTANCE ABUSE

*APA Committee on AIDS*

**Chp.:** Milton L. Wainberg, M.D.

**Participants:** Karl Goodkin, M.D., Steven L. Batki, M.D.

**COMPONENT WORKSHOP 13** 9:00 a.m. - 10:30 a.m.

Salons 12 & 13, Lower B-2 Level, Marriott

### IMGS: CHALLENGES AND SOLUTIONS

*APA Committee on International Medical Graduates*

**Co-Chps.:** Josie L. Olympia, M.D., Godehard Oepen, M.D.

**Participants:** Moitri N. Datta, M.D., Elizabeth J. Santos, M.D., Rolando R. Velasquez, L.L.B.

**COMPONENT WORKSHOP 14** 9:00 a.m. - 10:30 a.m.

Salons 14 & 15, Lower B-2 Level, Marriott

### NEW APA ETHICS PROCEDURES: IMPLICATIONS FOR THE PROFESSION, PART 1

*APA Ethics Appeal Board*

**Co-Chps.:** Richard D. Milone, M.D., Pedro Ruiz, M.D.

**Participants:** JoAnn Macbeth, J.D., Alfred Herzog, M.D., Alan A. Stone, M.D.

## TUESDAY

**COMPONENT WORKSHOP 15** 9:00 a.m. - 10:30 a.m.  
Golden Gate Hall A, B-2 Level, Marriott

### CAREER CHOICES IN PSYCHIATRY EXPLORING FELLOWSHIP TRAINING

*APA Assembly Committee of Area Member-in-Training Representatives*

**Chp.:** Caroline E. Fisher, M.D.

**Participants:** Mathieu Bermingham, M.D., John R. Chamberlain, M.D., Maria I. Fernandez, M.D., Joshua A. Israel, M.D., John C. Furman, M.D.

**COMPONENT WORKSHOP 16** 9:00 a.m. - 10:30 a.m.  
Pacific Conference Suite H, 4th Floor, Marriott

### IT DOESN'T HAPPEN TO US: INSIDER'S VIEW OF TRAUMA IN MINORITY COMMUNITIES

*APA/Center for Mental Health Services and APA/ AstraZeneca Minority Fellows*

**Chp.:** Napoleon B. Higgins, Jr., M.D.

**Participants:** Lacresha L. Hall, M.D., Aruna S. Rao, M.D., Jean-Marie Alves-Bradford, M.D., Eric R. Williams, M.D.

**COMPONENT WORKSHOP 17** 9:00 a.m. - 10:30 a.m.  
Pacific Conference Suite J, 4th Floor, Marriott

### RACISM: DIAGNOSTIC AND TREATMENT CONSIDERATIONS

*APA Committee of Black Psychiatrists*

**Chp.:** Michelle O. Clark, M.D.

**Participants:** Carl C. Bell, M.D., George L. Mallory, M.D.

### ISSUES 35-53

**ISSUE WORKSHOP 35** 9:00 a.m. - 10:30 a.m.  
Room 110, Exhibit Level, Moscone Center

### BRIEF PSYCHODYNAMIC PSYCHOTHERAPY OF PANIC: A LEARNING-STRATEGY APPROACH

**Co-Chps.:** Bryan K. Touchet, M.D., Kim A. Coon, L.P.C.

**ISSUE WORKSHOP 36** 9:00 a.m. - 10:30 a.m.  
Room 111, Exhibit Level, Moscone Center

### CONSENT EVALUATIONS: ASSESSING CAPACITY FOR DECISION MAKING AND FOR VOLUNTARISM

**Chp.:** Laura W. Roberts, M.D.

**ISSUE WORKSHOP 37** 9:00 a.m. - 10:30 a.m.  
Room 112, Exhibit Level, Moscone Center

### ARTISTIC USE OF THE CREATIVE UNCONSCIOUS IN THE THERAPEUTIC ALLIANCE

**Co-Chps.:** Ian E. Alger, M.D., Ferruccio A. di Cori, M.D.

**ISSUE WORKSHOP 38** 9:00 a.m. - 10:30 a.m.  
Room 113, Exhibit Level, Moscone Center

### PSYCHIATRY TRAINING FOR PRIMARY CARE PHYSICIANS: WHAT, HOW MUCH, AND HOW?

**Chp.:** Hoyle Leigh, M.D.

**Participants:** Deborah C. Stewart, M.D., Tana A. Grady-Weliky, M.D., Don R. Lipsitt, M.D., Seth M. Powsner, M.D.

**ISSUE WORKSHOP 39** 9:00 a.m. - 10:30 a.m.  
Room 114, Exhibit Level, Moscone Center

### DYNAMIC THERAPY WITH SELF-DESTRUCTIVE BORDERLINE PATIENTS

**Co-Chps.:** Eric M. Plakun, M.D., Edward R. Shapiro, M.D.

**ISSUE WORKSHOP 40** 9:00 a.m. - 10:30 a.m.  
Room 122, Exhibit Level, Moscone Center

### THE DEVELOPMENT, IMPLEMENTATION, AND OPERATION OF DIVERSE TELEPSYCHIATRY PROGRAMS

**Chp.:** Norman E. Alessi, M.D.

**Participants:** Donald M. Hilty, M.D., Beverly N. Jones, M.D.

**ISSUE WORKSHOP 41** 9:00 a.m. - 10:30 a.m.  
Room 123, Exhibit Level, Moscone Center

### CHALLENGING BEHAVIOR, MENTAL ILLNESS, AND DEVELOPMENTAL DISABILITIES

**Co-Chps.:** Earl L. Loschen, M.D., Robert J. Pary, M.D.

**Participant:** Josefina M. Baluga, M.D.

**ISSUE WORKSHOP 42** 9:00 a.m. - 10:30 a.m.  
Room 124, Exhibit Level, Moscone Center

### TREATMENT OF SCHIZOPHRENIA: ANTIPSYCHOTIC POLYPHARMACY VERSUS MONOTHERAPY

**Chp.:** Andre Tapp, M.D.

**Participants:** Donald C. Goff, M.D., William G. Honer, M.D., Alexander L. Miller, M.D., Robert A. Rosenheck, M.D.

**ISSUE WORKSHOP 43** 9:00 a.m. - 10:30 a.m.  
Room 125, Exhibit Level, Moscone Center

### RELEVANT DATA FOR THE PRACTICING PSYCHIATRIST: COMORBIDITIES/COMBINED TREATMENT

**Chp.:** Daniel A. Deutschman, M.D.

**Participants:** Terence L. Witham, M.D., John S. Lloyd, Ph.D., Robert J. Ronis, M.D., Stephen M. Goldfinger, M.D., Rebecca S. Bierman, D.O.



**ISSUE WORKSHOP 44** 9:00 a.m. - 10:30 a.m.  
 Rooms 272/274/276, Mezzanine Level, Moscone Center

**THE BENZODIAZEPINE CONTROVERSY**

**Co-Chps.:** Christopher K. Chung, M.D., Dean M. De Crisce, M.D.  
**Participants:** Stephen B. Seager, M.D., Ricardo P. Mendoza, M.D.,  
 John W. Tsuang, M.D.

**ISSUE WORKSHOP 45** 9:00 a.m. - 10:30 a.m.  
 Room 301, Esplanade Level, Moscone Center

**SURGEON GENERAL'S REPORT ON CULTURE,  
 RACE, AND ETHNICITY: CLINICAL IMPLICATIONS**

**Chp.:** Theresa M. Miskimen, M.D.  
**Participants:** Nang Du, M.D., James W. Thompson, M.D.

**ISSUE WORKSHOP 46** 9:00 a.m. - 10:30 a.m.  
 Room 302, Esplanade Level, Moscone Center

**THE PSYCHIATRIC CARE OF SURVIVORS OF  
 TORTURE**

**Chp.:** Asher D. Aladjem, M.D.  
**Participants:** Kimberly A. Busi, M.D., Sophia Banu, M.D.,  
 Hawthorne Smith, Ph.D.

**ISSUE WORKSHOP 47** 9:00 a.m. - 10:30 a.m.  
 Room 304, Esplanade Level, Moscone Center

**DEVELOPMENT OF THE SCHOOL-BASED  
 ADOLESCENT DEPRESSION AWARENESS  
 PROGRAM**

**Co-Chps.:** Karen L. Swartz, M.D., Todd S. Cox, M.D.  
**Participants:** Elizabeth A. Kastelic, M.D., Sallie Mink, R.N.

**ISSUE WORKSHOP 48** 9:00 a.m. - 10:30 a.m.  
 Room 306, Esplanade Level, Moscone Center

**DEVELOPMENTS IN COGNITIVE THERAPY FOR  
 SCHIZOPHRENIA**

**Chp.:** David G. Kingdon, M.D.  
**Participant:** Douglas Turkington, M.B.

**ISSUE WORKSHOP 49** 9:00 a.m. - 10:30 a.m.  
 Room 308, Esplanade Level, Moscone Center

**PSYCHIATRIC ILLNESS AND THE WORKPLACE**

**Chp.:** Steven E. Pflanz, M.D.

**ISSUE WORKSHOP 50** 9:00 a.m. - 10:30 a.m.  
 Room 309, Esplanade Level, Moscone Center

**PSYCHIATRIC PERSPECTIVES ON THE  
 EXECUTION PROCESS: A CONTINUING  
 CONUNDRUM**

**Chp.:** Howard J. Osofsky, M.D.  
**Participants:** Rahn K. Bailey, M.D., Alfred M. Freedman, M.D.,  
 Abraham L. Halpern, M.D., Donna M. Mancuso, M.D., Michael J.  
 Osofsky, Ira D. Glick, M.D.

**ISSUE WORKSHOP 51** 9:00 a.m. - 10:30 a.m.  
 Room 310, Esplanade Level, Moscone Center

**FROM NEUROPATHOLOGY TO TREATMENT:  
 EMERGING TREATMENT STRATEGIES FOR  
 ALZHEIMER'S DISEASE**

**Chp.:** Jacobo E. Mintzer, M.D.  
**Participants:** Gary L. Wenk, Ph.D., David Snowden, Ph.D.,  
 Rachele S. Doody, M.D.

**ISSUE WORKSHOP 52** 9:00 a.m. - 10:30 a.m.  
 Salons 1 & 2, Lower B-2 Level, Marriott

**THE EMERGING ROLE OF PSYCHIATRY IN A  
 BIOTERRORISM RESPONSE**

**Chp.:** Anthony T. Ng, M.D.  
**Participants:** Robert DeMartino, M.D., Kenneth S.  
 Thompson, M.D.

**ISSUE WORKSHOP 53** 9:00 a.m. - 10:30 a.m.  
 Salons 10 & 11, Lower B-2 Level, Marriott

**HOW TO LAUNCH A SUCCESSFUL PRIVATE  
 PRACTICE, PART 1**

**Co-Chps.:** William E. Callahan, Jr., M.D., Keith W. Young, M.D.  
**Participants:** Jacqueline M. Melonas, J.D., Martin G. Tracy, J.D.

**11:00 a.m. Sessions**

**DISCUSSION GROUPS 14-17**

11:00 a.m. - 12:30 p.m.

These sessions are limited to 25 participants on a first-come, first-served basis.

14 **Raphael J. Leo, M.D.**, on An Update on Pain Management  
*(Meet the Authors)*  
 Pacific Conference Suite B, 4th Floor, Marriott

*(Continued on next page)*

## TUESDAY

- 15 **Anita L.H. Clayton, M.D.**, on Clinical Implications of Sexual Dysfunction in Depression  
**Pacific Conference Suite C, 4th Floor, Marriott**
- 16 **Steven S. Sharfstein, M.D.**, on Psychiatric Leadership in the Medical Marketplace  
**Pacific Conference Suite E, 4th Floor, Marriott**
- 17 **Glen O. Gabbard, M.D.**, on Maintaining and Developing Family Relationships During Residency (*For Residents Only*)  
**Pacific Conference Suite I, 4th Floor, Marriott**

### FOCUS LIVE SESSION 2

9:00 a.m. – 10:30 a.m.  
Room 106, Exhibit Level, Moscone Center

**Moderators:** Deborah J. Hales, M.D., Mark H. Rapaport, M.D.  
**Presenter:** Kathleen T. Brady, M.D., on **Substance Abuse**

Expert clinicians, who served as the guest editors of the first two issues of *Focus* will lead lively multiple-choice, question-based discussions. The first session at 9:00 a.m. covers bipolar disorder and this session covers substance abuse. Presented with multiple-choice questions, participants will test their knowledge with an interactive audience response system, which instantly presents the audience responses as a histogram on the screen. Each participant is able to take a self-assessment exam with answers and discussion led by the expert faculty.

### LECTURES 11-12

#### LECTURE 11

11:00 a.m. - 12:30 p.m.

Rooms 130/131, Exhibit Level, Moscone Center

**Christopher A. Ross, M.D.**

**Neurogenetics: Insights Into Neurodegeneration and Approaches to Schizophrenia**

**Chp.:** Anand Pandurangi, M.D.

**Co-Chp.:** K. Roy MacKenzie, M.D.

Christopher A. Ross, M.D., will discuss how modern molecular genetic and neurobiologic techniques have led to great advances in our understanding of neurodegenerative diseases, and are beginning to provide insights into psychiatric disease such as schizophrenia. Many neurodegenerative diseases, including Huntington's Disease, Parkinson's Disease, and also Alzheimer's Disease, are now appreciated to involve protein misfolding and abnormal protein interactions. Huntington's Disease is an autosomal dominant genetic disorder caused by a triplet repeat expansion in the HD gene, resulting in a huntingtin protein with an abnormally long polyglutamine stretch

and altered conformation. Abnormal interactions with other proteins within the cell then cause neuronal cell death in selective regions of the brain, resulting in motor, cognitive, and emotional changes. Neuroimaging studies indicate that individuals with the HD gene mutation begin to have basal ganglia atrophy well before the clinically diagnosable syndrome, suggesting that when treatments are available they should begin in presymptomatic mutation-positive individuals. Parkinson's Disease, by contrast, had long been considered to be mostly sporadic, but rare families with genetic forms of the disease are yielding insight into a pathogenic pathway involved in all patients with the disease. Abnormal interactions involving parkin and alpha-synuclein contribute to the formation of the Lewy bodies, the characteristic neuropathology of the disease. The same kinds of techniques that have been so powerful in studying these neurodegenerative diseases are now being applied to schizophrenia. These techniques are beginning to provide cell biological evidence in favor of the hypothesis that schizophrenia involves abnormalities in cerebral cortical development.

**Frontiers of Science Lecture Series**  
**THIS SESSION WILL BE AUDIOTAPED.**

#### LECTURE 12

11:00 a.m. - 12:30 p.m.

Rooms 132/133, Exhibit Level, Moscone Center

**Julien Mendlewicz, M.D.**

**The Search for Genes of Bipolar Disorder: From Classical Genetics to Novel Molecular Targets**

**Chp.:** Lewis L. Judd, M.D.

**Co-Chp.:** Paul J. Goodnick, M.D.

Julien Mendlewicz, M.D., is Professor of Psychiatry at the Faculties of Medicine, Psychology, and Law at the University of Brussels; Chairman of the Department of Psychiatry at Erasme Hospital in Brussels; and Director of the Laboratory of Psychiatric Research of the Faculty of Medicine at the Free University of Brussels, Belgium. Professor Mendlewicz's research interests include molecular neurobiology and behavioral genetics, particularly of affective disorders, chronobiology and sleep; and neuropharmacology. The author of more than 600 scientific articles, Professor Mendlewicz is the Founding and Principal Editor of *Neuropsychobiology* and Editor of the international series *Advances in Biological Psychiatry*. An active member of many international scientific societies, Professor Mendlewicz is President-Elect of the European College of Neuropsychopharmacology. He has received numerous honors, including the A.E. Bennett Research Award from the American Society of Biological Psychiatry, the Anna Monika International Foundation Prize for Research in Depression, the Lieber Prize from the National Alliance for Research

on Schizophrenia and Depression, and the Emil Kraepelin Award from the Max-Planck-Institut for Psychiatrie. Professor Mendlewicz received his medical degree from the Free University of Brussels and his doctorate in human genetics and development from Columbia University in New York City, NY.  
**International Psychiatrist Lecture Series**  
**THIS SESSION WILL BE AUDIOTAPED.**

### MASTER EDUCATOR CLINICAL CONSULTATIONS 6-7

11:00 a.m. - 12:30 p.m.

These sessions are limited to 25 participants on a first-come, first-served basis.

- 6 **Stephen M. Goldfinger, M.D.**, on Engaging the Disengaged: Connecting With Marginalized Patients  
 Room 218, Mezzanine Level, Moscone Center
- 7 **Philip R. Muskin, M.D.**, on Rational or Rationalized Suicide? An Ethical/Clinical Dilemma  
 Room 220, Mezzanine Level, Moscone Center

**THESE SESSIONS ARE OPEN TO APA MEMBERS ONLY. BLUE REGISTRATION BADGE OR APA MEMBERSHIP CARD REQUIRED FOR ADMITTANCE.**

### MEDICAL UPDATE 2

11:00 a.m. - 12:30 p.m.

Room 300, Esplanade Level, Moscone Center

### MENOPAUSE: WHAT PSYCHIATRISTS NEED TO KNOW

Chp.: Natalie L. Rasgon, M.D.

Presenter: Louann Brizendine, M.D.

### RESEARCH CONSULTATION WITH

11:00 a.m. - 12:30 p.m.

This session is limited to 25 participants on a first-come, first-served basis.

- 1 **J. Raymond DePaulo, Jr., M.D.**, on the Genetics of Bipolar Disorder and Other Psychiatric Phenotypes  
 Sierra Conference Suite E, 5th Floor, Marriott

### SCIENTIFIC AND CLINICAL REPORT SESSIONS 8-18

#### SCIENTIFIC AND CLINICAL REPORT SESSION 8

11:00 a.m. - 12:30 p.m.

Room 110, Exhibit Level, Moscone Center

#### MOOD AND ANXIETY DISORDERS IN CHILDREN AND ADOLESCENTS

Chp.: Elizabeth B. Weller, M.D.

Co-Chp.: Eric R. Williams, M.D.

11:00 a.m.

#### 23 Management of Adolescent Mania

Melissa P. DelBello, M.D.

11:30 a.m.

#### 24 Exploratory Factor Analysis of BPD Criteria in Hospitalized Adolescents

Daniel F. Becker, M.D., Carlos M. Grilo, Ph.D., Charles A. Sanislow, Ph.D., Thomas H. McGlashan, M.D.

12 noon

#### 25 Gender Differences in Comorbidities in Child and Adolescent GAD

Atilla Turgay, M.D., Mansoor Zafar, M.D., Rubaba Ansari, M.A., Khalid M. Jat, M.D., Eyup S. Ercan, M.D.

**THIS SESSION WILL BE AUDIOTAPED.**

#### SCIENTIFIC AND CLINICAL REPORT SESSION 9

11:00 a.m. - 12:30 p.m.

Room 111, Exhibit Level, Moscone Center

### DEPRESSIVE DISORDERS

Chp.: Harvey Stabinsky, M.D.

Co-Chp.: Katherine G. Mellott, M.D.

11:00 a.m.

#### 26 Continuation Cognitive-Behavioral Therapy Maintains Attributional Style Improvement in Depressed Patients Responding Acutely to Fluoxetine.

Timothy J. Petersen, Ph.D., Yasmin Mahal, B.A., Joel A. Pava, Ph.D., Ella L. Masson, B.A., Maurizio Fava, M.D., Andrew A. Nierenberg, M.D., Amy H. Farabaugh, Ph.D.

11:30 a.m.

#### 27 The Potential Relationship Between Levels of Perceived Stress and Specific Subtypes of Major Depression

Amy H. Farabaugh, Ph.D., Pamela A. Roffi, B.S., Ella L. Masson, B.A., Dost Ongur, M.D., Timothy J. Petersen, Ph.D., Rebecca Harley, Ph.D., Maurizio Fava, M.D.

12 noon

#### 28 Symptom Severity and Exclusion From Antidepressant Efficacy Trials

Mark Zimmerman, M.D., Michael A. Posternak, M.D., Iwona Chelminski, Ph.D.

**THIS SESSION WILL BE AUDIOTAPED.**

**SCIENTIFIC AND CLINICAL REPORT SESSION 10**

11:00 a.m. - 12:30 p.m.

Room 112, Exhibit Level, Moscone Center

**NEUROPSYCHIATRY**

**Chp.:** Godehard Oepen, M.D.

**Co-Chp.:** David A. Casey, M.D.

11:00 a.m.

**29 Dyslexia as a Potential Index of Neurocognitive Impairments in Patients With Schizophrenia**

Giuseppe Bersani, M. Laura Maneschi, Carlo Leone, M. Maddalena Cacioppo

11:30 a.m.

**30 Previous Head Injuries in Psychiatric Inpatients**

Edward Kim, M.D., Michael Gara, Ph.D., Shula Minsky, Ed.D.

12 noon

**31 Neurofeedback to Increase Remission Rates in Depression**

Leo I. Jacobs, M.D., Shannon Doyle, Ph.D., Dan McDonnell, R.N.

**THIS SESSION WILL BE AUDIOTAPED.**

**SCIENTIFIC AND CLINICAL REPORT SESSION 11**

11:00 a.m. - 12:30 p.m.

Rooms 272/274/276, Mezzanine Level, Moscone Center

**ADULT ADHD**

**Chp.:** Gordon D. Strauss, M.D.

**Co-Chp.:** Keith McBurnett, Ph.D.

11:00 a.m.

**32 Efficacy and Safety of Atomoxetine in Adults With ADHD**

Thomas J. Spencer, M.D.

11:30 a.m.

**33 Adderall XR Dosed Once Daily in Adult Patients With ADHD**

Richard H. Weisler, M.D., Allan K. Chrisman, M.D., Timothy E. Wilens, M.D.

12 noon

**34 Alpha-1 Agonist Prazosin for ADHD: The Role of Norepinephrine in ADHD Pathology**

Fletcher B. Taylor III, M.D., Nancy Allison, P.D.

**THIS SESSION WILL BE AUDIOTAPED.**

**SCIENTIFIC AND CLINICAL REPORT SESSION 12**

11:00 a.m. - 12:30 p.m.

Room 302, Esplanade Level, Moscone Center

**TREATMENT OPTIONS IN ADHD**

**Chp.:** Roger M.Y. Wu, M.D.

**Co-Chp.:** Kiki D. Chang, M.D.

11:00 a.m.

**35 Placebo-Controlled Study of Once-Daily Atomoxetine in the School Setting**

Christopher J. Kratochvil, M.D.

11:30 a.m.

**36 Modafinil Improves ADHD Symptoms in Children in a Randomized, Double-Blind, Placebo-Controlled Study**

Joseph Biederman, M.D., James M. Swanson, M.D., Frank A. Lopez, M.D.

12 noon

**37 Safety and Efficacy of OROS MPH in Adolescents With ADHD**

Laurence L. Greenhill, M.D.

**THIS SESSION WILL BE AUDIOTAPED.**

**SCIENTIFIC AND CLINICAL REPORT SESSION 13**

11:00 a.m. - 12:30 p.m.

Room 308, Esplanade Level, Moscone Center

**PHARMACOTHERAPY OF DEPRESSION**

**Chp.:** John J. Schwab, M.D.

**Co-Chp.:** William A. James, M.D.

11:00 a.m.

**38 Onset and Maintenance of Antidepressant Efficacy for Duloxetine 60 mg QD**

Stephen K. Brannan, M.D., Craig H. Mallinckrodt, Ph.D., Gary D. Tollefson, M.D., Michael J. Detke, M.D., John G. Watkin, Ph.D.

11:30 a.m.

**39 Depressive Subtypes and Response to Augmentation or Dose Increase Among Outpatients Resistant to Fluoxetine 20 mg a Day**

Roy H. Perlis, M.D., Jonathan E. Alpert, M.D., Julie L. Ryan, B.A., Jessica L. Murakami, B.A., Andrew A. Nierenberg, M.D., Jerrold F. Rosenbaum, M.D., Maurizio Fava, M.D.

12 noon

**40 Treatment-Related Adverse Events in a 20 mg Open-Trial of Fluoxetine: Predictors of Emergence and Impact on the Course of Treatment**

George I. Papakostas, M.D., Timothy J. Petersen, Ph.D., Heidi D. Montoya, B.A., Yasmin Mahal, B.A., Andrew A. Nierenberg, M.D., Jonathan E. Alpert, M.D., Maurizio Fava, M.D.

**THIS SESSION WILL BE AUDIOTAPED.**

**SCIENTIFIC AND CLINICAL REPORT SESSION 14**

11:00 a.m. - 12:30 p.m.

Salons 3 & 4, Lower B-2 Level, Marriott

**MOOD DISORDERS AND SOMATIC ILLNESS**

**Chp.:** David K. Gittelman, M.D.

**Co-Chp.:** Mahmoud A. Mohamed, M.D.

11:00 a.m.

**41 Cardiovascular Risk Factors Predict Treatment Outcome in MDD**

Dan V. Iosifescu, M.D., Nicoletta Clementi-Craven, M.D., Julie L. Ryan, B.A., Andrew A. Nierenberg, M.D., George I. Papakostas, M.D., Jonathan E. Alpert, M.D., Maurizio Fava, M.D.

11:30 a.m.

**42 Prevalence and Characteristics of Patients With Depression and/or Chronic Pain**

Bruce A. Amow, Ph.D., Enid M. Hunkeler, M.A., Christine Blasey, Ph.D., Bruce Fireman, Ph.D., Janelle Lee, Ph.D., Rebecca Robinson, M.S., Chris Hayward, M.D.

12 noon

**43 Effectiveness of Collaborative Care in a Depressed, Poor, Primary Care Sample**

Lawson R. Wulsin, M.D., Shelley A. Evans, M.S., Terrance J. Wade, Ph.D., Orson Austin, M.D., Martha McCarthy, B.A., Heidi Meyer, B.A., Victoria E. Wells, M.D.

**THIS SESSION WILL BE AUDIOTAPED.****SCIENTIFIC AND CLINICAL REPORT SESSION 15**

11:00 a.m. - 12:30 p.m.

Salons 5 &amp; 6, Lower B-2 Level, Marriott

**CHILD AND ADOLESCENT PSYCHOPHARMACOLOGY**

Chp.: Richard E. D'Alli, M.D.

Co-Chp.: Anoop Karipott, M.D.

11:00 a.m.

**44 Modafinil in Children With ADHD: A Randomized, Placebo-Controlled Study**

James M. Swanson, M.D., Laurence L. Greenhill, M.D., Joseph Biederman, M.D.

11:30 a.m.

**45 Quetiapine Use in Children and Adolescents: A Literature Review**

Brian J. McConville, M.D.

12 noon

**46 Clinical Review of OROS MPH in Children, Adolescents, and Adults With ADHD**

Timothy E. Wilens, M.D.

**THIS SESSION WILL BE AUDIOTAPED.****SCIENTIFIC AND CLINICAL REPORT SESSION 16**

11:00 a.m. - 12:30 p.m.

Salons 12 &amp; 13, Lower B-2 Level, Marriott

**PREDICTORS OF SUICIDE**

Chp.: Kathleen B. Unger, M.D.

Co-Chp.: Barbara J. Justice, M.D.

11:00 a.m.

**47 Personality Traits as Predictors of Suicidality in Young Women**

Joel F. Paris, M.D., Gustavo Turecki, M.D., Mark Zoccolillo, M.D., Richard Tremblay, Ph.D.

11:30 a.m.

**48 Suicidal Behavior in Violent and Nonviolent Psychiatric Patients**

Menahem I. Krakowski, M.D.

12 noon

**49 Obstetric Complications and Suicide Risk in Adolescence and Young Adulthood**

Richard Neugebauer, Ph.D., M. Lynne Reuss, M.D.

**THIS SESSION WILL BE AUDIOTAPED.****SCIENTIFIC AND CLINICAL REPORT SESSION 17**

11:00 a.m. - 12:30 p.m.

Pacific Conference Suite H, 4th Floor, Marriott

**SCHIZOPHRENIA AND OTHER PSYCHOTIC DISORDERS**

Chp.: Ari B. Jaffe, M.D.

Co-Chp.: Adedapo B. Williams, M.D.

11:00 a.m.

**50 Elevated Maternal Cytokine Levels and Adult Schizophrenia Patients in Offspring**

Alan S. Brown, M.D., Jonathan Hooton, Ph.D., Eva Petkova, Catherine A. Schaefer, Ph.D., Vicki Babulas, M.P.H., Jack M. Gorman, M.D., Ezra S. Susser, M.D.

11:30 a.m.

**51 Association Between Psychotic Symptoms and Seizures in a Community Sample**

Christine L. Baker, M.P.H., Richard Neugebauer, Ph.D., Robert Kohn, M.D.

12 noon

**52 Biological Mechanisms in Schizophrenic Thought Disorder and Delusions**

Martin Harrow, Ph.D., Thomas H. Jobe, M.D., Ellen S. Herbener, Ph.D., Linda S. Grossman, Ph.D.

**THIS SESSION WILL BE AUDIOTAPED.****SCIENTIFIC AND CLINICAL REPORT SESSION 18**

11:00 a.m. - 12:30 p.m.

Pacific Conference Suite J, 4th Floor, Marriott

**EPIDEMIOLOGY**

Chp.: Duru Sakhrani M.D., M.D.

Co-Chp.: Meera Vaswani, Ph.D.

*(Continued on next page)*

11:00 a.m.

**53 Diagnoses in Behavioral Health Clinics: Impact on Perceived Burden of Mental Health**

Abigail L. Garvey-Wilson, M.D., Charles W. Hoge, M.D., Stephen C. Messer, Ph.D., Sandra E. Lesikar, Ph.D., Karen M. Eaton, M.S.

11:30 a.m.

**54 The Treatment Gap in Mental Health Care**

Robert Kohn, M.D., Shekhar Saxena, M.D., Itzhak Levav, M.D., Benedetto Saraceno, M.D.

12 noon

**55 Projecting National Survey Prevalences to Populations of Interest**

Stephen C. Messer, Ph.D., Xian Liu, Ph.D., Charles W. Hoge, M.D., David N. Cowan, Ph.D., Charles C. Engel, M.D.

**THIS SESSION WILL BE AUDIOTAPED.**

**WORKSHOPS**

**COMPONENT 18-22**

**COMPONENT WORKSHOP 18 11:00 a.m. - 12:30 p.m.**

Room 309, Esplanade Level, Moscone Center

**ENCOUNTERING THE SPIRITUAL IN PSYCHIATRIC (PSYCHOTHERAPY) PRACTICE**

*APA Northern California Psychiatric Society*

**Chp.:** Kalpana I. Nathan, M.D.

**Participants:** Randall Weingarten, M.D., Bruce Linenberg, Ph.D., Steven Fisdell, M.A.

**COMPONENT WORKSHOP 19 11:00 a.m. - 12:30 p.m.**

Room 310, Esplanade Level, Moscone Center

**SEXUAL HARASSMENT: VICTIMS FACE CONFIDENTIALITY ISSUES IN PSYCHIATRIC CARE**

*APA Committee on Women*

**Co-Chps.:** Rita R. Newman, M.D., Annette J. Hollander, M.D.

**Participants:** Maria T. Lymberis, M.D., David W. Garland, Esq., Francine Weiss, Esq.

**COMPONENT WORKSHOP 20 11:00 a.m. - 12:30 p.m.**

Salons 1 & 2, Lower B-2 Level, Marriott

**PATIENT SAFETY IN PSYCHIATRY: REDUCING INPATIENT SUICIDE**

*APA Committee on Quality Indicators*

**Co-Chps.:** Miles F. Shore, M.D., Alfred Herzog, M.D.

**Participant:** Paul Quinnett, M.D.

**COMPONENT WORKSHOP 21 11:00 a.m. - 12:30 p.m.**

Salons 14 & 15, Lower B-2 Level, Marriott

**NEW APA ETHICS PROCEDURES: IMPLICATIONS FOR THE PROFESSION, PART 2**

*APA Ethics Committee and APA Ethics Appeal Board*

**Chp.:** Wade C. Myers, M.D.

**Participants:** William Arroyo, M.D., Harriet C. Stern, M.D., Donald G. Langsley, M.D., Spencer Eth, M.D.

**COMPONENT WORKSHOP 22 11:00 a.m. - 12:30 p.m.**

Golden Gate Hall A, B-2 Level, Marriott

**AIDSISM, AGEISM, RACISM: PSYCHIATRIST'S ROLE IN THE GERIATRIC AIDS EPIDEMIC**

*APA New York County District Branch's AIDS Committee*

**Co-Chps.:** Kenneth B. Ashley, M.D., Mary Ann Cohen, M.D.

**Participants:** Kristina L. Jones, M.D., John A.R. Grimaldi, Jr., M.D.

**ISSUES 54-63**

**ISSUE WORKSHOP 54 11:00 a.m. - 12:30 p.m.**

Room 105, Exhibit Level, Moscone Center

**SPIRITUAL AND RELIGIOUS ASSESSMENT IN CLINICAL PRACTICE**

**Co-Chps.:** Francis G. Lu, M.D., Christina M. Puchalski, M.D.

**Participant:** James L. Griffith, M.D.

**ISSUE WORKSHOP 55 11:00 a.m. - 12:30 p.m.**

Room 113, Exhibit Level, Moscone Center

**CAREER DEVELOPMENT AND RISK MANAGEMENT**

**Co-Chps.:** Joseph M. Schwartz, M.D., George A. Fouras, M.D.

**Participants:** Martin G. Tracy, J.D., Jacqueline M. Melonas, J.D.

**ISSUE WORKSHOP 56 11:00 a.m. - 12:30 p.m.**

Room 114, Exhibit Level, Moscone Center

**THERAPEUTIC ISSUES IN SELF-INJURIOUS BEHAVIOR**

**Co-Chps.:** Jose A. Yaryura-Tobias, M.D., Fugen Neziroglu, Ph.D.

**ISSUE WORKSHOP 57 11:00 a.m. - 12:30 p.m.**

Room 121, Exhibit Level, Moscone Center

**TECHNOLOGY SERVES THE PATIENT: ALGORITHMS, MONITORING, AND DECISION SUPPORT**

**Chp.:** Daniel A. Deutschman, M.D.

**Participants:** Naakesh A. Dewan, M.D., Joshua E. Freedman, M.D., Seth M. Powsner, M.D.

**ISSUE WORKSHOP 58** 11:00 a.m. - 12:30 p.m.

Room 122, Exhibit Level, Moscone Center

**WOMEN IN ACADEMIC PSYCHIATRY:  
OPPORTUNITIES, OBSTACLES, AND STRATEGIES**

**Co-Chps.:** Carolyn B. Robinowitz, M.D., Carol C. Nadelson, M.D.  
**Participants:** Lynn C. Epstein, M.D., Joan A. Lang, M.D.,  
 Donna E. Stewart, M.D.

**ISSUE WORKSHOP 59** 11:00 a.m. - 12:30 p.m.

Room 123, Exhibit Level, Moscone Center

**THE ART OF THE UNCONSCIOUS: SHAKESPEARE,  
POETRY, FILM, AND PSYCHIATRY**

**Chp.:** Steven E. Pflanz, M.D.  
**Participant:** Charles R. Joy, M.D.

**ISSUE WORKSHOP 60** 11:00 a.m. - 12:30 p.m.

Room 124, Exhibit Level, Moscone Center

**ASIAN INDIANS IN INTERFAITH MARRIAGES:  
CHALLENGES, CONFLICTS, AND COMPROMISES***Indo-American Psychiatric Association*

**Chp.:** Jagannathan Srinivasaraghavan, M.D.  
**Participants:** Surinder S. Nand, M.D., Bala Sarma, M.D.,  
 Mina S. Bobdey, M.R.C., Iqbal Ahmed, M.D.

**ISSUE WORKSHOP 61** 11:00 a.m. - 12:30 p.m.

Room 125, Exhibit Level, Moscone Center

**THE ROLE OF THE SOUL: THE IMPACT OF  
SPIRITUAL BELIEF SYSTEMS OF HEALING**

**Chp.:** Walter R. Byrd, Jr., M.D.

**ISSUE WORKSHOP 62** 11:00 a.m. - 12:30 p.m.

Room 304, Esplanade Level, Moscone Center

**POST-GENOCIDE PSYCHOLOGICAL TRAUMA IN  
FILM: UNDER THE DOMIN TREE**

**Co-Chps.:** Maurice Preter, M.D., Harold J. Bursztajn, M.D.

**ISSUE WORKSHOP 63** 11:00 a.m. - 12:30 p.m.

Salons 10 &amp; 11, Lower B-2 Level, Marriott

**HOW TO LAUNCH A SUCCESSFUL PRIVATE  
PRACTICE, PART 2**

**Co-Chps.:** William E. Callahan, Jr., M.D., Keith W. Young, M.D.  
**Participants:** Tracy R. Gordy, M.D., Chester W.  
 Schmidt, Jr., M.D.

**12 noon Sessions****FORUMS 4-7****FORUM 4** 12 noon - 1:30 p.m.

Room 301, Esplanade Level, Moscone Center

**NEUROBIOLOGY OF PARENT-CHILD  
RELATIONSHIPS: APPLICATIONS TO  
PSYCHOTHERAPY***APA Committee on Psychotherapy by Psychiatrists*

**Chp.:** Bernard D. Beitman, M.D.  
**Co-Chp.:** Eva M. Szigethy, M.D.  
**Participants:** Robert J. Waldinger, M.D., David Reiss, M.D., Jill M.  
 Hooley, Ph.D.

**FORUM 5** 12 noon - 1:30 p.m.

Room 306, Esplanade Level, Moscone Center

**TERRORISM AND PSYCHOSOCIAL PREPAREDNESS**

**Chp.:** Howard J. Osofsky, M.D.  
**Participants:** Harold S. Kopplewicz, M.D., Joy D. Osofsky, Ph.D.,  
 Betty Pfefferbaum, M.D., Robert J. Ursano, M.D.

**FORUM 6** 12 noon - 1:30 p.m.

Room 307, Esplanade Level, Moscone Center

**PROZAC ON THE COUCH**

**Chp.:** Jonathan M. Metz, M.D.  
**Participants:** David M. McDowell, M.D., Joel T. Braslow, M.D.

**FORUM 7** 12 noon - 1:30 p.m.

Golden Gate Hall B, B-2 Level, Marriott

**INTIMATE PARTNER VIOLENCE AND ABUSE:  
IDENTIFICATION AND INTERVENTION WITHIN A  
BEHAVIORAL HEALTH STUDY**

**Chp.:** Penny K. Randall, M.D.  
**Participants:** Carole L. Warshaw, M.D., Patricia Salber, M.D.,  
 Robin A. Dea, M.D., Bridged MaCaw, M.D.

**NEW RESEARCH POSTER SESSION 6**

12 noon - 2:00 p.m.

Hall D, Exhibit Level, Moscone Center

**THERAPEUTICS; BIOLOGICAL, GERIATRIC,  
CONSULTATION, AND EMERGENCY PSYCHIATRY**

For further information on New Research Sessions, please refer  
 to the *New Research Program Book* included in your registration  
 packet.

---

**1:00 p.m. Sessions**

---



**COURSES 75-81**

Course descriptions are available in the *CME Course Brochure* included in your registration packet. Admission by ticket only.

---

**COURSE 75** **1:00 p.m. - 5:00 p.m.**

Franciscan Room B, Ballroom Level, Hilton

**PSYCHIATRIC DISORDERS IN PREGNANCY AND POSTPARTUM**

**Director:** Shaila Misri, M.D.

**Faculty:** Diana Carter, M.B., Maria Corall, M.D., Deirdre M. Ryan, M.B., Kristin S. Sivertz, M.D.

---

**COURSE 76** **1:00 p.m. - 5:00 p.m.**

Imperial Ballroom A, Ballroom Level, Hilton

**OVERVIEW AND UPDATE OF SLEEP DISORDERS MEDICINE**

**Director:** Karl Doghramji, M.D.

**Faculty:** Thomas D. Hurwitz, M.D., John W. Winkelman, M.D.

---

**COURSE 77** **1:00 p.m. - 5:00 p.m.**

Yosemite Room A, Ballroom Level, Hilton

**THE COMPLEXITIES OF CHRONIC PAIN: MULTIDISCIPLINARY TREATMENT APPROACHES**

**Co-Directors:** Allen Lebovits, Ph.D., Matthew B. Smith, M.D.

**Faculty:** Robert Cancro, M.D., Michael R. Clark, M.D., Michel Dubois, M.D., Jeffrey D. Rome, M.D.

---

**COURSE 78** **1:00 p.m. - 5:00 p.m.**

Union Square 5 & 6, Fourth Floor, Hilton

**THE JUVENILE JUSTICE CLINIC: ADMINISTRATIVE ISSUES AND TREATMENT OPTIONS**

**Director:** Gabriel Kaplan, M.D.

**Faculty:** Denise M.W. Johnson, Ph.D., Michael Swerdlow, Ph.D.

---

**COURSE 79** **1:00 p.m. - 5:00 p.m.**

Union Square 14, Fourth Floor, Hilton

**WRITING ABOUT CLINICAL EXPERIENCES**

**Director:** John S. Strauss, M.D.

---

**COURSE 80** **1:00 p.m. - 5:00 p.m.**

Union Square 15 & 16, Fourth Floor, Hilton

**HOW TO USE YOUR PALM OS PDA IN PSYCHIATRIC PRACTICE: ADVANCED**

**Director:** John S. Luo, M.D.

**Faculty:** Carlyle H. Chan, M.D., Raymond J. Kloss, M.D., Richard A. Montgomery, M.D., Charles J. Rainey, M.D., Hendry Ton, M.D.

---

**COURSE 81** **1:00 p.m. - 5:00 p.m.**

Union Square 19 & 20, Fourth Floor, Hilton

**AN INTEGRATIVE APPROACH TO FACILITATE THE WORKING-THROUGH PROCESS**

**Co-Directors:** Steven H. Lipsius, M.D., Harold J. Wain, Ph.D.

---

**2:00 p.m. Sessions**

---

**LECTURES 13-15**

**LECTURE 13**

2:00 p.m. - 3:30 p.m.

Rooms 130/131, Exhibit Level, Moscone Center

Carolyn B. Robinowitz, M.D.

Psychiatric Organized Leadership: Reflections, Predictions, and Proposals

Chp.: David A. Baron, D.O.

Co-Chp.: Patricia I. Ordonca, M.D.

The American Psychiatric Association has worked to enhance the science and the art of psychiatric care and to improve access to care for psychiatric patients. Yet, in recent years many psychiatrists have chosen not to join their specialty organization. Carolyn B. Robinowitz, M.D., discusses the current and future roles of organized medicine in general, and organized psychiatry in particular. A delegate from APA to the American Medical Association, Dr. Robinowitz is Clinical Professor of Psychiatry at Georgetown University School of Medicine and is in the private practice of general and child and adolescent psychiatry in Washington, D.C. From 1998 to 2000, she was Dean for Academic Affairs at Georgetown University School of Medicine. Previously she was Senior Deputy Medical Director at APA. She has served as President of several specialty organizations, including the American College of Psychiatrists and the American Board of Psychiatry and Neurology. Her many awards include the Distinguished Service Award and the Seymour D. Vestermark Award from APA. A graduate of Washington University School of Medicine in St.



Louis, MO, Dr. Robinowitz completed residency training in pediatrics and general psychiatry at the Bronx Municipal Hospital Center in New York and a fellowship in child psychiatry at Children's Hospital National Medical Center in Washington, D.C.

**Distinguished Psychiatrist Lecture Series**  
**THIS SESSION WILL BE AUDIOTAPED.**

#### LECTURE 14

2:00 p.m. - 3:30 p.m.

Rooms 132/133, Exhibit Level, Moscone Center

Rachel Naomi Remen, M.D.

**The Healer's Art: Undergraduate Education For Meaning And Commitment**

**Chp.:** Catherine C. Crone, M.D.

**Co-Chp.:** Susan Stabinsky, M.D.

Rachel N. Remen, M.D., one of the pioneers of the mind-body health movement, is Clinical Professor of Family and Community Medicine at the University of California San Francisco School of Medicine. She is Co-Founder and Medical Director of the Commonwealth Cancer Help Program and Founder and Director of the Institute for the Study of Health and Illness at Commonwealth in Bolinas, CA. She also is in the private practice of psycho-oncology. Dr. Remen has a 48-year personal history of chronic illness, and she blends the perspectives of patient and physician in her work. She is the recipient of numerous awards, among them the Rollo May Award from Saybrook Institute in recognition of her contribution to the field of health psychology. The author of numerous publications in professional journals, Dr. Remen also wrote the best-selling books *Kitchen Table Wisdom: Stories That Heal*, winner of the 1996 Wilbur Award for best work of spiritual nonfiction, and *My Grandfather's Blessings: Stories of Strength, Refuge, and Belonging*. Dr. Remen received her medical degree from Cornell University School of Medicine, completed her residency in pediatrics at the New York Hospital-Cornell Medical Center in New York City, and completed a fellowship in pediatric endocrinology at Stanford Medical Center in Palo Alto, CA.

**THIS SESSION WILL BE AUDIOTAPED.**

#### LECTURE 15

2:00 p.m. - 3:30 p.m.

Room 300, Esplanade Level, Moscone Center

Robert L. Okin, M.D.

**Mental Illness, Human Rights, Science, and Culture: A Videotaped Documentation of Conditions in Mexican Psychiatric Hospitals**

**Chp.:** David H. Taylor, M.D.

**Co-Chp.:** Harvey Stabinsky, M.D.

Robert L. Okin, M.D., will discuss attempts to place the needs of people with mental disabilities on the international human rights agenda so they can receive the advocacy and protections similar to other vulnerable populations. As an example of the need for such advocacy, he will describe the conditions of Mexican psychiatric hospitals and present a videotaped documentation of these conditions. Strategies to improve this situation will be described along with the concrete results of these strategies. He will then confront the questions of (1) whether psychiatrists from one nation which neglects its mentally ill citizens, have the responsibility, much less the right, to criticize the conditions experienced by the mentally ill in other nations; and (2) whether governments can mitigate their responsibilities to the mentally ill in all nations is an issue at the frontiers of science and culture.

**Frontiers of Science Lecture Series**

**THIS SESSION WILL BE AUDIOTAPED.**

#### PRESIDENTIAL SYMPOSIUM 2

2:00 p.m. - 5:00 p.m.

Room 301, Esplanade Level, Moscone Center

#### THE FOUNDATION OF MEDICAL ETHICS/INFORMED CONSENT

**Chp.:** William T. Carpenter, Jr., M.D.

**Co-Chp.:** Dilip V. Jeste, M.D.

**Participants:** William T. Carpenter, Jr., M.D., Dilip V. Jeste, M.D., Thomas Grisso, M.D., Charles Lidz, Ph.D., Scott Y. Kim, M.D.

**Discussant:** Paul S. Appelbaum, M.D.

**THIS SESSION WILL BE AUDIOTAPED.**

#### REVIEW OF PSYCHIATRY: SECTION 2

2:00 p.m. - 5:30 p.m.

Room 104, Exhibit Level, Moscone Center

#### MOLECULAR NEUROBIOLOGY FOR THE CLINICIAN

**Chp.:** Dennis S. Charney, M.D.

#### 6 Molecular Neurobiology and Substance Abuse

Lisa Monteggia, M.D.

#### 7 Molecular Neurobiology and New Drug Targets for Mood and Anxiety Disorders

Husseini K. Manji, M.D.

(Continued on next page)

- 8 Molecular Neurobiology and Schizophrenia: Implications for Etiology and Treatment**  
TBA
- 9 Molecular Neurobiology and Neuropsychiatric Disorders in Children: Present and Future**  
Jeremy Veenstra-VanderWeele, M.D.
- 10 Molecular Genetics and Psychiatric Disorders: A Role in Diagnosis and Treatment?**  
Francis J. McMahon, M.D.

**SYMPOSIA 29-59**

**SYMPOSIUM 29** 2:00 p.m. - 5:00 p.m.  
Room 100, Exhibit Level, Moscone Center

**INTEGRATED TREATMENT:  
PSYCHOPHARMACOLOGY AND PSYCHOTHERAPY**

Chp.: Hans Steiner, M.D.

- A Integrated Treatment: From Adolescence to Young Adulthood**  
Hans Steiner, M.D.
- B Integrated Treatment of BPD**  
Glen O. Gabbard, M.D.
- C Integrated Treatment of Eating Disorders**  
Kathryn J. Zerbe, M.D.
- D Psychiatric and Medical Illness**  
David Spiegel, M.D.

- E Integrated Treatment of Juvenile Bipolar Disorder**  
Kiki D. Chang, M.D., Jaqueline Martin, Ph.D., Maureen Hawkins, Ph.D.

**THIS SESSION WILL BE AUDIOTAPED.**

**SYMPOSIUM 30**  
2:00 p.m. - 5:00 p.m.  
Room 101, Exhibit Level, Moscone Center

**RECENT DEVELOPMENTS IN GAY AND LESBIAN MENTAL HEALTH: A GLOBAL PERSPECTIVE**

*APA Committee on Gay, Lesbian, and Bisexual Issues*

Chp.: Gene A. Nakajima, M.D.  
Co-Chp.: Jack Drescher, M.D.

- A From Long Yong and Dui Shi to Tongzhi: Homosexuality in China**  
Jin Wu, M.A.
- B Look to Norway? Gay Issues and Mental Health Across the Atlantic Ocean**  
Reidar Kjaer, M.D.

- C Voices From the Past: Treatments of Homosexuality in the United Kingdom Since 1950**  
Michael B. King, M.D., Annie Bartlett, M.D., Glen Smith, Ph.D.
- D Emergence of Lesbian and Gay Issues in International Psychiatry**  
Gene A. Nakajima, M.D.

Discussant: Melvin Sabshin, M.D.  
**THIS SESSION WILL BE AUDIOTAPED.**

**SYMPOSIUM 31**  
2:00 p.m. - 5:00 p.m.  
Room 105, Exhibit Level, Moscone Center

**NEW RESEARCH IN GAY, LESBIAN, AND BISEXUAL MENTAL HEALTH MORBIDITY**

Chp.: Robert M. Kertzner, M.D.  
Co-Chp.: Dan H. Karasic, M.D.

- A Estimates of Mental Health Morbidity Among Lesbian, Gay, and Bisexual Adults**  
Susan D. Cochran, Ph.D., Vicki M. Mays, Ph.D., Heather Corliss, M.P.H.
- B Sexual Orientation and Health: New Findings From a Dutch General-Population Survey**  
Theodorus G.M. Sandfort, Ph.D., Ine Vanwesenbeeck, Ph.D., Floor Bakker
- C Minority Stress and Mental Health in Lesbians, Gay Men, and Bisexuals**  
Ilan H. Meyer, Ph.D.
- D Depressive Distress in a Community Sample of Women: The Role of Sexual Orientation**  
Alicia K. Matthews, Ph.D., Towda L. Hughes, Ph.D., Timothy Johnson, Ph.D., Lisa A. Razzano, Ph.D., Roberta Cassidy, Ph.D.

- E Sexual Minority Status and Its Association With Suicidality and Depression**  
Jay P. Paul, Ph.D., Joseph A. Catania, Ph.D., Thomas C. Mills, M.D., Ron D. Stall, Ph.D., Lance Pollack, Ph.D.  
**THIS SESSION WILL BE AUDIOTAPED.**

**SYMPOSIUM 32**  
2:00 p.m. - 5:00 p.m.  
Room 106, Exhibit Level, Moscone Center

**AN UPDATE ON PARKINSON'S DISEASE AND ITS PSYCHIATRIC COMPLICATIONS**

Chp.: Matthew A. Menza, M.D.

- A Parkinson's Disease: Update on Treatment, Etiology, and Pathogenesis**  
Margery Mark, M.D.

**B Depression in Parkinson's Disease**

Jeffrey L. Cummings, M.D.

**C Psychosis in Parkinson's Disease**

Laura Marsh, M.D.

**D Cognitive Impairment, Dementia, and Parkinson's Disease**

Constantine Lyketsos, M.D.

**E Anxiety, Fatigue, and Sleep in Patients With Parkinson's Disease**

Matthew A. Menza, M.D.

**THIS SESSION WILL BE AUDIOTAPED.****SYMPOSIUM 33**

2:00 p.m. - 5:00 p.m.

Room 110, Exhibit Level, Moscone Center

**COPING WITH CATASTROPHE**

Chp.: John W. Barnhill, M.D.

Co-Chp.: Valentine Raiteri

**A Psychotherapy of the Dying Patient**

John W. Barnhill, M.D.

**B Illness in the Training Psychiatrist**

Gregory C. Dillon, M.D.

**C Treating Firefighters in the Aftermath of 9/11**

Kevin V. Kelly, M.D.

Discussant: Robert Michels, M.D.

**THIS SESSION WILL BE AUDIOTAPED.****SYMPOSIUM 34**

2:00 p.m. - 5:00 p.m.

Room 111, Exhibit Level, Moscone Center

**STRATEGIES TO OVERCOME RESISTANCE**

Chp.: Joseph DiGiacomo, M.D.

**A Resistance and Psychodynamics**

R. Rao Gogineni, M.D.

**B Overcoming Resistance: Techniques From Cognitive Therapy**

Donna M. Sudak, M.D.

**C Resistance by Families and Children in Psychotherapy**

G. Pirooz Sholevar, M.D.

**D Diagnostic and Treatment Algorithms for Refractory Depression**

Jay D. Amsterdam, M.D.

**THIS SESSION WILL BE AUDIOTAPED.****SYMPOSIUM 35**

2:00 p.m. - 5:00 p.m.

Room 112, Exhibit Level, Moscone Center

**DEVELOPING CULTURALLY COMPETENT SERVICES FOR MINORITY POPULATIONS***APA Assembly Committee of Representatives of Minority/Underrepresented Groups*

Chp.: James C.Y. Chou, M.D.

**A Psychiatric Care of Hispanic Americans: Problems and Solutions**

Pedro Ruiz, M.D.

**B Developing Services for African Americans**

William B. Lawson, M.D.

**C Developing Culturally Competent Mental Health Services for Asian Americans**

Evelyn Lee, Ph.D.

**D New Approaches for Developing Mental Health Services for Native Americans**

R. Dale Walker, M.D.

Discussant: Francis G. Lu, M.D.

**THIS SESSION WILL BE AUDIOTAPED.****SYMPOSIUM 36**

2:00 p.m. - 5:00 p.m.

Room 113, Exhibit Level, Moscone Center

**THE ETHNICITY FACTOR IN PSYCHIATRIC RESEARCH: IDENTITY AND METHODOLOGY ISSUES***American Society of Hispanic Psychiatry*

Chp.: Renato D. Alarcon, M.D.

Co-Chp.: Andres Heerlein, M.D.

**A Cultural Variables and Controversies: The Identity Issue**

Renato D. Alarcon, M.D.

**B Cultural Issues Among Hispanics: A Portrait of Heterogeneity**

Andres Heerlein, M.D.

**C Methodological Issues in Ethnicity Research**

Javier I. Escobar, M.D.

**D The Inclusion of Race and Ethnicity in Current Psychiatric Literature**

Roberto Lewis-Fernandez, M.D., Maria A. Oquendo, M.D., Naelys Diaz, M.S.W., Dana Wachtel, M.S.W., Renato D. Alarcon, M.D.

*(Continued on next page)*

**E Training Culturally Competent Researchers**  
Miguel R. Jorge, M.D.

**Discussant:** Darrel A. Regier, M.D.  
**THIS SESSION WILL BE AUDIOTAPED.**

**SYMPOSIUM 37**  
2:00 p.m. - 5:00 p.m.  
Room 114, Exhibit Level, Moscone Center

**WHAT THE GENERAL PSYCHIATRIST NEEDS TO KNOW ABOUT ADDICTION PSYCHIATRY**  
*APA Council on Addiction Psychiatry and American Academy of Addiction Psychiatry*

**Chp.:** Sheila B. Blume, M.D.  
**Co-Chp.:** Bryon H. Adinoff, M.D.

**A Neuroscience of Addictions**  
Bryon H. Adinoff, M.D.

**B Treatment of Addictions**  
Charles P. O'Brien, M.D.

**C Dual Diagnosis**  
Douglas M. Ziedonis, M.D., Sylvia Atdjian, M.D., Jon Krejci, M.D., Jeffrey A. Berman, M.D.

**D Consultation Psychiatrists: Frontline Observers of New Trends in Addiction**  
Joel E. Dimsdale, M.D.

**E Current Issues in Addiction Medicine: Club Drugs**  
Alvaro Camacho, M.D.  
**THIS SESSION WILL BE AUDIOTAPED.**

**SYMPOSIUM 38**  
2:00 p.m. - 5:00 p.m.  
Room 120, Exhibit Level, Moscone Center

**EARLY TRAUMA: STRATEGIES FOR INTERVENTION AND TREATMENT**

**Chp.:** Howard J. Osofsky, M.D.

**A The Early Trauma Treatment Network: Assessing and Treating Trauma in Young Children**  
Alicia F. Lieberman, Ph.D.

**B Treatment of PTSD in Infants and Young Children**  
Theodore J. Gaensbauer, M.D.

**C Prevention and Intervention for Young Children Exposed to Violence**  
Joy D. Osofsky, Ph.D.

**Discussants:** Harry H. Wright, M.D., Robert S. Pynoos, M.D.  
**THIS SESSION WILL BE AUDIOTAPED.**

**SYMPOSIUM 39**  
2:00 p.m. - 5:00 p.m.  
Room 121, Exhibit Level, Moscone Center

**EARLY INTERVENTION IN PSYCHOSIS: WHERE SCIENCE MEETS COMMUNITY PSYCHIATRY**  
*American Association of Community Psychiatrists*

**Chp.:** William R. McFarlane, M.D.  
**Co-Chp.:** David A. Pollack, M.D.

**A Early Detection and Management of Psychiatric Disorder in Young People in Melbourne, Australia**  
Patrick D. McGorry, M.D., Alison R. Yung, M.D., Lisa R. Phillips, B.S.C., Annemarie Wright, B.A., Andrew Chanen, M.B.B.S., Jane Edwards, Ph.D., Meredith Harris, M.A., Lisa Henry, M.A., Susy Hrrigan, M.A., Philippe Conus, M.D., Martin Lambert, M.D.

**B Intervention in the Schizophrenic Prodrome: The Prevention Through Risk Identification, Management, and Education Initiative**  
Thomas H. McGlashan, M.D., Tandy J. Miller, Ph.D., Robert B. Zipursky, M.D., Scott W. Woods, M.D., Diana O. Perkins, M.D., Keith A. Hawkins, Ph.D., Jean M. Addington, Ph.D.

**C Portland Identification and Early Referral: First-Year Outcomes in a Community-Wide Psychosis Prevention Program**  
William R. McFarlane, M.D., William L. Cook, Ph.D., Donna Downing, O.T.R.

**D A Comprehensive Approach to Early Intervention in Psychosis: The Prevention and Early Intervention Program for Psychosis Project (PEPP)**  
Ashok K. Malla, M.D., Ross M.G. Norman, Ph.D., Rahud Manchanda, M.D., Terry S. McLean, M.Ed., Derek J. Scholten, M.S.C., Laurel Townsend, Ph.D.

**E The Tips Project: Clinical and Organizational Prerequisites for Early Intervention in Psychosis**  
Jan O. Johannessen, M.D.

**F Implementing Early Psychosis Intervention in the Public Mental Health System**  
Robert M. Wolf, M.D., Tamara Sale, M.A.

**Discussant:** David A. Pollack, M.D.  
**THIS SESSION WILL BE AUDIOTAPED.**

**SYMPOSIUM 40**

2:00 p.m. - 5:00 p.m.

Room 122, Exhibit Level, Moscone Center

**DEHYDROEPIANDROSTERONE: NEUROSTEROID MECHANISMS, EPIDEMIOLOGY, AND APPLICATIONS IN PSYCHIATRY**

Chp.: Stephen J. Ferrando, M.D.

**A Dehydroepiandrosterones: Neurosteroid Modulator of Brain Excitability, Mood, Cognition, and Drug Dependence**

Maria Majewska, M.D.

**B Dehydroepiandrosterone Treatment of Alzheimer's Disease and Major Depression**

Victor I. Reus, M.D., Owen M. Wolkowitz, M.D.

**C Dehydroepiandrosterone Effects on Mood in HIV and Depressed Patients**

Judith G. Rabkin, Ph.D., Martin McElhiney, Ph.D., Richard Rabkin, M.D., Judy Chiu, B.A., Stephen J. Ferrando, M.D.

**SYMPOSIUM 41**

2:00 p.m. - 5:00 p.m.

Room 123, Exhibit Level, Moscone Center

**SCIENCE AND PSYCHIATRIC PARTICIPATION IN DISASTER RESPONSE**

Chp.: Lee McCabe, Ph.D.

Co-Chp.: Michael J. Kaminsky, M.D.

**A Psychiatry and Somatic Medicine in Disaster Response: Carved Out Again?**

Michael J. Kaminsky, M.D.

**B What You Need to Know to Get Yourself and Your Organization Ready to Respond to Disasters**

George Everly, Jr., Ph.D.

**C Current Science About Best Practices in Disaster Psychiatry and a Proposed Research Agenda**

Michael C. Heitt, Psy.D.

**D Post-Disaster Science of Therapeutic Healing**

Everett R. Siegel, M.D., Michael C. Heitt, Psy.D.

Discussant: Clete DiGiovanni, M.D.

**THIS SESSION WILL BE AUDIOTAPED.****SYMPOSIUM 42**

2:00 p.m. - 5:00 p.m.

Room 124, Exhibit Level, Moscone Center

**RECOVERY FROM SCHIZOPHRENIA: A CHALLENGE FOR THE 21ST CENTURY**

Chp.: Alex J. Kopelowicz, M.D.

**A Operational Criteria and Factors Related to Recovery From Schizophrenia**

Robert P. Liberman, M.D., Alex J. Kopelowicz, M.D., Joseph Ventura, Ph.D.

**B Recovery in First-Episode Schizophrenia**

Delbert G. Robinson, M.D., Margaret Woerner, Ph.D., Marjorie McMeniman, Ph.D.

**C Schizophrenia and Capacity for Vocational Recovery**

Zlatka L. Russinova, Ph.D., Nancy J. Wewiorski

**D The Process of Recovery From Schizophrenia**

LeRoy Spaniol, Ph.D., Nancy Wewiorski, Ph.D., Cheryl Gagne, M.S., William Anthony, Ph.D.

**E Multiple Dimensions of Recovery in Early Psychosis**

David Whitehorn, Ph.D., Jocelyn Brown, Heather Milliken, M.D., Julie Richard, B.A., Lili Kopala, M.D., Qing Rui, M.D.

**THIS SESSION WILL BE AUDIOTAPED.****SYMPOSIUM 43**

2:00 p.m. - 5:00 p.m.

Room 125, Exhibit Level, Moscone Center

**THE INVISIBLE PLAGUE: SEVERE MENTAL ILLNESS**

Chp.: Nigel M. Bark, M.D.

Co-Chp.: Richard Neugebauer, Ph.D.

**A Evidence for the Existence of Schizophrenia Before 1750 and What That May Mean**

Nigel M. Bark, M.D.

**B Management of the Mad in 17th-Century England: The Rise of Confinement**

Richard Neugebauer, Ph.D.

**C Political Influence on Psychiatry: Malevolent or Benevolent?**

Nasser F. Loza, M.B., Waleed A.R. Fawzi, M.S.C.

**D The Increasing Incidence of Psychoses From 1750 to the Present**

E. Fuller Torrey, M.D.

**E Criminalization of Persons With Mental Illness in the 20th and 21st Centuries**

H. Richard Lamb, M.D.

Discussant: Norman Dain, Ph.D.

**THIS SESSION WILL BE AUDIOTAPED.**

**TUESDAY**

---

**SYMPOSIUM 44**

2:00 p.m. - 5:00 p.m.

Rooms 272/274/276, Mezzanine Level, Moscone Center

**THE EVIL STANDARD: MILESTONES AND CHALLENGES**

**Chp.:** Michael M. Welner, M.D.

**A Undefined Evil: The Legal, Psychiatric, and Societal Consequences of Avoidance**

Michael M. Welner, M.D.

**B Researching the Depravity Standard: Reliability in Defining a Distinctive Crime**

James Seward, Ph.D.

**C The Depravity Scale in Relation to the Histories of 430 Convicted Killers**

Michael H. Stone, M.D.

**D The Civil Employment Depravity Scale: Preliminary Items and Research**

Michael M. Welner, M.D.

**THIS SESSION WILL BE AUDIOTAPED.**

**SYMPOSIUM 45**

2:00 p.m. - 5:00 p.m.

Room 302, Esplanade Level, Moscone Center

**BEREAVEMENT AFTER VIOLENT DEATH**

**Chp.:** Edward K. Rynearson, M.D.

**A The Effects of Violent Death on Bereavement**

Beverly Raphael, M.D.

**B Community-Based Interventions With Child and Adolescent Survivors of Homicide Victims**

Alison A. Salloum, M.S.W.

**C Survivors of Violent Loss Program**

Stephen R. Shuchter, M.D., Connie A. Saindon, M.A.

**D Terrorism Factors That Exacerbate the Experience of Victims**

Kathryn M. Turman

**E The Long-Term Psychological Effects of the World Trade Center Disaster: Community Strategies for Support**

Vilma Torres, M.S.W.

**THIS SESSION WILL BE AUDIOTAPED.**

**SYMPOSIUM 46**

2:00 p.m. - 5:00 p.m.

Room 304, Esplanade Level, Moscone Center

**DIVERSE APPROACHES TO ALZHEIMER'S SCREENING**

**Chp.:** John W. Ashford, Jr., M.D.

**Co-Chp.:** Frederick A. Schmitt, Ph.D.

**A Mini-Cog**

Soo Borson, M.D., James M. Scanlan, Ph.D.

**B Memory Impairment Screen**

Herman Buschke, M.D.

**C Brief Alzheimer's Screen**

Marta S. Mendiondo, Ph.D., John W. Ashford, Jr., M.D., Frederick A. Schmitt, Ph.D., Richard J. Kryscio, Ph.D.

**D The Computer-Administered Neuropsychological Screening for Mild Cognitive Impairment: Self-Administered Screening for Mild Cognitive Impairment**

Jane B. Tomatore, Ph.D., Emory Hill, Ph.D., Jo A. Laboff, B.S.

**E Bowles-Langley Technology/Ashford Memory Test Online Version**

John W. Ashford, Jr., M.D., Jon Livingston, Henry Bowles, Ted Langley, Ph.D., Paul Costa

**F Statistical Issues in Evaluating Alzheimer's Screening Tests**

Helena C. Kraemer, Ph.D.

**THIS SESSION WILL BE AUDIOTAPED.**

**SYMPOSIUM 47**

2:00 p.m. - 5:00 p.m.

Room 306, Esplanade Level, Moscone Center

**PERSONAL IDENTITY AND BIPOLAR DISORDER**

**Chp.:** Deborah Spitz, M.D.

**A Creating Narrative From Disjunction: The Clinical Picture**

Deborah Spitz, M.D.

**B Bipolar Disorder and Partisan Successive Selves**

Jennifer Radden, Ph.D.

**C Narrative Selves, Relations of Trust, and Bipolar Disorder**

Nancy Potter, Ph.D.

**D Values and the Nature of Bipolar Disorder**

Kenneth Fulford, D.Phil.

**THIS SESSION WILL BE AUDIOTAPED.**

## SYMPOSIUM 48

2:00 p.m. - 5:00 p.m.

Room 307, Esplanade Level, Moscone Center

## THE SPECTRUM OF SEXUAL VIOLENCE: CLINICAL AND CULTURAL IMPACT

*American Academy of Child and Adolescent Psychiatry*

Chp.: Larry K. Brown, M.D.

## A Childhood Sexual Abuse and Later Adolescent Risk Behavior

Larry K. Brown, M.D., Celia M. Lescano, Ph.D., Kelsey M. Latimer, B.A.

## B Perspectives on Sexual Molestation of Boys by Roman Catholic Priests

Lynn E. Ponton, M.D.

## C Sexual Violence on the Internet

Norman E. Alessi, M.D.

## D Dating Violence and African-American Adolescent Females' Sexual Health

Ralph DiClemente, Ph.D., Gina M. Wingood, Sc.D.

## E Adolescent Dating Violence: Screening Practices of Child and Adolescent Psychiatrists

Kristie Puster, Ph.D., Celia M. Lescano, Ph.D., Kelsey M. Latimer, B.A.

THIS SESSION WILL BE AUDIOTAPED.

## SYMPOSIUM 49

2:00 p.m. - 5:00 p.m.

Room 308, Esplanade Level, Moscone Center

## ADVANCES IN UNDERSTANDING AND TREATING CHRONIC DEPRESSION

Chp.: John C. Markowitz, M.D.

Co-Chp.: James H. Kocsis, M.D.

## A Classification and Natural History of Chronic Depression

Daniel N. Klein, Ph.D.

## B Cognitive-Behavioral Analysis System of Psychotherapy

Bruce A. Arnow, Ph.D.

## C Treating Chronic Depression: Psychosocial Outcomes

James H. Kocsis, M.D.

## D Continuation, Maintenance, and Crossover Results of Clinical Trials

Alan J. Gelenberg, M.D.

## E Interpersonal Psychotherapy for Chronic Depression

John C. Markowitz, M.D.

Discussant: Michael E. Thase, M.D.

THIS SESSION WILL BE AUDIOTAPED.

## SYMPOSIUM 50

2:00 p.m. - 5:00 p.m.

Room 309, Esplanade Level, Moscone Center

## BOUNDARY CROSSINGS: CREATIVE THERAPY OR SLIPPERY SLOPES?

Chp.: Gail E. Robinson, M.D.

## A Boundary Violations Versus Boundary Crossings

Gail E. Robinson, M.D.

## B Creative Moments and Challenging Events in Therapy: Bending Rules to Help

Gary R. Schoener, Psy.D.

## C Is Physical Touch Still a Taboo in Psychodynamic Psychotherapy?

Howard E. Book, M.D.

## D Professional Boundaries: Navigating Gray Areas and Avoiding Legal Trouble

Linda M. Jorgenson, J.D.

Discussant: Gail E. Robinson, M.D.

THIS SESSION WILL BE AUDIOTAPED.

## SYMPOSIUM 51

2:00 p.m. - 5:00 p.m.

Room 310, Esplanade Level, Moscone Center

## WOMEN PSYCHIATRISTS USING SCIENCE TO HEAL

Chp.: Marian I. Butterfield, M.D.

Co-Chp.: Sylvia W. Olarte, M.D.

## A Psychological Issues and Women Athletes: In a League of Their Own

Altha J. Stewart, M.D.

## B Catholic and Jewish Women Survivors of the Nazi Camps: Insights

Leah J. Dickstein, M.D.

## C Pursing Genetics Studies in Homogenous Portuguese Populations

Michelle T. Pato, M.D., Emanuela Mundo, M.D., Carlos N. Pato, M.D.

## D Outreach to the Indigent Mentally Ill in Rural India

Geetha Jayaram, M.D.

## E Innovative Models for Mental Health Services to Women in Hawaii

Leslie H. Gise, M.D.

*(Continued on next page)*

## TUESDAY

---

### **F From Bench to Bedside: Neurosteroids and Gender Differences in Psychiatry**

Christine E. Marx, M.D.

### **G HIV and Mental Illness Education Initiative in Sub-Saharan Africa**

Mary Kay Smith, M.D.

**Discussant:** Nada L. Stotland, M.D.

**THIS SESSION WILL BE AUDIOTAPED.**

### **SYMPOSIUM 52**

2:00 p.m. - 5:00 p.m.

Salons 1 & 2, Lower B-2 Level, Marriott

### **DARWINIAN EVOLUTION AND PSYCHOPATHOLOGY**

**Chp.:** Daniel R. Wilson, M.D.

**Co-Chp.:** Hagop S. Akiskal, M.D.

### **A Evolutionary Epidemiology and the Neuropsychiatry of Mania and Depression**

Daniel R. Wilson, M.D.

### **B Evolutionary Developmental Psychopathology**

Ian Pitchford, Ph.D.

### **C Clinical Equivalents in Phenotypic Expression: Implications for Research and Care**

Susan L. McElroy, M.D.

### **D Evolutionary Psychiatry: The End of the Beginning**

Hagop S. Akiskal, M.D.

**Discussant:** Hagop S. Akiskal, M.D.

**THIS SESSION WILL BE AUDIOTAPED.**

### **SYMPOSIUM 53**

2:00 p.m. - 5:00 p.m.

Salons 3 & 4, Lower B-2 Level, Marriott

### **COMORBID CONDITIONS IN SCHIZOPHRENIA: NEW TREATMENT TARGET OR NEW ILLNESS MODEL?**

**Chp.:** Stefano Pallanti, M.D.

**Co-Chp.:** Eric Hollander, M.D.

### **A Clinical Correlates and Chronology of Anxiety Comorbidity in Psychotic Disorders**

Giovanni B. Cassano, M.D., Liliana Dell'Osso, M.D., Marco Saettoni, Alessandra Papasogli, M.D., Concettina Mastrocinque, M.D., Serena Vignoli, Stefano Pini, M.D.

### **B Comorbid Schizophrenia Syndromes: New Therapy Target or New Illness Model?**

Samuel G. Siris, M.D., Paul C. Bermanzohn, M.D.

### **C Assessment and Characterization of Social Anxiety in Schizophrenia**

Stefano Pallanti, M.D., Leonardo Quercioli, M.D., Eric Hollander, M.D.

### **D Impulsivity and Aggression in Schizophrenia: New Treatment Target**

Eric Hollander, M.D., Stefano Pallanti, M.D., Nicolo Baldini-Rossi, M.D.

**Discussant:** Nancy C. Andreasen, M.D.

### **SYMPOSIUM 54**

2:00 p.m. - 5:00 p.m.

Salons 5 & 6, Lower B-2 Level, Marriott

### **ADHD: LONGER-TERM TREATMENT FOR A CHRONIC DISORDER**

**Chp.:** Timothy E. Wilens, M.D.

### **A ADHD Treatment With a Once-Daily Formulation of Methylphenidate: A Two-Year Study**

Timothy E. Wilens, M.D.

### **B Preliminary Results of a Six-Month Trial of Methylphenidate in Adults With ADHD**

Thomas J. Spencer, M.D.

### **C Longer-Term Effectiveness of Various Treatments for ADHD: Results From the Multimodal Treatment Study of ADHD**

Laurence L. Greenhill, M.D.

### **D A Ten-Year Follow-Up of ADHD Subjects**

Joseph Biederman, M.D.

### **E Does the Treatment of ADHD With Stimulant Medication Contribute to Illicit Drug Use and Abuse in Adulthood? Results From a Fifteen-Year Prospective Study**

Russell A. Barkley, Ph.D.

**THIS SESSION WILL BE AUDIOTAPED.**

### **SYMPOSIUM 55**

2:00 p.m. - 5:00 p.m.

Salons 10 & 11, Lower B-2 Level, Marriott

### **HOW TO LAUNCH A SUCCESSFUL PRIVATE PRACTICE, PART 3**

**Chp.:** William E. Callahan, Jr., M.D.

**Co-Chp.:** Keith W. Young, M.D.

### **A Personal Factors Leading to a Successful Private Practice**

William E. Callahan, Jr., M.D.

### **B Office Location and Design for Efficiency and Success**

Keith W. Young, M.D.



**C Streamlining Overhead and Managing Your Business in Private Practice**

Keith W. Young, M.D.

**D Marketing Your Unique Private Practice**

William E. Callahan, Jr., M.D.

**THIS SESSION WILL BE AUDIOTAPED.****SYMPOSIUM 56**

2:00 p.m. - 5:00 p.m.

Salons 12 &amp; 13, Lower B-2 Level, Marriott

**ETHICAL ISSUES IN THE U.S. AND FRANCE: VIVE LA DIFFERENCE****Chp.:** John A. Talbott, M.D.**Co-Chp.:** Francois C. Petitjean, M.D.**A From One Culture to Another**

Charles De Brito, M.D.

**B Impact of Culture on Ethics**

Ezra E.H. Griffith, M.D.

**C About Patients' Information in France: Is Electronic Medical Record Part of the Solution?**

Denis H. Chino, M.D., Veronique A. Olivier, M.D., Xavier Moine, Agnes Lemoux, Nariechrist Velut-Chino, M.D., Mordka Szpirko, M.D., Isabelle Teillet, M.D.

**D Patients Reading Their Own Records: Survey of the U.S. and Comment**

Thomas G. Gutheil, M.D.

**E Psychiatric Treatment for Women of Child-Bearing Age: Ethical Aspects**

Christine Germain, M.D., Francois C. Petitjean, M.D.

**F What Is a Psychiatrist Doing Here?**

Kathleen M. Mogul, M.D.

**Discussants:** Alexandra MacLean, M.D., Francois C. Petitjean, M.D.**THIS SESSION WILL BE AUDIOTAPED.****SYMPOSIUM 57**

2:00 p.m. - 5:00 p.m.

Salons 14 &amp; 15, Lower B-2 Level, Marriott

**PSYCHIATRISTS WITH PSYCHIATRIC DISORDERS: THE FEAR OF STIGMA****Chp.:** Sylvia P. Emmerich, M.D.**Co-Chp.:** Philip R. Muskin, M.D.**A Psychiatric Residents in Manhattan: A Survey of Personal Psychiatric Treatment**

Sylvia P. Emmerich, M.D.

**B Stigma Against the Mentally Ill and Its Effects on Treatment**

Paul J. Fink, M.D.

**C The Role of the Training Director in Resident Mental Health: Strategies for Encouraging Treatment and Reducing Stigma**

Elizabeth Auchincloss, M.D.

**D A Psychiatrist's Personal Encounter With Stigma**

Francine Cournos, M.D.

**THIS SESSION WILL BE AUDIOTAPED.****SYMPOSIUM 58**

2:00 p.m. - 5:00 p.m.

Golden Gate Hall A, B-2 Level, Marriott

**ADDICTIONS: CUTTING-EDGE TREATMENTS****Chp.:** Herbert D. Kleber, M.D.**Co-Chp.:** David M. McDowell, M.D.**A Treatment of Cocaine Dependence**

Adam M. Bisaga, M.D.

**B Treatments for Heroin Dependence**

Herbert D. Kleber, M.D.

**C Office-Based Treatment of Opioid Addiction**

Laura F. McNicholas, M.D.

**D Update on Marijuana and Club Drugs: Current and Potential Treatments**

David M. McDowell, M.D.

**E Treatment of Comorbid Conditions**

Frances R. Levin, M.D., Suzette M. Evans, Herbert D. Kleber, M.D.

**Discussant:** Edward V. Nunes, M.D.**THIS SESSION WILL BE AUDIOTAPED.****SYMPOSIUM 59**

2:00 p.m. - 5:00 p.m.

Golden Gate Hall B, B-2 Level, Marriott

**INTERNET: TECHNICAL, CLINICAL, AND SOCIETAL***American Association for Social Psychiatry and American Association for Technology in Psychiatry***Chp.:** Lawrence Hartmann, M.D.**Co-Chp.:** Ronnie S. Stangler, M.D.**A Addictions and the Internet**

Richard N. Rosenthal, M.D.

**B Sex and the Internet**

Zebulon C. Taintor, M.D.

*(Continued on next page)*

## TUESDAY

---

### **C Pseudocommunities on the Internet**

Steven E. Hyler, M.D.

### **D Internet Support: Self-Help Groups**

Robert C. Hsiung, M.D.

### **E Eating Disorders Meet the Internet: What Patients and Clinicians Encounter**

Joel Yager, M.D.

Discussant: Thomas A.M. Kramer, M.D.

**THIS SESSION WILL BE AUDIOTAPED.**

---

## **3:00 p.m. Session**

---

### **NEW RESEARCH POSTER SESSION 7**

3:00 p.m. - 5:00 p.m.

Hall D, Exhibit Level, Moscone Center

### **MOOD DISORDERS**

For further information on New Research Sessions, please refer to the *New Research Program Book* included in your registration packet.

---

## **7:00 p.m. Sessions**

---

### **INDUSTRY-SUPPORTED SYMPOSIA 35-41**

#### **INDUSTRY-SUPPORTED SYMPOSIUM 35**

7:00 p.m. - 10:00 p.m.

Gateway Ballroom, Exhibit Level, Moscone Center

#### **FACING UNMET NEEDS: ATYPICAL ANTIPSYCHOTICS FOR MOOD AND ANXIETY**

*Supported by Janssen Pharmaceutica*

Chp.: Mark Pollack, M.D.

#### **A Mechanism of Action of Atypical Antipsychotics in Mood and Anxiety Disorders**

Pierre Blier, M.D., Steven T. Szabo, Ph.D., Peter Berqvist, Jianming Dong, Ph.D.

#### **B Use of Atypical Antipsychotics in Mood Disorders**

Charles B. Nemeroff, M.D.

#### **C Treatment of Anxiety Disorders: Therapeutic Challenges of the Future**

Olga Brawman-Mintzer, M.D.

#### **D Atypical Antipsychotics in PTSD: Rationale and Role**

Murray B. Stein, M.D.

#### **E Working With the Patient as a Co-Therapist: Strategies to Enhance Treatment Adherence**

Michael W. Otto, Ph.D.

### **INDUSTRY-SUPPORTED SYMPOSIUM 36**

7:00 p.m. - 10:00 p.m.

Hall E, Exhibit Level, Moscone Center

### **BIPOLAR DISORDER ACROSS THE LIFE CYCLE**

*Supported by Abbott Laboratories*

Chp.: Charles L. Bowden, M.D.

#### **A Reproductive Health and Metabolic Correlates in Women Receiving Treatment for Bipolar Disorder**

Natalie L. Rasgon, M.D.

#### **B Bipolar Disorders in Adulthood**

John M. Zajecka, M.D.

#### **C Secondary Manias and Comorbid Conditions**

James C.Y. Chou, M.D.

#### **D Combination Treatments: What to Use and When**

Joseph R. Calabrese, M.D.

#### **E Management of Side Effects and Treating to Wellness**

Charles L. Bowden, M.D.

### **INDUSTRY-SUPPORTED SYMPOSIUM 37**

7:00 p.m. - 10:00 p.m.

Metropolitan, Second Level, Argent

### **SHOWING DISEASE PROGRESSION AND THE LONG-TERM MANAGEMENT OF DEMENTIA**

*Supported by Novartis Pharmaceuticals Corporation*

Chp.: Steven G. Potkin, M.D.

#### **A Mechanism of Disease Progression in Dementia**

Nigel Greig, Ph.D.

#### **B Targeting Cholinergic Therapy to Slow Disease Progression**

Steven G. Potkin, M.D.

#### **C Brain Imaging and CSF Cholinesterase Inhibition: Long-Term Data**

Agneta Nordberg, M.D.

#### **D A Critical Review of the Long-Term Data With Cholinesterase**

P. Murali Doraiswamy, M.D.

Discussants: Nigel Greig, Ph.D., P. Murali Doraiswamy, M.D.

**INDUSTRY-SUPPORTED SYMPOSIUM 38**

7:00 p.m. - 10:00 p.m.

Grand Ballroom Salon B, Grand Ballroom Level, Hilton

**OPTIMIZING TREATMENTS FOR PATIENTS WITH SCHIZOPHRENIA: TARGETING POSITIVE PATIENT OUTCOMES***Supported by Pfizer Inc.***Chp.:** Daniel E. Casey, M.D.**A The Science of Antipsychotics: Mechanistic Insight**

Daniel E. Casey, M.D.

**B Management of Acute Psychosis From Emergency to Stabilization**

Daniel L. Zimbroff, M.D.

**C Beyond Control of Acute Exacerbation: Enhancing Affective and Cognitive Outcomes**

Herbert Y. Meltzer, M.D.

**D Factors in Antipsychotic Drug Selection: Tolerability Considerations**

Henry A. Nasrallah, M.D.

**E Obesity, Diabetes, and Metabolic Syndrome: New Challenges in Antipsychotic Drug Therapy**

Enrique Caballero, M.D.

**F Long-Term Treatment Goals: Enhancing Healthy Outcomes**

Carol A. Tamminga, M.D.

**INDUSTRY-SUPPORTED SYMPOSIUM 39**

7:00 p.m. - 10:00 p.m.

Continental Ballroom, Ballroom Level, Hilton

**BIOLOGICAL AND PSYCHOLOGICAL ADVANCES IN THE TREATMENT OF SCHIZOPHRENIA: REVISITING AND UPDATING MEYER'S PSYCHOBIOLOGY FOR THE 21ST CENTURY***Supported by Bristol-Myers Squibb Company***Chp.:** Peter J. Weiden, M.D.**A Psychological Mechanisms of Psychosis: Implications for Psychotherapeutic Intervention**

Douglas Turkington, M.B.

**B Biologic Mechanisms of Psychosis: From Dopamine Excess to Dopamine Stabilization**

Bryan L. Roth, M.D.

**C What Is an Adequate Treatment Response? Establishing Therapeutic Goals in Schizophrenia**

Peter J. Weiden, M.D.

**D Long-Term Treatment of Schizophrenia: Moving From a Relapse-Prevention Model to a Recovery Model**

John M. Kane, M.D.

**E Diagnostic Boundaries Between Bipolar Disorder and Schizophrenia: Implications for Pharmacological Intervention**

Stephen M. Strakowski, M.D.

**Discussant:** Nina R. Schooler, Ph.D.**INDUSTRY-SUPPORTED SYMPOSIUM 40**

7:00 p.m. - 10:00 p.m.

Salons 7 &amp; 8, Lower B-2 Level, Marriott

**REAL-WORLD CHALLENGES IN DEPRESSION AND ANXIETY***Supported by GlaxoSmithKline***Chp.:** David L. Dunner, M.D.**A Long-Term Consequences of Social Anxiety Disorder: Breaking the Cycle**

Karen D. Wagner, M.D.

**B Depression and Anxiety in Medical Illness: The Brain-Body Interface**

Prakash S. Masand, M.D.

**C Overcoming Stigma and Optimizing Outcome in Late-Life Depression**

Lori J. Birdsong, M.D.

**D The Clinical Challenge of Depression in Bipolar Disorder**

David L. Dunner, M.D.

**INDUSTRY-SUPPORTED SYMPOSIUM 41**

7:00 p.m. - 10:00 p.m.

Salon 9, Lower B-2 Level, Marriott

**WOMEN AND PSYCHIATRIC DISORDERS: DOES GENDER MATTER FOR TREATMENT?***Supported by Wyeth Pharmaceuticals***Chp.:** Jerrold F. Rosenbaum, M.D.**Co-Chp.:** Lee S. Cohen, M.D.**A Hormones and the Brain**

Meir Steiner, M.D.

**B Sex, Hormones, and Depression: The Impact of Sex Steroids on Mood Across the Reproductive Life Cycle**

Claudio N. Soares, M.D.

**C Trauma and PTSD in Women**

Shamsah B. Sonawalla, M.D.

**D Women and Alcohol Use Disorders**

Shelly F. Greenfield, M.D.

**E Does Gender Matter to Treatment?**

Jerrold F. Rosenbaum, M.D.



• CME Courses •

• Distinguished Lecturers •

• Leadership and  
Career Development Seminars •  
*(for Residents and  
Early Career Psychiatrists)*

• Industry-Supported Symposia •

• Medical Updates •

• Symposia •

• Workshops •

• Debates •

• Forums •

• Full-Day Sessions •

• Poster Sessions •

• Discussion Groups •

• Innovative Programs •

• Clinical Consultations •



**INSTITUTE OBJECTIVES:**

At the conclusion of the 2003 Institute on Psychiatric Services, participants will:

1. Acquire new knowledge and skills in clinical psychiatry, which can be utilized to improve patient care;
2. Better understand how the current health care system affects patient care;
3. Gain new knowledge and skills useful in public psychiatry settings;
4. Understand the importance of gaining access to integrated mental health care for all patients; and
5. Recognize the important role the physician plays in helping the patient gain access to integrated mental health care.

*For further information, please call or write to our new address:*

**Institute on Psychiatric Services**  
American Psychiatric Association  
1000 Wilson Boulevard, Suite 1825  
Arlington, VA 22209-3901

Telephone: 1 (888) 357-7924 (Toll Free)

Fax: (703) 907-1090

E-Mail: [apa@psych.org](mailto:apa@psych.org)

Web: <http://www.psych.org>

*Did you know that...*

- ★ You can earn up to 48 hours of category 1 credit for attending the Institute?
- ★ APA members receive a 40% discount on their cost for registration?
- ★ Industry-Supported Breakfast, Lunch, and Dinner Symposia are presented each day?
- ★ All scientific sessions will be held in the Marriott Copley Place Hotel in Boston?
- ★ There are prize drawings, beverages, and receptions held daily in the exhibit hall?
- ★ The 2002 Institute had over 1,750 registrants and received the highest attendee-rated evaluations?



AMERICAN PSYCHIATRIC ASSOCIATION  
55th INSTITUTE ON PSYCHIATRIC SERVICES



*Access to Integrated  
Mental Health Care*

October 29–November 2, 2003



The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The APA designates this educational activity for up to 48 hours in category 1 credit towards the AMA Physician's Recognition Award and for the CME requirement of the APA. Each physician should claim only those hours of credit that he/she actually spent in the educational activity.

# WEDNESDAY, MAY 21, 2003

## 156TH ANNUAL MEETING

### 7:00 a.m. Sessions

#### PART 1 OF INDUSTRY-SUPPORTED BREAKFAST SYMPOSIA 42-45

##### INDUSTRY-SUPPORTED BREAKFAST SYMPOSIUM 42, PART 1

7:00 a.m. - 8:30 a.m.

Gateway Ballroom, Exhibit Level, Moscone Center

##### NEUROPSYCHIATRY IN THE AGE OF POLYPHARMACY

*Supported by Janssen Pharmaceutica*

Chp.: Prakash S. Masand, M.D.

##### A An Evidence-Based Approach to Rational Polypharmacy in Schizophrenia

Prakash S. Masand, M.D.

##### B Polypharmacy in the Treatment of Bipolar Disorder

Andrew L. Stoll, M.D.

##### INDUSTRY-SUPPORTED BREAKFAST SYMPOSIUM 43, PART 1

7:00 a.m. - 8:30 a.m.

Hall E, Exhibit Level, Moscone Center

##### TREATING ADHD ACROSS THE LIFE CYCLE

*Supported by Novartis Pharmaceuticals Corporation*

Chp.: Thomas J. Spencer, M.D.

Co-Chp.: Joseph Biederman, M.D.

##### A Pathophysiology of ADHD

Stephen V. Faraone, Ph.D.

##### B ADHD From Childhood to Adolescence:

Developmental Issues in Clinical Presentations

Russell A. Barkley, Ph.D.

Discussants: Betty Jo Salmeron, M.D., Michael Sanders, M.D.

##### INDUSTRY-SUPPORTED BREAKFAST SYMPOSIUM 44, PART 1

7:00 a.m. - 8:30 a.m.

Grand Ballroom Salon B, Grand Ballroom Level, Hilton

##### INSOMNIA IN TODAY'S SOCIETY: CONSEQUENCES AND TREATMENTS

*Supported by Sanofi-Synthelabo, Inc.*

Chp.: Gregory M. Asnis, M.D.

Co-Chp.: Shari Kohn, Ph.D.

##### A The Importance of Identifying and Treating Insomnia

David N. Neubauer, M.D.

##### B Pharmacotherapy of Insomnia

Gregory M. Asnis, M.D.

##### INDUSTRY-SUPPORTED BREAKFAST SYMPOSIUM 45, PART 1

7:00 a.m. - 8:30 a.m.

Salons 7 & 8, Lower B-2 Level, Marriott

##### OBESITY IN PSYCHIATRIC PRACTICE: RECOGNITION AND TREATMENT

*Supported by Ortho-McNeil Pharmaceuticals*

Chp.: B. Timothy Walsh, M.D.

##### A Obesity Update

Robert Kushner, M.D.

##### B Psychotropic Medication and Weight Gain

David B. Allison, Ph.D.

##### C Obesity and Psychiatric Disorders

Laurel Mayer, M.D.

### 8:00 a.m. Sessions



#### COURSES 82-89

Course descriptions are available in the *CME Course Brochure* included in your registration packet. Admission by ticket only.

#### COURSE 82

8:00 a.m. - 12 noon

Franciscan Room B, Ballroom Level, Hilton

#### PSYCHIATRIC INTERVENTIONS IN DISASTERS: LESSONS FROM EXPERIENCE

*APA Committee on Psychiatric Dimensions of Disaster*

Director: Carol S. North, M.D.

Faculty: Betty Pfefferbaum, M.D., Phebe M. Tucker, M.D.

#### COURSE 83

8:00 a.m. - 12 noon

Franciscan Room C, Ballroom Level, Hilton

#### INSANITY DEFENSE EVALUATIONS

Director: Phillip J. Resnick, M.D.

#### COURSE 84

8:00 a.m. - 12 noon

Yosemite Room A, Ballroom Level, Hilton

#### PSYCHIATRIC GENOMICS: APPLICATIONS FOR CLINICAL PRACTICE

Director: David A. Mrazek, M.D.

Faculty: John L. Black, M.D., Brett A. Koplin, M.D.

**COURSE 85** 8:00 a.m. - 12 noon

Union Square 1 & 2, Fourth Floor, Hilton

**MEDITATION FOR PSYCHOTHERAPISTS AND THE PARADIGM OF HEALTH**

Director: James T. Sacamano, M.D.  
Faculty: Ira Rechtshaffer, Ph.D.

**COURSE 86** 8:00 a.m. - 12 noon

Union Square 13, Fourth Floor, Hilton

**A PSYCHODYNAMIC APPROACH TO TREATMENT REFRACTORY MOOD DISORDERS**

Director: Eric M. Plakun, M.D.  
Faculty: David L. Mintz, M.D., Edward R. Shapiro, M.D.

**COURSE 87** 8:00 a.m. - 12 noon

Union Square 14, Fourth Floor, Hilton

**BEHAVIORAL NEUROANATOMY: AN INTRODUCTION**

Director: Nashaat N. Boutros, M.D.  
Faculty: David L. Clark, Ph.D., Edward C. Lauterbach, M.D.

**COURSE 88** 8:00 a.m. - 12 noon

Union Square 15 & 16, Fourth Floor, Hilton

**ASSESSING THE RISK OF VIOLENCE IN BOTH FORENSIC AND SEX OFFENDER SETTINGS**

Director: Bradley R. Johnson, M.D.  
Faculty: Judith V. Becker, Ph.D.

**COURSE 89** 8:00 a.m. - 5:00 p.m.

Imperial Ballroom B, Ballroom Level, Hilton

**OFFICE-BASED BUPRENORPHINE TREATMENT FOR OPIOID DEPENDENT PATIENTS**

*American Academy of Addiction Psychiatry and APA Council on Addiction Psychiatry*

Co-Directors: Eric C. Strain, M.D., Thomas R. Kosten, M.D.  
Faculty: Herbert D. Kleber, M.D., Laura F. McNicholas, M.D.

**9:00 a.m. Sessions**

**CLINICAL CASE CONFERENCE 3**

9:00 a.m. - 10:30 a.m.

Room 121, Exhibit Level, Moscone Center

**TREATING THE CHRONICALLY MEDICALLY ILL ADOLESCENT: A CASE STUDY**

Moderator: Gia M. Crecelius, M.D.  
Discussant: Margaret L. Stuber, M.D.

**THIS SESSION IS OPEN TO APA MEMBERS ONLY. BLUE REGISTRATION BADGE OR APA MEMBERSHIP CARD REQUIRED FOR ADMITTANCE.**

**CONTINUOUS CLINICAL CASE CONFERENCE 2: PART 1**

9:00 a.m. - 12 noon

Room 120, Exhibit Level, Moscone Center

**A CASE OF MURDER AND DISSOCIATIVE IDENTITY DISORDER: REAL OR MALINGERED MENTAL ILLNESS?**

Moderator: Britta Ostermeyer, M.D.  
Presenters: Thomas G. Cobb, M.D., Renee M. Sorrentino, M.D., Richard P. Kluft, M.D.

**THIS SESSION IS OPEN TO APA MEMBERS ONLY. BLUE REGISTRATION BADGE OR APA MEMBERSHIP CARD REQUIRED FOR ADMITTANCE.**



**COURSES 90-94**

Course descriptions are available in the *CME Course Brochure* included in your registration packet. Admission by ticket only.

**COURSE 90**

**WITHDRAWN**

**COURSE 91**

9:00 a.m. - 4:00 p.m.

Yosemite Room B, Ballroom Level, Hilton

**ALZHEIMER'S DISEASE: ADVANCED APPROACHES TO TREATMENT**

Director: William E. Reichman, M.D.  
Faculty: Peter M. Aupperle, M.D., Constantine Lyketsos, M.D., Jacobo E. Mintzer, M.D., David L. Sultzer, M.D., Pierre N. Tariot, M.D.

**COURSE 92** **9:00 a.m. - 4:00 p.m.**  
**Yosemite Room C, Ballroom Level, Hilton**

**BACK TO THE FUTURE: THE EVOLUTIONARY FRAMEWORK FOR PSYCHIATRY**

**Director:** John R. Ewaldson, M.D.

**Faculty:** Mark T. Erickson, M.D., Annette J. Hollander, M.D., David Mullen, M.D., Daniel R. Wilson, M.D.

**COURSE 93** **9:00 a.m. - 4:00 p.m.**  
**Union Square 19 & 20, Fourth Floor, Hilton**

**ADVANCED HYPNOSIS: APPLICATIONS IN PSYCHIATRY**

**Director:** Jose R. Maldonado, M.D.

**Faculty:** David Spiegel, M.D.

**COURSE 94** **9:00 a.m. - 4:00 p.m.**  
**Union Square 23 & 24, Fourth Floor, Hilton**

**TRAUMATIC BRAIN INJURY: NEUROPSYCHIATRIC ASSESSMENT**

**Director:** Robert P. Granacher, Jr., M.D.

**DISCUSSION GROUPS 18-20**

**9:00 a.m. - 10:30 a.m.**

These sessions are limited to 25 participants on a first-come, first-served basis.

- 18 Stephen C. Scheiber, M.D., on the Core Competencies: What It Means for Residents and Faculty (*Meet the Authors*)**  
**Pacific Conference Suite B, 4th Floor, Marriott**
- 19 Anthony F. Lehman, M.D., on Evidence-Based Psychiatry: The Promise and Pitfall of Translating Science Into Practice**  
**Pacific Conference Suite C, 4th Floor, Marriott**
- 20 Carolyn B. Robinowitz, M.D., on Women in Leadership: Problems, Prospects, and Proposals**  
**Pacific Conference Suite E, 4th Floor, Marriott**

**LECTURES 16-17**

**LECTURE 16**

**9:00 a.m. - 10:30 a.m.**

**Rooms 130/131, Exhibit Level, Moscone Center**

**APA'S GEORGE TARJAN AWARD LECTURE**

**Prakash N. Desai, M.D.**

**Health, Culture, and South-Asian Indians in North America**

**Chp:** Godehard Oepen, M.D.

Prakash N. Desai, M.D., is Professor of Psychiatry and Associate Dean in the College of Medicine at the University of Illinois at Chicago, Chief of Staff at the Veterans Affairs Chicago Health Care System/West Side Division, and an Associate Member of the Committee on South Asian Studies at the University of Chicago. A Distinguished Fellow of the American Psychiatric Association, Dr. Desai has held numerous positions in APA and was elected Speaker of the Assembly in 2002. His previous APA positions include Chair of the Caucus of International Medical Graduates, Chair of the Committee on Veterans Affairs, Area 4 Representative to the Assembly, and Assembly Recorder. Dr. Desai has written and lectured extensively on homelessness and community mental health and on psychological and medical aspects of Hindu tradition. A Past President of the National Association of VA Chiefs of Psychiatry and the American Association of South Asian Psychiatrists, Dr. Desai is the recipient of numerous honors, including the Oskar Pfister Award from APA for his contributions to the combined fields of psychiatry and religion. Dr. Desai received his medical degree from the University of Baroda, India, and completed his residency in psychiatry at Northwestern University Medical School in Chicago.

**THIS SESSION WILL BE AUDIOTAPED.**

**LECTURE 17**

**9:00 a.m. - 10:30 a.m.**

**Rooms 132/133, Exhibit Level, Moscone Center**

**Kenneth B. Wells, M.D.**

**Can Psychiatry Improve Community Welfare?  
 New Research and Practice Paradigm**

**Chp.:** Philip R. Muskin, M.D.

**Co-Chp.:** David M. McDowell, M.D.

Mental disorders are leading causes of disability worldwide, but treatment rates for many psychiatric disorders are low in community populations and there are disparities in quality and outcomes of care. Efforts to address unmet need have focused on improving quality of care in practice settings and evaluating the impact of legislative initiatives such as parity bills. These approaches have not led to broad or sustained gains in quality of care or economic welfare for communities. Kenneth B. Wells, M.D., will present a paradigm to extend services research approaches to reducing unmet need to community intervention techniques and societal welfare outcomes, to broaden the goals and reach of interventions to communities. The potential of this approach is illustrated with findings from Healthcare for Communities and Partners in Care. Kenneth B. Wells, M.D., is a

*(Continued on next page)*

Professor-in-Residence of Psychiatry and Biobehavioral Sciences at UCLA Neuropsychiatric Institute & Hospital and Senior Scientist at RAND. He is a psychiatrist and health services researcher. Dr. Wells is the Principal Investigator of the NIMH-funded UCLA/RAND Center for Research on Managed Care for Psychiatric Disorders; the Robert Wood Johnson-Funded Alcohol, Drug Abuse, and Mental Health Supplement to the Community Tracking Study; and of the Agency for Health Care Policy and Research (AHQPR) Patient Outcomes Research Team (PORT-II). Dr. Wells is an elected member of the Institute of Medicine of the National Academy of Sciences. In the last year, he was named Chair of this Board as the first applied scientist. He was the first recipient of the Young Investigator Award and more recently honored with the Distinguished Investigator Award by the Academy of Health Services Research.  
**Distinguished Psychiatrist Lecture Series**  
**THIS SESSION WILL BE AUDIOTAPED.**

**MASTER EDUCATOR CLINICAL CONSULTATION 8**

9:00 a.m. - 10:30 a.m.

This session is limited to 25 participants on a first-come, first-served

Carol C. Nadelson, M.D., on Women in Leadership: Understanding Achievement Obstacles  
 Room 218, Mezzanine Level, Moscone Center

**THIS SESSION IS OPEN TO APA MEMBERS ONLY. BLUE REGISTRATION BADGE OR APA MEMBERSHIP CARD REQUIRED FOR ADMITTANCE.**

**REVIEW OF PSYCHIATRY: SECTION 3**

9:00 a.m. - 10:30 a.m.

Room 104, Exhibit Level, Moscone Center

**STANDARDIZED EVALUATION IN CLINICAL PRACTICE**

Chp.: Michael B. First, M.D.

**11 Is There a Place for Research Diagnostic Methods in Clinic Settings?**

Monica A. Basco, Ph.D.

**12 Integrating the Assessment Methods of Researchers Into Routine Clinical Practice: The Rhode Island Methods to Improve Diagnostic Assessment and Services (MIDAS) Project**

Mark Zimmerman, M.D.

**13 Use of Structured Assessment for the Diagnosis of Childhood Disorders in Clinical Settings**

Christopher Lucas, M.D.

**14 Risk Factors for Suicidal Behavior: The Utility and Limitations of Research Instruments**

Maria A. Oquendo, M.D., Batsheva Halberstam, B.A., J. John Mann, M.D.

**15 Nationwide Implementation of Global Assessment of Functioning as an Indicator of Patient Severity and Service Outcomes**

William W. Van Stone, M.D., Kathy Henderson, M.D., Rudolf H. Moos, Ph.D., Robert Rosenheck, M.D., Mary Schon, M.D.

**WORKSHOPS**

**COMPONENT 23-29**

**COMPONENT WORKSHOP 23** 9:00 a.m. - 10:30 a.m.  
 Salons 3 & 4, Lower B-2 Level, Marriott

**WOMEN'S LEADERSHIP 101**

*APA Committee on Women*

Co-Chps.: Caroline E. Fisher, M.D., Jodi E. Star, M.D.

Participants: Leslie H. Gise, M.D., Donna M. Norris, M.D., Marcia K. Goin, M.D.

**COMPONENT WORKSHOP 24** 9:00 a.m. - 10:30 a.m.  
 Salons 5 & 6, Lower B-2 Level, Marriott

**GREAT EXPECTATIONS: INTEGRATING MIND AND BRAIN IN RESIDENT TRAINING**

*APA/GlaxoSmithKline Fellows*

Co-Chps.: Jodi J. Gold, M.D., Rebecca Brendel, M.D.

Participants: Abigail B. Schlesinger, John W. Grace, Alec O. Oskin

**COMPONENT WORKSHOP 25** 9:00 a.m. - 10:30 a.m.  
 Salons 10 & 11, Lower B-2 Level, Marriott

**PATIENT SAFETY IN PSYCHIATRY: REDUCING ADVERSE MEDICATION EVENTS**

*APA Task Force on Patient Safety*

Co-Chps.: Alfred Herzog, M.D., Miles F. Shore, M.D.

Participant: John W. Goethe, M.D.



**COMPONENT WORKSHOP 26** 9:00 a.m. - 10:30 a.m.  
Salons 12 & 13, Lower B-2 Level, Marriott

**WHAT IS THE ETHICAL STANCE? ISSUES RELATED TO WORLD PSYCHIATRY AND COURTS**

*APA Council on Psychiatry and Law and APA Committee on Judicial Action*

**Chp.:** Jeffrey L. Metzner, M.D.  
**Participants:** Alan A. Stone, M.D., Renee L. Binder, M.D., Richard Bonnie, L.L.B.

**COMPONENT WORKSHOP 27** 9:00 a.m. - 10:30 a.m.  
Salons 14 & 15, Lower B-2 Level, Marriott

**TEACHING COMPETENCE IN PSYCHOTHERAPY TO RESIDENTS: ARE FACULTY COMPETENT?**

*APA Committee on Psychotherapy by Psychiatrists*

**Chp.:** Lisa A. Mellman, M.D.  
**Participants:** Jerald Kay, M.D., David A. Goldberg, M.D., Joanna E. Steinglass, M.D., Jennifer K. Coffman, M.D.

**COMPONENT WORKSHOP 28** 9:00 a.m. - 10:30 a.m.  
Golden Gate Hall A, B-2 Level, Marriott

**GLOBAL TRAUMA: EXPERIENCE AND IMPLICATIONS FOR DSM-V**

*APA Council on Global Psychiatry*

**Co-Chps.:** Arthur M. Kleinman, M.D., Harold I. Eist, M.D.  
**Participants:** Robert J. Ursano, M.D., Lars Weisaeth, M.D., Arieh Y. Shalev, M.D., Elie G. Karam, M.D., Raphael Beverley, M.D.

**COMPONENT WORKSHOP 29** 9:00 a.m. - 10:30 a.m.  
Golden Gate Hall C, B-2 Level, Marriott

**TRAUMA AND HOMELESSNESS: PSYCHIATRIC ASPECTS OF A SOCIOECONOMIC PROBLEM**

*APA Northern California Psychiatric Society*

**Co-Chps.:** Adam P. Nelson, M.D., Byron J. Wittlin, M.D.  
**Participants:** Mary K. Connor, Jean A. Marsters, M.D., Robert A. Rosenheck, M.D.

**ISSUES 64-82**

**ISSUE WORKSHOP 64** 9:00 a.m. - 10:30 a.m.  
Room 110, Exhibit Level, Moscone Center

**CULTURE, RACE, ETHNICITY, AND PSYCHOPHARMACOLOGY: RECENT RESEARCH ADVANCES**

**Co-Chps.:** Pedro Ruiz, M.D., Keh-Ming Lin, M.D.  
**Participants:** Edmond H.T. Pi, M.D., Ricardo P. Mendoza, M.D., William B. Lawson, M.D., Tarek A. Okasha, M.D.

**ISSUE WORKSHOP 65** 9:00 a.m. - 10:30 a.m.  
Room 111, Exhibit Level, Moscone Center

**REVISION OF THE APA ETHICS ANNOTATIONS: FOSTERING DIALOGUE**

**Co-Chps.:** Laura W. Roberts, M.D., Scott Y. Kim, M.D.  
**Participants:** S. Nassir Ghaemi, M.D., Richard D. Milone, M.D., Michael R. Arambula, M.D., Jennifer Radden, Ph.D.

**ISSUE WORKSHOP 66** 9:00 a.m. - 10:30 a.m.  
Room 112, Exhibit Level, Moscone Center

**THE DISRUPTIVE PHYSICIAN AND HOSPITAL CULTURE**

**Co-Chps.:** Glenn N. Siegel, M.D., Mary Pittman, M.S.

**ISSUE WORKSHOP 67** 9:00 a.m. - 10:30 a.m.  
Room 113, Exhibit Level, Moscone Center

**THE UNWRITTEN RULES FOR SUCCESS AS A COMMUNITY PSYCHIATRIST**

**Co-Chps.:** Stephen M. Goldfinger, M.D., Charles W. Huffine, Jr., M.D.  
**Participants:** Stuart A. Anfang, M.D., Kenneth S. Thompson, M.D.

**ISSUE WORKSHOP 68** 9:00 a.m. - 10:30 a.m.  
Room 114, Exhibit Level, Moscone Center

**THE MONTGOMERY COUNTY EMERGENCY SERVICE DIVERSION MODEL: A COMPREHENSIVE CONTINUUM OF FORENSIC INTERVENTIONS**

**Chp.:** Rocio Nell, M.D.  
**Participant:** Donald S. Kline, Ph.D.

**ISSUE WORKSHOP 69** 9:00 a.m. - 10:30 a.m.  
Room 123, Exhibit Level, Moscone Center

**ELECTRONIC MEDICAL RECORDS ENHANCE QUALITY AND PRODUCTIVITY: THE TIME HAS COME**

**Chp.:** Daniel A. Deutschman, M.D.  
**Participants:** Robert C. Hsiung, M.D., Andrea I. Glasser, M.Ed., Jaskaran Singh, M.D., Jesse H. Wright, M.D.

**ISSUE WORKSHOP 70** 9:00 a.m. - 10:30 a.m.  
Room 124, Exhibit Level, Moscone Center

**INDIVIDUAL PSYCHOTHERAPY WITH MEN SUFFERING FROM FATHER LOSS**

**Chp.:** Lawrence L. Kennedy, M.D.

**WEDNESDAY**

---

**ISSUE WORKSHOP 71** 9:00 a.m. - 10:30 a.m.  
**Rooms 272/274/276, Mezzanine Level, Moscone Center**

**MATCHMAKER, MATCHMAKER MAKE ME A MATCH**

**Chp.:** Lawrence Bryskin, M.D.  
**Participants:** Abba E. Borowich, M.D., Esther Jungreis, Maurice Stein, Rabbi Zvi Schachtel, B.A., Rena Hirsch, B.A.

**ISSUE WORKSHOP 72** 9:00 a.m. - 10:30 a.m.  
**Room 300, Esplanade Level, Moscone Center**

**THE PORTRAYAL OF PSYCHIATRY IN RECENT AMERICAN FILM**

**Chp.:** Steven E. Pflanz, M.D.

**ISSUE WORKSHOP 73** 9:00 a.m. - 10:30 a.m.  
**Room 301, Esplanade Level, Moscone Center**

**WHEN PSYCHIATRISTS HAVE A MENTAL ILLNESS: THE STORIES OF THEIR LOVED ONES**

*National Alliance for the Mentally Ill*

**Co-Chps.:** Michael F. Myers, M.D., Leah J. Dickstein, M.D.  
**Participants:** Jane Baxter, Marian Fireman, M.D., Raymond M. Reyes, M.D., Suzanne E. Vogel-Scibilia, M.D., Andrew Vogel-Scibilia

**ISSUE WORKSHOP 74** 9:00 a.m. - 10:30 a.m.  
**Room 302, Esplanade Level, Moscone Center**

**CUTTING-EDGE ISSUES IN CROSS-CULTURAL PSYCHIATRY**

**Chp.:** Albert C. Gaw, M.D.  
**Participants:** Desmond S. Fung, M.D., Alice C. Tso, M.D., Phuong-Thuy Le, M.D.

**ISSUE WORKSHOP 75** 9:00 a.m. - 10:30 a.m.  
**Room 304, Esplanade Level, Moscone Center**

**THE PSYCHIATRIST'S NIGHTMARE: A MALPRACTICE LAWSUIT**

**Chp.:** David W. Preven, M.D.  
**Participants:** Susan Stabinsky, M.D., Jacqueline M. Melonas, J.D., Harvey Stabinsky, M.D.

**ISSUE WORKSHOP 76** 9:00 a.m. - 10:30 a.m.  
**Room 306, Esplanade Level, Moscone Center**

**COUNSELING COMMITTED COUPLES: RETHINKING THERAPEUTIC NEUTRALITY**

**Chp.:** Scott D. Haltzman, M.D.  
**Participants:** Jack Drescher, M.D., Janice R. Levine, Ph.D., Dorian F. Morar, M.D.

**ISSUE WORKSHOP 77** 9:00 a.m. - 10:30 a.m.  
**Room 308, Esplanade Level, Moscone Center**

**INTERGENERATIONAL TRANSMISSION OF TRAUMA IN PREVENTION OF LONG-TERM CONSEQUENCES OF TRAUMATIC STRESS**

**Chp.:** Andrei Novac, M.D.  
**Participants:** Rita R. Newman, M.D., Charles W. Portney, M.D.

**ISSUE WORKSHOP 78** 9:00 a.m. - 10:30 a.m.  
**Room 309, Esplanade Level, Moscone Center**

**INDIVIDUAL PSYCHOTHERAPY FOR MARITAL PROBLEMS**

**Co-Chps.:** Michael C. Hughes, M.D., Eva C. Ritvo, M.D.

**ISSUE WORKSHOP 79** 9:00 a.m. - 10:30 a.m.  
**Room 310, Esplanade Level, Moscone Center**

**HEPATITIS C INFECTION: THE NEXT PSYCHIATRIC EPIDEMIC**

**Chp.:** Andrew F. Angelino, M.D.  
**Participant:** Glenn J. Treisman, M.D.

**ISSUE WORKSHOP 80** 9:00 a.m. - 10:30 a.m.  
**Salons 1 & 2, Lower B-2 Level, Marriott**

**FAMILY THERAPY TRAINING FOR PSYCHIATRY RESIDENTS**

**Chp.:** Steven J. Wolin, M.D.  
**Participants:** Ellen M. Berman, M.D., John S. Rolland, M.D., John Sargent, M.D., Peter J. Steinglass, M.D.

**ISSUE WORKSHOP 81** 9:00 a.m. - 10:30 a.m.  
**Pacific Conference Suite H, 4th Floor, Marriott**

**FAMILY THERAPY FOR ANOREXIA NERVOSA**

**Chp.:** James D. Lock, M.D.  
**Participant:** Daniel Legrange, Ph.D.

**ISSUE WORKSHOP 82** 9:00 a.m. - 10:30 a.m.  
**Pacific Conference Suite J, 4th Floor, Marriott**

**HELPING THE HEALERS: PROVIDING IMPAIRMENT EDUCATION TO PHYSICIANS**

**Chp.:** Karen E. Broquet, M.D.

## 11:00 a.m. Sessions

### DISCUSSION GROUPS 21-24

11:00 a.m. - 12:30 p.m.

These sessions are limited to 25 participants on a first-come, first-served basis.

- 21 Robert G. Robinson, M.D.**, on Controversies in Vascular and Post-Stroke Depression  
Pacific Conference Suite B, 4th Floor, Marriott
- 22 Arnold E. Andersen, M.D.**, on Eating Disorders in Males: A Rising Tide  
Pacific Conference Suite C, 4th Floor, Marriott
- 23 Kathryn J. Zerbe, M.D.**, on Women's Mental Health  
Pacific Conference Suite E, 4th Floor, Marriott
- 24 Carl C. Bell, M.D.**, on Cross-Cultural Issues: When the Patient Is Different From You (For Residents Only)  
Pacific Conference Suite I, 4th Floor, Marriott

### LECTURES 18-19

#### LECTURE 18

11:00 a.m. - 12:30 p.m.

Rooms 130/131, Exhibit Level, Moscone Center

Marshal F. Folstein, M.D.

#### The Meaning of Cognitive Impairment

Chp.: Thomas N. Wise, M.D.

Co-Chp.: Paul J. Goodnick, M.D.

A low score on a measure of cognitive impairment can point to a variety of syndromes and pathological states, and accurate diagnosis is highly important for making use of the new opportunities for treatment on the horizon. Marshal F. Folstein, M.D., presents a plan for systematic assessment of cognitive impairment and discusses the range of clinical conditions associated with this impairment. Dr. Folstein is Dr. Frances S. Arkin Professor and Chair in the Department of Psychiatry at Tufts University School of Medicine and Psychiatrist-in-Chief in the Department of Psychiatry at New England Medical Center in Boston, MA. His research interests include the causes and treatment of cognitive disorders associated with aging. He is currently investigating the effects of micronutrients on cognition. The author or co-author of more than 225 research articles and book chapters, Dr. Folstein serves on the editorial boards of several journals, including the *American Journal of Geriatric Psychiatry* and *Alzheimer's Disease and Related Disorders*. He is a Fellow of the American Psychiatric Association, the American

College of Physicians, and the Gerontological Society of America. A graduate of Georgetown University School of Medicine, Dr. Folstein completed his residency in neurology at Cleveland Metropolitan General Hospital and his residency in psychiatry at the New York Hospital, Westchester Division.

Distinguished Psychiatrist Lecture Series  
THIS SESSION WILL BE AUDIOTAPED.

#### LECTURE 19

11:00 a.m. - 12:30 p.m.

Rooms 132/133, Exhibit Level, Moscone Center

Samuel H. Barondes, M.D.

#### Better Than Prozac: Creating New Psychiatric Drugs

Chp.: Peter D. Kramer, M.D.

Samuel H. Barondes, M.D., is the Jeanne and Sanford Robertson Professor of Neurobiology and Psychiatry and Director of the Center for Neurobiology and Psychiatry at the University of California, San Francisco. A leading authority on the application of molecular biology to psychiatry, Dr. Barondes is author of more than 200 original research articles, editor of the books *Cellular Dynamics of the Neuron* and *Neuronal Recognition*, and author of *Molecules and Mental Illness* and *Mood Genes: Hunting for Origins of Mania and Depression*. His book, *Better Than Prozac: Creating the Next Generation of Psychiatric Drugs*, is scheduled for publication by Oxford University Press in the spring of 2003. Dr. Barondes is a member of the Institute of Medicine of the National Academy of Sciences and a Fellow of the American College of Neuropsychopharmacology. A graduate of Columbia University College of Physicians and Surgeons in New York City, Dr. Barondes received his clinical training in medicine and psychiatry at Boston-area hospitals affiliated with Harvard Medical School (Peter Bent Brigham Hospital, McLean Hospital, and Massachusetts General Hospital) and received his training in molecular biology at the National Institutes of Health in Bethesda, MD.

Frontiers of Science Lecture Series  
THIS SESSION WILL BE AUDIOTAPED.

### MASTER EDUCATOR CLINICAL CONSULTATION 9

11:00 a.m. - 12:30 p.m.

This session is limited to 25 participants on a first-come, first-served

David V. Sheehan, M.D., on Anxiety Disorders  
Room 218, Mezzanine Level, Moscone Center

THIS SESSION IS OPEN TO APA MEMBERS ONLY.  
BLUE REGISTRATION BADGE OR APA MEMBERSHIP CARD REQUIRED FOR ADMITTANCE.

**MEDICAL UPDATE 3**

11:00 a.m. - 12:30 p.m.

Room 300, Esplanade Level, Moscone Center

**YOGIC BREATHING: NEUROPHYSIOLOGIC THEORY AND CLINICAL APPLICATIONS FOR TREATMENT OF STRESS RELATED DISORDERS, DEPRESSION, AND AGGRESSION**

Chp.: Philip R. Muskin, M.D.

Presenter: Richard P. Brown, M.D.

**THIS SESSION WILL BE AUDIOTAPED.**

**RESEARCH CONSULTATION WITH**

11:00 a.m. - 12:30 p.m.

These sessions are limited to 25 participants on a first-come, first-served basis.

- 2 Katherine L. Wisner, M.D., on Depression During Pregnancy and the Postpartum Period  
Sierra Conference Suite E, 5th Floor, Marriott

**SCIENTIFIC AND CLINICAL REPORT SESSIONS 19-28**

**SCIENTIFIC AND CLINICAL REPORT SESSION 19**

11:00 a.m. - 12:30 p.m.

Room 110, Exhibit Level, Moscone Center

**DIAGNOSTIC ISSUES**

Chp.: Sophia Vinogradov, M.D.

Co-Chp.: Michael J. Pratts, M.D.

11:00 a.m.

- 56 The Development of a Brief Adult Mental Health Screening Tool for Jails

Robert L. Trestman, M.D., Julian Foro, Ph.D., Janelle Mallet, Valerie Hogan, M.A.

11:30 a.m.

- 57 Diagnosing and Treating Infants and Toddlers in Public Mental Health Settings

Harry H. Wright, M.D., Rosetta H. Penny, M.S.W., Kristin M. Wieduwilt, M.S.

12 noon

- 58 Psychiatric Nomenclature

Roger Peele, M.D.

**THIS SESSION WILL BE AUDIOTAPED.**

**SCIENTIFIC AND CLINICAL REPORT SESSION 20**

11:00 a.m. - 12:30 p.m.

Room 111, Exhibit Level, Moscone Center

**BIOLOGICAL PSYCHIATRY AND NEUROSCIENCE**

Chp.: Anton C. Trinidad, M.D.

Co-Chp.: Caroline E. Fisher, M.D.

11:00 a.m.

- 59 TAK-375 Is a Highly Selective Agonist at the ML-1 Receptor

Keisuke Hirai, Ph.D., Kelli Nishiyama, Koki Kato, Ph.D., Shuui Hinuma, Ph.D., Osamu Uchikawa, Ph.D., Shigenori Ohkawa, Ph.D., Masaomi Miyamoto, Ph.D.

11:30 a.m.

- 60 Safety, Pharmacokinetics, and Pharmacodynamics of TAK-375 in Healthy Adults

Charlene M. Stubbs, Ph.D., Aziz Karim, Ph.D.

12 noon

- 61 Selectivity of the ML-1 Agonist TAK-375: Lack of Binding to NON-ML-1 Targets

Masaomi Miyamoto, Ph.D., Keisuke Hirai, Ph.D., Koki Kato, Ph.D., Osamu Uchikawa, Ph.D., Shigenori Ohkawa, Ph.D.

**THIS SESSION WILL BE AUDIOTAPED.**

**SCIENTIFIC AND CLINICAL REPORT SESSION 21**

11:00 a.m. - 12:30 p.m.

Rooms 272/274/276, Mezzanine Level, Moscone Center

**PEDIATRIC ADHD**

Chp.: Mohammad Shafii, M.D.

Co-Chp.: Duru Sakhrani M.D., M.D.

11:00 a.m.

- 62 An Open-Label Trial of Adderall XR: Quality-of-Life Assessments

Floyd R. Sallee, M.D., Paul J. Ambrosini, M.D., Frank A. Lopez, M.D., J. Jordan Storlazzi, M.D., Simon J. Tulloch, M.D., M. Alex Michaels, M.D.

11:30 a.m.

- 63 Long-Term Safety and Efficacy of Adderall XR in Children With ADHD

Mark C. Chandler, M.D., Frank A. Lopez, M.D., Joseph Biederman, M.D.

12 noon

- 64 An Open-Label, Community-Assessment Trial of Adderall XR in Pediatric ADHD

Paul J. Ambrosini, M.D., Frank A. Lopez, M.D., Mark C. Chandler, M.D., Simon J. Tulloch, M.D., M. Alex Michaels, M.D.

**THIS SESSION WILL BE AUDIOTAPED.**

**SCIENTIFIC AND CLINICAL REPORT SESSION 22**

11:00 a.m. - 12:30 p.m.

Room 302, Esplanade Level, Moscone Center

**GERIATRIC PSYCHIATRY****Chp.:** Paul P. Yeung, M.D.**Co-Chp.:** Mohammad Shafii, M.D.

11:00 a.m.

**65 NIMH Atypical Antipsychotic Effectiveness Trial In Alzheimer's CATIE-AD**

M. Saleem Ismail, M.D., Ge A. Donker, M.D., Karen S. Dagerman, M.S., Sonia Davis, D.P.H., Pierre N. Tariot, M.D.

11:30 a.m.

**66 Meta-Analysis of Risperidone for Dementia: The Price Paid for Efficacy**

Ge A. Donker, M.D., Karen S. Dagerman, M.S.

12 noon

**67 Switching Elderly Chronic Schizophrenia Patients to Olanzapine: A Prospective Study**

Yoram Barak, M.D., Eyal Z. Shamir, M.D., Ronit Weizman, M.D., Dov Aizenberg

**THIS SESSION WILL BE AUDIOTAPED.****SCIENTIFIC AND CLINICAL REPORT SESSION 23**

11:00 a.m. - 12:30 p.m.

Room 308, Esplanade Level, Moscone Center

**THE PROMISE OF SCIENCE: THE POWER OF HEALING****Chp.:** David H. Taylor, M.D.**Co-Chp.:** Barbara A. Fitzgerald, M.D.

11:00 a.m.

**68 Serum Lipid Fractions in Clozapine-Treated Patients Over a Two-Year Period**

Charles F. Caley, Pharm.D., Stephen B. Woolley, M.P.H., John W. Goethe, M.D.

11:30 a.m.

**69 The Influence of Group Psychoeducation on Quality of Life in Schizophrenia Patients and Their Relatives**

Lucie Motlova, M.D., Eva Dragomirecka, Ph.D., Filip Spaniel, M.D., Pavla Seleпова, Richard Zalesky, M.D., Eva Goppoldova

12 noon

**70 HIV-Related Stigma: Disclosure, Depression, and Social Support**

Rachel Power, Ph.D., Cheryl Koopman, Ph.D., Dennis M. Israelski, M.D., Ron Duran, Ph.D., David Spiegel, M.D.

**THIS SESSION WILL BE AUDIOTAPED.****SCIENTIFIC AND CLINICAL REPORT SESSION 24**

11:00 a.m. - 12:30 p.m.

Salons 3 &amp; 4, Lower B-2 Level, Marriott

**TOPICS IN SUICIDE AND VIOLENCE****Chp.:** Stephanie Z. Hall, M.D.**Co-Chp.:** Rahil Jummani, M.D.

11:00 a.m.

**71 Impulsivity, Suicide, and Prefrontal Hypometabolism in Borderline Personality**

Paul H. Soloff, M.D., Carolyn Meltzer, M.D., Carl Becker, B.A., Phil J. Greer, M.A., Thomas M. Kelly, Ph.D., Doreen Constantine, M.Ed.

11:30 a.m.

**72 Suicide Rates Over the Decade Across Civilian and Military Populations**

Abigail L. Garvey-Wilson, M.D., Karen M. Eaton, M.S., Charles W. Hoge, M.D., Stephen C. Messer, Ph.D., Sandra E. Lesikar, Ph.D.

12 noon

**73 Clozapine Reduces Violent Behavior in Heterogeneous Diagnostic Groups**

John E. Kraus, Jr., M.D., Brian B. Sheitman, M.D.

**THIS SESSION WILL BE AUDIOTAPED.****SCIENTIFIC AND CLINICAL REPORT SESSION 25**

11:00 a.m. - 12:30 p.m.

Salons 12 &amp; 13, Lower B-2 Level, Marriott

**ISSUES IN PSYCHIATRY****Chp.:** Tanya R. Anderson, M.D.**Co-Chp.:** Darrin L. Bailey, M.D.

11:00 a.m.

**74 Children Excluded From Primary School: Randomized, Controlled Trial of a Team Intervention**

Christos Panayiotopoulos, Ph.D., Michael J. Kerfoot, Ph.D.

11:30 a.m.

**75 Malpractice Liability and Managed Care: Is a Resolution in Sight?**

Eugene L. Lowenkopf, M.D., Abe M. Rychik, J.D.

12 noon

**76 The Power of Humor in Psychotherapy**

William F. Fry, Jr., M.D.

**THIS SESSION WILL BE AUDIOTAPED.**

SCIENTIFIC AND CLINICAL REPORT SESSION 26

11:00 a.m. - 12:30 p.m.

Golden Gate Hall C, B-2 Level, Marriott

PSYCHOPHARMACOLOGY OF HEADACHE AND ANXIETY DISORDERS

Chp.: Barbara L. Yates, M.D.

Co-Chp.: Ann M. Bogan, M.D.

11:00 a.m.

77 Clinical Experiments With Sertraline in Panic Disorder

Matig R. Mavissakalian, M.D.

11:30 a.m.

78 Double-Blind Oral Morphine in Treatment-Resistant OCD

Lorin M. Koran, M.D., Kim D. Bullock, M.D., Bettina E. Franz, M.D., Nona Gamel, M.S.W., Michael A. Elliott, M.A.

12 noon

79 Treatment of Tension Headache With Mirtazapine

Isin B. Kulaksizoglu, M.D., Sibel Gakir, M.D., Mustafa Ertas

THIS SESSION WILL BE AUDIOTAPED.

SCIENTIFIC AND CLINICAL REPORT SESSION 27

11:00 a.m. - 12:30 p.m.

Sierra Conference Suite H, 5th Floor, Marriott

INTERNATIONAL PSYCHIATRY

Chp.: Dilip V. Jeste, M.D.

Co-Chp.: Rose M. Pham, M.D.

11:00 a.m.

80 Excess Mortality in Schizophrenia in Stockholm County, Sweden

Massimo di Giannantonio, M.D., Nestor Correia, Lena Brandt, B.S.C., Anders Ekblom, M.D., Par Sparen, Ph.D.

11:30 a.m.

81 Sex Differences in Health Service Use and Functioning Associated With Depressive Symptoms: Findings From the Utrecht Health Project

Mirjam I. Geerlings, Ph.D., Huib Burger, Ph.D., Johan M. Havenaar, M.D., Mattijs E. Numans, M.D., Diederick E. Grobbee, Ph.D.

12 noon

82 Binge Eating Disorder in Fiji, A Small-Scale, Indigenous Society

Anne E. Becker, M.D., Rebecca A. Burwell, M.Phil., Kesaia Navara, Stephen E. Gilman, Sc.D.

THIS SESSION WILL BE AUDIOTAPED.

SCIENTIFIC AND CLINICAL REPORT SESSION 28

11:00 a.m. - 12:30 p.m.

Pacific Conference Suite J, 4th Floor, Marriott

CROSS-CULTURAL AND MINORITY ISSUES

Chp.: Anthony T. Ng, M.D.

Co-Chp.: Arthur M. Kleinman, M.D.

11:00 a.m.

83 Predictors of First Depressive Episode in Black and White Women in Mid Life

Joyce T. Bromberger, Ph.D., Howard M. Kravitz, D.O., Hsiao-Lan Wei, M.S., Karen A. Matthews, Ph.D., Charlotte Brown, Ph.D.

11:30 a.m.

84 When the Poetry No Longer Rhymes: Somalis in the American Psychiatric Clinic

Deborah L. Scuglik, M.D., Mark D. Williams, M.D., Kathleen Logan, M.D.

12 noon

85 Effectiveness and Tolerability of Newer Antidepressants Among Depressed Chinese-American Patients

Albert Yeung, M.D., Nicoletta Clementi-Craven, M.D., David Mischoulon, M.D., Jonathan E. Alpert, M.D., Andrew A. Nierenberg, M.D., Maurizio Fava, M.D., Jessica L. Murakami, B.A.

THIS SESSION WILL BE AUDIOTAPED.

WORKSHOPS

COMPONENTS 30-38

**COMPONENT WORKSHOP 30** 11:00 a.m. - 12:30 p.m.  
Room 124, Exhibit Level, Moscone Center

UNITED WE STAND: DEVELOPING PARTNERSHIPS FOR PATIENT ADVOCACY

*APA Committee on Public Affairs and APA Committee on Government Relations*

Chp.: Mary H. Davis, M.D.

Participants: Jeffrey Akaka, M.D., John Bush, Judith F. Kashtan, M.D.

**COMPONENT WORKSHOP 31** 11:00 a.m. - 12:30 p.m.  
Room 125, Exhibit Level, Moscone Center

CPT CODING AND DOCUMENTATION UPDATE

*APA Committee on RBRVS, Codes, and Reimbursements*

Co-Chps.: Chester W. Schmidt, Jr., M.D., Tracy R. Gordy, M.D.

Participants: Ronald A. Shellow, M.D., Gerald Rogan, M.D., Joseph M. Schwartz, M.D.

**COMPONENT WORKSHOP 32** 11:00 a.m. - 12:30 p.m.  
Room 309, Esplanade Level, Moscone Center

**RETIREMENT ISSUES FOR PSYCHIATRISTS AND THEIR SPOUSES**

*APA Lifers and APA Task Force on Senior Psychiatrists*

**Chp.:** Hugh C. Hendrie, M.D.

**Participants:** Irvin M. Cohen, M.D., Mary Austrom, Ph.D., Captane P. Thomson, M.D.

**COMPONENT WORKSHOP 33** 11:00 a.m. - 12:30 p.m.  
Room 310, Esplanade Level, Moscone Center

**STATE OF THE STATES FOR STATE HOSPITAL PSYCHIATRISTS**

*APA Caucus of State Hospital Psychiatrists*

**Co-Chps.:** Beatrice M. Kovaszny, M.D., Yadollah M. Jabbarpour, M.D.

**Participants:** Thomas W. Hester, M.D., Perry B. Bach, M.D., Anita Everett, M.D., Wayne F. Brown, M.D.

**COMPONENT WORKSHOP 34** 11:00 a.m. - 12:30 p.m.  
Salons 1 & 2, Lower B-2 Level, Marriott

**DEPRESSIVE DISORDERS AND HISPANICS: A DEVELOPMENTAL PERSPECTIVE**

*APA Committee of Hispanic Psychiatrists*

**Co-Chps.:** Ana E. Campo, M.D., Oscar E. Perez, M.D.

**Participants:** Daniel Castellanos, M.D., Sayonara Baez, M.D.

**COMPONENT WORKSHOP 35** 11:00 a.m. - 12:30 p.m.  
Salons 5 & 6, Lower B-2 Level, Marriott

**WHY PSYCHIATRY? SAYS MOM**

*APA Committee of Asian-American Psychiatrists*

**Co-Chps.:** John S. Luo, M.D., Surinder S. Nand, M.D.

**Participants:** Mona H. Gill, M.D., Sue Y. Lee, M.D., Mary Ann Barnovitz

**COMPONENT WORKSHOP 36** 11:00 a.m. - 12:30 p.m.  
Salons 10 & 11, Lower B-2 Level, Marriott

**CLINICAL ISSUES OF ETHNIC DIVERSITY IN LONG-TERM CARE FACILITIES**

*APA Committee on Ethnic Minority Elderly*

**Co-Chps.:** Ronald Brenner, M.D., Josepha A. Cheong, M.D.

**Participants:** Iqbal Ahmed, M.D., Warachal E. Faison, M.D., Mia J. Robinson, Ella Brodsky, M.D.

**COMPONENT WORKSHOP 37** 11:00 a.m. - 12:30 p.m.  
Salons 14 & 15, Lower B-2 Level, Marriott

**IMPLICATIONS OF FINANCING OF HEALTH CARE FOR PSYCHIATRIC EDUCATION AND PRACTICE**

*APA Council on Healthcare Systems and Financing*

**Chp.:** Barry F. Chaitin, M.D.

**Participants:** Nyapati R. Rao, M.D., Bruce J. Schwartz, M.D., Frederick J. Stoddard, Jr., M.D., Allison M. Wehr, M.D., Rebecca Brendel, M.D., Joyce A. Tinsley, M.D.

**COMPONENT WORKSHOP 38** 11:00 a.m. - 12:30 p.m.  
Golden Gate Hall A, B-2 Level, Marriott

**INTERSEX CONDITIONS: CONTROVERSIES AND NEW APPROACHES TO TREATMENT**

*APA Committee on Gay, Lesbian, and Bisexual Issues*

**Chp.:** Richard O. Hire, M.D.

**Participants:** Jack Drescher, M.D., Benjamin H. McCommon, Jr., M.D., Vernon A. Rosario, M.D.

**ISSUES 83-88**

**ISSUE WORKSHOP 83** 11:00 a.m. - 12:30 p.m.  
Room 112, Exhibit Level, Moscone Center

**DO I NEED AN MBA TO TRANSFORM MY CAREER?**

**Chp.:** Arthur L. Lazarus, M.D.

**ISSUE WORKSHOP 84** 11:00 a.m. - 12:30 p.m.  
Room 113, Exhibit Level, Moscone Center

**THE BEGINNING STAGES OF COUPLES' THERAPY: VIDEO CASE STUDIES**

**Chp.:** Ian E. Alger, M.D.

**ISSUE WORKSHOP 85** 11:00 a.m. - 12:30 p.m.  
Room 114, Exhibit Level, Moscone Center

**HEALING THE HURT CHILD: TREATING FETAL ALCOHOL SYNDROME SPECTRUM DISORDER CHILDREN**

**Chp.:** Peter D. Ganime, M.D.

**Participants:** Denise Aloisio, M.D., Grace Hickey, Psy.D., Joanne Dunnigan, M.S.W., Jennifer Smith, Ph.D.

**ISSUE WORKSHOP 86** 11:00 a.m. - 12:30 p.m.  
Room 122, Exhibit Level, Moscone Center

**GOING PUBLIC OVER PATIENT PRIVACY**

**Chp.:** Rodrigo A. Munoz, M.D.

**Participants:** Pamela J. Wright-Etter, M.D., Kevin M. Etter, M.D.

**WEDNESDAY**

**ISSUE WORKSHOP 87** 11:00 a.m. - 12:30 p.m.  
Room 123, Exhibit Level, Moscone Center

**CHILDREN OF PSYCHIATRISTS: INSIGHTS AND RECOMMENDATIONS FROM THOSE WHO KNOW**

**Co-Chps.:** Leah J. Dickstein, M.D., Michelle B. Riba, M.D.  
**Participants:** Cory Butterfield, David Robinowitz, M.D., Barbara Kamholz, M.D.

**ISSUE WORKSHOP 88** 11:00 a.m. - 12:30 p.m.  
Room 304, Esplanade Level, Moscone Center

**INTERNATIONAL PSYCHIATRIC/ PSYCHOPHARMACOLOGICAL ORGANIZATIONS' COLLABORATION**

*Collegium of International Neuropsychopharmacologicum, European College of Neuropsychopharmacology, World Federation of Societies of Biological Psychiatry, and World Psychiatric Association*

**Chp.:** Marcia K. Goin, M.D.  
**Participants:** Paul S. Appelbaum, M.D., Herbert Y. Meltzer, M.D., Yves LeCubrier, M.D., Ahmed Okasha, M.D., Carlos R. Hojaij, M.D.

**12 noon Sessions**

**FORUMS 8-10**

**FORUM 8** 12 noon - 1:30 p.m.  
Room 301, Esplanade Level, Moscone Center

**ABPN UPDATE: REQUIREMENTS FOR ABPN EXAMINATION**

**Chp.:** Stephen C. Scheiber, M.D.  
**Participants:** Michael H. Ebert, Larry R. Faulkner, M.D., Glen C. Davis, M.D., Naleen N. Andrade, M.D., David A. Mrazek, M.D., Burton V. Reifler, M.D., James H. Scully, Jr., M.D., Elizabeth B. Weller, M.D.

**FORUM 9** 12 noon - 1:30 p.m.  
Room 306, Esplanade Level, Moscone Center

**MEANINGFUL ACTIVITIES AND STRUCTURE MATTER: HOW A PREVOCATIONAL PROGRAM HELPS SEVERELY MENTALLY ILL CLIENTS**

**Chp.:** Amelia Truman  
**Participant:** Israel Katz, M.D.

**FORUM 10** 12 noon - 1:30 p.m.  
Golden Gate Hall B, B-2 Level, Marriott

**APA AND THE PHARMACEUTICAL INDUSTRY: CONTROVERSIES AND APPROACHES**

**Chp.:** Stephen M. Goldfinger, M.D.  
**Participants:** Charles R. Goldman, M.D., Geetha Jayaram, M.D., David M. McDowell, M.D., Daniel K. Winstead, M.D.

**NEW RESEARCH POSTER SESSION 8**  
12 noon - 2:00 p.m.  
Hall D, Exhibit Level, Moscone Center

**SCHIZOPHRENIA, SYSTEMS ISSUES, STIGMA, TECHNOLOGY, AND CREATIVELY**

For further information on New Research Sessions, please refer to the *New Research Program Book* included in your registration packet.

**1:00 p.m. Sessions**



**COURSES 95-99**  
Course descriptions are available in the *CME Course Brochure* included in your registration packet. Admission by ticket only.

**COURSE 95** 1:00 p.m. - 5:00 p.m.  
Franciscan Room B, Ballroom Level, Hilton

**MEN SEXUALLY ABUSED AS BOYS: MEANINGS, CONSEQUENCES, AND TREATMENT**

**Director:** Murray D. Schane, M.D.  
**Faculty:** Howard Fradkin, Ph.D., Richard Gartner, Ph.D., William Holmes, M.D., Larry A. Morris, Ph.D.

**COURSE 96** 1:00 p.m. - 5:00 p.m.  
Yosemite Room A, Ballroom Level, Hilton

**THE EVALUATION AND IDENTIFICATION OF THE MAJOR DEMENTIAS**

**Director:** Raymond A. Faber, M.D.  
**Faculty:** Kevin F. Gray, M.D., Randolph B. Schiffer, M.D.

**COURSE 97** 1:00 p.m. - 5:00 p.m.  
Union Square 14, Fourth Floor, Hilton

**PSYCHIATRY AND THE INTERNET**

**Director:** Robert S. Kennedy, M.A.  
**Faculty:** Robert C. Hsiung, M.D., Thomas A.M. Kramer, M.D.



**COURSE 98** 1:00 p.m. - 5:00 p.m.

Union Square 15 & 16, Fourth Floor, Hilton

**UPDATE ON SLEEP MEDICINE: ADVANCED TOPICS**

**Director:** Thomas D. Hurwitz, M.D.

**Faculty:** Max Hirshkowitz, Ph.D., Lois E. Krahn, M.D.

**COURSE 99** 1:00 p.m. - 5:00 p.m.

Union Square 21, Fourth Floor, Hilton

**TREATING MEDICAL STUDENTS AND PHYSICIANS**

**Co-Directors:** Michael F. Myers, M.D., Leah J. Dickstein, M.D.

**2:00 p.m. Sessions**

**LECTURES 20-22**

**LECTURE 20**

2:00 p.m. - 3:30 p.m.

Room 114, Exhibit Level, Moscone Center

**APA'S ALEXANDRA SYMONDS AWARD LECTURE**

**Donna E. Stewart, M.D.**

**International Determinants of Women's Mental Health**

**Chp.:** Sylvia W. Olarte, M.D.

**Co-Chair:** Deborah Spitz, M.D.

Donna E. Stewart, M.D., is the Lillian Love Chair in Women's Health at the University Health Network and the University of Toronto, where she is responsible for research, education, policy, and health service delivery for women's health. She is also Professor in the Faculty of Medicine in the Departments of Psychiatry, Obstetrics/Gynecology, Medicine, Anesthesia, Family and Community Medicine, and Surgery at the University of Toronto. Her research interests are in women's health and mental health, women's health education, psychological aspects of reproductive health, and psychological reactions to physical illness. She is active also in medical education and career development for women health care professionals. She has served as a consultant to Health Canada, the Population Health Council, the National Institutes of Health, and U.S. Public Health Service. A Distinguished Fellow of the American Psychiatric Association, Dr. Stewart formerly chaired the APA Committee on Women and currently chairs the Section of Women's Mental Health for the World Psychiatric Association. She is the author of more than 200 peer-

reviewed publications and co-editor of three books on women's mental health, including *A Clinician's Guide to Menopause*. In 2001 she was appointed Deputy Editor for American Psychiatric Publishing, Inc. **THIS SESSION WILL BE AUDIOTAPED.**

**LECTURE 21**

2:00 p.m. - 3:30 p.m.

Rooms 130/131, Exhibit Level, Moscone Center

**APA AWARD FOR RESEARCH IN PSYCHIATRY**

**Ming T. Tsuang, M.D.**

**Searching for Etiological Risk Factors of Schizophrenia**

**Chp.:** Alan F. Schatzberg, M.D.

**Co-Chp.:** Darrel A. Reiger, M.D.

Ming T. Tsuang, M.D., is Stanley Cobb Professor of Psychiatry and Psychobiology in the Departments of Psychiatry and Epidemiology at Harvard University and Director of the Harvard Institute of Psychiatric Epidemiology and Genetics. His current research aim is to advance the prevention of psychiatric disorders, particularly schizophrenia, by identifying traits that predispose a person to the disorder from both genetic and environmental perspectives. Dr. Tsuang has received numerous awards for his research in schizophrenia, manic-depressive illness, and substance abuse, including the Stanley Dean Award for Research in Schizophrenia, the Noyes Award for Research in Schizophrenia, the National Alliance for Research on Schizophrenia and Depression Distinguished Investigator Award, the Lifetime Achievement Award from the International Society of Psychiatric Genetics, and the Gold Medal Award from the Society of Biological Psychiatry. He is the author or coauthor of more than 400 publications and serves as Editor of *Neuropsychiatric Genetics*, a section of the *American Journal of Medical Genetics*. A Distinguished Life Fellow of the American Psychiatric Association and a Member of the Institute of Medicine, Dr. Tsuang is President-Elect of the American Psychopathological Association. He received his medical degree from National Taiwan University and his doctoral degrees in psychiatric epidemiology and genetics from the University of London.

**THIS SESSION WILL BE AUDIOTAPED.**

LECTURE 22

2:00 p.m. - 3:30 p.m.

Rooms 132/133, Exhibit Level, Moscone Center

Laurence H. Tecott, M.D.

**The Revolution in Mouse Molecular Genetics:  
New Approaches for Psychiatric Research**

Chp.: David H. Taylor, M.D.

Co-Chp.: David M. McDowell, M.D.

A remarkable degree of homology exists between the human and mouse genomes, and humans and mice share many features of brain organization, as well as many similar responses to pharmacological agents and to gene mutations. Laurence H. Tecott, M.D., describes the state of the art in the use of mouse molecular genetic technologies to discern mammalian neural gene function and to model the phenomenology of psychiatric diseases. Dr. Tecott is Associate Professor of Psychiatry and Associate Director of the Center for Neurobiology and Psychiatry at the University of California, San Francisco. He is the author of numerous scientific articles and book chapters and coauthor of the book *Atlas of the Developing Rat Brain*. He has received the March of Dimes Basil O'Connor Scholar Award and both the Young Investigator Award and Independent Investigator Award of the National Alliance for Research on Schizophrenia and Depression. Dr. Tecott received his medical degree from the University of California, San Francisco, where he also completed his residency in psychiatry and a fellowship in psychiatry and pharmacology. He received his doctoral degree in neuroscience from Stanford University in Stanford, California.

Frontiers of Science Lecture Series

THIS SESSION WILL BE AUDIOTAPED.

**REVIEW OF PSYCHIATRY: SECTION 4**

2:00 p.m. - 5:30 p.m.

Room 104, Exhibit Level, Moscone Center

**GERIATRIC PSYCHIATRY**

Chp.: Alan M. Mellow, M.D.

**16 Depression and Anxiety in Late Life**

Alan M. Mellow, M.D.

**17 Dementia**

Myron F. Weiner, M.D.

**18 Late-Life Psychoses**

George T. Grossberg, M.D.

**19 Late-Life Addictions**

Frederic C. Blow, Ph.D.

**20 Geriatric Psychiatry at the Crossroads of Public Policy and Clinical Practice**

Christine M. deVries, M.A.

**SYMPOSIA 60-82**

**SYMPOSIUM 60**

2:00 p.m. - 5:00 p.m.

Room 110, Exhibit Level, Moscone Center

**WORLD PSYCHIATRIC ASSOCIATION'S  
INTERNATIONAL GUIDELINES FOR DIAGNOSTIC  
ASSESSMENT**

Chp.: Juan E. Mezzich, M.D.

Co-Chp.: T. Bedirhan Ustun, M.D.

**A Interviewing and Extended Sources of Information**

Carlos E. Berganza, M.D.

**B Evaluation of Symptoms and Mental Status**

Andrew E. Skodol II, M.D.

**C Standardized and Idiographic Diagnostic Formulation**

Juan E. Mezzich, M.D.

**D Linking Diagnosis to Treatment**

Ahmed Okasha, M.D.

**E A Case Formulation According to the International  
Guidelines for Diagnostic Assessment**

Miguel R. Jorge, M.D.

Discussants: Francis G. Lu, M.D., Lguent Kuey, M.D.

THIS SESSION WILL BE AUDIOTAPED.

**SYMPOSIUM 61**

2:00 p.m. - 5:00 p.m.

Room 111, Exhibit Level, Moscone Center

**DIMENSIONALITY IN PSYCHIATRIC DISORDERS**

Chp.: Stephen B. Shanfield, M.D.

**A A Diagnostic Versus a Dimensional View of Delusions:  
A 20-Year Follow-Up**

Martin Harrow, Ph.D., Ellen S. Herbener, Ph.D., Kalman J. Kaplan, Ph.D., Joseph F. Goldberg, M.D., Eileen M. Martin, Ph.D.

**B Dimensions of Depression and Differential Sensitivity to  
Antidepressants**

Martin M. Katz, Ph.D., Alan Frazer, Ph.D., Charles L. Bowden, M.D.

**C Behavioral Dimensions of Bipolar Disorder**

Charles L. Bowden, M.D.

**D Dimensions of Personality Disorder**

Larry J. Siever, M.D.

**Discussant:** Stephen B. Shanfield, M.D.  
**THIS SESSION WILL BE AUDIOTAPED.**

**SYMPOSIUM 62** **2:00 p.m. - 5:00 p.m.**

Room 112, Exhibit Level, Moscone Center

**WORKPLACE ISSUES IN PSYCHOTHERAPY**

*APA Committee on Psychotherapy by Psychiatrists and APA Committee on APA/Business Relationships*

**Chp.:** Norman A. Clemens, M.D.**A Workplace Issues Are Vital in Psychotherapy**

Norman A. Clemens, M.D.

**B Disability and Psychotherapy**

Marcia A. Scott, M.D.

**C A Psychodynamic Model for Sexual and Other Forms of Workplace Harassment and Violence**

Stuart W. Twemlow, M.D.

**D Psychotherapy and Vocational Rehabilitation in Community Psychiatry**

Linda G. Gochfeld, M.D.

**Discussant:** Daniel B. Borenstein, M.D.  
**THIS SESSION WILL BE AUDIOTAPED.**

**SYMPOSIUM 63** **2:00 p.m. - 5:00 p.m.**

Room 113, Exhibit Level, Moscone Center

**THE NATURE AND TREATMENT OF BDD FROM CLINICIANS' AND PATIENTS' PERSPECTIVES****Chp.:** Fugen Neziroglu, Ph.D.**A An Overview of the Phenomenology and Diagnostic Issues in BDD**

James Claiborn, Ph.D.

**B New Cognitive Interventions for BDD**

Sabine Wilhelm, Ph.D.

**C Behavioral Treatment of BDD**

Fugen Neziroglu, Ph.D.

**D Addiction to Plastic Surgeries in People With BDD**

Eda E. Gorbis, Ph.D.

**E Biological Treatment for BDD**

Jose A. Yaryura-Tobias, M.D.

**Discussants:** Deborah Lowgren, Arie Winograd, M.A.  
**THIS SESSION WILL BE AUDIOTAPED.**

**SYMPOSIUM 64****2:00 p.m. - 5:00 p.m.**

Room 120, Exhibit Level, Moscone Center

**CLINICAL MANAGEMENT OF SCHIZOPHRENIA WITH COMORBID CONDITIONS****Chp.:** Michael Y. Hwang, M.D.**Co-Chp.:** Leslie L. Citrome, M.D.**A Clinical Management of Depression in Schizophrenia**

Samuel G. Siris, M.D.

**B Management of Schizophrenia With Comorbid Anxiety Disorders**

Michael Y. Hwang, M.D., Miklos F. Losonczy, M.D.

**C Schizophrenia and PTSD**

Lewis A. Opler, M.D., Mary Jane Alexander, Kristina H. Muenzenmaier, M.D., Anne-Marie Shelley, Ph.D.

**D Persistent Aggressive Behavior in Schizophrenia: Update 2003**

Leslie L. Citrome, M.D., Jan Volavka, M.D.

**THIS SESSION WILL BE AUDIOTAPED.****SYMPOSIUM 65** **2:00 p.m. - 5:00 p.m.**

Room 121, Exhibit Level, Moscone Center

**NEW RESEARCH AND NOVEL THERAPEUTIC STRATEGIES FOR OCD****Chp.:** Brian A. Fallon, M.D.**A Pharmacologic Strategies for Refractory OCD**

Brian A. Fallon, M.D., Suzanne Feinstein, Ph.D., Franklin R. Schneier, M.D., Raphael Campeas, M.D., Carlos Blanco-Jerez, M.D., Michael R. Liebowitz, M.D.

**B Neurosurgical Approaches to Treatment-Intractable OCD**

Steven A. Rasmussen, M.D., Benjamin D. Greenberg, M.D., George Noren, M.D., Richard Marslano, R.N., Jane L. Eisen, M.D.

**C The Role of Cognitive-Behavioral Therapy in the Treatment of OCD**

H. Blair Simpson, M.D., Michael R. Liebowitz, M.D.

**D Effects of Cognitive Therapy for OCD**

Gail Steketee, Ph.D., Sabine Wilhelm, Ph.D.

**E Kundalini Yoga Meditation for the Treatment of OCD**

David Shannahoff-Khalsa, B.S.

**THIS SESSION WILL BE AUDIOTAPED.**

**SYMPOSIUM 66** 2:00 p.m. - 5:00 p.m.  
**Room 122, Exhibit Level, Moscone Center**

**E-THERAPY, TELEPSYCHIATRY, AND VIRTUAL ENVIRONMENTS: THE EVOLUTION OF CYBERPSYCHIATRY**

**Chp.:** Henry J. Moller, M.D.

**A Frontiers in Psychiatric Computerology**  
James E. Swain, M.D.

**B Overcoming Impediments to Technological Advances in Psychiatry**  
Norman E. Alessi, M.D.

**C Measuring Consciousness: Virtual Environments in the Assessment of Human Performance**  
Henry J. Moller, M.D.

**D Virtual Environment for the Assessment of Attention and Memory Processes**  
Albert A. Rizzo, Ph.D.

**THIS SESSION WILL BE AUDIOTAPED.**

**SYMPOSIUM 67** 2:00 p.m. - 5:00 p.m.  
**Room 123, Exhibit Level, Moscone Center**

**REPLENISHING OURSELVES: SUPPLY OF PSYCHIATRISTS FOR THE PRESENT AND THE FUTURE**

**Chp.:** Nyapati R. Rao, M.D.  
**Co-Chp.:** Frederick S. Sierles, M.D.

**A Current Status of the Psychiatry Workforce in the U.S.**  
Darrel A. Regier, M.D., Joshua E. Wilk, Ph.D., Joyce C. West, Ph.D., Farifteh F. Duffy, Ph.D.

**B Implications of a Need-Based Approach to Psychiatric Workforce**  
Larry R. Faulkner, M.D.

**C Child and Adolescent Psychiatry Workforce: A Critical Shortage and National Challenge**  
Wun-Jung Kim, M.D.

**D School by School Trends in Medical Student Career Choice of Psychiatry, 1999-2001**  
Frederick S. Sierles, M.D., Stephen H. Dinwiddie, M.D., Delia Patroi, M.D., Nutan Atre-Vaidya, M.D., Michael J. Schrift, D.O.

**E Departments of Psychiatry With High Recruitment Into Psychiatry From 1999-2001: Implication for Medical Student Education**  
Darlene Shaw, Ph.D., Frederick S. Sierles, M.D., Joshua T. Thornhill IV, M.D., Kathleen A. Clegg, M.D., Lowell D. Tong, M.D.

**F An Analysis of Recent Trends in Program Size, Program Type, and Demographics in Psychiatric Residency Training and Its Workforce**  
Nyapati R. Rao, M.D.

**Discussant:** Richard A. Cooper, M.D.  
**THIS SESSION WILL BE AUDIOTAPED.**

**SYMPOSIUM 68** 2:00 p.m. - 5:00 p.m.  
**Room 124, Exhibit Level, Moscone Center**

**PTSD: A LATIN-AMERICAN NIGHTMARE**  
*American Society of Hispanic Psychiatry*

**Chp.:** Luis F. Ramirez, M.D.  
**Co-Chp.:** Renato D. Alarcon, M.D.

**A Trauma and PTSD: Some New Concepts**  
Jose M. Canive, M.D.

**B Neurobiological Findings on PTSD**  
Gerardo Villareal, M.D.

**C Resilience: A New Concept**  
Dora Cardona, M.D.

**D Trauma and Debriefing in the Colombian Army**  
Daniel Toledo, M.D.

**E PTSD and PET: The Malvinas Trauma**  
Roxana Galeno, M.D.

**F Comprehensive Management of the Patient With PTSD**  
Renato D. Alarcon, M.D.

**G Psychopharmacology and PTSD**  
Luis F. Ramirez, M.D.  
**THIS SESSION WILL BE AUDIOTAPED.**

**SYMPOSIUM 69** 2:00 p.m. - 5:00 p.m.  
**Room 125, Exhibit Level, Moscone Center**

**MANAGING SUICIDALITY IN BPD**

**Chp.:** Joel F. Paris, M.D.

**A Long-Term Outcome and Suicide in BPD**  
Joel F. Paris, M.D.

**B Suicide Prediction in BPD**  
Donald W. Black, M.D.

**C Chronic Suicidality and BPD**  
Randy A. Sansone, M.D.

**D Liability Issues in Litigation After Suicide**  
Thomas G. Gutheil, M.D.

**E The Application of Dialectical Behavior Therapy to Chronic Suicidality in BPD**  
Marsha M. Linehan, Ph.D.

**Discussant:** Thomas H. McGlashan, M.D.  
**THIS SESSION WILL BE AUDIOTAPED.**

**SYMPOSIUM 70** 2:00 p.m. - 5:00 p.m.  
**Rooms 272/274/276, Mezzanine Level, Moscone Center**

**TERRORISM, WAR, AND REFUGEES: PSYCHIATRIC EFFECTS AND PREVENTION?**

**Chp.:** Nigel M. Bark, M.D.  
**Co-Chp.:** Hamid Ghodse, Ph.D.

**A New York City Childrens' Reactions to Terrorism After 9/11**

Christina Hoven, D.P.H., Cristiane Duarte, Ph.D., Ping Wu, Ph.D., Donald Mandell, Cecile Birner, Julia Mooney, B.A.

**B Terrorism in Nairobi and New York: The Lessons Learned**

Frank G. Njenga, M.D.

**C Violence Against Civilians: A Historical Perspective**

Nasser F. Loza, M.B., Waleed A.R. Fawzi, M.S.C.

**D Mental Health Sequelae of the Lebanon Wars**

Elie G. Karam, M.D., Aimee N. Karam, Ph.D., John A. Fayyad, M.D., Caroline E. Cordahi, DEA, Zeina W. Mneimneh, M.P.H., Nadine Melhem, Ph.D.

**E Transgenerational Transmission of Aggression**

Sam Tyano, M.D.

**F Not Traumatized but Demoralized: Mental Health Needs of Asylum Seekers in Britian**

Patrick J. Bracken, M.D.

**Discussant:** Ezra S. Susser, M.D.  
**THIS SESSION WILL BE AUDIOTAPED.**

**SYMPOSIUM 71** 2:00 p.m. - 5:00 p.m.  
**Room 300, Esplanade Level, Moscone Center**

**NEUROPSYCHIATRIC ASPECTS OF HIV/AIDS: AN OVERVIEW, PART 1**

**Chp.:** Francine Cournos, M.D.

**A HIV Treatment Update**

Paul Volberding, M.D.

**B CNS Manifestations**

Marshall Forstein, M.D.

**C Case Discussion and Clinical Panel**

Warren M. Liang, M.D.

**THIS SESSION WILL BE AUDIOTAPED.**

**SYMPOSIUM 72** 2:00 p.m. - 5:00 p.m.  
**Room 301, Esplanade Level, Moscone Center**

**UNMET NEEDS IN BIPOLAR DISORDER: REDEFINING THE SPECTRUM AND ITS BOUNDARIES**

**Chp.:** Joseph R. Calabrese, M.D.  
**Co-Chp.:** Elie G. Hantouche, M.D.

**A OCD-Bipolar Comorbidity Redefined: Place of Cyclothymia**

Elie G. Hantouche, M.D.

**B The Atypical Depression: Bipolar II Borderline Connection**

Giulio Perugi, M.D., Hagop S. Akiskal, M.D.

**C Early Recognition of Soft-Spectrum Bipolar Disorder in Children**

Eric A. Youngstrom, Ph.D.

**D Eating Disorders and Bipolarity: Clinical and Treatment Issues**

Susan L. McElroy, M.D.

**E Contrasting Early Treatment of Bipolar Disorder With the 2002 APA Guidelines**

Joseph R. Calabrese, M.D., Robert M.A. Hirschfeld, M.D.

**Discussant:** Hagop S. Akiskal, M.D.  
**THIS SESSION WILL BE AUDIOTAPED.**

**SYMPOSIUM 73** 2:00 p.m. - 5:00 p.m.  
**Room 302, Esplanade Level, Moscone Center**

**GLUTAMATE: AN EXCITING NEUROTRANSMITTER**

**Chp.:** Jerrold F. Rosenbaum, M.D.

**A Neuroimaging of Human Glutamatergic Systems**  
John H. Krystal, M.D., Graeme Mason, Ph.D., Aysenil Belger, Ph.D.

**B The Role of Glutamate in Psychiatric Disorders**  
Dennis S. Charney, M.D.

**C Glutamate in Preclinical Models of Anxiety**  
Darryle Schoepp, Ph.D.

**D The Experience With a Glutamate Agonist in GAD**  
Jerrold F. Rosenbaum, M.D.

**THIS SESSION WILL BE AUDIOTAPED.**

**SYMPOSIUM 74** 2:00 p.m. - 5:00 p.m.  
**Room 304, Esplanade Level, Moscone Center**

**COGNITIVE DYSFUNCTION IN BIPOLAR DISORDER**

**Chp.:** Joseph F. Goldberg, M.D.  
**Co-Chp.:** Katherine E. Burdick, Ph.D.

- A Neuropsychological Functioning in Bipolar Disorder**  
Eduard Vieta, M.D., Anabel Martinez-Aran, Ph.D.
- B Psychomotor and Attentional Impairment in Bipolar Disorder**  
Katherine E. Burdick, Ph.D.
- C Working Memory in Bipolar Disorder: Neurocognitive and Functional Imaging Findings**  
Caleb M. Adler, M.D., Stephen M. Strakowski, M.D.
- D Differentiating Bipolar Disorder and ADHD: Comorbidity Versus Single Diagnosis**  
Joseph Biederman, M.D., Janet Wozniak, M.D., Eric Mick, Sc.D., Stephen V. Faraone, Ph.D.

**E Cognitive Side Effects of Mood Stabilizers**  
Joseph F. Goldberg, M.D., Katherine E. Burdick, Ph.D.  
**THIS SESSION WILL BE AUDIOTAPED.**

**SYMPOSIUM 75** 2:00 p.m. - 5:00 p.m.  
**Room 306, Esplanade Level, Moscone Center**

**ROLES FOR PSYCHIATRY IN END-OF-LIFE CARE**

**Chp.:** Maurice D. Steinberg, M.D.  
**Co-Chp.:** Joseph S. Weiner, M.D.

- A Depression at the End-of-Life: Is That all There Is?**  
Michael A. Weitzner, M.D.
- B Meaning-Centered Group Psychotherapy in Advanced Cancer Patients**  
William Breitbart, M.D., Christopher Gibson, Ph.D., Hayley Pessin, Ph.D., Mindy Greenstein, Ph.D., Barry D. Rosenfeld, Ph.D., Alexis Tomarken, M.S.W., Michael Kramer, Ph.D.
- C Complicated Grief: Conceptual Issues, Epidemiology, and Evidence-Based Clinical Implications**  
Holly G. Prigerson, Ph.D.
- D Emotional Barriers to End-of-Life Communication: An Innovative Training for Physicians**  
Joseph S. Weiner, M.D., Debra L. Roter, Ph.D., Steven A. Cole, M.D.
- E Oregon's Death With Dignity Act: Who Chooses Physician-Assisted Suicide?**  
Linda K. Ganzini, M.D., Elizabeth E. Goy, Ph.D.

**Discussant:** Edwin H. Cassem, M.D.

**SYMPOSIUM 76** 2:00 p.m. - 5:00 p.m.  
**Room 307, Esplanade Level, Moscone Center**

**NEW AND PRACTICAL WAYS TO EFFECTIVELY TREAT BORDERLINE PATIENTS**

**Chp.:** John G. Gunderson, M.D.  
**Co-Chp.:** James A. Chu, M.D.

- A A Psychoeducation Program for Borderline Patients**  
Mary C. Zanarini, Ed.D., John G. Gunderson, M.D.
  - B Effectiveness of Inpatient Dialectical Behavioral Therapy for BPD: A Controlled Trial**  
Martin Bohus, M.D.
  - C An Attachment-Theory-Based, Mentalization-Focused Psychotherapy for BPD: Theory and Practice**  
Peter Fonagy, Ph.D.
  - D Split Treatments: From Problem to Asset**  
John G. Gunderson, M.D.
  - E Boundaries, Liability, and Countertransference in the Treatment of BPD**  
Glen O. Gabbard, M.D.
- THIS SESSION WILL BE AUDIOTAPED.**

**SYMPOSIUM 77** 2:00 p.m. - 5:00 p.m.  
**Room 308, Esplanade Level, Moscone Center**

**THE DUAL-DIAGNOSIS CHALLENGE: ASSESSMENT AND TREATMENT**

**Chp.:** Michael B. First, M.D.

- A Using the Psychiatric Research Interview for Substance and Mental Disorders to Diagnose Psychotic Disorders in Substance Users**  
Deborah S. Hasin, Ph.D.
- B Application of the Lead Standard in Dual-Diagnosis Patients**  
Michael B. First, M.D.
- C Differentiating Primary Versus Drug-Induced Persisting Psychosis: Biological Markers**  
Nashaat N. Boutros, M.D.
- D Course of Substance Abuse Among Comorbid Psychotic Patients: Two-Year Follow-Up in First Admission Patients**  
Mark J. Sedler, M.D., Evelyn J. Bromet, Ph.D., Joseph E. Schwartz, Ph.D.
- E Peer Support for the Treatment Resistant: Will It Help?**  
Carol L.M. Caton, Ph.D., Sam Tsemberis, Ph.D., Robert E. Drake, M.D., Mindy J. Fullilove, M.D., Carlos E. Almeida, Jr., M.D., Henry L. McCurtis, M.D., Frederic I. Kass, M.D.

**THIS SESSION WILL BE AUDIOTAPED.**

**SYMPOSIUM 78** 2:00 p.m. - 5:00 p.m.

Room 309, Esplanade Level, Moscone Center

**IS THIS AN ACT OR AN ACT? APPROACHES TO ASSERTIVE COMMUNITY TREATMENT**

Chp.: Hunter L. McQuiston, M.D.

**A Adapting the Assertive Community Treatment Model to Work With Forensic MICA Population in Supported Apartments**

Michelle Des Roches, M.S.W.

**B Assertive Community Treatment With Homeless Individuals**

Ann L. Hackman, M.D.

**C Pathways to Housing: From Streets to Homes: Housing People With Dual Diagnosis Directly From the Streets**

Sam Tsemberis, Ph.D.

**D Assertive Community Treatment in New York: A Platform for Implementing Evidence-Based Practices**

Linda Rosenberg, M.S.W.

Discussant: Ronald J. Diamond, M.D.

**THIS SESSION WILL BE AUDIOTAPED.****SYMPOSIUM 79** 2:00 p.m. - 5:00 p.m.

Room 310, Esplanade Level, Moscone Center

**THE ESSENCE OF LEARNING PSYCHIATRY: CLINICAL SUPERVISION**

Chp.: Pete M. Ellis, B.M.

**A Models of Clinical Supervision**

Peter Burnett, B.M., Alexandra M. Cockram, M.Ed., Pete M. Ellis, B.M., David Burke, Brian Kelly, B.M.

**B Evidence for the Efficacy: Effectiveness of Supervision in Clinical Practice**

Alexandra M. Cockram, M.Ed., Pete M. Ellis, B.M., Brian Kelly, B.M., David Burke, Peter Burnett, B.M.

**C Supervision in Psychiatry Training: Current Status and Limitations**

Brian Kelly, B.M.

**D The Development of a Model for Training and Accrediting Supervisors**

David Burke, Alexandra M. Cockram, M.Ed., Pete M. Ellis, B.M., Brian Kelly, B.M., Peter Burnett, B.M.

**THIS SESSION WILL BE AUDIOTAPED.****SYMPOSIUM 80**

2:00 p.m. - 5:00 p.m.

Golden Gate Hall A, B-2 Level, Marriott

**META-ANALYSES OF THE EFFICACY OF SECOND VERSUS FIRST-GENERATION ANTIPSYCHOTICS**

Chp.: Ira D. Glick, M.D.

Co-Chp.: John M. Davis, M.D.

**A Systematic Reviews of Randomized Trials: The Example of the Atypical Antipsychotics**

John R. Geddes, M.R.C.

**B The Effects of Olanzapine on the Five Dimensions of Schizophrenia Derived by Factor Analysis**

John M. Davis, M.D., Nancy Chen, M.S.

**C Examples of How Meta-Analyses Can Inform Clinical Practice**

Stefan Leucht, M.D., Thomas Barnes, M.D., John M. Kane, M.D., Rolf Engel, Ph.D., Werner Kissling, M.D., Johannes Haman, M.D., Kristian Wahlbeck, M.D.

**D A Meta-Analysis of the Efficacy of Second-Generation Antipsychotics**

Ira D. Glick, M.D., John M. Davis, M.D., Nancy Chen, M.S.

Discussant: Stephen R. Marder, M.D.

**THIS SESSION WILL BE AUDIOTAPED.****SYMPOSIUM 81**

2:00 p.m. - 5:00 p.m.

Golden Gate Hall B, B-2 Level, Marriott

**THE PSYCHOLOGICAL IMPACT OF 9/11: RESULTS FROM FIVE MAJOR STUDIES**

Chp.: Lisa D. Butler, Ph.D.

**A Findings From the National Study of Americans' Reactions to 9/11**

William E. Schlenger, Ph.D., Juesta M. Caddell, Ph.D., Lori Ebert, Ph.D., John A. Fairbank, Ph.D., Richard A. Kulka, Ph.D.

**B A National Longitudinal Study of Psychological Consequences of 9/11**

Bradley D. Stein, M.D., Marc N. Elliott, Ph.D., Lisa H. Jaycox, Ph.D., Rebecca L. Collins, Ph.D., Sandra H. Berry, M.A., Mark A. Schuster, M.D.

**C PTSD in New York City After 9/11**

Sandro Galea, M.D., Heidi S. Resnick, Ph.D., Dean Kilpatrick, Ph.D., Jennifer Ahern, M.P.H., Joel Gold, M.D., Jennifer Stuber, Ph.D., David Vlahov, Ph.D.

**D Prior Tragedy Matters: Cross Community Responses to 9/11**

E. Alison Holman, Ph.D., Roxane Silver, Ph.D., Daniel McIntosh, Ph.D., Michael Poulin, B.A., Virginia Gilrivas, M.A.

*(Continued on next page)*

## WEDNESDAY

---

### **E Psychosocial Predictors of Resiliency in Coping With the Tragedy of 9/11**

Lisa D. Butler, Ph.D., Jay Azarow, Ph.D., Juliette C. Desjardins, M.D., Cheryl Koopman, Ph.D., Sue DiMiceli, B.A., David Spiegel, M.D.

**Discussant:** David Spiegel, M.D.

**THIS SESSION WILL BE AUDIOTAPED.**

---

### **SYMPOSIUM 82** **2:00 p.m. - 5:00 p.m.** **Golden Gate Hall C, B-2 Level, Marriott**

#### **GAY AND LESBIAN PARENTING**

*APA Committee on Gay, Lesbian, and Bisexual Issues*

**Chp.:** Brian N. Kleis, M.D.

**A Children of Gay and Lesbian Parents: Confronting Myths and Stereotypes**  
Ellen Haller, M.D.

**B Legal Issues for Gay and Lesbian Families: Protecting the Children**  
Charles Spiegel, J.D.

**C Gay Caucasian Couples Adopting Biracial Children at Birth**  
Brian N. Kleis, M.D.

**D New Avenues for Gay and Lesbian Parents: Fostering and International Adoptions**  
Margery S. Sved, M.D.

**E Gay Adoption, Stepparents, and Lesbian Moms: A New American Family**  
S. Zev Nathan, M.D.

**Discussant:** Renee L. Binder, M.D.

**THIS SESSION WILL BE AUDIOTAPED.**

---

### **3:00 p.m. Session**

---

#### **NEW RESEARCH POSTER SESSION 9**

**3:00 p.m. - 5:00 p.m.**

**Hall D, Exhibit Level, Moscone Center**

#### **EPIDEMIOLOGY; ADDICTIONS; EATING, ATTENTION SPECTRUM, AND PERSONALITY DISORDERS; CULTURAL, DIAGNOSTIC, CHILD/ADOLESCENT, AND GENDER ISSUES**

For further information on New Research Sessions, please refer to the *New Research Program Book* included in your registration packet.

---

### **7:00 p.m. Sessions**

---

#### **INDUSTRY-SUPPORTED SYMPOSIA 46-52**

##### **INDUSTRY-SUPPORTED SYMPOSIUM 46**

**7:00 p.m. - 10:00 p.m.**

**Gateway Ballroom, Exhibit Level, Moscone Center**

##### **COMPASSIONATE AND SAFE EMERGENT CARE: BEST PRACTICES IN ANTIPSYCHOTIC USE**

*Supported by Janssen Pharmaceutica*

**Chp.:** Glenn W. Currier, M.D.

**A Can Acute Care Be Compassionate?**  
Michael H. Allen, M.D.

**B Can Acute Care Be Compassionate? Provider/Nurse's Perspective**  
Grad Green, M.S.N.

**C Evaluating Equivalence of Antipsychotics: Oral Versus IM Administration for Acute Disorders**  
Glenn W. Currier, M.D.

**D Evidence-Based Medicine and the Evolving Standard of Care: Developing the Treatment Alliance**  
Frederick Vesper, M.D., Joseph J. Zealberg, M.D., Belynda D. Vesper, M.D.

**E Transitioning Patients for Long-Term Success**  
Robert R. Conley, M.D.

**Discussant:** Ira D. Glick, M.D.

##### **INDUSTRY-SUPPORTED SYMPOSIUM 47**

**7:00 p.m. - 10:00 p.m.**

**Hall E, Exhibit Level, Moscone Center**

##### **JUVENILE BIPOLAR DISORDER: CONTEMPORARY ISSUES IN RESEARCH**

*Supported by Novartis Pharmaceuticals Corporation*

**Chp.:** Timothy E. Wilens, M.D.

**A Diagnostic and Treatment Implications of Psychiatric Comorbidity in Juvenile Bipolar Disorder**  
Timothy E. Wilens, M.D.

**B Pediatric Mania: A Developmental Subtype of Bipolar Disorder?**  
Joseph Biederman, M.D., Eric Mick, Sc.D., Stephen V. Faraone, Ph.D., Thomas J. Spencer, M.D., Timothy E. Wilens, M.D., Janet Wozniak, M.D.

**C The Therapeutic Role of Atypical Antipsychotic Medications in Pediatric-Onset Bipolar Disorder**  
Janet Wozniak, M.D.



**D Treatment of Pediatric Bipolar Disorder With Anticonvulsant Mood Stabilizers**

Joseph M. Gonzalez-Heydrich, M.D.

**E Genetics of Early-Onset Bipolar Disorder**

Stephen V. Faraone, Ph.D.

**INDUSTRY-SUPPORTED SYMPOSIUM 48**

7:00 p.m. - 10:00 p.m.

Metropolitan, Second Level, Argent

**CHALLENGES IN DEMENTIA: EVIDENCE-BASED CONSIDERATIONS FROM EARLY DIAGNOSIS TO LONG-TERM MANAGEMENT**

*Supported by Eisai Inc., Pfizer Inc.*

**Chp.:** John H. Greist, M.D.

**A Validated Screening Tools for Dementia**

John H. Greist, M.D.

**B Real World Assessment and Management of Mild Cognitive Impairment: A Case Study**

M. Saleem Ismail, M.D.

**C Issues and Practical Lessons in Clinical Trials in Dementia**

Rachelle S. Doody, M.D.

**D Cholinesterase Inhibitors in Vascular Dementia: A New Treatment Model?**

Stephen P. Salloway, M.D.

**E Strategies for Keeping the Brain Young**

Gary W. Small, M.D.

**INDUSTRY-SUPPORTED SYMPOSIUM 49**

7:00 p.m. - 10:00 p.m.

Grand Ballroom Salon B, Grand Ballroom Level, Hilton

**COMBINED PHARMACOTHERAPY FOR BIPOLAR DISORDERS**

*Supported by GlaxoSmithKline*

**Chp.:** Frederick K. Goodwin, M.D.

**A The Rationale for Combined Pharmacotherapy**

Frederick K. Goodwin, M.D.

**B Potential Synergies in the Mechanisms of Actions of Mood Stabilizers**

L. Trevor Young, M.D.

**C Mood-Stabilizer Combinations: Multimodal Therapy or Polypharmacy?**

Terence A. Ketter, M.D.

**D Antidepressants in Combination Therapy of Bipolar Disorder**

S. Nassir Ghaemi, M.D.

**E Atypical Antipsychotics Combined With Standard Mood Stabilizers for Bipolar Disorder**

Joseph F. Goldberg, M.D.

**INDUSTRY-SUPPORTED SYMPOSIUM 50**

7:00 p.m. - 10:00 p.m.

Continental Ballroom, Ballroom Level, Hilton

**NOVEL THERAPEUTIC OPTIONS FOR PSYCHOTIC DISORDERS**

*Supported by Bristol-Myers Squibb Company*

**Chp.:** Rajiv Tandon, M.D.

**A The Evolution of Antipsychotic Therapy: A Mechanism-Based Evaluation**

W. Wolfgang Fleischhacker, M.D.

**B Limitations of Existing Antipsychotic Therapies**

Rajiv Tandon, M.D.

**C Developments in Antipsychotic Therapy: Real-World Clinical Experience**

Susan M. Maixner, M.D.

**D Emerging Clinical Developments in Schizophrenia and Psychotic Disorders Research**

T. Scott Stroup, M.D.

**INDUSTRY-SUPPORTED SYMPOSIUM 51**

7:00 p.m. - 10:00 p.m.

Salons 7 & 8, Lower B-2 Level, Marriott

**BIPOLAR DISORDER: CLINICAL AND PUBLIC HEALTH IMPLICATIONS OF MEDICAL AND PSYCHIATRIC COMORBIDITY**

*Supported by Ortho-McNeil Pharmaceuticals*

**Chp.:** Paul E. Keck, Jr., M.D.

**A Treatment Approaches for Managing Anxiety Disorder in the Bipolar Patient**

Patricia Suppes, M.D.

**B The Challenge of Treating Bipolar Disorder and Substance Abuse**

Mark A. Frye, M.D.

**C New Treatment Options for Eating Disorders and Obesity With Comorbid Bipolar Disorder**

Shishuka Malhotra, M.D.

**D Influence of Medical Comorbidities on Treatment Approaches in Bipolar Patients**

John L. Beyer, M.D.

**E Gender and Bipolar Disorder**

Lori L. Altshuler, M.D., Mark A. Frye, M.D.

**INDUSTRY-SUPPORTED SYMPOSIUM 52**

7:00 p.m. - 10:00 p.m.

Salon 9, Lower B-2 Level, Marriott

**STRIVING TO HEAL THE MIND: THE CHALLENGE OF PTSD**

*Supported by Wyeth Pharmaceuticals*

**Chp.:** Martin B. Keller, M.D.

**A The Global Burden of PTSD: Results From the World Health Organization International Consortium on Psychiatric Epidemiology**

Ronald C. Kessler, Ph.D.

**B Exposure to Stress and Trauma Across the Life Span: Neurobiological Consequences**

Linda L. Carpenter, M.D.

**C Early Intervention for PTSD Prophylaxis in Trauma Survivors: Emerging Evidence**

Arieh Y. Shalev, M.D.

**D Healing the Mind: Therapeutic Approaches for Chronic PTSD**

Barbara O. Rothbaum, Ph.D.

**E Medicines That Heal the Mind: Pharmacological Approaches for PTSD**

Jonathan R.T. Davidson, M.D.



# THURSDAY, MAY 22, 2003

## 156TH ANNUAL MEETING

### 7:00 a.m. Sessions

#### PART 2 OF INDUSTRY-SUPPORTED BREAKFAST SYMPOSIA 42-45

#### INDUSTRY-SUPPORTED BREAKFAST SYMPOSIUM 42, PART 2

7:00 a.m. - 8:30 a.m.

Gateway Ballroom, Exhibit Level, Moscone Center

#### NEUROPSYCHIATRY IN THE AGE OF POLYPHARMACY

*Supported by Janssen Pharmaceutica*

**Chp.:** Prakash S. Masand, M.D.

#### A Polypharmacy in the Treatment of Major Depression

Mark H. Rapaport, M.D.

#### B Combination Therapy for Alzheimer's Disease: What Are We Waiting for?

P. Murali Doraiswamy, M.D.

#### INDUSTRY-SUPPORTED BREAKFAST SYMPOSIUM 43, PART 2

7:00 a.m. - 8:30 a.m.

Hall E, Exhibit Level, Moscone Center

#### TREATING ADHD ACROSS THE LIFE CYCLE

*Supported by Novartis Pharmaceuticals Corporation*

**Chp.:** Thomas J. Spencer, M.D.

**Co-Chp.:** Joseph Biederman, M.D.

#### A ADHD in Adults: Developmental Issues in Clinical Presentations

Thomas J. Spencer, M.D.

#### B Treatment Options: Evolving Treatments for a Changing Disease

Joseph Biederman, M.D.

**Discussants:** Michael Sanders, M.D., Betty Jo Salmeron, M.D.

#### INDUSTRY-SUPPORTED BREAKFAST SYMPOSIUM 44, PART 2

7:00 a.m. - 8:30 a.m.

Grand Ballroom Salon B, Grand Ballroom Level, Hilton

#### INSOMNIA IN TODAY'S SOCIETY: CONSEQUENCES AND TREATMENTS

*Supported by Sanofi-Synthelabo, Inc.*

**Chp.:** Gregory M. Asnis, M.D.

**Co-Chp.:** Shari Kohn, Ph.D.

#### A Cognitive-Behavioral Therapy of Insomnia

Shari Kohn, Ph.D.

#### B When to Refer a Patient With Insomnia to a Sleep Specialist Laboratory

Michael Thorpy, M.D.

#### INDUSTRY-SUPPORTED BREAKFAST SYMPOSIUM 45, PART 2

7:00 a.m. - 8:30 a.m.

Salons 7 & 8, Lower B-2 Level, Marriott

#### OBESITY IN PSYCHIATRIC PRACTICE: RECOGNITION AND TREATMENT

*Supported by Ortho-McNeil Pharmaceuticals*

**Chp.:** B. Timothy Walsh, M.D.

#### A Psychological Treatment of Obesity and Binge Eating

Denise E. Wilfley, Ph.D.

#### B Pharmacotherapy of Obesity and Binge Eating

Susan L. McElroy, M.D.

### 8:00 a.m. Sessions



#### COURSES 100-102

Course descriptions are available in the *CME Course Brochure* included in your registration packet. Admission by ticket only.

#### COURSE 100

8:00 a.m. - 12 noon

Franciscan Room D, Ballroom Level, Hilton

#### RECOVERY FROM MENTAL ILLNESS AND STIGMA: INTEGRATION OF MEDICINE AND RECOVERY

**Director:** Eugene A. Oulvey, Ph.D.

**Faculty:** Shyam K. Bhat, M.D., Thomas O. Osinowo, M.D.,  
Denise Sommers, M.A., Karen L. Lee, M.A., Vivek Jain, M.D.

#### COURSE 101

8:00 a.m. - 12 noon

Yosemite Room C, Ballroom Level, Hilton

#### SEXUAL DISORDERS: DIAGNOSIS AND TREATMENT

**Director:** Waguih W. Ishak, M.D.

**Faculty:** Marina Bussel, M.D., Richard N. Chenik, J.D., Sofia  
M. Encamacion, M.D., Maria D.M. Leonido-Yee, M.D., Uri P.  
Peles, M.D., Henrik Zakari, M.D.

## THURSDAY

**COURSE 102** **8:00 a.m. - 12 noon**  
Union Square 14, Fourth Floor, Hilton

### ASSESSMENT AND TREATMENT OF DRUG-INDUCED MOVEMENT DISORDERS

**Co-Directors:** Herman M. Van Praag, M.D., Jaap B. Bakker, Ph.D.  
**Faculty:** Anton J.M. Loonen, M.D.

## 9:00 a.m. Sessions

### CLINICAL CASE CONFERENCE 4

9:00 a.m. - 10:30 a.m.

Room 121, Exhibit Level, Moscone Center

### DEALING WITH DIAGNOSTIC AMBIGUITY: WHEN SOMATIC MEMORY AND ANXIETY SYMPTOMS CONFUSE

**Moderator:** Jayne M. Stevenson, M.D.

**Discussant:** Joel Yager, M.D.

**THIS SESSION IS OPEN TO APA MEMBERS ONLY. BLUE REGISTRATION BADGE OR APA MEMBERSHIP CARD REQUIRED FOR ADMITTANCE.**

### CONTINUOUS CLINICAL CASE CONFERENCE 2: PART 2

9:00 a.m. - 12 noon

Room 120, Exhibit Level, Moscone Center

### A CASE OF MURDER AND DISSOCIATIVE IDENTITY DISORDER: REAL OR MALINGERED MENTAL ILLNESS?

**Moderator:** Britta Ostermeyer, M.D.

**Presenters:** Thomas G. Cobb, M.D., Renee M. Sorrentino, M.D., Richard P. Kluft, M.D., Phillip J. Resnick, M.D.

**THIS SESSION IS OPEN TO APA MEMBERS ONLY. BLUE REGISTRATION BADGE OR APA MEMBERSHIP CARD REQUIRED FOR ADMITTANCE.**

### DISCUSSION GROUP 25

9:00 a.m. - 10:30 a.m.

This session is limited to 25 participants on a first-come, first-served basis.

**A. John Rush, M.D.**, on Relevance of Treatment Algorithms in Clinical Care  
Pacific Conference Suite C, 4th Floor, Marriott

### LECTURE 23

9:00 a.m. - 10:30 a.m.

Rooms 132/133, Exhibit Level, Moscone Center

### APA'S KUN-PO SOO AWARD LECTURE

Masahisa Nishizono, M.D.

Remembering the Past and Living in the Now:  
Modernization in East Asian Countries and  
Psychotherapy

Chp.: John Luo, M.D.

Masahisa Nishizono, M.D., is Professor of Psychiatry and former Dean at Fukuoka University School of Medicine in Fukuoka, Japan. A pioneer in integrating community mental health care with hospital-based treatment in Japan, Dr. Nishizono is the author of more than 250 scientific articles and book chapters and the author or editor of several books. He has held several leadership positions in Japanese and international psychiatric and psychoanalytic societies, including the Presidency of the Japanese Society of Psychiatry and Neurology, the Japanese Psychoanalytical Association, the Japanese Psychoanalytical Society, and the Japanese Association for Emergency Psychiatry. Dr. Nishizono has been an active proponent of international collaboration in psychiatry and has served as President of the Pacific Rim College of Psychiatrists, the Association for Medical Education in the Western Pacific Region, and the Asian Society for Child and Adolescent Psychiatry and Allied Professions. A Corresponding Fellow of the American Psychiatric Association and a Fellow of the American Academy of Psychoanalysis, Dr. Nishizono has received numerous awards for his contributions to medical education and biopsychosocial treatment, including the Alexander Gralnick Award from the American Association for Psychosocial Rehabilitation.

**THIS SESSION WILL BE AUDIOTAPED.**

## WORKSHOPS

### COMPONENT 39-42

**COMPONENT WORKSHOP 39** **9:00 a.m. - 10:30 a.m.**

Room 308, Esplanade Level, Moscone Center

### NEVER-TAUGHT DILEMMAS: WHEN WORK AND DISABILITY ISSUES IMPACT PATIENT CARE

*APA Corresponding Committee on Psychiatry in the Workplace*

**Co-Chps.:** Steven E. Pflanz, M.D., Marcia A. Scott, M.D.

**Participants:** Daniel B. Borenstein, M.D., Jacquelyn B. Chang, M.D., Harry Prosen, M.D.

**COMPONENT WORKSHOP 40** 9:00 a.m. - 10:30 a.m.  
Salons 14 & 15, Lower B-2 Level, Marriott

**SUMMARY OF THE SURGEON GENERAL'S MEETING  
ON HEALTH OF THE MENTALLY RETARDED**

*APA Committee on Children with Mental or Developmental Disorders*

**Chp.:** Roxanne C. Dryden-Edwards, M.D.  
**Participants:** Carl B. Feinstein, M.D., Paula J. Lockhart, M.D.,  
Stephen B. Corbin, D.D.S., Timothy Shriver, Ph.D.

**COMPONENT WORKSHOP 41** 9:00 a.m. - 10:30 a.m.  
Golden Gate Hall A, B-2 Level, Marriott

**THE ADMINISTRATIVE PSYCHIATRY CREDENTIAL**

*APA Committee on Psychiatric Administration and Management*

**Chp.:** Stuart B. Silver, M.D.  
**Participants:** Paul Rodenhauer, M.D., S. Atezas Saeed, M.D.,  
Veena Garyali, M.D., Beth Ann Brooks, M.D.

**COMPONENT WORKSHOP 42** 9:00 a.m. - 10:30 a.m.  
Pacific Conference Suite H, 4th Floor, Marriott

**PRACTICING REWARDING PSYCHIATRY IN JAILS  
AND PRISONS: A PRACTICUM**

*APA Caucus of Psychiatrists Working in Correctional Settings*

**Chp.:** Henry C. Weinstein, M.D.  
**Participants:** Kathryn A. Burns, M.D., Kenneth G. Gilbert, M.D.,  
Annette L. Hanson, M.D., John S. Zil, M.D.

**ISSUES 89-110**

**ISSUE WORKSHOP 89** 9:00 a.m. - 10:30 a.m.  
Room 110, Exhibit Level, Moscone Center

**TEACHING PSYCHIATRIC ETHICS ENGAGINGLY,  
EFFECTIVELY**

*Association for Academic Psychiatry*

**Chp.:** Laura W. Roberts, M.D.

**ISSUE WORKSHOP 90** 9:00 a.m. - 10:30 a.m.  
Room 111, Exhibit Level, Moscone Center

**NEUROBIOLOGY OF LEARNING: MOVING FROM  
THE IVORY TOWER INTO THE CLASSROOM**

**Chp.:** Janet E. Osterman, M.D.

**ISSUE WORKSHOP 91** 9:00 a.m. - 10:30 a.m.  
Room 112, Exhibit Level, Moscone Center

**THE USES AND ABUSES OF PSYCHIATRIC  
INDEPENDENT MEDICAL EXAMINATIONS: AN  
ETHICAL DILEMMA?**

**Chp.:** Landy F. Sparr, M.D.  
**Participant:** Michael D. Freeman, Ph.D.

**ISSUE WORKSHOP 92** 9:00 a.m. - 10:30 a.m.  
Room 113, Exhibit Level, Moscone Center

**BEYOND THE CHALK BOARD: USING  
COMPUTERS TO ENHANCE PSYCHIATRIC  
EDUCATION**

**Chp.:** Sudha Prathikanti, M.D.  
**Participant:** Lee A. Rawitscher, M.D.

**ISSUE WORKSHOP 93** 9:00 a.m. - 10:30 a.m.  
Room 114, Exhibit Level, Moscone Center

**SPECIFIC PSYCHOTHERAPEUTIC TECHNIQUES  
FOR ADOLESCENTS**

**Chp.:** Eva M. Szigethy, M.D.  
**Participants:** Barbara L. Milrod, M.D., Lena Verdeli, Ph.D.

**ISSUE WORKSHOP 94** 9:00 a.m. - 10:30 a.m.  
Room 122, Exhibit Level, Moscone Center

**PSYCHIATRIC TREATMENT AND PERSONAL  
GROWTH: WHAT ABOUT US?**

**Co-Chps.:** Michael F. Myers, M.D., Leah J. Dickstein, M.D.  
**Participants:** Francine Cournos, M.D., Carl C. Bell, M.D.,  
Margery S. Sved, M.D.

**ISSUE WORKSHOP 95** 9:00 a.m. - 10:30 a.m.  
Room 123, Exhibit Level, Moscone Center

**A PROGRAM TO ENHANCE CULTURAL  
COMPETENCY IN RESIDENCY TRAINING**

**Chp.:** Hinda F. Dubin, M.D.  
**Participants:** Lisa D. Green-Paden, M.D., Theodora G.  
Balis, M.D.

**ISSUE WORKSHOP 96** 9:00 a.m. - 10:30 a.m.  
Room 124, Exhibit Level, Moscone Center

**CLINICAL MANAGEMENT OF DIFFICULT  
SCHIZOPHRENIA**

**Co-Chps.:** Michael Y. Hwang, M.D., Miklos F. Losonczy, M.D.  
**Participants:** Samuel G. Siris, M.D., Faiq A. Hameedi, M.D.,  
Naveed Iqbal, M.D.

**THURSDAY**

---

**ISSUE WORKSHOP 97** 9:00 a.m. - 10:30 a.m.  
**Room 125, Exhibit Level, Moscone Center**

**CD-ROMS FOR DUMMIES: A STEP-BY-STEP GUIDE FOR DEVELOPING EDUCATIONAL CDS**

**Chp.:** Kristi S. Williams, M.D.  
**Participants:** Marijo B. Tamburrino, M.D., Cindy J. Stengle, B.B.A.

**ISSUE WORKSHOP 98** 9:00 a.m. - 10:30 a.m.  
**Rooms 272/274/276, Mezzanine Level, Moscone Center**

**MAKING THE MEDIA WORK FOR YOU**

**Chp.:** Nada L. Stotland, M.D.

**ISSUE WORKSHOP 99** 9:00 a.m. - 10:30 a.m.  
**Room 300, Esplanade Level, Moscone Center**

**THE EMPATHIC HEALER: ARTIST OR SCIENTIST?**

**Chp.:** Michael J. Bennett, M.D.

**ISSUE WORKSHOP 100** 9:00 a.m. - 10:30 a.m.  
**Room 301, Esplanade Level, Moscone Center**

**TREATING ADDICTION: MEETING NEW NEEDS IN A NEW WORLD**

**Chp.:** Richard J. Frances, M.D.  
**Participants:** Sheila B. Blume, M.D., Sheldon I. Miller, M.D., Marc Galanter, M.D., Robert B. Millman, M.D., Lionel P. Solursh, M.D., Frances R. Levin, M.D.

**ISSUE WORKSHOP 101** 9:00 a.m. - 10:30 a.m.  
**Room 302, Esplanade Level, Moscone Center**

**PSYCHODYNAMICS IN TREATMENT-REFRACTORY DEPRESSION**

**Co-Chps.:** Eric M. Plakun, M.D., Edward R. Shapiro, M.D.  
**Participant:** David L. Mintz, M.D.

**ISSUE WORKSHOP 102** 9:00 a.m. - 10:30 a.m.  
**Room 304, Esplanade Level, Moscone Center**

**BRIDGES FOR HEALING: INTEGRATING FAMILY THERAPY AND PSYCHOPHARMACOLOGY**

**Chp.:** Roy O. Resnikoff, M.D.

**ISSUE WORKSHOP 103** 9:00 a.m. - 10:30 a.m.  
**Room 306, Esplanade Level, Moscone Center**

**MAKING TELEPSYCHIATRY MEDIA WORK FOR YOU**

**Co-Chps.:** Debra A. Katz, M.D., Rob Sprang, M.B.A.  
**Participants:** Timothy S. Allen, M.D., Shari G. Sistrunk, M.D.

**ISSUE WORKSHOP 104** 9:00 a.m. - 10:30 a.m.  
**Room 309, Esplanade Level, Moscone Center**

**DYSMORPHOLOGIES: RECOGNITION AND TREATMENT**

**Co-Chps.:** Syed S. A. Naqvi, M.D., Jeremy E. Revell, M.D.  
**Participant:** Robb Saito, M.D.

**ISSUE WORKSHOP 105** 9:00 a.m. - 10:30 a.m.  
**Room 310, Esplanade Level, Moscone Center**

**PSYCHIATRIC DISABILITY: THE ROLE OF PSYCHIATRIC ASSESSMENT**

**Chp.:** Edward A. Volkman, M.D.  
**Participant:** Janice Volkman, J.D.

**ISSUE WORKSHOP 106** 9:00 a.m. - 10:30 a.m.  
**Salons 1 & 2, Lower B-2 Level, Marriott**

**THE MEANING OF THE PACIFIC RIM FOR WORLD AND AMERICAN PSYCHIATRY**

*Pacific Rim College of Psychiatrists*

**Co-Chps.:** Francis G. Lu, M.D., Bruce Singh, M.D.  
**Participants:** Ching-Piao Chien, M.D., Robert O. Pasnau, M.D., Milton H. Miller, M.D.

**ISSUE WORKSHOP 107** 9:00 a.m. - 10:30 a.m.  
**Salons 3 & 4, Lower B-2 Level, Marriott**

**AN UPDATE ON MANAGEMENT OF SUICIDE ATTEMPTS: A REVIEW FOR CLINICIANS**

**Co-Chps.:** Jose de Leon, M.D., Maria A. Oquendo, M.D.  
**Participants:** Jeronimo Saiz-Ruiz, M.D., Enrique Baca-Garcia, M.D.

**ISSUE WORKSHOP 108** 9:00 a.m. - 10:30 a.m.  
**Salons 5 & 6, Lower B-2 Level, Marriott**

**ADHERENCE TO HIV MEDICATIONS IN THE PSYCHIATRICALY ILL: NEW FINDINGS**

**Chp.:** Dan H. Karasic, M.D.  
**Participants:** David Bangsberg, M.D., Joshua Bamberger, M.D., James L. Sorensen, Ph.D.

**ISSUE WORKSHOP 109** 9:00 a.m. - 10:30 a.m.  
**Salons 10 & 11, Lower B-2 Level, Marriott**

**INPATIENT VIOLENCE: LESSONS FROM THE INNER-CITY PSYCHIATRY HOSPITAL**

**Chp.:** Jeffrey M. Levine, M.D.  
**Participants:** Ali Khadivi, Ramon C. Patel, M.D., Merrill R. Rotter, M.D.

**ISSUE WORKSHOP 110** 9:00 a.m. - 10:30 a.m.  
Golden Gate Hall C, B-2 Level, Marriott

**PSYCHIATRIC CARE OF MUSLIM PATIENTS: A U.S. PERSPECTIVE**

**Co-Chps.:** Arif M. Shoaib, M.D., Pedro Ruiz, M.D.  
**Participants:** Syed A. Husain, M.D., Ayesha Mian, M.D.,  
Mohammad F. Danish, M.D.

**11:00 a.m. Sessions**

**DISCUSSION GROUP 26**

11:00 a.m. - 12:30 p.m.

This session is limited to 25 participants on a first-come, first-served basis.

**Larry E. Tune, M.D.**, on Delirium and Dementia  
Pacific Conference Suite C, 4th Floor, Marriott

**LECTURE 24**

11:00 a.m. - 12:30 p.m.

Rooms 130/131, Exhibit Level, Moscone Center

**APA'S SOLOMON CARTER FULLER AWARD LECTURE**

**James H. Carter, M.D.**

**Culture/Racism and Ethnic Diversity With Past Corrective Actions, Successes, and Failures**

**Chp.:** Michelle O. Clark, M.D.

James H. Carter, M.D., is Professor in the Department of Psychiatry and Behavioral Sciences at Duke University School of Medicine in Durham, North Carolina. He is also Senior Consulting Psychiatrist and Co-Founder of the Social Work-Mental Health Unit at Lincoln Community Health Center in Durham and Medical Director of the judicial substance abuse program South Light in Raleigh, North Carolina. He has written numerous scientific papers and is the author of two books, *Psychosocial Intervention With Aged African Americans* and *Death and Dying Among African Americans*. A Distinguished Life Fellow of the American Psychiatric Association, Dr. Carter is a recipient of the Order of the Long Leaf Pine, the highest honor given to North Carolina citizens for service to the people of the state. In 1994, the annual James H. Carter, Sr., Lecture Series, which provides a forum for cross-cultural issues, was endowed in his honor at Duke University. Dr. Carter received his medical degree from Howard University

College of Medicine in Washington, D.C., and completed his residency in psychiatry and a research fellowship in community and social psychiatry at Duke University Medical Center. Dr. Carter received his Master of Divinity degree from Shaw University Divinity School in Raleigh.  
**THIS SESSION WILL BE AUDIOTAPED.**

**MEDICAL UPDATE 4**

11:00 a.m. - 12:30 p.m.

Room 300, Esplanade Level, Moscone Center

**CLUB DRUGS: A PRIMER FOR MENTAL HEALTH PROFESSIONALS**

**Chp.:** Julie K. Schulman, M.D.

**Presenter:** David Smith, M.D.

**THIS SESSION WILL BE AUDIOTAPED.**

**SCIENTIFIC AND CLINICAL REPORT SESSIONS 29-40**

**SCIENTIFIC AND CLINICAL REPORT SESSION 29**

11:00 a.m. - 12:30 p.m.

Room 110, Exhibit Level, Moscone Center

**SECONDARY OUTCOMES IN ADHD**

**Chp.:** Lois T. Flaherty, M.D.

**Co-Chp.:** Nang Du, M.D.

11:00 a.m.

**86 Consistency of ADHD Parent/Teacher Symptom**

**Reports: Results of OROS MPH Studies**

Stephen V. Faraone, Ph.D.

11:30 a.m.

**87 Patient and Parent Satisfaction of Once-Daily OROS MPH Formulation for ADHD**

Mark A. Stein, Ph.D.

12 noon

**88 Driving Performance Among Adolescents With ADHD: Medication Effects**

Daniel J. Cox, Larry Merkel

**THIS SESSION WILL BE AUDIOTAPED.**

**SCIENTIFIC AND CLINICAL REPORT SESSION 30**

11:00 a.m. - 12:30 p.m.

Room 111, Exhibit Level, Moscone Center

**ETHICAL ISSUES IN THE TREATMENT OF PSYCHOSIS**

**Chp.:** Scott Y. Kim, M.D.

**Co-Chp.:** David Y. Kan, M.D.

11:00 a.m.

**89 Factors Associated With Determining Competence to Consent in Acute Psychoses**

Nicholas A. Keks, M.D., Vivienne Howe, Kellie M. Foister, Kym Jenkins, M.D., David L. Copolov, M.D.

11:30 a.m.

**90 Ethical Challenges of Managing Pregnant Patients Who Have Schizophrenia**

John H. Coverdale, M.D., Laurence B. McCullough, Ph.D., Frank A. Chervenak, M.D.

12 noon

**91 Schizophrenia and Suicide in the Managed Care Era**

Bentson H. McFarland, M.D., Lara Davis, B.S., Jo Mahler, M.A.

**THIS SESSION WILL BE AUDIOTAPED.**

**SCIENTIFIC AND CLINICAL REPORT SESSION 31**

11:00 a.m. - 12:30 p.m.

Room 125, Exhibit Level, Moscone Center

**ALCOHOL AND DRUG-RELATED DISORDERS**

**Chp.:** Petros Levounis, M.D.

**Co-Chp.:** Kewchang Lee, M.D.

11:00 a.m.

**92 Impulsivity, Sensation Seeking, and Coping Styles Among Substance Abusers**

Kevin P. Hill, M.D., Ashwin A. Patkar, M.D., Charles C. Thornton, Ph.D., Edward Gottheil, M.D., Anup M. Desai, M.D., Heather W. Murray, B.A., Michael J. Vergare, M.D.

11:30 a.m.

**93 Substance Abuse Disorders and History of Childhood Sexual Abuse in a Population of U.S. Veterans**

Jehangir B. Bastani, M.D., Martin Mellstrom, Ph.D., Vicki A. Alberts, M.D.

12 noon

**94 Attachments for In-Treatment Alcoholics and Teens Predicted to Be Addicts**

Marc A. Lindberg, Ph.D., Stuart Thomas, Ph.D.

**THIS SESSION WILL BE AUDIOTAPED.**

**SCIENTIFIC AND CLINICAL REPORT SESSION 32**

11:00 a.m. - 12:30 p.m.

Rooms 272/274/276, Mezzanine Level, Moscone Center

**AIDS AND HIV-RELATED DISORDERS**

**Chp.:** Frederick N. Parris, M.D.

**Co-Chp.:** Lishan Workeneh, M.D.

11:00 a.m.

**95 Psychiatric Effects Associated With Efavirenz: A Retrospective Study**

Talia Puzantian, Pharm.D., Jeannie Lee, Pharm.D., Regina J. Lee, Pharm.D., Janice Wong, Pharm.D., Li Liu, M.D., Dan H. Karasic, M.D.

11:30 a.m.

**96 PTSD and Acute Stress Reactions to Recent Life Events Among HIV Positive Persons**

Cheryl Koopman, Ph.D., Cheryl Gore-Felton, Ph.D., Negar Azimi, B.A., Kristian O'Shea, Rachel Power, Ph.D., Dennis M. Israelski, M.D., David Spiegel, M.D.

12 noon

**97 Use of Marijuana to Manage Distress Symptoms Among HIV-Infected Persons**

Diane Prentiss, M.A., Rachel Power, Ph.D., Gladys Balmas, M.P.H., Dennis M. Israelski, M.D.

**THIS SESSION WILL BE AUDIOTAPED.**

**SCIENTIFIC AND CLINICAL REPORT SESSION 33**

11:00 a.m. - 12:30 p.m.

Room 302, Esplanade Level, Moscone Center

**ADJUNCTIVE TREATMENTS IN SCHIZOPHRENIA**

**Chp.:** Charles S. Price, M.D.

**Co-Chp.:** Susan I. Hobbins

**98 -WITHDRAWN**

11:00 a.m.

**99 Rivastigmine and Glantamine Treatment for Schizophrenic Cognitive Impairment**

Mohammad Z. Hussain, M.D., Zubaida A. Chaudhry, M.D.

11:45 a.m.

**100 Modafinil as Adjunct Treatment in Schizophrenia: An Open-Label Study**

Murray H. Rosenthal, D.O., Sharon Bryant, Ph.D.

**THIS SESSION WILL BE AUDIOTAPED.**



**SCIENTIFIC AND CLINICAL REPORT SESSION 34**

11:00 a.m. - 12:30 p.m.

Room 308, Esplanade Level, Moscone Center

**WOMEN'S HEALTH****Chp.:** Susan Stabinsky, M.D.**Co-Chp.:** Caroline E. Fisher, M.D.

11:00 a.m.

**101 Sertraline Prevents Postpartum Depression**Katherine L. Wisner, M.D., Kathleen S. Peindl, Ph.D.,  
James M. Perel, Ph.D., Barbara H. Hanusa, Ph.D.,  
Catherine M. Plontek, M.D., Robert L. Findling, M.D.

11:30 a.m.

**102 Depressed Women Have Elevated Coagulation Factors in Mid Life**Ruby Castilla-Puentes, M.D., Zhang Yangang, M.S., Joyce T.  
Bromberger, Ph.D., James M. Perel, Ph.D., Karen A.  
Matthews, Ph.D.

12 noon

**103 HRT With Androgens as a Strategy to Treat Postmenopausal Depression**Rodrigo Dias, M.D., Florence Kerr-Correa, M.D., Luzia A.  
Trinca, Ph.D., Ricardo A. Moreno, M.D., Anagloria  
Pontes, M.D., Hans W. Halbe, M.D.**THIS SESSION WILL BE AUDIOTAPED.****SCIENTIFIC AND CLINICAL REPORT SESSION 35**

11:00 a.m. - 12:30 p.m.

Salons 3 &amp; 4, Lower B-2 Level, Marriott

**BIPOLAR DISORDERS****Chp.:** Patricia Suppes, M.D.**Co-Chp.:** Neha Bahadur, M.D.

11:00 a.m.

**104 Bipolar Disorder Treatment: Critical Synthesis of Guidelines and Algorithms**

Heinz C. Grunze, M.D.

11:30 a.m.

**105 Rapid-Cycling Bipolar Disorder: Focus on Treatment**Joseph F. Goldberg, M.D., S. Nassir Ghaemi, M.D., Martin  
Harrow, Ph.D.

12 noon

**106 Mood Stabilizers: Standard, New, and Putative**

Eduard Vieta, M.D., Anabel Martinez-Aran, Ph.D.

**THIS SESSION WILL BE AUDIOTAPED.****SCIENTIFIC AND CLINICAL REPORT SESSION 36**

11:00 a.m. - 12:30 p.m.

Salons 5 &amp; 6, Lower B-2 Level, Marriott

**VIOLENCE, TRAUMA, AND VICTIMIZATION****Chp.:** Jeffrey M. Friend, M.D.**Co-Chp.:** Keith McBurnett, Ph.D.

11:00 a.m.

**107 Treatment Outcome for Sexually Abused Children at One-Year Follow-Up**Judith A. Cohen, M.D., Anthony P. Mannarino, Ph.D.,  
Kraig Knudsen, M.P.H.

11:30 a.m.

**108 Psychological Symptoms Six Years After a Plane Crash**Christoffel J. Yzermans, Ph.D., Ge A. Donker, M.D.,  
Hiske E. Becker, M.D.

12 noon

**109 San Francisco Third Graders After 9/11: Three Windows to Healing**

Lenore C. Terr, M.D.

**SCIENTIFIC AND CLINICAL REPORT SESSION 37**

11:00 a.m. - 12:30 p.m.

Salons 12 &amp; 13, Lower B-2 Level, Marriott

**ISSUES IN THE TREATMENT OF DEPRESSION AND SEXUAL DYSFUNCTIONS****Chp.:** Thomas N. Wise, M.D.**Co-Chp.:** Eric R. Williams, M.D.

11:00 a.m.

**110 Maintaining Compliance and Remission in MDD With Sildenafil Prescription for SSRI-SD**

H. George Nurnberg, M.D., Paula L. Hensley, M.D.

11:30 a.m.

**111 Efficacy and Safety of Sildenafil Citrate in Men With Serotonergic-Antidepressant-Associated Erectile Dysfunction: Results of a Prospective, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial**Maurizio Fava, M.D., H. George Nurnberg, M.D., Stuart N.  
Seidman, M.D., Willis Holloway, Jr., M.D., Mildred  
Farmer, M.D., Susan Nicholas, Vera Stecher, Ph.D.

12 noon

**112 Pretreatment Characteristics of Placebo Response in Major Depression**Andrew F. Leuchter, M.D., Melinda Morgan, Ph.D., Ian A.  
Cook, M.D., Michelle Abrams, R.N., Jennifer Dunkin, Ph.D.,  
Elise Witte, Ph.D., Scott D. Greenwald, Ph.D.**THIS SESSION WILL BE AUDIOTAPED.****SCIENTIFIC AND CLINICAL REPORT SESSION 38**

11:00 a.m. - 12:30 p.m.

Golden Gate Hall B, B-2 Level, Marriott

**COGNITIVE BEHAVIORAL THERAPY****Chp.:** Anton C. Trinidad, M.D.**Co-Chp.:** Denise M. Richardson

113 WITHDRAWN

*(Continued on next page)*

11:00 a.m.

- 114 The Effective Delivery of Cognitive-Behavioral Therapy for Panic Disorder: An International Multicenter Trial**  
Justin A. Kenardy, Ph.D., Michael G. Dow, Ph.D., Craig G. Taylor, M.D., Derek W. Johnston, Ph.D., Michelle G. Newman, Ph.D.

11:45 a.m.

- 115 Efficacy of Self-Administered Cognitive-Behavior Therapy and Sertraline in Panic Disorder**  
Jacques Bradwejn, M.D., Diana Koszycki, Ph.D., Zindel V. Segal, Ph.D.

**THIS SESSION WILL BE AUDIOTAPED.**

**SCIENTIFIC AND CLINICAL REPORT SESSION 39**

11:00 a.m. - 12:30 p.m.

Sierra Conference Suite H, 5th Floor, Marriott

**OUTCOMES IN DEPRESSION**

**Chp.:** Emily K. Lee, M.D.

**Co-Chp.:** Elena F. Swartz, M.D.

11:00 a.m.

- 116 Problem-Solving Ability and Comorbid Personality Disorders in Depressed Outpatients**  
Rebecca Harley, Ph.D., Megan E. Hughes, B.A., Heidi D. Montoya, B.A., George I. Papakostas, M.D., Albert Yeung, M.D., Paolo Cassano, M.D., Amy H. Farabaugh, Ph.D., Maurizio Fava, M.D.

11:30 a.m.

- 117 A Comparison of Weight Changes Associated With Different Augmentation Strategies**  
Christina M. Dording, M.D., Megan E. Hughes, B.A., Pamela A. Roffi, B.S., Roy H. Perlis, M.D., Jonathan E. Alpert, M.D., Dan V. Iosifescu, M.D., Maurizio Fava, M.D.

12 noon

- 118 Depression Disease Management Improves Depression and QOL**  
Ron Aubert, Ph.D., Fang Xia, Ph.D., Cindy Woo, M.P.H., George Fulop, M.D.

**THIS SESSION WILL BE AUDIOTAPED.**

**SCIENTIFIC AND CLINICAL REPORT SESSION 40**

11:00 a.m. - 12:30 p.m.

Pacific Conference Suite J, 4th Floor, Marriott

**SLEEP DISORDERS**

**Chp.:** Thomas C. Neylan, M.D.

**Co-Chp.:** Richard A. Nathanson, M.D.

11:00 a.m.

- 119 Modafinil Improves Cognition in Narcolepsy Patients With Excessive Sleepiness**  
Jonathan R. L. Schwartz, M.D., Michael T. Nelson, Rod J. Hughes, Ph.D., Chris A. Veit, M.S.W., Kenneth C. Cobb, Elliott R. Schwartz, D.O.

11:30 a.m.

- 120 Modafinil as Adjunctive Therapy Improves Quality of Life in Sleep Apnea**  
Milton K. Erman, M.D.

12 noon

- 121 Modafinil Improves Quality of Life as Adjunct Treatment of Obstructive Sleep Apnea**  
Mary B. O'Malley, M.D.

**THIS SESSION WILL BE AUDIOTAPED.**

**WORKSHOPS**

**COMPONENTS 43-47**

**COMPONENT WORKSHOP 43 11:00 a.m. - 12:30 p.m.**

Room 304, Esplanade Level, Moscone Center

**BIRACIAL OR BICULTURAL AMERICANS: ISSUES AND INSIGHTS FOR THERAPY**

*APA Caucus of Asian-American Psychiatrists and APA Northern California Psychiatric Society's Committee on Asian-American Issues*

**Chp.:** Jacquelyn B. Chang, M.D.

**Participants:** Brett J. Sevilla, M.D., Naomi K. Lam, M.D., Annette Albright, M.D., Masaru J. Fisher, M.D.

**COMPONENT WORKSHOP 44 11:00 a.m. - 12:30 p.m.**

Room 309, Esplanade Level, Moscone Center

**TRANSITION INTO THE POSTRESIDENCY PERIOD**

*APA New York County District Branch*

**Co-Chps.:** Dinu P. Gangure, M.D., Scott R. Masters, M.D.

**Participants:** Evaristo O. Akerele, M.D., Marianne Guschwan, M.D., Carl Shusterman, Esq.

**COMPONENT WORKSHOP 45 11:00 a.m. - 12:30 p.m.**

Salons 1 & 2, Lower B-2 Level, Marriott

**COMBINED RESIDENCY TRAINING: NOW WHAT ARE YOU DOING?**

*APA Central California Psychiatric Society*

**Chp.:** Shannon T. Suo-Chan, M.D.

**Participants:** Susan Padrino-Iler, M.D., Quinton E. Moss, M.D., Jodi E. Star, M.D., Dylan P. Wint, M.D.

**COMPONENT WORKSHOP 46 11:00 a.m. - 12:30 p.m.**

Salons 14 & 15, Lower B-2 Level, Marriott

**UPDATE ON PRACTICE GUIDELINES: PTSD/ACUTE STRESS DISORDER**

*APA Steering Committee on Practice Guidelines*

**Chp.:** John S. McIntyre, M.D.

**Participants:** Laura J. Fochtmann, M.D., Robert J. Ursano, M.D., Carl C. Bell, M.D., Spencer Eth, M.D.

**COMPONENT WORKSHOP 47** 11:00 a.m. - 12:30 p.m.  
Golden Gate Hall A, B-2 Level, Marriott

**DADDY AND PAPA: A PSYCHOSOCIAL PROFILE OF GAY PARENTING**  
*APA Committee on Gay, Lesbian, and Bisexual Issues*

**Chp.:** Jack Drescher, M.D.  
**Participants:** Daniel W. Hicks, M.D., Diana C. Miller, M.D., Susan A. Turner, M.D.

ISSUES 111-118

**ISSUE WORKSHOP 111** 11:00 a.m. - 12:30 p.m.  
Room 113, Exhibit Level, Moscone Center

**THE POWER OF HEALING: SPIRITUALITY GROUP WORK WITH PSYCHIATRY STAFF**

**Chp.:** C. Paul Yang, M.D.  
**Participants:** Hendry Ton, M.D., Heather M. Hall, M.D.

**ISSUE WORKSHOP 112** 11:00 a.m. - 12:30 p.m.  
Room 114, Exhibit Level, Moscone Center

**HARM REDUCTION: A CRITICAL REVIEW**

**Co-Chps.:** Jeffrey N. Wilkins, M.D., Jack Kuo, M.D.  
**Participants:** Glenn Backef, Maria Chavez

**ISSUE WORKSHOP 113** 11:00 a.m. - 12:30 p.m.  
Room 122, Exhibit Level, Moscone Center

**PARENTING WITH THE BRAIN IN MIND: ATTACHMENT AND SELF-UNDERSTANDING**

**Chp.:** Daniel J. Siegel, M.D.  
**Participant:** Mary Hartzell, M.Ed.

**ISSUE WORKSHOP 114** 11:00 a.m. - 12:30 p.m.  
Room 123, Exhibit Level, Moscone Center

**SERVICE INTEGRATION AND CONTINUITY IN CALIFORNIA: PROGRAMS FROM HARBOR-UCLA**

**Chp.:** Mary E. Read, M.D.  
**Participants:** Michael W. Smith, M.D., Paul G. Arns, Ph.D., Leslie Groenewold, R.N.

**ISSUE WORKSHOP 115** 11:00 a.m. - 12:30 p.m.  
Room 124, Exhibit Level, Moscone Center

**BRIDGING THE GAP BETWEEN MENTAL HEALTH AND PRIMARY CARE FOR ASIAN AMERICANS**

**Co-Chps.:** Francis G. Lu, M.D., Henry Chung, M.D.  
**Participants:** Sue S. Chan, M.D., Teddy Chen, M.D., Albert Yeung, M.D.

**ISSUE WORKSHOP 116** 11:00 a.m. - 12:30 p.m.  
Room 310, Esplanade Level, Moscone Center

**COMPUTER-ASSISTED PSYCHOTHERAPY IN CLINICAL PRACTICE**

**Chp.:** Jesse H. Wright, M.D.

**ISSUE WORKSHOP 117** 11:00 a.m. - 12:30 p.m.  
Salons 10 & 11, Lower B-2 Level, Marriott

**RACIAL, ETHNIC, AND CULTURAL BIAS IN PSYCHOTHERAPY**

**Chp.:** Edmundo J. Ruiz, M.D.  
**Participant:** Homero R. Sanchez, M.D.

**ISSUE WORKSHOP 118** 11:00 a.m. - 12:30 p.m.  
Pacific Conference Suite A, 4<sup>th</sup> Floor, Marriott

**ESSENTIAL SKILLS 101: WRITING MANUSCRIPTS FOR PUBLICATION**

**Chp.:** Laura W. Roberts, M.D.

---

## 12 noon Session

---

**NEW RESEARCH POSTER SESSION 10**  
12 noon - 2:00 p.m.  
Hall D, Exhibit Level, Moscone Center

**VIOLENCE, TRAUMA, STRESS, ANXIETY, FORENSICS, COGNITION, AND OTHER TOPICS**

For further information on New Research Sessions, please refer to the *New Research Program Book* included in your registration packet.

---

## 2:00 p.m. Sessions

---

**SYMPOSIA 83-104**

**SYMPOSIUM 83** 2:00 p.m. - 5:00 p.m.  
Room 110, Exhibit Level, Moscone Center

**THE EFFECT OF PERSONALITY DISORDERS ON THE TREATMENT OF AXIS I DISORDERS**  
*Association for Research in Personality Disorders*

**Chp.:** James H. Reich, M.D.

**A The Anxious Personality Disorder Cluster and Outcome of Treatment of Axis I Disorders**  
James H. Reich, M.D.

*(Continued on next page)*

**THURSDAY**

---

**B The Effect of Axis II Diagnosis and Treatment of Axis I Disorders**

Cesare Maffei, M.D., Francesca Biondini, Ph.D.

**C Interventions for Axis II Patients With Comorbid Axis I Disorders**

David P. Bernstein, Ph.D.

**D Personality Disorders Predict Completion of Substance Abuse Treatment**

Per Vaglum, M.D., Edle Raundal, Ph.D.

**E Dialectic Behavior Therapy in Borderline Substance Abusers**

Wim Van Den Brink, M.D.

**F Emotional Dysregulation and Treatment of Axis I Disorders**

John Livesley, M.D.

Discussant: Joel F. Paris, M.D.

**THIS SESSION WILL BE AUDIOTAPED.**

**SYMPOSIUM 84** 2:00 p.m. - 5:00 p.m.

**Room 111, Exhibit Level, Moscone Center**

**THE DIFFICULT-TO-TREAT PSYCHIATRIC PATIENT**

Chp.: Mantosh J. Dewan, M.D.

**A The Difficult-to-Treat Eating-Disordered Patient**

Katherine A. Halmi, M.D., Wendy A. Harris, M.D., Claire Wiseman, Ph.D.

**B Working With the Difficult-to-Treat DID Patient**

Richard P. Kluff, M.D.

**C The Difficult-to-Treat PTSD Patient**

Randall D. Marshall, M.D., Elizabeth A. Hembree, Ph.D., Lee A. Fitzgibbons, Ph.D., Edna B. Foa, Ph.D.

**SYMPOSIUM 85** 2:00 p.m. - 5:00 p.m.

**Room 112, Exhibit Level, Moscone Center**

**QUALITY MEASUREMENT IN A CANADIAN INNER-CITY ACADEMIC ENVIRONMENT**

Chp.: Ian C. Dawe, M.D.

Co-Chp.: Paul S. Links, M.D.

**A Quality Measurement in Mental Health Care**

Ian C. Dawe, M.D.

**B Evaluation of a Mobile Crisis Service in the Inner City**

Nancy E. Read, M.S.C., Joanne C. Walsh, B.S.C.N., Sean B. Rourke, Ph.D., Ian C. Dawe, M.D.

**C Promoting Systems Evaluation of Inner-City Community Mental Health Programs**

Margaret Gehrs, R.N., John H. Langley, M.D.

**D Reduction in Mental Health Services Use in Severe and Persistent Mental Illness Clients With Assertive Community Treatment and Intensive Case Management**

Donald A. Wasylenko, M.D., Sean B. Rourke, Ph.D., Paul S. Links, M.D.

**E Using Outcome Data to Plan Mental Health Systems in the Inner-City**

Lorne A. Tugg, M.D.

**THIS SESSION WILL BE AUDIOTAPED.**

**SYMPOSIUM 86** 2:00 p.m. - 5:00 p.m.

**Room 114, Exhibit Level, Moscone Center**

**THE VETERANS ADMINISTRATION EXPERIENCE: TREATING COMORBID HEPATITIS C AND SUBSTANCE USE DISORDERS/PSYCHIATRIC ILLNESS**

Chp.: Peter Hauser, M.D.

**A Patterns in Hepatitis C: Prevalence and Comorbidities in Northwest Veterans**

Kevin L. Sloan, M.D., Kristy A. Straits-Troster, Ph.D., Jason A. Dominitz, M.D., Daniel R. Kivlahan, Ph.D.

**B Assessment and Management of Substance Use Disorders in Hepatitis C Patients**

Mark L. Willenbring, M.D., Eric W. Dieperink, M.D., Samuel Ho, M.D.

**C Evaluation and Management of Depression in Patients With Hepatitis C**

Eric W. Dieperink, M.D., Mark L. Willenbring, M.D., Peter Hauser, M.D., Samuel Ho, M.D.

**D PTSD and Hepatitis C Comorbidity and Implications for Interferon-Based Treatments**

Kristy A. Straits-Troster, Ph.D., Miles E. McFall, Ph.D., Kevin L. Sloan, M.D., Jason A. Dominitz, M.D.

Discussant: Michael J. Semyak, M.D.

**THIS SESSION WILL BE AUDIOTAPED.**

**SYMPOSIUM 87** 2:00 p.m. - 5:00 p.m.

**Room 120, Exhibit Level, Moscone Center**

**CHILDREN AT RISK FOR MENTAL ILLNESS IN LATIN AMERICA**

Chp.: Ruby Castilla-Puentes, M.D.

Co-Chp.: Lenn Murrelle, Ph.D.

**A Correlates of Serious Suicidal Ideation Among Central-American Youths**  
Lenn Murrelle, Ph.D., Leo Russo, Ph.D., Enrique Warner, M.P.H., Luis Sandi, M.D., Alfredo Moreno, M.D.

**B Phenomenology and Treatment of Psychosis in Children**  
Rosa E. Ulloa, M.D.

**C Diagnosis and Treatment of Children With ADHD: A Chilean Experience**  
Arturo Grau, M.D.

**D A Study of Risperidone in the Treatment of Children With Tourette's Syndrome**  
Carolina Remedi, M.D., Carlos Soria, M.D., Nestor Edelstein, M.D.

**E Anxiety, Depression, and Somatic Complaints in Traumatized Children**  
Ruby Castilla-Puentes, M.D., Miguel Habeych, M.D., Ivan Gomez, M.D., Sandra Castilla-Puentes, M.D., Wilma Castilla-Puentes, M.D., Maria C. Caballero, R.N., Gilmarosa De Contreras, M.S.W.

**Discussants:** Viviana J. Chiappe, M.D., Roberto Yunes, M.D.  
**THIS SESSION WILL BE AUDIOTAPED.**

**SYMPOSIUM 88** 2:00 p.m. - 5:00 p.m.  
**Room 121, Exhibit Level, Moscone Center**

**POLYPHARMACY: EVIDENCE BASIS VERSUS CLINICAL EXPERIENCE**

**Chp.:** James M. Ellison, M.D.  
**Co-Chp.:** David N. Osser, M.D.

**A Polypharmacy: Extent of the Problem and the Massachusetts Response**  
Annette Hanson, M.D.

**B The Placebo Effect in the Assessment of Polypharmacy**  
Walter A. Brown, M.D.

**C Coprescribing Antidepressants: Dual or Dueling Treatment?**  
James M. Ellison, M.D.

**D Combination Treatment in Schizophrenia**  
Donald C. Goff, M.D.

**E Treatment of Insomnia in the Psychiatric Patient**  
John W. Winkelman, M.D.

**Discussants:** Olivia I. Okereke, M.D., David N. Osser, M.D.  
**THIS SESSION WILL BE AUDIOTAPED.**

**SYMPOSIUM 89** 2:00 p.m. - 5:00 p.m.  
**Room 122, Exhibit Level, Moscone Center**

**TRUTH AND EXPECTATIONS IN PSYCHOPHARMACOLOGY RESEARCH**

**Chp.:** Rodrigo A. Munoz, M.D.  
**Co-Chp.:** Debra R. Lappin, J.D.

**A Psychotherapy and Informed Consent**  
Harold I. Eist, M.D.

**B New and Old Products in Psychiatric Practice**  
Rodrigo A. Munoz, M.D.

**C Truth and Expectations in the Changing Global Market Place**  
Debra R. Lappin, J.D.

**D Therapeutic Options in Periods of Ambiguity**  
Rosemary Quigley, J.D.

**Discussants:** Norman Sartorius, M.D., Juan J. Lopez-Ibor, Jr., M.D.

**SYMPOSIUM 90** 2:00 p.m. - 5:00 p.m.  
**Room 123, Exhibit Level, Moscone Center**

**MODEL PSYCHIATRY RESIDENCY PROGRAMS ON RELIGION AND SPIRITUALITY**

**Chp.:** Francis G. Lu, M.D.  
**Co-Chp.:** Christina M. Puchalski, M.D.

**A Teaching Spirituality at George Washington University**  
James L. Griffith, M.D.

**B University of California at Davis' Enhanced Curriculum in Spirituality and Psychiatry**  
Mark E. Servis, M.D.

**C Tulane University's Curriculum on Spirituality and Mental Health**  
Janet E. Johnson, M.D., Donald P. Owens, Jr., Ph.D., Patrick T. O'Neill, M.D.

**D The University of Washington's Curriculum on Spirituality and Culture in Psychiatry**  
Lorin D. Gardiner, M.D.

**E Religion, Mental Health, and Culture: The Harvard Longwood Course Five Years Later**  
John R. Peteet, M.D., Mary K. McCarthy, M.D.  
**THIS SESSION WILL BE AUDIOTAPED.**

**SYMPOSIUM 91** **2:00 p.m. - 5:00 p.m.**

Room 124, Exhibit Level, Moscone Center

**CONCEPTUALIZATIONS OF JEONG AND ITS APPLICATION TO THE HEALING PROCESS**

**Chp.:** Christopher K. Chung, M.D.  
**Co-Chp.:** Samson J. Cho, M.D.

- A Attachment and Jeong: Are They Connected?**  
David S. Rue, M.D.
- B A Comparative Analysis of Jeong of Korea and Amae of Japan**  
Byung Kun Min, M.D.
- C Restoring of Jeong Through the Use of Healing Rituals in Bereavement Periods**  
Soo Kyung Chang, M.D., Christopher K. Chung, M.D.
- D From We-Ness Perspectives: Dynamics of BPD and Hwabyung**  
Christopher K. Chung, M.D., Samson J. Cho, M.D., Tawnya L. Christiansen, M.D.
- E Psychotherapeutic Applications of Jeong and Haan**  
Luke Kim, M.D.

**Discussant:** Edmond H.T. Pi, M.D.  
**THIS SESSION WILL BE AUDIOTAPED.**

**SYMPOSIUM 92** **2:00 p.m. - 5:00 p.m.**

Room 125, Exhibit Level, Moscone Center

**BOUNDARIES EDUCATION: AN EXPERT UPDATE ON DIVERSE APPROACHES AND SETTINGS**

**Chp.:** Gregg E. Gorton, M.D.

- A Effective Boundaries Education**  
Gregg E. Gorton, M.D., Steven E. Samuel, Ph.D., Gail Zivin, Ph.D.
- B Tools for Preventive and Remedial Boundaries Training**  
Gary R. Schoener, Psy.D.
- C Supervision of Intense Affective Reactions to Patients and Construction of Optimal Boundaries**  
Nancy A. Bridges, L.C.S.W.
- D Teaching Boundaries to Physicians of All Kinds**  
Werner Tschan, M.D.

**THIS SESSION WILL BE AUDIOTAPED.**

**SYMPOSIUM 93** **2:00 p.m. - 5:00 p.m.**

Room 300, Esplanade Level, Moscone Center

**SCHIZOPHRENIA WITH COMORBIDITY: DIAGNOSES OR DIMENSIONS?**

**Chp.:** Lewis A. Opler, M.D.  
**Co-Chp.:** Michael Y. Hwang, M.D.

- A Clinical and Research Evidence for Comorbidity in Schizophrenia**  
Michael Y. Hwang, M.D.
- B Toward a Dimensional Approach to Psychiatric Nosology**  
Robert F. Krueger, Ph.D.
- C Using Symptom Dimensions to Guide Treatment**  
Lewis A. Opler, M.D., Anne-Marie Shelley, Ph.D., Joseph Battaglia, M.D., Jeffrey Lucey, M.D.
- D Diagnostic Models and Subjectivity**  
John S. Strauss, M.D.

**Discussants:** Ming T. Tsuang, M.D., Michael B. First, M.D.  
**THIS SESSION WILL BE AUDIOTAPED.**

**SYMPOSIUM 94** **2:00 p.m. - 5:00 p.m.**

Room 301, Esplanade Level, Moscone Center

**DELIRIUM SUBTYPES: DIAGNOSIS AND TREATMENT**

**Chp.:** Stephen M. Saravay, M.D.  
**Co-Chp.:** Paula T. Trzepacz, M.D.

- A Delirium After Post-Traumatic Brain Injury**  
Paula T. Trzepacz, M.D.
- B The Delirium Experience**  
William Breitbart, M.D., Christopher Gibson, Ph.D., Annie Tremblay, M.D.
- C Motoric Subtypes of Delirium: The Limerick Delirium Study**  
David J. Meagher, M.D., Maria Moran, M.B., Sinead Donnelly, M.D., Bangaru Raju, M.D.
- D Cholinesterase Inhibitors in the Intervention and Treatment of Delirium**  
Benjamin Liptzin, M.D.

**THIS SESSION WILL BE AUDIOTAPED.**

**SYMPOSIUM 95** **2:00 p.m. - 5:00 p.m.**

Room 302, Esplanade Level, Moscone Center

**A TERRORIST'S COMPETENCY TO STAND TRIAL: ASSESSING AMNESIA**

**Chp.:** Stuart B. Kleinman, M.D.

**A A Historical Approach to Assessing Recollection of an Alleged Terrorist**

Stuart B. Kleinman, M.D.

**B Prosecuting and Defending an Amnesic Individual Accused of Participating in Terrorism**

Andrew A. Rubin, J.D.

**C Competency in a Defendant Who Claims Amnesia**

Eric D. Goldsmith, M.D.

**D Assessing Competence to Stand Trial in an Alleged Terrorist: The Role of Psychological Testing**

Barry D. Rosenfeld, Ph.D.

**SYMPOSIUM 96** 2:00 p.m. - 5:00 p.m.

Room 304, Esplanade Level, Moscone Center

**NEW EVIDENCE ON EXPOSURE AND PRESENT-FOCUSED TREATMENTS FOR COMPLEX PTSD**

Chp.: Catherine Classen, Ph.D.

**A Trauma-Focused Versus Present-Focused Group Therapy for Survivors of Childhood Sexual Abuse**

Catherine Classen, Ph.D., Cheryl Koopman, Ph.D., David Spiegel, M.D.

**B Emotional Regulation and Interpersonal Skill as a Prerequisite to Emotional Processing of Traumatic Memories**

Marylene Cloitre, Ph.D.

**C Development and Initial Evaluation of Brief Integrative Therapy for PTSD in Female Childhood Sexual Abuse Survivors**

Annmarie McDonagh-Coyle, M.D., Julian Ford, Ph.D., Christine Demment, Ph.D.

**D Outcome of Trauma Treatment With Comorbid Substance Abuse**

Julian Ford, Ph.D., Linda Frisman, Ph.D.

Discussant: David Spiegel, M.D.

**THIS SESSION WILL BE AUDIOTAPED.****SYMPOSIUM 97** 2:00 p.m. - 5:00 p.m.

Room 306, Esplanade Level, Moscone Center

**THE NEUROPSYCHIATRIC ASPECTS OF HIV/AIDS: EVALUATION AND TREATMENT, PART 2**

Chp.: Marshall Forstein, M.D.

**A Evaluating the Neuropsychiatric Patient**

Karl Goodkin, M.D.

**B Six Things You Need to Know: Drug-Drug Interactions**

Marshall Forstein, M.D.

**C Managing Depression and Anxiety: Assessment and Treatment**

Stephen J. Ferrando, M.D.

**THIS SESSION WILL BE AUDIOTAPED.****SYMPOSIUM 98** 2:00 p.m. - 5:00 p.m.

Room 307, Esplanade Level, Moscone Center

**NEW RESEARCH IN THE BIOLOGY AND TREATMENT OF BULIMIA NERVOSA**

Chp.: Allan S. Kaplan, M.D.

Co-Chp.: David C. Jimerson, M.D.

**A Impaired Satiety in Bulimia Nervosa: State Versus Trait**

David C. Jimerson, M.D., Barbara E. Wolfe, Ph.D., Erand D. Metzger, M.D.

**B Disturbances in Satiety in Bulimia Nervosa**

B. Timothy Walsh, M.D., Michael J. Devlin, M.D., Ellen Zimmerli, Ph.D., Harry Kissileff, Ph.D., Janet L. Guss, M.A., Robyn Sysko, B.A.

**C Alterations of 5HT 1A and 2A Receptors Persist After Recovery From Bulimia Nervosa**

Walter H. Kaye, M.D., Guido K.W. Frank, M.D., Carolyn Meltzer, M.D., Julie Price, Ph.D., Wayne C. Drevets, M.D., Chester Mathis, Ph.D.

**D Pharmacotherapy of Bulimia Nervosa: A Review of Established Medications and Promising New Agents**

Allan S. Kaplan, M.D.

**E New Models for Disseminating Psychotherapy for Eating Disorders**

James E. Mitchell, M.D., Stephen A. Wonderlich, Ph.D., James L. Roerig, Ph.D., Martina de Zwaan, M.D., Ross D. Crosby, Ph.D.

**THIS SESSION WILL BE AUDIOTAPED.****SYMPOSIUM 99** 2:00 p.m. - 5:00 p.m.

Room 308, Esplanade Level, Moscone Center

**TERRORISM AND POLITICAL VIOLENCE IN THE 21ST CENTURY: NEW FORMS AND RESPONSES**

Chp.: Jerrold M. Post, M.D.

Co-Chp.: Stevan M. Weine, M.D.

**A The Violent True Believer: Homicidal and Suicidal States of Mind**

J. Reid Meloy, Ph.D.

**B The Psychology of Murder-Suicide: Relation to Suicidal Terrorism**

Melvyn M. Nizny, M.D.

**C Differentiating the Motivations and Constraints for Weapons of Mass-Destruction Terrorism**

Jerrold M. Post, M.D.

*(Continued on next page)*

**D Terror and War: Literary Perspectives**

Tvrtko Kulenovic, Ph.D.

**E Paths and Obstacles to Reconciliation in Kosovo**

Stevan M. Weine, M.D., Ferid Agami, M.D.

**Discussant:** David A. Rothstein, M.D.

**THIS SESSION WILL BE AUDIOTAPED.**

**SYMPOSIUM 100**

**2:00 p.m. - 5:00 p.m.**

**Room 309, Esplanade Level, Moscone Center**

**BIPOLAR SPECTRUM OR BORDERLINE PERSONALITY? A RELEVANT DISTINCTION?**

**Chp.:** Joseph F. Goldberg, M.D.

**Co-Chp.:** S. Nassir Ghaemi, M.D.

**A Borderline Personality or Bipolar II?**

Hagop S. Akiskal, M.D.

**B Borderline, Bipolar, and Beyond: Affective Illness as Precursor to Borderline Personality**

Michael H. Stone, M.D.

**C Dimensional Versus Categorical Psychopathology: Genetic Correlates**

Joseph F. Goldberg, M.D.

**D Differential Pharmacotherapy of Bipolar Spectrum and BPD**

S. Nassir Ghaemi, M.D.

**E Nosology and DSM-V: Lessons From the Bipolar-Borderline Controversy**

Paul R. McHugh, M.D.

**THIS SESSION WILL BE AUDIOTAPED.**

**SYMPOSIUM 101**

**2:00 p.m. - 5:00 p.m.**

**Room 310, Esplanade Level, Moscone Center**

**NEW INTRAVENOUS TREATMENTS: A NEW TOOL TO OVERCOME DIFFICULTIES AND RESISTANCE**

**Chp.:** Stefano Pallanti, M.D.

**Co-Chp.:** Lorrin M. Koran, M.D.

**A Intravenous Antidepressants: A Pharmacokinetic Perspective on Response and Resistance in Major Depression and OCD**

Emanuela Mundo, M.D., Silvio R. Barezzi, M.D., Carlo A. Altamura, M.D.

**B Intravenous Citalopram and Clomipramine in Major Depression: A Double-Blind Study**

Stefano Pallanti, M.D., Leonardo Quercioli, M.D.

**C Intravenous Antidepressant Therapy With Mirtazapine and Citalopram**

Siegfried Kasper, M.D., Anastasios Konstantinidis, M.D., Diethar Winkler, M.D., Juergen Stastny, M.D., Christian Barnas, M.D., Eva Hilger-Assem, M.D., Franz Mueller-Spahn, M.D.

**D Pulse-Loaded Intravenous Clomipramine for Refractory OCD**

Lorrin M. Koran, M.D.

**E Intravenous Clomipramine in Adolescents With Treatment-Resistant OCD and Depression**

Floyd R. Sallee, M.D.

**THIS SESSION WILL BE AUDIOTAPED.**

**SYMPOSIUM 102**

**2:00 p.m. - 5:00 p.m.**

**Salons 3 & 4, Lower B-2 Level, Marriott**

**INTERESTS AND VULNERABILITIES OF HEALTH CARE PRACTITIONERS**

**Chp.:** John O. Beahrs, M.D.

**A Beneficence and Nonreciprocity in Contemporary Health Care**

John O. Beahrs, M.D.

**B Psychiatry's Internal Dissension**

Michael T. McGuire, M.D.

**C Duties to Others: Medicolegal Aspects**

Thomas G. Gutheil, M.D.

**D Managed Care and the Dilemmas of Psychiatric Education**

Seymour L. Halleck, M.D.

**THIS SESSION WILL BE AUDIOTAPED.**

**SYMPOSIUM 103**

**2:00 p.m. - 5:00 p.m.**

**Golden Gate Hall A, B-2 Level, Marriott**

**COMORBIDITY WITH SUBSTANCE ABUSE**

**Chp.:** Marc Galanter, M.D.

**Co-Chp.:** Kathleen T. Brady, M.D.

**A Substance Abuse and Depression**

Edward V. Nunes, M.D.

**B Substance Abuse and PTSD**

Kathleen T. Brady, M.D., Susan Sonne, Ph.D., Therese Killeen, Ph.D., Aimee McRae, Ph.D.

**C Substance Abuse and ADD**

Timothy E. Wilens, M.D.



**D Substance Abuse and Social Phobia**

Hugh Myrick, M.D.

**Discussants:** Richard N. Rosenthal, M.D., Michael H. Gendel, M.D.

**THIS SESSION WILL BE AUDIOTAPED.**

**SYMPOSIUM 104**

**2:00 p.m. - 5:00 p.m.**

**Golden Gate Hall C, B-2 Level, Marriott**

**LOVE FROM PATHOLOGY TO NORMALITY:**

**FRENCH AND AMERICAN STYLE, PART 2**

**Chp.:** Richard Rechtman, M.D.

**Co-Chp.:** John A. Talbott, M.D.

**A Broken Hearts, Heavy Hearts: Narrative, Distress, and Compliance After an Infarct**

Danielle Groleau, Ph.D., Evelyne Hudon, M.D., Laurence J. Kirmayer, M.D., Francois Lesperance, M.D., Zeev Rosberger, Ph.D.

**B From Erotomania to Stalking**

Francois C. Petitjean, M.D., Natacha Fouilhoux, M.D., Agop Kaveojan, M.D.

**C The Love Life of Melancholics**

Peter D. Kramer, M.D.

**D The Medical Marriage**

Michael Myers, M.D.

**E The Clinical Meaning of Love**


Richard Rechtman, M.D., Eric J. Marcel, M.D.

**F Transcultural Aspects of Love**

James K. Boehnlein, M.D.

**Discussant:** Yves G. Thoret, M.D.

**THIS SESSION WILL BE AUDIOTAPED.**



**MAY 1-6, 2004**  
New York, New York

---

## CALL FOR PAPERS

---

### **PRESIDENT'S THEME:**

**Psychotherapy and Psychopharmacology: Dissolving the Mind-Brain Barrier**

*Marcia K. Goin, M.D.*  
*President*

*Geetha Jayaram, M.D., Chairperson*  
*Scientific Program Committee*

### **THE SUBMISSION SCHEDULE**

<b>Format</b>	<b>Deadline</b>
Industry-Supported Symposium	June 2, 2003
Course	September 3, 2003
Reports	September 3, 2003
Symposium	September 3, 2003
Workshops	Issue: September 3, 2003 Component: September 17, 2003
New Research	<b>December 5, 2003</b>

**Incomplete and/or Incorrect Forms Will Not Be Considered.**

***For complete submission forms, you may download the forms at [www.psych.org](http://www.psych.org), click on the Annual Meeting logo, then click on submission forms. You may also contact the APA toll free at 1-888-357-7924, and speak directly with an Answer Center Coordinator.***

If you want to volunteer to chair a session, please send a letter to the attention of Dr. Jayaram at the American Psychiatric Association. Please indicate your name, address, area of expertise, and the type of session you would like to chair. Please be aware that we receive more requests than available slots. If you are selected as a chairperson, you will be notified by the end of November.

# 2003 ANNUAL MEETING

## TOPIC AREAS FOR THE SCIENTIFIC PROGRAM

### DISORDERS

1. AIDS and HIV-Related Disorders
2. Alcohol and Drug-Related Disorders
3. Anxiety Disorders
4. Attention Spectrum Disorders
5. Cognitive Disorders (Delirium, Dementia, Amnestic, etc.)
6. Dissociative Disorders
7. Eating Disorders
8. Mental Retardation (Child/Adolescent/Adult)
9. Mood Disorders
10. Personality Disorders
11. Schizophrenia and Other Psychotic Disorders
12. Sexual and Gender Identity Disorders
13. Sleep Disorders
14. Somatoform Disorders

### PRACTICE AREAS/SETTINGS

15. Psychiatric Administration and Services: Public, Private, and University

### SUBSPECIALTY AREAS OR SPECIAL INTERESTS

16. Addiction Psychiatry
17. Biological Psychiatry and Neuroscience
18. Child and Adolescent Psychiatry and Disorders
19. Consultation-Liaison and Emergency Psychiatry
20. Cross-Cultural and Minority Issues
21. Diagnostic Issues
22. Epidemiology
23. Ethics and Human Rights
24. Forensic Psychiatry
25. Genetics
26. Geriatric Psychiatry
27. Neuropsychiatry
28. Psychiatric Education
29. Psychiatric Rehabilitation

30. Psychoanalysis
31. Research Issues
32. Social and Community Psychiatry
33. Stress
34. Suicide
35. Violence, Trauma, and Victimization

### TREATMENTS

36. Behavior and Cognitive Therapies
37. Combined Pharmacotherapy and Psychotherapy
38. Couple and Family Therapies
39. Group Therapy
40. Individual Psychotherapies
41. Psychopharmacology
42. Other Somatic Therapies
43. Treatment Techniques and Outcome Studies

### OTHER ISSUES

44. Computers
45. Creativity and the Arts
46. Gender Issues
47. Health Services Research
48. Historical Questions
49. Information Technology
50. Internet
51. Lesbian/Gay/Bisexual/Transgender Issues
52. Managed Care and Health Care Funding
53. Political Questions
54. Professional and Personal Issues
55. Religion, Spirituality, and Psychiatry
56. Resident and Medical Student Concerns
57. Presidential Theme: The Promise of Science – The Power of Healing
58. Stigma/Advocacy
59. Telepsychiatry
60. Virtual Reality
61. Women's Health Issues

---

### GUIDE TO USING THE TOPIC INDEX

Use this index to find sessions of interest to you. There are five overall topics: Disorders, Practice Areas/Settings, Subspecialty Areas or Special Interests, Treatments, and Other Issues. Under each overall topic, you will find subtopics listed in alphabetical order with the formats (type of session) listed alphabetically underneath. Within each format, you will find the title of the individual session listed by number. The listing will also show the page number the session appears on. You should refer to the page number in this *Program Book* to obtain further details about the session.

<b>DISORDERS</b>	<b>Page #</b>	<b>MASTER EDUCATOR CLINICAL CONSULTATION</b>	<b>Page #</b>
<b>TOPIC 1: AIDS AND HIV-RELATED DISORDERS</b>		9 Anxiety Disorders	67
<b>SCIENTIFIC AND CLINICAL REPORTS</b>			
95 Psychiatric Effects Associated With Efavirenz: A Retrospective Study	88	11 The Prevalence of PTSD in Canada	22
96 PTSD and Acute Stress Reactions to Recent Life Events Among HIV Positive Persons	88	12 A New Self-Report Screening Tool for DSM-IV Axis I Diagnosis	22
97 Use of Marijuana to Manage Distress Symptoms Among HIV-Infected Persons	88	13 Sexual Aversion Disorders in Primary Anxiety Disorders	22
<b>SYMPOSIA</b>		77 Clinical Experiments With Sertraline in Panic Disorder	70
71 Neuropsychiatric Aspects of HIV/AIDS: An Overview, Part 1	77	78 Double-Blind Oral Morphine in Treatment-Resistant OCD	70
97 The Neuropsychiatric Aspects of HIV/AIDS: Evaluation and Treatment, Part 2	95	<b>SYMPOSIA</b>	
<b>WORKSHOPS - COMPONENT</b>		12 OCD Spectrum Illnesses: What Does It Mean? Does It Help Our Treatment?	29
12 Psychiatric Management of HIV, Hepatitis C, and Substance Abuse	39	19 Novel Clinical Perspectives on the Pathophysiology and Treatment of PTSD	31
22 AIDSism, Ageism, Racism: Psychiatrist's Role in the Geriatric AIDS Epidemic	46	65 New Research and Novel Therapeutic Strategies for OCD	75
<b>WORKSHOP - ISSUE</b>		68 PTSD: A Latin-American Nightmare	76
108 Adherence to HIV Medications in the Psychiatrically Ill: New Findings	86	73 Glutamate: An Exciting Neurotransmitter	77
<b>TOPIC 2: ALCOHOL AND DRUG-RELATED DISORDERS</b>		96 New Evidence on Exposure and Present-Focused Treatments for Complex PTSD	95
<b>COURSE</b>		<b>WORKSHOP - COMPONENT</b>	
39 Integrated Model for Treatment of Co-Occurring Psychiatric and Substance Disorders	14	46 Update on Practice Guidelines: PTSD/Acute Stress Disorder	90
<b>FOCUS LIVE</b>		<b>TOPIC 4: ATTENTION SPECTRUM DISORDERS</b>	
2 Substance Abuse	42	<b>COURSES</b>	
<b>LECTURE</b>		1 ADD in Children and Adolescents	1
9 Current Perspectives on Our National Drug Control Strategy	38	16 ADD in Adults	5
<b>SCIENTIFIC AND CLINICAL REPORTS</b>		37 Advanced Assessment and Treatment of ADD	14
4 Effect of Modafinil on Cocaine Abstinence and Treatment Retention in Cocaine Dependence: Preliminary Results From an Open-Label Study	21	<b>INDUSTRY-SUPPORTED SYMPOSIA</b>	
92 Impulsivity, Sensation Seeking, and Coping Styles Among Substance Abusers	88	43 Treating ADHD Across the Life Cycle, Part 1	61
93 Substance Abuse Disorders and History of Childhood Sexual Abuse in a Population of U.S. Veterans	88	43 Treating ADHD Across the Life Cycle, Part 2	83
94 Attachments for In-Treatment Alcoholics and Teens Predicted to Be Addicts	88	<b>SCIENTIFIC AND CLINICAL REPORTS</b>	
<b>SYMPOSIA</b>		32 Efficacy and Safety of Atomoxetine in Adults With ADHD	44
5 Compulsive Buyers: Treating the Casualties of Consumerism	27	33 Adderall XR Dosed Once Daily in Adult Patients With ADHD	44
21 Update on Treatment of Stimulant Abuse	31	34 Alpha-1 Agonist Prazosin for ADHD: The Role of Norepinephrine in ADHD Pathology	44
58 Addictions: Cutting-Edge Treatments	57	62 An Open-Label Trial of Adderall XR: Quality-of-Life Assessments	68
86 The Veterans Administration Experience: Treating Comorbid Hepatitis C and Substance Use Disorders/Psychiatric Illness	92	63 Long-Term Safety and Efficacy of Adderall XR in Children With ADHD	68
103 Comorbidity With Substance Abuse	96	64 An Open-Label, Community-Assessment Trial of Adderall XR in Pediatric ADHD	68
<b>WORKSHOP - COMPONENT</b>		<b>SYMPOSIUM</b>	
4 Ambulatory Detoxification From Opioids: Doing It Well and Getting Paid Too	23	54 ADHD: Longer-Term Treatment for a Chronic Disorder	56
<b>TOPIC 3: ANXIETY DISORDERS</b>		<b>TOPIC 5: COGNITIVE DISORDERS (DELIRIUM, DEMENTIA, AMNESTIC, ETC.)</b>	
<b>INDUSTRY-SUPPORTED SYMPOSIA</b>		<b>ADVANCES IN RESEARCH</b>	
3 Anxiety Disorders: Sources, Signs, and Solutions	2	Advances in the Treatment of Alzheimer's Disease	
6 Beyond Benzodiazepines: New Molecules for the Treatment of Anxiety	3	19	
52 Striving to Heal the Mind: The Challenge of PTSD	82	<b>COURSES</b>	
<b>WORKSHOP - COMPONENT</b>		91 Alzheimer's Disease: Advanced Approaches to Treatment	62
4 Ambulatory Detoxification From Opioids: Doing It Well and Getting Paid Too	23	96 The Evaluation and Identification of the Major Dementias	72
<b>INDUSTRY-SUPPORTED SYMPOSIA</b>		<b>DISCUSSION GROUP</b>	
37 Slowing Disease Progression and the Long-Term Management of Dementia	58	26 Delirium and Dementia	
48 Challenges in Dementia: Evidence-Based Considerations From Early Diagnosis to Long-Term Management	81	<b>INDUSTRY-SUPPORTED SYMPOSIA</b>	
<b>LECTURE</b>		37 Slowing Disease Progression and the Long-Term Management of Dementia	58
18 The Meaning of Cognitive Impairment	67	48 Challenges in Dementia: Evidence-Based Considerations From Early Diagnosis to Long-Term Management	81

**RESEARCH ADVANCES IN MEDICINE** Page #  
Strokes 39

- SCIENTIFIC AND CLINICAL REPORTS**
- 5 Quetiapine Treatment of Hallucinations and Agitation of Lewy Body Disease 21
  - 29 Dyslexia as a Potential Index of Neurocognitive Impairments in Patients With Schizophrenia 44

- SYMPOSIA**
- 16 Cognitive Therapy in Novel Clinical Situations: Rationale, Issues, and Controversies 30
  - 46 Diverse Approaches to Alzheimer's Screening 54

**TOPIC 6: DISSOCIATIVE DISORDERS**

- CONTINUOUS CLINICAL CASE CONFERENCES**
- 1 A Case of Murder and Dissociative Identity Disorder: Real or Malingered Mental Illness? Part I 62
  - 2 A Case of Murder and Dissociative Identity Disorder: Real or Malingered Mental Illness? Part II 84

- SYMPOSIUM**
- 95 A Terrorist's Competency to Stand Trial: Assessing Amnesia 94

**TOPIC 7: EATING DISORDERS**

- COURSES**
- 5 Integrated Treatment of Eating Disorders 1
  - 21 Therapeutic Interventions in Eating Disorders: Basic Principles 6

- DISCUSSION GROUP**
- 22 Eating Disorders in Males: A Rising Tide 67

- INDUSTRY-SUPPORTED SYMPOSIA**
- 15 New Challenges in the Management of Depression 8
  - 45 Obesity in Psychiatric Practice: Recognition and Treatment, Part 1 61
  - 45 Obesity in Psychiatric Practice: Recognition and Treatment, Part 2 83

- SCIENTIFIC AND CLINICAL REPORT**
- 82 Binge Eating Disorder in Fiji, A Small-Scale, Indigenous Society 70

- SYMPOSIA**
- 4 Pathological Body Sculpting in the Athlete 27
  - 17 Eating Disorders 2003: From Laboratory to Practice 30
  - 98 New Research in the Biology and Treatment of Bulimia Nervosa 95

- WORKSHOPS - ISSUES**
- 14 Innovative Treatment in Bulimia Nervosa 18
  - 81 Family Therapy for Anorexia Nervosa 66

**TOPIC 8: MENTAL RETARDATION (CHILD/ADOLESCENT/ADULT)**

- WORKSHOP - COMPONENT**
- 40 Summary of the Surgeon General's Meeting on Health of the Mentally Retarded 85

- WORKSHOPS - ISSUES**
- 41 Challenging Behavior, Mental Illness, and Developmental Disabilities 40
  - 104 Dysmorphologies: Recognition and Treatment 86

**TOPIC 9: MOOD DISORDERS** Page #

- ADVANCES IN RESEARCH**
- The Latest Developments in the Genetics of Mood Disorders 19

- COURSES**
- 11 Neuroendocrinology in Mood Disorders: Dysregulation and Treatment 2
  - 34 Evidence-Based Management of SAD: Focus on Light Therapy 8
  - 38 ECT Practice Update 14
  - 50 The Conceptual Basis of Psychiatry 16

- DISCUSSION GROUP**
- 21 Controversies in Vascular and Post-Stroke Depression 67

- INDUSTRY-SUPPORTED SYMPOSIA**
- 2 Bipolar Disorder: Strategies for Stabilizing Patients Over the Long Term 2
  - 4 New Strategies for Managing Bipolar Disorder 2
  - 12 An Integrated Approach to the Management of Bipolar Disorder: An Alliance of Science and Medicine 6
  - 16 Issues in Treating Mania: Acute and Continuation Phase 9
  - 17 Tricks of the Trade in the Long-Term Treatment of Depression 9
  - 21 Peptides and Hormones as Targets in Antidepressant Treatment 10
  - 22 A Comprehensive Approach to Managing Bipolar Disorder: Bench to Bedside and Beyond 11
  - 32 Treating Depression: What Matters? Part 1 13
  - 32 Treating Depression: What Matters? Part 2 35
  - 34 Managing Anxiety and Sleep: A New Era for Gamma-Aminobutyric Acid, Part 1 14
  - 34 Managing Anxiety and Sleep: A New Era for Gamma-Aminobutyric Acid, Part 2 36
  - 35 Facing Unmet Needs: Atypical Antipsychotics for Mood and Anxiety 58
  - 36 Bipolar Disorder Across the Life Cycle 58
  - 40 Real-World Challenges in Depression and Anxiety 59
  - 49 Combined Pharmacotherapy for Bipolar Disorders 81
  - 51 Bipolar Disorder: Clinical and Public Health Implications of Medical and Psychiatric Comorbidity 81

- MASTER EDUCATOR CLINICAL CONSULTATION**
- 3 Treating Bipolar Depression 20

- RESEARCH ADVANCES IN MEDICINE**
- Vascular Depression 39
  - Depression and the Immune Response 39

- RESEARCH CONSULTATION**
- 1 The Genetics of Bipolar Disorder and Other Psychiatric Phenotypes 43

- SCIENTIFIC AND CLINICAL REPORTS**
- 17 Tridimensional Personality Questionnaire and Anxiety Disorder Comorbidity in MDD 22
  - 18 Difference in Subjective/Objective Sadness Predicts Drug Response 22
  - 19 Identifying Depression in Older Inpatients With the Geriatric Depression Scale and Structured Clinical Interview 22
  - 26 Continuation Cognitive-Behavioral Therapy Maintains Attributional Style Improvement in Depressed Patients Responding Acutely to Fluoxetine 43
  - 27 The Potential Relationship Between Levels of Perceived Stress and Specific Subtypes of Major Depression 43
  - 28 Symptom Severity and Exclusion From Antidepressant Efficacy Trials 43
  - 41 Cardiovascular Risk Factors Predict Treatment Outcome in MDD 45
  - 42 Prevalence and Characteristics of Patients With Depression and/or Chronic Pain 45
  - 43 Effectiveness of Collaborative Care in a Depressed, Poor, Primary Care Sample 45
  - 85 Effectiveness and Tolerability of Newer Antidepressants Among Depressed Chinese-American Patients 70

(Continued on next page)

## TOPIC INDEX

	Page #		Page #
104	89	<b>TOPIC 11: SCHIZOPHRENIA AND OTHER PSYCHOTIC DISORDERS</b>	
105	89	<b>ADVANCES IN RESEARCH</b>	
106	89	Pharmacologic Treatment of Schizophrenia: What Now, What Next?	19
116	90	<b>COURSE</b>	
117	90	58 Assessing Positive and Negative Symptoms in Psychosis With the PANSS	25
118	90	<b>DISCUSSION GROUP</b>	
		12 Schizophrenia and Aging	38
<b>SYMPOSIA</b>		<b>INDUSTRY-SUPPORTED SYMPOSIA</b>	
47	54	7 Enhancing Outcomes by Addressing Critical Challenges in the Treatment of Schizophrenia	3
49	55	25 Medical Considerations in the Management of Special Patient Populations	12
52	56	31 Managing the Spectrum of Psychotic Disorders, Part 1	13
72	77	31 Managing the Spectrum of Psychotic Disorders, Part 2	35
74	78	38 Optimizing Treatment for Patients With Schizophrenia: Targeting Positive Patient Outcomes	59
100	96	39 Biological and Psychological Advances in the Treatment of Schizophrenia: Revisiting and Updating Meyer's Psychobiology for the 21st Century	59
		50 Novel Therapeutic Options for Psychotic Disorders	81
<b>WORKSHOPS - COMPONENTS</b>		<b>LECTURES</b>	
7	23	6 Schizophrenia Is More Than a Neurodevelopmental Disease	25
34	71	11 Neurogenetics: Insights Into Neurodegeneration and Approaches to Schizophrenia	42
		21 Searching for Etiological Risk Factors of Schizophrenia	73
<b>TOPIC 10: PERSONALITY DISORDERS</b>		<b>MASTER EDUCATOR CLINICAL CONSULTATION</b>	
<b>COURSES</b>		1 Schizophrenia: What Is It? What Are Its Boundaries? Why Does It Persist in the Gene Pool?	17
2	1	<b>SCIENTIFIC AND CLINICAL REPORTS</b>	
6	1	14 Effects on Weight Change of Switching From Olanzapine to Quetiapine	22
55	25	50 Elevated Maternal Cytokine Levels and Schizophrenia in Adult Offspring	45
70	37	51 Association Between Psychotic Symptoms and Seizures in a Community Sample	45
<b>DEBATE</b>		52 Biological Mechanisms in Schizophrenic Thought Disorder and Delusions	45
Resolved: Personality Disorders Should Be Listed in Axis I DSM-V	16	80 Excess Mortality in Schizophrenia in Stockholm County, Sweden	70
<b>DISCUSSION GROUPS</b>		100 Modafinil as Adjunct Treatment in Schizophrenia: An Open-Label Study	88
5	20	<b>SYMPOSIA</b>	
7	20	28 Schizophrenia: Current Guidelines, Practices, and Effectiveness Research	33
<b>FOCUS LIVE</b>		39 Early Intervention in Psychosis: Where Science Meets Community Psychiatry	52
1	38	53 Comorbid Conditions in Schizophrenia: New Treatment Target or New Illness Model?	56
<b>MASTER EDUCATOR CLINICAL CONSULTATION</b>		64 Clinical Management of Schizophrenia With Comorbid Conditions	75
2	17	80 Meta-Analyses of the Efficacy of Second Versus First-Generation Antipsychotics	79
<b>SCIENTIFIC AND CLINICAL REPORTS</b>		93 Schizophrenia With Comorbidity: Diagnoses or Dimensions?	94
8	21	<b>WORKSHOP - ISSUE</b>	
9	21	96 Clinical Management of Difficult Schizophrenia	85
10	21		
<b>SYMPOSIA</b>			
1	26		
3	27		
69	76		
76	78		
83	91		
<b>WORKSHOP - ISSUE</b>			
31	24		

**TOPIC 12: SEXUAL AND GENDER IDENTITY DISORDERS** Page #

**COURSE**

101 Sexual Disorders: Diagnosis and Treatment 83

**DISCUSSION GROUP**

15 Clinical Implications of Sexual Dysfunction in Depression 42

**SYMPOSIUM**

24 Sexual and Gender Identity Disorders: Questions for DSM-V 32

**TOPIC 13: SLEEP DISORDERS**

**COURSES**

12 Dream Translation: One Empirically-Based Approach 2  
 31 Irresistible Sleep: Narcolepsy Update 8  
 53 Melatonin and Light Treatment of SAD, Sleep, and Other Body Clock Disorders 24  
 76 Overview and Update of Sleep Disorders Medicine 48  
 98 Update on Sleep Medicine: Advanced Topics 73

**INDUSTRY-SUPPORTED SYMPOSIA**

44 Insomnia in Today's Society: Consequences and Treatments, Part 1 61  
 44 Insomnia in Today's Society: Consequences and Treatments, Part 2 83

**SCIENTIFIC AND CLINICAL REPORTS**

119 Modafinil Improves Cognition in Narcolepsy Patients With Excessive Sleepiness 90  
 120 Modafinil as Adjunctive Therapy Improves Quality of Life in Sleep Apnea 90  
 121 Modafinil Improves Quality of Life as Adjunct Treatment of Obstructive Sleep Apnea 90

**TOPIC 14: SOMATOFORM DISORDERS**

**COURSE**

77 The Complexities of Chronic Pain: Multidisciplinary Treatment Approaches 48

**SYMPOSIUM**

63 The Nature and Treatment of BDD From Clinicians' and Patients' Perspectives 75

**PRACTICE AREAS/SETTINGS**

**TOPIC 15: PSYCHIATRIC ADMINISTRATION AND SERVICES: PUBLIC, PRIVATE, AND UNIVERSITY**

**COURSES**

8 Basic Concepts in Administrative Psychiatry I: Theory, Human Resources, and Fiscal Management 1  
 22 Basic Concepts in Administrative Psychiatry II: Care Management, Law, and Ethics 7

**DISCUSSION GROUP**

16 Psychiatric Leadership in the Medical Marketplace 42

**SYMPOSIA**

41 Science and Psychiatric Participation in Disaster Response 53  
 55 How to Launch a Successful Private Practice, Part 3 56

**WORKSHOPS - COMPONENTS**

31 CPT Coding and Documentation Update 70  
 33 State of the States for State Hospital Psychiatrists 71  
 41 The Administrative Psychiatry Credential 85

**WORKSHOPS - ISSUES**

53 How to Launch a Successful Private Practice, Part 1 41  
 55 Career Development and Risk Management 46  
 58 Women in Academic Psychiatry: Opportunities, Obstacles, and Strategies 47  
 63 How to Launch a Successful Private Practice, Part 2 47  
 66 The Disruptive Physician and Hospital Culture 65  
 67 The Unwritten Rules for Success as a Community Psychiatrist 65  
 105 Psychiatric Disability: The Role of Psychiatric Assessment 86

**SUBSPECIALTY AREAS OR SPECIAL INTERESTS**

**TOPIC 16: ADDICTION PSYCHIATRY**

**COURSES**

20 Achieving Effective Dual Diagnosis Treatment 5  
 89 Office-Based Buprenorphine Treatment for Opioid Dependent Patients 62

**DISCUSSION GROUP**

8 New Developments in Substance Dependence: Genetics, Criteria, and Treatment 20

**SCIENTIFIC AND CLINICAL REPORT**

2 Differences in Peripheral Noradrenergic Function Among Actively Drinking and Recently Abstinent Alcohol-Dependent 21

**SYMPOSIUM**

37 What the General Psychiatrist Needs to Know About Addiction Psychiatry 52

**WORKSHOPS - ISSUES**

100 Treating Addiction: Meeting New Needs in a New World 86  
 112 Harm Reduction: A Critical Review 91

**TOPIC 17: BIOLOGICAL PSYCHIATRY AND NEUROSCIENCE**

**COURSES**

9 Introduction to Transcranial Magnetic Stimulation 2  
 18 Behavioral Neuroanatomy: An Introduction 5  
 87 Behavioral Neuroanatomy: An Introduction 62  
 92 Back to the Future: The Evolutionary Framework for Psychiatry 63

**REVIEW OF PSYCHIATRY: SECTION 2**

Molecular Neurobiology for the Clinician 49

**SCIENTIFIC AND CLINICAL REPORTS**

3 Changes in Peripheral Noradrenaline and 5HT Levels and Craving During Alcohol Withdrawal 21  
 102 Depressed Women Have Elevated Coagulation Factors in Mid Life 89

**SYMPOSIA**

2 Mineral/Vitamin Modification of Mental Disorders and Brain Function 27  
 22 Interferon-Induced Neuropsychiatric Side Effects: New Data and Treatments 31

**WORKSHOP - ISSUE**

19 Ethnic Biodiversity in Substance Abuse and Mental Health Disorders 19

**TOPIC 18: CHILD AND ADOLESCENT PSYCHIATRY AND DISORDERS** Page #

**CLINICAL CASE CONFERENCES**

- 1 Diagnostic and Treatment Issues in the Care of an Adolescent With Comorbid Bipolar Disorder and ADHD 15
- 3 Treating the Chronically Medically Ill Adolescent: A Case Study 62

**INDUSTRY-SUPPORTED SYMPOSIA**

- 26 Treatment of Comorbidity in Neuropsychiatric Disorders in Children and Adolescents 12
- 47 Juvenile Bipolar Disorder: Contemporary Issues in Research 80

**LECTURE**

- 3 The Neurobiological Consequences of Child Abuse 16

**SCIENTIFIC AND CLINICAL REPORTS**

- 23 Management of Adolescent Mania 43
- 24 Exploratory Factor Analysis of BPD Criteria in Hospitalized Adolescents 43
- 25 Gender Differences in Comorbidities in Child and Adolescent GAD 43
- 35 Placebo-Controlled Study of Once-Daily Atomoxetine in the School Setting 44
- 36 Modafinil Improves ADHD Symptoms in Children in a Randomized, Double-Blind, Placebo-Controlled Study 44
- 37 Safety and Efficacy of OROS MPH in Adolescents With ADHD 44
- 44 Modafinil in Children With ADHD: A Randomized, Placebo-Controlled Study 45
- 45 Quetiapine Use in Children and Adolescents: A Literature Review 45
- 46 Clinical Review of OROS MPH in Children, Adolescents, and Adults With ADHD 45
- 74 Children Excluded From Primary School: Randomized, Controlled Trial of a Team Intervention 69
- 86 Consistency of ADHD Parent/Teacher Symptom Reports: Results of OROS MPH Studies 87
- 87 Patient and Parent Satisfaction of Once-Daily OROS MPH Formulation for ADHD 87
- 88 Driving Performance Among Adolescents With ADHD: Medication Effects 87

**SYMPOSIA**

- 6 Quality of Care for Children and Adolescents 28
- 25 Confronting Crises in Education, Mental Health, and Juvenile Justice 32

**WORKSHOPS - ISSUES**

- 85 Healing the Hurt Child: Treating Fetal Alcohol Syndrome Spectrum Disorder Children 71
- 93 Specific Psychotherapeutic Techniques for Adolescents 85
- 113 Parenting With the Brain in Mind: Attachment and Self-Understanding 91

**TOPIC 19: CONSULTATION-LIAISON AND EMERGENCY PSYCHIATRY**

**COURSES**

- 13 Psychiatric Consultations in Medical Settings: The Basics 5
- 41 Families Coping With Medical Illness: An Integrative Treatment Model 15
- 69 Med-Psych Drug-Drug Interactions: An Update 37

**DISCUSSION GROUP**

- 14 An Update on Pain Management (Meet the Authors) 41

**FORUM**

- 1 Working With Organized Medicine: The AMA and State Medical Societies 24

**INDUSTRY-SUPPORTED SYMPOSIUM** Page #

- 24 Psychiatry and Medicine: Common Patients, Different Perspectives 11

**LECTURE**

- 4 Making Health Care Safe 20

**MASTER EDUCATOR CLINICAL CONSULTATION**

- 6 Engaging the Disengaged: Connecting With Marginalized Patients 43

**RESEARCH ADVANCES IN MEDICINE**

- New and Improved Understanding of Headaches 39

**SCIENTIFIC AND CLINICAL REPORT**

- 6 Survey of Practice Preferences in the Pharmacotherapy of Delirium 21

**SYMPOSIUM**

- 75 Roles for Psychiatry in End-of-Life Care 78
- 94 Delirium Subtypes: Diagnosis and Treatment 94

**WORKSHOPS - COMPONENTS**

- 1 Restraints: Strategies to Reduce and Optimize Patient Safety 17
- 25 Patient Safety in Psychiatry: Reducing Adverse Medication Events 64

**WORKSHOP - ISSUE**

- 79 Hepatitis C Infection: The Next Psychiatric Epidemic 66

**TOPIC 20: CROSS-CULTURAL AND MINORITY ISSUES**

**COURSES**

- 46 DSM-IV-TR Cultural Formulations: Diagnosis and Therapy 15
- 67 The Clinical Application of Cultural Psychiatry 36

**DISCUSSION GROUPS**

- 3 Cross-Cultural Psychiatry: The Acculturation Process 16
- 24 Cross-Cultural Issues: When the Patient Is Different From You (For Residents Only) 67

**LECTURES**

- 15 Mental Illness, Human Rights, Science, and Culture: A Videotaped Documentation of Conditions in Mexican Psychiatric 49
- 16 Health, Culture, and South-Asian Indians in North America 63
- 23 Remembering the Past and Living in the Now: Modernization in East Asian Countries and Psychotherapy 84
- 24 Culture/Racism and Ethnic Diversity With Past Corrective Actions, Successes, and Failures 87

**MASTER EDUCATOR CLINICAL CONSULTATION**

- 4 Cross-Cultural Issues in Psychiatric Care 21

**SCIENTIFIC AND CLINICAL REPORT**

- 84 When the Poetry No Longer Rhymes: Somalis in the American Psychiatric Clinic 70

**SYMPOSIA**

- 8 Challenges in Cross-Cultural Psychiatry: Focus on Depression and Ethnopsychopharmacology 28
- 23 Roads to Healing in Mental Health in the Americas 32
- 35 Developing Culturally Competent Services for Minority Populations 51
- 87 Children at Risk for Mental Illness in Latin America 92
- 91 Conceptualizations of Jeong and Its Application to the Healing Process 94



**WORKSHOPS – COMPONENTS** **Page #**

16	It Doesn't Happen to Us: Insider's View of Trauma in Minority Communities	40
17	Racism: Diagnostic and Treatment Considerations	40
35	Why Psychiatry? Says Mom	71
36	Clinical Issues of Ethnic Diversity in Long-Term Care Facilities	71
43	Biracial or Bicultural Americans: Issues and Insights for Therapy	90

**WORKSHOPS - ISSUES**

30	Mind-Body Connection in Traditional Chinese Medicine	24
45	Surgeon General's Report on Culture, Race, and Ethnicity: Clinical Implications	41
60	Asian Indians in Interfaith Marriages: Challenges, Conflicts, and Compromises	47
64	Culture, Race, Ethnicity, and Psychopharmacology: Recent Research Advances	65
71	Matchmaker, Matchmaker Make Me a Match	66
74	Cutting-Edge Issues in Cross-Cultural Psychiatry	66
95	A Program to Enhance Cultural Competency in Residency Training	85
106	The Meaning of the Pacific Rim for World and American Psychiatry	86
110	Psychiatric Care of Muslim Patients: A U.S. Perspective	87
115	Bridging the Gap Between Mental Health and Primary Care for Asian Americans	91
117	Racial, Ethnic, and Cultural Bias in Psychotherapy	91

**TOPIC 21: DIAGNOSTIC ISSUES**

**CLINICAL CASE CONFERENCE**

4	Dealing With Diagnostic Ambiguity: When Somatic Memory and Anxiety Symptoms Confuse	84
---	---	----

**REVIEW OF PSYCHIATRY: SECTION 3**

Standardized Evaluation in Clinical Practice	64
--	----

**SCIENTIFIC AND CLINICAL REPORTS**

57	Diagnosing and Treating Infants and Toddlers in Public Mental Health Settings	68
58	Psychiatric Nomenclature	68

**SYMPOSIA**

11	Evaluating Clinical Competence: Current Options, Future Directions	29
60	World Psychiatric Association's International Guidelines for Diagnostic Assessment	74
61	Dimensionality in Psychiatric Disorders	74
77	The Dual-Diagnosis Challenge: Assessment and Treatment	78

**WORKSHOP - COMPONENT**

6	The Research Base for New Diagnostic Criteria for Depression	23
---	--	----

**WORKSHOP - ISSUE**

91	The Uses and Abuses of Psychiatric Independent Medical Examinations: An Ethical Dilemma?	85
----	--	----

**TOPIC 22: EPIDEMIOLOGY**

**SCIENTIFIC AND CLINICAL REPORTS**

53	Diagnoses in Behavioral Health Clinics: Impact on Perceived Burden of Mental Health	46
54	The Treatment Gap in Mental Health Care	46
55	Projecting National Survey Prevalences to Populations of Interest	46
81	Sex Differences in Health Service Use and Functioning Associated With Depressive Symptoms: Findings From the Utrecht Health Project	70

**TOPIC 23: ETHICS AND HUMAN RIGHTS** **Page #**

**COURSES**

23	Medical Ethics 101	7
78	The Juvenile Justice Clinic: Administrative Issues and Treatment Options	48

**FORUM**

10	APA and the Pharmaceutical Industry: Controversies and Approaches	72
----	---	----

**PRESIDENTIAL SYMPOSIA**

1	Moral and Philosophical Issues in Psychiatry	26
2	The Foundation of Medical Ethics/Informed Consent	49

**SCIENTIFIC AND CLINICAL REPORTS**

89	Factors Associated With Determining Competence to Consent in Acute Psychoses	88
90	Ethical Challenges of Managing Pregnant Patients Who Have Schizophrenia	88

**SYMPOSIUM**

56	Ethical Issues in the U.S. and France: Vive La Difference	57
----	---	----

**WORKSHOPS - COMPONENTS**

14	New APA Ethics Procedures: Implications for the Profession, Part 1	39
21	New APA Ethics Procedures: Implications for the Profession, Part 2	46
26	What Is the Ethical Stance? Issues Related to World Psychiatry and Courts	65

**WORKSHOPS - ISSUES**

3	Moral Aspects of Clinical Practice: A Functional Approach	17
10	Nonsexual Boundary Violations	18
36	Consent Evaluations: Assessing Capacity for Decision Making and for Voluntarism	40
46	The Psychiatric Care of Survivors of Torture	41
50	Psychiatric Perspectives on the Execution Process: A Continuing Conundrum	41
65	Revision of the APA Ethics Annotations: Fostering Dialogue	65
86	Going Public Over Patient Privacy	71
89	Teaching Psychiatric Ethics Engagingly, Effectively	85

**TOPIC 24: FORENSIC PSYCHIATRY**

**COURSES**

19	Contemporary Malpractice Liability: A Practical Guide	5
35	The Psychiatrist as Expert Witness	14
62	The Detection of Malingered Mental Illness	36
83	Insanity Defense Evaluations	61

**DISCUSSION GROUPS**

1	Infanticide: Psychosocial and Legal Perspectives of Mothers Who Kill (Meet the Authors)	16
13	An Introduction to Starting a Forensic Psychiatric Practice	38

**LECTURES**

1	Expert Testimony in the Age of Daubert	10
2	Labeling the Dissenter as Mad: Forensic Psychiatry in China and Its Political Abuses	16

**SCIENTIFIC AND CLINICAL REPORT**

75	Malpractice Liability and Managed Care: Is a Resolution in Sight?	69
----	---	----

**SYMPOSIUM**

44	The Evil Standard: Milestones and Challenges	54
----	--	----

**WORKSHOP - COMPONENT**

42	Practicing Rewarding Psychiatry in Jails and Prisons: A Practicum	85
----	---	----

## TOPIC INDEX

<b>WORKSHOPS – ISSUES</b>	<b>Page #</b>	<b>SCIENTIFIC AND CLINICAL REPORTS</b>	<b>Page #</b>
20 Distinguishing Mental Illness From Bad Behavior in Prisoners	19	30 Previous Head Injuries in Psychiatric Inpatients	44
23 Restorative Justice and Therapeutic Jurisprudence: An Enjoyable Exchange of Ideas	19	31 Neurofeedback to Increase Remission Rates in Depression	44
32 Discussing the Concept of Mental Health Courts	24	<b>SYMPOSIUM</b>	
34 Patient Responsibility for Addiction to Prescribed Substances	24	32 An Update on Parkinson's Disease and Its Psychiatric Complications	50
68 The Montgomery County Emergency Service Diversion Model: A Comprehensive Continuum of Forensic Interventions	65	<b>TOPIC 28: PSYCHIATRIC EDUCATION</b>	
75 The Psychiatrist's Nightmare: A Malpractice Lawsuit	66	<b>COURSES</b>	
<b>TOPIC 25: GENETICS</b>		33 Integrative Psychotherapy Supervision: Basic Tools	8
<b>COURSE</b>		40 Teaching Psychiatry? Let Hollywood Help!	14
84 Psychiatric Genomics: Applications for Clinical Practice	61	<b>FORUM</b>	
<b>INDUSTRY-SUPPORTED SYMPOSIUM</b>		8 ABPN Update: Requirements for ABPN Examination	72
5 Genetics and Psychiatry: Real Genes, Real Progress	3	<b>LECTURE</b>	
<b>LECTURES</b>		14 The Healer's Art: Undergraduate Education for Meaning and Commitment	49
10 Genes, Family Relationships, and DSM-V	38	<b>MEDICAL UPDATE</b>	
12 The Search for Genes of Bipolar Disorder: From Classical Genetics to Novel Molecular Targets	42	4 Club Drugs: A Primer for Mental Health Professionals	87
22 The Revolution in Mouse Molecular Genetics: New Approaches for Psychiatric Research	74	<b>SCIENTIFIC AND CLINICAL REPORT</b>	
<b>MEDICAL UPDATE</b>		20 Psychiatry Training in Primary Care: Current Status and Satisfaction	22
1 Ethnicity and Pharmacogenetics	21	<b>SYMPOSIA</b>	
<b>TOPIC 26: GERIATRIC PSYCHIATRY</b>		9 Core Competencies: How They Fit Into Certification and Recertification	28
<b>REVIEW OF PSYCHIATRY: SECTION 4</b>		13 Evolution of the Social Brain: Implications for Medical Education and Treatment	29
Geriatric Psychiatry	74	67 Replenishing Ourselves: Supply of Psychiatrists for the Present and the Future	76
<b>SCIENTIFIC AND CLINICAL REPORTS</b>		92 Boundaries Education: An Expert Update on Diverse Approaches and Settings	94
7 Hyponatremia Associated With the Use of Antidepressants in Geriatric Patients	21	<b>WORKSHOPS - COMPONENTS</b>	
65 NIMH Atypical Antipsychotic Effectiveness Trial In Alzheimer's CATIE-AD	69	10 Practical Tips on How to Be a Successful Author	39
66 Meta-Analysis of Risperidone for Dementia: The Price Paid for Efficacy	69	11 How to Provide Geriatric Psychiatry During Residency	39
67 Switching Elderly Chronic Schizophrenia Patients to Olanzapine: A Prospective Study	69	<b>WORKSHOPS - ISSUES</b>	
<b>WORKSHOPS - ISSUES</b>		8 Institute of Medicine Study: Incorporating Research Into Residency Training	18
15 Management of Disinhibition in Dementia	18	29 Psychotherapy With African-American Patients: Training Perspectives	23
51 From Neuropathology to Treatment: Emerging Treatment Strategies for Alzheimer's Disease	41	38 Psychiatry Training for Primary Care Physicians: What, How Much, and How?	40
<b>TOPIC 27: NEUROPSYCHIATRY</b>		90 Neurobiology of Learning: Moving From the Ivory Tower Into the Classroom	85
<b>COURSES</b>		<b>TOPIC 29: PSYCHIATRIC REHABILITATION</b>	
4 Determining Medical Fitness to Drive: Relevant Issues for Psychiatrists	1	<b>COURSE</b>	
17 Psychiatric Disorders Related to Epilepsy	5	100 Recovery From Mental Illness and Stigma: Integration of Medicine and Recovery	83
43 Update in Neuropsychiatry: Delirium, Traumatic Brain Injury, and Post-Stroke Depression	15	<b>SYMPOSIUM</b>	
44 Advances in Neuropsychiatry	15	42 Recovery From Schizophrenia: A Challenge for the 21st Century	53
94 Traumatic Brain Injury: Neuropsychiatric Assessment	63	<b>WORKSHOP - COMPONENT</b>	
<b>INDUSTRY-SUPPORTED SYMPOSIA</b>		39 Never-Taught Dilemmas: When Work and Disability Issues Impact Patient Care	84
11 Enhancing Skill Treating Comorbid Depression and Neurological Illness	6	<b>WORKSHOP - ISSUE</b>	
20 Depression, Apathy, and Fatigue in Neuropsychiatric Disorders	10	114 Service Integration and Continuity in California: Programs From Harbor-UCLA	91
28 Impairment of Structural Plasticity in Severe Mood Disorders: Causal or Collateral? Part 1	13		
28 Impairment of Structural Plasticity in Severe Mood Disorders: Causal or Collateral? Part 2	35		

**TOPIC 30: PSYCHOANALYSIS**

**SYMPOSIA**

33	Coping With Catastrophe	51
104	Love From Pathology to Normality: French and American Style, Part 2	97

**TOPIC 31: RESEARCH ISSUES**

**COURSES**

66	Doing Research on a Shoestring Budget	36
102	Assessment and Treatment of Drug-Induced Movement Disorders	84

**NEW RESEARCH SESSIONS**

1	Young Investigators' Poster Session	17
2	Young Investigators' Oral/Slide Session	25
3	Young Investigators' Oral/Slide Session	25
4	Young Investigators' Oral/Slide Session	25
5	Poster Session	33
6	Poster Session	47
7	Poster Session	58
8	Poster Session	72
9	Poster Session	80
10	Poster Session	91

**SYMPOSIA**

36	The Ethnicity Factor in Psychiatric Research: Identity and Methodology Issues	51
40	Dehydroepiandrosterone: Neurosteroid Mechanisms, Epidemiology, and Applications in Psychiatry	53

**TOPIC 32: SOCIAL AND COMMUNITY PSYCHIATRY**

**COURSES**

28	Organizational and Group Interventions Following Disasters	7
60	Disaster Psychiatry: Terrorism, Trauma, and Things to Do	36
82	Psychiatric Interventions in Disasters: Lessons From Experience	61

**FORUM**

9	Meaningful Activities and Structure Matter: How a Prevocational Program Helps Severely Mentally Ill Clients	72
---	---	----

**LECTURES**

5	Community Psychiatry: 1963-2003	20
17	Can Psychiatry Improve Community Welfare? New Research and Practice Paradigm	63

**SYMPOSIUM**

78	Is This an ACT or an Act? Approaches to Assertive Community Treatment	79
----	---	----

**WORKSHOP - COMPONENT**

29	Trauma and Homelessness: Psychiatric Aspects of a Socioeconomic Problem	65
----	---	----

**WORKSHOPS - ISSUES**

16	Preparing Psychiatrists for Mass-Casualty Events	19
21	Lessons Learned From September 11	19
25	Long-Term Structured Care: A Family Perspective	23
47	Development of the School-Based Adolescent Depression Awareness Program	41

**TOPIC 33: STRESS**

**COURSE**

54	Child Murder by Parents	24
----	-------------------------	----

**INDUSTRY-SUPPORTED SYMPOSIUM**

19	Stress, Psychopathology, and the Brain: Novel Intervention Strategies	9
----	---	---

**MEDICAL UPDATE**

3	Yogic Breathing: Neurophysiologic Theory and Clinical Applications for Treatment of Stress Related Disorders, Depression, and Aggression	68
---	--	----

**WORKSHOPS - ISSUES**

49	Psychiatric Illness and the Workplace	41
77	Intergenerational Transmission of Trauma in Prevention of Long-Term Consequences of Traumatic Stress	66

**TOPIC 34: SUICIDE**

**INDUSTRY-SUPPORTED SYMPOSIA**

27	Reducing Suicidality in Schizophrenia and Bipolar Disorder	12
29	Impulsivity, Aggression, and Suicide: Versatility of Lithium and Mood Stabilizers, Part 1	13
29	Impulsivity, Aggression, and Suicide: Versatility of Lithium and Mood Stabilizers, Part 2	35

**MASTER EDUCATOR CLINICAL CONSULTATION**

7	Rational or Rationalized Suicide? An Ethical/Clinical Dilemma	43
---	---	----

**SCIENTIFIC AND CLINICAL REPORTS**

47	Personality Traits as Predictors of Suicidality in Young Women	45
48	Suicidal Behavior in Violent and Nonviolent Psychiatric Patients	45
49	Obstetric Complications and Suicide Risk in Adolescence and Young Adulthood	45
71	Impulsivity, Suicide, and Prefrontal Hypometabolism in Borderline Personality	69
72	Suicide Rates Over the Decade Across Civilian and Military Populations	69

**WORKSHOP - COMPONENT**

20	Patient Safety in Psychiatry: Reducing Inpatient Suicide	46
----	--	----

**WORKSHOPS - ISSUES**

26	Imminent Risk of Suicide in Correctional Facilities	23
27	The Impact of Suicide on Clinicians	23
107	An Update on Management of Suicide Attempts: A Review for Clinicians	86

**TOPIC 35: VIOLENCE, TRAUMA, AND VICTIMIZATION**

**COURSES**

15	Risk Assessment for Violence	5
64	Sexual Harassment: Psychological and Legal Aspects	36
71	Personality and Political Behavior	37
88	Assessing the Risk of Violence in Both Forensic and Sex Offender Settings	62
95	Men Sexually Abused as Boys: Meanings, Consequences, and Treatment	72

**FORUMS**

5	Terrorism and Psychosocial Preparedness	47
7	Intimate Partner Violence and Abuse: Identification and Intervention Within a Behavioral Health Study	47

**REVIEW OF PSYCHIATRY: SECTION 1**

2003 Psychiatry Update: Trauma and Disaster Responses and Management	39
--	----

**SCIENTIFIC AND CLINICAL REPORTS**

73	Clozapine Reduces Violent Behavior in Heterogeneous Diagnostic Groups	69
107	Treatment Outcome for Sexually Abused Children at One-Year Follow-Up	89
108	Psychological Symptoms Six Years After a Plane Crash	89

## TOPIC INDEX

### SYMPOSIA

	Page #
18 Advances in the Treatment of Childhood Traumatic Grief	30
38 Early Trauma: Strategies for Intervention and Treatment	52
45 Bereavement After Violent Death	54
48 The Spectrum of Sexual Violence: Clinical and Cultural Impact	55
70 Terrorism, War, and Refugees: Psychiatric Effects and Prevention?	77
81 The Psychological Impact of 9/11: Results From Five Major Studies	79
99 Terrorism and Political Violence in the 21st Century: New Forms and Responses	95

### WORKSHOPS - COMPONENTS

2 Early Intervention Following Mass Violence: Designing an Effective Approach	17
19 Sexual Harassment: Victims Face Confidentiality Issues in Psychiatric Care	46
28 Global Trauma: Experience and Implications for DSM-V	65

### WORKSHOPS - ISSUES

24 Youth Violence: Principles of Prevention	19
52 The Emerging Role of Psychiatry in a Bioterrorism Response	41
62 Post-Genocide Psychological Trauma in Film: Under the Domain Tree	47
109 Inpatient Violence: Lessons From the Inner-City Psychiatry Hospital	86

## TREATMENTS

### TOPIC 36: BEHAVIOR AND COGNITIVE THERAPIES

#### COURSES

29 Cognitive Therapy for Schizophrenia	8
51 Cognitive Therapy: The Basics	24
56 Engaging Resistant and Hostile Patients Into Participatory Treatment	25
63 Integrating Psychotherapy and Pharmacotherapy	36
68 Cognitive Therapy for Severe Mental Disorders	37
73 Introduction to Cognitive-Behavioral Therapy	37
74 Basic Hypnosis: Principles and Applications	37
93 Advanced Hypnosis: Applications in Psychiatry	63

### SCIENTIFIC AND CLINICAL REPORTS

76 The Power of Humor in Psychotherapy	69
114 The Effective Delivery of Cognitive-Behavioral Therapy for Panic Disorder: An International Multicenter Trial	90

### WORKSHOPS - ISSUES

1 Teaching Cognitive-Behavior Therapy: Effective Training in Unexpected Settings	17
48 Developments in Cognitive Therapy for Schizophrenia	41
56 Therapeutic Issues in Self-Injurious Behavior	46

### TOPIC 37: COMBINED PHARMACOTHERAPY AND PSYCHOTHERAPY

#### COURSE

86 A Psychodynamic Approach to Treatment Refractory Mood Disorders	62
--	----

### INDUSTRY-SUPPORTED SYMPOSIUM

18 Pharmacological Treatment of Chronic Pain: Comorbidity With Depression and Other Psychotic Disorders	9
---	---

### SCIENTIFIC AND CLINICAL REPORT

115 Efficacy of Self-Administered Cognitive-Behavior Therapy and Sertraline in Panic Disorder	90
---	----

### SYMPOSIUM

29 Integrated Treatment: Psychopharmacology and Psychotherapy	50
---	----

### WORKSHOPS - ISSUES

	Page #
11 Psychological Management of Psychosis	18
101 Psychodynamics in Treatment-Refractory Depression	86
102 Bridges for Healing: Integrating Family Therapy and Psychopharmacology	86

### TOPIC 38: COUPLE AND FAMILY THERAPIES

#### WORKSHOPS - ISSUES

76 Counseling Committed Couples: Rethinking Therapeutic Neutrality	66
84 The Beginning Stages of Couples' Therapy: Video Case Studies	71

### TOPIC 39: GROUP THERAPY

#### COURSE

10 Group Therapy for People With Chronic Mental Illness	2
---	---

### TOPIC 40: INDIVIDUAL PSYCHOTHERAPIES

#### COURSES

3 Antipsychotic-Induced Movement Disorders: Assessment and Treatment	1
7 Interpersonal Psychotherapy	1
14 Interpersonal Psychotherapy	5
26 Davanloo's Intensive Short-Term Dynamic Psychotherapy in Clinical Practice	7
27 Brief Psychodynamic Psychotherapy: The Core Conflictual Relationship Theme Method	7
45 Psychiatry Update: In Spanish	15
49 Advanced Interviewing Techniques	15
57 The Advanced Practice of Psychotherapy	25
81 An Integrative Approach to Facilitate the Working-Through Process	48

#### FORUM

4 Neurobiology of Parent-Child Relationships: Applications to Psychotherapy	47
---	----

### SYMPOSIA

50 Boundary Crossings: Creative Therapy or Slippery Slopes?	55
62 Workplace Issues in Psychotherapy	75

### WORKSHOPS - ISSUES

7 Meditation: Theory, Therapy, Research, and Practice	18
12 Working Through in Psychotherapy	18
35 Brief Psychodynamic Psychotherapy of Panic: A Learning-Strategy Approach	40
39 Dynamic Therapy With Self-Destructive Borderline Patients	40
78 Individual Psychotherapy for Marital Problems	66

### TOPIC 41: PSYCHOPHARMACOLOGY

#### COURSE

36 Drug Treatment of Schizophrenia	14
------------------------------------	----

#### DISCUSSION GROUPS

4 Some Recent Advancements in Psychopharmacology	16
10 Practical Psychopharmacology for the Busy Clinician (Meet the Authors)	38

#### FORUM

6 Prozac on the Couch	47
-----------------------	----

### INDUSTRY-SUPPORTED SYMPOSIA

1 Schizophrenia Treatment in the Community: The Role of Long-Acting Antipsychotics	1
9 Diagnosis and Treatment: Mood Stabilizers Across the Psychiatric Spectrum	5
42 Neuropsychiatry in the Age of Polypharmacy, Part 1	61
42 Neuropsychiatry in the Age of Polypharmacy, Part 2	83

<b>LECTURE</b>	<b>Page #</b>	<b>FORUM</b>	<b>Page #</b>
19 Better Than Prozac: Creating New Psychiatric Drugs	67	2 The Placebo Effect: Science, Belief, and Clinical Practice	24
<b>SCIENTIFIC AND CLINICAL REPORTS</b>		<b>INDUSTRY-SUPPORTED SYMPOSIA</b>	
15 A Three-Week Comparison of Olanzapine Versus Risperidone in the Treatment of Bipolar Mania: Improvement in Manic and Depressive Symptoms and Treatment Adherence	22	13 Remission in Psychiatric Disorders: Definitions, Issues, and Treatments	6
16 Olanzapine/Fluoxetine Combination and Olanzapine in the Treatment of Bipolar Depression	22	14 Barriers to Optimal Outcome in Anxiety and Depression	8
38 Onset and Maintenance of Antidepressant Efficacy for Duloxetine 60 mg QD	44	23 A Rational Algorithm for Selecting Atypicals in Schizophrenia and Bipolar Disorders	11
39 Depressive Subtypes and Response to Augmentation or Dose Increase Among Outpatients Resistant to Fluoxetine 20 mg a Day	44	33 Evidence-Based Treatment of Psychiatric Disorders, Part 1	14
40 Treatment-Related Adverse Events in a 20 mg Open-Trial of Fluoxetine: Predictors of Emergence and Impact on the Course of Treatment	44	33 Evidence-Based Treatment of Psychiatric Disorders, Part 2	35
59 TAK-375 Is a Highly Selective Agonist at the ML-1 Receptor	68	<b>MASTER EDUCATOR CLINICAL CONSULTATION</b>	
60 Safety, Pharmacokinetics, and Pharmacodynamics of TAK-375 in Healthy Adults	68	5 Psychotherapeutic Diagnoses and Treatment Planning	39
61 Selectivity of the ML-1 Agonist TAK-375: Lack of Binding to NON-ML-1 Targets	68	<b>SCIENTIFIC AND CLINICAL REPORTS</b>	
68 Serum Lipid Fractions in Clozapine-Treated Patients Over a Two-Year Period	69	56 The Development of a Brief Adult Mental Health Screening Tool for Jails	68
79 Treatment of Tension Headache With Mirtazapine	70	69 The Influence of Group Psychoeducation on Quality of Life in Schizophrenia Patients and Their Relatives	69
99 Rivastigmine and Glantamine Treatment for Schizophrenic Cognitive Impairment	88	<b>SYMPOSIA</b>	
111 Efficacy and Safety of Sildenafil Citrate in Men With Serotonergic-Antidepressant-Associated Erectile Dysfunction: Results of a Prospective, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial	89	34 Strategies to Overcome Resistance	51
112 Pretreatment Characteristics of Placebo Response in Major Depression	89	84 The Difficult-to-Treat Psychiatric Patient	92
<b>SYMPOSIA</b>		<b>WORKSHOP - COMPONENT</b>	
88 Polypharmacy: Evidence Basis Versus Clinical Experience	93	3 Patient Safety in Psychiatry: Minimizing the Use of Restraint and Seclusion	17
101 New Intravenous Treatments: A New Tool to Overcome Difficulties and Resistance	96	<b>OTHER ISSUES</b>	
<b>WORKSHOPS - ISSUES</b>		<b>TOPIC 44: COMPUTERS</b>	
28 Evidence-Based Medicine: An Application in Child and Adolescent Psychopharmacology	23	<b>COURSES</b>	
42 Treatment of Schizophrenia: Antipsychotic Polypharmacy Versus Monotherapy	40	24 Build Your Own Relational Database Electronic Medical Record	7
44 The Benzodiazepine Controversy	41	32 Computer-Assisted Diagnostic Interview	8
<b>TOPIC 42: OTHER SOMATIC THERAPIES</b>		<b>WORKSHOPS - ISSUES</b>	
<b>COURSE</b>		43 Relevant Data for the Practicing Psychiatrist: Comorbidities/ Combined Treatment	40
42 Using Neurofeedback in Your Practice: Latest Trends and Hands-On Experience	15	57 Technology Serves the Patient: Algorithms, Monitoring, and Decision Support	46
<b>TOPIC 43: TREATMENT TECHNIQUES AND OUTCOME STUDIES</b>		69 Electronic Medical Records Enhance Quality and Productivity: The Time Has Come	65
<b>CLINICAL CASE CONFERENCE</b>		92 Beyond The Chalk Board: Using Computers to Enhance Psychiatric Education	85
2 Dyskinesias in a Somatically Preoccupied Patient After Treatment With Atypical Antipsychotics	37	116 Computer-Assisted Psychotherapy in Clinical Practice	91
<b>CONTINUOUS CLINICAL CASE CONFERENCES</b>		<b>TOPIC 45: CREATIVITY AND THE ARTS</b>	
1 Treatment of the VIP Patient: Two Patients, Two Therapists: Part 1	15	<b>COURSE</b>	
2 Treatment of the VIP Patient: Two Patients, Two Therapists: Part 2	37	79 Writing About Clinical Experiences	48
<b>DISCUSSION GROUP</b>		<b>FORUM</b>	
25 Relevance of Treatment Algorithms in Clinical Care	84	3 Music and the Mind: George Gershwin	24
		<b>LECTURE</b>	
		8 Horsemen of the Apocalypse: Terror, Nihilism, and Science	34
		<b>WORKSHOPS - ISSUES</b>	
		22 A Psychiatrist's View on Artists and the Arts	19
		37 Artistic Use of the Creative Unconscious in the Therapeutic Alliance	40
		59 The Art of the Unconscious: Shakespeare, Poetry, Film, and Psychiatry	47
		72 The Portrayal of Psychiatry in Recent American Film	66

**TOPIC INDEX**

<b>TOPIC 46: GENDER ISSUES</b>	<b>Page #</b>	<b>TOPIC 52: MANAGED CARE AND HEALTH CARE FUNDING</b>	<b>Page #</b>
<b>DISCUSSION GROUPS</b>		<b>COURSE</b>	
6 Gender and Cultural Issues in Diagnosis and Treatment	20	59 Current Coding and Documentation Requirements	25
20 Women in Leadership: Problems, Prospects, and Proposals	63	<b>SCIENTIFIC AND CLINICAL REPORT</b>	
<b>MASTER EDUCATOR CLINICAL CONSULTATION</b>		91 Schizophrenia and Suicide in the Managed Care Era	88
8 Women in Leadership: Understanding Achievement Obstacles	64	<b>WORKSHOP - COMPONENT</b>	
<b>WORKSHOPS - COMPONENTS</b>		37 Implications of Financing of Health Care for Psychiatric Education and Practice	71
23 Women's Leadership 101	64	<b>TOPIC 53: POLITICAL QUESTIONS</b>	
38 Intersex Conditions: Controversies and New Approaches to Treatment	71	<b>SYMPOSIUM</b>	
<b>WORKSHOP - ISSUE</b>		10 Psychiatry and the Pharmaceutical Industry: Where Is the Boundary?	28
70 Individual Psychotherapy With Men Suffering From Father Loss	65	<b>WORKSHOP - ISSUE</b>	
<b>TOPIC 47: HEALTH SERVICES RESEARCH</b>		88 International Psychiatric/Psychopharmacological Organizations' Collaboration	72
<b>SYMPOSIA</b>		<b>TOPIC 54: PROFESSIONAL AND PERSONAL ISSUES</b>	
43 The Invisible Plague: Severe Mental Illness	53	<b>COURSE</b>	
85 Quality Measurement in a Canadian Inner-City Academic Environment	92	72 Money Matters: Using Theory in Clinical Practice	37
89 Truth and Expectations in Psychopharmacology Research	93	<b>DISCUSSION GROUPS</b>	
<b>TOPIC 48: HISTORICAL QUESTIONS</b>		11 Protecting Clinical Autonomy	38
<b>LECTURE</b>		19 Evidence-Based Psychiatry: The Promise and Pitfall of Translating Science Into Practice	63
7 The Commitment of Psychiatrists: Lessons From Al-Andalus	26	<b>LECTURE</b>	
<b>TOPIC 49: INFORMATION TECHNOLOGY</b>		13 Psychiatric Organizational Leadership: Reflections, Predictions, and Proposals	48
<b>COURSES</b>		<b>SYMPOSIA</b>	
48 Evidence-Based Medicine: An Introduction for Psychiatrists	15	7 Practicing Psychiatry in 2003	28
52 How to Use Your Palm OS PDA in Psychiatric Practice: Basic	24	102 Interests and Vulnerabilities of Health Care Practitioners	96
80 How to Use Your Palm OS PDA in Psychiatric Practice: Advanced	48	<b>WORKSHOPS - COMPONENTS</b>	
<b>WORKSHOPS - ISSUES</b>		8 Medicare Update 2003	23
17 Implementing Web-Based Psychopharmacology Algorithms: Problems and Solutions	19	13 IMGs: Challenges and Solutions	39
97 CD-ROMs for Dummies: A Step-by-Step Guide for Developing Educational CDs	86	32 Retirement Issues for Psychiatrists and Their Spouses	71
98 Making the Media Work for You	86	<b>WORKSHOPS - ISSUES</b>	
<b>TOPIC 50: INTERNET</b>		6 Risk-Management Issues in Psychiatric Practice	18
<b>COURSE</b>		13 Depression and the Physician: When Being a "Good" Doctor Is Not Enough	18
97 Psychiatry and the Internet	72	33 Learning Psychotherapy in Private Practice	24
<b>SYMPOSIUM</b>		73 When Psychiatrists Have a Mental Illness: The Stories of Their Loved Ones	66
59 Internet: Technical, Clinical, and Societal	57	82 Helping the Healers: Providing Impairment Education to Physicians	66
<b>TOPIC 51: LESBIAN/GAY/BISEXUAL/TRANSGENDER ISSUES</b>		83 Do I Need an MBA to Transform My Career?	71
<b>SYMPOSIA</b>		87 Children of Psychiatrists: Insights and Recommendations From Those Who Know	72
30 Recent Developments in Gay and Lesbian Mental Health: A Global Perspective	50	94 Psychiatric Treatment and Personal Growth: What About Us?	85
31 New Research in Gay, Lesbian, and Bisexual Mental Health Morbidity	50	118 Essential Skills 101: Writing Manuscripts for Publication	91
82 Gay and Lesbian Parenting	80	<b>TOPIC 55: RELIGION, SPIRITUALITY, AND PSYCHIATRY</b>	
<b>WORKSHOP - COMPONENT</b>		<b>COURSES</b>	
47 Daddy and Papa: A Psychosocial Profile of Gay Parenting	91	25 Clinical Applications and Research in Transpersonal Psychiatry	7
<b>WORKSHOP - ISSUE</b>		47 Transpersonal Psychiatry: Clinical Applications	15
2 Understanding Transgendered Youth: Treatment and Service Strategies	17	85 Meditation for Psychotherapists and the Paradigm of Health	62
		<b>SYMPOSIA</b>	
		15 Spirituality and World View in Clinical Practice	30
		90 Model Psychiatry Residency Programs on Religion and Spirituality	93

<b>WORKSHOP – COMPONENT</b>	<b>Page #</b>
18 Encountering the Spiritual in Psychiatric (Psychotherapy) Practice	46

<b>WORKSHOPS - ISSUES</b>	
5 Santeria as a Religion in Mental Health Patients	18
54 Spiritual and Religious Assessment in Clinical Practice	46
61 The Role of the Soul: The Impact of Spiritual Belief Systems of Healing	47
111 The Power of Healing: Spirituality Group Work With Psychiatry Staff	91

**TOPIC 56: RESIDENT AND MEDICAL STUDENT CONCERNS**

<b>COURSE</b>	
99 Treating Medical Students and Physicians	73

<b>DISCUSSION GROUPS</b>	
9 Borderline Personality Disorder (For Residents Only)	20
17 Maintaining and Developing Family Relationships During Residency (For Residents Only)	42
18 The Core Competencies: What It Means for Residents and Faculty (Meet the Authors)	63

<b>RESIDENT'S SESSION</b>	
Meet the Experts: Sunny-Side Up	14

<b>SCIENTIFIC AND CLINICAL REPORT</b>	
22 What Increases the Frequency at Which Medical Students Ask Addiction Questions?	22

<b>WORKSHOPS - COMPONENTS</b>	
5 Practice Settings for Early Career Psychiatrists: A Primer	23
15 Career Choices in Psychiatry Exploring Fellowship Training	40
24 Great Expectations: Integrating Mind and Brain in Resident Training	64
27 Teaching Competence in Psychotherapy to Residents: Are Faculty Competent?	65
44 Transition Into the Postresidency Period	90
45 Combined Residency Training: Now What Are You Doing?	90

<b>WORKSHOPS - ISSUES</b>	
4 Multiculturalism Squared: Training Multicultural Residents to Treat Multicultural Patients	18
80 Family Therapy Training for Psychiatry Residents	66

**TOPIC 57: PRESIDENTIAL THEME: "THE PROMISE OF SCIENCE - THE POWER OF HEALING"**

<b>COURSE</b>	
61 Self-Regulation: The Brain and the Power of Healing Relationships	36

<b>INDUSTRY-SUPPORTED SYMPOSIUM</b>	
46 Compassionate and Safe Emergent Care: Best Practices in Anti-psychotic Use	80

<b>SCIENTIFIC AND CLINICAL REPORT</b>	
109 San Francisco Third Graders After 9/11: Three Windows to Healing	89

<b>SYMPOSIA</b>	
20 Integrating Interpersonal Neurobiology in Psychiatric Training and Practice	31
27 Applying Decision Science and Game Theory to Clinical Psychiatry	33
79 The Essence of Learning Psychiatry: Clinical Supervision	79

<b>WORKSHOP - ISSUE</b>	
99 The Empathic Healer: Artist or Scientist?	86

<b>TOPIC 58: STIGMA/ADVOCACY</b>	<b>Page #</b>
----------------------------------	---------------

<b>SCIENTIFIC AND CLINICAL REPORT SESSION</b>	
70 HIV-Related Stigma: Disclosure, Depression, and Social Support	69

<b>SYMPOSIA</b>	
26 Psychiatry and the Power of Advocacy	32
57 Psychiatrists With Psychiatric Disorders: The Fear of Stigma	57

<b>WORKSHOPS - COMPONENTS</b>	
9 Using Radio to Combat Stigma and Improve the Image of Psychiatry	23
30 United We Stand: Developing Partnerships for Patient Advocacy	70

**TOPIC 59: TELEPSYCHIATRY**

<b>COURSE</b>	
65 Expanding Health Care Delivery? Let Telepsychiatry Help!	36

<b>SCIENTIFIC AND CLINICAL REPORT</b>	
21 Retrospective Evaluation of Telemental Health Care Services for Remote Military Populations	22

<b>WORKSHOPS - ISSUES</b>	
9 Expanding Telepsychiatry Beyond Patient Care: Opportunities and Challenges	18
18 Telepsychiatry With Developmentally Disabled: Teaching, Training, and Treating	19
40 The Development, Implementation, and Operation of Diverse Telepsychiatry Programs	40
103 Making Telepsychiatry Work for You	86

**TOPIC 60: VIRTUAL REALITY**

<b>SYMPOSIUM</b>	
66 E-Therapy, Telepsychiatry, and Virtual Environments: The Evolution of Cyberspsychiatry	76

**TOPIC 61: WOMEN'S HEALTH ISSUES**

<b>COURSES</b>	
30 Treatment Issues for Women in Minority Groups	8
75 Psychiatric Disorders in Pregnancy and Postpartum	48

<b>DISCUSSION GROUPS</b>	
2 Depression in Perimenopausal Women	16
23 Women's Mental Health	67

<b>INDUSTRY-SUPPORTED SYMPOSIA</b>	
10 Moods, Cycles, and Motherhood	6
30 Bipolar Disorder in Women: Special Considerations and Evolving Treatment, Part 1	13
30 Bipolar Disorder in Women: Special Considerations and Evolving Treatment, Part 2	35
41 Women and Psychiatric Disorders: Does Gender Matter for Treatment?	59

<b>LECTURE</b>	
20 International Determinants of Women's Mental Health	73

<b>MEDICAL UPDATE</b>	
2 Menopause: What Psychiatrists Need to Know	43

<b>RESEARCH CONSULTATION</b>	
2 Depression During Pregnancy and the Postpartum Period	68

## TOPIC INDEX

---

<b>SCIENTIFIC AND CLINICAL REPORTS</b>		<b>Page #</b>
83	Predictors of First Depressive Episode in Black and White Women in Mid Life	70
101	Sertraline Prevents Postpartum Depression	89
103	HRT With Androgens as a Strategy to Treat Postmenopausal Depression	89
110	Maintaining Compliance and Remission in MDD With Sildenafil Prescription for SSRI-SD	89
<b>SYMPOSIA</b>		
14	Abortion: Scientific Data to Inform Clinical Care	29
51	Women Psychiatrists Using Science to Heal	55



# PARTICIPANT INDEX

## APA 156<sup>TH</sup> ANNUAL MEETING

<b>A</b>		
Abbey, Susan E.	21	
Abi-Dargham, Anissa	27	
Aboujaoude, Elias	27	
Abrams, Michael T.	18	
Abrams, Michelle	89	
Abramson, Ronald D.	28	
Addington, Jean M.	52	
Adinoff, Bryon H.	52	
Adityanjee, K.	27	
Adler, Caleb M.	78	
Agami, Ferid	96	
Agras, W. Stewart	30	
Ahern, Jennifer	79	
Ahmed, Iqbal	39, 47, 71	
Aizenberg, Dov	69	
Akaka, Jeffrey	70	
Akerele, Evaristo O.	90	
Akiskal, Hagop S.	56, 77, 96	
Aladjem, Asher D.	41	
Alarcon, Renato D.	32, 51, 76	
Alberto, Monchablow	32	
Alberts, Vicki A.	88	
Albright, Annette	90	
Alessi, Norman E.	23, 40, 55, 76	
Alexander, Mary Jane	75	
Alger, Ian E.	18, 40, 71	
Allen, Michael H.	9, 80	
Allen, Timothy S.	86	
Allison, David B.	61	
Allison, Nancy	44	
Almeida, Jr., Carlos E.	78	
Aloisio, Denise	71	
Alpert, Jonathan E.	44, 45, 70, 90	
Altamura, Carlo A.	96	
Altchuler, Steven I.	8, 17	
Altshuler, Lori L.	20, 35, 81	
Alves-Bradford, Jean-Marie	40	
Aman, Michael G.	32	
Ambrosini, Paul J.	68	
Amsel, Laurence V.	33	
Amsterdam, Jay D.	51	
Andersen, Arnold E.	30, 67	
Anderson, Peter D.	19	
Anderson, Tanya R.	69	
Andrade, Naleen N.	72	
Andreasen, Nancy C.	56	
Andrews, Linda B.	28	
Anfang, Stuart A.	65	
Angelino, Andrew F.	66	
Ansari, Rubaba	43	
Anthony, William	53	
Appelbaum, Paul S.	7, 10, 14, 16, 20, 33, 38, 49, 72	
Arambula, Michael R.	65	
Arciniegas, David B.	6	
Armstrong, Scott C.	37	
Arnold, Paul D.	29	
Amow, Bruce A.	45, 55	
Arns, Paul G.	91	
Aromin, Jr., Romulo A.	21	
Aron, Stephen C.	22	
Arroyo, William	46	
Arslanagic, Berina	30	
Ashford, Jr., John W.	54	
Ashley, Kenneth B.	46	
Asnis, Gregory M.	31, 61, 83	
Atdjian, Sylvia	52	
Atre-Vaidya, Nutan	76	
Aubert, Ron	90	
Auchincloss, Elizabeth	57	
Aupperle, Peter M.	62	
Austin, Linda S.	23	
Austin, Orson	45	
Austrom, Mary	71	
Aviram, Ron B.	21	
Azarow, Jay	80	
Azimi, Negar	88	
<b>B</b>		
Babulas, Vicki	45	
Baca-Garcia, Enrique	86	
Bach, Perry B.	71	
Backef, Glenn	91	
Bacz, Sayonara	71	
Bahadur, Neha	89	
Bailey, Darrin L.	69	
Bailey, Rahn K.	41	
Baker, Christine L.	45	
Baker, Robert W.	16, 22, 25	
Bakker, Floor	50	
Bakker, Jaap B.	84	
Baldassano, Claudia F.	11	
Baldessarini, Ross J.	12	
Baldini-Rossi, Nicolo	56	
Balis, Theodora G.	85	
Balmas, Gladys	88	
Balseiro, Sandra	22	
Baluga, Josefina M.	40	
Bamberger, Joshua	86	
Bangsberg, David	86	
Banu, Sophia	41	
Barak, Yoram	69	
Bareggi, Silvio R.	96	
Bark, Nigel M.	53, 77	
Barkley, Russell A.	56, 61	
Barnas, Christian	96	
Barnes, Thomas	79	
Barnett, David	32	
Barnhill, John W.	51	
Barnovitz, Mary Ann	71	
Baron, David A.	38, 48	
Barondes, Samuel H.	67	
Barry, John	5	
Barthwell, Andrea Grubb	38	
Bartlett, Annie	50	
Basco, Monica A.	37, 64	
Baskys, Andrius	21	
Bastani, Jehangir B.	88	
Batki, Steven L.	31, 39	
Battaglia, Joseph	94	
Battista, John R.	7	
Baum, Antonia L.	27	
Baxter, Elizabeth A.	32	
Baxter, Jane	66	
Behrs, John O.	29, 96	
Beaubrun, Gabrielle F.	15	
Bechara, Antoine	33	
Beck, Aaron T.	8	
Beck, Judith S.	17, 24	
Becker, Anne E.	70	
Becker, Carl	69	
Becker, Daniel F.	43	
Becker, Hiske E.	89	
Becker, Judith V.	62	
Beeber, Alan R.	7	
Beecher, Lee H.	28	
Beitman, Bernard D.	24, 29, 36, 47	
Belger, Aysenil	77	
Bell, Carl C.	19, 20, 40, 67, 85, 90	
Bender, Donna S.	21, 26	
Benedek, David M.	37	
Benedek, Elissa P.	10, 18	
Bennett, Michael J.	86	
Benoit, Marilyn B.	31	
Benton, David	27	
Beresin, Eugene V.	31	
Berganza, Carlos E.	74	
Bergen, Andrew	30	
Berlant, Jeffrey L.	31	
Berman, Ellen M.	66	
Berman, Jeffrey A.	31, 52	
Bermanzohn, Paul C.	56	
Bermingham, Mathieu	40	
Berns, Gregory S.	31	
Bernstein, Carol A.	7, 14, 28	
Bernstein, David P.	92	
Berqvist, Peter	58	
Berrettini, Wade H.	6, 30	
Berry, Sandra H.	79	
Bersani, Giuseppe	44	
Beverley, Raphael	65	
Beyer, John L.	81	
Bhat, Shyam K.	83	
Biederman, Joseph	44, 45, 56, 61, 68, 78, 80, 83	
Bierman, Rebecca S.	40	
Binder, Renee L.	33, 36, 65, 80	
Biondini, Francesca	92	
Birdsong, Lori J.	59	
Birner, Cecile	77	
Bisaga, Adam M.	57	
Black, Donald W.	27, 76	
Black, Jed E.	14	
Black, John L.	61	
Blanco-Jerez, Carlos	75	
Bland, Irma J.	23	
Blasey, Christine	45	
Bleiberg, Efram	15, 37	
Blier, Pierre	58	
Blinder, Barton J.	36	
Blow, Frederic C.	74	
Blume, Sheila B.	52, 86	
Blumenfield, Michael	23, 36	
Blumer, Dietrich P.	5	
Bobdey, Mina S.	47	
Boehnlein, James K.	97	
Bogan, Ann M.	70	
Bogunovic, Olivera J.	21	
Bohus, Martin	78	
Bonds, Curley L.	37	
Bonne, Orner	39	
Bonnie, Richard	65	
Book, Howard E.	7, 55	
Book, Jonathan D.	23	
Boorstein, Seymore	7	
Borenstein, Daniel B.	75, 84	
Borowich, Abba E.	30, 66	

**PARTICIPANT INDEX**

Borson, Soo .....54  
 Boutros, Nashaat N. .... 5, 62, 78  
 Bowden, Charles L. .... 2, 58, 74  
 Bowers, Jr., Theron C. ....18  
 Bowles, Henry .....54  
 Boyle, Michael .....22  
 Bracken, Patrick J. ....77  
 Bradwejn, Jacques .....90  
 Brady, Kathleen T. .... 42, 96  
 Brandt, Lena .....70  
 Brannan, Stephen K. ....44  
 Braslow, Joel T. ....47  
 Brawman-Mintzer, Olga .....58  
 Breitbart, William ..... 10, 78, 94  
 Brendel, David H. ....16  
 Brendel, Rebecca ..... 64, 71  
 Brenner, Ronald .....71  
 Bridges, Nancy A. ....94  
 Brizendine, Louann.....43  
 Brod, Thomas M. ....15  
 Brodkey, Amy C. ....28  
 Brodsky, Ella .....71  
 Bromberger, Joyce T. .... 70, 89  
 Bromet, Evelyn J. ....78  
 Brooks, Beth Ann .....85  
 Broquet, Karen E. ....66  
 Brown, Alan S. ....45  
 Brown, Charlotte .....70  
 Brown, Eileen .....22  
 Brown, Jocelyn .....53  
 Brown, Larry K. ....55  
 Brown, Richard P. ....68  
 Brown, Thomas E. .... 1, 5, 14  
 Brown, Walter A. ....93  
 Brown, Wayne F. ....71  
 Bryant, Sharon .....88  
 Bryskin, Lawrence .....66  
 Buchholz, David.....39  
 Buchsbaum, Monte S. ....27  
 Bulik, Cynthia M. ....30  
 Bullock, Kim D. .... 27, 70  
 Burdick, Katherine E. ....78  
 Burgard, Melissa A. ....30  
 Burger, Huib .....70  
 Burke, David.....79  
 Burlingame, Gary .....30  
 Burnett, Peter .....79  
 Burns, Kathryn A. ....85  
 Bursztajn, Harold J. .... 24, 47  
 Burwell, Rebecca A. ....70  
 Buscema, Charles A. ....32  
 Buschke, Herman.....54  
 Buse, John B. ....3  
 Bush, John .....70  
 Busi, Kimberly A. ....41  
 Bussel, Marina ..... 19, 83  
 Bussing, Regina.....28  
 Butler, Lisa D. .... 29, 79, 80  
 Butterfield, Cory .....72  
 Butterfield, Marian I. ....55  
 Byrd, Jr., Walter R. ....47

**C**

Caballero, Enrique .....59  
 Caballero, Maria C. ....93  
 Cacioppo, M. Maddalena.....44  
 Caddell, Juesta M. ....79  
 Calabrese, Joseph R. .... 2, 22, 58, 77  
 Calabrese, Lon .....8  
 Caley, Charles F. ....69  
 Caligiuri, Michael .....1

Caligor, Eve .....37  
 Callahan, Jr., William E. .... 41, 47, 56, 57  
 Camacho, Alvaro.....52  
 Campeas, Raphael .....75  
 Campo, Ana E. .... 26, 71  
 Cancro, Robert .....48  
 Canfield, Merle .....32  
 Canino, Glorisa.....28  
 Canive, Jose M.....76  
 Capuron, Lucile .....31  
 Cardona, Dora .....76  
 Carey, Karen T. ....32  
 Carfaginni, Jessica .....32  
 Carpenter, Linda L. ....82  
 Carpenter, Jr., William T. ....1, 49  
 Carter, Diana .....48  
 Carter, James H. ....87  
 Casey, Daniel E. ....59  
 Casey, David A. .... 22, 44  
 Cassano, Giovanni B. ....56  
 Cassano, Paolo .....90  
 Cassen, Edwin H. ....78  
 Cassidy, Roberta .....50  
 Castellanos, Daniel .....71  
 Castilla-Puentes, Ruby ..... 89, 92, 93  
 Castilla-Puentes, Sandra.....93  
 Castilla-Puentes, Wilma.....93  
 Catania, Joseph A. ....50  
 Caton, Carol L.M. ....78  
 Certa, Kenneth M. ....24  
 Chacko, Chowallur D. ....38  
 Chaitin, Barry F. ....71  
 Chamberlain, John R. .... 23, 40  
 Chan, Carlyle H. .... 24, 48  
 Chan, Sue S. ....91  
 Chandler, Mark C. ....68  
 Chanen, Andrew.....52  
 Chang, Jacquelyn B. .... 84, 90  
 Chang, Kiki D. .... 6, 44, 50  
 Chang, Linda .....36  
 Chang, Soo Kyung.....94  
 Chapman, Daniel P. ....18  
 Charat, Valerie .....30  
 Charney, Dennis S. .... 23, 49, 77  
 Chaskel, Roberto E. ....32  
 Chaudhry, Zubaida A. ....88  
 Chavez, Maria .....91  
 Chelminski, Iwona .....43  
 Chen, Guang .....11  
 Chen, Nancy .....79  
 Chen, Shirley.....29  
 Chen, Teddy.....91  
 Chenik, R. Nandi.....83  
 Cheong, Josepha A. .... 39, 71  
 Chervenak, Frank A. ....88  
 Chester, Adam R. ....23  
 Chester, Janis G. ....28  
 Chiappe, Viviana J. ....93  
 Chien, Ching-Piao .....86  
 Chinen, Allan B. ....7  
 Chino, Denis H. ....57  
 Chiu, Charles .....8  
 Chiu, Judy .....53  
 Cho, Samson J. ....94  
 Chou, James C.Y. .... 51, 58  
 Choy, YuJuan.....22  
 Chrisman, Allan K. ....44  
 Christiansen, Tawnya L. ....94  
 Chu, James A. ....78  
 Chung, Christopher K. .... 41, 94  
 Chung, Henry .....91  
 Chuong, Helen W. ....27

Citrome, Leslie L. .... 3, 75  
 Claiborn, James .....75  
 Clark, David L. .... 5, 62  
 Clark, Marlene .....18  
 Clark, Michael R. ....48  
 Clark, Michelle O. .... 40, 87  
 Clarkin, John F. ....26, 37  
 Classen, Catherine .....29, 95  
 Clausen, Bente.....15  
 Clayton, Anita L.H. .... 9, 42  
 Clegg, Kathleen A. ....76  
 Clemens, Norman A. ....75  
 Clementi-Craven, Nicoletta ..... 45, 70  
 Cloitre, Marylene.....95  
 Cobb, Kenneth C. ....90  
 Cobb, Thomas G. .... 62, 84  
 Cochran, Susan D. ....50  
 Cockram, Alexandra M. ....79  
 Coffey, C. Edward .....15  
 Coffman, Jennifer K. ....65  
 Cohane, Geoffrey .....27  
 Cohen, Irvin M. ....71  
 Cohen, Judith A. .... 31, 89  
 Cohen, Lee S. .... 12, 13, 35, 39  
 Cohen, Mary Ann .....46  
 Cole, Steven A. ....78  
 Collins, Rebecca L. ....79  
 Conley, Robert R. ....80  
 Connor, Mary K. ....65  
 Constantine, Doreen .....69  
 Contreras, Virginia.....18  
 Conus, Philippe .....52  
 Cook, Ian A. ....89  
 Cook, William L. ....52  
 Cooke, Edi.....18  
 Cookson, John .....6  
 Coon, Kim A. ....40  
 Cooper, Richard A. ....76  
 Copolov, David L. ....88  
 Corall, Maria .....48  
 Corbin, Stephen B. ....85  
 Cordahi, Caroline E. ....77  
 Cordova, Matthew J. ....29  
 Corliss, Heather .....50  
 Correia, Nestor.....70  
 Cortese, Leonardo .....1  
 Costa, Paul.....54  
 Coumos, Francine .....57, 77, 85  
 Coverdale, John H. .... 18, 88  
 Covington, Jr., Edward C. ....9  
 Cowan, David N. ....46  
 Cox, Daniel J. ....87  
 Cox, Todd S. ....41  
 Cozolino, Louis.....31  
 Cozza, Kelly L. ....37  
 Crecelius, Gia M. ....62  
 Croft, Harry A. ....23  
 Crone, Catherine C. .... 21, 49  
 Crosby, Ross D. ....95  
 Crow, Scott J. ....30  
 Crowder, Martin J. ....27  
 Crowley, Brian.....28  
 Culpepper, Larry ..... 8, 11  
 Cummings, Jeffrey L. .... 6, 10, 15, 51  
 Currier, Glenn W. ....80

**D**

Dackis, Charles A. ....21  
 Dagerman, Karen S. ....69  
 Dain, Norman.....53  
 D'Alli, Richard E. ....45

- Dalven, Jennifer.....30  
 Danies, E.L.....30  
 Danish, Mohammad F. ....87  
 Datta, Moitri N. ....39  
 Davidson, Jonathan R.T. ....2, 82  
 Davies, Rob.....30  
 Davis, Glenn C. ....72  
 Davis, John M. ....79  
 Davis, Lara .....88  
 Davis, Lori L. ....31  
 Davis, Mary H. ....70  
 Davis, Sonia .....69  
 Dawe, Ian C. ....92  
 Dea, Robin A. ....47  
 DeBattista, Charles.....11  
 deBeus, Roger.....15  
 De Brito, Charles.....57  
 De Contreras, Gilmarosa.....93  
 De Crisce, Dean M. ....41  
 de Jonghe, Frans.....19  
 De La Garza II, Richard.....31  
 de Leon, Jose .....86  
 DelBello, Melissa P. ....9, 43  
 Delgado, Pedro L. ....3, 15  
 Dell'Osso, Liliana .....56  
 DeMartino, Robert.....41  
 Demment, Christine.....95  
 DePaulo, Jr., J. Raymond .....19, 43  
 Des Roches, Michelle .....79  
 Desai, Anup M. ....21, 88  
 Desai, Prakash N. ....7, 63  
 Desjardins, Juliette C. ....80  
 Detke, Michael J. ....9, 44  
 Deutschman, Daniel A. ....7, 40, 46, 65  
 Devlin, Bernie.....30  
 Devlin, Michael J. ....95  
 deVries, Christine.....74  
 Dewan, Mantosh J. ....29, 36, 92  
 Dewan, Naakesh A. ....46  
 deZwaan, Martina.....30, 95  
 Diamond, Ronald J. ....79  
 Dias, Rodrigo.....89  
 Diaz, Naelys.....51  
 Dickstein, Leah J. ....20, 55, 66, 72, 73, 85  
 DiClemente, Ralph.....55  
 di Cori, Ferruccio A. ....40  
 Dieperink, Eric W. ....92  
 DiGiacomo, Joseph .....51  
 di Giannantonio, Massimo.....70  
 DiGiovanni, Clete .....53  
 Dillon, Gregory C. ....51  
 DiMiceli, Sue.....80  
 Dimsdale, Joel E. ....52  
 Dinwiddie, Stephen H. ....7, 76  
 Doghramji, Karl .....48  
 Domnitz, Jason A. ....92  
 Donegan, Nelson H. ....27  
 Dong, Jianming .....58  
 Donker, Ge A. ....69, 89  
 Donnelly, Sinead .....94  
 Doody, Rachelle S. ....41, 81  
 Dooley, Trish .....31  
 Doraiswamy, P. Murali .....58, 83  
 Dording, Christina M. ....90  
 Dorer, David J. ....30  
 Dow, Michael G. ....90  
 Downing, Donna .....52  
 Downs, Susan R. ....8  
 Doyle, Shannon.....44  
 Dragomirecka, Eva .....69  
 Drake, Robert E. ....78  
 Drescher, Jack .....32, 50, 66, 71, 91  
 Drevets, Wayne C. ....13, 23, 95  
 Dryden-Edwards, Roxanne C. ....85  
 Du, Nang .....41, 87  
 Duarte, Cristiane .....77  
 Dube, Sanjay .....22  
 Dubin, Hinda F. ....85  
 Dubois, Michel .....48  
 Dubovsky, Steven L. ....6  
 Duffy, Farifteh F. ....28, 76  
 Dulcan, Mina K. ....28  
 Dunayevich, Eduardo .....15  
 Dunkin, Jennifer .....89  
 Dunner, David L. ....59  
 Dunnigan, Joanne .....71  
 Duran, Ron .....69  
 Dvorak, Ramona .....8
- E**
- Eaton, Karen M. ....46, 69  
 Ebert, Lori .....79  
 Ebert, Michael H. ....72  
 Edelstein, Nestor .....93  
 Edwards, Jane .....52  
 Eisen, Jane L. ....75  
 Eist, Harold I. ....24, 28, 65, 93  
 Ekbohm, Anders .....70  
 Elliott, Marc N. ....79  
 Elliott, Michael A. ....70  
 Elliott, Richard L. ....5  
 Ellis, Pete M. ....79  
 Ellison, James M. ....93  
 Emmenich, Sylvia P. ....57  
 Encarnacion, Sofia M. ....83  
 Engel, Charles C. ....46  
 Engel, Rolf .....79  
 Epperson, C. Neill .....6  
 Epstein, Lynn C. ....47  
 Ercan, Eyup S. ....43  
 Erickson, Mark T. ....29, 63  
 Erman, Milton K. ....90  
 Ertas, Mustafa .....70  
 Escobar, Javier I. ....15, 51  
 Eth, Spencer .....46, 90  
 Etter, Kevin M. ....71  
 Evaldson, John R. ....29, 63  
 Evans, Angela R. ....22  
 Evans, Arom J. ....19  
 Evans, Dwight L. ....3  
 Evans, Shelley A. ....45  
 Evans, Suzette M. ....57  
 Everett, Anita .....71  
 Everly, Jr., George .....53  
 Eves, Anita .....27
- F**
- Faber, Raymond A. ....72  
 Faber, Ronald J. ....27  
 Factor, Robert M. ....29  
 Fagiolini, Andrea .....6  
 Fahrer, Rodolfo D. ....32  
 Fairbank, John A. ....79  
 Faison, Warachal E. ....71  
 Fallon, Brian A. ....75  
 Farabaugh, Amy H. ....22, 43, 90  
 Faraone, Stephen V. ....61, 78, 80, 81, 87  
 Fariba, Sam .....29  
 Farmer, Mildred .....89  
 Fasanello, Jo Ellen .....23  
 Faulkner, Larry R. ....72, 76  
 Fava, Maurizio .....9, 22, 43, 44, 45, 70, 89, 90  
 Fawcett, Jan A. ....12, 35  
 Fawzi, Waleed A.R. ....53, 77  
 Fayyad, John A. ....77  
 Feinstein, Carl B. ....85  
 Feinstein, Suzanne .....75  
 Feldman, Jacqueline M. ....1  
 Ferguson, Yvonne B. ....7  
 Fernandez, Maria I. ....40  
 Ferrando, Stephen J. ....53, 95  
 Fichtner, Christopher G. ....1, 7  
 Fields, Howard .....24  
 Fieve, Ronald R. ....22  
 Findling, Robert L. ....3, 12, 32, 89  
 Fink, Paul J. ....19, 32, 57  
 Fireman, Bruce .....45  
 Fireman, Marian .....66  
 First, Michael B. ....14, 64, 78, 94  
 Fischbein, Ellen R. ....18  
 Fisdell, Steven .....46  
 Fishbain, David .....9  
 Fisher, Caroline E. ....40, 64, 68, 89  
 Fisher, Masaru J. ....90  
 Fisher, Robert S. ....5  
 Fitzgerald, Barbara A. ....69  
 Fitzgibbons, Lee A. ....92  
 Fitzmaurice, Garrett .....28  
 Flaherty, Lois T. ....87  
 Fleischhacker, W. Wolfgang .....81  
 Fleming, Candace M. ....15  
 Flory, Curtis .....23  
 Foa, Edna B. ....92  
 Fochtman, Laura J. ....90  
 Foister, Kellie M. ....88  
 Folstein, Marshal F. ....67  
 Fonagy, Peter .....78  
 Foote, William W. ....7, 15  
 Ford, Julian .....95  
 Fore-Arcand, Lisa .....22  
 Foro, Julian .....68  
 Forstein, Marshall .....77, 95  
 Fouilhoux, Natacha .....97  
 Fouras, George A. ....46  
 Fradkin, Howard .....72  
 Frances, Richard J. ....86  
 Frank, Bradford L. ....22  
 Frank, Ellen .....6, 11  
 Frank, Guido K.W. ....95  
 Frankenburg, Frances R. ....21, 27  
 Franko, Debra L. ....30  
 Franz, Bettina E. ....70  
 Frazer, Alan .....74  
 Freedman, Alfred M. ....41  
 Freedman, Joshua E. ....7, 46  
 Freedman, Robert .....3  
 Freeman, Michael D. ....85  
 Friedman, Matthew J. ....17  
 Friend, Jeffrey M. ....89  
 Frisman, Linda .....95  
 Fromson, John A. ....23  
 Fry, Jr., William F. ....69  
 Frye, Mark A. ....2, 11, 35, 81  
 Fulbright, Robert K. ....27  
 Fulford, Kenneth .....26, 54  
 Fullilove, Mindy J. ....78  
 Fulop, George .....22, 90  
 Fung, Desmond S. ....66  
 Furman, John C. ....40

G

Gabbard, Glen O. ....	17, 25, 39, 42, 50, 78	Goodman, Robin F. ....	31	Hameed, Ahmad .....	22
Gaensbauer, Theodore J. ....	52	Goodnick, Paul J. ....	42, 67	Hameedi, Faiq A. ....	85
Gage, Fred .....	13	Goodwin, Frederick K. ....	23, 35, 81	Hammond, Sean M. ....	27
Gagne, Cheryl .....	53	Gopalakrishnan, Raman N. ....	21	Hampson, Sarah E. ....	27
Gakir, Sibel .....	70	Goppoldova, Eva .....	69	Hansen, Mark R. ....	8
Galanter, Marc .....	86, 96	Gorbis, Eda E. ....	75	Hanson, Annette .....	93
Galea, Sandro .....	79	Gordon, Edward .....	23, 28	Hanson, Annette L. ....	85
Galeno, Roxana .....	76	Gordy, Tracy R. ....	47, 70	Hantouche, Elie G. ....	77
Gallagher, Rollin .....	9	Gore, John C. ....	27	Hanusa, Barbara H. ....	89
Gamel, Nona .....	70	Gore-Felton, Cheryl .....	88	Hargreaves, Richard .....	11
Gangure, Dinu P. ....	90	Gorelick, David A. ....	31	Harley, Rebecca .....	43, 90
Ganime, Peter D. ....	71	Gorman, Jack M. ....	3, 36, 45	Harper III, R. Andrew .....	18
Ganter, Allison .....	32	Gorton, Gregg E. ....	94	Harris, Meredith .....	52
Ganzini, Linda K. ....	78	Gosnell, Blake A. ....	30	Harris, Patrice A. ....	32
Gara, Michael .....	44	Gottheil, Edward .....	88	Harris, Wendy A. ....	92
Gardiner, Lorin D. ....	93	Goy, Elizabeth E. ....	78	Harrow, Martin .....	45, 74, 89
Gardner, Patrick H. ....	19, 32	Grace, John W. ....	64	Hartmann, Lawrence .....	57
Garland, Russell .....	29	Grady, Brian J. ....	22	Hartston, Heidi .....	27
Garland, David W. ....	46	Grady-Weliky, Tana A. ....	40	Hartzell, Mary .....	91
Garraw, Cynthia W. ....	28	Granacher, Jr., Robert P. ....	63	Hasin, Deborah S. ....	78
Gartner, Richard .....	72	Grapentine, William L. ....	19	Hatti, Shivkumar .....	1
Garvey-Wilson, Abigail L. ....	46, 69	Grau, Arturo .....	93	Hauser, Peter .....	92
Garyali, Veena .....	85	Gray, Gregory E. ....	15	Havenaar, Johan M. ....	70
Gastfriend, David R. ....	31	Gray, Kevin F. ....	72	Hawkins, Keith A. ....	52
Gaw, Albert C. ....	7, 21, 66	Green, Grad .....	80	Hawkins, Maureen .....	50
Geddes, John R. ....	79	Green-Paden, Lisa D. ....	85	Hayward, Chris .....	45
Geerlings, Mirjam I. ....	70	Greenberg, Benjamin D. ....	75	Heerlein, Andres .....	51
Gehrs, Margaret .....	92	Greenfield, Shelly F. ....	59	Heim, Christine .....	2, 9
Gelenberg, Alan J. ....	6, 55	Greenhill, Laurence L. ....	44, 45, 56	Heitt, Michael C. ....	53
Gendel, Michael H. ....	97	Greenstein, Mindy .....	78	Hellerstein, David J. ....	21
George, Elizabeth .....	9	Greenwald, Scott D. ....	89	Hembree, Elizabeth A. ....	92
George, Mark S. ....	8, 15	Greer, Phil J. ....	69	Hen, Rene .....	3
Germain, Christine .....	57	Greig, Nigel .....	58	Henderson, David C. ....	1, 28
Gerson, Jessica .....	21	Greist, John H. ....	81	Henderson, Kathy .....	64
Gesch, C. Bernard .....	27	Grice, Dorothy E. ....	30	Hendrie, Hugh C. ....	71
Ghaemi, S. Nassir .....	2, 3, 16, 65, 81, 89, 96	Griffith, Ezra E.H. ....	57	Hennen, John .....	12, 21, 27
Ghodse, Hamid .....	77	Griffith, James L. ....	46, 93	Henry, Lisa .....	52
Gibson, Christopher .....	78, 94	Griolo, Carlos M. ....	21, 43	Henshaw, Stanley .....	29
Giese-Davis, Janine .....	29	Grimaldi, Jr., John A.R. ....	46	Hensley, Paula L. ....	89
Gijsbers van Wijk, Cecile M.T. ....	19	Grisso, Thomas .....	49	Herbener, Ellen S. ....	45, 74
Gilbert, Kenneth G. ....	85	Grobbee, Diederick E. ....	70	Herbert, Sarah E. ....	17
Gill, Mona H. ....	71	Groenewold, Leslie .....	91	Hernandez-Serrano, Ruben J. ....	32
Gillespie, Ian A. ....	1	Groleau, Danielle .....	97	Hersh, Richard G. ....	5
Gilman, Stephen E. ....	70	Grossberg, George T. ....	74	Herzog, Alfred .....	17, 39, 46, 64
Gilrivas, Virginia .....	79	Grossman, Linda S. ....	45	Herzog, David B. ....	30
Ginsberg, David L. ....	9	Grunebaum, Michael F. ....	11	Hester, Thomas W. ....	71
Gise, Leslie H. ....	55, 64	Grunhaus, Leon J. ....	2	Hiatt, John F. ....	7, 15
Gittelman, David K. ....	44	Grunze, Heinz C. ....	89	Hickey, Grace .....	71
Glasser, Andrea I. ....	65	Gunderson, John G. ....	21, 25, 26, 78	Hicks, Daniel W. ....	91
Glazer, William M. ....	32	Gupta, Sanjay .....	22	Higgins, Jr., Napoleon B. ....	40
Glick, Ira D. ....	13, 41, 79, 80	Guschwan, Marianne T. ....	90	Hilger-Assem, Eva .....	96
Gochfeld, Linda G. ....	75	Guss, Janet L. ....	95	Hill, Darryl B. ....	32
Goethe, John W. ....	64, 69	Gutheil, Thomas G. ....	57, 76, 96	Hill, Emory .....	54
Goff, Donald C. ....	10, 12, 40, 93	Gwynette, McLeod F. ....	18	Hill, Kevin P. ....	88
Gogineri, R. Rao .....	51			Hilty, Donald M. ....	40
Goin, Marcia K. ....	10, 20, 31, 33, 64, 72			Hinuma, Shuii .....	68
Goisman, Robert M. ....	17, 37			Hirai, Keisuke .....	68
Gold, Jodi J. ....	64			Hire, Richard O. ....	71
Gold, Joel .....	79			Hirsch, Rena .....	66
Goldberg, David A. ....	65			Hirschfeld, Robert M.A. ....	6, 8, 77
Goldberg, Joseph F. ....	6, 74, 78, 81, 89, 96			Hirshkowitz, Max .....	73
Goldfinger, Stephen M. ....	19, 40, 43, 65, 72			Ho, Andrew P. ....	5
Goldman, Charles R. ....	72			Ho, Samuel .....	92
Goldman, Morris B. ....	14			Hobbins, Susan I. ....	88
Goldsmith, Eric D. ....	95			Hoffman-Rieken, Kristina .....	1
Gomez, Ivan .....	93			Hogan, Valerie .....	68
Gonzalez-Heydrich, Joseph M. ....	81			Hoge, Charles W. ....	46, 69
Goodhue, Angelique D. ....	23			Hojaj, Carlos R. ....	72
Goodkin, Karl .....	39, 95			Hollander, Annette J. ....	46, 63
Goodman, Marianne .....	27			Hollander, Eric .....	5, 13, 35, 56
				Holloway, Jr., Willis .....	89
				Holman, E. Alison .....	79

H

- Holmes, William .....72  
Honer, William G. ....40  
Hooley, Jill M. ....47  
Hooton, Jonathan .....45  
Hora, Honorable Peggy ..... 19, 24  
Hoven, Christina .....77  
Howe, Edmund G. ....7  
Howe, Vivienne .....88  
Hrangan, Susy .....52  
Hsiung, Robert C. ....58, 65, 72  
Hudon, Evelyne .....97  
Hudson, James I. ....27  
Hudziak, James J. ....18  
Huffine, Jr., Charles W. ....65  
Hughes, Megan E. ....90  
Hughes, Michael C. ....66  
Hughes, Rod J. ....90  
Hughes, Towda L. ....50  
Hunkeler, Enid M. ....45  
Hurvitz, Thomas D. ....48, 73  
Husain, Syed A. ....87  
Hussain, Mohammad Z. ....88  
Hutchins, Erica C. ....30  
Hwang, Michael Y. ....75, 85, 94  
Hyler, Steven E. ....14, 36, 58
- I**
- Ickowicz, Abel .....29  
Iosifescu, Dan V. ....45, 90  
Iqbal, Naveed .....85  
Isaacs, Julian .....15  
Ishak, Waguih W. ....18, 83  
Ismail, M. Saleem .....69, 81  
Israel, Joshua A. ....40  
Israelski, Dennis M. ....69, 88
- J**
- Jabbarpour, Yadollah M. ....71  
Jacobs, Carla .....23  
Jacobs, Douglas G. ....12  
Jacobs, Leo I. ....44  
Jaffe, Ari B. ....45  
Jaffe, Ellen .....23  
Jaffe, Richard L. ....14  
Jain, Vivek .....83  
James, William A. ....44  
Jamison, Kay R. ....12  
Janicak, Philip G. ....14  
Janofsky, Jeffrey S. ....20  
Jat, Khalid M. ....43  
Jayaram, Geetha .....10, 19, 29, 55, 72  
Jaycox, Lisa H. ....79  
Jefferson, James W. ....38  
Jenkins, Kym .....88  
Jeste, Dilip V. ....38, 49, 70  
Jimerson, David C. ....6, 95  
Jobe, Thomas H. ....45  
Johannessen, Jan O. ....52  
Johnson, Bradley R. ....62  
Johnson, Brian .....24  
Johnson, Denise M.W. ....48  
Johnson, Janet E. ....93  
Johnson, Timothy .....50  
Johnston, Derek W. ....90  
Jones, Beverly N. ....40  
Jones, Kristina L. ....46  
Jorge, Miguel R. ....32, 52, 74  
Jorgenson, Linda M. ....18, 55  
Josephson, Allan M. ....30  
Joy, Charles R. ....47  
Judd, Lewis L. ....42
- Judd, Patricia .....20  
Jummani, Rahil .....69  
Jungreis, Esther .....66  
Justice, Barbara J. ....39, 45
- K**
- Kader, Philip F. ....19, 32  
Kalin, Ned H. ....9, 10, 11  
Kamholz, Barbara .....72  
Kaminsky, Michael J. ....53  
Kampman, Kyle M. ....21  
Kan, David Y. ....88  
Kanayama, Gen .....27  
Kane, John M. ....1, 19, 59, 79  
Kang, G. Shimi .....31  
Kapczynski, Flavio .....8  
Kaplan, Allan S. ....95  
Kaplan, Ana .....15  
Kaplan, Bonnie J. ....27  
Kaplan, Gabriel .....15, 48  
Kaplan, Kalman J. ....74  
Karam, Aimee N. ....77  
Karam, Elie G. ....65, 77  
Karasic, Dan H. ....32, 50, 86, 88  
Karasu, T. Byram .....25, 39  
Karim, Aziz .....68  
Kanippot, Anoop .....45  
Karp, Steven J. ....17  
Kashtan, Judith F. ....70  
Kasper, Siegfried .....96  
Kass, Frederic I. ....78  
Kastelic, Elizabeth A. ....41  
Kato, Koki .....68  
Katz, Bernard A. ....7  
Katz, Craig L. ....19  
Katz, Debra A. ....86  
Katz, Israel .....72  
Katz, Mark R. ....21  
Katz, Martin M. ....74  
Kaveojan, Agop .....97  
Kay, Jerald .....65  
Kaye, Walter H. ....30, 95  
Keating, Annie .....29  
Keck, Jr., Paul E. ....6, 81  
Keefe, Richard S. ....3, 14  
Keel, Pamela K. ....30  
Kehayan, V. Alex .....36  
Keith, Samuel J. ....33  
Keks, Nicholas A. ....88  
Keller, Martin B. ....82  
Kellner, Charles H. ....14  
Kelly, Brian .....79  
Kelly, Kevin V. ....51  
Kelly, Thomas M. ....69  
Kemeny, Margaret E. ....39  
Kenardy, Justin A. ....90  
Kennedy, James L. ....29  
Kennedy, John S. ....7, 17  
Kennedy, Lawrence L. ....1, 65  
Kennedy, Robert S. ....72  
Kent, Justine M. ....3  
Kerfoot, Michael J. ....69  
Kemberg, Otto F. ....26, 37  
Kerr-Correa, Florence .....89  
Kertzner, Robert M. ....50  
Kessler, Ronald C. ....82  
Kestenbaum, Clance J. ....18  
Ketter, Terence A. ....35, 81  
Khadivi, Ali .....86  
Khalid-Khan, Sarosh .....3  
Kiang, Michael W. ....21  
Killeen, Therese .....96
- Kilpatrick, Dean .....79  
Kilts, Clinton D. ....31  
Kim, Edward .....44  
Kim, Luke .....94  
Kim, Scott Y. ....49, 65, 88  
Kim, Wun-Jung .....76  
King, Michael B. ....50  
King, Steven A. ....9  
Kingdon, David G. ....41  
Kinzie, J. David .....36  
Kirmayer, Laurence J. ....97  
Kissileff, Harry .....95  
Kissling, Werner .....79  
Kivlahan, Daniel R. ....92  
Kjaer, Reidar .....50  
Kleber, Herbert D. ....57, 62  
Klein, Daniel N. ....55  
Klein, Ehud M. ....2  
Kleinman, Arthur M. ....65, 70  
Kleinman, Joel E. ....3  
Kleinman, Stuart B. ....94, 95  
Kleinplatz, Peggy J. ....32  
Kleis, Brian N. ....80  
Kline, Donald S. ....65  
Kloss, Raymond J. ....24, 48  
Kluft, Richard P. ....62, 84, 92  
Knudsen, Kraig .....89  
Kocsis, James H. ....55  
Koenigsberg, Harold W. ....27  
Kogan, Richard .....24  
Kohn, Robert .....45, 46  
Kohn, Shari .....31, 61, 83  
Kolodner, George F. ....23  
Konstantinidis, Anastasios .....96  
Koopman, Cheryl .....29, 69, 80, 88, 95  
Kopala, Lili .....53  
Kopelowicz, Alex J. ....53  
Koplewicz, Harold S. ....47  
Koplin, Brett A. ....61  
Koran, Lorin M. ....27, 70, 96  
Kornstein, Susan G. ....13, 35  
Kosten, Thomas R. ....23, 62  
Koszycki, Diana .....90  
Kovaszny, Beatrice M. ....71  
Kowatch, Robert A. ....23  
Koyfman, Sander .....19  
Koziupa, Diana M. ....29  
Kraemer, Helena C. ....54  
Krahn, Lois E. ....8, 73  
Krakowski, Menahem I. ....45  
Kramer, Michael .....78  
Kramer, Milton .....2  
Kramer, Peter D. ....67, 97  
Kramer, Thomas A.M. ....28, 58, 72  
Kratovich, Christopher J. ....44  
Kraus, Jr., John E. ....69  
Krauthammer, Charles .....34  
Kravitz, Howard M. ....70  
Krejci, Jon .....31, 52  
Krishnan, K. Ranga R. ....14, 35, 39  
Kronfol, Ziad A. ....31  
Krueger, Robert F. ....94  
Kryscio, Richard J. ....54  
Krystal, John H. ....77  
Kuey, Lguent .....74  
Kulaksizoglu, Isin B. ....70  
Kulenovic, Tvrtko .....96  
Kulka, Richard A. ....79  
Kuo, Jack .....19, 91  
Kupfer, David J. ....2, 6, 11, 23  
Kushner, Robert .....61

## L

- Laboff, Jo A. .... 54  
 Lafer, Beny ..... 13  
 Lam, Naomi K. .... 90  
 Lam, Raymond W. .... 8  
 Lamb, H. Richard ..... 23, 53  
 Lambert, Martin ..... 52  
 Lang, Joan A. .... 47  
 Lang, Meghan ..... 24  
 Langley, John H. .... 92  
 Langley, Ted ..... 54  
 Langsley, Donald G. .... 46  
 Lappin, Debra R. .... 93  
 Laruelle, Marc ..... 27  
 Latimer, Kelsey M. .... 55  
 Lauterbach, Edward C. .... 5, 62  
 Lawson, David ..... 31  
 Lawson, William B. .... 51, 65  
 Layne, Christopher M. .... 30  
 Lazarus, Arthur L. .... 71  
 Le, Phuong-Thuy ..... 66  
 Leape, Lucian L. .... 20  
 Lebovits, Allen ..... 48  
 LeCrubier, Yves ..... 72  
 Lee, Emily K. .... 90  
 Lee, Evelyn ..... 51  
 Lee, Janelle ..... 45  
 Lee, Jeannie ..... 88  
 Lee, Karen L. .... 83  
 Lee, Kathryn A. .... 24  
 Lee, Kewchang ..... 88  
 Lee, Regina J. .... 88  
 Lee, Sue Y. .... 71  
 Legrange, Daniel ..... 66  
 Lehman, Anthony F. .... 33, 63  
 Lehman, Gwen ..... 24  
 Leigh, Hoyle ..... 22, 40  
 LeMelle, Stephanie ..... 20  
 Lemoux, Agnes ..... 57  
 Lenert, Leslie L. .... 33  
 Lenhart, Sharyn A. .... 36  
 Leo, Raphael J. .... 41  
 Leon-Andrade, Carlos ..... 32  
 Leone, Carlo ..... 44  
 Leonido-Yeo, Maria D.M. .... 83  
 Lescano, Celia M. .... 55  
 Leskar, Sandra E. .... 46, 69  
 Lesperance, Francois ..... 97  
 Leucht, Stefan M. .... 79  
 Leuchter, Andrew F. .... 24, 89  
 Lev, Arlene I. .... 32  
 Levav, Itzhak ..... 46  
 Levendusky, Philip G. .... 37  
 Levenson, Alan I. .... 18  
 Levin, Frances R. .... 57, 86  
 Levine, Janice R. .... 66  
 Levine, Jeffrey M. .... 86  
 Levitt, Anthony J. .... 8  
 Levounis, Petros ..... 88  
 Lewis-Fernandez, Roberto ..... 15, 51  
 Lewy, Alfred J. .... 24  
 Liang, Warren M. .... 77  
 Liberman, Robert P. .... 53  
 Lidz, Charles ..... 49  
 Lieberman, Alicia F. .... 30, 52  
 Lieberman, Jeffrey A. .... 33  
 Liebowitz, Michael R. .... 75  
 Liffick, Thomas F. .... 3  
 Lim, Russell F. .... 15  
 Lin, Keh-Ming ..... 21, 36, 65  
 Lindberg, Marc A. .... 88  
 Lindy, David C. .... 19  
 Linehan, Marsha M. .... 27, 77  
 Linenberg, Bruce ..... 46  
 Links, Paul S. .... 92  
 Lipkin, Mack ..... 2  
 Lipsitt, Don R. .... 40  
 Lipsius, Steven H. .... 18, 48  
 Liptzin, Benjamin ..... 94  
 Lisanby, Sarah H. .... 2, 36  
 Liu, Li ..... 88  
 Liu, Xian ..... 46  
 Livesley, John ..... 92  
 Livingston, Jon ..... 54  
 Lloyd, John S. .... 7, 40  
 Loboprabhu, Sheila M. .... 18  
 Lock, James D. .... 66  
 Lockhart, Paula J. .... 85  
 Lockwood, Kari ..... 22  
 Logan, Kathleen ..... 70  
 Loonen, Anton J.M. .... 84  
 Lopez, Frank A. .... 44, 68  
 Lopez-Ibor, Jr., Juan J. .... 26, 93  
 Loschen, Earl L. .... 40  
 Losonczy, Miklos F. .... 75, 85  
 Lowenkopf, Eugene L. .... 5, 69  
 Lowgren, Deborah ..... 75  
 Loza, Nasser F. .... 53, 77  
 Lu, Francis G. .... 7, 15, 46, 51, 74, 86, 91, 93  
 Lubit, Roy H. .... 39  
 Lucas, Christopher ..... 64  
 Lucey, Jeffrey ..... 94  
 Ludwig, Antonia N. .... 18  
 Luo, John S. .... 24, 48, 71, 84  
 Lydiard, R. Bruce ..... 9  
 Lyketsos, Constantine ..... 19, 51, 62  
 Lymberis, Maria T. .... 46
- M**
- Macbeth, JoAnn ..... 39  
 MacKenzie, K. Roy ..... 42  
 Madhusoodanan, Subramoniam ..... 21  
 Maffei, Cesare ..... 92  
 Mahal, Yasmin ..... 43, 44  
 Mahler, Jo ..... 88  
 Maixner, Susan M. .... 81  
 Majewska, Maria ..... 53  
 Maldonado, Jose R. .... 15, 37, 63  
 Malhotra, Shishuka ..... 81  
 Malla, Ashok K. .... 52  
 Mallet, Janelle ..... 68  
 Mallinckrodt, Craig H. .... 44  
 Mallios, Ronna ..... 22  
 Mallory, George L. .... 40  
 Malmquist, Carl P. .... 18  
 Manchanda, Rahud ..... 52  
 Mancini, Catherine L. .... 22  
 Mancuso, Donna M. .... 41  
 Mandell, Donald ..... 77  
 Maneschi, M. Laura ..... 44  
 Manji, Husseini K. .... 11, 13, 35, 49  
 Mann, J. John ..... 11, 23, 64  
 Mannarino, Anthony P. .... 89  
 Manning, John ..... 29  
 Marangell, Lauren B. .... 12, 38  
 Marcel, Eric J. .... 97  
 Marchant, Nestor F. .... 32  
 Marcus, Eric R. .... 18  
 Marcus, Steven C. .... 33  
 Marder, Stephen R. .... 14, 35, 79  
 Marin, Robert S. .... 10  
 Mark, Margery ..... 50  
 Markowitz, John C. .... 5, 55  
 Marmar, Charles R. .... 31  
 Marsh, Laura ..... 51  
 Marshall, Randall D. .... 92  
 Marslano, Richard ..... 75  
 Marsters, Jean A. .... 65  
 Martin, Eileen M. .... 74  
 Martin, Jacqueline ..... 50  
 Martinez-Aran, Anabel ..... 78, 89  
 Marx, Christine E. .... 56  
 Masand, Prakash S. .... 22, 59, 61, 83  
 Mason, Graeme ..... 77  
 Masson, Ella L. .... 43  
 Masters, Scott R. .... 90  
 Masterson, James F. .... 1  
 Mastrocinque, Concettina ..... 56  
 Mathis, Chester ..... 95  
 Matorin, Anu A. .... 18, 23  
 Matthews, Alicia K. .... 50  
 Matthews, Karen A. .... 70, 89  
 Mattson, Marlin R.A. .... 17  
 Mavissakalian, Matig R. .... 70  
 MaWhinney, Joseph R. .... 28  
 Mayberg, Helen S. .... 13  
 Mayer, Laurel ..... 61  
 Mays, Vicki M. .... 50  
 McBurnett, Keith ..... 44, 89  
 McCabe, Lee ..... 53  
 McCall, W. Vaughn ..... 14  
 McCann, Kathleen ..... 17  
 McCarthy, Martha ..... 45  
 McCarthy, Mary K. .... 93  
 Mc Caskie, Alicia ..... 31  
 McCaw, Bridgid ..... 47  
 McCommon, Jr., Benjamin H. .... 71  
 McConville, Brian J. .... 45  
 McCullough, Laurence B. .... 88  
 McCurtis, Henry L. .... 18, 23, 78  
 McDermott, Stephen P. .... 30  
 McDonagh-Coyle, Annmarie ..... 95  
 McDonnell, Dan ..... 44  
 McDougle, Christopher J. .... 12  
 McDowell, David M. .... 16, 39, 47, 57, 63, 72, 74  
 McElhiney, Martin ..... 53  
 McElroy, Susan L. .... 11, 56, 77, 83  
 McFall, Miles E. .... 92  
 McFarland, Bentson H. .... 88  
 McFarlane, William R. .... 52  
 McGlashan, Thomas H. .... 21, 27, 43, 52, 77  
 McGorry, Patrick D. .... 52  
 McGregor, Jacqueline C. .... 18  
 McGuire, Michael T. .... 96  
 McHugh, Paul R. .... 96  
 McIntosh, Daniel ..... 79  
 McIntyre, John S. .... 16, 24, 33, 90  
 McKay, Dean ..... 29  
 McLean, Alexandra ..... 57  
 McLean, Andrew J. .... 32  
 McLean, Terry S. .... 52  
 McMahan, Francis J. .... 50  
 McMeniman, Marjorie ..... 53  
 McNicholas, Laura F. .... 57, 62  
 McParland, Michelle ..... 18  
 McQuiston, Hunter L. .... 79  
 McRae, Aimee ..... 96  
 Meagher, David J. .... 94  
 Meaney, Michael ..... 9  
 Meckstroth, Karen ..... 29  
 Mee-Lee, David ..... 25  
 Meerlein, Andres ..... 32  
 Mehl-Madrona, Lewis ..... 7  
 Melhem, Nadine ..... 77

- Meller, Ted .....22  
Mellman, Lisa A. .... 21, 65  
Mellott, Katherine G. .... 19, 43  
Mellow, Alan M. .... 74  
Mellstrom, Martin .....88  
Melonas, Jacqueline M. ....5, 18, 41, 46, 66  
Meloy, J. Reid .....95  
Meltzer, Carolyn ..... 69, 95  
Meltzer, Herbert Y. .... 12, 59, 72  
Mendiondo, Marta S. ....54  
Mendlewicz, Julien .....42  
Mendoza, Alejandro Y. ....19  
Mendoza, Ricardo P. .... 41, 65  
Menza, Matthew A. .... 50, 51  
Merkel, Larry .....87  
Messer, Stephen C. .... 46, 69  
Metzger, Erand D. ....95  
Metzl, Jonathan M. ....47  
Metzner, Jeffrey L. ....65  
Meyer, Heidi .....45  
Meyer, Ilan H. ....50  
Mezzich, Juan E. ....74  
Mian, Ayesha .....87  
Michaels, M. Alex .....68  
Michels, Robert .....51  
Mick, Eric ..... 78, 80  
Mikalac, Cecilia M. ....37  
Miklowitz, David J. ....2, 9  
Milke, Dennis J. ....17  
Miller, Alexander L. ....40  
Miller, Andrew H. ....31  
Miller, Diana C. ....91  
Miller, Glenn H. ....7  
Miller, Ivan W. ....6  
Miller, Milton H. ....86  
Miller, Paul R. ....8  
Miller, Sheldon I. ....86  
Miller, Tandy J. ....52  
Milliken, Heather .....53  
Millman, Robert B. ....86  
Mills, Thomas C. ....50  
Milone, Richard D. .... 39, 65  
Milrod, Barbara L. ....85  
Min, Byung Kun .....94  
Mink, Sallie .....41  
Minkoff, Kenneth .....14  
Minsky, Shula .....44  
Mintz, David L. .... 62, 86  
Mintzer, Jacobo E. .... 15, 41, 62  
Mischoulon, David ..... 28, 70  
Miskimen, Theresa M. ....41  
Misri, Shaila .....6, 48  
Mitchell, James E. .... 6, 30, 95  
Miyamoto, Masaomi .....68  
Mneimneh, Zeina W. ....77  
Moffic, H. Steven .....7  
Mogul, Kathleen M. ....57  
Mohamed, Mahmoud A. ....44  
Moine, Xavier .....57  
Moller, Henry J. ....76  
Monteggia, Lisa .....49  
Montgomery, Richard A. .... 24, 48  
Montgomery, Stuart A. ....3  
Montu, Daniel A. ....24  
Montoya, Heidi D. .... 44, 90  
Mooney, Julia .....77  
Moore, Gregory J. ....11  
Moos, Rudolf H. ....64  
Moran, Maria .....94  
Morar, Doriana F. ....66  
Moreno, Alfredo .....93  
Moreno, Ricardo A. ....89  
Morgan, Melinda .....89  
Morrell, Martha J. .... 13, 35  
Morris, Larry A. ....72  
Moser, Charles A. ....32  
Moss, Quinton E. ....90  
Motlova, Lucie .....69  
Mrazek, David A. .... 61, 72  
Mueller-Spahn, Franz .....96  
Muenzenmaier, Kristina H. ....75  
Mullen, David .....63  
Mundo, Emanuela ..... 29, 55, 96  
Munich, Richard L. .... 15, 37  
Munoz, Rodrigo A. .... 24, 28, 38, 71, 93  
Munro, Robin .....16  
Murakami, Jessica L. .... 44, 70  
Murray, Heather W. .... 21, 88  
Murray, Robin M. ....25  
Murrelle, Lenn ..... 92, 93  
Musacchio, Amelia E. ....32  
Muskin, Philip R. .... 24, 43, 57, 63, 68  
Musselman, Dominique L. .... 11, 31  
Muszynski, Irvin L. ....23  
Myers, Michael F. .... 18, 23, 36, 66, 73, 85, 97  
Myers, Wade C. ....46  
Myrick, Hugh .....5, 97
- N**
- Nadelson, Carol C. .... 25, 47, 64  
Nahas, Ziad H. ....2  
Nakajima, Gene A. ....50  
Nand, Surinder S. .... 47, 71  
Napoli, Joseph C. .... 17, 36  
Naqvi, Syed S. A. .... 19, 86  
Narrow, William E. .... 28, 33  
Naser, Jeffrey A. ....23  
Nasrallah, Henry A. .... 11, 59  
Nathan, Kalpana I. ....46  
Nathan, S. Zev .....80  
Nathanson, Richard A. ....90  
Navara, Kesaia .....70  
Nazarey, Margaret .....8  
Ndlela, J. Charles .....15  
Need, Name .....50  
Nell, Rocio .....65  
Nelson, Adam P. ....65  
Nelson, David .....32  
Nelson, Michael T. ....90  
Nemeroff, Charles B. .... 11, 16, 31, 58  
Neubauer, David N. ....61  
Neugebauer, Richard ..... 45, 53  
New, Antonia S. ....27  
Newcom, Jeffrey .....12  
Newell, Audrey R. ....19  
Newman, Michelle G. ....90  
Newman, Rita R. .... 46, 66  
Newport, D. Jeffrey .....2, 6  
Newton, Thomas .....5  
Neylan, Thomas C. ....90  
Neziroglu, Fugen ..... 29, 46, 75  
Ng, Anthony T. .... 19, 41, 70  
Nicholas, Susan .....89  
Nicholi, Jr., Armand M. ....30  
Nierenberg, Andrew A. .... 3, 13, 35, 43, 44, 45, 70  
Ninan, Philip T. .... 11, 14, 36  
Nishiyama, Kelli .....68  
Nishizono, Masahisa .....84  
Nizny, Melvyn M. ....95  
Njenga, Frank G. ....77  
Nonacs, Ruta M. ....13  
Nordberg, Agneta .....58  
Noreno, George .....75  
Norman, Ross M.G. ....52  
Norris, Donna M. .... 18, 64  
North, Carol S. .... 39, 61  
Northcott, Colleen J. ....39  
Norwood, Ann E. ....39  
Notman, Malkah T. ....18  
Novac, Andrei .....66  
Numans, Mattijs E. ....70  
Nunes, Edward V. ....57, 96  
Numberg, H. George .....89
- O**
- Oakman, Jonathan ..... 22  
O'Brien, Charles P. .... 21, 52  
Oepen, Godehard ..... 39, 44, 63  
Oesterheld, Jessica R. ....37  
O'Hara, Michael W. ....1  
Ohkawa, Shigenori .....68  
Okasha, Ahmed .....72, 74  
Okasha, Tarek A. ....65  
Okereke, Olivia I. ....93  
Okin, Robert L. ....49  
Olarie, Sylvia W. .... 8, 55, 73  
Oldham, John M. .... 16, 20, 39  
Olfsen, Mark .....33  
Olivier, Veronique A. ....57  
Olympia, Josie L. ....39  
O'Malley, Mary B. .... 10, 90  
O'Neill, Patrick T. ....93  
Ongur, Dost ..... 22, 43  
Opler, Lewis A. .... 18, 25, 75, 94  
Oquendo, Maria A. .... 11, 51, 64, 86  
Ordorica, Patricia I. .... 20, 38, 48  
Orengo, Claudia .....18  
O'Shea, Kristian .....88  
Osinowo, Thomas O. ....83  
Oskin, Alec O. ....64  
Osofsky, Howard J. .... 41, 47, 52  
Osofsky, Joy D. ....47, 52  
Osofsky, Michael J. ....41  
Osser, David N. .... 19, 93  
Osterman, Janet E. ....85  
Ostermeyer, Britta .....62, 84  
Otto, Michael W. ....58  
Oulvey, Eugene A. ....83  
Owens, Jr., Donald P. ....93
- P**
- Pacheco, Antonio .....32  
Padrino-Iler, Susan .....90  
Pagano, Maria E. ....21  
Pagnoni, Giuseppe .....31  
Painter, Albert F. ....8  
Pallanti, Stefano ..... 13, 56, 96  
Panayiotopoulos, Christos .....69  
Pandurangi, Ananda ..... 25, 42  
Pandya, Anand ..... 19, 22  
Papakostas, George I. .... 44, 45, 90  
Papasogli, Alessandra .....56  
Parachini, Elizabeth A. .... 21, 27  
Pardes, Herbert .....19  
Parikh, Rajesh M. ....28  
Paris, Joel F. .... 45, 76, 92  
Parris, Frederick N. ....88  
Pary, Robert J. ....40  
Pasnau, Robert O. ....86  
Patel, Ramon C. ....86  
Patkar, Ashwin A. .... 21, 88  
Pato, Carlos N. ....55  
Pato, Michelle T. .... 29, 36, 55  
Patroi, Delia .....76  
Paul, Jay P. ....50  
Pava, Joel A. ....43

## PARTICIPANT INDEX

- Pearlson, Godfrey D. ....17  
 Peele, Roger .....16, 24, 28, 68  
 Peindl, Kathleen S. ....89  
 Peles, Uri P. ....83  
 Penny, Rosetta H. ....68  
 Perel, James M. ....89  
 Perez, Gina .....19  
 Perez, Liliam .....18  
 Perez, Oscar E. ....71  
 Perkins, Diana O. ....3, 11, 52  
 Perlis, Roy H. ....9, 44, 90  
 Perugi, Giulio .....77  
 Peselow, Eric D. ....22  
 Pessin, Hayley .....78  
 Pessin, Neil .....19  
 Petect, John R. ....17, 30, 93  
 Petersen, Timothy J. ....43, 44  
 Petit, Jorge R. ....15  
 Petitjean, Francois C. ....57, 97  
 Petkova, Eva .....45  
 Pettinati, Helen .....21  
 Petty, Frederick .....31  
 Pfeffer, Cynthia R. ....30  
 Pfefferbaum, Betty .....47, 61  
 Pflanz, Steven E. ....41, 47, 66, 84  
 Pham, Rose M. ....70  
 Philip, Kader .....32  
 Phillips, James E. ....26  
 Phillips, Lisa R. ....52  
 Pi, Edmond H.T. ....65, 94  
 Picard, Sandrine .....31  
 Pierre, Joseph M. ....37  
 Pini, Stefano .....56  
 Pinson, Letitia A. ....15  
 Pipe, Beth .....22  
 Pitchford, Ian .....56  
 Pittman, Mary .....65  
 Pitts, Gloria .....8  
 Plakun, Eric M. ....23, 40, 62, 86  
 Pleak, Richard R. ....17  
 Plontek, Catherine M. ....89  
 Pollack, David A. ....19, 52  
 Pollack, Lance .....50  
 Pollack, Mark H. ....58  
 Pontes, Anagloria .....89  
 Ponton, Lynn E. ....55  
 Pope, Jr., Harrison G. ....27  
 Popper, Charles W. ....27  
 Portney, Charles W. ....66  
 Posey, David J. ....12  
 Post, Jerrold M. ....37, 95  
 Post, Robert M. ....2  
 Posternak, Michael A. ....43  
 Postolache, Teodor T. ....22  
 Potkin, Steven G. ....58  
 Potter, Nancy .....54  
 Poulin, Michael .....79  
 Power, Rachel .....69, 88  
 Powsner, Seth M. ....7, 40, 46  
 Prathikanti, Sudha .....85  
 Pratts, Michael J. ....68  
 Prentiss, Diane .....88  
 Preter, Maunce .....47  
 Preven, David W. ....18, 66  
 Price, Charles S. ....88  
 Price, Julie .....95  
 Prigerson, Holly G. ....78  
 Prince, Jefferson B. ....1, 5, 14  
 Printz, David J. ....11  
 Prosen, Harry .....84  
 Puchalski, Christina M. ....46, 93  
 Puster, Kristie .....55  
 Puzantian, Talia .....88  
 Pyles, Robert L. ....28  
 Pynoos, Robert S. ....30, 52
- Q**
- Quercioli, Leonardo .....56, 96  
 Quigley, Rosemary .....93  
 Quinnett, Paul .....46
- R**
- Rabinowitz, Dena .....29  
 Rabkin, Judith G. ....53  
 Rabkin, Richard .....53  
 Radden, Jennifer .....26, 54, 65  
 Rae, Donald S. ....28, 33  
 Rainey, Charles J. ....24, 48  
 Raison, Charles .....31  
 Raiteri, Valentine .....51  
 Rajkowska, Grazyna .....11  
 Raju, Bangaru .....94  
 Ramirez, Luis F. ....32, 76  
 Ramirez, Paul M. ....25  
 Randall, Penny K. ....47  
 Rao, Aruna S. ....40  
 Rao, Nyapati R. ....21, 71, 76  
 Rapaport, Mark H. ....38, 42, 83  
 Raphael, Beverley .....17, 54  
 Rasgon, Natalie L. ....2, 43, 58  
 Rasmussen, Steven A. ....75  
 Raundal, Edle .....92  
 Rawitscher, Lee A. ....85  
 Razzano, Lisa A. ....50  
 Read, Mary E. ....91  
 Read, Nancy E. ....92  
 Rechtman, Richard .....97  
 Rechtshaffer, Ira .....62  
 Reed, Michael D. ....12  
 Regier, Darrel A. ....23, 33, 52, 73, 76  
 Reich, James H. ....91  
 Reichman, William E. ....62  
 Reifler, Burton V. ....72  
 Reiss, David .....38, 47  
 Remedi, Carolina .....93  
 Remen, Rachel Naomi .....49  
 Renn, Rebecca .....30  
 Resnick, Heidi S. ....79  
 Resnick, Phillip J. ....5, 14, 24, 36, 61, 84  
 Resnikoff, Roy O. ....25, 86  
 Reus, Victor I. ....53  
 Reuss, M. Lynne .....45  
 Revell, Jeremy E. ....86  
 Reyes, Raymond M. ....66  
 Riba, Michelle B. ....18, 36, 72  
 Richard, Julie .....53  
 Richards, Jeffery .....9  
 Richards, Lawrence K. ....19, 24, 32  
 Richardson, Denise M. ....89  
 Richardson, Jarrett W. ....8  
 Richter, Margaret A. ....29  
 Riordan, Charles E. ....17  
 Risser, Richard C. ....22  
 Ritvo, Eva C. ....66  
 Rizzo, Albert A. ....76  
 Roberts, Laura W. ....40, 65, 85, 91  
 Robertson, Michael .....1  
 Robindra, Paul K. ....24  
 Robinowitz, Carolyn B. ....24, 47, 48, 63  
 Robinowitz, David .....72  
 Robinson, Delbert G. ....53  
 Robinson, Gail E. ....36, 55  
 Robinson, Mia J. ....71  
 Robinson, Rebecca .....45  
 Robinson, Robert G. ....39, 67  
 Rodenhauser, Paul .....8, 85  
 Roerig, James L. ....30, 95  
 Roffi, Pamela A. ....43, 90  
 Rogan, Gerald .....23, 70  
 Rogers, Robert D. ....33  
 Rolland, John S. ....15, 66  
 Rome, Jeffrey D. ....48  
 Rome, Lee H. ....19  
 Ronis, Robert J. ....40  
 Roose, Steven P. ....8  
 Rosario, Vernon A. ....71  
 Rosberger, Zeev .....97  
 Rosenbaum, Jerrold F. ....9, 44, 59, 77  
 Rosenberg, Linda .....79  
 Rosenfeld, Barry D. ....78, 95  
 Rosenheck, Robert A. ....40, 64, 65  
 Rosenthal, Murray .....88  
 Rosenthal, Richard N. ....31, 57, 97  
 Ross, Christopher A. ....42  
 Roter, Debra L. ....78  
 Roth, Bryan L. ....59  
 Roth, Loren H. ....10  
 Rothbaum, Barbara O. ....25, 82  
 Rothstein, David A. ....96  
 Rotter, Merrill R. ....86  
 Rourke, Sean B. ....92  
 Rozanski, Chris .....32  
 Ruben, Harvey L. ....23  
 Rubin, Andrew A. ....95  
 Rubio-Stipeć, Maritza .....28  
 Rudisill, John R. ....8  
 Rue, David S. ....94  
 Rui, Qing .....53  
 Ruiz, Edmundo J. ....91  
 Ruiz, Pedro .....7, 12, 16, 23, 39, 51, 65, 87  
 Rush, A. John .....6, 11, 84  
 Russakoff, L. Mark .....1  
 Russinova, Zlatka L. ....53  
 Russo, Leo .....93  
 Ryall, Jo-Ellyn M. ....7  
 Ryan, Deirdre M. ....48  
 Ryan, J. Michael .....5, 13  
 Ryan, Joan .....27  
 Ryan, Julie L. ....44, 45  
 Rychik, Abe M. ....5, 69  
 Rynearson, Edward K. ....23, 54  
 Rynn, Moira A. ....3
- S**
- Sabshin, Melvin .....50  
 Sacamano, James T. ....62  
 Sachs, Gary S. ....9, 11  
 Sadler, John Z. ....26  
 Saeed, S. Atezzaz .....1, 30, 85  
 Saettoni, Marco .....56  
 Said, Tewfik .....7  
 Saindon, Connie A. ....54  
 Saito, Robb .....86  
 Saiz-Ruiz, Jeronimo .....86  
 Sakhrani M.D., Duru .....45, 68  
 Salber, Patricia .....47  
 Sale, Tamara .....52  
 Sallee, Floyd R. ....27, 68, 96  
 Salloum, Alison A. ....54  
 Salloway, Stephen P. ....81  
 Salmeron, Betty Jo .....61, 83  
 Saltzman, William S. ....30



Samuel, Steven E. ....	94	Seward, James ....	54	Spaniol, LeRoy ....	53
Sanchez, Homero R. ....	91	Shabo, Honorable Harold E. ....	24	Sparen, Par ....	70
Sanders, Michael ....	61, 83	Shaffer, David ....	23	Sparr, Landy F. ....	85
Sandfort, Theodoros G.M. ....	50	Shafii, Mohammad ....	69	Spencer, Thomas J. ....	44, 56, 61, 80, 83
Sandi, Luis ....	93	Shafii, Sobia H. ....	68	Spiegel, Charles ....	80
Sandson, Neil B. ....	37	Shalev, Arie Y. ....	65, 82	Spiegel, David ....	24, 29, 37, 50, 63, 69, 80, 88, 95
Sanislow, Charles A. ....	27, 43	Shamir, Eyal Z. ....	69	Spinelli, Margaret G. ....	16
Sanjurjo, Teresita ....	38	Shanfield, Stephen B. ....	74, 75	Spitz, Deborah ....	26, 54, 73
Sansone, Randy A. ....	76	Shannahoff-Khalsa, David ....	75	Spitzer, Robert L. ....	32
Santos, Elizabeth J. ....	39	Shapiro, Edward R. ....	23, 40, 62, 86	Sprang, Rob ....	86
Sapolsky, Robert ....	9, 13	Shapiro, Shauna ....	18	Srinivasaraghavan, Jagannathan ....	47
Saraceno, Benedetto ....	46	Sharfstein, Steven S. ....	42	Stabinsky, Harvey ....	18, 43, 49, 66
Saravay, Stephen M. ....	94	Sharon, Estee ....	31	Stabinsky, Susan ....	18, 49, 66, 89
Sargent, John ....	66	Shaw, Darlene ....	76	Stack, Kathleen M. ....	22
Sarma, Bala ....	47	Shea, M. Tracie ....	21	Stahl, Stephen M. ....	2, 36
Sartorius, Norman ....	23, 93	Shea, Shawn C. ....	8, 15	Stall, Ron D. ....	50
Satish, Usha G. ....	29	Sheehan, David V. ....	3, 8, 67	Stangler, Ronnie S. ....	57
Saxena, Kirti ....	13	Sheitman, Brian B. ....	69	Stanley, Barbara H. ....	21
Saxena, Shekhar ....	46	Shelley, Anne-Marie ....	75, 94	Star, Jodi E. ....	22, 64, 90
Scanlan, James M. ....	54	Shellow, Ronald A. ....	70	Stastny, Juerren ....	96
Schachar, Russell ....	29	Sher, Leo ....	11	Stecher, Vera ....	89
Schachtel, Rabbi Zvi ....	66	Shoab, Arif M. ....	87	Stein, Bradley D. ....	79
Schafer, Catherine A. ....	45	Shoji, Adrianna ....	32	Stein, Mark A. ....	87
Schaffner, Kenneth F. ....	26	Sholevar, G. Pirooz ....	51	Stein, Maurice ....	66
Schane, Murray D. ....	72	Shore, Miles F. ....	17, 46, 64	Stein, Murray B. ....	2, 58
Schatzberg, Alan F. ....	6, 10, 16, 39, 73	Shriver, Timothy ....	85	Stein, Seth P. ....	23
Scheiber, Stephen C. ....	28, 63, 72	Shuchter, Stephen R. ....	54	Steinberg, Maurice D. ....	78
Scherl, Donald J. ....	33	Shulman, Kenneth I. ....	12	Steiner, Hans ....	13, 50
Schetky, Diane H. ....	10	Shusterman, Carl ....	90	Steiner, Meir ....	59
Schiffer, Randolph B. ....	72	Siegel, Daniel J. ....	31, 36, 91	Steinglass, Joanna E. ....	21, 65
Schlenger, William E. ....	79	Siegel, Everett R. ....	53	Steinglass, Peter J. ....	66
Schlesinger, Abigail B. ....	64	Siegel, Glenn N. ....	65	Stekete, Gail ....	75
Schmidt, Jr., Chester W. ....	25, 47, 70	Sierles, Frederick S. ....	29, 76	Stengle, Cindy J. ....	86
Schmitt, Frederick A. ....	54	Siever, Larry J. ....	27, 75	Stern, Harriet C. ....	46
Schneier, Franklin R. ....	75	Silberman, Edward K. ....	36	Stettin, Glen ....	22
Schoener, Gary R. ....	55, 94	Silver, Roxane ....	79	Stevenson, Jayne M. ....	21, 84
Schoepp, Darryle ....	77	Silver, Stuart B. ....	1, 85	Stewart, Altha J. ....	55
Scholten, Derek J. ....	52	Silverman, Samuel M. ....	23	Stewart, Deborah C. ....	22, 40
Schon, Mary ....	64	Simeon, Daphne ....	13	Stewart, Donna E. ....	16, 39, 47, 73
Schooler, Nina R. ....	59	Simpatico, Thomas A. ....	1	Stoddard, Jr., Frederick J. ....	71
Schore, Allan N. ....	36	Simpson, H. Blair ....	75	Stoll, Andrew L. ....	61
Schrift, Michael J. ....	76	Singh, Bruce ....	86	Stone, Alan A. ....	39, 65
Schubmehl, James Q. ....	7	Singh, Jaskaran ....	65	Stone, Michael H. ....	26, 54, 96
Schuckit, Marc A. ....	20	Sinis, Samuel G. ....	56, 75, 85	Stone, Walter N. ....	2
Schuh, Leslie ....	22	Sistrunk, Shari G. ....	86	Storlazzi, J. Jordan ....	68
Schulman, Julie K. ....	87	Sivertz, Kristin S. ....	48	Stotland, Nada L. ....	29, 30, 56, 86
Schultz, Charles S. ....	12	Skodol II, Andrew E. ....	21, 26, 74	Stowe, Zachary N. ....	6
Schulz, S. Charles ....	27	Skudlarski, Pawel ....	27	Strain, Eric C. ....	62
Schuster, Mark A. ....	79	Sloan, Kevin L. ....	92	Strain, James J. ....	22
Schuyler, Dean ....	24	Small, Gary W. ....	81	Straits-Troster, Kristy A. ....	92
Schwab, John J. ....	44	Smelson, David A. ....	31	Strakowski, Stephen M. ....	59, 78
Schwartz, Bruce J. ....	71	Smith, David ....	87	Straub, Richard ....	3
Schwartz, Elliott R. ....	90	Smith, Glen ....	50	Strauss, Gordon D. ....	22, 44
Schwartz, Jonathan R. L. ....	90	Smith, Hawthorne ....	41	Strauss, John S. ....	48, 94
Schwartz, Joseph E. ....	78	Smith, Jennifer ....	71	Strayhorn, Earlene E. ....	15
Schwartz, Joseph M. ....	46, 70	Smith, Mary Kay ....	56	Streltzer, Jon M. ....	36
Schwartz, Thomas L. ....	22	Smith, Matthew B. ....	48	Streufert, Siegfried ....	29
Scott, Jan L. ....	8, 30	Smith, Michael W. ....	15, 91	Stroup, T. Scott ....	81
Scott, Marcia A. ....	75, 84	Snowdon, David ....	41	Stuart, Scott P. ....	1
Scotton, Bruce W. ....	7	Soares, Claudio N. ....	28, 59	Stubbs, Charlene M. ....	68
Scuglik, Deborah L. ....	70	Sokol, Mae S. ....	1	Stuber, Jennifer ....	79
Scully, Jr., James H. ....	7, 28, 72	Soloff, Paul H. ....	69	Stuber, Margaret L. ....	62
Seager, Stephen B. ....	41	Solursh, Lionel P. ....	86	Sudak, Donna M. ....	17, 51
Sedler, Mark J. ....	78	Sommers, Denise ....	83	Sultzter, David L. ....	62
Segal, Gerald ....	36	Sonawalla, Shamsah B. ....	28, 59	Suo-Chan, Shannon T. ....	22, 90
Segal, Zindel V. ....	90	Sonne, Susan ....	96	Suppes, Patricia ....	81, 89
Seidman, Stuart N. ....	89	Sood, Erica ....	13	Susser, Ezra S. ....	45, 77
Selepova, Pavla ....	69	Sorensen, James L. ....	86	Sussman, Norman ....	6
Sellers, Brealyn M. ....	23	Soria, Carlos ....	93	Sved, Margery S. ....	80, 85
Sernyak, Michael J. ....	92	Sorrentino, Renee M. ....	62, 84	Swain, James E. ....	76
Servis, Mark E. ....	30, 93	Soto, Jose M. ....	18	Swann, Alan C. ....	5
Sevilla, Brett J. ....	90	Sowers, Wesley ....	7	Swanson, James M. ....	44, 45
Sevy, Serge M. ....	33	Spaniel, Filip ....	69	Swartz, Elena F. ....	90

**PARTICIPANT INDEX**

Swartz, Holly A. .... 2, 6, 11  
 Swartz, Karen L. .... 41  
 Swerdlow, Michael ..... 48  
 Sysko, Robyn ..... 95  
 Szabo, Steven T. .... 58  
 Szeftel, Roxanne F. .... 19  
 Szigethy, Eva M. .... 47, 85  
 Szpirko, Mordka ..... 57

**T**

Taintor, Zebulon C. .... 57  
 Talbott, John A. .... 7, 57, 97  
 Tamburrino, Marijo B. .... 86  
 Tamminga, Carol A. .... 5, 59  
 Tandon, Rajiv ..... 11, 14, 81  
 Tapp, Andre ..... 40  
 Tariot, Pierre N. .... 13, 35, 62, 69  
 Tart, Charles ..... 18  
 Taylor, Craig G. .... 90  
 Taylor, David H. .... 49, 69, 74  
 Taylor III, Fletcher B. .... 44  
 Tecott, Laurence H. .... 74  
 Teillet, Isabelle ..... 57  
 Terr, Lenore C. .... 33, 89  
 Tesler, Pauline H. .... 19, 24  
 Thase, Michael E. .... 3, 14, 25, 37, 55  
 Thielman, Samuel B. .... 30  
 Thomas, Christopher R. .... 18  
 Thomas, Stuart ..... 88  
 Thompson, James W. .... 41  
 Thompson, Kenneth S. .... 19, 41, 65  
 Thomson, Captane P. .... 71  
 Thoret, Yves G. .... 97  
 Thornhill IV, Joshua T. .... 76  
 Thornton, Charles C. .... 88  
 Thorpy, Michael ..... 83  
 Tighe, Patti ..... 23  
 Tillman, Jane G. .... 23  
 Tinsley, Joyce A. .... 71  
 Tohen, Mauricio F. .... 22  
 Toledo, Daniel ..... 76  
 Tollefson, Gary D. .... 44  
 Tomarken, Alexis ..... 78  
 Ton, Hendry ..... 24, 48, 91  
 Tondo, Leonardo ..... 12  
 Tong, Lowell D. .... 76  
 Tornatore, Jane B. .... 54  
 Torres, Vilma ..... 54  
 Torrey, E. Fuller ..... 23, 53  
 Touchet, Bryan K. .... 40  
 Townsend, Laurel ..... 52  
 Tracy, Martin G. .... 18, 41, 46  
 Treisman, Glenn J. .... 66  
 Tremblay, Annie ..... 94  
 Tremblay, Richard ..... 45  
 Trestman, Robert L. .... 68  
 Trimble, Michael R. .... 15  
 Trinca, Luzia A. .... 89  
 Trinidad, Anton C. .... 30, 68, 89  
 Truman, Amelia ..... 72  
 Trzepacz, Paula T. .... 94  
 Tschan, Werner ..... 94  
 Tsemberis, Sam ..... 78, 79  
 Tseng, Wen-Shing ..... 36  
 Tso, Alice C. .... 8, 66  
 Tsuang, John W. .... 5, 41  
 Tsuang, Ming T. .... 73, 94  
 Tucker, Gary J. .... 6  
 Tucker, Phebe M. .... 61  
 Tucker, William M. .... 36  
 Tugg, Lorne A. .... 92

Tuinebreyer, Wilco ..... 19  
 Tulloch, Simon J. .... 68  
 Tune, Larry E. .... 87  
 Turecki, Gustavo ..... 45  
 Turgay, Atilla ..... 43  
 Turkington, Douglas ..... 41, 59  
 Turman, Kathryn M. .... 54  
 Turner, Susan A. .... 91  
 Twemlow, Stuart W. .... 75  
 Tyano, Sam ..... 77

**U**

Uchikawa, Osamu ..... 68  
 Ulloa, Rosa E. .... 93  
 Unger, Kathleen Bell ..... 45  
 Urbaitis, John C. .... 28  
 Ursano, Robert J. .... 39, 47, 65, 90  
 Ustun, T. Bedirhan ..... 23, 74

**V**

Vaglum, Per ..... 92  
 Van Ameringen, Michael A. .... 22  
 Van Den Brink, Wim ..... 92  
 Vander Voort, Sarah ..... 29  
 Van Praag, Herman M. .... 84  
 Van Stone, William W. .... 64  
 Vanwesenbeeck, Ine ..... 50  
 Varma, Sujit R. .... 23  
 Vaswani, Meera ..... 45  
 Veenstra-VanderWeele, Jeremy ..... 50  
 Veit, Chris A. .... 90  
 Velasquez, Rolando R. .... 39  
 Velut-Chino, Narielchrist ..... 57  
 Ventura, Joseph ..... 53  
 Verdeli, Lena ..... 85  
 Vergare, Michael J. .... 21, 88  
 Vesper, Belynda D. .... 80  
 Vesper, Frederick ..... 80  
 Vickar, Garry M. .... 28  
 Victor, Bruce S. .... 7, 33  
 Vieta, Eduard ..... 22, 78, 89  
 Vignoli, Serena ..... 56  
 Viguera, Adele C. .... 35  
 Villareal, Gerardo ..... 76  
 Vinogradov, Sophia ..... 68  
 Virk, Subhdeep ..... 22  
 Visser, Hetty M. .... 19  
 Vlahov, David ..... 79  
 Vogel-Scibilia, Andrew ..... 66  
 Vogel-Scibilia, Suzanne E. .... 66  
 Volavka, Jan ..... 75  
 Volberding, Paul ..... 77  
 Volkman, Edward A. .... 86  
 Volkman, Janice ..... 86  
 Vujanovic, Anna A. .... 27  
 Vythilingham, Meena ..... 35

**W**

Wachtel, Dana ..... 51  
 Wade, Terrance J. .... 45  
 Wagner, Karen D. .... 8, 59  
 Wahlbeck, Kristian ..... 79  
 Wain, Harold J. .... 48  
 Wainberg, Milton L. .... 39  
 Waldinger, Robert J. .... 47  
 Walker, R. Dale ..... 21, 51  
 Walsh, B. Timothy ..... 61, 83, 95  
 Walsh, Joanne C. .... 92  
 Walsh, Roger N. .... 7, 18

Warnbach, Beth N. .... 30  
 Warner, Enrique ..... 93  
 Warshaw, Carole L. .... 47  
 Wasylenki, Donald A. .... 92  
 Watkin, John G. .... 44  
 Watson, Chris ..... 22  
 Watson, Patricia J. .... 39  
 Weaver, Karl E. .... 23  
 Weber, Elke V. .... 33  
 Wehr, Allison M. .... 71  
 Wei, Hsiao-Lan ..... 70  
 Weiden, Peter J. .... 11, 59  
 Weinberger, Daniel R. .... 3  
 Weine, Stevan M. .... 95, 96  
 Weiner, Joseph S. .... 78  
 Weiner, Myron F. .... 74  
 Weiner, Richard D. .... 14  
 Weingarten, Randall ..... 46  
 Weinstein, Henry C. .... 85  
 Weinstein, Stephen P. .... 21  
 Weisaeth, Lars ..... 65  
 Weisberg, Risa B. .... 11  
 Weisler, Richard H. .... 44  
 Weiss, Francine ..... 46  
 Weitzner, Michael A. .... 78  
 Weizman, Ronit ..... 69  
 Weller, Elizabeth B. .... 43, 72  
 Wells, Kenneth B. .... 63  
 Wells, Victoria E. .... 45  
 Welner, Michael M. .... 54  
 Wenk, Gary L. .... 41  
 West, Joyce C. .... 28, 33, 76  
 Westermeyer, Joseph J. .... 36  
 Wewiorski, Nancy J. .... 53  
 Wewiorski, Nancy ..... 53  
 Wexler, Bruce E. .... 27  
 Whitehorn, David ..... 53  
 Wieduwilt, Kristin M. .... 68  
 Wiesner, Irving S. .... 30  
 Wilens, Timothy E. .... 44, 45, 56, 80, 96  
 Wilfley, Denise E. .... 6, 83  
 Wilhelm, Sabine ..... 75  
 Wilk, Joshua E. .... 33, 76  
 Wilkins, Jeffrey N. .... 19, 91  
 Willenbring, Mark L. .... 92  
 Williams, Adedapo B. .... 45  
 Williams, Eric R. .... 40, 43, 89  
 Williams, Jill ..... 31  
 Williams, Kristi S. .... 86  
 Williams, Mark D. .... 70  
 Williams, Richard ..... 1  
 Willoughby, Brian ..... 32  
 Wilson, Daniel R. .... 56, 63  
 Wilson, G. Terrence ..... 30  
 Wilson, Katherine ..... 32  
 Wingood, Gina M. .... 55  
 Winkelman, John W. .... 10, 48, 93  
 Winkler, Diethar ..... 96  
 Winograd, Arie ..... 75  
 Winstead, Daniel K. .... 28, 72  
 Wint, Dylan P. .... 90  
 Wise, Thomas N. .... 67, 89  
 Wiseman, Claire ..... 92  
 Wisner, Katherine L. .... 68, 89  
 Witham, Terence L. .... 7, 40  
 Witte, Elise ..... 89  
 Wittlin, Avi ..... 31  
 Wittlin, Byron J. .... 65  
 Woerner, Margaret G. .... 53  
 Wolf, Nancy S. .... 31  
 Wolf, Robert M. .... 52  
 Wolfe, Barbara E. .... 95

Wolin, Steven J. ....	66
Wolkowitz, Owen M. ....	53
Wonderlich, Stephen A. ....	30, 95
Wong, Janice ....	88
Woo, Cindy ....	90
Wood, William G. ....	7
Woods, Scott W. ....	52
Woods, Sherwyn M. ....	10
Woolley, Stephen B. ....	69
Workeneh, Lishan ....	88
Wozniak, Janet ....	12, 78, 80
Wright, Annemarie ....	52
Wright, Harry H. ....	52, 68
Wright, Jesse H. ....	8, 17, 37, 65, 91
Wright-Etter, Pamela J. ....	71
Wu, Jin ....	50
Wu, Ping ....	77
Wu, Roger M.Y. ....	44
Wulsin, Lawson R. ....	45
Wynn, Gary H. ....	37

## X


Xia, Fang ....	90
----------------	----

## Y

Yager, Joel ....	6, 18, 30, 58, 84
Yang, C. Paul ....	91
Yang, Jing-Duan ....	24
Yangang, Zhang ....	89
Yaryura-Tobias, Jose A. ....	29, 46, 75
Yates, Barbara L. ....	70
Yatham, Lakshmi N. ....	3
Yeomans, Frank E. ....	26, 37
Yeung, Albert ....	28, 70, 90, 91
Yeung, Paul P. ....	16, 22, 69
Yonkers, Kimberly A. ....	6
Young, Elizabeth A. ....	11
Young, Keith W. ....	41, 47, 56, 57
Young, L. Trevor ....	81
Youngstrom, Eric A. ....	77
Yudofsky, Stuart C. ....	13, 35
Yunes, Roberto ....	93
Yung, Alison R. ....	52
Yzermans, Christoffel J. ....	89

## Z

Zafar, Mansoor ....	43
Zajecka, John M. ....	58
Zakari, Henrik ....	19, 83
Zalesky, Richard ....	69
Zanarini, Mary C. ....	21, 27, 78
Zarate, Jr., Carlos M. ....	2, 22
Zealberg, Joseph J. ....	80
Zerbe, Kathryn J. ....	1, 50, 67
Ziedonis, Douglas M. ....	31, 52
Ziegler, Penelope P. ....	23
Zil, John S. ....	85
Zima, Bonnie T. ....	28
Zimbhoff, Daniel L. ....	59
Zimmerli, Ellen ....	95
Zimmerman, Mark ....	43, 64
Zipursky, Robert B. ....	52
Zivin, Gail ....	94
Zoccolillo, Mark ....	45



# THE FIRST AND LAST

## At Your Annual Meeting Bookstore

### APPI BOOKSTORE AT THE 2003 APA ANNUAL MEETING

Grow professionally and increase your knowledge of psychiatric practices through the extensive selection at the APPI bookstore. Our wide variety of topics allows you to pick up the titles you've always wanted or find a title to complete series collections and annual reviews. We look forward to seeing you!

Make sure to visit the APPI bookstore when you're in San Francisco—you won't be disappointed!

### APPI Bookstore Hours during the 2003 APA Annual Meeting

Saturday, May 17	11 am-5 pm
Sunday, May 18	11 am-4:30 pm
Monday, May 19	10 am-6 pm
Tuesday, May 20	10 am-6 pm
Wednesday, May 21	10 am-3 pm

### Sunrise Special! Members-in-Training ONLY

American Psychiatric Publishing, Inc. is committed to helping APA Members-in-Training gain the knowledge needed to excel in the psychiatric profession. We are pleased to announce that we are bringing back the APPI Bookstore's Members-in-Training Sunrise Special. Between the hours of **8am and 11am, on Sunday, May 18, the APPI Bookstore will be open for members-in-training only, and will offer a 25% discount.** Don't miss out on this special offer!

American  
**Psychiatric**  
Publishing, Inc.

#### The *First* and *Last* Word in Psychiatry

American Psychiatric Publishing, Inc.  
1000 Wilson Boulevard, Suite 1825  
Arlington, VA 22209-3901  
Phone: 703-907-7322 or 1-800-368-5777  
Mon.-Fri., 9 am to 5:30 pm, ET  
Fax: 703-907-1091  
Email: [appi@psych.org](mailto:appi@psych.org)  
Web: [www.appi.org](http://www.appi.org)

Please reference priority code *AH326* when ordering

CD-ROM  
INCLUDED!



### The American Psychiatric Publishing Textbook of Clinical Psychiatry, Fourth Edition

Edited by Robert E. Hales, M.D., M.B.A., and  
Stuart C. Yudofsky, M.D.

This densely informative textbook comprises 40 scholarly, authoritative chapters by 89 experts and combines junior and senior authors alike to enhance the rich diversity and quality of clinical perspectives. The editors have added a chapter on interpersonal therapy and updated all chapters to include the latest references and research findings. Selected chapters have been completely rewritten by new authors.

2003 • 1776 pages • ISBN 1-58562-032-7 • hardcover  
\$229.00 • Item #62032



### Manual of Clinical Psychopharmacology, Fourth Edition

Alan F. Schatzberg, M.D.,  
Jonathan Cole, M.D., and  
Charles DeBattista, M.D.

A deeply informative yet eminently practical manual on this complex subject. Here, three senior psychopharmacologists offer a unique clinical perspective and practical advice on applying psychotropic medications to the treatment of specific psychiatric conditions.

2003 • 736 pages • ISBN 0-88048-865-4 • paperback  
\$59.00 • Item #8865

NEW!



### FOCUS The Journal of Lifelong Learning in Psychiatry

Editors: Deborah J. Hales, M.D., and  
Mark Hyman Rapaport, M.D.

FOCUS is the first integrated approach to staying current in your field. Each issue focuses on a major subject in psychiatry and updates you with original clinical and review articles, and reprints of the most important articles as selected by experts. FOCUS provides a comprehensive clinical review of current practice that helps you stay abreast of developments in psychiatry—each issue is like a review course in itself.

2003 • Volume 1, 4 issues • ISSN 1541-4094  
Please call for pricing information

Prices subject to change without notice.

# WORD IN PSYCHIATRY

## REVIEW OF PSYCHIATRY VOLUME 22

Series Editors: John M. Oldham, M.D., M.S.,  
and Michelle B. Riba, M.D., M.S.

### Trauma and Disaster Responses and Management

Edited by Robert J. Ursano, M.D., and  
Ann E. Norwood, M.D.  
2003 • 208 pages • ISBN 1-58562-115-3 • paperback  
\$31.95 • Item #62115

### Molecular Neurobiology for the Clinician

Edited by Dennis S. Charney, M.D.  
2003 • 208 pages • ISBN 1-58562-113-7 • paperback  
\$31.95 • Item #62113

### Standardized Evaluation in Clinical Practice

Edited by Michael B. First, M.D.  
2003 • 208 pages • ISBN 1-58562-114-5 • paperback  
\$31.95 • Item #62114

### Geriatric Psychiatry

Edited by Alan M. Mellow, M.D., Ph.D.  
2003 • 208 pages • ISBN 1-58562-116-1 • paperback  
\$31.95 • Item #62116

### SET of Review of Psychiatry Volume 22

2003 • \$102.00 • Item #5074 (SAVE \$25.80!)

## JANUARY

### Concise Guide to Anxiety Disorders

Eric Hollander, M.D., and  
Daphne Simeon, M.D.  
2003 • 272 pages • ISBN 1-58562-080-7 • paperback  
\$27.95 • Item #62080

### Textbook of Family and Couples Therapy: Clinical Applications

Edited by G. Pirooz Sholevar, M.D.,  
with Linda D. Schworer, Ph.D.  
2003 • 976 pages • ISBN 0-88048-518-3 • hardcover  
\$59.00 • Item #8518

### The Dementias: Diagnosis, Treatment, and Research, Third Edition

Edited by Myron F. Weiner, M.D., and  
Anne M. Lipton, M.D., Ph.D.  
2003 • 596 pages • ISBN 1-58562-043-2 • paperback  
\$84.95 • Item #62043

## FEBRUARY

### Agitation in Patients With Dementia: A Practical Guide to Diagnosis and Management

Edited by Donald P. Hay, M.D., David T. Klein,  
Psy.D., Linda K. Hay, R.N., Ph.D.,  
George T. Grossberg, M.D., and  
John S. Kennedy, M.D., F.R.C.P.C.  
2003 • 272 pages • ISBN 0-88048-843-3 • paperback  
\$43.95 • Item #8843

## MARCH

### Evidence-Based Practices in Mental Health Care

American Psychiatric Association  
2003 • 128 pages • ISBN 0-89042-294-X • paperback  
\$19.95 • Item #2294

### Neuroleptic Malignant Syndrome and Related Conditions, Second Edition

Stephan C. Mann, M.D., Stanley N. Caroff,  
M.D., Paul E. Keck, M.D., and Arthur Lazarus,  
M.D., M.B.A.  
2003 • 192 pages • ISBN 1-58562-011-4 • paperback  
\$29.95 • Item #62011

### Core Competencies for Psychiatric Practice: What Clinicians Need to Know

(A Report of the American Board of Psychiatry  
and Neurology)  
Edited by Stephen C. Scheiber, M.D.,  
Thomas A. M. Kramer, M.D., and  
Susan E. Adamowski, Ed.D.  
2003 • 192 pages • ISBN 1-58562-112-9 • paperback  
\$29.00 • Item #62112

### Psychoneuroendocrinology: The Scientific Basis of Clinical Practice

Edited by Owen M. Wolkowitz, M.D., and  
Anthony J. Rothschild, M.D.  
2003 • 608 pages • ISBN 0-88048-857-3 • paperback  
\$69.00 • Item #8857

## APRIL

### Fundamentals of Psychiatric Treatment Planning, Second Edition

James A. Kennedy, M.D.  
2003 • 368 pages • ISBN 1-58562-061-0 • spiralbound  
\$49.00 • Item #62061

### Mastering the Kennedy Axis V: A New Psychiatric Assessment of Patient Functioning

James A. Kennedy, M.D.  
2003 • 320 pages • ISBN 1-58562-062-9 • spiralbound  
\$44.00 • Item #62062

### Concise Guide to Pain Management for Psychiatrists

Raphael J. Leo, M.D.  
2003 • 352 pages • ISBN 1-58562-103-X • paperback  
\$27.95 • Item #62103

### American Psychiatric Glossary, Eighth Edition

Edited by Narriman C. Shahrokh, and  
Robert E. Hales, M.D., M.B.A.  
2003 • 272 pages • ISBN 1-58562-093-9 • paperback  
\$34.95 • Item #62093  
2003 • 272 pages • ISBN 1-58562-146-3 • hardcover  
\$44.95 • Item #62146

## MAY

### Schizophrenia Into Later Life: Treatment, Research, and Policy

Edited by Carl I. Cohen, M.D.  
2003 • 336 pages • ISBN 1-58562-037-8 • paperback  
\$36.00 • Item #62037

### Concise Guide to Drug Interaction Principles for Medical Practice: Cytochrome P450, UGTs, P-Glycoproteins, Second Edition

Kelly L. Cozza, M.D., Scott C. Armstrong, M.D.,  
and Jessica R. Oesterheld, M.D.  
2003 • 560 pages • ISBN 1-58562-111-0 • paperback  
\$34.95 • Item #62111

### Concise Guide to Child and Adolescent Psychiatry, Third Edition

Mina K. Dulcan, M.D., D. Richard Martini,  
M.D., and MaryBeth Lake, M.D.  
2003 • 400 pages • ISBN 1-58562-074-2 • paperback  
\$27.95 • Item #62074

### Network Therapy for Alcohol and Drug Abuse: Effective Office-Based Treatment

Marc Galanter, M.D.  
2003 • Approx. 39 min. • ISBN 1-58562-142-0 • VHS  
\$49.95 • Item #62142

### The Clinical Interview of the Child, Third Edition

Stanley I. Greenspan, M.D., with  
Nancy Thorndike Greenspan  
2003 • 320 pages • ISBN 1-58562-137-4 • paperback  
\$29.95 until May 31, 2003, \$39.95 thereafter • Item #62137

### Medical Illness and Schizophrenia

Edited by Jonathan M. Meyer, M.D., and  
Henry A. Nasrallah, M.D.  
2003 • 352 pages • ISBN 1-58562-106-4 • paperback  
price TBA • Item #62106

### Autism Spectrum Disorders: A Research Review for Practitioners

Edited by Sally Ozonoff, Ph.D., Sally J. Rogers,  
Ph.D., and Robert L. Hendren, D.O.  
2003 • 320 pages • ISBN 1-58562-119-6 • paperback  
price TBA • Item #62119

### Personality Disorders Over Time: Precursors, Course, and Outcome

Joel Paris, M.D.  
2003 • 240 pages • ISBN 1-58562-040-8 • paperback  
\$33.00 • Item #62040

### Drug Interactions Casebook: The Cytochrome P450 System and Beyond

Neil B. Sandson, M.D.  
2003 • 288 pages • ISBN 1-58562-091-2 • paperback  
\$33.00 • Item #62091

**INDUSTRY-SUPPORTED SYMPOSIUM 1**  
**Saturday, May 17, 2003, 12:30 p.m. - 3:30 p.m.**  
**Gateway Ballroom, Exhibit Level, Moscone Center**



A symposium to be held during  
the APA 2003 Annual Meeting

**Saturday, May 17, 2003**  
**Gateway Ballroom • Moscone Center**  
**San Francisco, CA**

## Schizophrenia Treatment in the Community: The Role of Long-Acting Antipsychotics

### Agenda

<p>12:00 – 12:30 PM <b>Lunch</b></p> <p>12:30 – 12:40 PM <b>Welcome and Introduction</b> John M. Kane, MD (Chair) Hillside Hospital</p> <p>12:40 – 1:10 PM <b>Key Issues in Long-Term Pharmacotherapy of Schizophrenia</b> William T. Carpenter, Jr., MD Maryland Psychiatric Research Center</p> <p>1:10 – 1:40 PM <b>The Latest Advance in Long-Acting Antipsychotic Therapy</b> John M. Kane, MD</p>	<p>1:40 – 2:15 PM <b>Translating From Clinical Trials to Community Care of Patients With Schizophrenia</b> Jacqueline M. Feldman, MD University of Alabama School of Medicine</p> <p>2:15 – 2:45 PM <b>Overcoming Obstacles to Patient Acceptance of Long-Acting Antipsychotics</b> David C. Henderson, MD Massachusetts General Hospital</p> <p>2:45 – 3:30 PM <b>Questions and Answers</b></p>	<p><b>At the conclusion of this symposium, the participant should be able to:</b></p> <ul style="list-style-type: none"> <li>■ Evaluate the probability of poor medication adherence and understand its consequences</li> <li>■ Assess the role of long-acting risperidone in the treatment of schizophrenia</li> <li>■ Discuss key information and important gaps in clinical data relevant to community practice</li> <li>■ Effectively encourage patients to accept and adhere to pharmacologic treatment</li> </ul>
---	--	---

The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.


The APA designates this educational activity for a maximum of 3 category 1 credits toward the AMA Physician's Recognition Award and for the CME requirement of the APA. Each physician should claim only those credits that he/she actually spent in the educational activity.

Attendees must be registered for the APA Annual Meeting to attend this symposium. Seating is limited and will be on a first-come-first-serve basis. For more information about the meeting, please visit the APA website at [www.psych.org](http://www.psych.org) or contact the APA toll free at 1-888-357-7924 (within the U.S. or Canada) or at 703-907-7300.

Supported by an unrestricted educational grant from **JANSSEN**   Sponsored by the American Psychiatric Association 

RS-1178A

**INDUSTRY-SUPPORTED SYMPOSIUM 2**  
**Saturday, May 17, 2003, 12:30 p.m. - 3:30 p.m.**  
**Salons 7 & 8, Lower B-2 Level, Marriott**



APA 2003 Annual Meeting • CME Symposium

## BIPOLAR DISORDER: STRATEGIES FOR STABILIZING PATIENTS OVER THE LONG TERM

**SATURDAY  
MAY 17**

**12–12:30 PM Lunch**  
**12:30–3:30 PM Clinical Program**  
**San Francisco Marriott • Salons 7 & 8**  
**Lower B-2 Level**

*Symposium Chair*  
**Joseph R. Calabrese, MD**  
 University Hospitals of Cleveland  
 Case Western Reserve University  
 School of Medicine

*New Results From the Stanley Bipolar  
Treatment Network*  
**Robert M. Post, MD**  
 Chevy Chase, Maryland



*Update on Anticonvulsants in Bipolar Disorder*  
**Charles L. Bowden, MD**  
 The University of Texas Health Science Center  
 Medical School

*Practical Strategies to Avoid Medication-Induced  
Mood Destabilization*  
**Carlos A. Zarate, Jr., MD**  
 Germantown, Maryland

*Psychosocial Strategies to Promote Stabilization  
& Enhance Coping in Patients with Bipolar Disorder*  
**David J. Miklowitz, PhD**  
 University of Colorado

**EDUCATIONAL OBJECTIVES**  
 Contrast outcomes of treating bipolar depression with antidepressants; evaluate new data on use of anticonvulsants in BPD; identify and avoid clinical pharmacotherapy situations that may lead to illness destabilization; assess psychosocial factors and develop an early warning plan to avoid destabilization.

**AGENDA**  
 12:00 PM Lunch  
 12:30 PM Introduction - J. Calabrese, MD  
 12:50 PM Speaker presentations  
 2:45 PM Question & answer session  
 3:30 PM Program concludes

For more information about the meeting, please visit the APA website at [www.psych.org](http://www.psych.org) or contact the APA toll free at 1-888-357-7924 (within the U.S. or Canada) or 703-907-7300. Supported by an unrestricted educational grant from  

Sponsored by the American Psychiatric Association. The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The APA designates this educational activity for a maximum of 3 category 1 credits toward the AMA Physician Recognition Award and for the CME requirement of the APA. Each physician should claim only those credits that he/she actually spent in the activity. Attendees must be registered for the APA 2003 Annual Meeting to attend this symposium. Seating is limited and will be based on first-come, first-served.

**INDUSTRY-SUPPORTED SYMPOSIUM 3**  
**Saturday, May 17, 2003, 12:30 p.m. - 3:30 p.m.**  
**Salon 9, Lower B-2 Level, Marriott**

*APA 2003 Annual Meeting*  
**Anxiety Disorders: Sources, Signs, and Solutions**

**Saturday, May 17, 2003**  
 Lunch: 12:00 PM - 12:30 PM  
 Scientific Program: 12:30 PM - 3:30 PM

**Marriott San Francisco**  
 Salon 9, Lower B-2 Level  
 San Francisco, California

The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The APA designates this educational activity for a maximum of 3 category 1 credits toward the AMA Physician's Recognition Award and for the CME requirement of the APA. Each physician should claim only those credits that he/she actually spent in the educational activity.

Attendees must be registered for the APA 2003 Annual Meeting to attend this symposium. Seating is limited and will be based on first-come, first-served. For more information about the meeting, please visit the APA Website at [www.psych.org](http://www.psych.org) or contact the APA toll free at 1-888-357-7924 (within the US or Canada) or 703-907-7300.

**Educational Objectives:**

- Review the incidence, impact, symptomology, cause, and treatment of anxiety disorders, with an emphasis on new therapies
- Evaluate the possible impact of generalized anxiety disorder on the patient and society and review potential pharmacological treatments for this disorder
- Understand the potential childhood basis of anxiety disorders, and discuss possible early interventions
- Discuss the somatic symptoms associated with anxiety disorders and propose solutions for collaborative management that involve both the primary care physician and the psychiatrist
- Understand the potential neurobiological basis for panic disorder and obsessive-compulsive disorder and how pharmacological treatments could serve to modulate the underlying disrupted neurochemistry
- Recognize the possible origins and treatments of social anxiety disorder

**12:30 PM Introduction**  
 Jonathan R.T. Davidson, MD—Chairman  
 Duke University Medical Center

**12:40 Examining Anxiety's Underpinnings**  
 Christine Heim, PhD • Emory University School of Medicine

**1:05 Anxious Body, Anxious Self, Anxious Psychiatrist**  
 Mack Lipkin Jr., MD • New York University School of Medicine

**1:30 Facing Up to Social Anxiety Disorder**  
 Murray B. Stein, MD • University of California, San Diego


**1:55 Generalized Anxiety Disorder: Beneath the Surface**  
 Jonathan R.T. Davidson, MD

**2:20 The Neurobiology of Panic Disorder and OCD**  
 Stephen M. Stahl, MD, PhD • University of California, San Diego

**2:45 Question and Answer Session**

**3:30 Conclusion**


Sponsored by the American Psychiatric Association

Supported by an unrestricted educational grant from  
  
**FOREST PHARMACEUTICALS, INC.**  
 Pharmaceuticals • Therapeutics • Healthcare • Managed Care • Specialty Sales

**INDUSTRY-SUPPORTED SYMPOSIUM 4**  
**Saturday, May 17, 2003, 6:00 p.m. - 9:00 p.m.**  
**Gateway Ballroom, Exhibit Level, Moscone Center**

A symposium to be held during the APA 2003 Annual Meeting

**Saturday  
 May 17, 2003  
 Gateway Ballroom  
 Moscone Center  
 San Francisco, CA**



## New Strategies for Managing Bipolar Disorder


**Agenda**


5:30 - 6:00 PM <b>Dinner</b>	7:10 - 7:40 PM <b>Emerging Treatments for Bipolar Disorder: A New Role for Atypical Antipsychotics</b> Lakshmi N. Yatham, MB, FRCP University of British Columbia	<b>At the conclusion of this symposium, the participant should be able to:</b>
6:00 - 6:10 PM <b>Welcome and Introduction</b> S. Nassir Ghaemi, MD (Chair) Cambridge Hospital	7:40 - 8:10 PM <b>Complexities in the Treatment of Juvenile Bipolar Disorder</b> Robert L. Findling, MD University Hospitals of Cleveland	
6:10 - 6:40 PM <b>Clinical Management of Bipolar Patients: A Difficult Task</b> Dwight L. Evans, MD University of Pennsylvania	8:10 - 9:00 PM <b>Questions and Answers</b> S. Nassir Ghaemi, MD	<ul style="list-style-type: none"> <li>• Implement new strategies for the management of acutely ill bipolar patients</li> <li>• Implement new strategies for the maintenance treatment of bipolar patients</li> <li>• Understand challenges in diagnosis and describe current research data and treatment options in juvenile bipolar disorder</li> </ul>

The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The APA designates this educational activity for a maximum of 3 category 1 credits toward the AMA Physician's Recognition Award and for the CME requirement of the APA. Each physician should claim only those credits that he/she actually spent in the educational activity.

Attendees must be registered for the APA Annual Meeting to attend this symposium. Seating is limited and will be on a first-come-first-serve basis. For more information about the meeting, please visit the APA website at [www.psych.org](http://www.psych.org) or contact the APA toll free at 1-888-357-7924 (within the U.S. or Canada) or at 703-907-7300.

Supported by an unrestricted educational grant from **JANSSEN** 

Sponsored by the American Psychiatric Association 

RS-1178B

**INDUSTRY-SUPPORTED SYMPOSIUM 5**  
**Saturday, May 17, 2003, 6:00 p.m. - 9:00 p.m.**  
**Grand Ballroom Salon B, Grand Ballroom Level, Hilton**

**GENETICS AND PSYCHIATRY:  
 REAL GENES, REAL PROGRESS**

**SATURDAY, MAY 17, 2003 • DINNER: 5:30-6:00 PM • SYMPOSIUM: 6:00-9:00 PM**

**HILTON SAN FRANCISCO, GRAND BALLROOM, SALON B, GRAND BALLROOM LEVEL • SAN FRANCISCO, CALIFORNIA**

This symposium will be conducted on May 17, 2003, during the 2003 Annual Meeting of the American Psychiatric Association

**AGENDA:**

<b>5:30-6:00 PM</b> Dinner	<b>7:00-7:25 PM</b> Gene and Protein Expression in Brain: It Depends on Inheritance <i>Joel E. Kleinman, MD</i> <i>National Institute of Mental Health</i>
<b>6:00-6:10 PM</b> Welcome and Opening Remarks <i>Daniel R. Weinberger, MD</i> <i>(Symposium Chairperson)</i> <i>National Institute of Mental Health</i>	<b>7:25-7:50 PM</b> Rethinking the Concept of Phenotype in Psychiatry <i>Robert Freedman, MD</i> <i>University of Colorado</i>
<b>6:10-6:35 PM</b> Genetic Engineering in Animals: New Insights About Anxiety and Antidepressants <i>Rene Hen, PhD</i> <i>Columbia University</i>	<b>7:50-8:15 PM</b> In Vivo Approaches to Identifying Genetic Mechanisms of Susceptibility <i>Daniel R. Weinberger, MD</i> <i>National Institute of Mental Health</i>
<b>6:35-7:00 PM</b> A Schizophrenia Gene: From Linkage to Function <i>Richard E. Straub, PhD</i> <i>National Institute of Mental Health</i>	<b>8:15-9:00 PM</b> Question and Answer Session <i>All Faculty</i>
	<b>9:00 PM</b> Adjourn

**LEARNING OBJECTIVES:**

After attending this symposium, participants will be able to:

- Describe how genes and environment interact to modify behavior and complicate phenotype identification; review the evolving concept of phenotype; understand the effects of psychiatric susceptibility genes and brain information processing; review gene and protein expression as it relates to genetic background; understand the behavioral effects of antidepressants
- Describe how genes relate to neuropathology of schizophrenia.
- Explain the basic statistical genetic concepts and methodologies of gene localization, linkage, and association utilizing twin data as it is applied to finding specific genes for schizophrenia. Once appraised of the strengths and limitations of current gene-finding methods, illustrate how this approach has identified a schizophrenia susceptibility gene, dysbindin, and how this gene affects brain function.
- Discuss the evolving concept of phenotype
- Identify the implications of genetic variation on brain function and how this increases susceptibility for mental illness.

**CME STATEMENT:**

This symposium will be conducted on May 17, 2003, during the 2003 Annual Meeting of the American Psychiatric Association.

The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The APA designates this educational activity for a maximum of 3 category 1 credits towards the AMA Physician's Recognition Award and for the CME requirement of the APA. Each physician should claim only those credits that he/she actually spent in the educational activity.

Attendance credit is requested for the APA Annual Meeting or when the symposium "Genetics and Psychiatry: Real Genes, Real Progress" is attended on a first-come, first-served basis. For more information about the meeting, please visit the APA Web site at [www.psych.org](http://www.psych.org) or contact the APA toll free at 1-888-357-7924 (within the United States or Canada) or 703-907-7300.


The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The APA designates this educational activity for a maximum of 3 category 1 credits towards the AMA Physician's Recognition Award and for the CME requirement of the APA. Each physician should claim only those credits that he/she actually spent in the educational activity.



Sponsored by the American Psychiatric Association

Supported by an unrestricted educational grant from



**INDUSTRY-SUPPORTED SYMPOSIUM 6**  
**Saturday, May 17, 2003, 6:00 p.m. - 9:00 p.m.**  
**Continental Ballroom, Ballroom Level, Hilton**

**BEYOND BENZODIAZEPINES:**  
 New Molecules for the Treatment of **ANXIETY**  
**Saturday, May 17, 2003**  
**6:00-9:00 PM** Hilton San Francisco Continental Ballroom Ballroom Level San Francisco, California

At the conclusion of this symposium, participants should be able to:

*Objectives*

- Recognize the frequency of childhood anxiety disorders and what is known about long-term treatment outcomes;
- Assess the economic, educational, marital, social, and health care burden associated with anxiety disorders;
- Recognize the burden of illness of generalized anxiety disorder (GAD) and compare and contrast the advantages and disadvantages of existing and potential new treatments for GAD;
- Identify new molecular targets for potential anti-anxiety medications by reviewing current strategies.

*APA 156th Annual Meeting*

Attendees must be registered for the APA Annual Meeting to attend this symposium. Seating is limited and will be on a first-come, first-served basis. For more information about the meeting, please visit the APA Web site at [www.psych.org](http://www.psych.org) or contact the APA toll free at 1-888-357-7924 (within the United States or Canada) or 703-907-7300.

The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The APA designates this educational activity for a maximum of 3 category 1 credits towards the AMA Physician's Recognition Award and for the CME requirement of the APA. Each physician should claim only those credits that he/she actually spent in the educational activity.



Sponsored by the American Psychiatric Association



Supported by an unrestricted educational grant from Pfizer Inc.

*Agenda*

<b>5:30-6:00 PM</b> Dinner	
<b>6:00</b>	<b>Welcome and Introduction</b> Jack M. Gorman, MD, Program Chairperson Interim Chairman, Department of Psychiatry Mount Sinai School of Medicine New York, New York
<b>6:15</b>	<b>Childhood Anxiety Disorders: Does Treatment Affect Long-Term Outcome?</b> Maira Rynn, MD Assistant Professor of Psychiatry Medical Director, Mood and Anxiety Disorders Section University of Pennsylvania School of Medicine Philadelphia, Pennsylvania
<b>6:45</b>	<b>The Burden of Anxiety Disorders</b> David V. Sheehan, MD, MBA Professor of Psychiatry Director, Office of Psychiatry Research University of South Florida Institute for Research in Psychiatry Tampa, Florida
<b>7:15</b>	<b>Treatment for GAD: Current and Near Term</b> Stuart Montgomery, MD Professor of Psychiatry Imperial College, University of London London, England
<b>7:45</b>	<b>Future Directions: New Molecular Targets for the Treatment of Anxiety</b> Jack M. Gorman, MD
<b>8:15</b>	<b>Question and Answer Session</b>
<b>9:00</b>	<b>Adjourn</b>



**INDUSTRY-SUPPORTED SYMPOSIUM 7**  
**Saturday, May 17, 2003, 6:00 p.m. - 9:00 p.m.**  
**Salons 7 & 8, Lower B-2 Level, Marriott**

**Don't Miss This Important Educational Dinner Program!**

**5:30PM-6:00PM Dinner**

**6:00PM Welcome and Introduction**  
 Diana D. Perkins, MD, MPH  
 Program Chairperson  
 Schizophrenia Treatment and Evaluation Program  
 University of North Carolina at Chapel Hill School of Medicine

**6:10PM Schizophrenia: New Understandings of the Early Stage of Illness**  
 Diana O. Perkins, MD, MPH  
 Program Chairperson

**6:35PM Improving Cognition for Quality Outcomes**  
 Richard S.E. Keele, PhD  
 Duke University Medical Center

**7:00PM Treatment Challenges for the Patient With Acute Agitation**  
 Leslie Citrome, MD, MPH  
 New York University  
 Clinical Research and Evaluation Facility  
 Nathan S. Kline Institute for Psychiatric Research

**7:25PM Metabolic Issues With Antipsychotic Therapy**  
 John B. Buse, MD, PhD  
 Diabetes Care Center  
 University of North Carolina at Chapel Hill

**7:50PM Maintenance Strategies: Balancing Efficacy and Safety to Prevent Relapse**  
 Thomas F. Liffick, MD  
 Indiana University School of Medicine  
 Northwestern Indiana Mental Health Center, Inc.

**8:15PM Question and Answer Session**

**9:00PM Program Adjournment**

**Program Description**

The past decade has seen the development and refinement of treatments for schizophrenia. Emerging scientific research strategies to improve individual outcomes, including early intervention and use of atypical antipsychotics. Even with recent advances, several treatment challenges remain. Relapse and acute agitation pose a significant clinical challenge for patient management. The presenters in this symposium will discuss new data on optimizing treatment of patients with schizophrenia. First, Diana O. Perkins, MD, MPH, will review the potential benefits of early identification and intervention on illness prognosis and treatment of patients in their first episode of psychosis. Richard S.E. Keele, PhD, then will discuss how impairments in neurocognitive function impact clinical outcomes, and the impact of atypical antipsychotics on neurocognitive function. Next, Leslie Citrome, MD, MPH, will discuss the causes and consequences of agitation in patients with schizophrenia. John B. Buse, MD, PhD, then will discuss epidemiological and clinical data that review the risk of diabetes with atypical antipsychotics. Finally, Thomas F. Liffick, MD, will address optimizing long-term treatment outcomes by reducing relapse risk and improving functional outcome, while minimizing risk of treatment-related adverse effects. Lectures, visual aids, and a dinner refreshment will be utilized to engage the attendees and enhance the learning process.

Attendance must be registered for the APA Annual Meeting to attend this symposium. Seating is limited and will be based on first-come, first-served. For more information about the meeting, please visit the APA Web site at [www.psych.org](http://www.psych.org) or contact the APA toll free at 1-888-357-7924 (within the US or Canada) or 703-907-7300.

**Learning Objectives**

- Upon completion of the program, participants should be able to:
1. Recognize the challenges of schizophrenia to improve treatment selection and improve patient outcomes.
  2. Describe the elements of optimal clinical care in the treatment of a first episode of schizophrenia.
  3. Discuss the importance of optimizing treatment for the patient with schizophrenia to improve quality of life outcomes.
  4. Recognize the availability of new and novel approaches to the management of agitation in patients with schizophrenia.
  5. Understand that there is a worldwide epidemic of diabetes, that there are no major differences in the risk of hyperglycemia associated with various agents, and that, with appropriate follow-up, diabetes-associated risks of antipsychotic agents should be minimized.
  6. Recognize the advantages of newer generation antipsychotic medications with respect to relapse rates and improved productivity.
  7. Recognize issues of long-term side effects from antipsychotic drugs.
  8. Recognize differential tolerability among newer generation antipsychotic medications.

**Accreditation Statement**

The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

**Credit Designation Statement**

The APA designates this educational activity for a maximum of 3.0 category 1 credits toward the AMA Physician's Recognition Award and for the CME requirement of the APA. Each physician should claim only those credits that he/she actually spent in the activity.

Held During the APA 2003 Annual Meeting  
**Enhancing Outcomes by Addressing Critical Challenges in the Treatment of Schizophrenia**



**Saturday, May 17, 2003**

**5:30PM-6:00PM Dinner**  
**6:00PM-9:00PM Educational Program**

**San Francisco Marriott**  
**Yerba Buena Ballroom, Salons 7 and 8**  
**Lower B2 Level**



Sponsored by the American Psychiatric Association supported by an unrestricted educational grant from Eli Lilly and Company.

**INDUSTRY-SUPPORTED SYMPOSIUM 8**  
**Saturday, May 17, 2003, 6:00 p.m. - 9:00 p.m.**  
**Salon 9, Lower B-2 Level, Marriott**

**APA 2003 ANNUAL MEETING | SATURDAY, MAY 17, 2003 | 6:00-9:00 PM, DINNER 5:30-6:00 PM**  
**SALON 9, LOWER B-2 LEVEL | SAN FRANCISCO MARRIOTT**

**Optimizing Efficacy and Tolerability of Antidepressant Therapy: Does Selectivity of Action Matter?**

6:00-6:10 pm

**Welcome and Introduction**

6:10-6:40 pm

**The Alphabet Soup of Antidepressant Pharmacology: From TCAs and MAOIs to SSRIs, SNRIs, and Beyond**

Pedro L. Delgado, MD  
 Case Western Reserve University School of Medicine

6:40-6:45 pm

**Questions**

6:45-7:15 pm

**SSRIs and Beyond: Spectrum of Efficacy of Newer Antidepressants**

Justine M. Kent, MD  
 Columbia University College of Physicians and Surgeons

7:15-7:20 pm

**Questions**

7:20-7:50 pm

**Efficacy of Newer Antidepressants**

Michael E. Thase, MD  
 University of Pittsburgh School of Medicine

7:50-7:55 pm

**Questions**

7:55-8:25 pm

**Generally Well Tolerated: Comparative Adverse Event Profiles of Newer Antidepressants**

Andrew A. Nierenberg, MD  
 Massachusetts General Hospital

8:25-9:00 pm

**Questions**

**At the conclusion of this symposium participants should be able to:**

- recognize that different classes of antidepressants have distinct pharmacologic effects that contribute both to efficacy and side effects;
- appreciate the efficacy of SSRIs and other newer antidepressants for the treatment of a broad range of psychiatric disorders;
- evaluate the evidence pertaining to the comparative effects of different antidepressants;
- understand the risks and adverse events associated with newer antidepressants; and
- be familiar with the different choices for the treatment of depression, as well as their pros and cons.

The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.



The APA designates this educational activity for a maximum of 3 category 1 credits toward the AMA Physician Recognition Award and for the CME requirement of the APA. Each physician should claim only those credits that he/she actually spent in the activity.

Attendees must be registered for the APA Annual Meeting to attend this symposium. Seating is limited and will be based on first-come, first-served. For more information about the meeting, please visit the APA website at [www.psych.org](http://www.psych.org) or contact the APA toll free at 1-888-357-7924 (within the U.S. or Canada) or 703-907-7300.


This program is sponsored by the American Psychiatric Association and supported by an unrestricted educational grant from Forest Pharmaceuticals.




**INDUSTRY-SUPPORTED SYMPOSIUM 9**  
**Sunday, May 18, 2003, 8:00 a.m. - 11:00 a.m.**  
**Gateway Ballroom, Exhibit Level, Moscone Center**

<p><i>Diagnosis and Treatment:</i>  <b>Mood Stabilizers</b>  <i>Across the Psychiatric Spectrum</i></p> <p><b>LEARNING OBJECTIVES</b></p> <ul style="list-style-type: none"> <li>■ Review the clinical treatment targets for mood stabilizers.</li> <li>■ Discuss the evidence in various conditions and diagnoses for clinical efficacy.</li> </ul> <p><b>CREDIT DESIGNATION</b></p> <p>The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.</p> <p>The APA designates this educational activity for a maximum of 3 category 1 credits towards the AMA Physician's Recognition Award and for the CME requirement of the APA. Each physician should claim only those credits that he/she actually spent in the educational activity.</p> <p><i>Attendees must be registered for the APA Annual Meeting to attend this symposium. Seating is limited and will be based on first-come, first-served. For more information about the meeting, please visit the APA Website at <a href="http://www.psych.org">www.psych.org</a> or contact the APA toll-free at 1-888-357-7924 (within the US or Canada) or 703-907-7300.</i></p> <p> This activity is supported by an unrestricted educational grant from Abbott Laboratories.</p> <p> Sponsored by the American Psychiatric Association and held at the APA 2003 Annual Meeting.</p>	<p><i>Sunday, May 18th, 2003</i></p> <p><i>Gateway Ballroom, Exhibit Level, Moscone Center</i></p> <p>7:30 - 8:00 am Breakfast</p> <p>8:00 - 8:05 am Introduction</p> <p>8:05 - 9:00 am A Systematic Approach to Treatment of Impulsivity  <i>Alan C. Stearns, MD</i>  <i>University of Texas Medical School at Houston</i></p> <p>8:05 - 9:05 am The Role of Mood Stabilizers in the Management of Agitation in Dementia  <i>J. Michael Ryan, MD</i>  <i>University of Rochester Medical Center</i></p> <p>8:30 - 9:20 am Efficacy of Treatment with Mood Stabilizers in Acute Schizophrenia  <i>Carol A. Tamminga, MD - Program Chairman</i>  <i>University of Texas Southwestern Medical School</i></p> <p>8:30 - 9:15 am Comorbidities and Treatment Issues in Substance Use Disorders  <i>Hugh Myrick, MD</i>  <i>Medical University of South Carolina</i></p> <p>9:05 - 10:15 am Affective Instability and Impulsive Aggression in Cluster B and Developmental Disorders  <i>Eric Hollander, MD</i>  <i>Mt. Sinai School of Medicine</i></p> <p>10:15 - 11:00 am Q &amp; A</p>
--	--

**INDUSTRY-SUPPORTED SYMPOSIUM 10**  
**Sunday, May 18, 2003, 8:00 a.m. - 11:00 a.m.**  
**Grand Ballroom Salon B, Grand Ballroom Level, Hilton**

<p><b>MOODS, CYCLES &amp; MOTHERHOOD</b></p> <p><i>A breakfast symposium to be held at the American Psychiatric Association 136th Annual Meeting</i></p> <p><i>Sponsored by the American Psychiatric Association</i></p> <p><b>SUNDAY, MAY 18, 2003</b>  <b>8:00 AM - 11:00 AM</b>  <b>Hilton San Francisco</b>  <b>Grand Ballroom Salon B</b>  <b>Grand Ballroom Level</b>  <b>San Francisco, California</b></p>	<p><b>PROGRAM OBJECTIVES</b></p> <p>After attending this continuing medical education symposium, the psychiatrist should be able to:</p> <ul style="list-style-type: none"> <li>• Understand the consequences of treatment vs. nontreatment in pregnant and postpartum women and assess individual patient needs before changing or discontinuing antidepressant treatment</li> <li>• Understand neurobiologic changes associated with premenstrual dysphoric disorder (PMDD) and develop rational therapeutic approaches for patients with PMDD</li> <li>• Examine the latest evidence on the pathogenesis of menopause, its sequelae, and medical strategies for managing symptoms and comorbidities.</li> </ul> <p> The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.</p> <p>The APA designates this educational activity for a maximum of 3 category 1 credits toward the AMA Physician Recognition Award and for the CME requirement of the APA. Each physician should claim only those credits that he/she actually spent in the activity.</p> <p>Attendees must be registered for the APA Annual Meeting to attend this symposium. Seating is limited and will be based on first-come, first-served. For more information about the meeting, please visit the APA website at <a href="http://www.psych.org">www.psych.org</a> or contact the APA toll free at 1-888-357-7924 (within the US or Canada) or 703-907-7300.</p> <p><i>Supported by an unrestricted educational grant from GlaxoSmithKline</i></p>	<p><b>AGENDA</b></p> <p>7:30 AM-8:00 AM Breakfast</p> <p>8:00 AM Welcome and Introduction  <b>SHAILA MISRI, MD, FRCPC</b>  <i>Symposium Chair</i>  <i>University of British Columbia</i></p> <p>8:10 AM Depression in Pregnancy and Lactation: Making Informed Decisions to Protect the Mother and Infant  <b>ZACHARY N. STOWE, MD</b>  <i>Emory University School of Medicine</i></p> <p>8:40 AM Mothers, Babies and Children: Mental Health in the Postpartum and Beyond  <b>SHAILA MISRI, MD, FRCPC</b></p> <p>9:10 AM Pharmacological Treatment of Premenstrual Dysphoria, What Is Sufficient?  <b>KIMBERLY A. YONKERS, MD</b>  <i>Yale University School of Medicine</i></p> <p>9:40 AM Is it Just Me or Is it Hot in Here? What Every Psychiatrist Should Know About Menopause  <b>C. NEILL EPPERSON, MD</b>  <i>Yale University School of Medicine</i></p> <p>10:10 AM Panel Discussion With Questions and Answers</p> <p>10:55 AM Closing Remarks, Adjournment  <b>SHAILA MISRI, MD, FRCPC</b></p>
---	--	--

**INDUSTRY-SUPPORTED SYMPOSIUM 11**  
 Sunday, May 18, 2003, 8:00 a.m. - 11:00 a.m.  
 Continental Ballroom, Ballroom Level, Hilton



Enhancing Skill in *Treating* Comorbid  
*Depression* and Neurological Illness

**APA 156th Annual Meeting**  
**Sunday, May 18, 2003**  
**7:30-8:00 AM Breakfast • 8:00-11:00 AM Symposium**  
**San Francisco Hilton • Continental Ballroom, Ballroom Level**


Program Chair: **Steven L. Dubovsky, MD** • University of Colorado Health Sciences Center

<p>8:00 - 8:10 AM <b>Introduction</b>  <b>Steven L. Dubovsky, MD</b>                  University of Colorado Health Sciences Center</p> <p>8:10 - 8:35 AM <b>Depression in Neurological Disorders</b>  <b>Gary Tucker, MD</b>                  University of Washington</p> <p>8:35 - 9:00 AM <b>Depression in Dementing Disorders</b>  <b>Jeffrey L. Cummings, MD</b>                  University of California, Los Angeles</p> <p>9:00 - 9:25 AM <b>Depression Following Traumatic Brain Injury</b>  <b>David B. Arciniegas, MD</b>                  University of Colorado Health Sciences Center</p>	<p>9:25 - 9:50 AM <b>Treatment of Depression in Patients With Life-Threatening and Terminal Illnesses</b>  <b>Norman Sussman, MD</b>                  New York University</p> <p>9:50 - 10:15 AM <b>Targeting Antidepressant Therapy to Medical Comorbidity</b>  <b>Steven L. Dubovsky, MD</b>                  University of Colorado Health Sciences Center</p> <p>10:15 - 11:00 AM <b>Questions and Answers</b></p>
---	--


**Educational Objectives:** At the conclusion of this symposium, the participant should be able to understand the neurobiology of depression in patients with medical and neurological illnesses and how these comorbidities influence and affect antidepressant choices.

**Accreditation**  
 The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.  
 The APA designates this educational activity for a maximum of 3 category 1 credits toward the AMA Physician Recognition Award and for the CME requirements of the APA. Each physician should claim only those credits that he/she actually spent in the activity.

**Attendees must be registered for the APA Annual Meeting to attend this symposium. Seating is limited and will be based on first-come, first-served. For more information about the meeting, please visit the APA website at [www.psych.org](http://www.psych.org) or contact the APA toll free at 1-888-357-7924 (within the US or Canada) or 703-907-7300.**



Sponsored by the American Psychiatric Association



Supported by an unrestricted educational grant from Organon Inc.

**INDUSTRY-SUPPORTED SYMPOSIUM 12**  
 Sunday, May 18, 2003, 8:00 a.m. - 11:00 a.m.  
 Salons 7 & 8, Lower B-2 Level, Marriott

Held During the APA 2003 Annual Meeting

*An Integrated Approach*  
 to the Management of Bipolar Disorder:  
 An Alliance of Science and Medicine

**Sunday, May 18, 2003**

7:30AM-8:00AM Breakfast  
 8:00AM-11:00AM Educational Program  
 San Francisco Marriott  
 Yerba Buena Ballroom, Salons 7 and 8  
 Lower B2 Level

**Don't Miss This Important Educational Breakfast Program!**

**7:00AM**  
*Bipolar Depression and Substance Abuse: Which Is the Driving Force?*  
**Joseph F. Goldberg, MD**  
 West Medical College of Cornell University  
 Bipolar Disorder Research Clinic  
 New York Presbyterian Hospital

**7:30AM-8:00AM**  
**Breakfast**

**8:00AM**  
**Welcome and Introduction**  
**Robert M.A. Hirschfeld, MD**  
 Program Chairperson  
 University of Texas Medical Branch

**8:10AM**  
**The Role of Genetics in Bipolar Disease**  
**Wade Berrettini, MD, PhD**  
 Center for Neurobiology and Behavior  
 University of Pennsylvania School of Medicine


**8:55AM**  
**The Importance of Mood Stabilization in the Treatment of Mania**  
**John Cookson, BM, DPhil, FRCP, FRCPsych**  
 The Royal London Hospital

**9:25AM**  
**A Disease Management Strategy for Bipolar Disorder**  
**Ellen Frank, PhD**  
 University of Pittsburgh School of Medicine  
 Western Psychiatric Institute and Clinic

**9:50AM**  
**Optimizing Treatment to Prevent Relapse**  
**Paul E. Keck, Jr, MD**  
 University of Cincinnati College of Medicine

**10:15AM**  
**Question and Answer Session**

**11:00AM**  
**Program Adjournment**



**Program Description**  
 The primary goals of these educational programs in the management of bipolar disorder (1) are the treatment of acute phases. In fact, the burden of bipolar disorder is often, but not always, caused by a severe exacerbation of acute and episodic. Effective management includes treatment of bipolar depression, management of comorbidity, post-manicure and post-psychotic, and strategies to prevent future episodes. With regard to the treatment of acute mania, the newly published APA Practice Guidelines recommends a combined mood stabilizer and antipsychotic. Recent data indicate that the continued use of an atypical antipsychotic with an antidepressant may limit a rapid and robust response to depressive symptoms. Research has demonstrated that post-educational programs can be effectively helped by adjunctive and provision of resources. These programs include education about the illness and treatment, management of social rhythms, and strategies for detection of early warning signs. Recent studies have indicated strategies to improve prognosis, utilizing structured mood stabilizers and atypical antipsychotics. This symposium will present data on the above issues and will seek to provide a preliminary structure for an integrative approach to the management of patients with bipolar disorder. Lectures, visual aids, and a course syllabus will be attached throughout the program to engage the attendees and enhance the learning process.

**Learning Objectives**  
 Upon completion of the program, participants should be able to:

1. Discuss the most current research data regarding the efficacy of treatment management for all aspects of bipolar disorder.
2. Recognize the complex heterogeneous nature of the genetic influences on bipolar disorder.
3. Provide rational drug therapy to patients with bipolar disorder using newer pharmacotherapies.
4. Describe essential elements of a bipolar disease management strategy and be familiar with evidence for its efficacy in preventing manic and depressive recurrences.
5. Recognize the behavioral and clinical points of convergence between bipolar depression and substance abuse, and describe the transition of these comorbidities into optimal treatment approaches.
6. Recognize the indications for mood therapy and combination therapy for bipolar disorder to prevent relapse.

**Accreditation Statement**  
 The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

**Credit Designation Statement**  
 The APA designates this educational activity for a maximum of 3.0 category 1 credits toward the AMA Physician Recognition Award and for the CME requirements of the APA. Each physician should claim only those credits that he/she actually spent in the activity.

Sponsored by the American Psychiatric Association supported by an unrestricted educational grant from Eli Lilly and Company.

Attendees must be registered for the APA Annual Meeting to attend this symposium. Seating is limited and will be based on first-come, first-served. For more information about the meeting, please visit the APA Web site at [www.psych.org](http://www.psych.org) or contact the APA toll free at 1-888-357-7924 (within the US or Canada) or 703-907-7300.

131

INDUSTRY-SUPPORTED SYMPOSIUM 13  
 Sunday, May 18, 2003, 8:00 a.m. - 11:00 a.m.  
 Salon 9, Lower B-2 Level, Marriott

Presented at the APA  
 156th Annual Meeting

**REMISSION IN PSYCHIATRIC DISORDERS**  
 Definitions, Issues, and Treatments



Sunday, May 18, 2003 • 8:00 AM-11:00 AM

San Francisco Marriott  
 Salon 9, Lower B-2 Level  
 San Francisco, California

**Faculty and Agenda:**

7:30 AM - 8:00 AM  
 8:00 AM - 10:15 AM

- Breakfast  
 Symposium  
**Psychosocial Functioning in Depression**  
 Ivan W. Miller, PhD  
 Providence, Rhode Island  
**Remission in Major Depression:  
 A Frequently Illusive Goal**  
 Alan F. Schatzberg, MD  
 Stanford, California  
**Response and Remission in Generalized Anxiety Disorder**  
 Alan J. Gelenberg, MD, Chairperson  
 Tucson, Arizona  
**Remission in Bipolar Disorder Across the Lifespan**  
 Kiki D. Cheng, MD  
 Stanford, California  
**Response and Remission in Depression:  
 The ACNP Consensus Report**  
 John Rush, MD  
 Dallas, Texas  
 10:15 AM - 11:00 AM  
 Question-and-Answer Session

**Overview:**

As potentially more effective pharmacological treatments have been introduced in psychiatry, there has been a greater emphasis on aiming to achieve remission rather than response (ie, moderate symptom improvement). In this symposium, we explore various aspects of remission: its possible definition in specific syndromes; using psychosocial measures to define functional improvement and remission in major depression; treatment strategies for achieving remission in generalized anxiety disorder (GAD); and attaining remission in bipolar disorders in childhood and adolescence.

**Target Audience:**

This activity is designed specifically for practicing psychiatrists.

**Learning Objectives:**

Upon completion of this symposium, the participants should be able to:

- Employ alternative definitions of remission
- Understand recent data on differential effectiveness
- Understand the need for longer trials

**Accreditation:**

The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The APA designates this educational activity for a maximum of 3 category 1 credits towards the AMA Physician Recognition Award and for the CME requirement of the APA. Each physician should claim only those credits that he/she actually spent in the educational activity.

**Registration Policy:**

Attendees must be registered for the APA Annual Meeting to attend this symposium. Seating is limited and will be based on first-come, first-served. For more information about the meeting, please visit the APA website at [www.psych.org](http://www.psych.org) or contact the APA toll-free at (888) 357-7924 (within the US or Canada) or (703) 907-7300.



Sponsored by the American Psychiatric Association  
 Supported by an unrestricted educational grant from Wyeth Pharmaceuticals

INDUSTRY-SUPPORTED SYMPOSIUM 14  
 Sunday, May 18, 2003, 1:30 p.m. - 4:30 p.m.  
 Gateway Ballroom, Exhibit Level, Moscone Center

**BARRIERS TO OPTIMAL OUTCOME IN ANXIETY AND DEPRESSION**

*A lunch symposium to be held at the American Psychiatric Association 156th Annual Meeting*  
 Sponsored by the American Psychiatric Association

SUNDAY, MAY 18, 2003  
 1:30 PM - 4:30 PM

Moscone Convention Center  
 Gateway Ballroom  
 Exhibit Level  
 San Francisco, California

**PROGRAM OBJECTIVES**

After attending the continuing medical education symposium, the psychiatrist should be able to:

- Develop and maintain better therapeutic alliances
- Appreciate the effect of medication non-adherence on therapeutic outcome in the treatment of mood and anxiety disorders
- Understand the underlying technology of controlled-release drug formulations
- Understand the need for and application of evidence-based medicine in the practice of psychiatry.



The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The APA designates this educational activity for a maximum of 3 category 1 credits toward the AMA Physician Recognition Award and for the CME requirement of the APA. Each physician should claim only those credits that he/she actually spent in the activity.

Attendees must be registered for the APA Annual Meeting to attend this symposium. Seating is limited and will be based on first-come, first-served. For more information about the meeting, please visit the APA website at [www.psych.org](http://www.psych.org) or contact the APA toll free at 1-888-357-7924 (within the US or Canada) or 703-907-7300.

Supported by an unrestricted educational grant from GlaxoSmithKline

**AGENDA**

- 1:00 PM-  
 1:30 PM **Lunch**
- 1:30 PM **Welcome and Introduction**  
 DAVID V. SHEEHAN, MD, MBA  
*Symposium Chair*  
 University of South Florida
- 1:35 PM **From Medication Noncompliance to Medication Interest:  
 The Art of Discussing Medications With Patients**  
 SHAWN C. SHEA, MD  
 Dartmouth Medical School
- 2:05 PM **Controlled-Release Antidepressant Formulations:  
 Advantages and Limitations**  
 DAVID V. SHEEHAN, MD, MBA
- 2:35 PM **An Evidence-Based Approach to Clinical Trials in Anxiety and Depression**  
 FLAVIO KAPCZINSKI, MD, PHD  
 Universidade Federal  
 Do Rio Grande Do Sul
- 3:05 PM **Case-Based Approach to Optimal Outcome in Depression and Anxiety**  
 LORI CALABRESE, MD  
 Eastern Connecticut Health Network
- 3:35 PM **Panel Discussion With Questions and Answers**
- 4:20 PM **Closing Remarks, Adjournment**  
 DAVID V. SHEEHAN, MD, MBA

**INDUSTRY-SUPPORTED SYMPOSIUM 15**  
**Sunday, May 18, 2003, 1:30 p.m. - 4:30 p.m.**  
**Metropolitan, Second Level, Argent**

## New Challenges in the Management of Depression

**Sunday, May 18, 2003**  
 Lunch: 1:00 PM – 1:30 PM  
 Scientific Program: 1:30 PM – 4:30 PM  
 Argent Hotel  
 Metropolitan Room, Second Level  
 San Francisco, California.

The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The APA designates this educational activity for a maximum of 3 category 1 credits toward the AMA Physician's Recognition Award and for the CME requirement of the APA. Each physician should claim only those credits that he/she actually spent in the educational activity.

Attendees must be registered for the APA Annual Meeting to attend this symposium. Seating is limited and will be based on first-come, first-served. For more information about the meeting, please visit the APA Website at [www.psych.org](http://www.psych.org) or contact the APA toll free at 1-888-357-7924 (within the US or Canada) or 703-907-7300.

**APA 2003 Annual Meeting**

**1:30 PM Introduction**  
 Karen Dineen Wagner, MD, PhD—Chair • University of Texas Medical Branch

**1:40 PM Solving the Conundrum of Childhood Depression**  
 Karen Dineen Wagner, MD, PhD

**2:05 PM Achieving Rapid Onset of Action and Remission in Depressed Adults**  
 Robert M. Hirschfeld, MD • University of Texas Medical Branch

**2:30 PM Tickling the Brain: Advances in Antidepressant Brain Stimulation Techniques**  
 Mark S. George, MD • Medical University of South Carolina

**2:55 PM Enhancing Collaboration Between the Primary Care Physician and the Psychiatrist**  
 Larry Culpepper, MD, MPH • Boston University School of Medicine

**3:20 PM Maintaining Quality of Life in the Elderly**  
 Steven P. Roose, MD • College of Physicians and Surgeons of Columbia University

**3:45 PM Question and Answer Session**

**4:30 PM Conclusion**

Sponsored by the American Psychiatric Association

Supported by an unrestricted educational grant from  
**FOREST PHARMACEUTICALS, INC.**  
 Pharmaceuticals • Therapeutics • Treatments • Managed Care • Specialty Sales

**Educational Objectives:**

- Demonstrate increased knowledge about managing depression across the spectrum of age ranges and treatment settings, including identifying and managing depression in children; establish collaborative relationships with primary care physicians; achieve rapid onset of antidepressant response and remission in adults; and improve quality of life in depressed elderly patients
- Discuss how primary care doctors treat depression and present a model of an effective interaction between the primary care doctor and psychiatrist for the optimal treatment of the depressed patient
- Improve onset of action of antidepressant treatment and become better able to achieve remission in the treatment of patients with depression
- Describe and evaluate brain stimulation techniques for the treatment of depression, including electroconvulsive therapy and transcranial magnetic stimulation
- Understand the challenges associated with the treatment of depression in the elderly
- Increase knowledge about the clinical presentation of depression in children and adolescents, identify effects of parental depression, and obtain information about treatment and prevention strategies for depressed youths

**INDUSTRY-SUPPORTED SYMPOSIUM 16**  
**Sunday, May 18, 2003, 1:30 p.m. - 4:30 p.m.**  
**Grand Ballroom Salon B, Grand Ballroom Level, Hilton**

## ISSUES IN TREATING MANIA: ACUTE AND CONTINUATION PHASE

**SUNDAY, MAY 18, 2003 • LUNCH: 1:00–1:30 PM • SYMPOSIUM: 1:30–4:30 PM**

**HILTON SAN FRANCISCO, GRAND BALLROOM, SALON B, GRAND BALLROOM LEVEL • SAN FRANCISCO, CALIFORNIA**

This symposium will be conducted on May 18, 2003, during the 2003 Annual Meeting of the American Psychiatric Association

AGENDA:		LEARNING OBJECTIVES:
<p><b>1:00–1:30 PM</b> Lunch</p> <p><b>1:30–1:40 PM</b> Welcome and Opening Remarks  <i>Michael H. Allen, MD</i>  <i>(Symposium Chairperson)</i>  <i>University of Colorado</i></p> <p><b>1:40–2:05 PM</b> Managing Acute Mania in the Emergency Room  <i>Michael H. Allen, MD</i>  <i>University of Colorado</i></p> <p><b>2:05–2:30 PM</b> Pharmacological Options for the Treatment of Pediatric Mania  <i>Melissa P. DelBello, MD</i>  <i>University of Cincinnati</i></p> <p><b>2:30–2:55 PM</b> Approaches to the Treatment of Mania  <i>Roy H. Perlis, MD</i>  <i>Massachusetts General Hospital</i></p>	<p><b>2:55–3:20 PM</b> Family Intervention and Pharmacotherapy in the Post-Episode Phase of Bipolar Disorder  <i>David J. Miklowitz, MD</i>  <i>University of Colorado</i></p> <p><b>3:20–3:45 PM</b> Identifying Suicidal Behavior and At-Risk Patients  <i>Gary S. Sachs, MD</i>  <i>Massachusetts General Hospital</i></p> <p><b>3:45–4:30 PM</b> Question and Answer Session  <i>All Faculty</i></p> <p><b>4:30 PM</b> Adjourn</p>	<p>After attending this symposium, participants will be able to:</p> <ul style="list-style-type: none"> <li>• Describe how family psychoeducational treatment can be used effectively with medication during the stabilization and maintenance phases of bipolar disorder, treat disorder by combining family intervention with pharmacotherapy for adult- or childhood-onset patients, and with core therapeutics of family educational approaches</li> <li>• Review treatment options and strategies useful over the first several months for management of patients with manic or mixed episodes</li> <li>• Identify treatment targets in mania and weigh efficacy data and side effect profiles in the context of treatment guidelines</li> <li>• Identify the most troublesome target symptoms associated with acute mania and describe intensive approaches to oral and parenteral treatment</li> <li>• Diagnose and identify effective treatment strategies for pediatric mania</li> </ul>
<p><b>CME STATEMENT:</b>  <small>This symposium will be conducted on May 18, 2003, during the 2003 Annual Meeting of the American Psychiatric Association.</small></p> <p><small>The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.</small></p> <p><small>The APA designates this educational activity for a maximum of 3.5 category 1 credits toward the AMA Physician's Recognition Award and for the CME requirement of the APA. Each physician should claim only those credits that he/she actually spent in the activity.</small></p>		<p><small>Attendees must be registered for the APA Annual Meeting to obtain the symposium. Seating is limited and will be based on first-come, first-served. For more information about the meeting, please visit the APA Website at <a href="http://www.psych.org">www.psych.org</a> or contact the APA toll free at 1-888-357-7924 (within the US or Canada) or 703-907-7300.</small></p> <p><small>If any statement of educational activity is a basis of accreditation, please call 800-434-3022 on May 1, 2003, in order to receive service.</small></p>
<p>Sponsored by the American Psychiatric Association</p> <p>Supported by an unrestricted educational grant from</p>		

**INDUSTRY-SUPPORTED SYMPOSIUM 17**  
**Sunday, May 18, 2003, 1:30 p.m. - 4:30 p.m.**  
**Continental Ballroom, Ballroom Level, Hilton**

*Tricks of the Trade  
in the Long-term  
Treatment of Depression*




**APA 156th Annual Meeting**  
**Sunday, May 18, 2003**

**1:00 – 1:30 PM Luncheon • 1:30 – 4:30 PM Symposium**  
 San Francisco Hilton • Continental Ballroom, Ballroom Level

<b>Program Chair:</b> Anita Clayton, MD University of Virginia	<b>2:30 PM</b>	<b>Antidepressant-Induced Cognitive Changes and Apathy: Are There Any Antidotes?</b> Jerrold F. Rosenbaum, MD Massachusetts General Hospital	
<b>Co-Chair:</b> Maurizio Fava, MD Massachusetts General Hospital			
<b>1:30 PM</b>	<b>Introduction</b> Anita Clayton, MD University of Virginia	<b>2:55 PM</b>	<b>Management of Psychiatric and Medical Comorbidity in Major Depression</b> R. Bruce Lydiard, PhD, MD University of South Carolina
<b>1:40 PM</b>	<b>Sexual Dysfunction in Depression</b> Anita Clayton, MD University of Virginia	<b>3:20 PM</b>	<b>Sleep Changes During Long-term Treatment With Antidepressants</b> Maurizio Fava, MD Massachusetts General Hospital
<b>2:05 PM</b>	<b>Practical Approaches to Antidepressant-Induced Weight Gain</b> David L. Ginsberg, MD NYU Medical Center	<b>3:45 PM</b>	<b>Questions and Answers</b>

**Educational Objectives:** At the conclusion of this symposium, participants will be able to recognize and manage factors complicating treatment of depression.  
 The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The APA designates this educational activity for a maximum of 3 category 1 credits toward the AMA Physician Recognition Award and for the CME requirements of the APA. Each physician should claim only those credits that he/she actually spent in the activity.  
 Attendees must be registered for the APA Annual Meeting to attend this symposium. Seating is limited and will be based on first-come, first-served. For more information about the meeting, please visit the APA website at [www.psych.org](http://www.psych.org) or contact the APA toll free at 1-888-357-7924 (within the US or Canada) or 703-907-7300.

 Supported by an unrestricted educational grant from Organon Inc.

 Sponsored by the American Psychiatric Association

**INDUSTRY-SUPPORTED SYMPOSIUM 18**  
**Sunday, May 18, 2003, 1:30 p.m. - 4:30 p.m.**  
**Salons 7 & 8, Lower B-2 Level, Marriott**

*Pharmacological Treatment of  
 Chronic Pain: Comorbidity With Depression  
 and Other Psychiatric Disorders*

**1:00PM-1:30PM  
 Luncheon**

**1:30PM  
 Welcome and  
 Introduction**  
 David A. Fishbain, MD, FAPA  
 Program Chairperson

University of Miami School of Medicine  
 University of Miami Comprehensive  
 Pain and Rehabilitation Center

**1:35PM  
 Psychiatric and  
 Other Comorbidities  
 Associated With  
 Chronic Pain**  
 David A. Fishbain, MD, FAPA  
 Program Chairperson

**1:55PM  
 The Neurobiology  
 of Pain**  
 Edward C. Covington, MD  
 Cleveland Clinic Foundation

**2:20PM  
 Adjuvants as Analgesics:  
 Mechanism-Based  
 Pharmacotherapy in Pain  
 Medicine**  
 Rollin M. Gallagher, MD, MPH  
 Pain Medication  
 Rehabilitation Center,  
 Drexel College of Medicine

**2:40PM  
 Depression With Painful  
 Physical Symptoms:  
 Treatment With  
 Serotonin/Norepinephrine  
 Antidepressants**  
 Michael J. Detke, MD, PhD  
 Lilly Research Laboratories  
 Indiana University School of Medicine  
 McLean Hospital,  
 Harvard Medical School

**3:05PM  
 The Use of Opioid  
 Analgesics for Chronic  
 Pain: Controversies  
 and Challenges**  
 Steven A. King, MD, MS  
 Pain Center, Hospital for Joint  
 Disease-Orthopaedic Institute  
 NYU School of Medicine

**3:25PM  
 Adjuvant Analgesics:  
 Efficacy Evidence  
 for the Treatment of  
 Neuropathic Pain**  
 David A. Fishbain, MD, FAPA  
 Program Chairperson

**3:45PM  
 Question and  
 Answer Session**

**4:30PM  
 Program Adjournment**

Held During the APA 2003 Annual Meeting  
**Sunday, May 18, 2003**

**1:00PM-1:30PM Luncheon**  
**1:30PM-4:30PM Educational Program**  
**San Francisco Marriott**  
**Yerba Buena Ballroom, Salons 7 and 8**  
**Lower B2 Level**

**Don't Miss This  
 Important Educational  
 Luncheon Program!**

**Program Description**

Recently, there has been increasing psychiatric interest in the treatment of a large group of underserved patients: those suffering from chronic pain (CP). This interest has culminated in the development of an additional ABPN subspecialty board, *Board Qualification in Pain Management*. This symposium will bring together an eminent group of four pain clinicians/research psychiatrists, each board-certified in pain management (ABPM), pain medicine (AAPM), or both, and one pharmacological researcher. Each presentation has been designed to be of interest to those psychiatrists practicing, or contemplating practicing, pain medicine psychiatry, or those wishing to review the most recent advances in the psychopharmacological management of CP. In addition, recent research on the use of dual action antidepressants in the treatment of depression associated with painful physical symptoms, as well as the use of adjunct analgesics in the treatment of CP associated with psychiatric comorbidity, will be discussed.

**Learning Objectives**

- Upon completion of the program, participants should be able to:
1. Recognize which psychiatric and other comorbidities are commonly found in chronic pain patients and their relative prevalence, and identify some etiologic issues surrounding these two groups of comorbidities.
  2. Discuss the data supporting the efficacy of dual serotonin and norepinephrine reuptake inhibitors in treating both the painful physical symptoms of depression and pain disorders.
  3. Recognize and diagnose neuropathic pain within chronic pain patients.
  4. Delineate which psychopharmacological agents demonstrate the greatest efficacy in the treatment of neuropathic pain.
  5. Discuss indications for and the proper use of opioids, and identify potential problems that can be associated with their use.
  6. Explain both the principles and practical aspects of the mechanism-based pharmacotherapy of chronic pain disorders.

**Accreditation Statement**

The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

**Credit Designation Statement**

The APA designates this educational activity for a maximum of 3.0 category 1 credits toward the AMA Physician's Recognition Award and for the CME requirement of the APA. Each physician should claim only those credits that he/she actually spent in the activity.

Attendees must be registered for the APA Annual Meeting to attend this symposium. Seating is limited and will be based on first-come, first-served. For more information about the meeting, please visit the APA Web site at [www.psych.org](http://www.psych.org) or contact the APA toll free at 1-888-357-7924 (within the US or Canada) or 703-907-7300.

Sponsored by the American Psychiatric Association  
 Supported by an unrestricted educational grant from  
 Eli Lilly and Company



INDUSTRY-SUPPORTED SYMPOSIUM 19  
 Sunday, May 18, 2003, 1:30 p.m. - 4:30 p.m.  
 Salon 9, Lower B-2 Level, Marriott

Presented at the APA  
 156th Annual Meeting

**STRESS, PSYCHOPATHOLOGY, AND THE BRAIN**  
 Novel Intervention Strategies



Sunday, May 18, 2003 • 1:30 PM - 4:30 PM

San Francisco Marriott, Salon 9, Lower B-2 Level  
 San Francisco, California

**Faculty and Agenda:**

1:00 PM - 1:30 PM  
 1:30 PM - 3:45 PM

Lunch

Symposium

**Overview of the Relationship Between Stress, Depression, and Anxiety**

Christine Heim, PhD  
 Atlanta, Georgia

**The Potential for Gene Therapy in the Treatment of Stress and Related Disorders**

Robert Sapolsky, PhD  
 Stanford, California

**The Biology of Stress and Vulnerability**

Michael Meaney, PhD  
 Montreal, Canada

**Novel Pharmacological Strategies to Treat Stress-Related Psychopathology and Medical Illness**

Ned H. Kalin, MD, Chairperson  
 Madison, Wisconsin

3:45 PM - 4:30 PM

Question-and-Answer Session

**Target Audience:**

This activity is designed specifically for clinicians and clinician scientists.



Sponsored by the American Psychiatric Association  
 Supported by an unrestricted educational grant from Wyeth Pharmaceuticals

**Overview:**

This symposium will focus on the important relations between stress vulnerability, psychopathology, and brain plasticity. For years, it has been known that stress can lead to the development and exacerbation of psychopathology. Some individuals are vulnerable in that they are sensitive to the effects of stress, whereas others seem to be resilient. More recently, it has been discovered that both stress exposure and psychopathology can lead to long-term structural and functional brain changes. This symposium will: 1) address issues related to the genetic and environmental effects of stress, 2) review new data documenting stress-induced structural and functional brain changes and the mechanisms underlying these changes, and 3) present data supporting novel therapies, including gene therapies, that have the potential to decrease stress vulnerability and diminish the likelihood of the development of deleterious brain changes.

**Learning Objectives:**

Upon completion of this symposium, the participants should be able to:

- Understand the relationship between stress and psychopathology
- Understand the basic mechanisms underlying vulnerability for stress
- Understand principles of gene therapy and how they may be used in the future for the treatment of stress-related disorders
- Understand potential new treatments for depression and anxiety-blockade of cortisol and CRF receptors

**Accreditation:**

The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The APA designates this educational activity for a maximum of 3 category 1 credits towards the AMA Physician Recognition Award and for the CME requirement of the APA. Each physician should claim only those credits that he/she actually spent in the educational activity.

**Registration Policy:**

Attendees must be registered for the APA Annual Meeting to attend this symposium. Seating is limited and will be based on first-come, first-served. For more information about the meeting, please visit the APA website at [www.psych.org](http://www.psych.org) or contact the APA toll-free at (888) 357-7924 (within the US or Canada) or (703) 907-7300.

INDUSTRY-SUPPORTED SYMPOSIUM 20  
 Sunday, May 18, 2003, 1:30 p.m. - 4:30 p.m.  
 Grand Ballroom, Mezzanine Level, Westin St. Francis

**Depression, Apathy and Fatigue in Neuropsychiatric Disorders** APA 2003 Annual Meeting

The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The APA designates this educational activity for a maximum of 3 category 1 credits toward the AMA Physician Recognition Award and for the CME requirement of the APA. Each physician should claim only those credits that he/she actually spent in the activity.

**Educational Objectives**

At the conclusion of this symposium, the participant should be able to:

Distinguish between, and provide the differential diagnoses and intervention options for, daytime fatigue, apathy and excess daytime sleepiness in patients with psychiatric disorders.

**Participation**

Attendees must be registered for the APA Annual Meeting to attend this symposium. Seating is limited and will be based on first-come, first-served. For more information about the meeting, please visit the APA website at [www.psych.org](http://www.psych.org) or contact the APA toll free at 1-888-357-7924 (within the U.S. or Canada) or 703-907-7300.

**Educational Council**

Chairperson  
 John W. Winkelman, MD, PhD  
 Harvard Medical School  
 Boston, MA

Jeffrey L. Cummings, MD  
 UCLA Alzheimer's Disease Center  
 Los Angeles, CA

Mary B. O'Malley, MD, PhD  
 Norwalk Hospital  
 Norwalk, CT

Robert S. Marin, MD  
 University of Pittsburgh  
 School of Medicine  
 Pittsburgh, PA

William S. Breitbart  
 Memorial Sloan-Kettering  
 Cancer Center  
 New York, NY

Donald C. Goff  
 Massachusetts General Hospital  
 Boston, MA

Sponsored by the  
 American Psychiatric  
 Association



Supported by an  
 unrestricted educational  
 grant from Cephalon, Inc.

**Cephalon**

**Agenda (Sunday, May 18, 2003)**

Lunch will be served from 1:00 PM to 1:30 PM

**1:30 PM - 1:40 PM**

Welcome & Introductions  
 John W. Winkelman, MD, PhD

**1:40 PM - 2:00 PM**

Disorders of Motivation:  
 The Third Domain of Psychopathology  
 Robert S. Marin, MD

**2:00 PM - 2:20 PM**

Fatigue and Depression in Cancer  
 and AIDS  
 William S. Breitbart, MD

**2:20 PM - 2:45 PM**

Apathy in Neuropsychiatric Disorders  
 Jeffrey L. Cummings, MD

**2:45 PM - 3:10 PM**

Depression, Fatigue, and Excess  
 Daytime Sleepiness in Sleep Disorders  
 Mary B. O'Malley, MD, PhD

**3:10 PM - 3:30 PM**

Apathy in Schizophrenia  
 Donald C. Goff, MD

**3:30 PM - 3:45 PM**

Discussant  
 John W. Winkelman, MD, PhD


**3:45 PM - 4:30 PM**

Panel Discussion/Q & A  
 Panel

**INDUSTRY-SUPPORTED SYMPOSIUM 21**  
 Sunday, May 18, 2003, 7:00 p.m. - 10:00 p.m.  
 Gateway Ballroom, Exhibit Level, Moscone Center

**JOIN US AT THE APA 156th Annual Meeting** IN SAN FRANCISCO CALIFORNIA

## PEPTIDES and HORMONES as Targets in ANTIDEPRESSANT Treatment



**May 18, 2003**  
 7:00 - 10:00 pm  
 Moscone Center Gateway Ballroom  
 Exhibit Level

**Dinner served 6:30 - 7:00 pm**  
**Chair** Alan F. Schatzberg, MD  
**Co-Chair** Ned H. Kalin, MD

**LEARNING OBJECTIVES**

- Understand how peptide and hormone systems are involved in mood regulation; have a working knowledge of new antidepressants that involve peptide and hormone receptors as targets.
- To understand estrogen's effects on serotonin systems, and anxiety and mood systems
- Understand the role of PET IMAGING in the drug development process
- Specify the neuroanatomy and function of Substance P and relevant receptors, and be conversant with studies of Substance P antagonists for depressive disorders
- Understand how CRF systems work in the brain and how CRF antagonists may provide a new therapeutic potential for treatment of depression and anxiety disorders

**ACCREDITATION**

The American Psychiatric Association is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. The APA designates this education activity for a maximum of 3 category 1 credits toward the AMA Physician Recognition Award and for the CME requirement of the APA. Each physician should claim only those credits he/she actually spent in the activity.

**REGISTRATION**

Attendees must be registered for the **APA 2003 Annual Meeting** to attend this Symposium. Seating is limited and will be based on first-come, first-served. For more information about the meeting, please visit the APA website at [www.psych.org](http://www.psych.org) or contact the APA toll free at 1-888-357-7924 (within the U.S. or Canada) or 703-907-7300

Advanced medical studies focusing on alternative novel mechanisms, which aid in the treatment of depressive or mood disorders, will be presented. Topics include:

**7:00 - 7:05**  
**Welcome and Introduction**  
 Alan F. Schatzberg, MD  
 Kenneth T. Norris, Jr.  
 Professor and Chairman  
 Department of Psychiatry & Behavioral Sciences  
 Stanford University School of Medicine

**7:05 - 7:30 / 7:30 - 7:40 Q&A**  
**Development of a PET Tracer for Clinical Trials of Substance P Antagonists**  
 Richard Hargreaves, PhD

**7:40 - 8:05 / 8:05 - 8:15 Q&A**  
**Recent Studies on Substance P Antagonists**  
 John Rush, MD  
 Professor and Vice-Chairman for Research at the Department of Psychiatry at the University of Texas Southwestern Medical Center

**8:15 - 8:40 / 8:40 - 8:50 Q&A**  
**The Therapeutic Potential of Corticotrophin-Releasing Factor Antagonists**  
 Ned H. Kalin, MD  
 Chairman, Department of Psychiatry  
 University of Wisconsin

**8:50 - 9:15 / 9:15 - 9:25 Q&A**  
**Estrogen and Mood**  
 Elizabeth A. Young, MD  
 Professor, Department of Psychiatry  
 University of Michigan

**9:25 - 9:50 / 9:50 - 10:00 Q&A**  
**The Role of Antiglucocorticoid Agents in the Treatment of Major Depression**  
 Charles DeBattista, MD  
 Assistant Professor of Psychiatry  
 Director of Depression Clinic  
 Director of Psychopharmacology Clinic  
 Stanford University School of Medicine




SPONSORED BY THE  
American Psychiatric Association



SUPPORTED BY AN  
unrestricted educational  
grant from Merck & Company

**INDUSTRY-SUPPORTED SYMPOSIUM 22**  
 Sunday, May 18, 2003, 7:00 p.m. - 10:00 p.m.  
 Metropolitan, Second Level, Argent



**A COMPREHENSIVE  
 APPROACH TO MANAGING  
 BIPOLAR DISORDER**

*Bench to Bedside  
 and Beyond*

**PROGRAM AGENDA**

6:30 PM - 7:00 PM RECEPTION

7:00 PM - 7:05 PM WELCOME AND INTRODUCTION  
 PROGRAM CHAIRMAN, GARY S. SACHS, MD - Massachusetts General Hospital

7:05 PM - 7:30 PM NEUROPLASTICITY AND CELLULAR RESILIENCE IN BIPOLAR DISORDER  
 HUSSEIN K. MANJI, MD - National Institute of Mental Health

7:30 PM - 7:55 PM THE TREATMENT OF ACUTE MANIA  
 MARK A. FRYE, MD - UCLA School of Medicine

7:55 PM - 8:20 PM TREATMENT OF BIPOLAR DISORDER WITH COMORBID PSYCHIATRIC OR MEDICAL DISORDERS  
 SUZAN L. McLEROY, MD - University of Cincinnati College of Medicine

8:20 PM - 8:45 PM MANAGEMENT OF SUICIDE PREVENTION IN BIPOLAR DISORDER PATIENTS  
 MARIA A. OQUENDO, MD - Columbia Presbyterian Medical Center

8:45 PM - 9:10 PM PSYCHOTHERAPY FOR BIPOLAR DISORDER?  
 ELLEN FRANK, PHD - University of Pittsburgh School of Medicine

9:10 PM - 9:15 PM SUMMARY AND CONCLUSIONS  
 GARY S. SACHS, MD

9:15 PM - 10:00 PM QUESTIONS AND ANSWERS

10:00 PM - 10:30 PM REFRESHMENTS

*An educational symposium to be presented at the 2003 Annual Meeting of the American Psychiatric Association*

SUNDAY, MAY 18, 2003  
 THE ARGENT HOTEL  
 METROPOLITAN, SECOND LEVEL  
 SAN FRANCISCO, CALIFORNIA

**EDUCATIONAL OBJECTIVES**

Upon completion of the program, participants should be able to understand the usage of laboratory trials and clinical results to deliver treatment to patients with bipolar disorder.

**ACCREDITATION STATEMENT**

The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education (CME) for physicians. The APA designates this educational activity for a maximum of 3 Category 1 credits toward the AMA Physician's Recognition Award and for the CME requirement of the APA. Each physician should claim only those credits that he/she actually spent in the educational activity.

Attendees must be registered for the APA Annual Meeting to attend this symposium. Seating is limited and will be based on first-come, first-served. For more information about the meeting, please visit the APA website at [www.psych.org](http://www.psych.org) or contact the APA, toll free, at 1-888-357-7924 (within the US or Canada) or 703-907-7300.

Sponsored by the American Psychiatric Association

Supported by an unrestricted educational grant from  
 Ortho-McNeil Pharmaceutical, Inc.

**ORTHO-MCNEIL**



**INDUSTRY-SUPPORTED SYMPOSIUM 23**  
**Sunday, May 18, 2003, 7:00 p.m. - 10:00 p.m.**  
**Grand Ballroom Salon B, Grand Ballroom Level, Hilton**

## A RATIONAL ALGORITHM FOR SELECTING ATYPICALS IN SCHIZOPHRENIA AND BIPOLAR DISORDERS

**SUNDAY, MAY 18, 2003 • DINNER: 6:30–7:00 PM • SYMPOSIUM: 7:00–10:00 PM**


**HILTON SAN FRANCISCO, GRAND BALLROOM, SALON B, GRAND BALLROOM LEVEL • SAN FRANCISCO, CALIFORNIA**

This symposium will be conducted on May 18, 2003, during the 2003 Annual Meeting of the American Psychiatric Association

---


<p><b>AGENDA:</b></p> <p><b>6:30–7:00 PM</b> Dinner</p> <p><b>7:00–7:10 PM</b> Welcome and Opening Remarks  <b>Henry A. Nasrallah, MD</b>  <i>(Symposium Chairperson)</i>  <i>University of Cincinnati Medical Center</i></p> <p><b>7:10–7:35 PM</b> Efficacy of Atypical Antipsychotics: How Do They Compare?  <b>Rajiv Tandon, MD</b>  <i>University of Michigan Medical Center</i></p> <p><b>7:35–8:00 PM</b> Minimizing Specific Medical Problems by Customizing Antipsychotic Selection  <b>Henry A. Nasrallah, MD</b>  <i>University of Cincinnati Medical Center</i></p>	<p><b>8:00–8:25 PM</b> Serious Medical Morbidity and Atypicals: Defining and Avoiding Thresholds of Risk  <b>Diana D. Perkins, MD, MPH</b>  <i>University of North Carolina, Chapel Hill</i></p> <p><b>8:25–8:50 PM</b> Bipolar Disorders and Schizophrenia: Similarities and Differences in Susceptibilities to Side Effects  <b>Claudia F. Baldassano, MD</b>  <i>University of Pennsylvania</i></p> <p><b>8:50–9:15 PM</b> Efficacy to Effectiveness When Treating Schizophrenia  <b>Peter J. Weiden, MD</b>  <i>SUNY Downstate Medical Center</i></p> <p><b>9:15–10:00 PM</b> Question and Answer Session  <i>All Faculty</i></p> <p><b>10:00 PM</b> Adjourn</p>	<p><b>LEARNING OBJECTIVES:</b>              After attending this symposium, participants will be able to:</p> <ul style="list-style-type: none"> <li>• Explain how atypical antipsychotics demonstrate a broader spectrum of efficacy than conventional agents; how they appear to be more efficacious in otherwise treatment-refractory patients, with clozapine possessing the best track record in this regard; review a comparison of "first-line" (not clozapine) atypical antipsychotics across all available clinical trial data; and explain how appropriate dosing is critical toward optimizing efficacy</li> <li>• Describe the potential increased health risks associated with atypical antipsychotics and discuss health assessment strategies and potential intervention strategies to reduce risk of cardiovascular and endocrine disease in patients</li> <li>• Identify the risk of side effects with atypical neuroleptics in the treatment of bipolar disorder and schizophrenia</li> <li>• Demonstrate how certain populations are susceptible to certain medical side effects (eg, EPS in the elderly, diabetes in obese individuals) and that selection of a specific antipsychotic for each patient, based on his/her medical risk profile, is a rational approach</li> <li>• Discuss current understanding of the difference between efficacy and effectiveness as it pertains to the treatment of schizophrenia</li> </ul>
---	--	--

---



Sponsored by the  
American Psychiatric Association

Supported by an unrestricted educational grant from



AstraZeneca

**CME STATEMENT:**  
 This program will be presented at May 18, 2003, during the 2003 Annual Meeting of the American Psychiatric Association.

The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The APA designates this educational activity for a maximum of 3.0 category 1 credit(s) towards the AMA Physician's Recognition Award and for the CME requirement of the APA. Each physician should claim only those credits that he/she actually spent in the educational activity.

Attendees must be registered for the APA Annual Meeting to attend this symposium. Seating is limited and will be on a first-come, first-served basis. For more information about the meeting, please visit the APA Web site at [www.psych.org](http://www.psych.org) or contact the APA toll free at 1-888-357-7924 (within the United States or Canada) or 703-967-7300.

The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The APA designates this educational activity for a maximum of 3.0 category 1 credit(s) towards the AMA Physician's Recognition Award and for the CME requirement of the APA. Each physician should claim only those credits that he/she actually spent in the educational activity.

**INDUSTRY-SUPPORTED SYMPOSIUM 24**  
**Sunday, May 18, 2003, 7:00 p.m. - 10:00 p.m.**  
**Continental Ballroom, Ballroom Level, Hilton**

*Sunday, May 18, 2003*  
**7:00 PM - 10:00 PM**

## Psychiatry & MEDICINE:

*Common Patients, Different Perspectives*

---

<p><b>AGENDA</b></p> <p><b>6:30–7:00 PM</b> Dinner</p> <p><b>7:00</b> Welcome and Introduction  <b>Charles B. Nemeroff, MD, PhD,</b>  <i>Program Chairperson</i>              Professor and Chairman              Department of Psychiatry and Behavioral Sciences              Emory University Medical School              Atlanta, Georgia</p> <p><b>7:10</b> The Pathophysiology and Psychopharmacology of Comorbid Cardiovascular Disease and Depression  <b>Charles B. Nemeroff, MD, PhD</b></p> <p><b>7:35</b> Medical Illness and Depression: <i>A Delicate Interplay Between Body and Brain</i>  <b>Dominique L. Muselman, MD</b>              Assistant Professor              Department of Psychiatry and Behavioral Sciences              Emory University Medical School              Atlanta, Georgia</p>	<p><b>8:00</b> Management of Anxiety Disorders in Primary Care: <i>Implications for Psychiatrists</i>  <b>Risa B. Weisberg, PhD</b>              Assistant Professor              Department of Psychiatry and Human Behavior              Brown University              Providence, Rhode Island</p> <p><b>8:25</b> Long-Term Treatment of Anxiety and Depression: <i>Why, When, and How?</i>  <b>Philip T. Ninan, MD</b>              Professor of Psychiatry and Behavioral Sciences Director, Mood and Anxiety Disorders Program              Emory University Medical School              Atlanta, Georgia</p> <p><b>8:50</b> The Successful Intervention: <i>Management of the Patient with Medical Comorbidities</i>  <b>Larry Calpeppet, MD, MPH</b>              Professor and Chairman of Family Medicine              Boston University Medical Center              Boston, Massachusetts</p> <p><b>9:15</b> Question and Answer Session              Faculty Panel</p> <p><b>10:00</b> Adjourn</p>	<p><b>OBJECTIVES</b></p> <p>At the conclusion of this symposium, participants should be able to:</p> <ul style="list-style-type: none"> <li>• Understand why the recognition of depression in patients with cardiovascular disease (CVD) is important when establishing treatment options.</li> <li>• Recognize the interrelationship between depression and comorbid medical illnesses and understand how treating the depression can improve a medical patient's overall quality of life.</li> <li>• Recognize the need for early identification and treatment of anxiety disorders in primary care.</li> <li>• Understand the significance of long-term treatment of depression and anxiety.</li> <li>• Compare and contrast the approaches to treating patients with depression and medical comorbidities in the psychiatric and primary care settings.</li> </ul> <p><b>APA 156th Annual Meeting</b></p> <p><i>Hilton San Francisco</i>  <b>Continental Ballroom, Ballroom Level</b>  <b>San Francisco, California</b></p> <p style="font-size: x-small;">Attendees must be registered for the APA Annual Meeting to attend this symposium. Seating is limited and will be on a first-come, first-served basis. For more information about the meeting, please visit the APA Web site at <a href="http://www.psych.org">www.psych.org</a> or contact the APA toll free at 1-888-357-7924 (within the United States or Canada) or 703-967-7300.</p> <p>The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.</p> <p>The APA designates this educational activity for a maximum of 3 category 1 credit(s) towards the AMA Physician's Recognition Award and for the CME requirement of the APA. Each physician should claim only those credits that he/she actually spent in the educational activity.</p>
--	--	--

---



Sponsored by the  
American Psychiatric Association



Supported by an  
unrestricted educational  
grant from Pfizer Inc.

**INDUSTRY-SUPPORTED SYMPOSIUM 25**  
**Sunday, May 18, 2003, 7:00 p.m. - 10:00 p.m.**  
**Salons 7 & 8, Lower B-2 Level, Marriott**

## Medical Considerations in the Management of Special Patient Populations

**6:30PM-7:00PM Dinner**

**7:00PM: Welcome and Introduction**  
**Pedro Ruiz, MD**  
 Program Chairperson  
 Mental Sciences Institute  
 University of Texas Medical School at Houston

**7:10PM: Medical Comorbidity in Bipolar Disorder**  
**Donald C. Goff, MD**  
 Massachusetts General Hospital  
 Harvard Medical School

**7:35PM: Medical Comorbidity in Bipolar Disorder**  
**Lauren B. Marangell, MD**  
 Baylor College of Medicine

**8:00PM: Medical Comorbidity in Psychiatric Populations: The Comorbidity Paradigm**  
 Psychiatry, Multisite With Emphasis on Women and Adolescent Patients  
**William R. Schatzkin, MD**  
 University of Minnesota Medical School

**8:25PM: Course and Treatment of Bipolar Illness During Pregnancy, Postpartum, and Lactation**  
**Lee S. Cohen, MD**  
 Massachusetts General Hospital  
 Harvard Medical School

**8:50PM: Medical Comorbidity and Bipolar Disorders in the Age-Related Impact on Diagnosis, Treatment, and Outcome**  
**Kenneth I. Shulman, MD**  
 Sunnybrook and Women's University of Toronto

**9:15PM: Question and Answer Session**

**10:00PM: Program Adjournment**

**Held During the APA 2003 Annual Meeting**

**Program Description**  
 Psychiatric illness has long been established as correlating with a significant risk and burden of morbidity. The clinical management of psychiatric illness requires careful benefit-risk assessment to achieve satisfactory outcomes and reduce morbidity. Throughout the course of patient care, there are considerations associated with treatment goals, patient satisfaction, minimization of medically contraindicating pharmacological events, special patient population needs, and medical comorbidities.

Available data will be presented focusing on medical comorbidities and therapeutic impact in bipolar disorder, schizophrenia, and special populations, including the elderly, women, and child and adolescent patients. Lectures, visual aids, and a course syllabus will be utilized throughout the program to engage the attendees and enhance the learning process.

**Learning Objectives**  
 Upon completion of the program, participants should be able to:

1. Discuss medical comorbidities commonly seen in special patient populations with mental illness.
2. Recognize, monitor, and intervene with respect to risk factors that elevate morbidity rates among people with schizophrenia.
3. Provide treatment management strategies for patients with medical comorbidities and bipolar disorder.
4. Understand the use of and medical risks associated with combined pharmacotherapy in the treatment of psychiatric onset bipolar disorder and its clinical conditions.
5. Implement the appropriate treatment of bipolar disorder in pregnancy and the postpartum period.
6. Discuss an approach to identifying medical/neurologic comorbidity and managing such patients with appropriate pharmacologic therapy.

**Accreditation Statement**  
 The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

**Credit Designation Statement**  
 The APA designates this educational activity for a maximum of 3.0 category 1 credits toward the AMA Physician's Recognition Award and for the CME requirement of the APA. Each physician should claim only those credits that he/she actually spent in the activity.

Attendees must be registered for the APA Annual Meeting to attend this symposium. Seating is limited and will be based on first-come, first-served. For more information about the meeting, please visit the APA Web site at [www.psych.org](http://www.psych.org) or contact the APA toll free at 1-888-357-7924 (within the US or Canada) or 703-907-7300.

**Don't Miss This Important Educational Dinner Program!**

**Sunday, May 18, 2003**  
**6:30PM-7:00PM Dinner**  
**7:00PM-10:00PM Educational Program**

**San Francisco Marriott**  
**Yerba Buena Ballroom, Salons 7 and 8**  
**Lower B2 Level**

Sponsored by the American Psychiatric Association  
 Supported by an unrestricted educational grant from Eli Lilly and Company

**INDUSTRY-SUPPORTED SYMPOSIUM 26**  
**Sunday, May 18, 2003, 7:00 p.m. - 10:00 p.m.**  
**Salon 9, Lower B-2 Level, Marriott**

A symposium to be held during the APA 2003 Annual Meeting

**Sunday, May 18, 2003**  
**Salon 9, San Francisco Marriott**  
**San Francisco, CA**

## Treatment of Comorbidity in Neuropsychiatric Disorders in Children and Adolescents

**6:30 - 7:00 PM Dinner**

**7:00 - 7:10 PM Welcome and Introduction**  
**Robert L. Findling, MD (Chair)**  
 University Hospitals of Cleveland

**7:10 - 7:35 PM Understanding the Concept of Spectrum and Comorbidity in Child and Adolescent Psychiatric Disorders: Pediatric Bipolar Disorder as a Model**  
**Janet Wozniak, MD**  
 Harvard Medical School

**7:35 - 8:00 PM Rational Management of Disruptive Behavior Disorder and Comorbidity**  
**Jeffrey Nowcorn, MD**  
 Mt. Sinai School of Medicine

**8:00 - 8:25 PM Combined Pharmacotherapy in the Management of Bipolar Disorder**  
**Robert L. Findling, MD**

**8:25 - 8:50 PM Recent Advances in the Pharmacotherapy of Pervasive Development Disorder Spectrum**  
**Christopher J. McDougle, MD**  
 Indiana University School of Medicine

**8:50 - 9:15 PM Clinically Relevant Drug-Drug Interactions in Pediatric Psychiatry**  
**Michael D. Reed, PharmD**  
 Case Western Reserve University School of Medicine

**9:15 - 10:00 PM Questions and Answers**

**At the conclusion of this symposium, the participant should be able to:**

- Understand the rationale for combination pharmacotherapy in pediatric psychiatry
- Describe common comorbidities in pediatric psychiatry
- Describe the risks of polypharmacy in pediatric psychiatry

The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.


The APA designates this educational activity for a maximum of 3 category 1 credits toward the AMA Physician's Recognition Award and for the CME requirement of the APA. Each physician should claim only those credits that he/she actually spent in the educational activity.

Attendees must be registered for the APA Annual Meeting to attend this symposium. Seating is limited and will be on a first-come-first-serve basis. For more information about the meeting, please visit the APA website at [www.psych.org](http://www.psych.org) or contact the APA toll free at 1-888-357-7924 (within the U.S. or Canada) or at 703-907-7300.

Supported by an unrestricted educational grant from Sponsored by the American Psychiatric Association

RS-1178C

**INDUSTRY-SUPPORTED SYMPOSIUM 27**  
**Sunday, May 18, 7:00 p.m. - 10:00 p.m.**  
**Grand Ballroom, Mezzanine Level, Westin St. Francis**



**Reducing Suicidality  
in Schizophrenia and  
Bipolar Disorder**

**Presented at the  
APA 156th Annual Meeting**

**Sunday, May 18, 2003**  
**7:00 PM - 10:00 PM**  
**Westin St. Francis**  
**Mezzanine Level, Grand Ballroom**  
**San Francisco, California**

**Faculty and Agenda**

Reception and Dinner: 6:30 PM - 7:00 PM

7:00 PM	Welcome and Introduction Herbert Y. Meltzer, MD, Chair Vanderbilt University Medical Center	8:15 PM	Reducing Suicidality in Schizophrenia and Schizoaffective Disorder Herbert Y. Meltzer, MD
7:15 PM	Suicidality and Its Management in Schizophrenia and Bipolar Disorder Kay R. Jamison, PhD Johns Hopkins University	8:45 PM	Treatment and Suicide Risks Ross J. Baldessarini, MD Harvard Medical School
7:45 PM	A Model for Suicide Assessment Douglas G. Jacobs, MD Screening for Mental Health	9:15 PM	Question and Answer Session

**Target Audience**

This continuing education activity is designed for psychiatrists and other clinicians who diagnose and treat schizophrenia and bipolar disorder.

**Learning Objectives**

At the conclusion of this symposium, the participant should be able to recognize the patients with bipolar disorder or schizophrenia who are at greater risk for suicidality, assess the level of risk, and apply the most appropriate pharmacologic and psychotherapeutic techniques to deal with current crises and minimize future suicidality.

**Accreditation**

The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The APA designates this educational activity for a maximum of 3 category 1 credits towards the AMA Physician's Recognition Award and for the CME requirements of the APA. Each physician should claim only those credits that he/she actually spent in the educational activity.

**Registration Policy**

Attendees must be registered for the APA Annual Meeting to attend this symposium. Seating is limited and will be on a first-come, first-served basis. For more information about the meeting, please visit the APA Web site at [www.psych.org](http://www.psych.org) or contact the APA toll-free at (888) 357-7924 (within the US or Canada) or (703) 907-7300.



Sponsored by the American Psychiatric Association  
 Supported by an unrestricted educational grant from Novartis

**INDUSTRY-SUPPORTED SYMPOSIUM 28**  
**Monday, May 19, and Tuesday, May 20, 7:00 a.m. - 8:30 a.m.**  
**Gateway Ballroom, Exhibit Level, Moscone Center**

*Impairments of  
Structural Plasticity in Severe  
Mood Disorders:  
Causal or Collateral?*

**LEARNING OBJECTIVES**


- Discuss mechanisms involved in neurogenesis, cellular atrophy and cell death.
- Discuss neuroimaging and the effects of mood stabilizers on specific molecular and cellular targets.


**CREDIT DESIGNATION**

The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The APA designates this educational activity for a maximum of 3 category 1 credits towards the AMA Physician's Recognition Award and for the CME requirement of the APA. Each physician should claim only those credits that he/she actually spent in the educational activity.

*Attendees must be registered for the APA Annual Meeting to attend this symposium. Seating is limited and will be based on first-come, first-served. For more information about the meeting, please visit the APA Website at [www.psych.org](http://www.psych.org) or contact the APA toll-free at 1-888-357-7924 (within the US or Canada) or 703-907-7300.*

 This activity is supported by an unrestricted educational grant from Abbott Laboratories.

 Sponsored by the American Psychiatric Association and held at the APA 2003 Annual Meeting.

**Monday, May 19th, 2003**

Gateway Ballroom, Exhibit Level, Moscone Center

7:00 - 7:00 am	Breakfast
7:00 - 7:05 am	Introduction Pierre N. Tariot, MD - Program Co-chair University of Rochester Medical Center
7:05 - 7:25 am	Stress, Glucocorticoids and Neuron Damage: Current Status Robert Sapolsky, PhD Stanford University School of Medicine
7:25 - 7:30 am	Regulation of Functional Neurogenesis in the Adult Brain Fred H. Gage, PhD Salk Institute
7:30 - 8:15 am	Neuromorphometric and Neuropathological Abnormalities in Mood Disorders Wayne C. Drevets, MD University of Pittsburgh School of Medicine National Institute of Mental Health, NIH, HHS
8:15 - 8:30 am	Q & A

**Tuesday, May 20th, 2003**

7:00 - 7:00 am	Breakfast
7:00 - 7:10 am	Introduction and Review Hussein K. Manji, MD, FRCP - Program Co-chair National Institute of Mental Health, NIH, HHS
7:10 - 7:35 am	Reduced Hippocampal Volume in Adult Major Depression: The Role of Childhood Trauma Meena Vythilingam, MD National Institute of Mental Health, NIH, HHS
7:35 - 8:00 am	Targeting Structural Plasticity for Optimal Treatment of Severe Mood Disorders Hussein K. Manji, MD, FRCP - Program Co-chair
8:00 - 8:30 am	Q & A

**INDUSTRY-SUPPORTED SYMPOSIUM 29**  
**Monday, May 19, and Tuesday, May 20, 7:00 a.m. - 8:30 a.m.**  
**Metropolitan, Second Level, Argent**

**IMPULSIVITY, AGGRESSION, AND SUICIDE: VERSATILITY OF LITHIUM AND MOOD STABILIZERS (Parts 1 & 2)**

Breakfast will be served on both days from 6:30 AM – 7:00 AM.

**Monday, May 19 (Part 1)**

- 7:00 AM – 7:30 AM Treating Impulsivity in Impulse Control and Personality Disorders  
*Eric Hollander, MD; New York, NY*
- 7:30 AM – 7:50 AM Primary and Secondary Disorders of Aggression in Youth: Mood Stabilizers, Atypicals, and Stimulants  
*Hans Steiner, MD; Stamford, CA*
- 7:50 AM – 8:10 AM Strategies for Augmentation of Psychopharmacological Intervention in Youth with Disorders of Aggression  
*Kirti Saxena, MD; Palo Alto, CA*
- 8:10 AM – 8:30 AM Question & Answer Session

**Tuesday, May 20 (Part 2)**

- 7:00 AM – 7:30 AM Lithium Treatment of Patients with Suicidal Affective Disorder: Risk Factors and Mediators  
*Jan A. Fawcett, MD; Chicago, IL*
- 7:30 AM – 8:00 AM Effects of Lithium on Impulsivity, Aggression, and Suicide  
*Frederick K. Goodwin, MD; Washington, DC*
- 8:00 AM – 8:30 AM Question & Answer Session

**Overall Objective:** At the conclusion of this symposium, the participant should be able to recognize contributing factors to the development of impulsivity, aggression, and suicide, and adopt effective management strategies to reduce these problem behaviors.

Attendees must be registered for the APA 2003 Annual Meeting to attend this symposium. Seating is limited and will be based on first-come, first-served. For more information about the meeting, please visit the APA website at [www.psych.org](http://www.psych.org) or contact the APA toll free at 1-888-357-7924 (within the U.S. or Canada) or 703-907-7300.

The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The APA designates this educational activity for a maximum of 3 category 1 credits toward the AMA Physician Recognition Award and for the CME requirement of the APA. Each physician should claim only those credits that he/she actually spent in the activity.

This program is supported by an unrestricted educational grant from Solvay Pharmaceuticals, Inc.

Sponsored by the American Psychiatric Association.

**INDUSTRY-SUPPORTED SYMPOSIUM 30**  
**Monday, May 19, and Tuesday, May 20, 7:00 a.m. - 8:30 a.m.**  
**Grand Ballroom Salon B, Grand Ballroom Level, Hilton**

*APA 2003 Annual Meeting – Two-Part Breakfast CME Symposium*

**Monday & Tuesday, May 19–20**

6:30–7 AM Breakfast ~ 7–8:30 AM Clinical Program  
 Hilton San Francisco – Grand Ballroom Salon B

**Bipolar Disorder in Women:  
 Special Considerations & Evolving Treatment Strategies**

**Lee S. Cohen, MD**, *Symposium Chair*  
**Martha J. Morrell, MD**, *Symposium Co-Chair*

*Bipolar Disorder in Women: Phenomenology & Gender Based Differences*

**Ruta M. Nonacs, MD, PhD**  
 Massachusetts General Hospital  
 Harvard Medical School

*Course & Treatment of Bipolar Disorder During Pregnancy*

**Lee S. Cohen, MD**  
 Massachusetts General Hospital  
 Harvard Medical School

*Bipolar Illness & the Postpartum Period: Clinical Issues & Controversies*

**Adele C. Viguera, MD**  
 Massachusetts General Hospital  
 Harvard Medical School

*Use of Antiepileptic Medications in Women*

**Martha J. Morrell, MD**  
 Columbia University College of Physicians & Surgeons

**Two-Part Breakfast Series Agenda – May 19–20**

- 6:30 AM Breakfast  
 7:00 AM Introduction – L. Cohen, MD  
 7:10 AM Speaker presentations  
 8:05 AM Question & answer session  
 8:30 AM Program concludes



Sponsored by the American Psychiatric Association. The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The APA designates this educational activity for a maximum of

3 category 1 credits toward the AMA Physician Recognition Award and for the CME requirement of the APA. Each physician should claim only those credits that he/she actually spent in the activity. Attendees must be registered for the APA 2003 Annual Meeting to attend this symposium. Seating is limited and will be based on first-come, first-served.

For more information about the meeting, please visit the APA website at [www.psych.org](http://www.psych.org) or contact the APA toll-free at 1-888-357-7924 (within the US or Canada) or 703-907-7300.


Supported by an unrestricted educational grant from Solvay Pharmaceuticals.

**Educational Objective**

Examine clinical management issues for bipolar women ranging from efficacy of treatment to the impact of treatment on reproductive endocrine function.



**INDUSTRY-SUPPORTED SYMPOSIUM 31**  
**Monday, May 19, and Tuesday, May 20, 7:00 a.m. - 8:30 a.m.**  
**Continental Ballroom, Ballroom Level, Hilton**



## Managing the Spectrum of Psychotic Disorders

Monday, May 19 & Tuesday, May 20, 2003

Hilton San Francisco  
 333 O'Farrell Street  
 Continental Ballroom

Breakfast: 6:30 AM - 7:00 AM  
 Symposium: 7:00 AM - 8:30 AM

Chair: Robert E. Hales, MD, MBA  
 Co-Chair: Stuart C. Yudofsky, MD

---

APA 2003  
ANNUAL  
MEETING

**Agenda**


<p><b>MONDAY, MAY 19, 2003 (DAY ONE)</b></p> <p>7:00 AM <b>Welcome and Introductions</b>                  Robert E. Hales, MD, MBA                  University of California, Davis School of Medicine                  Stuart C. Yudofsky, MD                  Baylor College of Medicine</p> <p>7:05 AM <b>Clinical Considerations in the Management of First Episode and Acute Exacerbation of Schizophrenia</b>                  Ira D. Gluck, MD                  Stanford University School of Medicine</p> <p>7:30 AM <b>Challenges in the Management of Psychosis in Special Populations</b>                  J. Michael Ryan, MD                  University of Rochester Medical Center</p> <p>7:55 AM <b>Summary Remarks</b>                  Robert E. Hales, MD, MBA                  Stuart C. Yudofsky, MD</p> <p>8:05 AM <b>Panel Discussion/Q&amp;A</b></p>	<p><b>TUESDAY, MAY 20, 2003 (DAY TWO)</b></p> <p>7:00 AM <b>Welcome and Introductions: Brief Overview of Day One</b>                  Robert E. Hales, MD, MBA                  Stuart C. Yudofsky, MD</p> <p>7:05 AM <b>Long-Term Effectiveness of Antipsychotic Therapies: Real-World Considerations</b>                  Stephen R. Marder, MD                  Veterans Affairs Greater Los Angeles Healthcare System</p> <p>7:30 AM <b>Evolving Role of Novel Antipsychotics for the Management of Acute Mania</b>                  Terence A. Ketter, MD                  Stanford University School of Medicine</p> <p>7:55 AM <b>Summary Remarks</b>                  Robert E. Hales, MD, MBA                  Stuart C. Yudofsky, MD</p> <p>8:05 AM <b>Panel Discussion/Q&amp;A</b></p>
--	---


**Learning Objectives**


*After completion of this 2-day symposium, the participants should be better able to:*

- Understand the importance and goals of treatment for first-episode and acute psychosis, and the pros/cons of currently available antipsychotics for acute-phase pharmacotherapy
- Identify patient populations that pose particular challenges to treatment for psychosis, and describe psychosocial, pharmacologic, or other interventions that may be appropriate for these patients
- Understand the shortcomings that reduce, and the challenges that must be met to improve, the real-world effectiveness of antipsychotic therapy
- Describe the pros/cons of pharmacologic treatments for acute mania in patients with bipolar disorders, including the use of currently available and novel antipsychotics

Supported by an unrestricted educational grant from Bristol-Myers Squibb Company and Otsuka America Pharmaceutical, Inc.

 Bristol-Myers Squibb Company

 Otsuka America Pharmaceutical, Inc.

Sponsored by the  
 American Psychiatric Association.

The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The APA designates this educational activity for a maximum of 3 category 1 credits toward the AMA Physician Recognition Award and for the CME requirement of the APA. Each physician should claim only those credits that he/she actually spent in the activity. Attendees must be registered for the APA Annual Meeting to attend this symposium. Seating is limited and will be based on first-come, first-served. For more information about the meeting, please visit the APA website at [www.psych.org](http://www.psych.org) or contact the APA toll free at 1-888-357-7924 (within the U.S. or Canada) or 703-907-7300.

**INDUSTRY-SUPPORTED SYMPOSIUM 32**  
**Monday, May 19, and Tuesday, May 20, 7:00 a.m. - 8:30 a.m.**  
**Salons 7 & 8, Lower B-2 Level, Marriott**

**Don't Miss These Important Educational Breakfast Programs!**

Held During the APA 2003 Annual Meeting



**Program Description**

This symposium will address what matters in the treatment of depression. Dr. Mayberg will discuss the latest in the understanding of depression by examining brain systems that involve cortical, subcortical, and limbic sites that appear to be dysregulated. Findings from functional neuroimaging will be presented that highlight those pathways that appear to change with successful treatment, fail to change with unsuccessful treatment, and are also associated with relapse risk. Dr. Kornblith will discuss the implications of gender in the treatment of depression. Some studies suggest that women may respond preferentially to serotonergic agents, while men might respond more favorably to those antidepressants that have norepinephrine effects. Dr. Altschuler will discuss the treatment of bipolar depression. Antidepressants have mixed data showing that the antidepressants are effective, but can also induce mania, cycling, and treatment resistance. Dr. Laker will discuss the treatment delay in antidepressant response, the duration of treatment necessary for optimal outcome, and the timing of critical decision points. The duration of continuation and maintenance treatment will also be discussed. Dr. Nierenberg will discuss the risks and benefits of antidepressants along with the range of optimal strategies to maximize outcome. A focus on the outcome of remission, sustained remission, and recovery from an episode will be emphasized.

**Treating Depression: What Matters?**

**Monday, May 19 and Tuesday, May 20, 2003**

6:30AM-7:00AM Breakfast  
 7:00AM-8:30AM Educational Program  
 San Francisco Marriott  
 Yerba Buena Ballroom, Salons 7 and 8  
 Lower B2 Level

**Monday, May 19, 2003**

**Part One**

6:30AM-7:00AM Breakfast

7:00AM **Welcome and Introduction**  
 Andrew A. Nierenberg, MD  
 Program Chairperson  
 Massachusetts General Hospital  
 Harvard Medical School

7:05AM **Brain Matters**  
 Helen S. Mayberg, MD, FRCP(C)  
 Rotman Research Institute  
 University of Toronto

7:25AM **Gender Matters**  
 Susan G. Kornblith, MD  
 Program Co-Chairperson  
 Medical College of Virginia Campus  
 Virginia Commonwealth University

7:45AM **Time Matters**  
 Benny Laker, MD  
 Institute of Psychiatry  
 University of São Paulo Medical School

8:05AM **Question and Answer Session**  
 8:30AM **Program Adjournment**

**Tuesday, May 20, 2003**

**Part Two**

6:30AM-7:00AM Breakfast

7:00AM **Welcome and Introduction**  
 Andrew A. Nierenberg, MD  
 Program Chairperson

7:15AM **Bipolarity Matters**  
 Lori L. Altschuler, MD  
 University of California, Los Angeles

7:40AM **Treatment Matters**  
 Andrew A. Nierenberg, MD  
 Program Chairperson

8:05AM **Question and Answer Session**  
 8:30AM **Program Adjournment**

**Learning Objectives**

Upon completion of these programs, participants should be able to:

1. Identify the characteristics and burden of those difficult to treat depressions and describe the clinical challenges associated with the more difficult to treat depression, including bipolar depression, treatment-resistant depression, and psychotic depression.
2. Understand and recognize imaging approaches to the study of brain changes in treatment-resistant depression.
3. Understand gender differences in the evaluation and treatment of depression.
4. Recognize the importance of time to response, the appropriate time to switch or optimize, and the duration of acute and maintenance treatments in the clinical management of major depression.
5. Recognize the symptoms of bipolar depression, be familiar with the literature on treatment approaches to bipolar depression, and be aware of potential augmentation strategies in treating resistant bipolar depression.
6. Identify the differences in the benefits and risks of antidepressants and the optimal treatment tactics to obtain remission.

**Accreditation Statement**  
 The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

**Credit Designation Statement**  
 The APA designates each part of this educational activity for a maximum of 1.5 category 1 credits toward the AMA Physician's Recognition Award and for the CME requirement of the APA. Each physician should claim only those credits that he/she actually spent in the activity.

Sponsored by the American Psychiatric Association  
 Supported by an unrestricted educational grant from Eli Lilly and Company



Attendees must be registered for the APA Annual Meeting to attend this symposium. Seating is limited and will be based on first-come, first-served. For more information about the meeting, please visit the APA Web site at [www.psych.org](http://www.psych.org) or contact the APA toll free at 1-888-357-7924 (within the US or Canada) or 703-907-7300.

**INDUSTRY-SUPPORTED SYMPOSIUM 33**  
**Monday, May 19, and Tuesday, May 20, 7:00 a.m. - 8:30 a.m.**  
**Salon 9, Lower B-2 Level, Marriott**

Presented at the APA  
156th Annual Meeting

**EVIDENCE-BASED TREATMENT OF PSYCHIATRIC DISORDERS**  
**PARTS 1 & 2**



**Monday, May 19, and Tuesday, May 20, 2003**  
**7:00 AM - 8:30 AM**  
**San Francisco Marriott, Salon 9, Lower B-2 Level**  
**San Francisco, California**

**Faculty and Agenda:**

**Monday May 19, 2003**

6:30 AM - 7:00 AM  
7:00 AM - 8:05 AM

**Part 1**

Breakfast:

**Evidence-Based Medicine: What is It?**  
Ranga R. Krishnan, MD, Chairperson  
Durham, North Carolina

**Evidence-Based Medicine and Depression Treatments**

Michael E. Thase, MD  
Pittsburgh, Pennsylvania

**Evidence-Based Medicine: Schizophrenia**

Richard S. Keefe, PhD  
Durham, North Carolina

Question-and-Answer Session

8:05 AM - 8:30 AM

**Tuesday May 20, 2003**

8:30 AM - 7:00 AM  
7:00 AM - 8:05 AM

**Part 2**

Breakfast:

**Evidence-Supportive Therapies for GAD and Social Anxiety Disorder**

Jack M. Gorman, MD  
New York, New York

**Evidence-Based ECT and Transcranial**

**Magnetic Stimulation**

Sarah H. Lisanby, MD  
New York, New York

Question-and-Answer Session

8:05 AM - 8:30 AM



Sponsored by the American Psychiatric Association  
Supported by an unrestricted educational grant from Wyeth Pharmaceuticals

**Overview:**

This symposium will focus on developing and evaluating the evidence base for the management of various psychiatric disorders. Evidence-based medicine is not cookbook medicine. It is also not a cost-cutting venture. It is the integration of best evidence with the best clinical knowledge to enhance the treatment of patients. In this symposium, Dr. Ranga Krishnan will first give an overview of what evidence-based medicine is. He will describe how it is practiced and how to ask questions, evaluate the evidence, appraise it, and use it to make decisions. Dr. Michael Thase will then describe the evidence for different treatment modalities in the management of unipolar depression. Dr. Jack Gorman will describe the evidence for different treatment modalities for generalized anxiety disorders and social phobia. Dr. Richard Keefe will describe what the evidence is for case management psychotherapy and atypical medication use in the short-term and long-term management of schizophrenia. Dr. Sarah Lisanby will describe the evidence for the use of electroconvulsive therapy (ECT) and transcranial magnetic stimulation in mood disorder.

**Target Audience:**

This activity is designed specifically for psychiatrists.

**Learning Objectives:**

Upon completion of this symposium, the participants should be able to:

- Understand the principles of evidence-based medicine

**Accreditation:**

The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The APA designates this educational activity for a maximum of 3 category 1 credits towards the AMA Physician Recognition Award and for the CME requirement of the APA. Each physician should claim only those credits that he/she actually spent in the educational activity.

**Registration Policy:**

Attendees must be registered for the APA Annual Meeting to attend this symposium. Seating is limited and will be based on first-come, first-served. For more information about the meeting, please visit the APA website at [www.psych.org](http://www.psych.org) or contact the APA toll-free at (888) 357-7924 (within the US or Canada) or (703) 907-7300.

**INDUSTRY-SUPPORTED SYMPOSIUM 34**  
**Monday, May 19, and Tuesday, May 20, 7:00 a.m. - 8:30 a.m.**  
**Grand Ballroom, Mezzanine Level, Westin St. Francis**



APA 2003  
Annual  
Meeting

Sponsored by the  
American Psychiatric Association

**Managing Anxiety and Sleep:**  
**A New Era for Gamma-Aminobutyric Acid**

**Educational Council**

Chairperson

**Philip T. Ninan, MD**

Emory University  
Atlanta, GA

**Linda Chang, MD**

Brookhaven National  
Laboratory  
Upton, NY

**Jed E. Black, MD**

Stanford University  
Stanford, CA

**Stephen M. Stahl, MD, PhD**

Neuroscience Education Institute  
University of California, San Diego  
Carlsbad, CA

**Educational Objectives:**

At the conclusion of this symposium, the participant should be able to:

- Describe the physiologic and potential pathophysiologic roles of GABA.
- Explain the differences between the management of neuropsychiatric syndromes versus symptoms, particularly with novel GABAergic medications.

**Participation**

Attendees must be registered for the APA Annual Meeting to attend this symposium. Seating is limited and will be based on first-come, first-served. For more information about the meeting, please visit the APA website at [www.psych.org](http://www.psych.org) or contact the APA toll-free at 1-888-357-7924 (within the U.S. or Canada) or 703-907-7300.

The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The APA designates this educational activity for a maximum of 3 category 1 credits toward the AMA Physician Recognition Award and for the CME requirement of the APA. Each physician should claim only those credits that he/she actually spent in the activity.

**Agenda**

**Monday, May 19, 2003**

Breakfast will be served from 6:30am to 7:00am

7:00am-7:10am

Welcome & Introduction

**Philip T. Ninan, MD**

7:10am-7:35am

Nuances of Inhibition: Gamma-Aminobutyric Acid in the Human Brain

**Philip T. Ninan, MD**

7:35am-8:00am

Gamma-Aminobutyric Acid Mechanisms in Sleep Disorders

**Jed E. Black, MD**

8:00am-8:30am

Questions & Answers, Panel

**Tuesday, May 20, 2003**

Breakfast will be served from 6:30am to 7:00am

7:00am-7:10am

Welcome & Introduction

**Philip T. Ninan, MD**

7:10am-7:35am

Novel Gamma-Aminobutyric Acid Treatments in Neuropsychiatric Disorders

**Stephen M. Stahl, MD**

7:35am-8:00am

In Vivo Measurements of Gamma-Aminobutyric Acid in Neuropsychiatric Disorders

**Linda Chang, MD**


8:00am-8:30am

Questions & Answers, Panel

**Cephalon** - Supported by an unrestricted educational grant from Cephalon, Inc.

**INDUSTRY-SUPPORTED SYMPOSIUM 35**  
**Tuesday, May 20, 7:00 p.m. - 10:00 p.m.**  
**Gateway Ballroom, Exhibit Level, Moscone Center**

A symposium to be held during the APA 2003 Annual Meeting



**Tuesday, May 20, 2003**  
**Gateway Ballroom**  
**Moscone Center**  
**San Francisco, CA**

## Facing Unmet Needs: Atypical Antipsychotics for Mood and Anxiety





### Agenda

<p>6:30 – 7:00 PM <b>Dinner</b></p> <p>7:00 – 7:10 PM <b>Welcome and Introduction</b> Mark Pollack, MD (Chair) Massachusetts General Hospital</p> <p>7:10 – 7:35 PM <b>Mechanism of Action of Atypical Antipsychotics in Mood and Anxiety Disorders</b> Pierre Blier, MD, PhD University of Florida McKnight Brain Institute</p> <p>7:35 – 8:00 PM <b>Use of Atypical Antipsychotics in Mood Disorders</b> Charles B. Nemeroff, MD, PhD Emory University School of Medicine</p>	<p>8:00 – 8:25 PM <b>Treatment of Anxiety Disorders: Therapeutic Challenges for the Future</b> Olga Brawman-Mintzer, MD Medical University of South Carolina</p> <p>8:25 – 8:50 PM <b>Atypical Antipsychotics in PTSD: Rationale and Role</b> Murray B. Stein, MD University of CA, San Diego School of Medicine</p> <p>8:50 – 9:15 PM <b>Working With the Patient as a Cotherapist: Strategies to Enhance Treatment Adherence</b> Michael W. Otto, PhD Massachusetts General Hospital</p>	<p>9:15 – 10:00 PM <b>Questions and Answers</b></p> <p><b>At the conclusion of this symposium, the participant should be able to:</b></p> <ul style="list-style-type: none"> <li>■ Discuss the benefits, as well as limitations, of the current therapeutic modalities for the treatment of mood and anxiety disorders</li> <li>■ Examine the potential role of atypical antipsychotics to improve patient outcomes</li> </ul>
---	--	--

The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The APA designates this educational activity for a maximum of 3 category 1 credits toward the AMA Physician's Recognition Award and for the CME requirement of the APA. Each physician should claim only those credits that he/she actually spent in the educational activity.

Attendees must be registered for the APA Annual Meeting to attend this symposium. Seating is limited and will be on a first-come-first-serve basis. For more information about the meeting, please visit the APA website at [www.psych.org](http://www.psych.org) or contact the APA toll free at 1-888-357-7924 (within the U.S. or Canada) or at 703-907-7300.

Supported by an unrestricted educational grant from **JANSSEN**    Sponsored by the American Psychiatric Association 

RS-11780

**INDUSTRY-SUPPORTED SYMPOSIUM 36**  
**Tuesday, May 20, 7:00 p.m. - 10:00 p.m.**  
**Hall E, Exhibit Level, Moscone Center**

## Bipolar Disorders

### Across the Life Cycle

*Tuesday, May 20th, 2003*

Hall E, Exhibit Level, Moscone Center

**LEARNING OBJECTIVES**


- Discuss the impact of early diagnosis and comorbidities on a bipolar disorder patient's course of illness.
- Review pharmacologic treatment strategies for bipolar disorder throughout phases of the illness and life cycle.


**CREDIT DESIGNATION**

The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The APA designates this educational activity for a maximum of 3 category 1 credits towards the AMA Physician's Recognition Award and for the CME requirement of the APA. Each physician should claim only those credits that he/she actually spent in the educational activity.

*Attendees must be registered for the APA Annual Meeting to attend this symposium. Seating is limited and will be based on first-come, first-served. For more information about the meeting, please visit the APA Website at [www.psych.org](http://www.psych.org) or contact the APA toll-free at 1-888-357-7924 (within the US or Canada) or 703-907-7300.*

 This activity is supported by an unrestricted educational grant from Abbott Laboratories.

 Sponsored by the American Psychiatric Association and held at the APA 2003 Annual Meeting.

<p>6:30 – 7:00 PM <b>Dinner</b></p> <p>7:00 – 7:30 PM <b>Introduction</b></p> <p>7:30 – 8:10 PM <b>Reproductive Health and Metabolic Correlates in Women Receiving Treatment for Bipolar Disorder</b> Natalie Rasgon, MD, PhD Stanford University School of Medicine</p> <p>8:30 – 8:45 PM <b>Bipolar Disorders in Adulthood</b> John M. Zajecka, MD Rush-Presbyterian-St. Luke's Medical Center</p> <p>8:45 – 8:50 PM <b>Secondary Manias and Comorbid Conditions</b> James C.-Y. Chou, MD New York University School of Medicine</p> <p>8:50 – 9:15 PM <b>Combination Treatments: What to Use and When</b> Joseph R. Calabrese, MD Case Western Reserve School of Medicine</p> <p>9:15 – 9:30 PM <b>Management of Side Effects and Treating to Wellness</b> Charles L. Bowden, MD – Program Chairman The University of Texas Health Science Center</p> <p>9:30 – 10:00 PM <b>Q &amp; A</b></p>
--

**INDUSTRY-SUPPORTED SYMPOSIUM 37**  
**Tuesday, May 20, 7:00 p.m. - 10:00 p.m.**  
**Metropolitan, Second Level, Argent**

**INVITATION** Slowing Disease Progression and the Long-term Management of Dementia

Tuesday, May 20, 2003  
 7:00-10:00 PM  
 Metropolitan Ballroom  
 Argent Hotel  
 San Francisco  
 Dinner: 6:30-7:00 PM



APA 2003 Annual Meeting

- 7:00 Chairs' Welcome**  
*Steven G Potkin, MD; Professor and Director of Clinical Research, and Robert R. Sprague Director; Brain Imaging Center; University of California, Irvine; California*
- 7:10 Mechanisms of Disease Progression in Dementia\***  
*Nigel H Greig, PhD; Chief of Drug Design and Development Section; National Institute on Aging; Baltimore, Maryland*
- 7:40 Targeting Cholinergic Therapy to Slow Disease Progression\***  
*Steven G Potkin, MD, as above*
- 8:10 Brain Imaging and CSF Cholinesterase Inhibition: Long-term Data\***  
*Agneta Nordberg, MD; Professor of Clinical Neuroscience; Huddinge University Hospital; Karolinska Institute; Stockholm, Sweden*
- 8:40 A Critical Review of the Long-Term Data with Cholinesterase Inhibitors\***  
*P Murali Doraiswamy, MD; Chief, Division of Biological Psychiatry, Department of Psychiatry; Duke University Medical Center; Durham, North Carolina*
- 9:10 Questions and Answers**

Attendees must be registered for the APA Annual Meeting to attend this symposium. Seating is limited and will be based on first-come, first-served. For more information about the meeting, please visit the APA website at [www.psych.org](http://www.psych.org) or contact the APA toll free at 1-888-357-7924 (within the US or Canada) or 703-907-7300.

Sponsored by the American Psychiatric Association.

Supported by an unrestricted educational grant from Novartis Pharmaceuticals Corporation.

The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The APA designates this educational activity for a maximum of 3 category 1 credits towards the AMA Physician's Recognition Award and for the CME requirement of the APA. Each physician should claim only those credits that he/she actually spent in the activity.

After attending this symposium, the participant should be able to:

- \*Describe the neurobiologic and neurochemical changes associated with the progression of dementia, the role of cholinesterase (ChE) enzymes in Alzheimer's disease, and the impact of inhibiting such enzymes
- \*Discuss the pharmacologic and pharmacokinetic differences among ChE inhibitors and how such differences may be harnessed to tailor treatment to individual patient needs
- \*Define the roles of neuroimaging and assessment of central ChE activities and cognitive function in monitoring therapeutic interventions during long-term treatment of dementia
- \*Explain how symptomatic benefits of cholinergic therapy can be maintained over the long term by customized treatment strategies including dose changes, switching, and combination therapy



**INDUSTRY-SUPPORTED SYMPOSIUM 38**  
**Tuesday, May 20, 7:00 p.m. - 10:00 p.m.**  
**Grand Ballroom Salon B, Grand Ballroom Level, Hilton**

APA 156th Annual Meeting

**OPTIMIZING TREATMENT FOR PATIENTS WITH SCHIZOPHRENIA: TARGETING POSITIVE OUTCOMES**

Attendees must be registered for the APA Annual Meeting to attend this symposium. Seating is limited and will be on a first-come, first-served basis. For more information about the meeting, please visit the APA Web site at [www.psych.org](http://www.psych.org) or contact the APA toll free at 1-888-357-7924 (within the United States or Canada) or at 703-907-7300.

The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The APA designates this educational activity for a maximum of 3 category 1 credits towards the AMA Physician's Recognition Award and for the CME requirement of the APA. Each physician should claim only those hours of credit that he/she actually spent in the educational activity.

**TUESDAY, MAY 20, 2003**  
 6:30-7:00 pm Dinner; 7:00-10:00 pm Symposium  
 Hilton San Francisco, Grand Ballroom Salon B, Grand Ballroom Level  
 San Francisco, California

**SCHIZOPHRENIA:**  
**TARGETING POSITIVE OUTCOMES**

**6:30-7:00 PM DINNER**

- 7:00 WELCOME AND INTRODUCTION**  
 Daniel E. Casey, MD, Program Chairperson  
 Chief, Psychiatry Research/Psychopharmacology  
 Associate Director of Research, VISN 20 MIRECC  
 Veterans Affairs Medical Center, Portland, Oregon
- 7:15 THE SCIENCE OF ANTIPSYCHOTICS: MECHANISTIC INSIGHT**  
 Daniel E. Casey, MD
- 7:35 MANAGEMENT OF ACUTE PSYCHOSIS FROM EMERGENCY TO STABILIZATION**  
 Dan L. Zimbroff, MD  
 Medical Director  
 Pacific Clinical Research Medical Group  
 San Bernardino, California
- 7:55 BEYOND CONTROL OF ACUTE EXACERBATION: ENHANCING AFFECTIVE AND COGNITIVE OUTCOMES**  
 Herbert Meltzer, MD  
 Bixler Professor of Psychiatry and Pharmacology  
 Director, Division of Psychopharmacology  
 Department of Psychiatry  
 Vanderbilt University School of Medicine  
 Nashville, Tennessee

**OBJECTIVES**

At the conclusion of this symposium, participants should be able to:


- Describe the history of antipsychotics and recognize how the role of receptors has formed the basis for the development of effective treatments for patients with schizophrenia.
- Discuss the challenges of stabilizing and managing the acute psychotic patient.
- Review the effective treatments to produce positive outcomes in the areas of cognition and affect for patients with schizophrenia.
- Recognize the impact of stabilizing on antipsychotic medication selection.
- Identify the key factors that should be assessed in schizophrenic patients and the propensity of different antipsychotic medications to elicit diabetes, and metabolic syndrome.
- Describe the goals of long-term therapy for persons with schizophrenia.

- 8:15 FACTORS IN ANTIPSYCHOTIC DRUG SELECTION: TOLERABILITY CONSIDERATIONS**  
 Henry A. Nasrallah, MD  
 Professor of Psychiatry, Neurology, and Internal Medicine  
 Chief, Mental Health Services  
 VA Medical Center, Jackson, Mississippi
- 8:35 OBESITY, DIABETES, AND METABOLIC SYNDROME: NEW CHALLENGES IN ANTIPSYCHOTIC DRUG THERAPY**  
 Enrique Caballero, MD  
 Instructor in Medicine, Harvard Medical School  
 Endocrinologist/Researcher, Joslin Diabetes Center  
 Boston, Massachusetts
- 8:55 LONG-TERM TREATMENT GOALS: ENHANCING HEALTHY OUTCOMES**  
 Carol Tamminga, MD  
 Professor, Department of Psychiatry  
 University of Maryland School of Medicine  
 Deputy Director  
 Maryland Psychiatric Research Center  
 Baltimore, Maryland
- 9:15 QUESTION AND ANSWER SESSION**
- 10:00 ADJOURNMENT**





**INDUSTRY-SUPPORTED SYMPOSIUM 39**  
**Tuesday, May 20, 7:00 p.m. - 10:00 p.m.**  
**Continental Ballroom, Ballroom Level, Hilton**



SAN FRANCISCO

## Biologic and Psychologic Advances in the Treatment of Schizophrenia:

*Revisiting and Updating Meyer's Psychobiology for the 21st Century*

Tuesday, May 20, 2003

Hilton San Francisco  
333 O'Farrell Street  
Continental Ballroom

Dinner: 6:30 PM - 7:00 PM  
Symposium: 7:00 PM - 10:00 PM

Chair: Peter J. Weiden, MD

APA 2003  
ANNUAL  
MEETING

**Agenda**

7:00 PM **Welcome and Introductions: Models of the Mind and Meyer's Psychobiology**  
Peter J. Weiden, MD  
State University of New York Health Science Center at Brooklyn

7:10 PM **Biologic Mechanisms of Psychosis: From Dopamine Excess to Dopamine Stabilization**  
Bryan L. Roth, MD, PhD  
Case Western Reserve University School of Medicine

7:35 PM **What is an Adequate Treatment Response? Establishing Therapeutic Goals in Schizophrenia**  
Peter J. Weiden, MD

8:00 PM **Psychologic Mechanisms of Psychosis: Implications for Psychotherapeutic Intervention**  
Douglas Turkington, FRCPsych  
University of Newcastle-upon-Tyne

8:25 PM **Long-Term Treatment of Schizophrenia: Moving from a Relapse Prevention Model to a Recovery Model**  
John M. Kane, MD  
Albert Einstein College of Medicine

8:50 PM **Diagnostic Boundaries Between Bipolar Disorder and Schizophrenia: Implications for Pharmacologic Intervention**  
Stephen M. Strakowski, MD  
University of Cincinnati College of Medicine

9:15 PM **Q&A/Panel Discussion**

**Learning Objectives**

*After completion of this symposium, the participants should be better able to*

- State the goals and potential symptomatic benefits that can be achieved with the use of CBT as an adjunct to antipsychotic medication in the management of patients with schizophrenia
- Understand the mechanisms of action of currently available and newer antipsychotic medications, and how these mechanisms result in both efficacy and side effects profiles
- Understand how clinical trial data can be used to optimize care and the limitations in adaptation of such information to clinical practice
- Discuss the barriers that exist in the pharmacologic and psychosocial management of psychotic disorders, how they influence patients' overall health, and potential ways to overcome these barriers




■ Discuss the appropriate use of the newer antipsychotic agents, alone and in combination with other agents, in the management of a range of neurologic and psychiatric disorders

The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The APA designates this educational activity for a maximum of 3 category 1 credits toward the AMA Physician Recognition Award and for the CME requirement of the APA. Each physician should claim only those credits that he/she actually spent in the activity.

Attendees must be registered for the APA Annual Meeting to attend this symposium. Seating is limited and will be based on first-come, first-served. For more information about the meeting, please visit the APA website at [www.psych.org](http://www.psych.org) or contact the APA toll free at 1-888-357-7924 (within the U.S. or Canada) or 703-907-7300.

Supported by an unrestricted educational grant from Bristol-Myers Squibb Company and Otsuka America Pharmaceutical, Inc.

**INDUSTRY-SUPPORTED SYMPOSIUM 40**  
**Tuesday, May 20, 7:00 p.m. - 10:00 p.m.**  
**Salons 7 & 8, Lower B-2 Level, Marriott**

## REAL-WORLD CHALLENGES IN DEPRESSION AND ANXIETY

*A dinner symposium to be held at the American Psychiatric Association 156th Annual Meeting*

*Sponsored by the American Psychiatric Association*


**TUESDAY, MAY 20, 2003**  
7:00 PM - 10:00 PM

**San Francisco Marriott**  
Salons 7 & 8, Lower B-2 Level  
San Francisco, California

**PROGRAM OBJECTIVES**

After attending this continuing medical education program, the psychiatrist should be able to:

- Recognize the importance of early diagnosis and treatment of social anxiety disorder
- Understand the bidirectional comorbidity of medical illnesses and mood and anxiety disorders
- Demonstrate the risk factors for late-life depression and discuss treatment strategies
- Discuss the issues associated with treating the depressive component of bipolar disorder.



The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The APA designates this educational activity for a maximum of 3 category 1 credits toward the AMA Physician Recognition Award and for the CME requirement of the APA. Each physician should claim only those credits that he/she actually spent in the activity. Attendees must be registered for the APA Annual Meeting to attend this symposium. Seating is limited and will be based on first-come, first-served. For more information about the meeting, please visit the APA website at [www.psych.org](http://www.psych.org) or contact the APA toll free at 1-888-357-7924 (within the US or Canada) or 703-907-7300.

*Supported by an unrestricted educational grant from GlaxoSmithKline*

**AGENDA**

6:30 PM - 7:00 PM **Dinner**

7:00 PM **Welcome and Program Introduction**  
DAVID L. DUNNER, MD  
*Symposium Chair*  
University of Washington

7:05 PM **Long-Term Consequences of Social Anxiety Disorder: Breaking the Cycle**  
KAREN DINEEN WAGNER, MD, PhD  
University of Texas Medical Branch

7:35 PM **Depression and Anxiety in Medical Illness: The Brain-Body Interface**  
PRAKASH S. MASAND, MD  
Duke University Medical Center

8:05 PM **Overcoming Stigma and Optimizing Outcome in Late-Life Depression**  
LORI BIRDSONG, MD  
University of Washington

8:35 PM **The Clinical Challenge of Depression in Bipolar Disorder**  
DAVID L. DUNNER, MD

9:05 PM **Panel Discussion With Questions and Answers**

9:50 PM **Closing Remarks, Adjournment**  
DAVID L. DUNNER, MD

**INDUSTRY-SUPPORTED SYMPOSIUM 41**  
**Tuesday, May 20, 7:00 p.m. - 10:00 p.m.**  
**Salon 9, Lower B-2 Level, Marriott**

Presented at the APA  
 156th Annual Meeting

**WOMEN AND PSYCHIATRIC DISORDERS**  
**Does Gender Matter to Treatment?**



**Tuesday, May 20, 2003 • 7:00 PM - 10:00 PM**

San Francisco Marriott, Salon 9, Lower B-2 Level  
 San Francisco, California

**Faculty and Agenda:**

- 6:30 PM - 7:00 PM Dinner
- 7:00 PM - 7:30 PM **Hormones and the Brain**  
Meir Steiner, MD - Hamilton, Canada
- 7:30 PM - 8:00 PM **Sex, Hormones, and Depression: The Impact of Sex Steroids on Mood Across the Reproductive Life Cycle**  
Claudio N. Soares, MD - Boston, Massachusetts
- 8:00 PM - 8:25 PM **Trauma and Posttraumatic Stress Disorder in Women**  
Shamasah B. Sonwalla, MD - Boston, Massachusetts
- 8:25 PM - 8:50 PM **Women and Alcohol Use Disorders**  
Shelly F. Greenfield, MD - Belmont, Massachusetts
- 8:50 PM - 9:15 PM **Does Gender Matter to Treatment?**  
Jerrold F. Rosenbaum, MD, Chairperson - Boston, Massachusetts  
(individual discussions to follow each presentation.)
- 9:15 PM - 10:00 PM **Wrap-up Question-and-Answer Session**

**Target Audience:**

This activity is designed specifically for psychiatrists.

**Learning Objectives:**

Upon completion of this symposium, the participants should be able to:

- Appreciate the extent to which gender may affect the phenomenology and response to treatment across a spectrum of psychiatric disorders



Sponsored by the American Psychiatric Association  
 Supported by an unrestricted educational grant from Wyeth Pharmaceuticals

**Overview:**

This symposium will examine gender-based differences in risk for psychiatric disorders and response to treatment. The complex interaction between female reproductive biology and other factors which may contribute to emergence of psychiatric disorders, including past history of psychiatric illness and a wide spectrum of psychosocial variables, are also being studied. This symposium will include presentations that highlight advances in previously understudied areas in women's mental health. Dr. Meir Steiner will provide a conceptual framework for understanding the basis by which gonadal steroids may affect central nervous system neuromodulation across the life cycle of women. Dr. Claudio Soares will review recent findings which evaluate the potential role of estrogen as a treatment for reproductive-associated mood disturbance in both younger and older populations of women. Dr. Shamasah Sonwallah will present an overview of recent systematic studies of trauma in women, including the pathophysiology of posttraumatic stress disorder and its treatment. Dr. Shelly Greenfield will address special considerations with respect to the recognition and management of alcohol abuse in women. Lastly, Dr. Jerrold F. Rosenbaum will speak about the various factors which may contribute to gender and culturally based differences in clinical presentation of psychiatric disorder in women, as well as potential mechanisms which may underlie differences in response to treatment for mood disorder across populations of women, particularly those treated with different classes of antidepressants.

**Accreditation:**

The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The APA designates this educational activity for a maximum of 3 category 1 credits towards the AMA Physician Recognition Award and for the CME requirement of the APA. Each physician should claim only those credits that he/she actually spent in the educational activity.

**Registration Policy:**

Attendees must be registered for the APA Annual Meeting to attend this symposium. Seating is limited and will be based on first-come, first-served. For more information about the meeting, please visit the APA website at [www.psych.org](http://www.psych.org) or contact the APA toll-free at (888) 357-7924 (within the US or Canada) or (703) 907-7300.

**INDUSTRY-SUPPORTED SYMPOSIUM 42**  
**Wednesday, May 21, and Thursday, May 22, 7:00 a.m. - 8:30 a.m.**  
**Gateway Ballroom, Exhibit Level, Moscone Center**

A symposium to be held during the APA 2003 Annual Meeting

Wednesday, May 21, 2003,  
 and Thursday, May 22, 2003  
 Gateway Ballroom  
 Moscone Center  
 San Francisco, CA

## Neuropsychiatry in the Age of Polypharmacy

**Agenda, Day 1**

6:30 - 7:00 AM  
**Breakfast**

7:00 - 7:05 AM  
**Welcome and Introduction**  
 Prakash Masand, MD (Chair)  
 Duke University Medical Center

7:05 - 7:35 AM  
**An Evidence-Based Approach to Rational Polypharmacy in Schizophrenia**  
 Prakash Masand, MD

7:35 - 8:05 AM  
**Polypharmacy in the Treatment of Bipolar Disorder**  
 Andrew L. Stoll, MD  
 Harvard Medical School

8:05 - 8:30 AM  
**Questions and Answers**

**Agenda, Day 2**

6:30 - 7:00 AM  
**Breakfast**

7:00 - 7:05 AM  
**Welcome and Introduction**  
 Prakash Masand, MD (Chair)  
 Duke University Medical Center

7:05 - 7:35 AM  
**Polypharmacy in the Treatment of Major Depression**  
 Mark H. Rapaport, MD  
 Cedars-Sinai Medical Center

7:35 - 8:05 AM  
**Combination Therapy for Alzheimer's Disease: What Are We Waiting For?**  
 P. Murali Doraiswamy, MD  
 Duke University Medical Center

8:05 - 8:30 AM  
**Questions and Answers**

**At the conclusion of this symposium, the participant should be able to:**

- Discuss the rationale for combining medications from different or the same chemical classes in treatment of psychiatric disorders based on the mechanisms of action and potential efficacy and safety benefits
- Identify gaps in the evidence supporting polypharmacologic approaches to the management of several important mental illnesses

The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The APA designates this educational activity for a maximum of 3 category 1 credits toward the AMA Physician's Recognition Award and for the CME requirement of the APA. Each physician should claim only those credits that he/she actually spent in the educational activity.


Attendees must be registered for the APA Annual Meeting to attend this symposium. Seating is limited and will be on a first-come-first-serve basis. For more information about the meeting, please visit the APA website at [www.psych.org](http://www.psych.org) or contact the APA toll free at 1-888-357-7924 (within the U.S. or Canada) or at 703-907-7300.

Supported by an unrestricted educational grant from **JANSSEN**

Sponsored by the American Psychiatric Association

RS-1178F

**INDUSTRY-SUPPORTED SYMPOSIUM 43**  
**Wednesday, May 21, and Thursday, May 22, 7:00 a.m. - 8:30 a.m.**  
**Hall E, Exhibit Level, Moscone Center**



**Treating  
ADHD  
Across the  
Life Cycle**

Part I: May 21, 2003  
 Part II: May 22, 2003  
 6:30 AM - 7:00 AM  
 Breakfast  
 7:00 AM - 8:30 AM  
 Scientific Program

A CME Breakfast Symposium at the APA 2003 Annual Meeting  
 Moscone Convention Center • Hall E • Exhibit Level  
 San Francisco, CA

**Registration**  
 Attendees must be registered for the APA Annual Meeting to attend this symposium. Seating is limited and will be based on first-come, first-served. For more information about the meeting, please visit the APA website at [www.psych.org](http://www.psych.org) or contact the APA toll free at 1-888-357-7924 (within the US or Canada) or 703-907-7300.

**Accreditation**  
 The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.  
 The APA designates this educational activity for a maximum of 3 category 1 credits toward the AMA Physician's Recognition Award and for the CME requirement of the APA. Each physician should claim only those credits that he/she actually spent in the activity.

**Agenda**

**May 21, 2003 — Part I**


6:30 AM	Breakfast
7:00 AM	Welcome and Introduction <i>Thomas J. Spencer, MD, Massachusetts General Hospital</i>
7:10 AM	Pathophysiology of ADHD <i>Stephen V. Faraone, PhD, Massachusetts General Hospital</i>
7:40 AM	ADHD From Childhood to Adolescence: Developmental Issues in Clinical Presentation <i>Russell A. Barkley, PhD, Medical University of South Carolina</i>
8:10 AM	Panel Discussion and Questions From the Audience
8:30 AM	Conclusion of Part I

**May 22, 2003 — Part II**


6:30 AM	Breakfast
7:00 AM	Welcome and Review of Part I <i>Thomas J. Spencer, MD</i>
7:10 AM	ADHD in Adults: Developmental Issues in Clinical Presentation <i>Thomas J. Spencer, MD</i>
7:40 AM	Treatment Options: Evolving Treatments for a Changing Disease <i>Joseph Biederman, MD, Massachusetts General Hospital</i>
8:10 AM	Panel Discussion and Questions From the Audience
8:30 AM	Conclusion of Program

At the conclusion of this symposium, participants should be able to:

- Recognize the pathophysiology of ADHD
- Describe ADHD developmental issues in children, adolescents, and adults
- Compare emerging treatment options for ADHD




Supported by an unrestricted educational grant from Novartis



Sponsored by the American Psychiatric Association

**INDUSTRY-SUPPORTED SYMPOSIUM 44**  
**Wednesday, May 21, and Thursday, May 22, 7:00 a.m. - 8:30 a.m.**  
**Grand Ballroom Salon B, Grand Ballroom Level, Hilton**

## Insomnia in Today's Society: Consequences and Treatments




**Agenda**

Wednesday, May 21, 2003	Thursday, May 22, 2003
6:30-7:00 AM Breakfast	6:30-7:00 AM Breakfast
7:00 <b>Welcome and Introduction</b> <i>Gregory M. Acses, MD, Gatchapeian Professor of Psychiatry, Director, Anxiety and Depression Program, Montefiore Medical Center, Bronx, New York</i>	7:00 <b>Welcome and Introduction</b> <i>Shari R. Kohn, PhD, Gatchapeian Assistant Professor of Psychiatry and Behavioral Sciences, Montefiore Medical Center, Department of Psychiatry, Bronx, New York</i>
7:05 <b>The Importance of Identifying and Treating Insomnia</b> <i>David N. Jaydson, MD, Associate Director, Johns Hopkins Sleep Disorders Center, Johns Hopkins University, Baltimore, Maryland</i>	7:05 <b>Cognitive-Behavioral Therapy of Insomnia</b> <i>Shari R. Kohn, PhD</i>
7:35 <b>Pharmacotherapy of Insomnia</b> <i>Gregory M. Acses, MD</i>	7:35 <b>When to Refer a Patient with Insomnia to a Sleep Specialist Laboratory</b> <i>Michael J. Thorpy, MD, Director, Sleep-Wake Disorders Center, Montefiore Medical Center, Department of Neurology, Bronx, New York</i>
8:05 <b>Question and Answer Session</b>	8:05 <b>Question and Answer Session</b>
8:30 <b>Adjournment</b>	8:30 <b>Adjournment</b>

**APA 156th Annual Meeting**  
 May 21-22, 2003  
 7:00-8:30 AM  
 Hilton San Francisco  
 Grand Ballroom Salon B  
 Grand Ballroom Level  
 San Francisco, California

**Objectives**  
 At the conclusion of this symposium, participants should be able to:

- Understand the interrelationship between insomnia and psychiatric disorders;
- Attain knowledge of the available pharmacological treatments for insomnia;
- Use various cognitive-behavioral treatments for insomnia;
- Recognize when to refer insomnia patients to a sleep specialist.



Sponsored by the American Psychiatric Association

Supported by an unrestricted educational grant from Sanofi-Synthelabo, Inc.


**sanofi-synthelabo**

Attendees must be registered for the APA Annual Meeting to attend this symposium. Seating is limited and will be on a first-come, first-served basis. For more information about the meeting, please visit the APA Web site at [www.psych.org](http://www.psych.org) or contact the APA toll free at 1-888-357-7924 (within the United States or Canada) or 703-907-7300.

The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The APA designates this educational activity for a maximum of 3 category 1 credits toward the AMA Physician's Recognition Award and for the CME requirement of the APA. Each physician should claim only those credits that he/she actually spent in the educational activity.

**INDUSTRY-SUPPORTED SYMPOSIUM 45**  
**Wednesday, May 21, and Thursday, May 22, 7:00 a.m. - 8:30 a.m.**  
**Salons 7 & 8, Lower B-2 Level, Marriott**



**RECOGNITION AND TREATMENT  
PARTS 1 AND 2**


*An educational symposium to be presented  
at the 2003 Annual Meeting of the American  
Psychiatric Association*

**PART 1: WEDNESDAY, MAY 21, 2003**  
**PART 2: THURSDAY, MAY 22, 2003**  
**SAN FRANCISCO MARRIOTT**  
**SALONS 7 AND 8, LOWER B-2 LEVEL**  
**SAN FRANCISCO, CALIFORNIA**

**ACREDITATION STATEMENT**  
 The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education (CME) for physicians.  
 The APA designates this educational activity for a maximum of 3 Category 1 credits toward the AMA Physician's Recognition Award and for the CME requirement of the APA. Each physician should claim only those credits that he/she actually spent in the educational activity.  
 Attendees must be registered for the APA Annual Meeting to attend this symposium. Seating is limited and will be based on first-come, first-served. For more information about the meeting, please visit the APA website at [www.psych.org](http://www.psych.org) or contact the APA toll free at 1-888-357-7924 (within the US only) or at 703-907-7300.

**EDUCATIONAL OBJECTIVES**  
 Upon completion of the program, participants should be able to recognize factors that place patients at risk for obesity, and know what treatment options are available.

Sponsored by the American Psychiatric Association.

Supported by an unrestricted educational grant from  
  
 Ortho-McNeil Pharmaceutical, Inc.

**PROGRAM AGENDA**

**WEDNESDAY, MAY 21, 2003**

6:30 AM - 7:00 AM BREAKFAST

7:00 AM - 7:05 AM WELCOME AND INTRODUCTION  
PROGRAM CHAIRMAN  
B. TIMOTHY WALSH, MD  
Columbia University

7:05 AM - 7:20 AM OBESITY UPDATE  
ROBERT F. KUSHNER, MD  
Northwestern University Feinberg School of Medicine

7:20 AM - 7:40 AM PSYCHOTROPIC MEDICATION AND WEIGHT GAIN  
DAVID B. ALLISON, PhD  
University of Alabama at Birmingham

7:40 AM - 8:00 AM OBESITY AND PSYCHIATRIC DISORDERS  
LAUREL E. S. MAYER, MD  
Columbia University

8:00 AM - 8:05 AM SUMMARY AND CONCLUSIONS  
B. TIMOTHY WALSH, MD

8:05 AM - 8:30 AM QUESTIONS AND ANSWERS

**THURSDAY, MAY 22, 2003**

6:30 AM - 7:00 AM BREAKFAST

7:00 AM - 7:05 AM WELCOME AND INTRODUCTION  
RECAP OF MAY 21ST SESSION  
PROGRAM CHAIRMAN  
B. TIMOTHY WALSH, MD  
Columbia University

7:05 AM - 7:30 AM PSYCHOLOGICAL TREATMENT OF OBESITY AND BINGE EATING  
DENISE E. WILFLEY, PhD  
Washington University School of Medicine


7:30 AM - 8:00 AM PHARMACOTHERAPY OF OBESITY AND BINGE EATING  
SUSAN L. MCELROY, MD  
University of Cincinnati College of Medicine

8:00 AM - 8:05 AM SUMMARY AND CONCLUSIONS  
B. TIMOTHY WALSH, MD

8:05 AM - 8:30 AM QUESTIONS AND ANSWERS

**INDUSTRY-SUPPORTED SYMPOSIUM 46**  
**Wednesday, May 21, 7:00 p.m. - 10:00 p.m.**  
**Gateway Ballroom, Exhibit Level, Moscone Center**

A symposium to be held during  
the APA 2003 Annual Meeting






Wednesday, May 21, 2003  
Gateway Ballroom, Moscone Center  
San Francisco, CA

## Compassionate and Safe Emergent Care: Best Practices in Antipsychotic Use

**Agenda**

<p>6:30 - 7:00 PM <b>Dinner</b></p> <p>7:00 - 7:05 PM <b>Welcome and Introduction</b> Glenn W. Currier, MD, MPH (Chair) University of Rochester Medical Center</p> <p>7:05 - 7:25 PM <b>Can Acute Care Be Compassionate?</b> Michael H. Allen, MD University of Colorado Health Sciences Center</p> <p>7:25 - 7:45 PM <b>Can Acute Care Be Compassionate: Provider/Nurse's Perspective</b> Brad Green, MSN, APRN, BC University of San Francisco School of Nursing</p>	<p>7:45 - 8:10 PM <b>Evaluating Equivalence of Antipsychotics: Oral vs IM Administration for Acute Disorders</b> Glenn W. Currier, MD, MPH</p> <p>8:10 - 8:35 PM <b>Evidence-Based Medicine and the Evolving Standard of Care: Developing the Treatment Alliance</b> Frederick Veser, MD Medical University of South Carolina</p> <p>8:35 - 9:00 PM <b>Transitioning Patients for Long-Term Success</b> Robert R. Conley, MD University of Maryland School of Medicine</p>	<p>9:00 - 9:15 PM <b>Session Recap</b> Ira D. Glick, MD (Discussant) Stanford University School of Medicine</p> <p>9:15 - 10:00 PM <b>Questions and Answers</b></p> <p><b>At the conclusion of this symposium, the participant should be able to:</b></p> <ul style="list-style-type: none"> <li>■ Summarize currently available psychopharmacological treatment options in acute care</li> <li>■ Evaluate the equivalence of various orally and/or intramuscularly applied antipsychotic agents</li> <li>■ Identify the impact of quality of acute antipsychotic care for the success of long-term treatment</li> </ul>
--	--	--


The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.  
 The APA designates this educational activity for a maximum of 3 category 1 credits toward the AMA Physician's Recognition Award and for the CME requirement of the APA. Each physician should claim only those credits that he/she actually spent in the educational activity.  
 Attendees must be registered for the APA Annual Meeting to attend this symposium. Seating is limited and will be on a first-come-first-serve basis. For more information about the meeting, please visit the APA website at [www.psych.org](http://www.psych.org) or contact the APA toll free at 1-888-357-7924 (within the U.S. or Canada) or at 703-907-7300.  
 Supported by an unrestricted educational grant from   Sponsored by the American Psychiatric Association 

RS-1178E

**INDUSTRY-SUPPORTED SYMPOSIUM 47**  
**Wednesday, May 21, 7:00 p.m. - 10:00 p.m.**  
**Hall E, Exhibit Level, Moscone Center**

## Juvenile Bipolar Disorder: Contemporary Issues in Research

Presented at the APA 156th Annual Meeting



**Wednesday, May 21, 2003**  
**7:00 PM - 10:00 PM**  
 Moscone Center (Hall E, Exhibit Level)  
 San Francisco, California

**Faculty and Agenda**

Reception and Dinner: 6:30 PM - 7:00 PM  
 Symposium: 7:00 PM - 10:00 PM

**7:00 PM Welcome and Introduction**  
 Timothy E. Wilens, MD, Boston, Massachusetts

**7:15 PM Pediatric Mania: A Developmental Subtype of Bipolar Disorder?**  
 Joseph Biederman, MD, Boston, Massachusetts

**7:40 PM Diagnostic and Treatment Implications of Psychiatric Comorbidity in Juvenile Bipolar Disorder**  
 Timothy E. Wilens, MD, Boston, Massachusetts

**8:05 PM Treatment of Pediatric Bipolar Disorder with Anticonvulsant Mood Stabilizers**  
 Joseph M. Gonzalez-Heydrich, MD, Boston, Massachusetts

**8:30 PM The Therapeutic Role of Atypical Antipsychotic Medications in Pediatric-onset Bipolar Disorder**  
 Janet Wozniak, MD, Boston, Massachusetts

**8:55 PM Genetics of Early-onset Bipolar Disorder**  
 Stephen Faraone, PhD, Boston, Massachusetts

**9:15 PM Question-and-Answer Session**

Sponsored by the American Psychiatric Association

NOVARTIS Supported by an unrestricted educational grant from Novartis.

**Overview**  
 Despite the increasing recognition of bipolar disorder (BPD) in youth, controversy and clinical confusion exist as to its clinical presentation, comorbidity, biological underpinnings, and treatment. In this symposium, recent information on the similarities and differences of BPD in youth and adults will be evaluated. The neurobiology and familial evidence of BPD and subtypes of BPD will be explored. The literature suggests very high levels of psychiatric comorbidity with BPD in youth. The overlap of specific comorbidities with BPD will be presented, with an emphasis on the clinical presentation and treatment implications. Treatment of youths with BPD continues to be a complex issue. A review and recent work on the use of lithium and anticonvulsants—alone and in combination—in children and adolescents with BPD will be presented. Contemporary findings on the use of atypical antipsychotics in youth with BPD will also be reported, as well as data on efficacy and adverse effects of the various medications used in this group and on the treatment of special cases (eg, preschoolers, comorbidity).

**Target Audience**  
 This continuing education activity is designed for psychiatrists and other clinicians who diagnose and treat juvenile BPD.

**Learning Objectives**  
 Upon completion of this symposium, the participant should be able to understand the:

- Clinical presentation of juvenile BPD and how it relates to the adult form of the disorder
- Major comorbid conditions with BPD in youth and treatment strategies
- Treatment issues in managing mania, depression, and comorbidity in youth with BPD

**Accreditation**  
 The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The APA designates this educational activity for a maximum of 3 category 1 credits towards the AMA Physician's Recognition Award and for the CME requirements of the APA. Each physician should claim only those credits that he/she actually spent in the educational activity.

**Registration Policy**  
 Attendees must be registered for the APA Annual Meeting to attend this symposium. Seating is limited and will be on a first-come, first-served basis. For more information about the meeting, please visit the APA Web site at [www.psych.org](http://www.psych.org) or contact the APA toll-free at (888) 357-7924 (within the US or Canada) or (703) 907-7300.

**INDUSTRY-SUPPORTED SYMPOSIUM 48**  
**Wednesday, May 21, 7:00 p.m. - 10:00 p.m.**  
**Metropolitan, Second Level, Argent**

## CHALLENGES IN Dementia

EVIDENCE-BASED CONSIDERATIONS FROM EARLY DIAGNOSIS TO LONG-TERM MANAGEMENT

WEDNESDAY, MAY 21, 2003, 7:00 - 10:00 PM  
 THE ARGENT HOTEL, SAN FRANCISCO, CALIFORNIA



APA 156th ANNUAL MEETING

**AGENDA**

<p>6:30-7:00 PM <b>Dinner</b></p> <p>7:00 <b>Welcome and Introductions</b></p> <p>7:10 <b>Validated Screening Tools in the Detection and Treatment of Alzheimer's Disease</b></p> <p>7:35 <b>Real-World Assessment and Management of Mild Cognitive Impairment: A Case Study</b></p> <p>8:00 <b>Practical Lessons from Clinical Trials in Cholinesterase Inhibitors</b></p>	<p>8:25 <b>Cholinesterase Inhibitors in Vascular Dementia: A New Treatment Model?</b></p> <p>8:50 <b>Strategies for Keeping the Brain Young</b></p> <p>9:15 <b>Question and Answer Session</b></p> <p>10:00 <b>Adjournment</b></p>	<p><i>At the conclusion of this program, participants should be able to</i></p> <ul style="list-style-type: none"> <li>• Identify potential screening tools for the detection and treatment of Alzheimer's disease;</li> <li>• Recognize the symptoms of mild cognitive impairment and its implications for Alzheimer's disease;</li> <li>• Understand the role of cholinesterase inhibitors in treating Alzheimer's disease;</li> <li>• Recognize the symptoms of vascular dementia and the potential benefits of treatment with cholinesterase inhibitors;</li> <li>• Discuss strategies and lifestyle choices that may help protect the brain.</li> </ul> <p style="font-size: x-small;">Attendees must be registered for the APA Annual Meeting to attend this symposium. Seating is limited and will be on a first-come, first-served basis. For more information about the meeting, please visit the APA Web site at <a href="http://www.psych.org">www.psych.org</a> or contact the APA toll free at 1-888-357-7924 (within the United States or Canada) or at 703-907-7300.</p> <p style="font-size: x-small;">The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.</p> <p style="font-size: x-small;">The APA designates this educational activity for a maximum of 3 category 1 credits toward the AMA Physician's Recognition Award and for the CME requirement of the APA. Each physician should claim only those credits that he/she actually spent in the activity.</p>
---	--	---

Sponsored by the American Psychiatric Association
Supported by an unrestricted educational grant from Eisai Inc. and Pfizer Inc.

INDUSTRY-SUPPORTED SYMPOSIUM 49  
 Wednesday, May 21, 7:00 p.m. - 10:00 p.m.  
 Grand Ballroom Salon B, Grand Ballroom Level, Hilton

APA 2003 Annual Meeting ~ CME Symposium

# COMBINED PHARMACOTHERAPY FOR BIPOLAR DISORDERS

Wednesday, May 21

Hilton San Francisco ~ Grand Ballroom Salon B  
 6:30-7 PM Dinner ~ 7-10 PM Clinical Program

Frederick K. Goodwin, MD, Symposium Chair

**The Rationale for Combined Pharmacotherapy**

Frederick K. Goodwin, MD  
 George Washington University Medical Center  
 Co-author of the standard medical text  
*Manic-Depressive Illness*

**Potential Synergies in the Mechanisms of Actions of Mood Stabilizers**

L. Trevor Young, MD, PhD  
 University of Toronto

**Mood Stabilizer Combinations: Multimodal Therapy or Polypharmacy?**

Terence A. Ketter, MD  
 Stanford University School of Medicine

**Antidepressants in Combination Therapy of Bipolar Disorder**

S. Nassir Ghaemi, MD  
 Cambridge Hospital  
 Harvard Medical School

**Atypical Antipsychotics Combined with Standard Mood Stabilizers for Bipolar Disorder**

Joseph F. Goldberg, MD  
 Payne Whitney Clinic  
 New York Presbyterian Hospital  
 Weill Medical College of Cornell University



Sponsored by the American Psychiatric Association, the American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The APA designates this educational activity for a maximum of 3 category 1 credits toward the AMA Physician Recognition Award and for the CME requirement of the APA. Each physician should claim only those credits that he/she actually spent in the activity.

Attendees must be registered for the APA 2003 Annual Meeting to attend this symposium. Seating is limited and will be based on first-come, first-served.

For more information about the meeting, please visit the APA website at [www.psych.org](http://www.psych.org) or contact the APA toll free at 1-888-357-7924 (within the US or Canada) or 703-907-7300.

Supported by an unrestricted educational grant from GlaxoSmithKline

**LEARNING OBJECTIVE**

Identify bipolar patients who may benefit from specific combined pharmacotherapy, and manage such patients with effective therapy over the long term.

**AGENDA**

6:30 PM Dinner  
 7:00 PM Introduction  
 T. Goodwin, MD  
 7:05 PM Speaker presentations  
 9:15 PM Question & answer session  
 10:00 PM Program concludes

INDUSTRY-SUPPORTED SYMPOSIUM 50  
 Wednesday, May 21, 7:00 p.m. - 10:00 p.m.  
 Continental Ballroom, Ballroom Level, Hilton



## Novel Therapeutic Options for Psychotic Disorders

Wednesday, May 21, 2003

Hilton San Francisco  
 333 O'Farrell Street  
 Continental Ballroom

Dinner: 6:30 PM - 7:00 PM  
 Symposium: 7:00 PM - 10:00 PM

Chair: Rajiv Tandon, MD

APA 2003  
 ANNUAL  
 MEETING

SAN FRANCISCO CALIFORNIA

**Agenda**

- 7:00 PM **Welcome and Introductions**  
Rajiv Tandon, MD  
University of Michigan School of Medicine
- 7:05 PM **The Evolution of Antipsychotic Therapy: A Mechanism-Based Evaluation**  
W. Wolfgang Fleischhacker, MD  
Innsbruck University Clinics
- 7:35 PM **Limitations of Existing Antipsychotic Therapies**  
Rajiv Tandon, MD
- 8:05 PM **Developments in Antipsychotic Therapy: Real-World Clinical Experience**  
Susan M. Maixner, MD  
University of Michigan School of Medicine
- 8:35 PM **Antipsychotic Therapy: Recent and Ongoing Clinical Trials**  
T. Scott Stroup, MD, MPH  
University of North Carolina at Chapel Hill School of Medicine
- 9:05 PM **Summary Remarks**  
Rajiv Tandon, MD
- 9:15 PM **Panel Discussion/Q&A**

**Learning Objectives**

After completion of this symposium, the participants should be better able to

- Describe the evolution of antipsychotic agents
- Recognize the clinical implications of differences in the pharmacologic profiles of various antipsychotic agents
- Evaluate comparative outcomes associated with various antipsychotic drugs and discuss the influence of tolerability on the overall effectiveness of antipsychotic therapy
- Describe real-world challenges to achieving optimal therapeutic outcome
- Discuss the role of clinical experience in guiding state-of-the-art practice
- Review recent and ongoing clinical trial results with existing and emerging antipsychotic therapies and their implications for optimizing treatment for patients with psychotic disorders

The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The APA designates this educational activity for a maximum of 3 category 1 credits toward the AMA Physician Recognition Award and for the CME requirement of the APA. Each physician should claim only those credits that he/she actually spent in the activity.

Attendees must be registered for the APA Annual Meeting to attend this symposium. Seating is limited and will be based on first-come, first-served. For more information about the meeting, please visit the APA website at [www.psych.org](http://www.psych.org) or contact the APA toll free at 1-888-357-7924 (within the U.S. or Canada) or 703-907-7300.

Supported by an unrestricted educational grant from Bristol-Myers Squibb Company and Otsuka America Pharmaceutical, Inc.

Bristol-Myers Squibb Company

Otsuka America Pharmaceutical, Inc.

Sponsored by the American Psychiatric Association.

**INDUSTRY-SUPPORTED SYMPOSIUM 51**  
**Wednesday, May 21, 7:00 p.m. - 10:00 p.m.**  
**Salons 7 & 8, Lower B-2 Level, Marriott**



An educational symposium to be presented at the 2003 Annual Meeting of the American Psychiatric Association

WEDNESDAY, MAY 21, 2003  
 SAN FRANCISCO MARRIOTT  
 SALONS 7 AND 8, LOWER B-2 LEVEL  
 SAN FRANCISCO, CALIFORNIA

**CLINICAL AND PUBLIC HEALTH IMPLICATIONS OF MEDICAL AND PSYCHIATRIC COMORBIDITY**

**PROGRAM AGENDA**

6:30 PM - 7:00 PM RECEPTION

7:00 PM - 7:05 PM WELCOME AND INTRODUCTION  
 PROGRAM CHAIRMAN, PAUL E. KECK, JR, MD - University of Cincinnati College of Medicine

7:05 PM - 7:30 PM TREATMENT APPROACHES FOR MANAGING ANXIETY DISORDER IN THE BIPOLAR PATIENT  
 TRISHA SHUPES, MD, PhD - University of Texas Southwestern Medical Center at Dallas

7:30 PM - 7:55 PM THE CHALLENGE OF TREATING BIPOLAR DISORDER AND SUBSTANCE ABUSE  
 MARK A. FRYE, MD - UCLA School of Medicine

7:55 PM - 8:20 PM NEW TREATMENT OPTIONS FOR EATING DISORDERS AND OBESITY WITH COMORBID BIPOLAR DISORDER  
 SHISHUKA MALHOTRA, MD - United Health Network Clinical Research Associates

8:20 PM - 8:45 PM INFLUENCE OF MEDICAL COMORBIDITIES ON TREATMENT APPROACHES IN BIPOLAR PATIENTS  
 JOHN L. BEYER, MD - Duke University Medical Center

8:45 PM - 9:10 PM GENDER AND BIPOLAR DISORDER  
 LORI L. AITSHULER, MD - UCLA School of Medicine

9:10 PM - 9:15 PM SUMMARY AND CONCLUSIONS  
 PAUL E. KECK, JR, MD

9:15 PM - 10:00 PM QUESTIONS AND ANSWERS

10:00 PM - 10:30 PM REFRESHMENTS

**EDUCATIONAL OBJECTIVE**

Upon completion of the program, participants should be able to understand the high prevalence of medical and psychiatric comorbidity in bipolar disorder; the impact of comorbid conditions on prognosis, and their implications for concurrent treatment.

**ACCREDITATION STATEMENT**

The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education (CME) for physicians.

The APA designates this educational activity for a maximum of 3 Category 1 credits toward the AMA Physician's Recognition Award and for the CME requirement of the APA. Each physician should claim only those credits that he/she actually spent in the educational activity.

Attendees must be registered for the APA Annual Meeting to attend this symposium. Seating is limited and will be based on first-come, first-served. For more information about the meeting, please visit the APA website at [www.psych.org](http://www.psych.org) or contact the APA, toll free, at 1-888-357-7924 (within the US or Canada) or 703-907-7300.

Sponsored by the American Psychiatric Association.


Supported by an unrestricted educational grant from Ortho-McNeil Pharmaceutical, Inc.



**INDUSTRY-SUPPORTED SYMPOSIUM 52**  
**Wednesday, May 21, 7:00 p.m. - 10:00 p.m.**  
**Salon 9, Lower B-2 Level, Marriott**

Presented at the APA  
 156th Annual Meeting

**STRIVING TO HEAL THE MIND:**  
 the challenge of PTSD



**Wednesday, May 21, 2003**  
**7:00 PM - 10:00 PM**

San Francisco Marriott, Salon 9, Lower B-2 Level, San Francisco, California

**Faculty and Agenda:**

6:30 PM - 7:00 PM Butler Symposium

7:00 PM - 9:15 PM

**Overview**  
 Martin B. Keller, MD  
 Brown University School of Medicine, Providence, Rhode Island

**The Global burden of PTSD: results from the WHO ICPE**  
 Ronald C. Kessler, PhD  
 Harvard Medical School Healthcare Policy, Boston, Massachusetts

**Exposure to stress and trauma across the lifespan: neurobiological consequences**  
 Linda L. Carpenter, MD  
 Brown University School of Medicine Butler Hospital, Providence, Rhode Island

**Healing the mind: therapeutic approaches for chronic PTSD**  
 Barbara O. Rothbaum, PhD  
 Emory University School of Medicine, Atlanta, Georgia

**Early intervention for PTSD prophylaxis in trauma survivors: emerging evidence**  
 Ariele Y. Shalev, MD  
 Hadassah University Hospital, Jerusalem, Israel

**Medicines that heal the mind: pharmacological approaches for PTSD**  
 Jonathan RT Davidson, MD  
 Duke University Medical Center, Durham, North Carolina

9:15 PM - 10:00 PM Question and Answer Session

**Overview:**  
 Post-traumatic stress disorder (PTSD) is being increasingly recognized as a major psychiatric illness worldwide. Experimental and clinical research is demonstrating that exposure to stressful events during critical periods of development can induce chronic changes in neuroendocrine function and stress reactivity. The challenge for clinicians is to recognize patients with PTSD or those that may be at risk of PTSD following exposure to stressful/traumatic events. Emerging data suggest that early intervention may prevent the future diagnosis of PTSD and this will be discussed along with the treatment and management strategies for patients with PTSD.

**Target Audience:**  
 This activity is designed specifically for practicing psychiatrists, psychotherapists, social workers, and epidemiologists.

**Learning Objectives:**  
 At the conclusion of the symposium, the participants should be able to:

- understand the prevalence and the traumas most likely to cause PTSD
- appreciate the neurobiology of PTSD
- demonstrate an understanding of early intervention following trauma to prevent later onset of PTSD
- diagnose and appropriately treat PTSD.

**Accreditation:**  
 The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.



The APA designates this educational activity for a maximum of 3.0 category 1 credits towards the AMA Physician's Recognition Award and for the CME requirement of the APA. Each physician should claim only those credits he/she actually spent in the educational activity.

**Registration Policy:**  
 Attendees must be registered for the APA Annual Meeting to attend this symposium. Seating is limited and will be on a first-come, first-served basis. For more information about the meeting, please visit the APA website at [www.psych.org](http://www.psych.org) or contact the APA toll-free at 1 (888) 357-7924 (within the US or Canada) or (703) 907-7300.



Sponsored by the American Psychiatric Association  
 Supported by an unrestricted educational grant from Wyeth Pharmaceuticals

# Get Connected to the American Psychiatric Association



## **The Promise of the Profession is in the Power of APA Membership**

Annual meeting attendees visiting the APA Resource Center will find new research abstracts on CD-ROM, the latest publications of APA programs, resident fellowship opportunities, HIV/AIDS treatment information, position openings, practice tools, and how to report, track, and attain additional CME credits as well as other useful resources. Visitors can also consult with government affairs representatives regarding the latest regulations and upcoming legislation. It's all just part of the way that APA is working to keep psychiatrists engaged with the progress of the field.

So whether you're a prospective, new, long-time, or international member, visit the Resource Center and find out how APA can help your professional life.

**APA Resource Center**  
Hall D, Exhibit Level  
Moscone Center

### *Hours of Operation*

Sat, May 17: 10:00 a.m. - 5:00 p.m.

Sun, May 18: 8:00 a.m. - 4:30 p.m.\*

Mon, May 19: 10:00 a.m. - 6:00 p.m.

Tues, May 20: 10:00 a.m. - 6:00 p.m.

Wed, May 21: 10:00 a.m. - 3:00 p.m.

\*Early closing for Opening Session